22,O
-,O
oxacalcitriol,B
suppresses,O
secondary,O
hyperparathyroidism,O
without,O
inducing,O
low,O
bone,O
turnover,O
in,O
dogs,O
with,O
renal,O
failure,O
.,O
BACKGROUND,O
:,O
Calcitriol,B
therapy,O
suppresses,O
serum,O
levels,O
of,O
parathyroid,O
hormone,O
(,O
PTH,B
),O
in,O
patients,O
with,O
renal,O
failure,O
but,O
has,O
several,O
drawbacks,O
",",O
including,O
hypercalcemia,B
and,O
/,O
or,O
marked,O
suppression,O
of,O
bone,O
turnover,O
",",O
which,O
may,O
lead,O
to,O
adynamic,O
bone,O
disease,O
.,O
A,O
new,O
vitamin,B
D,I
analogue,I
",",O
22,O
-,O
oxacalcitriol,B
(,O
OCT,I
),O
",",O
has,O
been,O
shown,O
to,O
have,O
promising,O
characteristics,O
.,O
This,O
study,O
was,O
undertaken,O
to,O
determine,O
the,O
effects,O
of,O
OCT,I
on,O
serum,O
PTH,B
levels,O
and,O
bone,O
turnover,O
in,O
states,O
of,O
normal,O
or,O
impaired,O
renal,O
function,O
.METHODS,O
:,O
Sixty,O
dogs,O
were,O
either,O
nephrectomized,O
(,O
Nx,O
",",O
N,O
=,O
38,O
),O
or,O
sham,O
-,O
operated,O
(,O
Sham,O
",",O
N,O
=,O
22,O
),O
.,O
The,O
animals,O
received,O
supplemental,O
phosphate,B
to,O
enhance,O
PTH,B
secretion,O
.,O
Fourteen,O
weeks,O
after,O
the,O
start,O
of,O
phosphate,B
supplementation,O
",",O
half,O
of,O
the,O
Nx,O
and,O
Sham,O
dogs,O
received,O
doses,O
of,O
OCT,B
(,O
three,O
times,O
per,O
week,O
),O
;,O
the,O
other,O
half,O
were,O
given,O
vehicle,O
for,O
60,O
weeks,O
.,O
Thereafter,O
",",O
the,O
treatment,O
modalities,O
for,O
a,O
subset,O
of,O
animals,O
were,O
crossed,O
over,O
for,O
an,O
additional,O
eight,O
months,O
.,O
Biochemical,O
and,O
hormonal,O
indices,O
of,O
calcium,B
and,O
bone,O
metabolism,O
were,O
measured,O
throughout,O
the,O
study,O
",",O
and,O
bone,O
biopsies,O
were,O
done,O
at,O
baseline,O
",",O
60,O
weeks,O
after,O
OCT,B
or,O
vehicle,O
treatment,O
",",O
and,O
at,O
the,O
end,O
of,O
the,O
crossover,O
period,O
.,O
RESULTS,O
:,O
In,O
Nx,O
dogs,O
",",O
OCT,B
significantly,O
decreased,O
serum,O
PTH,B
levels,O
soon,O
after,O
the,O
induction,O
of,O
renal,O
insufficiency,O
.,O
In,O
long,O
-,O
standing,O
secondary,O
hyperparathyroidism,O
",",O
OCT,B
(,O
0,O
.,O
3,O
microg,O
/,O
kg,O
),O
stabilized,O
serum,O
PTH,B
levels,O
during,O
the,O
first,O
months,O
.,O
Serum,O
PTH,B
levels,O
rose,O
thereafter,O
",",O
but,O
the,O
rise,O
was,O
less,O
pronounced,O
compared,O
with,O
baseline,O
than,O
the,O
rise,O
seen,O
in,O
Nx,O
control,O
.,O
These,O
effects,O
were,O
accompanied,O
by,O
episodes,O
of,O
hypercalcemia,B
and,O
hyperphosphatemia,B
.,O
In,O
animals,O
with,O
normal,O
renal,O
function,O
",",O
OCT,B
induced,O
a,O
transient,O
decrease,O
in,O
serum,O
PTH,B
levels,O
at,O
a,O
dose,O
of,O
0,O
.,O
1,O
microg,O
/,O
kg,O
",",O
which,O
was,O
not,O
sustained,O
with,O
lowering,O
of,O
the,O
doses,O
.,O
In,O
Nx,O
dogs,O
",",O
OCT,B
reversed,O
abnormal,O
bone,O
formation,O
",",O
such,O
as,O
woven,O
osteoid,B
and,O
fibrosis,O
",",O
but,O
did,O
not,O
significantly,O
alter,O
the,O
level,O
of,O
bone,O
turnover,O
.,O
In,O
addition,O
",",O
OCT,B
improved,O
mineralization,O
lag,O
time,O
",",O
(,O
that,O
is,O
",",O
the,O
rate,O
at,O
which,O
osteoid,B
mineralizes,O
),O
in,O
both,O
Nx,O
and,O
Sham,O
dogs,O
.,O
CONCLUSIONS,O
:,O
These,O
results,O
indicate,O
that,O
even,O
though,O
OCT,B
does,O
not,O
completely,O
prevent,O
the,O
occurrence,O
of,O
hypercalcemia,B
in,O
experimental,O
dogs,O
with,O
renal,O
insufficiency,O
",",O
it,O
may,O
be,O
of,O
use,O
in,O
the,O
management,O
of,O
secondary,O
hyperparathyroidism,B
because,O
it,O
does,O
not,O
induce,O
low,O
bone,O
turnover,O
and,O
",",O
therefore,O
",",O
does,O
not,O
increase,O
the,O
risk,O
of,O
adynamic,O
bone,O
disease,O
.,O
Hypotension,O
",",O
bradycardia,O
",",O
and,O
asystole,O
after,O
high,O
-,O
dose,O
intravenous,O
methylprednisolone,B
in,O
a,O
monitored,O
patient,O
.,O
We,O
report,O
a,O
case,O
of,O
hypotension,O
",",O
bradycardia,O
",",O
and,O
asystole,O
after,O
intravenous,O
administration,O
of,O
high,O
-,O
dose,O
methylprednisolone,B
in,O
a,O
73,O
-,O
year,O
-,O
old,O
patient,O
who,O
underwent,O
electrocardiographic,O
(,O
ECG,B
),O
monitoring,O
throughout,O
the,O
episode,O
.,O
There,O
was,O
a,O
history,O
of,O
ischemic,B
cardiac,I
disease,I
9,O
years,O
earlier,O
.,O
The,O
patient,O
was,O
admitted,O
with,O
a,O
pulmonary,B
-,O
renal,I
syndrome,I
with,O
hemoptysis,O
",",O
rapidly,O
progressive,O
renal,B
failure,I
",",O
and,O
hypoxemia,O
that,O
required,O
mechanical,O
ventilation,O
in,O
the,O
intensive,O
care,O
unit,O
.,O
After,O
receiving,O
advanced,O
cardiopulmonary,B
resuscitation,I
",",O
the,O
patient,O
recovered,O
cardiac,B
rhythm,I
.,O
The,O
ECG,O
showed,O
a,O
junctional,O
rhythm,O
without,O
ventricular,O
arrhythmia,O
.,O
This,O
study,O
reviews,O
the,O
current,O
proposed,O
mechanisms,O
of,O
sudden,O
death,O
after,O
a,O
high,O
dose,O
of,O
intravenous,B
methylprednisolone,I
(,O
IVMP,B
),O
.,O
These,O
mechanisms,O
are,O
not,O
well,O
understood,O
because,O
",",O
in,O
most,O
cases,O
",",O
the,O
patients,O
were,O
not,O
monitored,O
at,O
the,O
moment,O
of,O
the,O
event,O
.,O
Rapid,O
infusion,O
and,O
underlying,O
cardiac,O
disease,O
were,O
important,O
risk,O
factors,O
in,O
the,O
case,O
reported,O
here,O
",",O
and,O
the,O
authors,O
discount,O
ventricular,O
arrhythmia,O
as,O
the,O
main,O
mechanism,O
.,O
Worsening,O
of,O
levodopa,B
-,O
induced,O
dyskinesias,O
by,O
motor,O
and,O
mental,O
tasks,O
.,O
Ten,O
patients,O
who,O
had,O
Parkinson,B
',O
s,O
disease,O
with,O
disabling,O
dyskinesia,O
were,O
included,O
in,O
this,O
study,O
to,O
evaluate,O
the,O
role,O
of,O
mental,O
(,O
mental,O
calculation,O
),O
and,O
motor,O
(,O
flexion,O
/,O
extension,O
of,O
right,O
fingers,O
",",O
flexion,O
/,O
extension,O
of,O
left,O
fingers,O
",",O
flexion,O
/,O
extension,O
of,O
the,O
neck,O
",",O
speaking,O
aloud,O
),O
tasks,O
on,O
the,O
worsening,O
of,O
peak,O
-,O
dose,O
dyskinesia,O
following,O
administration,O
of,O
an,O
effective,O
single,O
dose,O
of,O
apomorphine,B
.,O
Compared,O
with,O
the,O
score,O
at,O
rest,O
(,O
1,O
.,O
3,O
+,O
/,O
-,O
0,O
.,O
3,O
),O
",",O
a,O
significant,O
aggravation,O
of,O
the,O
dyskinesia,B
score,O
was,O
observed,O
during,O
speaking,O
aloud,O
(,O
5,O
.,O
2,O
+,O
/,O
-,O
1,O
.,O
1,O
",",O
p,O
<,O
0,O
.,O
5,O
),O
",",O
movements,O
of,O
right,O
(,O
4,O
.,O
5,O
+,O
/,O
-,O
1,O
.,O
0,O
",",O
p,O
<,O
0,O
.,O
5,O
),O
",",O
and,O
left,O
(,O
3,O
.,O
7,O
+,O
/,O
-,O
0,O
",",O
p,O
<,O
0,O
.,O
5,O
),O
",",O
fingers,O
",",O
movements,O
of,O
the,O
neck,O
(,O
5,O
.,O
1,O
+,O
/,O
-,O
1,O
.,O
0,O
",",O
p,O
<,O
0,O
.,O
5,O
.,O
),O
",",O
and,O
mental,O
calculation,O
(,O
3,O
.,O
1,O
+,O
/,O
-,O
1,O
.,O
0,O
",",O
p,O
<,O
0,O
.,O
5,O
.,O
),O
.,O
These,O
results,O
suggest,O
that,O
activation,O
tasks,O
such,O
as,O
speaking,O
aloud,O
could,O
be,O
used,O
for,O
objective,O
assessment,O
of,O
dyskinesia,O
severity,O
.,O
Urine,O
N,B
-,I
acetyl,I
-,I
beta,I
-,I
D,I
-,I
glucosaminidase,I
-,I
-,I
a,O
marker,O
of,O
tubular,O
damage,O
?,O
BACKGROUND,O
:,O
Although,O
an,O
indicator,O
of,O
renal,O
tubular,O
dysfunction,O
",",O
an,O
increased,O
urinary,O
N,B
-,I
acetyl,I
-,I
beta,I
-,I
D,I
-,I
glucosaminidase,I
(,I
NAG,I
),I
activity,O
might,O
reflect,O
increased,O
lysosomal,O
activity,O
in,O
renal,O
tubular,O
cells,O
.,O
METHODS,O
:,O
Puromycin,B
aminonucleoside,I
(,O
PAN,B
),O
was,O
administered,O
to,O
Sprague,O
Dawley,O
rats,O
to,O
induce,O
proteinuria,O
.,O
Total,O
protein,B
",",O
albumin,B
",",O
NAG,B
activity,O
and,O
protein,O
electrophoretic,O
pattern,O
were,O
assessed,O
in,O
daily,O
urine,O
samples,O
for,O
33,O
days,O
.,O
The,O
morphological,O
appearance,O
of,O
the,O
kidneys,O
was,O
examined,O
on,O
days,O
three,O
",",O
four,O
",",O
six,O
",",O
eight,O
and,O
thirty,O
three,O
and,O
the,O
NAG,B
isoenzyme,O
patterns,O
on,O
days,O
zero,O
",",O
four,O
",",O
eight,O
and,O
thirty,O
three,O
.,O
RESULTS,O
:,O
Following,O
intravenous,O
PAN,B
urine,O
volume,O
and,O
urine,O
NAG,B
activity,O
increased,O
significantly,O
by,O
day,O
two,O
",",O
but,O
returned,O
to,O
normal,O
by,O
day,O
four,O
.,O
After,O
day,O
four,O
all,O
treated,O
animals,O
exhibited,O
a,O
marked,O
rise,O
in,O
urine,O
albumin,B
",",O
total,O
protein,O
excretion,O
and,O
NAG,B
activity,O
.,O
Electrophoresis,O
showed,O
a,O
generalised,O
increase,O
in,O
middle,O
and,O
high,O
molecular,O
weight,O
urine,O
proteins,O
from,O
day,O
four,O
onwards,O
.,O
Protein,B
droplets,O
first,O
appeared,O
prominent,O
in,O
tubular,O
cells,O
on,O
day,O
four,O
.,O
Peak,O
urine,O
NAG,B
activity,O
and,O
a,O
change,O
in,O
NAG,B
isoenzyme,O
pattern,O
coincided,O
with,O
both,O
the,O
peak,O
proteinuria,O
and,O
the,O
reduction,O
in,O
intracellular,O
protein,B
and,O
NAG,B
droplets,O
(,O
day,O
six,O
onwards,O
),O
.,O
CONCLUSIONS,O
:,O
This,O
animal,O
model,O
demonstrates,O
that,O
an,O
increase,O
in,O
lysosomal,O
turnover,O
and,O
hence,O
urine,O
NAG,B
activity,O
",",O
occurs,O
when,O
increased,O
protein,B
is,O
presented,O
to,O
the,O
tubular,O
cells,O
.,O
Urine,O
NAG,B
activity,O
is,O
thus,O
a,O
measure,O
of,O
altered,O
function,O
in,O
the,O
renal,B
tubules,O
and,O
not,O
simply,O
an,O
indicator,O
of,O
damage,O
.,O
Cauda,O
equina,O
syndrome,O
after,O
spinal,O
anaesthesia,O
with,O
hyperbaric,O
5,B
%,O
lignocaine,B
:,O
a,O
review,O
of,O
six,O
cases,O
of,O
cauda,O
equina,O
syndrome,O
reported,O
to,O
the,O
Swedish,O
Pharmaceutical,O
Insurance,O
1993,O
-,O
1997,O
.,O
Six,O
cases,O
of,O
cauda,B
equina,I
syndrome,I
with,O
varying,O
severity,O
were,O
reported,O
to,O
the,O
Swedish,O
Pharmaceutical,O
Insurance,O
during,O
the,O
period,O
1993,O
-,O
1997,O
.,O
All,O
were,O
associated,O
with,O
spinal,O
anaesthesia,O
using,O
hyperbaric,O
5,B
%,I
lignocaine,I
.,O
Five,O
cases,O
had,O
single,O
-,O
shot,O
spinal,O
anaesthesia,O
and,O
one,O
had,O
a,O
repeat,O
spinal,O
anaesthetic,O
due,O
to,O
inadequate,O
block,O
.,O
The,O
dose,O
of,O
hyperbaric,O
5,B
%,I
lignocaine,I
administered,O
ranged,O
from,O
60,O
to,O
120,O
mg,O
.,O
Three,O
of,O
the,O
cases,O
were,O
most,O
likely,O
caused,O
by,O
direct,O
neurotoxicity,O
of,O
hyperbaric,O
5,B
%,I
lignocaine,I
.,O
In,O
the,O
other,O
3,O
cases,O
",",O
direct,O
neurotoxicity,O
was,O
also,O
probable,O
",",O
but,O
unfortunately,O
radiological,O
investigations,O
were,O
not,O
done,O
to,O
definitely,O
exclude,O
a,O
compressive,O
aetiology,O
.,O
All,O
cases,O
sustained,O
permanent,O
neurological,O
deficits,O
.,O
We,O
recommend,O
that,O
hyperbaric,O
lignocaine,B
should,O
be,O
administered,O
in,O
concentrations,O
not,O
greater,O
than,O
2,O
%,O
and,O
at,O
a,O
total,O
dose,O
preferably,O
not,O
exceeding,O
60,O
mg,O
.,O
Systemic,O
toxicity,O
following,O
administration,O
of,O
sirolimus,B
(,O
formerly,O
rapamycin,I
),O
for,O
psoriasis,O
:,O
association,O
of,O
capillary,O
leak,O
syndrome,O
with,O
apoptosis,O
of,O
lesional,O
lymphocytes,O
.,O
BACKGROUND,O
:,O
Sirolimus,B
(,O
formerly,O
rapamycin,O
),O
is,O
an,O
immunosuppressive,O
agent,O
that,O
interferes,O
with,O
T,B
-,O
cell,O
activation,O
.,O
After,O
2,O
individuals,O
with,O
psoriasis,O
developed,O
a,O
capillary,O
leak,O
syndrome,O
following,O
treatment,O
with,O
oral,O
sirolimus,B
lesional,O
skin,O
cells,O
and,O
activated,O
peripheral,O
blood,O
cells,O
were,O
analyzed,O
for,O
induction,O
of,O
apoptosis,O
.,O
OBSERVATIONS,O
:,O
A,O
keratome,O
skin,O
specimen,O
from,O
1,O
patient,O
with,O
sirolimus,B
-,O
induced,O
capillary,O
leak,O
syndrome,O
had,O
a,O
2,O
.,O
3,O
-,O
fold,O
increase,O
in,O
percentage,O
of,O
apoptotic,O
cells,O
(,O
to,O
48,O
%,O
),O
compared,O
with,O
an,O
unaffected,O
sirolimus,B
-,O
treated,O
patient,O
with,O
psoriasis,O
(,O
21,O
%,O
),O
.,O
Activated,O
peripheral,O
blood,O
T,O
cells,O
from,O
patients,O
with,O
psoriasis,O
tended,O
to,O
exhibit,O
greater,O
spontaneous,O
or,O
dexamethasone,B
-,O
induced,O
apoptosis,O
than,O
did,O
normal,O
T,O
cells,O
",",O
particularly,O
in,O
the,O
presence,O
of,O
sirolimus,B
.,O
CONCLUSIONS,O
:,O
Severe,O
adverse,O
effects,O
of,O
sirolimus,B
include,O
fever,O
",",O
anemia,O
",",O
and,O
capillary,B
leak,I
syndrome,I
.,O
These,O
symptoms,O
may,O
be,O
the,O
result,O
of,O
drug,O
-,O
induced,O
apoptosis,O
of,O
lesional,O
leukocytes,O
",",O
especially,O
activated,O
T,B
lymphocytes,I
",",O
and,O
possibly,O
release,O
of,O
inflammatory,O
mediators,O
.,O
Because,O
patients,O
with,O
severe,O
psoriasis,O
may,O
develop,O
capillary,B
leak,I
from,O
various,O
systemic,O
therapies,O
",",O
clinical,O
monitoring,O
is,O
advisable,O
for,O
patients,O
with,O
inflammatory,O
diseases,O
who,O
are,O
treated,O
with,O
immune,O
modulators,O
.,O
Effect,O
of,O
lithium,B
maintenance,I
therapy,I
on,O
thyroid,B
and,O
parathyroid,B
function,O
.,O
OBJECTIVES,O
:,O
To,O
assess,O
changes,O
induced,O
by,O
lithium,B
maintenance,I
therapy,I
on,O
the,O
incidence,O
of,O
thyroid,B
",",O
parathyroid,B
and,O
ion,O
alterations,O
.,O
These,O
were,O
evaluated,O
with,O
respect,O
to,O
the,O
duration,O
of,O
lithium,B
therapy,I
",",O
age,O
",",O
sex,O
",",O
and,O
family,O
history,O
(,O
whether,O
or,O
not,O
the,O
patient,O
had,O
a,O
first,O
-,O
degree,O
relative,O
with,O
thyroid,B
disease,O
),O
.,O
DESIGN,O
:,O
Prospective,O
study,O
.,O
SETTING,O
:,O
Affective,O
Disorders,O
Clinic,O
at,O
St,O
.,O
Mary,O
',O
s,O
Hospital,O
",",O
Montreal,O
.,O
PATIENTS,O
:,O
One,O
hundred,O
and,O
one,O
patients,O
(,O
28,O
men,O
and,O
73,O
women,O
),O
with,O
bipolar,O
disorder,O
receiving,O
lithium,B
maintenance,O
therapy,O
ranging,O
from,O
1,O
year,O
',O
s,O
to,O
32,O
years,O
',O
duration,O
.,O
The,O
control,O
group,O
consisted,O
of,O
82,O
patients,O
with,O
no,O
psychiatric,O
or,O
endocrinological,O
diagnoses,O
from,O
the,O
hospital,O
',O
s,O
out,O
-,O
patient,O
clinics,O
.,O
OUTCOME,O
MEASURES,O
:,O
Laboratory,O
analyses,O
of,O
calcium,B
",",O
magnesium,B
and,O
thyroid,B
-,O
stimulating,O
hormone,O
levels,O
performed,O
before,O
beginning,O
lithium,O
therapy,O
and,O
at,O
biannual,O
follow,O
-,O
up,O
.,O
RESULTS,O
:,O
Hypothyroidism,O
developed,O
in,O
40,O
patients,O
",",O
excluding,O
8,O
patients,O
who,O
were,O
hypothyroid,O
at,O
baseline,O
.,O
All,O
patients,O
having,O
first,O
-,O
degree,O
relatives,O
affected,O
by,O
thyroid,B
illness,O
had,O
accelerated,O
onset,O
of,O
hypothyroidism,O
(,O
3,O
.,O
7,O
years,O
after,O
onset,O
of,O
lithium,B
therapy,O
)-7,O
compared,O
with,O
patients,O
without,O
a,O
family,O
history,O
(,O
8,O
.,O
6,O
years,O
after,O
onset,O
of,O
lithium,B
therapy,O
)-25,O
.,O
Women,O
over,O
60,O
years,O
of,O
age,O
were,O
more,O
often,O
affected,O
by,O
hypothyroidism,B
than,O
women,O
under,O
60,O
years,O
of,O
age,O
(,O
34,O
.,O
6,O
%,O
versus,O
31,O
.,O
9,O
%,O
)-56,O
.,O
Magnesium,B
levels,O
in,O
patients,O
on,O
lithium,B
treatment,O
were,O
unchanged,O
from,O
baseline,O
levels,O
.,O
After,O
lithium,B
treatment,O
",",O
calcium,B
levels,O
were,O
higher,O
than,O
either,O
baseline,O
levels,O
or,O
control,O
levels,O
.,O
Thus,O
",",O
lithium,B
treatment,O
counteracted,O
the,O
decrease,O
in,O
plasma,O
calcium,B
levels,O
associated,O
with,O
aging,O
.,O
CONCLUSIONS,O
:,O
Familial,O
thyroid,O
illness,O
is,O
a,O
risk,O
factor,O
for,O
hypothyroidism,O
and,O
hypercalcemia,B
during,O
lithium,B
therapy,O
.,O
Severe,O
immune,B
hemolytic,I
anemia,I
associated,O
with,O
prophylactic,O
use,O
of,O
cefotetan,B
in,O
obstetric,O
and,O
gynecologic,O
procedures,O
.,O
Second,O
-,O
and,O
third,O
-,O
generation,O
cephalosporins,B
",",O
especially,O
cefotetan,B
",",O
are,O
increasingly,O
associated,O
with,O
severe,O
",",O
sometimes,O
fatal,O
immune,B
hemolytic,I
anemia,I
.,O
We,O
noticed,O
that,O
10,O
of,O
our,O
35,O
cases,O
of,O
cefotetan,B
-,O
induced,O
hemolytic,I
anemias,I
were,O
in,O
patients,O
who,O
had,O
received,O
cefotetan,B
prophylactically,O
for,O
obstetric,O
and,O
gynecologic,O
procedures,O
.,O
Eight,O
of,O
these,O
cases,O
of,O
severe,O
immune,O
hemolytic,B
anemia,I
are,O
described,O
.,O
Effects,O
of,O
nonsteroidal,B
anti,I
-,I
inflammatory,I
drugs,I
on,O
hemostasis,O
in,O
patients,O
with,O
aneurysmal,O
subarachnoid,O
hemorrhage,O
.,O
Platelet,O
function,O
is,O
impaired,O
by,O
nonsteroidal,B
anti,I
-,I
inflammatory,I
drugs,I
(,O
NSAIDs,B
),O
with,O
prominent,O
anti,O
-,O
inflammatory,O
properties,O
.,O
Their,O
safety,O
in,O
patients,O
undergoing,O
intracranial,O
surgery,O
is,O
under,O
debate,O
.,O
Patients,O
with,O
aneurysmal,O
subarachnoid,O
hemorrhage,O
(,O
SAH,B
),O
were,O
randomized,O
to,O
receive,O
either,O
ketoprofen,B
",",O
100,O
mg,O
",",O
three,O
times,O
a,O
day,O
(,O
ketoprofen,O
group,O
",",O
n,O
=,O
9,O
),O
or,O
a,O
weak,O
NSAID,B
",",O
acetaminophen,B
",",O
1,O
g,O
",",O
three,O
times,O
a,O
day,O
(,O
acetaminophen,O
group,O
",",O
n,O
=,O
9,O
),O
starting,O
immediately,O
after,O
the,O
diagnosis,O
of,O
aneurysmal,O
SAH,B
.,O
Treatment,O
was,O
continued,O
for,O
3,O
days,O
postoperatively,O
.,O
Test,O
blood,O
samples,O
were,O
taken,O
before,O
treatment,O
and,O
surgery,O
as,O
well,O
as,O
on,O
the,O
first,O
",",O
third,O
",",O
and,O
fifth,O
postoperative,O
mornings,O
.,O
Maximal,O
platelet,O
aggregation,O
induced,O
by,O
6,O
microM,O
of,O
adenosine,B
diphosphate,I
decreased,O
after,O
administration,O
of,O
ketoprofen,B
.,O
Aggregation,O
was,O
lower,O
(,O
P,O
<,O
.,O
5,O
),O
in,O
the,O
ketoprofen,B
group,O
than,O
in,O
the,O
acetaminophen,B
group,O
just,O
before,O
surgery,O
and,O
on,O
the,O
third,O
postoperative,O
day,O
.,O
In,O
contrast,O
",",O
maximal,O
platelet,O
aggregation,O
increased,O
in,O
the,O
acetaminophen,B
group,O
on,O
the,O
third,O
postoperative,O
day,O
as,O
compared,O
with,O
the,O
pretreatment,O
platelet,O
aggregation,O
results,O
(,O
P,B
<,O
.,O
5,O
),O
.,O
One,O
patient,O
in,O
the,O
ketoprofen,B
group,O
developed,O
a,O
postoperative,O
intracranial,O
hematoma,O
.,O
Coagulation,O
(,O
prothrombin,B
time,I
[,O
PT,B
"],",O
",",O
activated,B
partial,I
thromboplastin,I
time,I
[,O
APPT,B
"],",O
",",O
fibrinogen,B
concentration,I
",",O
and,O
antithrombin,B
III,I
[,O
AT,B
III,I
"],",O
was,O
comparable,O
between,O
the,O
two,O
groups,O
.,O
Ketoprofen,B
but,O
not,O
acetaminophen,B
impaired,O
platelet,O
function,O
in,O
patients,O
with,O
SAH,B
.,O
If,O
ketoprofen,B
is,O
used,O
before,O
surgery,O
on,O
cerebral,O
artery,O
aneurysms,O
",",O
it,O
may,O
pose,O
an,O
additional,O
risk,O
factor,O
for,O
hemorrhage,O
.,O
Nitric,B
oxide,I
synthase,I
expression,O
in,O
the,O
course,O
of,O
lead,B
-,I
induced,I
hypertension,I
.,O
We,O
recently,O
showed,O
elevated,O
reactive,O
oxygen,B
species,I
(,O
ROS,B
),O
",",O
reduced,O
urinary,O
excretion,O
of,O
NO,B
metabolites,I
(,O
NOx,B
),O
",",O
and,O
increased,O
NO,B
sequestration,O
as,O
nitrotyrosine,B
in,O
various,O
tissues,O
in,O
rats,O
with,O
lead,B
-,I
induced,I
hypertension,I
.,O
This,O
study,O
was,O
designed,O
to,O
discern,O
whether,O
the,O
reduction,O
in,O
urinary,O
NOx,B
in,O
lead,B
-,I
induced,I
hypertension,I
is,O
",",O
in,O
part,O
",",O
due,O
to,O
depressed,O
NO,B
synthase,I
(,I
NOS,I
),I
expression,O
.,O
Male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
randomly,O
assigned,O
to,O
a,O
lead,B
-,I
treated,I
group,O
(,O
given,O
lead,O
acetate,O
",",O
100,O
ppm,O
",",O
in,O
drinking,O
water,O
and,O
regular,O
rat,O
chow,O
),O
",",O
a,O
group,O
given,O
lead,O
and,O
vitamin,O
E,O
-,O
fortified,O
chow,O
",",O
or,O
a,O
normal,O
control,O
group,O
given,O
either,O
regular,O
food,O
and,O
water,O
or,O
vitamin,O
E,O
-,O
fortified,O
food,O
for,O
12,O
weeks,O
.,O
Tail,O
blood,O
pressure,O
",",O
urinary,O
NOx,B
excretion,O
",",O
plasma,O
malondialdehyde,B
(,O
MDA,I
),O
",",O
and,O
endothelial,O
and,O
inducible,O
NOS,B
(,O
eNOS,I
and,O
iNOS,I
),O
isotypes,O
in,O
the,O
aorta,O
and,O
kidney,O
were,O
measured,O
.,O
The,O
lead,O
-,O
treated,O
group,O
exhibited,O
a,O
rise,O
in,O
blood,O
pressure,O
and,O
plasma,O
MDA,B
concentration,O
",",O
a,O
fall,O
in,O
urinary,O
NOx,B
excretion,O
",",O
and,O
a,O
paradoxical,O
rise,O
in,O
vascular,O
and,O
renal,O
tissue,O
eNOS,B
and,O
iNOS,I
expression,O
.,O
Vitamin,B
E,I
supplementation,O
ameliorated,O
hypertension,O
",",O
lowered,O
plasma,O
MDA,B
concentration,O
",",O
and,O
raised,O
urinary,O
NOx,B
excretion,O
while,O
significantly,O
lowering,O
vascular,O
",",O
but,O
not,O
renal,O
",",O
tissue,O
eNOS,B
and,O
iNOS,B
expression,O
.,O
Vitamin,B
E,I
supplementation,O
had,O
no,O
effect,O
on,O
either,O
blood,O
pressure,O
",",O
plasma,O
MDA,B
",",O
or,O
NOS,B
expression,O
in,O
the,O
control,O
group,O
.,O
The,O
study,O
also,O
revealed,O
significant,O
inhibition,O
of,O
NOS,B
enzymatic,O
activity,O
by,O
lead,O
in,O
cell,O
-,O
free,O
preparations,O
.,O
In,O
conclusion,O
",",O
lead,O
-,O
induced,O
hypertension,O
in,O
this,O
model,O
was,O
associated,O
with,O
a,O
compensatory,O
upregulation,O
of,O
renal,O
and,O
vascular,O
eNOS,B
and,O
iNOS,B
expression,O
.,O
This,O
is,O
",",O
in,O
part,O
",",O
due,O
to,O
ROS,B
-,O
mediated,O
NO,B
inactivation,O
",",O
lead,O
-,O
associated,O
inhibition,O
of,O
NOS,B
activity,O
",",O
and,O
perhaps,O
stimulatory,O
actions,O
of,O
increased,O
shear,O
stress,O
associated,O
with,O
hypertension,O
.,O
Glyceryl,B
trinitrate,I
induces,O
attacks,O
of,O
migraine,O
without,O
aura,O
in,O
sufferers,O
of,O
migraine,O
with,O
aura,O
.,O
Migraine,O
with,O
aura,O
and,O
migraine,O
without,O
aura,O
have,O
the,O
same,O
pain,O
phase,O
",",O
thus,O
indicating,O
that,O
migraine,O
with,O
aura,O
and,O
migraine,O
without,O
aura,O
share,O
a,O
common,O
pathway,O
of,O
nociception,O
.,O
In,O
recent,O
years,O
",",O
increasing,O
evidence,O
has,O
suggested,O
that,O
the,O
messenger,O
molecule,O
nitric,B
oxide,I
(,O
NO,B
),O
is,O
involved,O
in,O
pain,O
mechanisms,O
of,O
migraine,O
without,O
aura,O
.,O
In,O
order,O
to,O
clarify,O
whether,O
the,O
same,O
is,O
TRUE,O
for,O
migraine,O
with,O
aura,O
",",O
in,O
the,O
present,O
study,O
we,O
examined,O
the,O
headache,O
response,O
to,O
intravenous,O
infusion,O
of,O
glyceryl,B
trinitrate,I
(,O
GTN,B
),O
(,O
0,O
.,O
5,O
microg,O
/,O
kg,O
/,O
min,O
for,O
20,O
min,O
),O
in,O
12,O
sufferers,O
of,O
migraine,O
with,O
aura,O
.,O
The,O
specific,O
aim,O
was,O
to,O
elucidate,O
whether,O
an,O
aura,O
and,O
/,O
or,O
an,O
attack,O
of,O
migraine,O
without,O
aura,O
could,O
be,O
induced,O
.,O
Fourteen,O
healthy,O
subjects,O
served,O
as,O
controls,O
.,O
Aura,O
symptoms,O
were,O
not,O
elicited,O
in,O
any,O
subject,O
.,O
Headache,O
was,O
more,O
severe,O
in,O
migraineurs,O
than,O
in,O
the,O
controls,O
during,O
and,O
immediately,O
after,O
GTN,B
infusion,O
(,O
p,O
=,O
0,O
.,O
37,O
),O
as,O
well,O
as,O
during,O
the,O
following,O
11,O
h,O
(,O
p,O
=,O
0,O
.,O
8,O
),O
.,O
In,O
the,O
controls,O
",",O
the,O
GTN,B
-,O
induced,O
headache,O
gradually,O
disappeared,O
",",O
whereas,O
in,O
migraineurs,O
peak,O
headache,O
intensity,O
occurred,O
at,O
a,O
mean,O
time,O
of,O
240,O
min,O
post,O
-,O
infusion,O
.,O
At,O
this,O
time,O
the,O
induced,O
headache,O
in,O
6,O
of,O
12,O
migraineurs,O
fulfilled,O
the,O
diagnostic,O
criteria,O
for,O
migraine,B
without,I
aura,I
of,I
the,I
International,I
Headache,I
Society,I
.,O
The,O
results,O
therefore,O
suggest,O
that,O
NO,B
is,O
involved,O
in,O
the,O
pain,O
mechanisms,O
of,O
migraine,B
with,I
aura,I
.,O
Since,O
cortical,O
spreading,O
depression,O
has,O
been,O
shown,O
to,O
liberate,O
NO,B
in,O
animals,O
",",O
this,O
finding,O
may,O
help,O
our,O
understanding,O
of,O
the,O
coupling,O
between,O
cortical,O
spreading,O
depression,O
and,O
headache,O
in,O
migraine,B
with,I
aura,I
.,O
Rapid,O
reversal,O
of,O
life,O
-,O
threatening,O
diltiazem,B
-,O
induced,O
tetany,O
with,O
calcium,B
chloride,I
.,O
We,O
describe,O
a,O
patient,O
who,O
developed,O
tetany,O
with,O
sudden,O
respiratory,O
arrest,O
after,O
the,O
infusion,O
of,O
intravenous,O
diltiazem,B
.,O
The,O
administration,O
of,O
calcium,B
chloride,I
rapidly,O
resolved,O
the,O
patient,O
',O
s,O
tetany,O
with,O
prompt,O
recovery,O
of,O
respiratory,O
function,O
",",O
averting,O
the,O
need,O
for,O
more,O
aggressive,O
airway,O
management,O
and,O
ventilatory,O
support,O
.,O
The,O
emergency,O
physician,O
should,O
be,O
aware,O
that,O
life,O
-,O
threatening,O
tetany,O
may,O
accompany,O
the,O
administration,O
of,O
intravenous,O
diltiazem,B
and,O
that,O
calcium,B
chloride,I
may,O
be,O
a,O
rapid,O
and,O
effective,O
remedy,O
.,O
Predictors,O
of,O
decreased,O
renal,O
function,O
in,O
patients,O
with,O
heart,O
failure,O
during,O
angiotensin,O
-,O
converting,O
enzyme,O
inhibitor,O
therapy,O
:,O
results,O
from,O
the,O
studies,O
of,O
left,O
ventricular,O
dysfunction,O
(,O
SOLVD,O
),O
BACKGROUND,O
:,O
Although,O
angiotensin,O
-,O
converting,O
enzyme,O
inhibitor,O
therapy,O
reduces,O
mortality,O
rates,O
in,O
patients,O
with,O
congestive,O
heart,O
failure,O
(,O
CHF,O
),O
",",O
it,O
may,O
also,O
cause,O
decreased,O
renal,O
function,O
.,O
Little,O
information,O
is,O
available,O
to,O
predict,O
which,O
patients,O
are,O
at,O
highest,O
risk,O
for,O
this,O
complication,O
.,O
OBJECTIVE,O
:,O
To,O
quantify,O
specific,O
clinical,O
predictors,O
of,O
reduction,O
in,O
renal,B
function,O
in,O
patients,O
with,O
CHF,O
who,O
are,O
prescribed,O
angiotensin,B
-,I
converting,I
enzyme,I
inhibitor,I
therapy,O
.,O
METHOD,O
:,O
We,O
analyzed,O
data,O
from,O
the,O
Studies,O
of,O
Left,O
Ventricular,O
Dysfunction,O
(,O
SOLVD,O
),O
",",O
a,O
randomized,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
of,O
enalapril,O
for,O
the,O
treatment,O
of,O
CHF,O
.,O
There,O
were,O
3379,O
patients,O
randomly,O
assigned,O
to,O
enalapril,B
with,O
a,O
median,O
follow,O
-,O
up,O
of,O
974,O
days,O
and,O
3379,O
patients,O
randomly,O
assigned,O
to,O
placebo,B
with,O
a,O
mean,O
follow,O
-,O
up,O
of,O
967,O
days,O
.,O
Decreased,O
renal,O
function,O
was,O
defined,O
as,O
a,O
rise,O
in,O
serum,B
creatinine,B
>,O
/,O
=,O
0,O
.,O
5,O
mg,O
/,O
dL,O
(,O
44,O
micromol,B
/,O
L,O
from,O
baseline,O
.,O
We,O
used,O
time,O
-,O
to,O
-,O
event,O
analysis,O
to,O
identify,O
potential,O
predictors,O
of,O
decrease,O
in,O
renal,O
function,O
including,O
age,O
",",O
baseline,O
ejection,O
fraction,O
",",O
baseline,O
creatinine,B
",",O
low,O
systolic,O
blood,O
pressure,O
(,O
<,O
100,O
mm,O
Hg,O
),O
",",O
history,O
of,O
hypertension,O
",",O
diabetes,O
",",O
and,O
use,O
of,O
antiplatelet,B
",",O
diuretic,B
",",O
and,O
beta,B
-,I
blocker,I
therapy,I
.,O
RESULTS,O
:,O
Patients,O
randomly,O
assigned,O
to,O
enalapril,B
had,O
a,O
33,O
%,O
greater,O
likelihood,O
of,O
decreased,O
renal,O
function,O
than,O
controls,O
(,O
P,O
=,O
.,O
3,O
):,O
By,O
multivariate,O
analysis,O
",",O
in,O
both,O
the,O
placebo,O
and,O
enalapril,B
groups,O
older,O
age,O
",",O
diuretic,O
therapy,O
",",O
and,O
diabetes,O
were,O
associated,O
with,O
decreased,O
renal,O
function,O
",",O
whereas,O
beta,B
-,I
blocker,I
therapy,O
and,O
higher,O
ejection,O
fraction,O
were,O
renoprotective,O
.,O
Older,O
age,O
was,O
associated,O
with,O
a,O
greater,O
risk,O
of,O
developing,O
decreased,O
renal,B
function,O
in,O
both,O
groups,O
",",O
but,O
significantly,O
more,O
so,O
in,O
the,O
enalapril,B
group,O
(,O
enalapril,B
:,O
risk,O
ratio,O
[,O
RR,O
],O
1,O
.,O
42,O
per,O
10,O
years,O
",",O
95,O
%,O
confidence,O
interval,O
[,O
CI,O
],O
1,O
.,O
32,O
-,O
1,O
.,O
52,O
with,O
enalapril,B
;,O
placebo,O
:,O
RR,O
1,O
.,O
18,O
",",O
95,O
%,O
CI,O
1,O
.,O
12,O
-,O
1,O
.,O
25,O
),O
.,O
Diuretic,B
therapy,O
was,O
likewise,O
associated,O
with,O
a,O
greater,O
risk,O
of,O
decreased,O
renal,B
function,O
in,O
the,O
enalapril,B
group,O
(,O
RR,O
1,O
.,O
89,O
",",O
95,O
%,O
CI,O
1,O
.,O
70,O
-,O
2,O
.,O
8,O
),O
than,O
in,O
the,O
placebo,B
group,O
(,O
RR,O
1,O
.,O
35,O
",",O
95,O
%,O
CI,O
1,O
.,O
9,O
-,O
1,O
.,O
66,O
),O
.,O
Conversely,O
",",O
enalapril,B
had,O
a,O
relative,O
renoprotective,O
effect,O
(,O
RR,O
1,O
.,O
33,O
",",O
95,O
%,O
CI,O
1,O
.,O
13,O
-,O
1,O
.,O
53,O
),O
compared,O
with,O
placebo,O
(,O
RR,O
1,O
.,O
96,O
",",O
95,O
%,O
CI,O
1,O
.,O
57,O
-,O
2,O
.,O
44,O
),O
in,O
patients,O
with,O
diabetes,O
.,O
A,O
lower,O
risk,O
of,O
renal,B
impairment,I
was,O
seen,O
in,O
both,O
groups,O
with,O
beta,B
-,I
blocker,I
therapy,I
(,O
RR,O
0,O
.,O
70,O
",",O
95,O
%,O
CI,O
0,O
.,O
57,O
-,O
0,O
.,O
85,O
in,O
patients,O
with,O
higher,O
baseline,O
ejection,O
fraction,O
(,O
RR,O
0,O
.,O
93,O
per,O
5,O
%,O
increment,O
",",O
95,O
%,O
CI,O
91,O
-,O
0,O
.,O
96,O
)-5,O
.,O
CONCLUSIONS,O
:,O
Enalapril,B
use,O
caused,O
a,O
33,O
%,O
increase,O
in,O
the,O
risk,O
of,O
decreased,O
renal,O
function,O
in,O
patients,O
with,O
CHF,O
.,O
Diuretic,B
use,O
and,O
advanced,O
age,O
increased,O
this,O
risk,O
.,O
Diabetes,B
was,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
renal,O
impairment,O
in,O
all,O
patients,O
with,O
CHF,O
",",O
but,O
this,O
risk,O
was,O
reduced,O
in,O
the,O
enalapril,B
group,O
compared,O
with,O
the,O
placebo,O
group,O
.,O
beta,B
-,O
Blocker,O
therapy,O
and,O
higher,O
ejection,O
fraction,O
were,O
renoprotective,O
in,O
all,O
patients,O
regardless,O
of,O
therapy,O
.,O
Hypomania,B
-,O
like,O
syndrome,O
induced,O
by,O
olanzapine,B
.,O
We,O
report,O
a,O
female,O
patient,O
with,O
a,O
diagnosis,O
of,O
a,O
not,O
otherwise,O
specified,O
psychotic,O
disorder,O
(,O
DSM,B
-,I
IV,I
),O
who,O
developed,O
hypomania,O
shortly,O
after,O
the,O
introduction,O
of,O
olanzapine,B
treatment,O
.,O
Acetazolamide,B
-,O
induced,O
Gerstmann,B
syndrome,I
.,O
Acute,O
confusion,O
induced,O
by,O
acetazolamide,B
is,O
a,O
well,O
known,O
adverse,O
drug,O
reaction,O
in,O
patients,O
with,O
renal,O
impairment,O
.,O
We,O
report,O
a,O
case,O
of,O
acetazolamide,B
-,O
induced,O
Gerstmann,B
syndrome,I
in,O
a,O
patient,O
with,O
normal,O
renal,O
function,O
",",O
to,O
highlight,O
predisposing,O
factors,O
that,O
are,O
frequently,O
overlooked,O
.,O
Vasopressin,B
in,O
the,O
treatment,O
of,O
milrinone,B
-,O
induced,O
hypotension,O
in,O
severe,O
heart,O
failure,O
.,O
The,O
use,O
of,O
phosphodiesterase,O
inhibitors,O
such,O
as,O
milrinone,B
in,O
the,O
treatment,O
of,O
severe,O
heart,O
failure,O
is,O
frequently,O
restricted,O
because,O
they,O
cause,O
vasodilation,O
and,O
hypotension,O
.,O
In,O
patients,O
with,O
decompensated,O
heart,O
failure,O
with,O
hypotension,O
after,O
treatment,O
with,O
milrinone,B
",",O
low,O
doses,O
of,O
vasopressin,B
restored,O
blood,O
pressure,O
without,O
inhibiting,O
the,O
inotropic,O
effect,O
of,O
milrinone,B
.,O
Treatment,O
of,O
tacrolimus,B
-,O
related,O
adverse,O
effects,O
by,O
conversion,O
to,O
cyclosporine,B
in,O
liver,O
transplant,O
recipients,O
.,O
When,O
tacrolimus,B
side,O
effects,O
persist,O
despite,O
dose,O
reduction,O
",",O
conversion,O
to,O
cyclosporine,B
-,O
based,O
immunosuppression,O
(,O
CyA,B
),O
is,O
necessary,O
.,O
We,O
characterized,O
tacrolimus,B
side,O
effects,O
that,O
warranted,O
discontinuation,O
of,O
the,O
drug,O
",",O
and,O
outcomes,O
after,O
conversion,O
.,O
Of,O
388,O
liver,B
recipients,O
who,O
received,O
tacrolimus,B
as,O
primary,O
immunosuppression,O
",",O
70,O
required,O
conversion,O
to,O
CyA,B
.,O
We,O
recorded,O
indication,O
for,O
conversion,O
",",O
whether,O
conversion,O
was,O
early,O
or,O
late,O
after,O
transplantation,O
",",O
tacrolimus,B
dose,O
and,O
trough,O
blood,O
level,O
at,O
conversion,O
",",O
and,O
incidence,O
of,O
rejection,O
after,O
conversion,O
.,O
Conversion,B
was,O
early,O
in,O
29,O
patients,O
(,O
41,O
.,O
4,O
%,O
),O
and,O
late,O
in,O
41,O
(,O
58,O
.,O
6,O
%,O
),O
.,O
Indications,O
for,O
early,O
conversion,O
were,O
neurotoxicity,B
(,O
20,O
),O
",",O
(,O
insulin,B
-,I
dependent,I
),I
diabetes,I
mellitus,I
(,I
IDDM,I
),I
(,O
5,O
),O
",",O
nephrotoxicity,B
(,O
3,O
),O
",",O
gastrointestinal,B
(,O
GI,O
),O
toxicity,O
(,O
6,O
),O
",",O
and,O
cardiomyopathy,B
(,O
1,O
),O
",",O
and,O
for,O
late,O
conversion,O
were,O
neurotoxicity,B
(,O
15,O
),O
",",O
IDDM,B
(,O
12,O
),O
",",O
nephrotoxicity,B
(,O
3,O
),O
",",O
GI,B
(,O
toxicity,O
),O
(,O
5,O
),O
",",O
hepatotoxicity,B
(,O
6,O
),O
",",O
post,O
-,O
transplant,O
lmphoproliferate,O
disease,O
(,O
PTLD,O
),O
(,O
2,O
),O
",",O
cardiomyopathy,B
(,O
1,O
),O
",",O
hemolytic,B
anemia,I
(,O
1,O
),O
",",O
and,O
pruritus,B
(,O
1,O
),O
.,O
All,O
early,O
-,O
conversion,O
patients,O
showed,O
improvement,O
/,O
resolution,O
of,O
symptoms,O
.,O
Among,O
late,O
-,O
conversion,O
patients,O
",",O
37,O
(,O
90,O
.,O
2,O
%,O
),O
had,O
improvement,O
/,O
resolution,O
;,O
in,O
4,O
(,O
9,O
.,O
8,O
%,O
),O
",",O
adverse,O
effects,O
persisted,O
.,O
The,O
overall,O
rejection,O
rate,O
was,O
30,O
%,O
.,O
Sixty,O
-,O
two,O
patients,O
(,O
88,O
.,O
6,O
%,O
),O
are,O
alive,O
with,O
functioning,O
grafts,O
686,O
+,O
/,O
-,O
362,O
days,O
(,O
range,O
",",O
154,O
-,O
1433,O
days,O
),O
after,O
conversion,O
.,O
When,O
tacrolimus,B
side,O
effects,O
are,O
unresponsive,O
to,O
dose,O
reduction,O
",",O
conversion,O
to,O
CyA,B
can,O
be,O
accomplished,O
safely,O
",",O
with,O
no,O
increased,O
risk,O
of,O
rejection,O
and,O
excellent,O
long,O
-,O
term,O
outcome,O
.,O
Ocular,B
manifestations,O
of,O
juvenile,B
rheumatoid,I
arthritis,I
.,O
We,O
followed,O
210,O
cases,O
of,O
juvenile,B
rheumatoid,I
arthritis,I
closely,O
for,O
eleven,O
years,O
.,O
Thirty,O
-,O
six,O
of,O
the,O
210,O
patients,O
(,O
17,O
.,O
2,O
%,O
),O
developed,O
iridocyclitis,B
.,O
Iridocyclitis,B
was,O
seen,O
most,O
frequently,O
in,O
young,O
female,O
patients,O
(,O
0,O
to,O
4,O
years,O
),O
with,O
the,O
monoarticular,O
or,O
pauciatricular,O
form,O
of,O
the,O
arthritis,O
.,O
However,O
",",O
30,O
%,O
of,O
the,O
patients,O
developed,O
uveitis,B
after,O
16,O
years,O
of,O
age,O
.,O
Although,O
61,O
%,O
of,O
patients,O
had,O
a,O
noncontributory,O
ocular,O
history,O
on,O
entry,O
",",O
42,O
%,O
had,O
active,O
uveitis,B
on,O
entry,O
.,O
Our,O
approach,O
was,O
effective,O
in,O
detecting,O
uveitis,B
in,O
new,O
cases,O
and,O
exacerbations,O
of,O
uveitis,B
in,O
established,O
cases,O
.,O
Forty,O
-,O
four,O
percent,O
of,O
patients,O
with,O
uveitis,B
had,O
one,O
or,O
more,O
identifiable,O
signs,O
or,O
symptoms,O
",",O
such,O
as,O
red,O
eye,O
",",O
ocular,O
pain,O
",",O
decreased,O
visual,O
acuity,O
",",O
or,O
photophobia,O
",",O
in,O
order,O
of,O
decreasing,O
frequency,O
.,O
Even,O
after,O
early,O
detection,O
and,O
prompt,O
treatment,O
",",O
41,O
%,O
of,O
cases,O
of,O
uveitis,B
did,O
not,O
respond,O
to,O
more,O
than,O
six,O
months,O
of,O
intensive,O
topical,O
treatment,O
with,O
corticosteroids,B
and,O
mydriatics,B
.,O
Despite,O
this,O
",",O
there,O
was,O
a,O
dramatic,O
decrease,O
in,O
the,O
50,O
%,O
incidence,O
of,O
blinding,O
complications,O
of,O
uveitis,B
cited,O
in,O
earlier,O
studies,O
.,O
Cataract,B
and,O
band,B
keratopathy,I
occurred,O
in,O
only,O
22,O
and,O
13,O
%,O
of,O
our,O
group,O
",",O
respectively,O
.,O
We,O
used,O
chloroquine,B
or,O
hydroxychloroquine,B
in,O
173,O
of,O
210,O
cases,O
and,O
found,O
only,O
one,O
case,O
of,O
chorioretinopathy,B
attributable,O
to,O
these,O
drugs,O
.,O
Systemically,O
administered,O
corticosteroids,B
were,O
used,O
in,O
75,O
of,O
210,O
cases,O
;,O
a,O
significant,O
number,O
of,O
posterior,B
subcapsular,I
cataracts,I
was,O
found,O
.,O
Typical,O
keratoconjunctivitis,B
sicca,I
developed,O
in,O
three,O
of,O
the,O
uveitis,B
cases,O
.,O
This,O
association,O
with,O
uveitis,B
and,O
JRA,O
was,O
not,O
noted,O
previously,O
.,O
Surgical,O
treatment,O
of,O
cataracts,B
",",O
band,B
keratopathy,I
",",O
and,O
glaucoma,B
achieved,O
uniformly,O
discouraging,O
results,O
.,O
Cyclophosphamide,B
-,I
induced,I
cystitis,I
in,O
freely,O
-,O
moving,O
conscious,O
rats,O
:,O
behavioral,O
approach,O
to,O
a,O
new,O
model,O
of,O
visceral,O
pain,O
.,O
PURPOSE,O
:,O
To,O
develop,O
a,O
model,O
of,O
visceral,O
pain,O
in,O
rats,O
using,O
a,O
behavioral,O
approach,O
.,O
Cyclophosphamide,B
(,O
CP,B
),O
",",O
an,O
antitumoral,O
agent,O
known,O
to,O
produce,O
toxic,O
effects,O
on,O
the,O
bladder,O
wall,O
through,O
its,O
main,O
toxic,O
metabolite,O
acrolein,B
",",O
was,O
used,O
to,O
induce,O
cystitis,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
CP,B
was,O
administered,O
at,O
doses,O
of,O
50,O
",",O
100,O
and,O
200,O
mg,O
.,O
kg,O
.,O
i,O
.,O
p,O
.,O
to,O
male,O
rats,O
",",O
and,O
their,O
behavior,O
observed,O
and,O
scored,O
.,O
The,O
effects,O
of,O
morphine,B
(,O
0,O
.,O
5,O
to,O
4,B
mg,I
.,O
/,O
kg,O
.,O
i,O
.,O
v,O
.,O
on,O
CP,B
-,I
induced,I
behavioral,I
modifications,I
were,O
tested,O
administered,O
alone,O
and,O
after,O
naloxone,B
(,O
1,O
mg,I
.,O
/,O
kg,O
.,O
s,O
.,O
c,O
.,O
.,O
In,O
addition,O
",",O
90,O
minutes,O
after,O
CP,B
injection,I
",",O
that,O
is,O
",",O
at,O
the,O
time,O
of,O
administration,O
of,O
morphine,B
",",O
the,O
bladder,O
was,O
removed,O
in,O
some,O
rats,O
for,O
histological,O
examination,O
.,O
Finally,O
",",O
to,O
show,O
that,O
the,O
bladder,O
is,O
essential,O
for,O
the,O
CP,B
-,I
induced,O
behavioral,O
modifications,O
",",O
female,O
rats,O
also,O
received,O
CP,B
at,O
doses,O
of,O
200,O
mg,O
.,O
/,O
kg,O
.,O
i,O
.,O
p,O
.,O
and,O
of,O
20,O
mg,O
.,O
by,O
the,O
intravesical,O
route,O
",",O
and,O
acrolein,B
at,O
doses,O
of,O
0,O
.,O
5,O
mg,O
.,O
by,O
the,O
intravesical,O
route,O
and,O
of,O
5,O
mg,O
.,O
/,O
kg,O
.,O
i,O
.,O
v,O
.,O
RESULTS,O
:,O
CP,B
dose,O
-,O
relatedly,O
induced,O
marked,O
behavioral,O
modifications,O
in,O
male,O
rats,O
:,O
breathing,O
rate,O
decrease,O
",",O
closing,O
of,O
the,O
eyes,O
and,O
occurrence,O
of,O
specific,O
postures,O
.,O
Morphine,B
dose,O
-,O
dependently,O
reversed,O
these,O
behavioral,O
disorders,O
.,O
A,O
dose,O
of,O
0,O
.,O
5,O
mg,O
.,O
/,O
kg,O
.,O
produced,O
a,O
reduction,O
of,O
almost,O
50,O
%,O
of,O
the,O
behavioral,O
score,O
induced,O
by,O
CP,B
200,O
mg,O
.,O
/,O
kg,O
.,O
This,O
effect,O
was,O
completely,O
prevented,O
by,O
pretreatment,O
with,O
naloxone,B
.,O
At,O
the,O
time,O
of,O
administration,O
of,O
morphine,B
",",O
histological,O
modifications,O
of,O
the,O
bladder,O
wall,O
",",O
such,O
as,O
chorionic,O
and,O
muscle,O
layer,O
edema,O
",",O
were,O
observed,O
.,O
In,O
female,O
rats,O
",",O
CP,B
200,I
mg,I
.,O
/,O
kg,O
.,O
i,O
.,O
p,O
produced,O
the,O
same,O
marked,O
behavioral,O
modifications,O
as,O
those,O
observed,O
in,O
male,O
rats,O
.,O
Administered,O
at,O
the,O
dose,O
of,O
20,B
mg,I
.,O
intravesically,O
",",O
CP,B
did,O
not,O
produce,O
any,O
behavioral,O
effects,O
",",O
whereas,O
acrolein,B
at,O
0,B
.,O
5,I
mg,I
.,O
intravesically,O
induced,O
behavioral,O
modifications,O
identical,O
to,O
those,O
under,O
CP,B
200,I
mg,I
.,O
kg,O
.,O
i,O
.,O
p,O
.,O
",",O
with,O
the,O
same,O
maximal,O
levels,O
.,O
Conversely,O
",",O
acrolein,B
5,O
mg,O
.,O
/,O
kg,O
.,O
i,O
.,O
v,O
.,O
did,O
not,O
produce,O
any,O
behavioral,O
effects,O
at,O
all,O
.,O
CONCLUSIONS,O
:,O
Overall,O
",",O
these,O
results,O
indicate,O
that,O
this,O
experimental,O
model,O
of,O
CP,B
-,I
induced,O
cystitis,O
may,O
be,O
an,O
interesting,O
new,O
behavioral,O
model,O
of,O
inflammatory,O
visceral,O
pain,O
",",O
allowing,O
a,O
better,O
understanding,O
of,O
these,O
painful,O
syndromes,O
and,O
thus,O
a,O
better,O
therapeutic,O
approach,O
to,O
them,O
.,O
Prednisolone,B
-,O
induced,O
muscle,O
dysfunction,O
is,O
caused,O
more,O
by,O
atrophy,O
than,O
by,O
altered,O
acetylcholine,B
receptor,I
expression,O
.,O
Large,O
doses,O
of,O
glucocorticoids,B
can,O
alter,O
muscle,O
physiology,O
and,O
susceptibility,O
to,O
neuromuscular,O
blocking,O
drugs,O
by,O
mechanisms,O
not,O
clearly,O
understood,O
.,O
We,O
investigated,O
the,O
effects,O
of,O
moderate,O
and,O
large,O
doses,O
of,O
prednisolone,B
on,O
muscle,O
function,O
and,O
pharmacology,O
",",O
and,O
their,O
relationship,O
to,O
changes,O
in,O
muscle,O
size,O
and,O
acetylcholine,B
receptor,I
(,I
AChR,I
),I
expression,O
.,O
With,O
institutional,O
approval,O
",",O
35,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
randomly,O
allocated,O
to,O
receive,O
daily,O
subcutaneous,O
doses,O
of,O
10,O
mg,O
/,O
kg,O
prednisolone,B
(,O
P10,O
group,O
),O
",",O
100,O
mg,O
/,O
kg,O
prednisolone,B
(,O
P100,O
group,O
),O
",",O
or,O
an,O
equal,O
volume,O
of,O
saline,B
(,O
S,O
group,O
),O
for,O
7,O
days,O
.,O
A,O
fourth,O
group,O
of,O
rats,O
was,O
pair,O
fed,O
(,O
food,O
restricted,O
),O
with,O
the,O
P100,O
rats,O
for,O
7,O
days,O
(,O
FR,O
group,O
),O
.,O
On,O
Day,O
8,O
",",O
the,O
nerve,O
-,O
evoked,O
peak,O
twitch,O
tensions,O
",",O
tetanic,O
tensions,O
",",O
and,O
fatigability,O
",",O
and,O
the,O
dose,O
-,O
response,O
curves,O
of,O
d,B
-,I
tubocurarine,I
in,O
the,O
tibialis,O
cranialis,O
muscle,O
were,O
measured,O
in,O
vivo,O
and,O
related,O
to,O
muscle,O
mass,O
or,O
expression,O
of,O
AChRs,B
.,O
Rate,O
of,O
body,O
weight,O
gain,O
was,O
depressed,O
in,O
the,O
P100,O
",",O
FR,O
",",O
and,O
P10,O
groups,O
compared,O
with,O
the,O
S,O
group,O
.,O
Tibialis,B
muscle,I
mass,I
was,O
smaller,O
in,O
the,O
P100,O
group,O
than,O
in,O
the,O
P10,O
or,O
S,O
groups,O
.,O
The,O
evoked,O
peak,O
twitch,O
and,O
tetanic,O
tensions,O
were,O
less,O
in,O
the,O
P100,O
group,O
than,O
in,O
the,O
P10,O
or,O
S,O
groups,O
",",O
however,O
",",O
tension,O
per,O
milligram,O
of,O
muscle,O
mass,O
was,O
greater,O
in,O
the,O
P100,O
group,O
than,O
in,O
the,O
S,O
group,O
.,O
The,O
50,O
%,O
effective,O
d,B
-,I
tubocurarine,I
(,O
microg,B
/,I
kg,I
),O
in,O
the,O
tibialis,B
muscle,I
was,O
smaller,O
in,O
the,O
P10,O
(,O
33,O
.,O
6,O
+,O
/,O
-,O
5,O
.,O
4,B
),O
than,O
in,O
the,O
S,B
(,O
61,O
.,O
9,O
+,O
/,O
-,O
5,O
.,O
0,O
),O
or,O
the,O
P100,B
(,O
71,O
.,O
3,O
+,O
/,O
-,O
9,O
.,O
6,O
),O
groups,O
.,O
AChR,B
expression,O
was,O
less,O
in,O
the,O
P10,B
group,O
than,O
in,O
the,O
S,B
group,O
.,O
The,O
evoked,O
tensions,O
correlated,O
with,O
muscle,O
mass,O
(,O
r,O
(,O
2,O
),O
=,O
0,O
.,O
32,O
",",O
P,O
<,O
0,O
.,O
1,O
),O
",",O
however,O
",",O
not,O
with,O
expression,O
of,O
AChR,B
.,O
The,O
50,O
%,O
effective,O
dose,O
of,O
d,O
-,O
tubocurarine,B
did,O
not,O
correlate,O
with,O
muscle,O
mass,O
or,O
AChR,B
expression,O
.,O
Our,O
results,O
suggest,O
that,O
the,O
neuromuscular,O
dysfunction,O
after,O
prednisolone,B
is,O
dose,O
-,O
dependent,O
",",O
and,O
derives,O
primarily,O
from,O
muscle,O
atrophy,O
and,O
derives,O
less,O
so,O
from,O
changes,O
in,O
AChR,B
expression,O
.,O
IMPLICATIONS,O
:,O
The,O
mechanisms,O
by,O
which,O
chronic,O
glucocorticoid,O
therapy,O
alters,O
neuromuscular,O
physiology,O
and,O
pharmacology,O
are,O
unclear,O
.,O
We,O
suggest,O
that,O
the,O
observed,O
effects,O
are,O
dose,O
-,O
dependent,O
and,O
derive,O
primarily,O
from,O
muscle,O
atrophy,O
and,O
derive,O
less,O
from,O
changes,O
in,O
acetylcholine,B
receptor,I
expression,I
.,O
Apomorphine,B
:,O
an,O
underutilized,O
therapy,O
for,O
Parkinson,B
',I
s,I
disease,I
.,O
Apomorphine,B
was,O
the,O
first,O
dopaminergic,O
drug,O
ever,O
used,O
to,O
treat,O
symptoms,O
of,O
Parkinson,B
',I
s,I
disease,I
.,O
While,O
powerful,O
antiparkinsonian,O
effects,O
had,O
been,O
observed,O
as,O
early,O
as,O
1951,O
",",O
the,O
potential,O
of,O
treating,O
fluctuating,O
Parkinson,O
',O
s,O
disease,O
by,O
subcutaneous,O
administration,O
of,O
apomorphine,B
has,O
only,O
recently,O
become,O
the,O
subject,O
of,O
systematic,O
study,O
.,O
A,O
number,O
of,O
small,O
scale,O
clinical,O
trials,O
have,O
unequivocally,O
shown,O
that,O
intermittent,O
subcutaneous,O
apomorphine,B
injections,O
produce,O
antiparkinsonian,O
benefit,O
close,O
if,O
not,O
identical,O
to,O
that,O
seen,O
with,O
levodopa,B
and,O
that,O
apomorphine,B
rescue,O
injections,O
can,O
reliably,O
revert,O
off,O
-,O
periods,O
even,O
in,O
patients,O
with,O
complex,O
on,O
-,O
off,O
motor,O
swings,O
.,O
Continuous,O
subcutaneous,O
apomorphine,B
infusions,O
can,O
reduce,O
daily,O
off,O
-,O
time,O
by,O
more,O
than,O
50,O
%,O
in,O
this,O
group,O
of,O
patients,O
",",O
which,O
appears,O
to,O
be,O
a,O
stronger,O
effect,O
than,O
that,O
generally,O
seen,O
with,O
add,O
-,O
on,O
therapy,O
oral,O
dopamine,B
agonists,O
or,O
COMT,B
inhibitors,O
.,O
Extended,O
follow,O
-,O
up,O
studies,O
of,O
up,O
to,O
8,O
years,O
have,O
demonstrated,O
long,O
-,O
term,O
persistence,O
of,O
apomorphine,B
efficacy,O
.,O
In,O
addition,O
",",O
there,O
is,O
convincing,O
clinical,O
evidence,O
that,O
monotherapy,O
with,O
continuous,O
subcutaneous,B
apomorphine,B
infusions,O
is,O
associated,O
with,O
marked,O
reductions,O
of,O
preexisting,O
levodopa,B
-,I
induced,I
dyskinesias,I
.,O
The,O
main,O
side,O
effects,O
of,O
subcutaneous,B
apomorphine,I
treatment,O
are,O
related,O
to,O
cutaneous,O
tolerability,O
problems,O
",",O
whereas,O
sedation,O
and,O
psychiatric,O
complications,O
play,O
a,O
lesser,O
role,O
.,O
Given,O
the,O
marked,O
degree,O
of,O
efficacy,O
of,O
subcutaneous,O
apomorphine,B
treatment,O
in,O
fluctuating,O
Parkinson,O
',O
s,O
disease,O
",",O
this,O
approach,O
seems,O
to,O
deserve,O
more,O
widespread,O
clinical,O
use,O
.,O
Probing,O
peripheral,O
and,O
central,O
cholinergic,B
system,O
responses,O
.,O
OBJECTIVE,O
:,O
The,O
pharmacological,O
response,O
to,O
drugs,O
that,O
act,O
on,O
the,O
cholinergic,B
system,O
of,O
the,O
iris,O
has,O
been,O
used,O
to,O
predict,O
deficits,O
in,O
central,O
cholinergic,B
functioning,O
due,O
to,O
diseases,O
such,O
as,O
Alzheimer,B
',O
s,O
disease,O
",",O
yet,O
correlations,O
between,O
central,O
and,O
peripheral,O
responses,O
have,O
not,O
been,O
properly,O
studied,O
.,O
This,O
study,O
assessed,O
the,O
effect,O
of,O
normal,O
aging,O
on,O
(,O
1,O
),O
the,O
tropicamide,B
-,O
induced,O
increase,O
in,O
pupil,O
diameter,O
",",O
and,O
(,O
2,O
),O
the,O
reversal,O
of,O
this,O
effect,O
with,O
pilocarpine,B
.,O
Scopolamine,B
was,O
used,O
as,O
a,O
positive,O
control,O
to,O
detect,O
age,O
-,O
dependent,O
changes,O
in,O
central,O
cholinergic,O
functioning,O
in,O
the,O
elderly,O
.,O
DESIGN,O
:,O
Randomized,O
double,O
-,O
blind,O
controlled,O
trial,O
.,O
PARTICIPANTS,O
:,O
Ten,O
healthy,O
elderly,O
(,O
mean,O
age,O
70,O
),O
and,O
9,O
young,O
(,O
mean,O
age,O
33,O
),O
volunteers,O
.,O
INTERVENTIONS,O
:,O
Pupil,O
diameter,O
was,O
monitored,O
using,O
a,O
computerized,O
infrared,O
pupillometer,O
over,O
4,O
hours,O
.,O
The,O
study,O
involved,O
4,O
sessions,O
.,O
In,O
1,O
session,O
",",O
tropicamide,B
(,O
20,O
microL,O
",",O
0,O
.,O
1,O
%,O
),O
was,O
administered,O
to,O
one,O
eye,O
and,O
placebo,O
to,O
the,O
other,O
.,O
In,O
another,O
session,O
",",O
tropicamide,B
(,O
20,O
microL,O
",",O
0,O
.,O
1,O
%,O
),O
was,O
administered,O
to,O
both,O
eyes,O
",",O
followed,O
23,O
minutes,O
later,O
by,O
the,O
application,O
of,O
pilocarpine,B
(,O
20,O
microL,O
",",O
0,O
.,O
1,O
%,O
),O
to,O
one,O
eye,O
and,O
placebo,B
to,O
the,O
other,O
.,O
All,O
eye,O
drops,O
were,O
given,O
in,O
a,O
randomized,O
order,O
.,O
In,O
2,O
separate,O
sessions,O
",",O
a,O
single,O
dose,O
of,O
scopolamine,B
(,O
0,O
.,O
5,O
mg,O
",",O
intravenously,O
),O
or,O
placebo,O
was,O
administered,O
",",O
and,O
the,O
effects,O
on,O
word,O
recall,O
were,O
measured,O
using,O
the,O
Buschke,O
Selective,O
Reminding,O
Test,O
over,O
2,O
hours,O
.,O
OUTCOME,O
MEASURES,O
:,O
Pupil,O
size,O
at,O
time,O
points,O
after,O
administration,O
of,O
tropicamide,B
and,O
pilocarpine,B
;,O
scopolamine,B
-,O
induced,O
impairment,O
in,O
word,O
recall,O
.,O
RESULTS,O
:,O
There,O
was,O
no,O
significant,O
difference,O
between,O
elderly,O
and,O
young,O
volunteers,O
in,O
pupillary,O
response,O
to,O
tropicamide,B
at,O
any,O
time,O
point,O
(,O
p,O
>,O
0,O
.,O
5,O
),O
.,O
The,O
elderly,O
group,O
had,O
a,O
significantly,O
greater,O
pilocarpine,B
-,O
induced,O
net,O
decrease,O
in,O
pupil,O
size,O
85,O
",",O
125,O
",",O
165,O
and,O
215,O
minutes,O
after,O
administration,O
",",O
compared,O
with,O
the,O
young,O
group,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
.,O
Compared,O
with,O
the,O
young,O
group,O
",",O
the,O
elderly,O
group,O
had,O
greater,O
scopolamine,B
-,I
induced,O
impairment,O
in,O
word,O
recall,O
60,O
",",O
90,O
and,O
120,O
minutes,O
after,O
administration,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
.,O
CONCLUSION,O
:,O
There,O
is,O
an,O
age,O
-,O
related,O
pupillary,O
response,O
to,O
pilocarpine,B
that,O
is,O
not,O
found,O
with,O
tropicamide,B
.,O
Thus,O
",",O
pilocarpine,B
may,O
be,O
useful,O
to,O
assess,O
variations,O
in,O
central,O
cholinergic,O
function,O
in,O
elderly,O
patients,O
.,O
Pain,B
responses,O
in,O
methadone,B
-,O
maintained,O
opioid,B
abusers,O
.,O
Providing,O
pain,O
management,O
for,O
known,O
opioid,B
abusers,O
is,O
a,O
challenging,O
clinical,O
task,O
",",O
in,O
part,O
because,O
little,O
is,O
known,O
about,O
their,O
pain,O
experience,O
and,O
analgesic,O
requirements,O
.,O
This,O
study,O
was,O
designed,O
to,O
describe,O
pain,O
tolerance,O
and,O
analgesic,O
response,O
in,O
a,O
sample,O
of,O
opioid,B
addicts,O
stabilized,O
in,O
methadone,B
-,O
maintenance,O
(,O
MM,O
),O
treatment,O
(,O
n,O
=,O
60,O
),O
in,O
comparison,O
to,O
matched,O
nondependent,O
control,O
subjects,O
(,O
n,O
=,O
60,O
),O
.,O
By,O
using,O
a,O
placebo,B
-,O
controlled,O
",",O
two,O
-,O
way,O
factorial,O
design,O
",",O
tolerance,O
to,O
cold,B
-,I
pressor,I
(,O
CP,B
),O
pain,O
was,O
examined,O
",",O
both,O
before,O
and,O
after,O
oral,O
administration,O
of,O
therapeutic,O
doses,O
of,O
common,O
opioid,B
(,O
hydromorphone,B
2,O
mg,O
),O
and,O
nonsteroidal,B
anti,I
-,I
inflammatory,I
(,O
ketorolac,B
10,O
mg,O
),O
analgesic,O
agents,O
.,O
Results,O
showed,O
that,O
MM,O
individuals,O
were,O
significantly,O
less,O
tolerant,O
of,O
CP,B
pain,O
than,O
control,O
subjects,O
",",O
replicating,O
previous,O
work,O
.,O
Analgesic,O
effects,O
were,O
significant,O
neither,O
for,O
medication,O
nor,O
group,O
.,O
These,O
data,O
indicate,O
that,O
MM,O
opioid,B
abusers,O
represent,O
a,O
pain,O
-,O
intolerant,O
subset,O
of,O
clinical,O
patients,O
.,O
Their,O
complaints,O
of,O
pain,O
should,O
be,O
evaluated,O
seriously,O
and,O
managed,O
aggressively,O
.,O
High,O
-,O
dose,O
methylprednisolone,B
may,O
do,O
more,O
harm,O
for,O
spinal,O
cord,O
injury,O
.,O
Because,O
of,O
the,O
National,B
Acute,I
Spinal,I
Cord,I
Injury,I
Studies,I
(,O
NASCIS,B
),O
",",O
high,O
-,O
dose,O
methylprednisolone,B
became,O
the,O
standard,O
of,O
care,O
for,O
the,O
acute,O
spinal,O
cord,O
injury,O
.,O
In,O
the,O
NASCIS,B
",",O
there,O
was,O
no,O
mention,O
regarding,O
the,O
possibility,O
of,O
acute,O
corticosteroid,B
myopathy,I
that,O
high,O
-,O
dose,O
methylprednisolone,O
may,O
cause,O
.,O
The,O
dosage,O
of,O
methylprednisolone,B
recommended,O
by,O
the,O
NASCIS,O
3,O
is,O
the,O
highest,O
dose,O
of,O
steroids,B
ever,O
being,O
used,O
during,O
a,O
2,O
-,O
day,O
period,O
for,O
any,O
clinical,O
condition,O
.,O
We,O
hypothesize,O
that,O
it,O
may,O
cause,O
some,O
damage,O
to,O
the,O
muscle,O
of,O
spinal,O
cord,O
injury,O
patients,O
.,O
Further,O
",",O
steroid,B
myopathy,I
recovers,O
naturally,O
and,O
the,O
neurological,O
improvement,O
shown,O
in,O
the,O
NASCIS,O
may,O
be,O
just,O
a,O
recording,O
of,O
this,O
natural,O
motor,O
recovery,O
from,O
the,O
steroid,B
myopathy,I
",",O
instead,O
of,O
any,O
protection,O
that,O
methylprednisolone,B
offers,O
to,O
the,O
spinal,O
cord,O
injury,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
discussion,O
considering,O
the,O
possibility,O
that,O
the,O
methylprednisolone,B
recommended,O
by,O
NASCIS,O
may,O
cause,O
acute,O
corticosteroid,O
myopathy,O
.,O
Conversion,O
to,O
rapamycin,B
immunosuppression,O
in,O
renal,O
transplant,O
recipients,O
:,O
report,O
of,O
an,O
initial,O
experience,O
.,O
BACKGROUND,O
:,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
evaluate,O
the,O
effects,O
of,O
RAPA,B
conversion,O
in,O
patients,O
undergoing,O
cyclosporine,B
(,O
CsA,O
),O
or,O
tacrolimus,B
(,O
Tac,O
),O
toxicity,O
.,O
METHODS,O
:,O
Twenty,O
renal,O
transplant,O
recipients,O
were,O
switched,O
to,O
fixed,O
dose,O
rapamycin,B
(,O
RAPA,B
),O
(,O
5,O
mg,O
/,O
day,O
),O
0,O
to,O
204,O
months,O
posttransplant,O
.,O
Drug,O
monitoring,O
was,O
not,O
initially,O
used,O
to,O
adjust,O
doses,O
.,O
The,O
indications,O
for,O
switch,O
were,O
chronic,O
CsA,B
or,O
Tac,B
nephrotoxicity,O
(,O
12,O
),O
",",O
acute,O
CsA,B
or,O
Tac,B
toxicity,O
(,O
3,O
),O
",",O
severe,O
facial,O
dysmorphism,O
(,O
2,O
),O
",",O
posttransplant,O
lymphoproliferative,O
disorder,O
(,O
PTLD,B
),O
in,O
remission,O
(,O
2,O
),O
",",O
and,O
hepatotoxicity,O
in,O
1,O
.,O
Follow,O
-,O
up,O
is,O
7,O
to,O
24,O
months,O
.,O
RESULTS,O
:,O
In,O
the,O
12,O
patients,O
switched,O
because,O
of,O
chronic,O
nephrotoxicity,B
there,O
was,O
a,O
significant,O
decrease,O
in,O
serum,B
creatinine,I
[,O
233,O
+,O
/,O
-,O
34,O
to,O
210,O
+,O
/,O
-,O
56,O
micromol,O
/,O
liter,O
(,O
P,O
<,O
0,O
.,O
5,O
),O
at,O
6,O
months,O
].,O
Facial,O
dysmorphism,O
improved,O
in,O
two,O
patients,O
.,O
No,O
relapse,O
of,O
PTLD,B
was,O
observed,O
.,O
Five,O
patients,O
developed,O
pneumonia,B
(,O
two,O
Pneumocystis,B
carinii,I
pneumonia,I
",",O
one,O
infectious,B
mononucleosis,I
with,O
polyclonal,O
PTLD,B
lung,O
infiltrate,O
),O
and,O
two,O
had,O
bronchiolitis,B
obliterans,I
.,O
There,O
were,O
no,O
deaths,O
.,O
RAPA,O
was,O
discontinued,O
in,O
four,O
patients,O
",",O
because,O
of,O
pneumonia,B
in,O
two,O
",",O
PTLD,B
in,O
one,O
",",O
and,O
oral,O
aphtous,O
ulcers,O
in,O
one,O
.,O
RAPA,B
levels,O
were,O
high,O
(,O
>,O
15,O
ng,O
/,O
ml,O
),O
in,O
7,O
of,O
13,O
(,O
54,O
%,O
),O
patients,O
.,O
CONCLUSIONS,O
:,O
RAPA,B
conversion,O
provides,O
adequate,O
immunosuppression,O
to,O
enable,O
CsA,O
withdrawal,O
.,O
However,O
",",O
when,O
converting,O
patients,O
to,O
RAPA,B
drug,O
levels,O
should,O
be,O
monitored,O
to,O
avoid,O
over,O
-,O
immunosuppression,O
and,O
adequate,O
antiviral,O
and,O
Pneumocystis,B
carinii,I
pneumonia,I
prophylaxis,O
should,O
be,O
given,O
.,O
Electro,B
-,O
oculography,O
",",O
electroretinography,B
",",O
visual,O
evoked,O
potentials,O
",",O
and,O
multifocal,O
electroretinography,B
in,O
patients,O
with,O
vigabatrin,B
-,O
attributed,O
visual,O
field,O
constriction,O
.,O
PURPOSE,O
:,O
Symptomatic,O
visual,O
field,O
constriction,O
thought,O
to,O
be,O
associated,O
with,O
vigabatrin,B
has,O
been,O
reported,O
.,O
The,O
current,O
study,O
investigated,O
the,O
visual,O
fields,O
and,O
visual,O
electrophysiology,O
of,O
eight,O
patients,O
with,O
known,O
vigabatrin,B
-,O
attributed,O
visual,O
field,O
loss,O
",",O
three,O
of,O
whom,O
were,O
reported,O
previously,O
.,O
Six,O
of,O
the,O
patients,O
were,O
no,O
longer,O
receiving,O
vigabatrin,B
.,O
METHODS,O
:,O
The,O
central,O
and,O
peripheral,O
fields,O
were,O
examined,O
with,O
the,O
Humphrey,O
Visual,O
Field,O
Analyzer,O
.,O
Full,O
visual,O
electrophysiology,O
",",O
including,O
flash,O
electroretinography,B
(,O
ERG,I
),O
",",O
pattern,O
electroretinography,B
",",O
multifocal,O
ERG,B
using,O
the,O
VERIS,O
system,O
",",O
electro,O
-,O
oculography,O
",",O
and,O
flash,O
and,O
pattern,O
visual,O
evoked,O
potentials,O
",",O
was,O
undertaken,O
.,O
RESULTS,O
:,O
Seven,O
patients,O
showed,O
marked,O
visual,O
field,O
constriction,O
with,O
some,O
sparing,O
of,O
the,O
temporal,O
visual,O
field,O
.,O
The,O
eighth,O
exhibited,O
concentric,O
constriction,O
.,O
Most,O
electrophysiological,O
responses,O
were,O
usually,O
just,O
within,O
normal,O
limits,O
;,O
two,O
patients,O
had,O
subnormal,O
Arden,B
electro,I
-,I
oculography,I
indices,O
;,O
and,O
one,O
patient,O
showed,O
an,O
abnormally,O
delayed,O
photopic,B
b,I
wave,I
.,O
However,O
",",O
five,O
patients,O
showed,O
delayed,O
30,O
-,O
Hz,O
flicker,O
b,O
waves,O
",",O
and,O
seven,O
patients,O
showed,O
delayed,O
oscillatory,O
potentials,O
.,O
Multifocal,O
ERG,O
showed,O
abnormalities,O
that,O
sometimes,O
correlated,O
with,O
the,O
visual,O
field,O
appearance,O
and,O
confirmed,O
that,O
the,O
deficit,O
occurs,O
at,O
the,O
retinal,O
level,O
.,O
CONCLUSION,O
:,O
Marked,O
visual,O
field,O
constriction,O
appears,O
to,O
be,O
associated,O
with,O
vigabatrin,B
therapy,O
.,O
The,O
field,O
defects,O
and,O
some,O
electrophysiological,O
abnormalities,O
persist,O
when,O
vigabatrin,B
therapy,O
is,O
withdrawn,O
.,O
Myocardial,B
ischemia,O
due,O
to,O
coronary,B
artery,I
spasm,O
during,O
dobutamine,B
stress,I
echocardiography,I
.,O
Dobutamine,B
stress,I
echocardiography,I
(,O
DSE,B
),O
is,O
a,O
useful,O
and,O
safe,O
provocation,O
test,O
for,O
myocardial,B
ischemia,O
.,O
Until,O
now,O
",",O
the,O
test,O
has,O
been,O
focused,O
only,O
on,O
the,O
organic,O
lesion,O
in,O
the,O
coronary,B
artery,I
",",O
and,O
positive,O
DSE,O
has,O
indicated,O
the,O
presence,O
of,O
significant,O
fixed,O
coronary,B
artery,I
stenosis,I
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
is,O
to,O
examine,O
whether,O
myocardial,O
ischemia,O
due,O
to,O
coronary,B
spasm,I
is,O
induced,O
by,O
dobutamine,B
.,O
We,O
performed,O
DSE,O
on,O
51,O
patients,O
with,O
coronary,B
spastic,I
angina,I
but,O
without,O
significant,O
fixed,O
coronary,B
artery,I
stenosis,I
.,O
All,O
patients,O
had,O
anginal,O
attacks,O
at,O
rest,O
with,O
ST,O
elevation,O
on,O
the,O
electrocardiogram,O
(,O
variant,O
angina,O
),O
.,O
Coronary,B
spasm,I
was,O
induced,O
by,O
intracoronary,O
injection,O
of,O
acetylcholine,B
",",O
and,O
no,O
fixed,O
coronary,B
artery,I
stenosis,I
was,O
documented,O
on,O
angiograms,O
in,O
all,O
patients,O
.,O
DSE,O
was,O
performed,O
with,O
intravenous,O
dobutamine,B
infusion,O
with,O
an,O
incremental,O
doses,O
of,O
5,O
",",O
10,O
",",O
20,O
",",O
30,O
",",O
and,O
40,O
microg,B
/,I
kg,I
/,I
min,I
every,O
5,O
minutes,O
.,O
Of,O
the,O
51,O
patients,O
",",O
7,O
patients,O
showed,O
asynergy,O
with,O
ST,B
elevation,O
.,O
All,O
7,O
patients,O
(,O
13,O
.,O
7,O
%,O
),O
had,O
chest,O
pain,O
during,O
asynergy,O
",",O
and,O
both,O
chest,O
pain,O
and,O
electrocardiographic,O
changes,O
were,O
preceded,O
by,O
asynergy,O
.,O
These,O
findings,O
indicate,O
that,O
dobutamine,B
can,O
provoke,O
coronary,B
spasm,O
in,O
some,O
patients,O
with,O
coronary,B
spastic,I
angina,I
.,O
When,O
DSE,O
is,O
performed,O
to,O
evaluate,O
coronary,B
artery,I
disease,I
",",O
not,O
only,O
fixed,O
coronary,B
stenosis,I
",",O
but,O
also,O
coronary,B
spasm,O
should,O
be,O
considered,O
as,O
a,O
genesis,O
of,O
asynergy,O
.,O
Effect,O
of,O
intravenous,O
metoprolol,B
or,O
intravenous,O
metoprolol,B
plus,O
glucagon,B
on,O
dobutamine,B
-,O
induced,O
myocardial,O
ischemia,O
.,O
STUDY,O
OBJECTIVE,O
:,O
To,O
determine,O
the,O
effect,O
of,O
metoprolol,B
on,O
dobutamine,O
stress,O
testing,O
with,O
technetium,B
-,I
99m,I
sestamibi,I
single,O
-,O
photon,O
emission,O
computed,O
tomography,O
imaging,O
and,O
ST,B
-,I
segment,I
monitoring,I
",",O
and,O
to,O
assess,O
the,O
impact,O
of,O
intravenous,O
glucagon,B
on,O
metoprolol,O
',O
s,O
effects,O
.,O
DESIGN,O
:,O
Randomized,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
.,O
SETTING,O
:,O
Community,O
hospital,O
.,O
PATIENTS,O
:,O
Twenty,O
-,O
two,O
patients,O
with,O
known,O
reversible,O
perfusion,O
defects,O
.,O
INTERVENTION,O
:,O
Patients,O
underwent,O
dobutamine,B
stress,I
tests,I
per,O
standard,O
protocol,O
.,O
Before,O
dobutamine,B
was,O
begun,O
",",O
no,O
therapy,O
was,O
given,O
during,O
the,O
first,O
visit,O
",",O
and,O
patients,O
were,O
randomized,O
on,O
subsequent,O
visits,O
to,O
receive,O
metoprolol,B
or,O
metoprolol,B
plus,O
glucagon,B
1,O
mg,O
.,O
Metoprolol,B
was,O
dosed,O
to,O
achieve,O
a,O
resting,O
predobutamine,O
heart,O
rate,O
below,O
65,O
beats,O
/,O
minute,O
or,O
a,O
total,O
intravenous,O
dose,O
of,O
20,O
mg,O
.,O
MEASUREMENTS,O
AND,O
MAIN,O
RESULTS,O
:,O
Metoprolol,B
reduced,O
maximum,O
heart,O
rate,O
31,O
%,O
",",O
summed,O
stress,O
scores,O
29,O
%,O
",",O
and,O
summed,O
difference,O
scores,O
43,O
%,O
versus,O
control,O
.,O
Metoprolol,B
plus,O
glucagon,B
also,O
reduced,O
the,O
maximum,O
heart,O
rate,O
29,O
%,O
versus,O
control,O
.,O
Summed,O
stress,O
and,O
summed,O
difference,O
scores,O
were,O
not,O
significantly,O
reduced,O
",",O
although,O
they,O
were,O
18,O
%,O
and,O
30,O
%,O
lower,O
",",O
respectively,O
",",O
than,O
control,O
.,O
No,O
significant,O
differences,O
were,O
found,O
in,O
any,O
parameter,O
between,O
metoprolol,B
and,O
metoprolol,B
-,O
glucagon,B
.,O
CONCLUSION,O
:,O
During,O
dobutamine,O
stress,O
testing,O
",",O
metoprolol,B
attenuates,O
or,O
eliminates,O
evidence,O
of,O
myocardial,O
ischemia,O
.,O
Glucagon,B
1,O
mg,O
",",O
although,O
somewhat,O
effective,O
",",O
does,O
not,O
correct,O
this,O
effect,O
to,O
the,O
extent,O
that,O
it,O
can,O
be,O
administered,O
clinically,O
.,O
Evidence,O
of,O
functional,O
somatotopy,O
in,O
GPi,B
from,O
results,O
of,O
pallidotomy,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
explore,O
the,O
functional,O
anatomy,O
of,O
the,O
globus,O
pallidus,O
internus,O
(,O
GPi,B
),O
by,O
studying,O
the,O
effects,O
of,O
unilateral,O
pallidotomy,O
on,O
parkinsonian,O
',O
off,O
',O
signs,O
and,O
levodopa,B
-,O
induced,O
dyskinesias,O
(,O
LID,B
),O
.,O
We,O
found,O
significant,O
positive,O
correlations,O
between,O
the,O
preoperative,O
levodopa,B
responsiveness,O
of,O
motor,O
signs,O
and,O
the,O
levodopa,B
responsiveness,O
of,O
scores,O
in,O
timed,O
tests,O
(,O
Core,B
Assessment,I
Program,I
for,I
Intracerebral,I
Transplantations,I
),O
in,O
the,O
contralateral,O
limbs,O
and,O
the,O
improvement,O
in,O
these,O
scores,O
after,O
surgery,O
",",O
whereas,O
there,O
was,O
no,O
correlation,O
with,O
the,O
improvement,O
in,O
LID,B
.,O
We,O
also,O
found,O
a,O
highly,O
significant,O
correlation,O
(,O
P,B
:,O
<,O
0,O
.,O
1,O
",",O
r,O
=,O
0,O
.,O
8,O
),O
between,O
the,O
volume,O
of,O
the,O
ventral,O
lesion,O
in,O
the,O
GPi,B
and,O
the,O
improvement,O
in,O
LID,B
in,O
the,O
contralateral,O
limbs,O
",",O
whereas,O
there,O
was,O
no,O
correlation,O
between,O
the,O
ventral,O
volume,O
and,O
the,O
improvement,O
in,O
parkinsonian,O
',O
off,O
',O
signs,O
.,O
The,O
volumes,O
of,O
the,O
total,O
lesion,O
cylinder,O
and,O
the,O
dorsal,O
lesion,O
did,O
not,O
correlate,O
with,O
the,O
outcome,O
of,O
either,O
dyskinesias,B
or,O
parkinsonian,O
',O
off,O
',O
signs,O
.,O
The,O
differential,O
predictive,O
value,O
of,O
levodopa,B
responsiveness,O
for,O
the,O
outcome,O
of,O
parkinsonian,O
',O
off,O
',O
signs,O
and,O
LID,B
and,O
the,O
different,O
correlations,O
of,O
ventral,O
lesion,O
volume,O
with,O
dyskinesias,B
and,O
parkinsonian,O
',O
off,O
',O
signs,O
indicate,O
that,O
different,O
anatomical,O
or,O
pathophysiological,O
substrates,O
may,O
be,O
responsible,O
for,O
the,O
generation,O
of,O
parkinsonian,O
',O
off,O
',O
signs,O
and,O
dyskinesias,B
.,O
Whereas,O
cells,O
in,O
a,O
wider,O
area,O
of,O
the,O
GPi,B
may,O
be,O
implicated,O
in,O
parkinsonism,O
",",O
the,O
ventral,O
GPi,B
seems,O
to,O
be,O
crucial,O
for,O
the,O
manifestation,O
of,O
LID,B
.,O
We,O
suggest,O
that,O
our,O
observations,O
are,O
additional,O
proof,O
of,O
the,O
functional,O
somatotopy,O
of,O
the,O
systems,O
within,O
the,O
GPi,B
that,O
mediate,O
parkinsonism,O
and,O
dyskinesias,O
",",O
especially,O
along,O
the,O
dorsoventral,O
trajectory,O
used,O
in,O
pallidotomy,B
.,O
The,O
outcome,O
of,O
pallidotomy,O
in,O
which,O
the,O
lesion,O
involves,O
the,O
ventral,O
and,O
dorsal,O
GPi,B
could,O
be,O
the,O
net,O
effect,O
of,O
alteration,O
in,O
the,O
activity,O
of,O
pathways,O
which,O
mediate,O
different,O
symptoms,O
",",O
and,O
hence,O
could,O
be,O
variable,O
.,O
Screening,O
for,O
stimulant,O
use,O
in,O
adult,O
emergency,O
department,O
seizure,O
patients,O
.,O
OBJECTIVE,O
:,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
the,O
prevalence,O
of,O
positive,O
plasma,O
drug,O
screening,O
for,O
cocaine,B
or,O
amphetamine,B
in,O
adult,O
emergency,O
department,O
seizure,O
patients,O
.,O
METHODS,O
:,O
This,O
prospective,O
study,O
evaluated,O
consecutive,O
eligible,O
seizure,O
patients,O
who,O
had,O
a,O
plasma,O
sample,O
collected,O
as,O
part,O
of,O
their,O
clinical,O
evaluation,O
.,O
Plasma,O
was,O
tested,O
for,O
amphetamine,B
and,O
the,O
cocaine,B
metabolite,I
benzoylecgonine,I
using,O
enzyme,O
-,O
mediated,O
immunoassay,O
methodology,O
.,O
Plasma,O
samples,O
with,O
benzoylecgonine,B
greater,O
than,O
150,O
ng,O
/,O
mL,O
or,O
an,O
amphetamine,B
greater,O
than,O
500,O
ng,O
/,O
mL,O
were,O
defined,O
as,O
positive,O
.,O
Patient,O
demographics,O
",",O
history,O
of,O
underlying,O
drug,B
or,O
alcohol,B
-,O
related,O
seizure,O
disorder,O
",",O
estimated,O
time,O
from,O
seizure,O
to,O
sample,O
collection,O
",",O
history,O
or,O
suspicion,O
of,O
cocaine,B
or,O
amphetamine,B
abuse,O
",",O
results,O
of,O
clinical,O
urine,O
testing,O
for,O
drugs,O
of,O
abuse,O
",",O
and,O
assay,O
results,O
were,O
recorded,O
without,O
patient,O
identifiers,O
.,O
RESULTS,O
:,O
Fourteen,O
of,O
248,O
(,O
5,O
.,O
6,O
%,O
",",O
95,O
%,O
CI,O
2,O
.,O
7,O
%,O
-,O
8,O
%,O
),O
plasma,O
samples,O
were,O
positive,O
by,O
immunoassay,O
testing,O
for,O
benzoylecgonine,B
and,O
no,O
samples,O
(,O
0,O
%,O
",",O
95,O
%,O
CI,O
0,O
-,O
1,O
.,O
2,O
%,O
),O
were,O
positive,O
for,O
amphetamine,B
.,O
Positive,O
test,O
results,O
were,O
more,O
common,O
in,O
patient,O
visits,O
where,O
there,O
was,O
a,O
history,O
or,O
suspicion,O
of,O
cocaine,O
or,O
amphetamine,O
abuse,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
.,O
CONCLUSIONS,O
:,O
During,O
this,O
study,O
period,O
",",O
routine,O
plasma,O
screening,O
for,O
cocaine,B
and,O
amphetamines,B
in,O
adult,O
seizure,O
patients,O
had,O
a,O
low,O
yield,O
.,O
As,O
a,O
result,O
",",O
routine,O
plasma,O
screening,O
would,O
yield,O
few,O
cases,O
of,O
stimulant,O
drug,O
in,O
which,O
there,O
was,O
neither,O
a,O
history,O
nor,O
suspicion,O
of,O
drug,O
abuse,O
in,O
this,O
population,O
.,O
Contribution,O
of,O
sodium,B
valproate,I
to,O
the,O
syndrome,O
of,O
inappropriate,O
secretion,O
of,O
antidiuretic,B
hormone,I
.,O
We,O
report,O
the,O
case,O
of,O
a,O
62,O
-,O
year,O
-,O
old,O
man,O
who,O
was,O
administered,O
sodium,B
valproate,I
(,O
VPA,B
),O
and,O
who,O
subsequently,O
developed,O
the,O
syndrome,O
of,O
inappropriate,O
secretion,O
of,O
antidiuretic,B
hormone,I
(,O
SIADH,B
),O
.,O
He,O
had,O
been,O
taking,O
VPA,B
for,O
treatment,O
of,O
idiopathic,O
generalized,O
tonic,O
-,O
clonic,O
convulsions,O
since,O
he,O
was,O
56,O
years,O
old,O
.,O
After,O
substituting,O
VPA,B
with,O
zonisamide,B
",",O
the,O
serum,O
sodium,B
level,I
returned,O
to,O
normal,O
.,O
We,O
consider,O
this,O
episode,O
of,O
SIADH,B
to,O
be,O
the,O
result,O
of,O
a,O
combination,O
of,O
factors,O
including,O
a,O
weakness,O
of,O
the,O
central,O
nervous,O
system,O
and,O
the,O
long,O
-,O
term,O
administration,O
of,O
VPA,B
.,O
Association,O
of,O
nitric,B
oxide,I
production,O
and,O
apoptosis,O
in,O
a,O
model,O
of,O
experimental,O
nephropathy,B
.,O
BACKGROUND,O
:,O
In,O
recent,O
studies,O
increased,O
amounts,O
of,O
nitric,B
oxide,I
(,O
NO,B
),O
and,O
apoptosis,O
have,O
been,O
implicated,O
in,O
various,O
pathological,O
conditions,O
in,O
the,O
kidney,O
.,O
We,O
have,O
studied,O
the,O
role,O
of,O
NO,B
and,O
its,O
association,O
with,O
apoptosis,O
in,O
an,O
experimental,O
model,O
of,O
nephrotic,O
syndrome,O
induced,O
by,O
a,O
single,O
injection,O
of,O
adriamycin,B
(,O
ADR,B
),O
.,O
METHODS,O
:,O
The,O
alteration,O
in,O
the,O
NO,B
pathway,O
was,O
assessed,O
by,O
measuring,O
nitrite,B
levels,O
in,O
serum,O
/,O
urine,O
and,O
by,O
evaluating,O
the,O
changes,O
in,O
vascular,O
reactivity,O
of,O
the,O
isolated,O
perfused,O
rat,O
kidney,O
(,O
IPRK,O
),O
system,O
.,O
Rats,O
were,O
stratified,O
into,O
control,O
groups,O
and,O
ADR,O
-,O
induced,O
nephropathy,O
groups,O
.,O
These,O
two,O
groups,O
were,O
then,O
divided,O
into,O
:,O
group,O
1,O
",",O
animals,O
receiving,O
saline,O
;,O
and,O
group,O
2,O
",",O
animals,O
receiving,O
aminoguanidine,B
(,O
AG,O
),O
which,O
is,O
a,O
specific,O
inhibitor,O
of,O
inducible,O
-,O
NO,B
synthase,O
.,O
On,O
day,O
21,O
",",O
rats,O
were,O
sacrificed,O
after,O
obtaining,O
material,O
for,O
biochemical,O
analysis,O
.,O
RESULTS,O
:,O
Histopathological,O
examination,O
of,O
the,O
kidneys,O
of,O
rats,O
treated,O
with,O
ADR,B
revealed,O
focal,O
areas,O
of,O
mesangial,O
proliferation,O
and,O
mild,O
tubulointerstitial,O
inflammation,O
.,O
They,O
also,O
had,O
significantly,O
higher,O
levels,O
of,O
proteinuria,B
compared,O
with,O
control,O
and,O
treatment,O
groups,O
(,O
P,B
<,O
0,O
.,O
5,O
),O
.,O
Urine,O
nitrite,B
levels,O
were,O
significantly,O
increased,O
in,O
the,O
ADR,B
-,O
nephropathy,I
group,O
(,O
P,O
<,O
0,O
.,O
5,O
),O
.,O
In,O
the,O
IPRK,O
phenylephrine,B
and,O
acetylcholine,B
related,O
responses,O
were,O
significantly,O
impaired,O
in,O
the,O
ADR,B
-,O
nephropathy,I
group,O
.,O
Apoptosis,O
was,O
not,O
detected,O
in,O
controls,O
.,O
However,O
",",O
in,O
the,O
ADR,B
-,O
nephropathy,I
group,O
",",O
numerous,O
apoptotic,O
cells,O
were,O
identified,O
in,O
the,O
tubulointerstitial,O
areas,O
.,O
Double,O
staining,O
revealed,O
numerous,O
interstitial,O
apoptotic,B
cells,O
to,O
stain,O
for,O
ED1,B
",",O
a,O
marker,O
for,O
monocytes,B
/,O
macrophages,I
.,O
Treatment,O
with,O
AG,B
prevented,O
the,O
impairment,O
of,O
renal,O
vascular,O
bed,O
responses,O
and,O
reduced,O
both,O
urine,O
nitrite,B
levels,O
and,O
apoptosis,B
to,O
control,O
levels,O
.,O
CONCLUSION,O
:,O
We,O
suggest,O
that,O
interactions,O
between,O
NO,B
and,O
apoptosis,B
are,O
important,O
in,O
the,O
pathogenesis,O
of,O
the,O
ADR,B
-,O
induced,O
nephrosis,O
.,O
Dual,O
effects,O
of,O
melatonin,B
on,O
barbiturate,B
-,I
induced,I
narcosis,I
in,O
rats,O
.,O
Melatonin,B
affects,O
the,O
circadian,O
sleep,O
/,O
wake,O
cycle,O
",",O
but,O
it,O
is,O
not,O
clear,O
whether,O
it,O
may,O
influence,O
drug,O
-,O
induced,O
narcosis,O
.,O
Sodium,B
thiopenthal,I
was,O
administered,O
intraperitoneally,O
into,O
male,O
rats,O
pre,O
-,O
treated,O
with,O
melatonin,B
(,O
0,O
.,O
5,O
",",O
0,O
.,O
5,O
",",O
5,O
and,O
50,B
mg,I
/,I
kg,I
),O
.,O
Melatonin,B
pre,O
-,O
treatment,O
affected,O
in,O
a,O
dual,O
manner,O
barbiturate,B
narcosis,I
",",O
however,O
",",O
no,O
dose,O
-,O
effect,O
correlation,O
was,O
found,O
.,O
In,O
particular,O
",",O
low,O
doses,O
reduced,O
the,O
latency,O
to,O
and,O
prolonged,O
the,O
duration,O
of,O
barbiturate,B
narcosis,I
.,O
In,O
contrast,O
",",O
the,O
highest,O
dose,O
of,O
melatonin,B
(,O
50,B
mg,I
/,I
kg,I
),O
caused,O
a,O
paradoxical,O
increase,O
in,O
the,O
latency,O
and,O
produced,O
a,O
sustained,O
reduction,O
of,O
the,O
duration,O
of,O
narcosis,O
",",O
and,O
a,O
reduction,O
in,O
mortality,O
rate,O
.,O
Melatonin,B
0,O
.,O
5,O
and,O
5,O
mg,O
/,O
kg,O
influenced,O
the,O
duration,O
but,O
not,O
the,O
latency,O
of,O
ketamine,B
-,O
or,O
diazepam,B
-,O
induced,O
narcosis,O
.,O
Thus,O
",",O
the,O
dual,O
action,O
of,O
melatonin,B
on,O
pharmacological,O
narcosis,O
seems,O
to,O
be,O
specific,O
for,O
the,O
barbiturate,O
mechanism,O
of,O
action,O
.,O
Reduced,O
cardiotoxicity,O
and,O
preserved,O
antitumor,O
efficacy,O
of,O
liposome,B
-,O
encapsulated,O
doxorubicin,B
and,O
cyclophosphamide,B
compared,O
with,O
conventional,O
doxorubicin,B
and,O
cyclophosphamide,B
in,O
a,O
randomized,O
",",O
multicenter,O
trial,O
of,O
metastatic,O
breast,O
cancer,O
.,O
PURPOSE,O
:,O
To,O
determine,O
whether,O
Myocet,B
(,O
liposome,B
-,I
encapsulated,I
doxorubicin,I
;,O
The,O
Liposome,B
Company,I
",",O
Elan,B
Corporation,I
",",O
Princeton,B
",",O
NJ,B
),O
in,O
combination,O
with,O
cyclophosphamide,B
significantly,O
reduces,O
doxorubicin,B
cardiotoxicity,O
while,O
providing,O
comparable,O
antitumor,O
efficacy,O
in,O
first,O
-,O
line,O
treatment,O
of,O
metastatic,O
breast,O
cancer,O
(,O
MBC,B
),O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
Two,O
hundred,O
ninety,O
-,O
seven,O
patients,O
with,O
MBC,B
and,O
no,O
prior,O
chemotherapy,O
for,O
metastatic,O
disease,O
were,O
randomized,O
to,O
receive,O
either,O
60,O
mg,O
/,O
m,O
(,O
2,O
),O
of,O
Myocet,B
(,O
M,B
),O
or,O
conventional,O
doxorubicin,B
(,O
A,B
),O
",",O
in,O
combination,O
with,O
600,O
mg,O
/,O
m,O
(,O
2,O
),O
of,O
cyclophosphamide,B
(,O
C,B
),O
",",O
every,O
3,O
weeks,O
until,O
disease,O
progression,O
or,O
unacceptable,O
toxicity,O
.,O
Cardiotoxicity,O
was,O
defined,O
by,O
reductions,O
in,O
left,B
-,I
ventricular,I
ejection,I
fraction,I
",",O
assessed,O
by,O
serial,O
multigated,O
radionuclide,O
angiography,O
scans,O
",",O
or,O
congestive,B
heart,I
failure,I
(,O
CHF,B
),O
.,O
Antitumor,O
efficacy,O
was,O
assessed,O
by,O
objective,O
tumor,B
response,I
rates,I
(,O
World,B
Health,I
Organization,I
criteria,I
),O
",",O
time,O
to,O
progression,O
",",O
and,O
survival,O
.,O
RESULTS,O
:,O
Six,O
percent,O
of,O
MC,O
patients,O
versus,O
21,O
%,O
(,O
including,O
five,O
cases,O
of,O
CHF,O
),O
developed,O
cardiotoxicity,O
(,O
P,O
=,O
.,O
2,O
),O
.,O
Median,O
cumulative,O
doxorubicin,B
dose,O
at,O
onset,O
was,O
more,O
than,O
2,O
",",O
220,O
mg,O
/,O
m,O
(,O
2,O
),O
for,O
MC,O
versus,O
480,O
mg,O
/,O
m,O
(,O
2,O
),O
for,O
AC,O
(,O
P,O
=,O
.,O
1,O
",",O
hazard,O
ratio,O
",",O
5,O
.,O
4,O
),O
.,O
MC,O
patients,O
also,O
experienced,O
less,O
grade,O
4,O
neutropenia,O
.,O
Antitumor,O
efficacy,O
of,O
MC,B
versus,O
AC,B
was,O
comparable,O
:,O
objective,O
response,O
rates,O
",",O
43,O
%,O
versus,O
43,O
%,O
;,O
median,O
time,O
to,O
progression,O
",",O
5,O
.,O
1,O
%,O
versus,O
5,O
.,O
5,O
months,O
;,O
median,O
time,O
to,O
treatment,O
failure,O
",",O
4,O
.,O
6,O
versus,O
4,O
.,O
4,O
months,O
;,O
and,O
median,O
survival,O
",",O
19,O
versus,O
16,O
months,O
.,O
CONCLUSION,O
:,O
Myocet,B
improves,O
the,O
therapeutic,O
index,O
of,O
doxorubicin,B
by,O
significantly,O
reducing,O
cardiotoxicity,O
and,O
grade,O
4,O
neutropenia,B
and,O
provides,O
comparable,O
antitumor,O
efficacy,O
",",O
when,O
used,O
in,O
combination,O
with,O
cyclophosphamide,B
as,O
first,O
-,O
line,O
therapy,O
for,O
MBC,O
.,O
The,O
role,O
of,O
nitrergic,B
system,O
in,O
lidocaine,B
-,I
induced,I
convulsion,I
in,O
the,O
mouse,O
.,O
The,O
effects,O
of,O
N,B
-,I
nitro,I
-,I
L,I
-,I
arginine,I
-,I
methyl,I
ester,I
(,O
L,B
-,I
NAME,I
),O
a,O
nitric,B
oxide,I
(,O
NO,B
),O
synthase,O
inhibitor,O
and,O
L,B
-,I
arginine,I
",",O
a,O
NO,B
precursor,O
",",O
were,O
investigated,O
on,O
lidocaine,B
-,I
induced,I
convulsions,I
.,O
In,O
the,O
first,O
experiment,O
",",O
four,O
groups,O
of,O
mice,O
received,O
physiological,O
saline,B
(,O
0,O
.,O
9,O
%,O
),O
",",O
L,B
-,I
arginine,I
(,O
300,O
mg,O
/,O
kg,O
",",O
i,O
.,O
p,O
.,O
),O
",",O
L,B
-,I
NAME,I
(,O
100,O
mg,O
/,O
kg,O
",",O
i,O
.,O
p,O
.,O
),O
and,O
diazepam,B
(,O
2,O
mg,O
/,O
kg,O
),O
",",O
respectively,O
.,O
Thirty,O
minutes,O
after,O
these,O
injections,O
",",O
all,O
mice,O
received,O
lidocaine,B
(,O
50,O
mg,O
/,O
kg,O
",",O
i,O
.,O
p,O
.,O
),O
.,O
In,O
the,O
second,O
experiment,O
",",O
four,O
groups,O
of,O
mice,O
received,O
similar,O
treatment,O
in,O
the,O
first,O
experiment,O
",",O
and,O
30,O
min,O
after,O
these,O
injections,O
",",O
all,O
mice,O
received,O
a,O
higher,O
dose,O
of,O
lidocaine,B
(,O
80,O
mg,O
/,O
kg,O
),O
.,O
L,B
-,I
NAME,I
(,O
100,O
mg,O
/,O
kg,O
",",O
i,O
.,O
p,O
.,O
),O
and,O
diazepam,B
(,O
2,O
mg,O
/,O
kg,O
),O
significantly,O
decreased,O
the,O
incidence,O
of,O
lidocaine,B
(,O
50,O
mg,O
/,O
kg,O
),O
-,O
induced,O
convulsions,O
.,O
In,O
contrast,O
",",O
the,O
L,B
-,I
arginine,I
treatment,O
increased,O
the,O
incidence,O
of,O
lidocaine,B
(,O
80,O
mg,O
/,O
kg,O
",",O
i,O
.,O
p,O
.,O
),O
-,O
induced,O
convulsions,O
significantly,O
.,O
These,O
results,O
may,O
suggest,O
that,O
NO,B
is,O
a,O
proconvulsant,O
mediator,O
in,O
lidocaine,B
-,O
induced,O
convulsions,O
.,O
Erythropoietin,B
restores,O
the,O
anemia,B
-,O
induced,O
reduction,O
in,O
cyclophosphamide,B
cytotoxicity,O
in,O
rat,O
tumors,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
examine,O
the,O
impact,O
of,O
anemia,B
prevention,O
by,O
recombinant,O
human,O
erythropoietin,B
(,O
rHuEPO,O
),O
treatment,O
on,O
the,O
cytotoxicity,O
of,O
cyclophosphamide,B
in,O
solid,O
experimental,O
tumors,O
.,O
Anemia,B
was,O
induced,O
using,O
a,O
single,O
dose,O
of,O
carboplatin,B
(,O
50,O
mg,O
/,O
kg,O
i,O
.,O
v.,O
).,O
resulting,O
in,O
a,O
long,O
-,O
lasting,O
reduction,O
(,O
30,O
%,O
),O
of,O
the,O
hemoglobin,B
concentration,O
.,O
In,O
a,O
second,O
group,O
",",O
the,O
development,O
of,O
anemia,B
was,O
prevented,O
by,O
rHuEPO,B
(,O
1000,O
IU,O
/,O
kg,O
),O
administered,O
s.,O
c.,O
three,O
times,O
/,O
week,O
starting,O
7,O
days,O
before,O
carboplatin,O
application,O
.,O
Four,O
days,O
after,O
carboplatin,O
treatment,O
",",O
tumors,O
(,O
DS,B
-,I
sarcoma,I
of,I
the,I
rat,I
),O
were,O
implanted,O
s.,O
c.,O
onto,O
the,O
hind,O
food,O
dorsum,O
.,O
Neither,O
carboplatin,B
nor,O
rHuEPO,B
treatment,O
influenced,O
tumor,O
growth,O
rate,O
per,O
se,O
.,O
When,O
tumors,O
were,O
treated,O
with,O
a,O
single,O
dose,O
of,O
cyclophosphamide,B
(,O
60,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
5,O
days,O
after,O
implantation,O
",",O
a,O
growth,O
delay,O
with,O
a,O
subsequent,O
regrowth,O
of,O
the,O
tumors,O
was,O
observed,O
.,O
In,O
the,O
anemia,O
group,O
",",O
the,O
growth,O
delay,O
was,O
significantly,O
shorter,O
compared,O
with,O
nonanemic,O
controls,O
(,O
13,O
.,O
3,O
days,O
versus,O
8,O
.,O
6,O
days,O
)-7,O
.,O
In,O
the,O
group,O
where,O
anemia,B
was,O
prevented,O
by,O
rHuEPO,B
treatment,O
",",O
growth,O
delay,O
was,O
comparable,O
with,O
that,O
of,O
nonanemic,O
controls,O
(,O
13,O
.,O
3,O
days,O
)-34,O
.,O
These,O
results,O
suggest,O
that,O
chemotherapy,O
-,O
induced,O
anemia,B
reduces,O
cytotoxicity,O
of,O
cyclophosphamide,B
in,O
tumors,O
",",O
whereas,O
correction,O
of,O
anemia,B
by,O
rHuEPO,B
treatment,O
(,O
epoetin,B
alpha,I
),O
increases,O
the,O
sensitivity,O
",",O
probably,O
as,O
a,O
result,O
of,O
an,O
improved,O
oxygen,B
supply,O
to,O
tumor,O
tissue,O
.,O
Fatal,O
haemorrhagic,O
myocarditis,O
secondary,O
to,O
cyclophosphamide,B
therapy,O
.,O
Haemorrhagic,O
myocarditis,O
is,O
a,O
rare,O
but,O
important,O
complication,O
of,O
cyclophosphamide,B
therapy,O
.,O
Echocardiographic,O
identification,O
of,O
the,O
disorder,O
can,O
be,O
made,O
.,O
We,O
believe,O
that,O
the,O
ultrasound,O
features,O
of,O
this,O
disorder,O
have,O
not,O
been,O
previously,O
reported,O
.,O
Effects,O
of,O
verapamil,B
on,O
atrial,O
fibrillation,O
and,O
its,O
electrophysiological,O
determinants,O
in,O
dogs,O
.,O
BACKGROUND,O
:,O
Atrial,O
tachycardia,O
-,O
induced,O
remodeling,O
promotes,O
the,O
occurrence,O
and,O
maintenance,O
of,O
atrial,O
fibrillation,O
(,O
AF,B
),O
and,O
decreases,O
L,O
-,O
type,O
Ca,B
(,O
2,O
+,O
),O
current,O
.,O
There,O
is,O
also,O
a,O
clinical,O
suggestion,O
that,O
acute,O
L,O
-,O
type,O
Ca,B
(,O
2,O
),O
channel,O
blockade,O
can,O
promote,O
AF,B
",",O
consistent,O
with,O
an,O
AF,B
promoting,O
effect,O
of,O
Ca,B
(,O
2,O
+,O
),O
channel,O
inhibition,O
.,O
METHODS,O
:,O
To,O
evaluate,O
the,O
potential,O
mechanisms,O
of,O
AF,O
promotion,O
by,O
Ca,B
(,O
2,I
+,I
),O
channel,O
blockers,O
",",O
we,O
administered,O
verapamil,B
to,O
morphine,O
-,O
chloralose,O
anesthetized,O
dogs,O
.,O
Diltiazem,B
was,O
used,O
as,O
a,O
comparison,O
drug,O
and,O
autonomic,O
blockade,O
with,O
atropine,B
and,O
nadolol,B
was,O
applied,O
in,O
some,O
experiments,O
.,O
Epicardial,O
mapping,O
with,O
240,O
epicardial,O
electrodes,O
was,O
used,O
to,O
evaluate,O
activation,O
during,O
AF,O
.,O
RESULTS,O
:,O
Verapamil,B
caused,O
AF,B
promotion,O
in,O
six,O
dogs,O
",",O
increasing,O
mean,O
duration,O
of,O
AF,B
induced,O
by,O
burst,O
pacing,O
",",O
from,O
8,O
+,O
/,O
-,O
4,O
s,O
(,O
mean,O
+,O
/,O
-,O
S,O
.,O
E,O
.,O
),O
to,O
95,O
+,O
/,O
-,O
39,O
s,O
(,O
P,O
<,O
0,O
.,O
1,O
vs,O
.,O
control,O
),O
at,O
a,O
loading,O
dose,O
of,O
0,O
.,O
1,O
mg,B
/,O
kg,O
and,O
228,O
+,O
/,O
-,O
101,O
s,O
(,O
P,O
<,O
0,O
.,O
5,O
vs,O
.,O
control,O
),O
at,O
a,O
dose,O
of,O
0,O
.,O
2,O
mg,B
/,O
kg,O
.,O
Underlying,O
electrophysiological,O
mechanisms,O
were,O
studied,O
in,O
detail,O
in,O
five,O
additional,O
dogs,O
under,O
control,O
conditions,O
and,O
in,O
the,O
presence,O
of,O
the,O
higher,O
dose,O
of,O
verapamil,B
.,O
In,O
these,O
experiments,O
",",O
verapamil,B
shortened,O
mean,O
effective,O
refractory,O
period,O
(,O
ERP,B
),O
from,O
122,O
+,O
/,O
-,O
5,O
to,O
114,O
+,O
/,O
-,O
4,O
ms,O
(,O
P,O
<,O
0,O
.,O
2,O
),O
at,O
a,O
cycle,O
length,O
of,O
300,O
ms,O
",",O
decreased,O
ERP,B
heterogeneity,O
(,O
from,O
15,O
+,O
/,O
-,O
1,O
to,O
10,O
+,O
/,O
-,O
1,O
%,O
",",O
P,O
<,O
0,O
.,O
5,O
),O
",",O
heterogeneously,O
accelerated,O
atrial,O
conduction,O
and,O
decreased,O
the,O
cycle,O
length,O
of,O
AF,B
(,O
94,O
+,O
/,O
-,O
4,O
to,O
84,O
+,O
/,O
-,O
3,O
ms,O
",",O
P,O
<,O
0,O
.,O
5,O
),O
.,O
Diltiazem,B
did,O
not,O
affect,O
ERP,B
",",O
AF,B
cycle,O
length,O
or,O
AF,B
duration,O
",",O
but,O
produced,O
conduction,O
acceleration,O
similar,O
to,O
that,O
caused,O
by,O
verapamil,B
(,O
n,O
=,O
5,O
),O
.,O
In,O
the,O
presence,O
of,O
autonomic,O
blockade,O
",",O
verapamil,B
failed,O
to,O
promote,O
AF,B
and,O
increased,O
",",O
rather,O
than,O
decreasing,O
",",O
refractoriness,O
.,O
Neither,O
verapamil,B
nor,O
diltiazem,B
affected,O
atrial,O
conduction,O
in,O
the,O
presence,O
of,O
autonomic,O
blockade,O
.,O
Epicardial,O
mapping,O
suggested,O
that,O
verapamil,B
promoted,O
AF,O
by,O
increasing,O
the,O
number,O
of,O
simultaneous,O
wavefronts,O
reflected,O
by,O
separate,O
zones,O
of,O
reactivation,O
in,O
each,O
cycle,O
.,O
CONCLUSIONS,O
:,O
Verapamil,B
promotes,O
AF,O
in,O
normal,O
dogs,O
by,O
promoting,O
multiple,O
circuit,O
reentry,O
",",O
an,O
effect,O
dependent,O
on,O
intact,O
autonomic,O
tone,O
and,O
not,O
shared,O
by,O
diltiazem,B
.,O
Calcitonin,B
gene,I
-,I
related,I
peptide,I
levels,O
during,O
nitric,B
oxide,I
-,I
induced,I
headache,I
in,O
patients,O
with,O
chronic,O
tension,O
-,O
type,O
headache,O
.,O
It,O
has,O
been,O
proposed,O
that,O
nitric,B
oxide,I
(,O
NO,B
),O
induced,O
headache,O
in,O
primary,O
headaches,O
may,O
be,O
associated,O
with,O
release,O
of,O
calcitonin,B
gene,I
-,I
related,I
peptide,I
(,O
CGRP,B
),O
.,O
In,O
the,O
present,O
study,O
we,O
aimed,O
to,O
investigate,O
plasma,O
levels,O
of,O
CGRP,B
during,O
headache,O
induced,O
by,O
the,O
NO,B
donor,O
glyceryl,O
trinitrate,O
(,O
GTN,B
),O
in,O
16,O
patients,O
with,O
chronic,O
tension,O
-,O
type,O
headache,O
and,O
16,O
healthy,O
controls,O
.,O
The,O
subjects,O
were,O
randomly,O
allocated,O
to,O
receive,O
0,O
.,O
5,B
microg,I
/,I
kg,I
/,I
min,I
GTN,B
or,O
placebo,O
over,O
20,O
min,O
on,O
two,O
headache,O
-,O
free,O
days,O
.,O
Blood,O
samples,O
were,O
collected,O
at,O
baseline,O
",",O
10,O
",",O
20,O
and,O
60,O
min,O
after,O
start,O
of,O
infusion,O
.,O
Both,O
patients,O
and,O
controls,O
developed,O
significantly,O
stronger,O
immediate,O
headache,O
on,O
the,O
GTN,B
day,O
than,O
on,O
the,O
placebo,O
day,O
and,O
the,O
headache,O
was,O
significantly,O
more,O
pronounced,O
in,O
patients,O
than,O
in,O
controls,O
.,O
There,O
was,O
no,O
difference,O
between,O
the,O
area,O
under,O
the,O
CGRP,B
curve,O
(,O
AUCCGRP,B
),O
on,O
GTN,B
vs,O
.,O
placebo,O
day,O
in,O
either,O
patients,O
(,O
P,O
=,O
0,O
.,O
65,O
),O
or,O
controls,O
(,O
P,O
=,O
0,O
.,O
48,O
),O
.,O
The,O
AUCCGRP,B
recorded,O
on,O
the,O
GTN,B
day,O
did,O
not,O
differ,O
between,O
patients,O
and,O
controls,O
(,O
P,O
=,O
0,O
.,O
36,O
),O
.,O
Both,O
in,O
patients,O
and,O
controls,O
",",O
CGRP,B
levels,O
changed,O
significantly,O
over,O
time,O
",",O
on,O
both,O
the,O
GTN,B
and,O
placebo,O
days,O
(,O
P,O
<,O
0,O
.,O
5,O
),O
.,O
The,O
present,O
study,O
indicates,O
that,O
NO,B
-,O
induced,O
immediate,O
headache,O
is,O
not,O
associated,O
with,O
release,O
of,O
CGRP,B
.,O
Fluconazole,B
-,O
induced,O
torsade,O
de,O
pointes,O
.,O
OBJECTIVE,O
:,O
To,O
present,O
a,O
case,O
of,O
fluconazole,B
-,O
associated,O
torsade,O
de,O
pointes,O
(,O
TDP,O
),O
and,O
discuss,O
fluconazole,B
',O
s,O
role,O
in,O
causing,O
TDP,O
.,O
CASE,O
SUMMARY,O
:,O
A,O
68,O
-,O
year,O
-,O
old,O
white,O
woman,O
with,O
Candida,B
glabrata,I
isolated,O
from,O
a,O
presacral,O
abscess,O
developed,O
TDP,O
eight,O
days,O
after,O
commencing,O
oral,O
fluconazole,B
The,O
patient,O
had,O
no,O
other,O
risk,O
factors,O
for,O
TDP,O
",",O
including,O
coronary,O
artery,O
disease,O
",",O
cardiomyopathy,O
",",O
congestive,O
heart,O
failure,O
",",O
and,O
electrolyte,O
abnormalities,O
There,O
was,O
a,O
temporal,O
association,O
between,O
the,O
initiation,O
of,O
fluconazole,B
and,O
TDP,O
.,O
The,O
TDP,B
resolved,O
when,O
fluconazole,B
was,O
discontinued,O
;,O
however,O
",",O
the,O
patient,O
continued,O
to,O
have,O
premature,O
ventricular,O
contractions,O
and,O
nonsustained,O
ventricular,O
tachycardia,O
(,O
NSVT,B
),O
until,O
six,O
days,O
after,O
drug,O
cessation,O
DISCUSSION,O
:,O
Use,O
of,O
the,O
Naranjo,O
probability,O
scale,O
indicates,O
a,O
probable,O
relationship,O
between,O
the,O
use,O
of,O
fluconazole,B
and,O
the,O
development,O
of,O
TDP,B
.,O
The,O
possible,O
mechanism,O
is,O
depression,O
of,O
rapidly,O
activating,O
delayed,O
rectifier,O
potassium,B
currents,O
.,O
In,O
our,O
patient,O
",",O
there,O
was,O
no,O
other,O
etiology,O
identified,O
that,O
could,O
explain,O
QT,O
prolongation,O
or,O
TDP,O
The,O
complete,O
disappearance,O
of,O
NSVT,O
and,O
premature,O
ventricular,O
contractions,O
followed,O
by,O
normalization,O
of,O
QT,O
interval,O
after,O
the,O
drug,O
was,O
stopped,O
strongly,O
suggests,O
fluconazole,B
as,O
the,O
etiology,O
.,O
CONCLUSIONS,O
:,O
Clinicians,O
should,O
be,O
aware,O
that,O
fluconazole,B
",",O
even,O
at,O
low,O
doses,O
",",O
may,O
cause,O
prolongation,O
of,O
the,O
QT,B
interval,O
",",O
leading,O
to,O
TDP,B
.,O
Serial,O
electrocardiographic,O
monitoring,O
may,O
be,O
considered,O
when,O
fluconazole,B
is,O
administered,O
in,O
patients,O
who,O
are,O
at,O
risk,O
for,O
ventricular,O
arrhythmias,O
.,O
Cutaneous,O
leucocytoclastic,O
vasculitis,O
associated,O
with,O
oxacillin,B
.,O
A,O
67,O
-,O
year,O
-,O
old,O
man,O
who,O
was,O
treated,O
with,O
oxacillin,B
for,O
one,O
week,O
because,O
of,O
Staphylococcus,B
aureus,I
bacteremia,O
",",O
developed,O
renal,B
failure,O
and,O
diffuse,O
",",O
symmetric,O
",",O
palpable,O
purpuric,O
lesions,O
on,O
his,O
feet,O
.,O
Necrotic,B
blisters,O
were,O
noted,O
on,O
his,O
fingers,O
.,O
Skin,B
biopsies,O
showed,O
findings,O
diagnostic,O
of,O
leucocytoclastic,B
vasculitis,O
.,O
Oxacillin,B
was,O
discontinued,O
and,O
patient,O
was,O
treated,O
with,O
corticosteroids,B
.,O
The,O
rash,O
disappeared,O
after,O
three,O
weeks,O
and,O
renal,O
function,O
returned,O
to,O
normal,O
.,O
Leucocytoclastic,B
vasculitis,I
presents,O
as,O
palpable,O
purpura,O
of,O
the,O
lower,O
extremities,O
often,O
accompanied,O
by,O
abdominal,O
pain,O
",",O
arthralgia,O
",",O
and,O
renal,O
involvement,O
.,O
Etiologic,O
factors,O
or,O
associated,O
disorders,O
include,O
infections,O
",",O
medications,O
",",O
collagen,B
vascular,I
disease,I
and,O
neoplasia,O
.,O
However,O
",",O
in,O
half,O
of,O
the,O
cases,O
no,O
etiologic,O
factor,O
is,O
identified,O
.,O
Usually,O
it,O
is,O
a,O
self,O
-,O
limited,O
disorder,O
",",O
but,O
corticosteroid,O
therapy,O
may,O
be,O
needed,O
in,O
life,O
-,O
threatening,O
cases,O
since,O
early,O
treatment,O
with,O
corticosteroids,O
in,O
severe,O
cases,O
can,O
prevent,O
complications,O
.,O
Oxacillin,B
should,O
be,O
included,O
among,O
the,O
drugs,O
that,O
can,O
cause,O
leucocytoclastic,B
vasculitis,O
.,O
The,O
renal,O
pathology,O
in,O
a,O
case,O
of,O
lithium,B
-,I
induced,I
diabetes,I
insipidus,I
.,O
A,O
case,O
of,O
lithium,B
-,I
induced,I
diabetes,I
insipidus,I
is,O
reported,O
.,O
At,O
necropsy,O
microscopy,O
shoed,O
unique,O
and,O
extensive,O
damage,O
to,O
cells,O
lining,O
the,O
distal,O
nephron,O
.,O
It,O
is,O
suggested,O
that,O
these,O
changes,O
represent,O
a,O
specific,O
toxic,O
effect,O
of,O
lithium,B
",",O
reported,O
here,O
for,O
the,O
first,O
time,O
in,O
man,O
.,O
Cholestatic,B
jaundice,I
associated,O
with,O
the,O
use,O
of,O
metformin,B
.,O
We,O
report,O
a,O
patient,O
who,O
developed,O
cholestatic,B
jaundice,I
shortly,O
after,O
initiation,O
of,O
treatment,O
with,O
metformin,B
hydrochloride,I
.,O
Ultrasound,O
of,O
the,O
liver,B
and,O
abdominal,O
CT,O
were,O
normal,O
.,O
An,O
ERCP,O
showed,O
normal,O
biliary,O
anatomy,O
.,O
A,O
percutaneous,O
liver,B
biopsy,O
was,O
obtained,O
showing,O
marked,O
cholestasis,B
",",O
with,O
portal,O
edema,O
",",O
ductular,O
proliferation,O
",",O
and,O
acute,O
inflammation,O
.,O
Metformin,B
hydrochloride,I
was,O
discontinued,O
",",O
and,O
the,O
patient,O
',O
s,O
jaundice,B
resolved,O
slowly,O
over,O
a,O
period,O
of,O
several,O
months,O
.,O
Given,O
the,O
onset,O
of,O
his,O
jaundice,O
2,O
wk,O
after,O
the,O
initiation,O
of,O
metformin,B
",",O
we,O
believe,O
that,O
this,O
case,O
represents,O
an,O
example,O
of,O
metformin,B
-,O
associated,O
hepatotoxicity,O
",",O
the,O
first,O
such,O
case,O
reported,O
.,O
Systemic,O
toxicity,O
and,O
resuscitation,O
in,O
bupivacaine,B
-,O
",",O
levobupivacaine,B
-,O
",",O
or,O
ropivacaine,B
-,O
infused,O
rats,O
.,O
We,O
compared,O
the,O
systemic,O
toxicity,O
of,O
bupivacaine,B
",",O
levobupivacaine,B
",",O
and,O
ropivacaine,B
in,O
anesthetized,O
rats,O
0.15,O
We,O
also,O
compared,O
the,O
ability,O
to,O
resuscitate,O
rats,O
after,O
lethal,O
doses,O
of,O
these,O
local,O
anesthetics,O
0.31,O
Bupivacaine,B
",",O
levobupivacaine,B
",",O
or,O
ropivacaine,B
was,O
infused,O
at,O
a,O
rate,O
of,O
2,O
mg,O
0.46,O
kg,O
(,O
-,O
1,O
),O
0.52,O
min,O
(,O
-,O
1,O
),O
while,O
electrocardiogram,O
",",O
electroencephalogram,O
",",O
and,O
arterial,O
pressure,O
were,O
continuously,O
monitored,O
0.69,O
When,O
asystole,O
was,O
recorded,O
",",O
drug,O
infusion,O
was,O
stopped,O
and,O
a,O
resuscitation,O
sequence,O
was,O
begun,O
.,O
Epinephrine,B
0,I
.,O
1,I
mg,I
/,I
kg,I
was,O
administered,O
at,O
1,O
-,O
min,O
intervals,O
while,O
external,O
cardiac,O
compressions,O
were,O
applied,O
.,O
Resuscitation,O
was,O
considered,O
successful,O
when,O
a,O
systolic,O
arterial,O
pressure,O
>,O
or,O
=,O
100,O
mm,O
Hg,O
was,O
achieved,O
within,O
5,O
min,O
.,O
The,O
cumulative,O
doses,O
of,O
levobupivacaine,B
and,O
ropivacaine,B
that,O
produced,O
seizures,O
were,O
similar,O
and,O
were,O
larger,O
than,O
those,O
of,O
bupivacaine,B
.,O
The,O
cumulative,O
doses,O
of,O
levobupivacaine,B
that,O
produced,O
dysrhythmias,O
and,O
asystole,O
were,O
smaller,O
than,O
the,O
corresponding,O
doses,O
of,O
ropivacaine,B
",",O
but,O
they,O
were,O
larger,O
than,O
those,O
of,O
bupivacaine,B
.,O
The,O
number,O
of,O
successful,O
resuscitations,O
did,O
not,O
differ,O
among,O
groups,O
.,O
However,O
",",O
a,O
smaller,O
dose,O
of,O
epinephrine,B
was,O
required,O
in,O
the,O
Ropivacaine,O
group,O
than,O
in,O
the,O
other,O
groups,O
.,O
We,O
conclude,O
that,O
the,O
systemic,O
toxicity,O
of,O
levobupivacaine,O
is,O
intermediate,O
between,O
that,O
of,O
ropivacaine,O
and,O
bupivacaine,O
when,O
administered,O
at,O
the,O
same,O
rate,O
and,O
that,O
ropivacaine,O
-,O
induced,O
cardiac,O
arrest,O
appears,O
to,O
be,O
more,O
susceptible,O
to,O
treatment,O
than,O
that,O
induced,O
by,O
bupivacaine,O
or,O
levobupivacaine,O
.,O
Amphotericin,B
B-,I
-,I
induced,O
seizures,O
in,O
a,O
patient,O
with,O
AIDS,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
multiple,O
episodes,O
of,O
seizure,O
activity,O
in,O
an,O
AIDS,O
patent,O
following,O
amphotericin,B
B,I
infusion,O
.,O
CASE,O
SUMMARY,O
:,O
A,O
46,O
-,O
year,O
-,O
old,O
African,O
-,O
American,O
man,O
experienced,O
recurrent,O
grand,O
mal,O
seizures,O
during,O
intravenous,O
infusion,O
of,O
amphotericin,B
B,I
",",O
then,O
petit,O
mal,O
seizures,O
as,O
the,O
infusion,O
was,O
stopped,O
and,O
the,O
drug,O
concentrations,O
decreased,O
with,O
time,O
.,O
The,O
patients,O
concurrent,O
medications,O
included,O
didanosine,B
",",O
hydroxyzine,B
",",O
promethazine,B
",",O
hydrocortisone,B
",",O
and,O
prochlorperazine,B
.,O
Despite,O
administration,O
of,O
phenytoin,B
and,O
lorazepam,B
",",O
the,O
seizures,O
persisted,O
and,O
occurred,O
only,O
during,O
amphotercin,B
B,I
administration,O
.,O
DISCUSSION,O
:,O
AIDS,B
and,O
cryptococcal,B
meningitis,I
",",O
both,O
of,O
which,O
the,O
patient,O
had,O
",",O
can,O
potentially,O
cause,O
seizures,O
.,O
The,O
patient,O
had,O
a,O
history,O
of,O
alcohol,B
abuse,I
;,O
alcohol,B
intake,O
as,O
well,O
as,O
withdrawal,O
can,O
also,O
cause,O
seizures,O
.,O
Didanosine,B
also,O
has,O
a,O
potential,O
for,O
inducing,O
seizures,O
.,O
However,O
",",O
these,O
other,O
potential,O
causes,O
of,O
seizure,O
were,O
ruled,O
out,O
.,O
The,O
time,O
course,O
of,O
events,O
suggested,O
that,O
amphotericin,B
B,I
was,O
the,O
cause,O
of,O
the,O
seizures,O
in,O
this,O
AIDS,O
patient,O
.,O
CONCLUSIONS,O
:,O
Amphotericin,B
B,I
seems,O
to,O
be,O
the,O
probable,O
cause,O
of,O
the,O
seizures,O
.,O
To,O
date,O
",",O
only,O
three,O
cases,O
of,O
seizures,O
associated,O
with,O
amphotericin,B
B,I
have,O
been,O
reported,O
in,O
the,O
literature,O
",",O
but,O
healthcare,O
providers,O
should,O
be,O
aware,O
of,O
the,O
potential,O
for,O
this,O
rare,O
adverse,O
effect,O
.,O
Sirolimus,B
and,O
mycophenolate,B
mofetil,I
for,O
calcineurin,B
-,I
free,I
immunosuppression,I
in,O
renal,O
transplant,O
recipients,O
.,O
Calcineurin,B
inhibitors,O
",",O
such,O
as,O
cyclosporine,B
and,O
tacrolimus,B
",",O
have,O
been,O
available,O
for,O
almost,O
20,O
years,O
.,O
Although,O
these,O
drugs,O
are,O
highly,O
effective,O
and,O
represent,O
the,O
mainstay,O
of,O
transplant,O
immunosuppression,O
",",O
they,O
are,O
associated,O
with,O
acute,B
and,O
chronic,B
nephrotoxicity,I
.,O
Acute,B
nephrotoxicity,I
",",O
which,O
occurs,O
in,O
the,O
early,O
period,O
after,O
transplantation,O
",",O
leads,O
to,O
a,O
higher,O
rate,O
of,O
dialysis,O
",",O
and,O
chronic,B
nephrotoxicity,I
may,O
eventually,O
result,O
in,O
graft,O
loss,O
.,O
Acute,O
and,O
chronic,O
nephrotoxicity,O
is,O
becoming,O
more,O
common,O
as,O
the,O
use,O
of,O
marginal,O
kidneys,O
for,O
transplantation,O
increases,O
.,O
Two,O
recently,O
available,O
immunosuppressive,O
agents,O
",",O
mycophenolate,B
mofetil,I
and,O
sirolimus,B
(,O
rapamycin,I
),O
",",O
have,O
no,O
nephrotoxicity,O
.,O
The,O
use,O
of,O
these,O
drugs,O
in,O
combination,O
with,O
other,O
agents,O
has,O
led,O
to,O
the,O
development,O
of,O
new,O
paradigms,O
of,O
immunosuppressive,O
therapy,O
.,O
This,O
paper,O
reviews,O
the,O
results,O
of,O
clinical,O
trials,O
that,O
have,O
investigated,O
these,O
new,O
approaches,O
to,O
immunosuppression,O
in,O
renal,O
transplant,O
recipients,O
.,O
Tolerability,O
of,O
nimesulide,B
and,O
paracetamol,B
in,O
patients,O
with,O
NSAID,O
-,O
induced,O
urticaria,O
/,O
angioedema,O
.,O
Previous,O
studies,O
evaluated,O
the,O
tolerance,O
of,O
nimesulide,B
and,O
paracetamol,B
in,O
subjects,O
with,O
cutaneous,O
",",O
respiratory,O
and,O
anaphylactoid,O
reactions,O
induced,O
by,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,O
),O
.,O
In,O
this,O
study,O
we,O
investigated,O
tolerability,O
and,O
reliability,O
of,O
nimesulide,B
and,O
paracetamol,B
in,O
a,O
very,O
large,O
number,O
of,O
patients,O
with,O
an,O
exclusive,O
well,O
-,O
documented,O
history,O
of,O
NSAID,B
-,O
induced,O
urticaria,O
/,O
angioedema,O
.,O
Furthermore,O
",",O
we,O
evaluated,O
whether,O
some,O
factors,O
have,O
the,O
potential,O
to,O
increase,O
the,O
risk,O
of,O
reaction,O
to,O
paracetamol,B
and,O
nimesulide,B
.,O
A,O
single,O
-,O
placebo,O
-,O
controlled,O
oral,O
challenge,O
procedure,O
with,O
nimesulide,B
or,O
paracetamol,B
was,O
applied,O
to,O
829,O
patients,O
with,O
a,O
history,O
of,O
NSAID,B
-,O
induced,O
urticaria,O
/,O
angioedema,O
.,O
A,O
total,O
of,O
75,O
/,O
829,O
(,O
9,O
.,O
4,O
%,O
),O
patients,O
experienced,O
reactions,O
to,O
nimesulide,B
or,O
paracetamol,B
.,O
Of,O
the,O
715,O
patients,O
tested,O
with,O
nimesulide,B
62,O
(,O
8,O
.,O
6,O
%,O
),O
showed,O
a,O
positive,O
test,O
",",O
while,O
of,O
114,O
subjects,O
submitted,O
to,O
the,O
challenge,O
with,O
paracetamol,B
",",O
13,O
(,O
9,O
.,O
6,O
%,O
),O
did,O
not,O
tolerate,O
this,O
drug,O
.,O
Furthermore,O
",",O
18,O
.,O
28,O
%,O
of,O
patients,O
with,O
a,O
history,O
of,O
chronic,O
urticaria,B
and,O
11,O
.,O
8,O
%,O
of,O
subjects,O
with,O
an,O
history,O
of,O
NSAID,B
-,I
induced,I
urticaria,I
/,I
angioedema,I
or,O
angioedema,I
alone,O
(,O
with,O
or,O
without,O
chronic,O
urticaria,O
),O
resulted,O
to,O
be,O
intolerant,O
to,O
alternative,O
drugs,O
.,O
Taken,O
together,O
",",O
our,O
results,O
confirm,O
the,O
good,O
tolerability,O
of,O
nimesulide,B
and,O
paracetamol,B
in,O
patients,O
who,O
experienced,O
urticaria,O
/,O
angioedema,O
caused,O
by,O
NSAIDs,B
.,O
However,O
",",O
the,O
risk,O
of,O
reaction,O
to,O
these,O
alternative,O
study,O
drugs,O
is,O
statistically,O
increased,O
by,O
a,O
history,O
of,O
chronic,O
urticaria,O
and,O
",",O
above,O
all,O
",",O
by,O
a,O
history,O
of,O
NSAID,B
-,O
induced,O
angioedema,O
.,O
Comparison,O
of,O
aqueous,B
and,O
gellan,B
ophthalmic,I
timolol,I
with,O
placebo,O
on,O
the,O
24,O
-,O
hour,O
heart,O
rate,O
response,O
in,O
patients,O
on,O
treatment,O
for,O
glaucoma,O
.,O
PURPOSE,O
:,O
Topical,O
beta,B
-,I
blocker,I
treatment,O
is,O
routine,O
therapy,O
in,O
the,O
management,O
of,O
patients,O
with,O
glaucoma,O
.,O
Therapy,O
results,O
in,O
systemic,O
absorption,O
",",O
however,O
",",O
the,O
degree,O
of,O
reduction,O
of,O
resting,O
and,O
peak,O
heart,O
rate,O
has,O
not,O
been,O
quantified,O
.,O
DESIGN,O
:,O
This,O
trial,O
evaluated,O
the,O
effect,O
of,O
placebo,B
",",O
0,O
.,O
5,O
%,O
aqueous,O
timolol,B
(,O
timolol,I
solution,I
),O
and,O
a,O
0,O
.,O
5,O
%,O
timolol,B
suspension,I
that,O
forms,O
a,O
gel,O
on,O
application,O
to,O
the,O
conjunctiva,B
(,O
timolol,I
gellan,I
),O
on,O
the,O
24,O
-,O
hour,O
heart,O
rate,O
in,O
patients,O
currently,O
being,O
treated,O
for,O
glaucoma,O
to,O
quantify,O
the,O
reduction,O
in,O
mean,O
heart,O
rate,O
.,O
METHODS,O
:,O
Forty,O
-,O
three,O
Caucasian,O
patients,O
with,O
primary,O
open,O
-,O
angle,O
glaucoma,B
or,O
ocular,O
hypertension,O
with,O
a,O
mean,O
(,O
+,O
/,O
-,O
SD,O
),O
age,O
of,O
63,O
(,O
+,O
/,O
-,O
8,O
),O
years,O
were,O
randomized,O
and,O
crossed,O
over,O
in,O
a,O
double,O
-,O
masked,O
manner,O
to,O
14,O
days,O
of,O
treatment,O
with,O
placebo,B
(,O
morning,O
and,O
evening,O
in,O
both,O
eyes,O
),O
",",O
timolol,B
solution,O
(,O
morning,O
and,O
evening,O
in,O
both,O
eyes,O
),O
",",O
or,O
timolol,B
gellan,O
(,O
morning,O
in,O
both,O
eyes,O
with,O
placebo,O
in,O
the,O
evening,O
),O
.,O
On,O
the,O
13th,O
day,O
of,O
each,O
period,O
",",O
heart,O
rate,O
was,O
recorded,O
continuously,O
during,O
a,O
typical,O
",",O
ambulant,O
24,O
-,O
hour,O
period,O
.,O
RESULTS,O
:,O
Both,O
timolol,B
solution,O
and,O
timolol,B
gellan,O
reduced,O
the,O
mean,O
24,O
-,O
hour,O
heart,O
rate,O
compared,O
with,O
placebo,O
(,O
P,O
<,O
or,O
=,O
0.001,O
),O
",",O
and,O
this,O
reduction,O
was,O
most,O
pronounced,O
during,O
the,O
daytime,O
(,O
-,O
7,O
0.62,O
5,O
%,O
change,O
in,O
mean,O
heart,B
rate,I
",",O
-,O
5,O
.,O
7,O
beats,O
/,O
min,O
),O
.,O
Timolol,B
gellan,I
showed,O
a,O
numerically,O
but,O
not,O
significantly,O
smaller,O
reduction,O
in,O
24,O
-,O
hour,O
heart,B
rate,I
",",O
compared,O
with,O
timolol,B
solution,I
.,O
During,O
the,O
night,O
",",O
the,O
mean,O
12,O
-,O
hour,O
heart,B
rate,I
on,O
placebo,B
and,O
timolol,B
gellan,I
were,O
both,O
significantly,O
less,O
than,O
on,O
timolol,B
solution,I
;,O
the,O
difference,O
between,O
solution,I
and,O
gellan,I
treatments,O
was,O
statistically,O
significant,O
(,O
P,B
=,O
.,O
1,O
),O
.,O
CONCLUSIONS,O
:,O
Both,O
timolol,B
solution,O
and,O
timolol,B
gellan,O
decrease,O
the,O
mean,O
24,O
-,O
hour,O
heart,O
rate,O
compared,O
with,O
placebo,O
.,O
This,O
response,O
was,O
most,O
pronounced,O
during,O
the,O
active,O
daytime,O
period,O
.,O
These,O
data,O
quantify,O
the,O
modest,O
bradycardia,O
associated,O
with,O
ophthalmic,O
beta,B
-,O
blocker,O
therapy,O
in,O
a,O
typical,O
patient,O
population,O
on,O
therapy,O
for,O
glaucoma,O
.,O
Although,O
exercise,O
performance,O
was,O
not,O
assessed,O
in,O
this,O
trial,O
",",O
reductions,O
of,O
this,O
magnitude,O
should,O
not,O
have,O
substantial,O
clinical,O
consequences,O
.,O
Management,O
strategies,O
for,O
ribavirin,B
-,O
induced,O
hemolytic,O
anemia,O
in,O
the,O
treatment,O
of,O
hepatitis,O
C,O
:,O
clinical,O
and,O
economic,O
implications,O
.,O
OBJECTIVES,O
:,O
Recently,O
published,O
studies,O
have,O
demonstrated,O
increased,O
efficacy,O
and,O
cost,O
-,O
effectiveness,O
of,O
combination,O
therapy,O
with,O
interferon,O
and,O
alpha,O
-,O
2b,O
/,O
ribavirin,B
compared,O
with,O
interferon,O
-,O
alpha,O
monotherapy,O
in,O
the,O
treatment,O
of,O
chronic,O
hepatitis,O
C,O
(,O
CHC,O
),O
.,O
Combination,O
therapy,O
is,O
associated,O
with,O
a,O
clinically,O
important,O
adverse,O
effect,O
:,O
ribavirin,B
-,O
induced,O
hemolytic,O
anemia,O
(,O
RIHA,B
),O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
direct,O
health,O
-,O
care,O
costs,O
and,O
management,O
of,O
RIHA,B
during,O
treatment,O
of,O
CHC,O
in,O
a,O
clinical,O
trial,O
setting,O
.,O
METHODS,O
:,O
A,O
systematic,O
literature,O
review,O
was,O
conducted,O
to,O
synthesize,O
information,O
on,O
the,O
incidence,O
and,O
management,O
of,O
RIHA,B
.,O
Decision,O
-,O
analytic,O
techniques,O
were,O
used,O
to,O
estimate,O
the,O
cost,O
of,O
treating,O
RIHA,B
.,O
Uncertainty,O
was,O
evaluated,O
using,O
sensitivity,O
analyses,O
.,O
RESULTS,O
:,O
RIHA,B
",",O
defined,O
as,O
a,O
reduction,O
in,O
hemoglobin,B
to,O
less,O
than,O
100,O
g,O
/,O
L,O
",",O
occurs,O
in,O
approximately,O
7,O
%,O
to,O
9,O
%,O
of,O
patients,O
treated,O
with,O
combination,O
therapy,O
.,O
The,O
standard,O
of,O
care,O
for,O
management,O
of,O
RIHA,B
is,O
reduction,O
or,O
discontinuation,O
of,O
the,O
ribavirin,B
dosage,O
.,O
We,O
estimated,O
the,O
direct,O
cost,O
of,O
treating,O
clinically,O
significant,O
RIHA,O
to,O
be,O
170,O
per,O
patient,O
receiving,O
combination,O
therapy,O
per,O
48,O
-,O
week,O
treatment,O
course,O
(,O
range,O
68,O
-,O
692,O
),O
.,O
The,O
results,O
of,O
the,O
one,O
-,O
way,O
sensitivity,O
analyses,O
ranged,O
from,O
57,O
to,O
317,O
.,O
In,O
comparison,O
",",O
the,O
cost,O
of,O
48,O
weeks,O
of,O
combination,O
therapy,O
is,O
16,O
",",O
459,O
.,O
CONCLUSIONS,O
:,O
The,O
direct,O
cost,O
of,O
treating,O
clinically,O
significant,O
RIHA,B
is,O
1,O
%,O
(,O
170,O
/,O
16,O
",",O
459,O
),O
of,O
drug,O
treatment,O
costs,O
.,O
Questions,O
remain,O
about,O
the,O
optimal,O
dose,O
of,O
ribavirin,B
and,O
the,O
incidence,O
of,O
RIHA,B
in,O
a,O
real,O
-,O
world,O
population,O
.,O
Despite,O
these,O
uncertainties,O
",",O
this,O
initial,O
evaluation,O
of,O
the,O
direct,O
cost,O
of,O
treating,O
RIHA,B
provides,O
an,O
estimate,O
of,O
the,O
cost,O
and,O
management,O
implications,O
of,O
this,O
clinically,O
important,O
adverse,O
effect,O
.,O
Preliminary,O
efficacy,O
assessment,O
of,O
intrathecal,O
injection,O
of,O
an,O
American,O
formulation,O
of,O
adenosine,B
in,O
humans,O
.,O
BACKGROUND,O
:,O
Preclinical,O
studies,O
of,O
intrathecal,O
adenosine,B
suggest,O
it,O
may,O
be,O
effective,O
in,O
the,O
treatment,O
of,O
acute,O
and,O
chronic,O
pain,O
in,O
humans,O
",",O
and,O
preliminary,O
studies,O
in,O
volunteers,O
and,O
patients,O
with,O
a,O
Swedish,O
formulation,O
of,O
adenosine,B
suggests,O
it,O
may,O
be,O
effective,O
in,O
hypersensitivity,O
states,O
but,O
not,O
with,O
acute,O
noxious,O
stimulation,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
screen,O
for,O
efficacy,O
of,O
a,O
different,O
formulation,O
of,O
adenosine,B
marketed,O
in,O
the,O
US,O
",",O
using,O
both,O
acute,O
noxious,O
stimulation,O
and,O
capsaicin,B
-,I
evoked,O
mechanical,O
hypersensitivity,O
.,O
METHODS,O
:,O
Following,O
Food,O
and,O
Drug,O
Administration,O
and,O
institutional,O
review,O
board,O
approval,O
and,O
written,O
informed,O
consent,O
",",O
65,O
volunteers,O
were,O
studied,O
in,O
two,O
trials,O
:,O
an,O
open,O
-,O
label,O
",",O
dose,O
-,O
escalating,O
trial,O
with,O
intrathecal,O
adenosine,B
doses,O
of,O
0,O
.,O
25,O
-,O
2,O
.,O
0,O
mg,O
and,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
of,O
adenosine,B
",",O
2,O
mg,O
.,O
Cerebrospinal,O
fluid,O
was,O
obtained,O
for,O
pharmacokinetic,O
analysis,O
",",O
and,O
pain,O
ratings,O
in,O
response,O
to,O
acute,O
heat,O
stimuli,O
and,O
areas,O
of,O
mechanical,O
hyperalgesia,O
and,O
allodynia,O
after,O
intradermal,O
capsaicin,B
injection,O
were,O
determined,O
.,O
RESULTS,O
:,O
Adenosine,B
produced,O
no,O
effect,O
on,O
pain,O
report,O
to,O
acute,O
noxious,O
thermal,O
or,O
chemical,B
stimulation,O
but,O
reduced,O
mechanical,O
hyperalgesia,O
and,O
allodynia,O
from,O
intradermal,O
capsaicin,B
injection,O
for,O
at,O
least,O
24,O
h,O
.,O
In,O
contrast,O
",",O
residence,O
time,O
of,O
adenosine,B
in,O
cerebrospinal,O
fluid,O
was,O
short,O
(,O
<,O
4,O
h,O
),O
.,O
CONCLUSIONS,O
:,O
These,O
results,O
show,O
selective,O
inhibition,O
by,O
intrathecal,O
adenosine,B
of,O
hypersensitivity,O
",",O
presumed,O
to,O
reflect,O
central,O
sensitization,O
in,O
humans,O
after,O
peripheral,O
capsaicin,B
injection,O
.,O
The,O
long,O
-,O
lasting,O
effect,O
is,O
consistent,O
with,O
that,O
observed,O
in,O
preliminary,O
reports,O
of,O
patients,O
with,O
chronic,O
neuropathic,O
pain,O
and,O
is,O
not,O
due,O
to,O
prolonged,O
residence,O
of,O
adenosine,B
in,O
cerebrospinal,B
fluid,O
.,O
Delayed,O
-,O
onset,O
heparin,B
-,O
induced,O
thrombocytopenia,O
.,O
BACKGROUND,O
:,O
Heparin,B
-,O
induced,O
thrombocytopenia,O
presents,O
5,O
to,O
12,O
days,O
after,O
heparin,B
exposure,O
",",O
with,O
or,O
without,O
arterial,O
or,O
venous,O
thromboemboli,O
.,O
Delayed,O
recognition,O
and,O
treatment,O
of,O
heparin,B
-,O
induced,O
thrombocytopenia,O
contribute,O
to,O
poor,O
patient,O
outcomes,O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
and,O
increase,O
awareness,O
of,O
a,O
clinical,O
scenario,O
in,O
which,O
the,O
onset,O
or,O
manifestations,O
of,O
heparin,B
-,O
induced,O
thrombocytopenia,O
are,O
delayed,O
.,O
DESIGN,O
:,O
Retrospective,O
case,O
series,O
.,O
SETTING,O
:,O
Three,O
large,O
urban,O
hospitals,O
(,O
with,O
active,O
cardiovascular,O
surgery,O
programs,O
),O
.,O
PATIENTS,O
:,O
14,O
patients,O
seen,O
over,O
a,O
3,O
-,O
year,O
period,O
in,O
whom,O
heparin,B
-,O
induced,O
thrombocytopenia,O
became,O
apparent,O
on,O
delayed,O
presentation,O
with,O
thromboembolic,O
complications,O
.,O
MEASUREMENTS,O
:,O
Platelet,B
counts,O
",",O
onset,O
of,O
objectively,O
determined,O
thromboembolism,O
",",O
results,O
of,O
heparin,B
-,O
induced,O
platelet,I
factor,I
4,I
antibody,I
tests,O
",",O
and,O
outcomes,O
.,O
RESULTS,O
:,O
Patients,O
went,O
home,O
after,O
hospitalizations,O
that,O
had,O
included,O
heparin,B
exposure,O
-,O
-,O
in,O
most,O
cases,O
",",O
with,O
no,O
thrombocytopenia,O
recognized,O
-,O
-,O
only,O
to,O
return,O
to,O
the,O
hospital,O
(,O
median,O
",",O
day,O
14,O
),O
with,O
thromboembolic,O
complications,O
.,O
Thromboemboli,O
were,O
venous,O
(,O
12,O
patients,O
",",O
7,O
with,O
pulmonary,O
emboli,O
),O
or,O
arterial,O
(,O
4,O
patients,O
),O
or,O
both,O
.,O
Platelet,B
counts,O
were,O
mildly,O
decreased,O
in,O
all,O
but,O
2,O
patients,O
on,O
second,O
presentation,O
.,O
On,O
readmission,O
",",O
11,O
patients,O
received,O
therapeutic,O
heparin,B
",",O
which,O
worsened,O
the,O
patients,O
',O
clinical,O
condition,O
and,O
",",O
in,O
all,O
11,O
cases,O
",",O
decreased,O
the,O
platelet,B
count,O
(,O
mean,O
at,O
readmission,O
",",O
143,O
x,O
10,O
(,O
9,O
),O
cells,O
/,O
L,O
;,O
mean,O
nadir,O
after,O
heparin,B
re,O
-,O
exposure,O
",",O
39,O
x,O
10,O
(,O
9,O
),O
cells,O
/,O
L,O
.,O
Results,O
of,O
serologic,O
tests,O
for,O
heparin,B
-,O
induced,O
antibodies,O
were,O
positive,O
in,O
all,O
patients,O
.,O
Subsequent,O
treatments,O
included,O
alternative,O
anticoagulants,O
(,O
11,O
patients,O
),O
",",O
thrombolytic,O
drugs,O
(,O
3,O
patients,O
),O
",",O
inferior,O
vena,O
cava,O
filters,O
(,O
3,O
patients,O
),O
and,O
",",O
eventually,O
",",O
warfarin,B
(,O
11,O
patients,O
),O
.,O
Three,O
patients,O
died,O
.,O
CONCLUSIONS,O
:,O
Delayed,O
-,O
onset,O
heparin,B
-,O
induced,O
thrombocytopenia,O
is,O
increasingly,O
being,O
recognized,O
.,O
To,O
avoid,O
disastrous,O
outcomes,O
",",O
physicians,O
must,O
consider,O
heparin,B
-,O
induced,O
thrombocytopenia,O
whenever,O
a,O
recently,O
hospitalized,O
patient,O
returns,O
with,O
thromboembolism,O
;,O
therapy,O
with,O
alternative,O
anticoagulants,O
",",O
not,O
heparin,B
",",O
should,O
be,O
initiated,O
.,O
Treatment,O
of,O
risperidone,B
-,O
induced,O
hyperprolactinemia,O
with,O
a,O
dopamine,B
agonist,O
in,O
children,O
.,O
BACKGROUND,O
:,O
Risperidone,B
",",O
a,O
potent,O
antagonist,O
of,O
both,O
serotonergic,B
(,O
5HT2A,B
),O
and,O
dopaminergic,B
D2,I
receptors,O
is,O
associated,O
with,O
hyperprolactinemia,O
in,O
adults,O
and,O
children,O
.,O
Chronically,O
elevated,O
prolactin,B
levels,O
in,O
children,O
with,O
prolactinomas,O
may,O
be,O
associated,O
with,O
arrested,O
growth,O
and,O
development,O
resulting,O
in,O
either,O
delayed,O
puberty,O
or,O
short,O
stature,O
.,O
These,O
possibilities,O
stress,O
the,O
importance,O
of,O
developing,O
a,O
safe,O
and,O
effective,O
approach,O
to,O
drug,O
-,O
induced,O
hyperprolactinemia,O
in,O
youth,O
.,O
We,O
report,O
the,O
successful,O
treatment,O
of,O
risperidone,B
-,O
induced,O
hyperprolactinemia,O
with,O
cabergoline,B
in,O
youth,O
.,O
METHODS,O
:,O
We,O
undertook,O
a,O
retrospective,O
case,O
review,O
of,O
four,O
children,O
with,O
risperidone,B
-,O
induced,O
hyperprolactinemia,O
treated,O
with,O
cabergoline,B
.,O
RESULTS,O
:,O
Four,O
males,O
(,O
age,O
6,O
-,O
11,O
years,O
),O
with,O
Diagnostic,O
and,O
Statistical,O
Manual,O
of,O
Mental,O
Disorders,O
(,O
fourth,O
edition,O
),O
bipolar,O
disorder,O
or,O
psychoses,O
",",O
with,O
risperidone,B
-,O
induced,O
elevations,O
in,O
serum,O
prolactin,B
levels,O
(,O
57,O
.,O
5,O
-,O
129,O
ng,O
/,O
mL,O
",",O
normal,O
5,O
-,O
15,O
ng,O
/,O
mL,O
),O
",",O
were,O
treated,O
with,O
cabergoline,B
(,O
mean,O
dose,O
2,O
.,O
13,O
+,O
/,O
-,O
0,O
.,O
9,O
mg,B
/,O
week,O
),O
.,O
When,O
serum,O
prolactin,B
levels,O
normalized,O
in,O
all,O
four,O
subjects,O
(,O
mean,O
11,O
.,O
2,O
+,O
/,O
-,O
10,O
9,O
ng,B
/,O
mL,O
"),",O
the,O
cabergoline,B
dose,O
was,O
reduced,O
to,O
1,O
mg,B
/,O
week,O
in,O
three,O
of,O
four,O
subjects,O
.,O
The,O
mean,O
duration,O
of,O
therapy,O
with,O
cabergoline,B
was,O
523,O
.,O
5,O
+,O
/,O
-,O
129,O
.,O
7,O
days,O
",",O
and,O
the,O
mean,O
duration,O
of,O
therapy,O
with,O
risperidone,B
was,O
788,O
.,O
5,O
+,O
/,O
-,O
162,O
.,O
5,O
days,O
.,O
Cabergoline,B
was,O
well,O
tolerated,O
without,O
adverse,O
effects,O
.,O
CONCLUSIONS,O
:,O
Cabergoline,B
may,O
be,O
useful,O
for,O
the,O
treatment,O
of,O
risperidone,B
-,O
induced,O
hyperprolactinemia,O
in,O
youth,O
;,O
however,O
",",O
further,O
research,O
is,O
needed,O
.,O
Acute,O
cholestatic,O
hepatitis,O
after,O
exposure,O
to,O
isoflurane,B
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
acute,O
cholestatic,O
hepatitis,O
following,O
exposure,O
to,O
the,O
inhalational,O
anesthetic,O
isoflurane,B
.,O
CASE,O
SUMMARY,O
:,O
A,O
70,O
-,O
year,O
-,O
old,O
healthy,O
woman,O
from,O
Iraq,O
developed,O
acute,O
cholestatic,B
hepatitis,I
3,O
weeks,O
following,O
repair,O
of,O
the,O
right,O
rotator,O
cuff,O
under,O
general,O
anesthesia,O
.,O
There,O
was,O
no,O
evidence,O
for,O
viral,O
",",O
autoimmune,O
",",O
or,O
metabolic,O
causes,O
of,O
hepatitis,O
.,O
No,O
other,O
medications,O
were,O
involved,O
except,O
for,O
dipyrone,B
for,O
analgesia,O
.,O
The,O
alanine,B
aminotransferase,I
was,O
elevated,O
to,O
a,O
peak,O
concentration,O
of,O
1533,O
U,O
/,O
L,O
and,O
the,O
serum,O
bilirubin,B
reached,O
a,O
peak,O
of,O
17,O
.,O
0,O
mg,O
/,O
dL,O
There,O
was,O
slow,O
improvement,O
over,O
4,O
months,O
.,O
Accidental,O
reexposure,O
by,O
the,O
patient,O
to,O
dipyrone,B
was,O
uneventful,O
.,O
DISCUSSION,O
:,O
The,O
clinical,O
and,O
histologic,O
picture,O
of,O
this,O
case,O
resembles,O
halothane,B
hepatitis,I
",",O
which,O
has,O
a,O
significant,O
mortality,O
rate,O
.,O
CONCLUSIONS,O
:,O
Isoflurane,B
",",O
a,O
common,O
anesthetic,O
agent,O
",",O
can,O
cause,O
severe,O
cholestatic,O
hepatitis,O
.,O
Torsade,O
de,O
pointes,O
induced,O
by,O
metoclopramide,B
in,O
an,O
elderly,O
woman,O
with,O
preexisting,O
complete,O
left,O
bundle,O
branch,O
block,O
.,O
There,O
is,O
a,O
growing,O
list,O
of,O
drugs,O
implicated,O
in,O
acquired,O
long,O
QT,B
syndrome,O
and,O
torsade,O
de,O
pointes,O
.,O
However,O
",",O
the,O
torsadogenic,O
potential,O
of,O
metoclopramide,B
",",O
a,O
commonly,O
used,O
antiemetic,O
and,O
prokinetic,O
drug,O
",",O
has,O
not,O
been,O
reported,O
in,O
the,O
literature,O
",",O
despite,O
its,O
chemical,O
similarity,O
to,O
procainamide,B
.,O
We,O
report,O
on,O
a,O
92,O
-,O
year,O
-,O
old,O
woman,O
with,O
preexisting,O
complete,O
left,O
bundle,O
branch,O
block,O
who,O
developed,O
torsade,O
de,O
pointes,O
after,O
intravenous,O
and,O
oral,O
administration,O
of,O
metoclopramide,B
.,O
This,O
patient,O
also,O
developed,O
torsade,O
de,O
pointes,O
when,O
cisapride,B
and,O
erythromycin,B
were,O
given,O
simultaneously,O
.,O
These,O
two,O
episodes,O
were,O
suppressed,O
successfully,O
after,O
discontinuing,O
the,O
offending,O
drugs,O
and,O
administering,O
class,O
IB,O
drugs,O
.,O
This,O
is,O
the,O
first,O
documentation,O
that,O
metoclopramide,B
provokes,O
torsade,O
de,O
pointes,O
clinically,O
.,O
Metoclopramide,B
should,O
be,O
used,O
cautiously,O
in,O
patients,O
with,O
a,O
risk,O
of,O
torsade,B
de,I
pointes,I
.,O
Dopamine,B
D2,I
receptor,I
signaling,O
controls,O
neuronal,O
cell,O
death,O
induced,O
by,O
muscarinic,B
and,O
glutamatergic,B
drugs,O
.,O
Dopamine,B
(,O
DA,B
),O
",",O
through,O
D1,B
/,I
D2,I
receptor,I
-,I
mediated,I
signaling,O
",",O
plays,O
a,O
major,O
role,O
in,O
the,O
control,O
of,O
epileptic,O
seizures,O
arising,O
in,O
the,O
limbic,O
system,O
.,O
Excitotoxicity,O
leading,O
to,O
neuronal,O
cell,O
death,O
in,O
the,O
affected,O
areas,O
is,O
a,O
major,O
consequence,O
of,O
seizures,O
at,O
the,O
cellular,O
level,O
.,O
In,O
this,O
respect,O
",",O
little,O
is,O
known,O
about,O
the,O
role,O
of,O
DA,B
receptors,O
in,O
the,O
occurrence,O
of,O
epilepsy,O
-,O
induced,O
neuronal,O
cell,O
death,O
.,O
Here,O
we,O
analyze,O
the,O
occurrence,O
of,O
seizures,O
and,O
neurotoxicity,O
in,O
D2R,B
-,O
/,O
-,O
mice,O
treated,O
with,O
the,O
cholinergic,B
agonist,O
pilocarpine,B
.,O
We,O
compared,O
these,O
results,O
with,O
those,O
previously,O
obtained,O
with,O
kainic,B
acid,I
(,O
KA,B
),O
",",O
a,O
potent,O
glutamate,B
agonist,O
.,O
Importantly,O
",",O
D2R,O
-,O
/,O
-,O
mice,O
develop,O
seizures,O
at,O
doses,O
of,O
both,O
drugs,O
that,O
are,O
not,O
epileptogenic,O
for,O
WT,O
littermates,O
and,O
show,O
greater,O
neurotoxicity,O
.,O
However,O
",",O
pilocarpine,B
-,O
induced,O
seizures,O
result,O
in,O
a,O
more,O
widespread,O
neuronal,O
death,O
in,O
both,O
WT,O
and,O
D2R,O
-,O
/,O
-,O
brains,O
in,O
comparison,O
to,O
KA,B
.,O
Thus,O
",",O
the,O
absence,O
of,O
D2R,B
lowers,O
the,O
threshold,O
for,O
seizures,O
induced,O
by,O
both,O
glutamate,B
and,O
acetylcholine,B
.,O
Moreover,O
",",O
the,O
dopaminergic,O
control,O
of,O
epilepsy,O
-,O
induced,O
neurodegeneration,O
seems,O
to,O
be,O
mediated,O
by,O
distinct,O
interactions,O
of,O
D2R,B
signaling,O
with,O
these,O
two,O
neurotransmitters,O
.,O
Steroid,B
structure,O
and,O
pharmacological,O
properties,O
determine,O
the,O
anti,O
-,O
amnesic,O
effects,O
of,O
pregnenolone,B
sulphate,I
in,O
the,O
passive,O
avoidance,O
task,O
in,O
rats,O
.,O
Pregnenolone,B
sulphate,I
(,O
PREGS,B
),O
has,O
generated,O
interest,O
as,O
one,O
of,O
the,O
most,O
potent,O
memory,O
-,O
enhancing,O
neurosteroids,O
to,O
be,O
examined,O
in,O
rodent,O
learning,O
studies,O
",",O
with,O
particular,O
importance,O
in,O
the,O
ageing,O
process,O
.,O
The,O
mechanism,O
by,O
which,O
this,O
endogenous,O
steroid,O
enhances,O
memory,O
formation,O
is,O
hypothesized,O
to,O
involve,O
actions,O
on,O
glutamatergic,B
and,O
GABAergic,B
systems,O
.,O
This,O
hypothesis,O
stems,O
from,O
findings,O
that,O
PREGS,B
is,O
a,O
potent,O
positive,O
modulator,O
of,O
N,B
-,I
methyl,I
-,I
d,I
-,I
aspartate,I
receptors,O
(,O
NMDARs,B
),O
and,O
a,O
negative,O
modulator,O
of,O
gamma,B
-,I
aminobutyric,I
acid,I
(,O
A,B
),O
receptors,O
(,O
GABA,B
(,O
A,I
),O
Rs,O
),O
.,O
Moreover,O
",",O
PREGS,B
is,O
able,O
to,O
reverse,O
the,O
amnesic,O
-,O
like,O
effects,O
of,O
NMDAR,B
and,O
GABA,B
(,O
A,I
),O
R,O
ligands,O
.,O
To,O
investigate,O
this,O
hypothesis,O
",",O
the,O
present,O
study,O
in,O
rats,O
examined,O
the,O
memory,O
-,O
altering,O
abilities,O
of,O
structural,O
analogs,O
of,O
PREGS,B
",",O
which,O
differ,O
in,O
their,O
modulation,O
of,O
NMDAR,B
and,O
/,O
or,O
GABA,B
(,O
A,O
),O
R,O
function,O
.,O
The,O
analogs,O
tested,O
were,O
:,O
11,B
-,I
ketopregnenolone,I
sulphate,I
(,O
an,O
agent,O
that,O
is,O
inactive,O
at,O
GABA,B
(,O
A,O
),O
Rs,O
and,O
NMDARs,O
),O
",",O
epipregnanolone,B
(,O
[,O
3beta,B
-,I
hydroxy,I
-,I
5beta,I
-,I
pregnan,I
-,I
20,I
-,I
one,I
],O
sulphate,I
",",O
an,O
inhibitor,O
of,O
both,O
GABA,B
(,O
A,O
),O
Rs,O
and,O
NMDARs,O
),O
",",O
and,O
a,O
newly,O
synthesized,O
(,O
-,O
),O
PREGS,B
enantiomer,O
(,O
which,O
is,O
identical,O
to,O
PREGS,B
in,O
effects,O
on,O
GABA,B
(,O
A,O
),O
Rs,O
and,O
NMDARs,O
),O
.,O
The,O
memory,O
-,O
enhancing,O
effects,O
of,O
PREGS,B
and,O
its,O
analogs,O
were,O
tested,O
in,O
the,O
passive,O
avoidance,O
task,O
using,O
the,O
model,O
of,O
scopolamine,B
-,O
induced,O
amnesia,O
.,O
Both,O
PREGS,B
and,O
its,O
(,O
-,O
),O
enantiomer,O
blocked,O
the,O
effects,O
of,O
scopolamine,B
.,O
The,O
results,O
show,O
that,O
",",O
unlike,O
PREGS,B
",",O
11,O
-,O
ketopregnenolone,B
sulphate,I
and,O
epipregnanolone,B
sulphate,I
failed,O
to,O
block,O
the,O
effect,O
of,O
scopolamine,B
",",O
suggesting,O
that,O
altering,O
the,O
modulation,O
of,O
NMDA,B
receptors,O
diminishes,O
the,O
memory,O
-,O
enhancing,O
effects,O
of,O
PREGS,B
.,O
Moreover,O
",",O
enantioselectivity,O
was,O
demonstrated,O
by,O
the,O
ability,O
of,O
natural,O
PREGS,B
to,O
be,O
an,O
order,O
of,O
magnitude,O
more,O
effective,O
than,O
its,O
synthetic,O
enantiomer,O
in,O
reversing,O
scopolamine,B
-,O
induced,O
amnesia,O
.,O
These,O
results,O
identify,O
a,O
novel,O
neuropharmacological,O
site,O
for,O
the,O
modulation,O
of,O
memory,O
processes,O
by,O
neuroactive,O
steroids,B
.,O
Activation,O
of,O
poly,B
(,O
ADP,B
-,I
ribose,I
),O
polymerase,O
contributes,O
to,O
development,O
of,O
doxorubicin,B
-,I
induced,I
heart,I
failure,I
.,O
Activation,O
of,O
the,O
nuclear,O
enzyme,O
poly,B
(,O
ADP,B
-,I
ribose,I
),O
polymerase,O
(,O
PARP,B
),O
by,O
oxidant,O
-,O
mediated,O
DNA,B
damage,I
is,O
an,O
important,O
pathway,O
of,O
cell,O
dysfunction,O
and,O
tissue,O
injury,O
in,O
conditions,O
associated,O
with,O
oxidative,O
stress,O
.,O
Increased,O
oxidative,O
stress,O
is,O
a,O
major,O
factor,O
implicated,O
in,O
the,O
cardiotoxicity,O
of,O
doxorubicin,B
(,O
DOX,B
),O
",",O
a,O
widely,O
used,O
antitumor,O
anthracycline,O
antibiotic,O
.,O
Thus,O
",",O
we,O
hypothesized,O
that,O
the,O
activation,O
of,O
PARP,B
may,O
contribute,O
to,O
the,O
DOX,B
-,O
induced,O
cardiotoxicity,O
.,O
Using,O
a,O
dual,O
approach,O
of,O
PARP,B
-,O
1,O
suppression,O
",",O
by,O
genetic,O
deletion,O
or,O
pharmacological,O
inhibition,O
with,O
the,O
phenanthridinone,O
PARP,B
inhibitor,O
PJ34,O
",",O
we,O
now,O
demonstrate,O
the,O
role,O
of,O
PARP,B
in,O
the,O
development,O
of,O
cardiac,O
dysfunction,O
induced,O
by,O
DOX,B
.,O
PARP,B
-,O
1,O
+,O
/,O
+,O
and,O
PARP,B
-,O
1,O
-,O
/,O
-,O
mice,O
received,O
a,O
single,O
injection,O
of,O
DOX,B
(,O
25,O
mg,O
/,O
kg,O
i,O
.,O
p,O
),O
.,O
Five,O
days,O
after,O
DOX,B
administration,O
",",O
left,O
ventricular,O
performance,O
was,O
significantly,O
depressed,O
in,O
PARP,B
-,O
1,O
+,O
/,O
+,O
mice,O
",",O
but,O
only,O
to,O
a,O
smaller,O
extent,O
in,O
PARP,B
-,O
1,O
-,O
/,O
-,O
ones,O
.,O
Similar,O
experiments,O
were,O
conducted,O
in,O
BALB,B
/,O
c,O
mice,O
treated,O
with,O
PJ34,B
or,O
vehicle,O
.,O
Treatment,O
with,O
a,O
PJ34,B
significantly,O
improved,O
cardiac,O
dysfunction,O
and,O
increased,O
the,O
survival,O
of,O
the,O
animals,O
.,O
In,O
addition,O
PJ34,B
significantly,O
reduced,O
the,O
DOX,B
-,I
induced,I
increase,O
in,O
the,O
serum,O
lactate,B
dehydrogenase,I
and,O
creatine,B
kinase,I
activities,O
but,O
not,O
metalloproteinase,O
activation,O
in,O
the,O
heart,O
.,O
Thus,O
",",O
PARP,B
activation,O
contributes,O
to,O
the,O
cardiotoxicity,O
of,O
DOX,B
.,O
PARP,B
inhibitors,O
may,O
exert,O
protective,O
effects,O
against,O
the,O
development,O
of,O
severe,O
cardiac,O
complications,O
associated,O
with,O
the,O
DOX,B
treatment,O
.,O
Spironolactone,B
:,O
is,O
it,O
a,O
novel,O
drug,O
for,O
the,O
prevention,O
of,O
amphotericin,B
B,I
-,I
related,O
hypokalemia,O
in,O
cancer,O
patients,O
?,O
OBJECTIVE,O
:,O
Nephrotoxicity,O
is,O
the,O
major,O
adverse,O
effect,O
of,O
amphotericin,B
B,I
(,I
AmB,I
),I
",",O
often,O
limiting,O
administration,O
of,O
full,O
dosage,O
.,O
Selective,O
distal,O
tubular,O
epithelial,O
toxicity,O
seems,O
to,O
be,O
responsible,O
for,O
the,O
profound,O
potassium,B
wasting,O
that,O
is,O
a,O
major,O
clinical,O
side,O
effect,O
of,O
treatment,O
with,O
AmB,B
.,O
Potassium,B
depletion,O
also,O
potentiates,O
the,O
tubular,O
toxicity,O
of,O
AmB,B
.,O
This,O
study,O
was,O
designed,O
to,O
assess,O
the,O
ability,O
of,O
spironolactone,O
to,O
reduce,O
potassium,B
requirements,O
and,O
to,O
prevent,O
hypokalemia,O
in,O
neutropenic,O
patients,O
on,O
AmB,B
treatment,O
.,O
METHODS,O
:,O
In,O
this,O
study,O
26,O
patients,O
with,O
various,O
hematological,O
disorders,O
were,O
randomized,O
to,O
receive,O
either,O
intravenous,O
AmB,B
alone,O
or,O
AmB,B
and,O
oral,O
spironolactone,B
100,O
mg,O
twice,O
daily,O
when,O
developing,O
a,O
proven,O
or,O
suspected,O
fungal,O
infection,O
.,O
RESULTS,O
:,O
Patients,O
receiving,O
concomitant,O
AmB,B
and,O
spironolactone,B
had,O
significantly,O
higher,O
plasma,O
potassium,B
levels,O
than,O
those,O
receiving,O
AmB,B
alone,O
(,O
P,O
=,O
0,O
.,O
27,O
),O
.,O
Those,O
patients,O
receiving,O
AmB,B
and,O
spironolactone,B
required,O
significantly,O
less,O
potassium,O
supplementation,O
to,O
maintain,O
their,O
plasma,O
potassium,O
within,O
the,O
normal,O
range,O
(,O
P,O
=,O
0,O
.,O
22,O
),O
.,O
Moreover,O
",",O
urinary,O
potassium,O
losses,O
were,O
significantly,O
less,O
in,O
patients,O
receiving,O
AmB,B
and,O
spironolactone,B
than,O
those,O
receiving,O
AmB,B
alone,O
(,O
P,O
=,O
0,O
.,O
40,O
),O
.,O
CONCLUSION,O
:,O
This,O
study,O
showed,O
that,O
spironolactone,B
can,O
reduce,O
potassium,O
requirements,O
and,O
prevent,O
hypokalemia,O
by,O
reducing,O
urinary,O
potassium,O
loss,O
in,O
neutropenic,O
patients,O
on,O
AmB,B
treatment,O
.,O
Erectile,O
dysfunction,O
occurs,O
following,O
substantia,O
nigra,O
lesions,O
in,O
the,O
rat,O
.,O
Erectile,O
function,O
was,O
assessed,O
6,O
weeks,O
following,O
uni,O
-,O
and,O
bilateral,O
injections,O
of,O
6,B
-,I
hydroxydopamine,I
in,O
the,O
substantia,O
nigra,O
nucleus,O
of,O
the,O
brain,O
.,O
Behavioral,O
apomorphine,B
-,O
induced,O
penile,O
erections,O
were,O
reduced,O
(,O
5,O
/,O
8,O
),O
and,O
increased,O
(,O
3,O
/,O
8,O
),O
in,O
uni,O
-,O
and,O
bilateral,O
lesioned,O
animals,O
.,O
Intracavernous,O
pressures,O
",",O
following,O
electrical,O
stimulation,O
of,O
the,O
cavernous,O
nerve,O
",",O
decreased,O
in,O
lesioned,O
animals,O
.,O
Lesions,O
of,O
the,O
substantia,O
nigra,B
were,O
confirmed,O
by,O
histology,O
.,O
Concentration,O
of,O
dopamine,B
and,O
its,O
metabolites,O
were,O
decreased,O
in,O
the,O
striatum,O
of,O
substantia,B
nigra,I
lesioned,O
rats,O
.,O
Lesions,O
of,O
the,O
substantia,B
nigra,I
are,O
therefore,O
associated,O
with,O
erectile,O
dysfunction,O
in,O
rats,O
and,O
may,O
serve,O
as,O
a,O
model,O
to,O
study,O
erectile,O
dysfunction,O
in,O
Parkinson,O
',O
s,O
disease,O
.,O
Nicotine,B
potentiation,O
of,O
morphine,B
-,O
induced,O
catalepsy,O
in,O
mice,O
.,O
In,O
the,O
present,O
study,O
",",O
effects,O
of,O
nicotine,B
on,O
catalepsy,O
induced,O
by,O
morphine,B
in,O
mice,O
have,O
been,O
investigated,O
.,O
Morphine,B
but,O
not,O
nicotine,B
induced,O
a,O
dose,O
-,O
dependent,O
catalepsy,O
.,O
The,O
response,O
of,O
morphine,B
was,O
potentiated,O
by,O
nicotine,B
.,O
Intraperitoneal,O
administration,O
of,O
atropine,B
",",O
naloxone,B
",",O
mecamylamine,B
",",O
and,O
hexamethonium,B
to,O
mice,O
reduced,O
catalepsy,O
induced,O
by,O
a,O
combination,O
of,O
morphine,B
with,O
nicotine,B
.,O
Intracerebroventricular,O
injection,O
of,O
atropine,B
",",O
hexamethonium,B
",",O
and,O
naloxone,B
also,O
decreased,O
catalepsy,O
induced,O
by,O
morphine,B
plus,O
nicotine,B
.,O
Intraperitoneal,O
administration,O
of,O
atropine,B
",",O
but,O
not,O
intraperitoneal,O
or,O
intracerebroventricular,O
injection,O
of,O
hexamethonium,B
",",O
decreased,O
the,O
effect,O
of,O
a,O
single,O
dose,O
of,O
morphine,B
.,O
It,O
was,O
concluded,O
that,O
morphine,B
catalepsy,O
can,O
be,O
elicited,O
by,O
opioid,B
and,O
cholinergic,B
receptors,O
",",O
and,O
the,O
potentiation,O
of,O
morphine,B
induced,O
by,O
nicotine,B
may,O
also,O
be,O
mediated,O
through,O
cholinergic,B
receptor,O
mechanisms,O
.,O
Force,O
overflow,O
and,O
levodopa,B
-,O
induced,O
dyskinesias,O
in,O
Parkinson,O
',O
s,O
disease,O
.,O
We,O
assessed,O
force,O
coordination,O
of,O
the,O
hand,O
in,O
Parkinson,O
',O
s,O
disease,O
and,O
its,O
relationship,O
to,O
motor,O
complications,O
of,O
levodopa,B
therapy,O
",",O
particularly,O
to,O
levodopa,B
-,O
induced,O
dyskinesias,O
(,O
LID,O
),O
.,O
We,O
studied,O
two,O
groups,O
of,O
Parkinson,B
',I
s,I
disease,I
patients,O
with,O
(,O
Parkinson,B
',I
s,I
disease,I
+,O
LID,O
",",O
n,O
=,O
23,O
),O
and,O
without,O
levodopa,B
-,O
induced,O
dyskinesias,O
(,O
Parkinson,B
',I
s,I
disease,I
-,O
LID,O
",",O
n,O
=,O
10,O
),O
",",O
and,O
age,O
-,O
matched,O
healthy,O
controls,O
.,O
The,O
motor,O
score,O
of,O
the,O
Unified,O
Parkinson,B
',I
s,I
Disease,I
Rating,I
Scale,I
",",O
a,O
dyskinesia,O
score,O
and,O
force,O
in,O
a,O
grip,O
-,O
lift,O
paradigm,O
were,O
assessed,O
ON,O
and,O
OFF,O
levodopa,B
.,O
A,O
pathological,O
increase,O
of,O
forces,O
was,O
seen,O
in,O
ON,B
-,O
state,O
in,O
Parkinson,B
',O
s,O
disease,O
+,O
LID,O
only,O
.,O
In,O
Parkinson,B
',O
s,O
disease,O
+,O
LID,O
",",O
the,O
force,O
involved,O
in,O
pressing,O
down,O
the,O
object,O
before,O
lifting,O
was,O
significantly,O
increased,O
by,O
levodopa,B
(,O
by,O
61,O
%,O
",",O
P,O
<,O
0,O
.,O
5,O
),O
.,O
An,O
overshooting,O
of,O
peak,O
grip,O
force,O
by,O
51,O
%,O
(,O
P,O
<,O
0,O
.,O
5,O
),O
and,O
of,O
static,O
grip,O
force,O
by,O
45,O
%,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
was,O
observed,O
in,O
the,O
ON,O
-,O
compared,O
with,O
the,O
OFF,O
-,O
drug,O
condition,O
.,O
In,O
contrast,O
",",O
no,O
excessive,O
force,O
was,O
found,O
in,O
Parkinson,O
',O
s,O
disease,O
-,O
LID,O
.,O
Peak,O
grip,O
force,O
in,O
ON,O
-,O
state,O
was,O
140,O
%,O
(,O
P,O
<,O
0,O
.,O
5,O
),O
higher,O
in,O
Parkinson,O
',O
s,O
disease,O
+,O
LID,O
than,O
in,O
Parkinson,O
',O
s,O
disease,O
-,O
LID,O
",",O
while,O
static,O
grip,O
force,O
was,O
increased,O
by,O
138,O
%,O
(,O
P,O
<,O
0,O
1,O
),O
between,O
groups,O
.,O
Severity,O
of,O
peak,O
-,O
dose,O
dyskinesias,O
was,O
strongly,O
correlated,O
with,O
grip,O
force,O
in,O
ON,O
-,O
state,O
(,O
r,O
=,O
0,O
.,O
79,O
with,O
peak,O
force,O
",",O
P,O
<,O
0,O
.,O
1,O
),O
.,O
No,O
correlation,O
was,O
observed,O
between,O
forces,O
and,O
the,O
motor,O
score,O
as,O
well,O
as,O
with,O
the,O
daily,O
dose,O
of,O
dopaminergic,O
medication,O
.,O
Force,O
excess,O
was,O
only,O
observed,O
in,O
patients,O
with,O
LID,O
and,O
motor,O
fluctuations,O
.,O
A,O
close,O
relationship,O
was,O
seen,O
between,O
the,O
overshooting,O
of,O
forces,O
and,O
dyskinesias,O
in,O
the,O
ON,O
-,O
drug,O
condition,O
.,O
We,O
postulate,O
that,O
both,O
LID,B
and,O
grip,O
force,O
excess,O
share,O
common,O
pathophysiological,O
mechanisms,O
related,O
to,O
motor,O
fluctuations,O
.,O
Behavioral,O
effects,O
of,O
MK,B
-,I
801,I
on,O
reserpine,B
-,O
treated,O
mice,O
.,O
The,O
effects,O
of,O
dizocilpine,B
(,O
MK,B
-,I
801,I
),O
",",O
a,O
noncompetitive,O
N,B
-,I
methyl,I
-,I
D,I
-,I
aspartate,I
(,O
NMDA,B
),O
receptor,O
antagonist,O
",",O
were,O
studied,O
on,O
dopamine,B
-,O
related,O
behaviors,O
induced,O
by,O
reserpine,B
treatments,O
.,O
This,O
study,O
focuses,O
on,O
behavioral,O
syndromes,O
that,O
may,O
used,O
as,O
models,O
for,O
Parkinson,O
',O
s,O
disease,O
",",O
or,O
tardive,O
dyskinesia,O
",",O
and,O
its,O
response,O
after,O
glutamatergic,O
blockage,O
.,O
Reserpine,B
(,O
1,B
mg,I
/,I
kg,I
),O
",",O
administered,O
once,O
every,O
other,O
day,O
for,O
4,O
days,O
",",O
produced,O
increases,O
in,O
orofacial,O
dyskinesia,O
",",O
tongue,O
protrusion,O
and,O
vacuous,O
chewing,O
in,O
mice,O
",",O
which,O
are,O
signs,O
indicative,O
of,O
tardive,O
dyskinesia,O
.,O
Reserpine,B
also,O
produced,O
tremor,B
and,O
catalepsy,B
",",O
which,O
are,O
signs,O
suggestive,O
of,O
Parkinson,B
',I
s,I
disease,I
.,O
MK,B
-,O
801,I
(,O
0,O
.,O
1,O
mg,O
/,O
kg,O
),O
",",O
administered,O
30,O
min,O
before,O
the,O
observation,O
test,O
",",O
prevented,O
the,O
vacuous,O
chewing,O
movements,O
",",O
tongue,O
protrusions,O
and,O
catalepsy,B
induced,O
by,O
reserpine,B
.,O
However,O
",",O
MK,B
-,O
801,I
injection,O
produced,O
a,O
significant,O
increase,O
of,O
tremor,B
in,O
reserpine,B
-,O
treated,O
mice,O
.,O
Reserpine,B
(,O
1,O
mg,O
/,O
kg,O
),O
",",O
administered,O
90,O
min,O
before,O
the,O
test,O
and,O
followed,O
by,O
apomophine,B
injection,O
(,O
0,O
.,O
1,O
mg,O
/,O
kg,O
),O
5,O
min,O
before,O
the,O
test,O
",",O
did,O
not,O
produce,O
oral,O
dyskinesia,O
in,O
mice,O
.,O
On,O
the,O
other,O
hand,O
",",O
reserpine,B
induced,O
increases,O
in,O
tremor,B
and,O
catalepsy,B
compared,O
to,O
control,O
mice,O
.,O
MK,B
-,I
801,I
(,O
0,O
.,O
1,O
mg,O
/,O
kg,O
),O
administration,O
attenuated,O
the,O
catalepsy,B
and,O
tremor,B
induced,O
by,O
reserpine,B
.,O
Pretreatment,O
with,O
reserpine,B
(,O
1,O
mg,O
/,O
kg,O
),O
24,O
h,O
before,O
the,O
observation,O
test,O
produced,O
increases,O
in,O
vacuous,O
chewing,O
movements,O
and,O
tongue,O
protrusion,O
",",O
as,O
well,O
as,O
increases,O
in,O
tremor,O
and,O
catalepsy,O
",",O
whereas,O
MK,B
-,O
801,I
(,O
0,O
.,O
1,O
mg,O
/,O
kg,O
),O
injection,O
90,O
min,O
before,O
the,O
test,O
reversed,O
the,O
effects,O
of,O
reserpine,B
.,O
These,O
results,O
show,O
that,O
reserpine,B
produces,O
different,O
and,O
abnormal,O
movements,O
",",O
which,O
are,O
related,O
to,O
dose,O
and,O
schedule,O
employed,O
and,O
can,O
be,O
considered,O
as,O
parkinsonian,O
-,O
like,O
and,O
tardive,O
dsykinesia,O
signs,O
.,O
The,O
glutamatergic,O
blockage,O
produced,O
by,O
NMDA,B
can,O
restore,O
these,O
signs,O
",",O
such,O
as,O
vacuous,O
chewing,O
movements,O
",",O
tongue,O
protrusions,O
",",O
catalepsy,O
and,O
tremor,O
according,O
to,O
the,O
employed,O
model,O
.,O
Risperidone,B
-,I
associated,I
",",O
benign,O
transient,O
visual,O
disturbances,O
in,O
schizophrenic,O
patients,O
with,O
a,O
past,O
history,O
of,O
LSD,B
abuse,O
.,O
Two,O
schizophrenic,O
patients,O
",",O
who,O
had,O
a,O
prior,O
history,O
of,O
LSD,B
abuse,O
and,O
who,O
had,O
previously,O
developed,O
EPS,B
with,O
classic,O
antipsychotics,O
",",O
were,O
successfully,O
treated,O
with,O
risperidone,B
.,O
They,O
both,O
reported,O
short,O
episodes,O
of,O
transient,O
visual,O
disturbances,O
",",O
which,O
appeared,O
immediately,O
after,O
starting,O
treatment,O
with,O
risperidone,B
.,O
This,O
imagery,O
resembled,O
visual,O
disturbances,O
previously,O
experienced,O
as,O
flashbacks,B
related,O
to,O
prior,O
LSD,B
consumption,O
.,O
Risperidone,O
administration,O
was,O
continued,O
and,O
the,O
visual,O
disturbances,O
gradually,O
wore,O
off,O
.,O
During,O
a,O
six,O
-,O
month,O
follow,O
-,O
up,O
period,O
",",O
there,O
was,O
no,O
recurrence,O
of,O
visual,O
disturbances,O
.,O
This,O
phenomenon,O
may,O
be,O
interpreted,O
as,O
a,O
benign,O
",",O
short,O
-,O
term,O
and,O
self,O
-,O
limiting,O
side,O
effect,O
which,O
does,O
not,O
contraindicate,O
the,O
use,O
of,O
risperidone,O
or,O
interfere,O
with,O
treatment,O
.,O
Conclusions,O
based,O
on,O
two,O
case,O
reports,O
should,O
be,O
taken,O
with,O
appropriate,O
caution,O
.,O
Topiramate,B
-,O
induced,O
nephrolithiasis,O
.,O
Topiramate,B
is,O
a,O
recently,O
developed,O
antiepileptic,O
medication,O
that,O
is,O
becoming,O
more,O
widely,O
prescribed,O
because,O
of,O
its,O
efficacy,O
in,O
treating,O
refractory,O
seizures,O
.,O
Urologists,O
should,O
be,O
aware,O
that,O
this,O
medication,O
can,O
cause,O
metabolic,O
acidosis,O
in,O
patients,O
secondary,O
to,O
inhibition,O
of,O
carbonic,B
anhydrase,I
.,O
In,O
addition,O
",",O
a,O
distal,O
tubular,O
acidification,O
defect,O
may,O
result,O
",",O
thus,O
impairing,O
the,O
normal,O
compensatory,O
drop,O
in,O
urine,O
pH,O
.,O
These,O
factors,O
can,O
lead,O
to,O
the,O
development,O
of,O
calcium,B
phosphate,I
nephrolithiasis,I
.,O
We,O
report,O
the,O
first,O
two,O
cases,O
of,O
topiramate,B
-,I
induced,I
nephrolithiasis,I
in,O
the,O
urologic,O
literature,O
.,O
Ketamine,B
in,O
war,O
/,O
tropical,O
surgery,O
(,O
a,O
final,O
tribute,O
to,O
the,O
racemic,O
mixture,O
),O
.,O
A,O
technique,O
of,O
continuous,O
intravenous,O
anaesthesia,O
with,O
ketamine,B
was,O
used,O
successfully,O
during,O
the,O
Somalia,O
civil,O
war,O
in,O
1994,O
and,O
in,O
north,O
Uganda,O
in,O
1999,O
for,O
64,O
operations,O
in,O
62,O
patients,O
",",O
aged,O
from,O
6,O
weeks,O
to,O
70,O
years,O
",",O
undergoing,O
limb,O
and,O
abdominal,O
surgery,O
including,O
caesarian,O
sections,O
and,O
interventions,O
in,O
neonates,O
.,O
Operations,O
lasting,O
up,O
to,O
2h,O
could,O
be,O
performed,O
in,O
the,O
absence,O
of,O
sophisticated,O
equipment,O
such,O
as,O
pulse,O
oximeters,O
or,O
ventilators,O
in,O
patients,O
on,O
spontaneous,O
ventilation,O
breathing,O
air,O
/,O
oxygen,B
only,O
.,O
After,O
premedication,O
with,O
diazepam,B
",",O
glycopyrrolate,B
and,O
local,O
anaesthesia,O
",",O
and,O
induction,O
with,O
standard,O
doses,O
of,O
ketamine,B
",",O
a,O
maintenance,O
dose,O
of,O
10,O
-,O
20,O
microg,O
/,O
kg,O
/,O
min,O
of,O
ketamine,B
proved,O
safe,O
and,O
effective,O
.,O
Emphasis,O
was,O
placed,O
on,O
bedside,O
clinical,O
monitoring,O
",",O
relying,O
heavily,O
on,O
the,O
heart,B
rate,I
.,O
Diazepam,B
",",O
unless,O
contraindicated,O
or,O
risky,O
",",O
remains,O
the,O
only,O
necessary,O
complementary,O
drug,O
to,O
ketamine,B
as,O
it,O
buffers,O
its,O
cardiovascular,O
response,O
and,O
decreases,O
the,O
duration,O
and,O
intensity,O
of,O
operative,O
and,O
postoperative,O
hallucinations,O
.,O
Local,O
anaesthetic,B
blocks,O
were,O
useful,O
in,O
decreasing,O
the,O
requirement,O
for,O
postoperative,O
analgesia,O
.,O
An,O
antisialogue,B
was,O
usually,O
unnecessary,O
in,O
operations,O
lasting,O
up,O
to,O
2,O
h,O
",",O
glycopyrrolate,B
being,O
the,O
best,O
choice,O
for,O
its,O
lowest,O
psychotropic,O
and,O
chronotropic,O
effects,O
",",O
especially,O
in,O
a,O
hot,O
climate,O
.,O
Experience,O
in,O
war,O
/,O
tropical,O
settings,O
suggests,O
this,O
technique,O
could,O
be,O
useful,O
in,O
civilian,O
contexts,O
such,O
as,O
outdoor,O
life,O
-,O
saving,O
emergency,O
surgery,O
or,O
in,O
mass,O
casualties,O
where,O
",",O
e,O
.,O
g,O
.,O
amputation,O
and,O
rapid,O
extrication,O
were,O
required,O
.,O
Intravenous,O
ribavirin,B
treatment,O
for,O
severe,O
adenovirus,B
disease,O
in,O
immunocompromised,O
children,O
.,O
BACKGROUND,O
:,O
Adenovirus,B
is,O
an,O
important,O
cause,O
of,O
morbidity,O
and,O
mortality,O
in,O
the,O
immunocompromised,O
host,O
.,O
The,O
incidence,O
of,O
severe,O
adenovirus,B
disease,O
in,O
pediatrics,O
is,O
increasing,O
in,O
association,O
with,O
growing,O
numbers,O
of,O
immunocompromised,O
children,O
",",O
where,O
case,O
fatality,O
rates,O
as,O
high,O
as,O
50,O
%,O
to,O
80,O
%,O
have,O
been,O
reported,O
.,O
There,O
are,O
no,O
approved,O
antiviral,B
agents,O
with,O
proven,O
efficacy,O
for,O
the,O
treatment,O
of,O
severe,O
adenovirus,B
disease,O
",",O
nor,O
are,O
there,O
any,O
prospective,O
randomized,O
",",O
controlled,O
trials,O
of,O
potentially,O
useful,O
anti,B
-,I
adenovirus,I
therapies,O
.,O
Apparent,O
clinical,O
success,O
in,O
the,O
treatment,O
of,O
severe,O
adenovirus,B
disease,O
is,O
limited,O
to,O
a,O
few,O
case,O
reports,O
and,O
small,O
series,O
.,O
Experience,O
is,O
greatest,O
with,O
intravenous,O
ribavirin,B
and,O
cidofovir,B
.,O
Ribavirin,B
",",O
a,O
guanosine,B
analogue,O
",",O
has,O
broad,O
antiviral,O
activity,O
against,O
both,O
RNA,B
and,O
DNA,B
viruses,O
",",O
including,O
documented,O
activity,O
against,O
adenovirus,B
in,O
vitro,O
.,O
Ribavirin,B
is,O
licensed,O
in,O
aerosol,O
form,O
for,O
the,O
treatment,O
of,O
respiratory,O
syncytial,O
virus,O
infection,O
",",O
and,O
orally,O
in,O
combination,O
with,O
interferon,B
to,O
treat,O
hepatitis,B
C,I
.,O
Intravenous,O
ribavirin,B
is,O
the,O
treatment,O
of,O
choice,O
for,O
infection,O
with,O
hemorrhagic,O
fever,O
viruses,O
.,O
The,O
most,O
common,O
adverse,O
effect,O
of,O
intravenous,O
ribavirin,B
is,O
reversible,O
mild,O
anemia,O
.,O
The,O
use,O
of,O
cidofovir,B
in,O
severe,O
adenovirus,O
infection,O
has,O
been,O
limited,O
by,O
adverse,O
effects,O
",",O
the,O
most,O
significant,O
of,O
which,O
is,O
nephrotoxicity,O
.,O
OBJECTIVE,O
:,O
We,O
report,O
our,O
experience,O
with,O
intravenous,O
ribavirin,B
therapy,O
for,O
severe,O
adenovirus,B
disease,O
in,O
a,O
series,O
of,O
immunocompromised,O
children,O
and,O
review,O
the,O
literature,O
.,O
DESIGN,O
/,O
METHODS,O
:,O
We,O
retrospectively,O
reviewed,O
the,O
medical,O
records,O
of,O
5,O
children,O
treated,O
with,O
intravenous,O
ribavirin,B
for,O
documented,O
severe,O
adenovirus,B
disease,O
.,O
Two,O
patients,O
developed,O
adenovirus,B
hemorrhagic,I
cystitis,I
after,O
cardiac,O
and,O
bone,O
marrow,O
transplants,O
",",O
respectively,O
.,O
The,O
bone,O
marrow,O
transplant,O
patient,O
also,O
received,O
intravenous,O
cidofovir,B
for,O
progressive,O
disseminated,O
disease,O
.,O
An,O
additional,O
3,O
children,O
developed,O
adenovirus,B
pneumonia,I
;,O
2,O
were,O
neonates,O
",",O
1,O
of,O
whom,O
had,O
partial,O
DiGeorge,B
syndrome,I
.,O
The,O
remaining,O
infant,O
had,O
recently,O
undergone,O
a,O
cardiac,O
transplant,O
.,O
Intravenous,O
ribavirin,B
was,O
administered,O
on,O
a,O
compassionate,O
-,O
use,O
protocol,O
.,O
RESULTS,O
:,O
Complete,O
clinical,O
recovery,O
followed,O
later,O
by,O
viral,O
clearance,O
was,O
observed,O
in,O
2,O
children,O
:,O
the,O
cardiac,O
transplant,O
recipient,O
with,O
adenovirus,B
hemorrhagic,I
cystitis,I
and,O
the,O
immunocompetent,O
neonate,O
with,O
adenovirus,B
pneumonia,I
.,O
The,O
remaining,O
3,O
children,O
died,O
of,O
adenovirus,B
disease,O
.,O
Intravenous,O
ribavirin,B
therapy,O
was,O
well,O
tolerated,O
.,O
Use,O
of,O
cidofovir,B
in,O
1,O
child,O
was,O
associated,O
with,O
progressive,O
renal,O
failure,O
and,O
neutropenia,O
.,O
DISCUSSION,O
:,O
Our,O
series,O
of,O
patients,O
is,O
representative,O
of,O
the,O
spectrum,O
of,O
immunocompromised,O
children,O
at,O
greatest,O
risk,O
for,O
severe,O
adenovirus,B
disease,O
",",O
namely,O
solid,O
-,O
organ,O
and,O
bone,O
marrow,O
transplant,O
recipients,O
",",O
neonates,O
",",O
and,O
children,O
with,O
immunodeficiency,O
.,O
Although,O
intravenous,O
ribavirin,B
was,O
not,O
effective,O
for,O
all,O
children,O
with,O
severe,O
adenovirus,B
disease,I
in,O
this,O
series,O
or,O
in,O
the,O
literature,O
",",O
therapy,O
is,O
unlikely,O
to,O
be,O
of,O
benefit,O
if,O
begun,O
late,O
in,O
the,O
course,O
of,O
the,O
infection,O
.,O
Early,O
identification,O
",",O
eg,O
by,O
polymerase,O
chain,O
reaction,O
of,O
those,O
patients,O
at,O
risk,O
of,O
disseminated,O
adenovirus,B
disease,I
may,O
permit,O
earlier,O
antiviral,O
treatment,O
and,O
better,O
evaluation,O
of,O
therapeutic,O
response,O
.,O
CONCLUSIONS,O
:,O
Two,O
of,O
5,O
children,O
with,O
severe,O
adenovirus,B
disease,O
treated,O
with,O
intravenous,O
ribavirin,B
recovered,O
.,O
The,O
availability,O
of,O
newer,O
rapid,O
diagnostic,O
techniques,O
",",O
such,O
as,O
polymerase,O
chain,O
reaction,O
",",O
may,O
make,O
earlier,O
",",O
more,O
effective,O
treatment,O
of,O
adenovirus,B
infection,O
possible,O
.,O
Given,O
the,O
seriousness,O
and,O
increasing,O
prevalence,O
of,O
adenovirus,B
disease,O
in,O
certain,O
hosts,O
",",O
especially,O
children,O
",",O
a,O
large,O
",",O
multicenter,O
clinical,O
trial,O
of,O
potentially,O
useful,O
anti,O
-,O
adenoviral,O
therapies,O
",",O
such,O
as,O
intravenous,O
ribavirin,B
",",O
is,O
clearly,O
required,O
to,O
demonstrate,O
the,O
most,O
effective,O
and,O
least,O
toxic,O
therapy,O
.,O
Delayed,O
asystolic,O
cardiac,O
arrest,O
after,O
diltiazem,B
overdose,O
;,O
resuscitation,O
with,O
high,O
dose,O
intravenous,O
calcium,B
.,O
A,O
51,O
year,O
old,O
man,O
took,O
a,O
mixed,O
overdose,O
including,O
1,O
.,O
8,O
-,O
3,O
.,O
6,O
g,O
of,O
diltiazem,B
",",O
paracetamol,B
",",O
aspirin,B
",",O
isosorbide,B
nitrate,I
",",O
and,O
alcohol,B
.,O
He,O
initially,O
presented,O
to,O
hospital,O
after,O
six,O
hours,O
with,O
mild,O
hypotension,O
and,O
was,O
treated,O
with,O
activated,O
charcoal,B
and,O
intravenous,O
fluids,O
.,O
Eighteen,O
hours,O
after,O
the,O
overdose,O
he,O
had,O
two,O
generalised,O
tonic,O
-,O
clonic,O
seizures,O
.,O
The,O
patient,O
remained,O
unresponsive,O
with,O
junctional,O
bradycardia,O
",",O
unrecordable,O
blood,B
pressure,I
",",O
and,O
then,O
became,O
asystolic,O
.,O
He,O
was,O
resuscitated,O
with,O
high,O
dose,O
(,O
13,O
.,O
5,O
g,O
),O
intravenous,O
calcium,B
and,O
adrenaline,B
(,O
epinephrine,B
),O
.,O
He,O
required,O
inotropic,O
support,O
and,O
temporary,O
pacing,O
over,O
the,O
next,O
48,O
hours,O
.,O
This,O
case,O
suggests,O
there,O
is,O
a,O
role,O
for,O
aggressive,O
high,O
dose,O
intravenous,O
calcium,B
therapy,O
in,O
severe,O
diltiazem,O
overdose,O
",",O
particularly,O
with,O
the,O
onset,O
of,O
asystole,O
.,O
It,O
should,O
be,O
considered,O
early,O
in,O
cases,O
of,O
cardiac,O
arrest,O
after,O
diltiazem,O
overdose,O
.,O
The,O
case,O
also,O
highlights,O
the,O
problems,O
with,O
delayed,O
toxicity,O
when,O
whole,O
bowel,O
irrigation,O
is,O
not,O
administered,O
.,O
Low,B
-,I
molecular,I
-,I
weight,I
heparin,I
for,O
the,O
treatment,O
of,O
patients,O
with,O
mechanical,O
heart,O
valves,O
.,O
BACKGROUND,O
:,O
The,O
interruption,O
of,O
oral,O
anticoagulant,O
(,O
OAC,B
),O
administration,O
is,O
sometimes,O
indicated,O
in,O
patients,O
with,O
mechanical,O
heart,O
valves,O
",",O
mainly,O
before,O
noncardiac,O
surgery,O
",",O
non,O
-,O
surgical,O
interventions,O
",",O
and,O
pregnancy,O
.,O
Unfractionated,B
heparin,I
(,O
UH,B
),O
is,O
currently,O
the,O
substitute,O
for,O
selected,O
patients,O
.,O
Low,B
-,I
molecular,I
-,I
weight,I
heparin,I
(,O
LMWH,B
),O
offers,O
theoretical,O
advantages,O
over,O
UH,B
",",O
but,O
is,O
not,O
currently,O
considered,O
in,O
clinical,O
guidelines,O
as,O
an,O
alternative,O
to,O
UH,B
in,O
patients,O
with,O
prosthetic,O
valves,O
.,O
HYPOTHESIS,O
:,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
review,O
the,O
data,O
accumulated,O
so,O
far,O
on,O
the,O
use,O
of,O
LMWH,B
in,O
this,O
patient,O
population,O
and,O
to,O
discuss,O
its,O
applicability,O
in,O
common,O
practice,O
.,O
METHODS,O
:,O
For,O
this,O
paper,O
",",O
the,O
current,O
medical,O
literature,O
on,O
LMWH,B
in,O
patients,O
with,O
mechanical,O
heart,O
valves,O
was,O
extensively,O
reviewed,O
.,O
RESULTS,O
:,O
There,O
were,O
eight,O
series,O
and,O
six,O
case,O
reports,O
.,O
None,O
of,O
the,O
studies,O
was,O
randomized,O
",",O
and,O
only,O
one,O
was,O
prospective,O
.,O
Data,O
to,O
establish,O
the,O
thromboembolic,O
risk,O
were,O
incomplete,O
.,O
After,O
excluding,O
case,O
reports,O
",",O
the,O
following,O
groups,O
were,O
constructed,O
:,O
(,O
a,O
),O
short,O
-,O
term,O
administration,O
",",O
after,O
valve,O
insertion,O
(,O
n,O
=,O
212,O
),O
;,O
(,O
b,O
),O
short,O
-,O
term,O
",",O
perioperative,O
(,O
noncardiac,O
),O
/,O
periprocedural,O
(,O
n,O
=,O
114,O
),O
;,O
(,O
c,O
),O
long,O
-,O
term,O
",",O
due,O
to,O
intolerance,O
to,O
OAC,B
(,O
n,O
=,O
16,O
),O
;,O
(,O
d,O
),O
long,O
-,O
term,O
",",O
in,O
pregnancy,O
(,O
n,O
=,O
10,O
),O
.,O
The,O
incidence,O
rate,O
of,O
thromboembolism,B
was,O
0,O
.,O
9,O
%,O
for,O
all,O
the,O
studies,O
and,O
0,O
.,O
5,O
",",O
0,O
",",O
20,O
",",O
and,O
0,O
%,O
in,O
groups,O
a,O
",",O
b,O
",",O
c,O
",",O
and,O
d,O
",",O
respectively,O
;,O
for,O
hemorrhage,B
",",O
the,O
overall,O
rate,O
was,O
3,O
.,O
4,O
%,O
(,O
3,O
.,O
8,O
",",O
2,O
.,O
6,O
",",O
10,O
",",O
and,O
0,O
%,O
for,O
the,O
respective,O
groups,O
.,O
CONCLUSIONS,O
:,O
In,O
patients,O
with,O
mechanical,O
heart,O
valves,O
",",O
short,O
-,O
term,O
LMWH,B
therapy,O
compares,O
favorably,O
with,O
UH,B
.,O
Data,O
on,O
mid,B
-,I
and,I
long,I
-,I
term,I
LMWH,B
administration,O
in,O
these,O
patients,O
are,O
sparse,O
.,O
Further,O
randomized,O
studies,O
are,O
needed,O
to,O
confirm,O
the,O
safety,O
and,O
precise,O
indications,O
for,O
the,O
use,O
of,O
LMWH,B
in,O
patients,O
with,O
mechanical,O
heart,O
valves,O
.,O
Cardiac,O
arrest,O
after,O
intravenous,O
metoclopramide,B
-,I
a,O
case,O
of,O
five,O
repeated,O
injections,O
of,O
metoclopramide,B
causing,O
five,O
episodes,O
of,O
cardiac,O
arrest,O
.,O
We,O
describe,O
a,O
patient,O
where,O
intravenous,O
injection,O
of,O
metoclopramide,B
was,O
immediately,O
followed,O
by,O
asystole,O
repeatedly,O
.,O
The,O
patient,O
received,O
metoclopramide,B
10,O
mg,O
i,O
.,O
v,O
five,O
times,O
during,O
48,O
h,O
.,O
After,O
interviewing,O
the,O
attending,O
nurses,O
and,O
reviewing,O
the,O
written,O
documentation,O
",",O
it,O
is,O
clear,O
that,O
every,O
administration,O
of,O
metoclopramide,B
was,O
immediately,O
(,O
within,O
s,O
),O
followed,O
by,O
asystole,O
.,O
The,O
asystole,O
lasted,O
15,O
-,O
30,O
s,O
on,O
four,O
occasions,O
",",O
on,O
one,O
occasion,O
it,O
lasted,O
2,O
min,O
.,O
The,O
patient,O
received,O
atropine,B
0,O
.,O
5,O
-,O
1,O
mg,O
and,O
chest,O
compressions,O
",",O
before,O
sinus,O
rhythm,O
again,O
took,O
over,O
.,O
We,O
interpret,O
this,O
as,O
episodes,O
of,O
cardiac,O
arrest,O
caused,O
by,O
metoclopramide,B
.,O
The,O
rapid,O
injection,O
via,O
the,O
central,O
venous,O
route,O
and,O
the,O
concomitant,O
tapering,O
of,O
dopamine,O
infusion,O
might,O
have,O
contributed,O
in,O
precipitating,O
the,O
adverse,O
drug,O
reaction,O
.,O
Immunohistochemical,O
study,O
on,O
inducible,O
type,O
of,O
nitric,B
oxide,I
(,O
iNOS,B
),O
",",O
basic,B
fibroblast,I
growth,I
factor,I
(,O
bFGF,B
),O
and,O
tumor,B
growth,I
factor,I
-,I
beta1,I
(,O
TGF,B
-,I
beta1,I
),O
in,O
arteritis,O
induced,O
in,O
rats,O
by,O
fenoldopam,O
and,O
theophylline,O
",",O
vasodilators,O
.,O
Arteritis,O
induced,O
in,O
rats,O
by,O
vasodilators,O
",",O
fenoldopam,O
and,O
theophylline,O
",",O
was,O
examined,O
immunohistochemically,O
for,O
expressions,O
of,O
inducible,O
type,O
of,O
nitric,B
oxide,I
synthase,I
(,O
iNOS,B
),O
",",O
basic,B
fibroblast,I
growth,I
factor,I
(,O
bFGF,B
),O
and,O
tumor,B
growth,I
factor,I
-,I
beta1,I
(,O
TGF,B
-,I
beta1,I
),O
.,O
Rats,O
were,O
administered,O
fenoldopam,B
for,O
24,O
hours,O
by,O
intravenous,O
infusion,O
with,O
or,O
without,O
following,O
repeated,O
daily,O
oral,O
administrations,O
of,O
theophylline,B
.,O
Irrespective,O
of,O
theophylline,B
administration,O
",",O
iNOS,B
antigens,O
were,O
remarkably,O
abundant,O
in,O
ED,O
-,O
1,O
-,O
positive,O
cells,O
on,O
day,O
5,O
and,O
8,O
post,O
-,O
fenoldopam,B
-,O
infusion,O
(,O
DPI,O
),O
;,O
bFGF,B
antigens,O
were,O
remarkably,O
abundant,O
in,O
ED,O
-,O
1,O
-,O
positive,O
cells,O
on,O
1,O
and,O
3,O
DPI,O
;,O
TGF,B
-,O
beta1,I
antigens,O
were,O
observed,O
in,O
ED,O
-,O
1,O
-,O
positive,O
cells,O
on,O
and,O
after,O
5,O
DPI,O
.,O
These,O
results,O
suggest,O
that,O
the,O
peak,O
expression,O
of,O
iNOS,B
antigen,O
was,O
followed,O
by,O
that,O
of,O
bFGF,B
antigen,O
",",O
and,O
bFGF,B
may,O
have,O
a,O
suppressive,O
effect,O
on,O
iNOS,B
expression,O
in,O
these,O
rat,O
arteritis,O
models,O
.,O
On,O
the,O
other,O
hand,O
",",O
TGF,B
-,O
beta1,I
was,O
not,O
considered,O
to,O
have,O
a,O
suppressive,O
effect,O
on,O
iNOS,B
expression,O
in,O
these,O
models,O
.,O
The,O
striatum,B
as,O
a,O
target,O
for,O
anti,O
-,O
rigor,O
effects,O
of,O
an,O
antagonist,O
of,O
mGluR1,B
",",O
but,O
not,O
an,O
agonist,O
of,O
group,O
II,O
metabotropic,O
glutamate,B
receptors,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
find,O
out,O
whether,O
the,O
metabotropic,O
receptor,O
1,O
(,O
mGluR1,B
),O
and,O
group,O
II,O
mGluRs,O
",",O
localized,O
in,O
the,O
striatum,B
",",O
are,O
involved,O
in,O
antiparkinsonian,O
-,O
like,O
effects,O
in,O
rats,O
.,O
Haloperidol,B
(,O
1,O
mg,O
/,O
kg,O
ip,O
),O
induced,O
parkinsonian,O
-,O
like,O
muscle,O
rigidity,O
",",O
measured,O
as,O
an,O
increased,O
resistance,O
of,O
a,O
rat,O
',O
s,O
hind,O
foot,O
to,O
passive,O
flexion,O
and,O
extension,O
at,O
the,O
ankle,O
joint,O
.,O
(,O
RS,B
),O
-,O
1,B
-,I
aminoindan,I
-,I
1,I
",",O
5,O
-,O
dicarboxylic,O
acid,O
(,O
AIDA,B
;,O
0,O
.,O
5,O
-,O
15,O
microg,O
/,O
0,O
.,O
5,O
microl,O
),O
",",O
a,O
potent,O
and,O
selective,O
mGluR1,B
antagonist,O
",",O
or,O
(,O
2R,B
",",O
4R,I
),O
-,O
4,I
-,I
aminopyrrolidine,I
-,I
2,I
",",O
4,I
-,I
dicarboxylate,I
(,O
2R,I
",",O
4R,I
-,I
APDC,I
;,O
7,O
.,O
5,O
-,O
15,O
microg,B
/,O
0,O
.,O
5,O
microl,B
),O
",",O
a,O
selective,O
group,O
II,O
agonist,O
",",O
was,O
injected,O
bilaterally,O
into,O
the,O
striatum,B
of,O
haloperidol,B
-,O
treated,O
animals,O
.,O
AIDA,B
in,O
doses,O
of,O
7,O
.,O
5,O
-,O
15,O
microg,B
/,O
0,O
.,O
5,O
microl,B
diminished,O
the,O
haloperidol,B
-,O
induced,O
muscle,O
rigidity,O
.,O
In,O
contrast,O
",",O
2R,B
",",O
4R,B
-,O
APDC,B
injections,O
were,O
ineffective,O
.,O
The,O
present,O
results,O
may,O
suggest,O
that,O
the,O
blockade,O
of,O
striatal,O
mGluR1,B
",",O
but,O
not,O
the,O
stimulation,O
of,O
group,O
II,O
mGluRs,O
",",O
may,O
ameliorate,O
parkinsonian,O
muscle,O
rigidity,O
.,O
A,O
phase,O
II,O
study,O
of,O
thalidomide,B
in,O
advanced,O
metastatic,O
renal,O
cell,O
carcinoma,O
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
the,O
toxicity,O
and,O
activity,O
of,O
thalidomide,B
in,O
patients,O
with,O
advanced,O
metastatic,O
renal,O
cell,O
cancer,O
and,O
to,O
measure,O
changes,O
of,O
one,O
angiogenic,O
factor,O
",",O
vascular,O
endothelial,O
growth,O
factor,O
(,O
VEGF,B
),O
165,O
",",O
with,O
therapy,O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
29,O
patients,O
were,O
enrolled,O
on,O
a,O
study,O
of,O
thalidomide,B
using,O
an,O
intra,O
-,O
patient,O
dose,O
escalation,O
schedule,O
.,O
Patients,O
began,O
thalidomide,B
at,O
400,O
mg,O
/,O
d,O
and,O
escalated,O
as,O
tolerated,O
to,O
1200,O
mg,O
/,O
d,O
by,O
day,O
54,O
.,O
Fifty,O
-,O
nine,O
per,O
cent,O
of,O
patients,O
had,O
had,O
previous,O
therapy,O
with,O
IL,B
-,O
2,O
and,O
52,O
%,O
were,O
performance,O
status,O
2,O
or,O
3,O
.,O
Systemic,O
plasma,O
VEGF165,B
levels,O
were,O
measured,O
by,O
dual,O
monoclonal,O
ELISA,O
in,O
8,O
patients,O
.,O
RESULTS,O
:,O
24,O
patients,O
were,O
evaluable,O
for,O
response,O
with,O
one,O
partial,O
response,O
of,O
11,O
months,O
duration,O
of,O
a,O
patient,O
with,O
hepatic,O
and,O
pulmonary,O
metastases,O
(,O
4,O
%,O
),O
",",O
one,O
minor,O
response,O
",",O
and,O
2,O
patients,O
stable,O
for,O
over,O
6,O
months,O
.,O
Somnolence,O
and,O
constipation,O
were,O
prominent,O
toxicities,O
and,O
most,O
patients,O
could,O
not,O
tolerate,O
the,O
1200,O
mg,O
/,O
day,O
dose,O
level,O
.,O
Systemic,O
plasma,O
VEGF165,B
levels,O
did,O
not,O
change,O
with,O
therapy,O
.,O
CONCLUSION,O
:,O
These,O
results,O
are,O
consistent,O
with,O
a,O
low,O
level,O
of,O
activity,O
of,O
thalidomide,B
in,O
renal,O
cell,O
carcinoma,O
.,O
Administration,O
of,O
doses,O
over,O
800,O
mg,O
/,O
day,O
was,O
difficult,O
to,O
achieve,O
in,O
this,O
patient,O
population,O
",",O
however,O
lower,O
doses,O
were,O
practical,O
.,O
The,O
dose,O
-,O
response,O
relationship,O
",",O
if,O
any,O
",",O
of,O
thalidomide,B
for,O
renal,O
cell,O
carcinoma,O
is,O
unclear,O
.,O
Can,O
lidocaine,B
reduce,O
succinylcholine,B
induced,O
postoperative,O
myalgia,O
?,O
This,O
study,O
was,O
undertaken,O
to,O
determine,O
the,O
effect,O
of,O
lidocaine,B
pretreatment,O
on,O
reduction,O
of,O
succinylcholine,B
-,O
induced,O
myalgia,O
in,O
patients,O
undergoing,O
general,O
anesthesia,O
for,O
gynecological,O
surgery,O
.,O
One,O
hundred,O
and,O
thirty,O
-,O
five,O
patients,O
were,O
assigned,O
to,O
one,O
of,O
three,O
groups,O
in,O
a,O
prospective,O
",",O
double,O
blind,O
",",O
randomized,O
manner,O
.,O
Group,O
PS,O
",",O
the,O
control,O
group,O
",",O
received,O
normal,B
saline,I
and,O
succinylcholine,B
1,O
0.5,O
mg,O
x,O
kg,O
(,O
-,O
1,O
),O
;,O
Group,O
LS,O
",",O
lidocaine,B
1,O
0.5,O
mg,O
x,O
kg,O
(,O
-,O
1,O
),O
and,O
succinylcholine,B
1,O
0.5,O
mg,O
x,O
kg,O
(,O
-,O
1,O
),O
;,O
Group,O
PR,O
",",O
normal,B
saline,I
and,O
rocuronium,B
0,O
0.5,O
mg,O
x,O
kg,O
(,O
-,O
1,O
),O
.,O
6,O
mg,O
x,O
kg,O
(,O
-,O
1,O
),O
.,O
Morphine,B
0,O
.,O
1,O
mg,O
x,O
kg,O
(,O
-,O
1,O
),O
iv,O
was,O
given,O
for,O
premedication,O
and,O
all,O
patients,O
were,O
monitored,O
with,O
a,O
noninvasive,O
blood,O
pressure,O
monitor,O
",",O
ECG,B
and,O
pulse,O
oximetry,O
.,O
Anesthesia,O
was,O
induced,O
with,O
5,O
mg,O
.,O
kg,O
(,O
-,O
1,O
),O
thiopental,B
iv,O
.,O
followed,O
by,O
succinylcholine,B
(,O
Group,O
PS,O
",",O
LS,O
),O
or,O
rocuronium,B
(,O
Group,O
PR,O
),O
for,O
tracheal,O
intubation,O
.,O
Following,O
administration,O
of,O
these,O
agents,O
",",O
the,O
presence,O
",",O
and,O
degree,O
of,O
fasciculation,O
were,O
assessed,O
visually,O
on,O
a,O
four,O
point,O
scale,O
by,O
one,O
investigator,O
who,O
was,O
blinded,O
to,O
the,O
drug,O
administered,O
.,O
The,O
blood,O
pressure,O
and,O
heart,O
rate,O
of,O
each,O
patient,O
were,O
monitored,O
on,O
nine,O
occasions,O
.,O
Twenty,O
-,O
four,O
hours,O
later,O
",",O
any,O
myalgia,O
experienced,O
was,O
assessed,O
according,O
to,O
a,O
structured,O
questionaire,O
and,O
graded,O
by,O
a,O
four,O
point,O
scale,O
by,O
one,O
investigator,O
blinded,O
to,O
the,O
intraoperative,O
management,O
.,O
The,O
results,O
indicate,O
that,O
muscle,O
fasciculation,O
was,O
not,O
found,O
in,O
Group,O
PR,O
while,O
the,O
patients,O
in,O
Group,O
LS,O
had,O
a,O
lower,O
incidence,O
of,O
muscle,O
fasciculation,O
than,O
those,O
in,O
Group,O
PS,O
(,O
p,O
<,O
0,O
0.001,O
),O
.,O
At,O
24,O
h,O
",",O
the,O
incidence,O
of,O
myalgia,O
was,O
higher,O
in,O
Group,O
PS,O
than,O
in,O
Group,O
LS,O
and,O
PR,O
(,O
p,O
<,O
0,O
0.05,O
),O
.,O
A,O
correlation,O
was,O
not,O
found,O
between,O
the,O
incidence,O
of,O
myalgia,O
and,O
the,O
occurrence,O
of,O
muscle,O
fasciculation,O
.,O
The,O
changes,O
in,O
systolic,O
and,O
diastolic,O
blood,B
pressure,I
and,O
heart,B
rate,I
were,O
not,O
significant,O
among,O
the,O
three,O
groups,O
.,O
In,O
conclusion,O
",",O
where,O
succinylcholine,B
is,O
used,O
",",O
lidocaine,B
is,O
proven,O
to,O
be,O
the,O
useful,O
pretreatment,O
agent,O
for,O
the,O
reduction,O
of,O
postoperative,O
myalgia,O
.,O
Reduced,O
sodium,B
channel,I
density,I
",",O
altered,O
voltage,O
dependence,O
of,O
inactivation,O
",",O
and,O
increased,O
susceptibility,O
to,O
seizures,O
in,O
mice,O
lacking,O
sodium,B
channel,I
beta,I
2,I
-,I
subunits,I
.,O
Sodium,B
channel,I
beta,B
-,O
subunits,O
modulate,O
channel,O
gating,O
",",O
assembly,O
",",O
and,O
cell,O
surface,O
expression,O
in,O
heterologous,O
cell,O
systems,O
.,O
We,O
generated,O
beta2,B
(,O
-,O
/,O
-,O
),O
mice,O
to,O
investigate,O
the,O
role,O
of,O
beta2,B
in,O
control,O
of,O
sodium,B
channel,I
density,O
",",O
localization,O
",",O
and,O
function,O
in,O
neurons,O
in,O
vivo,O
.,O
Measurements,O
of,O
[,O
(,O
3,O
),O
H,O
],O
saxitoxin,B
(,O
STX,B
),O
binding,O
showed,O
a,O
significant,O
reduction,O
in,O
the,O
level,O
of,O
plasma,O
membrane,O
sodium,B
channels,I
in,O
beta2,B
(,O
-,O
/,O
-,O
),O
neurons,O
.,O
The,O
loss,O
of,O
beta2,B
resulted,O
in,O
negative,O
shifts,O
in,O
the,O
voltage,O
dependence,O
of,O
inactivation,O
as,O
well,O
as,O
significant,O
decreases,O
in,O
sodium,B
current,I
density,I
in,O
acutely,O
dissociated,O
hippocampal,O
neurons,O
.,O
The,O
integral,O
of,O
the,O
compound,O
action,O
potential,O
in,O
optic,O
nerve,O
was,O
significantly,O
reduced,O
",",O
and,O
the,O
threshold,O
for,O
action,O
potential,O
generation,O
was,O
increased,O
",",O
indicating,O
a,O
reduction,O
in,O
the,O
level,O
of,O
functional,O
plasma,O
membrane,O
sodium,B
channels,O
.,O
In,O
contrast,O
",",O
the,O
conduction,O
velocity,O
",",O
the,O
number,O
and,O
size,O
of,O
axons,O
in,O
the,O
optic,B
nerve,I
",",O
and,O
the,O
specific,O
localization,O
of,O
Na,B
(,O
v,O
),O
1,O
0.28,O
6,O
channels,O
in,O
the,O
nodes,O
of,O
Ranvier,O
were,O
unchanged,O
0.38,O
beta2,B
(,O
-,O
/,O
-,O
),O
mice,O
displayed,O
increased,O
susceptibility,O
to,O
seizures,O
",",O
as,O
indicated,O
by,O
reduced,O
latency,O
and,O
threshold,O
for,O
pilocarpine,B
-,O
induced,O
seizures,O
",",O
but,O
seemed,O
normal,O
in,O
other,O
neurological,O
tests,O
0.72,O
Our,O
observations,O
show,O
that,O
beta2,B
-,O
subunits,O
play,O
an,O
important,O
role,O
in,O
the,O
regulation,O
of,O
sodium,B
channel,I
density,O
and,O
function,O
in,O
neurons,O
in,O
vivo,O
and,O
are,O
required,O
for,O
normal,O
action,O
potential,O
generation,O
and,O
control,O
of,O
excitability,O
.,O
Acute,O
liver,B
failure,I
with,O
concurrent,O
bupropion,B
and,O
carbimazole,B
therapy,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
fatal,O
liver,B
failure,I
possibly,O
associated,O
with,O
concurrent,O
use,O
of,O
bupropion,B
and,O
carbimazole,B
.,O
CASE,O
SUMMARY,O
:,O
A,O
41,O
-,O
year,O
-,O
old,O
Chinese,O
man,O
with,O
a,O
history,O
of,O
hyperthyroidism,B
had,O
been,O
treated,O
with,O
carbimazole,B
and,O
propranolol,B
for,O
the,O
past,O
5,O
years,O
.,O
He,O
received,O
a,O
10,O
-,O
day,O
course,O
of,O
bupropion,B
as,O
an,O
aid,O
for,O
smoking,O
cessation,O
10,O
weeks,O
prior,O
to,O
presentation,O
.,O
He,O
developed,O
acute,O
liver,B
failure,O
with,O
rapid,O
deterioration,O
of,O
renal,B
function,O
.,O
Liver,B
biopsy,O
showed,O
evidence,O
of,O
nonspecific,O
drug,B
-,O
induced,O
acute,O
liver,O
injury,O
.,O
His,O
condition,O
was,O
further,O
complicated,O
by,O
sepsis,B
and,O
coagulopathy,O
.,O
Death,O
resulted,O
19,O
days,O
after,O
the,O
onset,O
of,O
symptoms,O
.,O
The,O
likelihood,O
that,O
bupropion,B
induced,O
hepatotoxicity,O
in,O
our,O
patient,O
was,O
possible,O
",",O
based,O
on,O
the,O
Naranjo,O
probability,O
scale,O
.,O
DISCUSSION,O
:,O
Although,O
there,O
is,O
increasing,O
evidence,O
of,O
hepatotoxicity,O
induced,O
by,O
bupropion,B
",",O
this,O
is,O
the,O
first,O
case,O
of,O
fatality,O
that,O
could,O
have,O
resulted,O
from,O
acute,O
liver,O
failure,O
in,O
a,O
patient,O
receiving,O
bupropion,B
while,O
on,O
concomitant,O
treatment,O
with,O
carbimazole,B
.,O
CONCLUSIONS,O
:,O
Clinicians,O
should,O
be,O
aware,O
of,O
the,O
possibility,O
of,O
acute,O
liver,O
insult,O
induced,O
by,O
bupropion,B
given,O
concurrently,O
with,O
other,O
hepatotoxic,O
drugs,O
.,O
Pyeloureteral,B
filling,I
defects,I
associated,O
with,O
systemic,O
anticoagulation,O
:,O
a,O
case,O
report,O
.,O
The,O
etiology,O
of,O
pyeloureteritis,B
cystica,I
has,O
long,O
been,O
attributed,O
to,O
chronic,O
infection,O
and,O
inflammation,O
.,O
A,O
case,O
is,O
presented,O
that,O
is,O
unique,O
in,O
that,O
the,O
acute,O
onset,O
and,O
the,O
rapid,O
resolution,O
of,O
pyeloureteral,B
filling,I
defects,I
in,O
this,O
patient,O
were,O
documented,O
by,O
radiography,O
.,O
There,O
is,O
no,O
evidence,O
of,O
antecedent,O
or,O
concurrent,O
infection,O
in,O
this,O
patient,O
.,O
The,O
disease,O
occurred,O
subsequent,O
to,O
the,O
initiation,O
of,O
heparin,B
therapy,O
for,O
suspected,O
pelvic,O
thrombophlebitis,O
and,O
cleared,O
rapidly,O
subsequent,O
to,O
its,O
discontinuation,O
.,O
The,O
rate,O
of,O
resolution,O
of,O
the,O
radiographic,O
findings,O
may,O
be,O
helpful,O
in,O
distinguishing,O
between,O
TRUE,O
pyeloureteritis,O
cystica,O
and,O
submucosal,O
hemorrhage,O
.,O
Nephrotoxic,O
effects,O
in,O
high,O
-,O
risk,O
patients,O
undergoing,O
angiography,O
.,O
BACKGROUND,O
:,O
The,O
use,O
of,O
iodinated,B
contrast,I
medium,I
can,O
result,O
in,O
nephropathy,O
.,O
Whether,O
iso,B
-,O
osmolar,I
contrast,I
medium,I
is,O
less,O
nephrotoxic,O
than,O
low,B
-,O
osmolar,I
contrast,I
medium,I
in,O
high,O
-,O
risk,O
patients,O
is,O
uncertain,O
.,O
METHODS,O
:,O
We,O
conducted,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
",",O
prospective,O
",",O
multicenter,O
study,O
comparing,O
the,O
nephrotoxic,O
effects,O
of,O
an,O
iso,B
-,O
osmolar,I
",",O
dimeric,O
",",O
nonionic,O
contrast,I
medium,I
",",O
iodixanol,B
",",O
with,O
those,O
of,O
a,O
low,B
-,O
osmolar,I
",",O
nonionic,O
",",O
monomeric,O
contrast,I
medium,I
",",O
iohexol,B
.,O
The,O
study,O
involved,O
129,O
patients,O
with,O
diabetes,O
with,O
serum,O
creatinine,B
concentrations,O
of,O
1,O
.,O
5,O
to,O
3,O
.,O
5,O
mg,O
per,O
deciliter,O
who,O
underwent,O
coronary,O
or,O
aortofemoral,O
angiography,O
.,O
The,O
primary,O
end,O
point,O
was,O
the,O
peak,O
increase,O
from,O
base,O
line,O
in,O
the,O
creatinine,B
concentration,O
during,O
the,O
three,O
days,O
after,O
angiography,O
.,O
Other,O
end,O
points,O
were,O
an,O
increase,O
in,O
the,O
creatinine,B
concentration,O
of,O
0,O
.,O
5,O
mg,O
per,O
deciliter,O
or,O
more,O
",",O
an,O
increase,O
of,O
1,O
.,O
0,O
mg,O
per,O
deciliter,O
or,O
more,O
",",O
and,O
a,O
change,O
in,O
the,O
creatinine,B
concentration,O
from,O
day,O
0,O
to,O
day,O
7,O
.,O
RESULTS,O
:,O
The,O
creatinine,B
concentration,O
increased,O
significantly,O
less,O
in,O
patients,O
who,O
received,O
iodixanol,B
.,O
From,O
day,O
0,O
to,O
day,O
3,O
",",O
the,O
mean,O
peak,O
increase,O
in,O
creatinine,B
was,O
0,O
.,O
13,O
mg,O
per,O
deciliter,O
in,O
the,O
iodixanol,B
group,O
and,O
0,O
.,O
55,O
mg,O
per,O
deciliter,O
in,O
the,O
iohexol,B
group,O
(,O
P,O
=,O
0,O
.,O
1,O
;,O
the,O
increase,O
with,O
iodixanol,B
minus,O
the,O
increase,O
with,O
iohexol,B
",",O
-,O
0,O
.,O
42,O
mg,O
per,O
deciliter,O
[,O
95,O
percent,O
confidence,O
interval,O
",",O
-,O
0,O
.,O
73,O
to,O
-,O
0,O
.,O
22,O
],O
),O
.,O
Two,O
of,O
the,O
64,O
patients,O
in,O
the,O
iodixanol,B
group,O
(,O
3,O
percent,O
),O
had,O
an,O
increase,O
in,O
the,O
creatinine,B
concentration,O
of,O
0,O
.,O
5,O
mg,O
per,O
deciliter,O
or,O
more,O
",",O
as,O
compared,O
with,O
17,O
of,O
the,O
65,O
patients,O
in,O
the,O
iohexol,B
group,O
(,O
26,O
percent,O
),O
(,O
P,O
=,O
0,O
.,O
2,O
;,O
odds,O
ratio,O
for,O
such,O
an,O
increase,O
in,O
the,O
iodixanol,B
group,O
",",O
0,O
.,O
9,O
[,O
95,O
percent,O
confidence,O
interval,O
",",O
0,O
.,O
2,O
to,O
0,O
.,O
41,O
],O
),O
.,O
No,O
patient,O
receiving,O
iodixanol,B
had,O
an,O
increase,O
of,O
1,O
.,O
0,O
mg,O
per,O
deciliter,O
or,O
more,O
",",O
but,O
10,O
patients,O
in,O
the,O
iohexol,B
group,O
(,O
15,O
percent,O
),O
did,O
.,O
The,O
mean,O
change,O
in,O
the,O
creatinine,B
concentration,O
from,O
day,O
0,O
to,O
day,O
7,O
was,O
0,O
.,O
7,O
mg,O
per,O
deciliter,O
in,O
the,O
iodixanol,B
group,O
and,O
0,O
.,O
24,O
mg,O
per,O
deciliter,O
in,O
the,O
iohexol,B
group,O
(,O
P,O
=,O
0,O
.,O
3,O
;,O
value,O
in,O
the,O
iodixanol,B
group,O
minus,O
the,O
value,O
in,O
the,O
iohexol,B
group,O
",",O
-,O
0,O
.,O
17,O
mg,O
per,O
deciliter,O
[,O
95,O
percent,O
confidence,O
interval,O
",",O
-,O
0,O
.,O
34,O
to,O
-,O
0,O
.,O
7,O
].,O
.,O
CONCLUSIONS,O
:,O
Nephropathy,O
induced,O
by,O
contrast,O
medium,O
may,O
be,O
less,O
likely,O
to,O
develop,O
in,O
high,O
-,O
risk,O
patients,O
when,O
iodixanol,B
is,O
used,O
rather,O
than,O
a,O
low,O
-,O
osmolar,O
",",O
nonionic,O
contrast,O
medium,O
.,O
Protective,O
effect,O
of,O
edaravone,B
against,O
streptomycin,B
-,O
induced,O
vestibulotoxicity,O
in,O
the,O
guinea,O
pig,O
.,O
This,O
study,O
investigated,O
alleviation,O
of,O
streptomycin,B
-,O
induced,O
vestibulotoxicity,O
by,O
edaravone,B
in,O
guinea,O
pigs,O
.,O
Edaravone,B
",",O
a,O
free,O
radical,O
scavenger,O
",",O
has,O
potent,O
free,O
radical,O
quenching,O
action,O
and,O
is,O
used,O
in,O
clinical,O
practice,O
to,O
treat,O
cerebral,O
infarction,O
.,O
Streptomycin,B
was,O
administered,O
to,O
the,O
inner,O
ear,O
by,O
osmotic,O
pump,O
for,O
24,O
h,O
",",O
and,O
edaravone,B
(,O
n,O
=,O
8,O
),O
or,O
saline,B
(,O
n,O
=,O
6,O
),O
was,O
intraperitoneally,O
injected,O
once,O
a,O
day,O
for,O
7,O
days,O
.,O
We,O
observed,O
horizontal,O
vestibulo,O
-,O
ocular,O
reflex,O
as,O
a,O
marker,O
of,O
postoperative,O
vestibular,O
function,O
.,O
Animals,O
injected,O
with,O
saline,B
showed,O
statistically,O
smaller,O
gains,O
than,O
those,O
injected,O
with,O
edaravone,B
.,O
These,O
results,O
suggest,O
that,O
edaravone,B
suppresses,O
streptomycin,B
-,I
induced,O
vestibulotoxicity,O
.,O
Levodopa,B
-,I
induced,O
oromandibular,O
dystonia,O
in,O
progressive,O
supranuclear,O
palsy,O
.,O
Levodopa,B
-,I
induced,O
dyskinesias,O
have,O
been,O
reported,O
in,O
Parkinson,O
',O
s,O
disease,O
and,O
multiple,O
system,O
atrophy,O
.,O
Cranial,O
dystonias,O
are,O
rare,O
in,O
patients,O
with,O
progressive,O
supranuclear,O
palsy,O
(,O
PSP,O
),O
.,O
In,O
this,O
report,O
we,O
describe,O
an,O
unusual,O
case,O
of,O
reversible,O
levodopa,B
-,O
induced,O
Oromandibular,B
dystonia,I
(,O
OMD,B
),O
in,O
a,O
PSP,O
patient,O
to,O
highlight,O
the,O
importance,O
of,O
recognizing,O
this,O
drug,O
related,O
complication,O
in,O
the,O
management,O
of,O
PSP,O
",",O
and,O
discuss,O
the,O
possible,O
underlying,O
pathophysiology,O
.,O
Case,O
report,O
:,O
Dexatrim,B
(,O
Phenylpropanolamine,B
),O
as,O
a,O
cause,O
of,O
myocardial,O
infarction,O
.,O
Phenylpropanolamine,B
(,O
PPA,B
),O
is,O
a,O
sympathetic,O
amine,O
used,O
in,O
over,O
-,O
the,O
-,O
counter,O
cold,O
remedies,O
and,O
weight,O
-,O
control,O
preparations,O
worldwide,O
.,O
Its,O
use,O
has,O
been,O
associated,O
with,O
hypertensive,O
episodes,O
and,O
hemorrhagic,O
strokes,O
in,O
younger,O
women,O
.,O
Several,O
reports,O
have,O
linked,O
the,O
abuse,O
of,O
PPA,B
with,O
myocardial,O
injury,O
",",O
especially,O
when,O
overdose,O
is,O
involved,O
.,O
We,O
report,O
here,O
the,O
first,O
case,O
of,O
Dexatrim,B
(,O
PPA,B
),O
-,O
induced,O
myocardial,O
injury,O
in,O
a,O
young,O
woman,O
who,O
was,O
using,O
it,O
at,O
recommended,O
doses,O
for,O
weight,O
control,O
.,O
In,O
addition,O
",",O
we,O
review,O
the,O
7,O
other,O
cases,O
of,O
PPA,B
related,O
myocardial,O
injury,O
that,O
have,O
been,O
reported,O
so,O
far,O
.,O
Physicians,O
and,O
patients,O
should,O
be,O
alert,O
to,O
the,O
potential,O
cardiac,O
risk,O
associated,O
with,O
the,O
use,O
of,O
PPA,B
",",O
even,O
at,O
doses,O
generally,O
considered,O
to,O
be,O
safe,O
.,O
Differential,O
diagnosis,O
of,O
high,O
serum,O
creatine,B
kinase,I
levels,O
in,O
systemic,B
lupus,I
erythematosus,I
.,O
We,O
report,O
the,O
clinical,O
and,O
bioptic,O
findings,O
for,O
a,O
57,O
-,O
year,O
-,O
old,O
woman,O
with,O
severe,O
chloroquine,B
-,I
induced,I
myopathy,I
.,O
Since,O
1989,O
",",O
she,O
had,O
been,O
suffering,O
from,O
systemic,B
lupus,I
erythematosus,I
(,O
SLE,B
),O
with,O
renal,O
involvement,O
and,O
undergone,O
periods,O
of,O
treatment,O
with,O
azathioprine,B
and,O
cyclophosphamide,B
.,O
Additional,O
therapy,O
with,O
chloroquine,B
(,O
CQ,B
),O
was,O
started,O
because,O
of,O
arthralgia,O
.,O
At,O
the,O
same,O
time,O
",",O
slightly,O
increased,O
creatine,B
kinase,I
(,O
CK,B
),O
levels,O
were,O
noted,O
.,O
Myositis,O
was,O
suspected,O
",",O
and,O
the,O
patient,O
was,O
treated,O
with,O
steroids,O
.,O
The,O
CK,B
increase,O
persisted,O
",",O
however,O
",",O
and,O
she,O
developed,O
progressive,O
muscular,O
weakness,O
and,O
muscular,O
atrophy,O
.,O
Routine,O
controls,O
revealed,O
markedly,O
elevated,O
CK,B
levels,O
of,O
1,O
",",O
700,O
U,O
/,O
l,O
.,O
The,O
neurological,O
and,O
electrophysiological,O
findings,O
were,O
not,O
typical,O
of,O
myositis,O
.,O
Thus,O
",",O
muscle,O
biopsy,O
of,O
the,O
deltoid,O
muscle,O
was,O
performed,O
in,O
order,O
to,O
exclude,O
polymyositis,O
or,O
toxic,O
myopathy,O
.,O
As,O
it,O
revealed,O
chloroquine,B
-,I
induced,I
myopathy,I
",",O
medication,O
was,O
stopped,O
.,O
Discriminating,O
between,O
primary,O
SLE,B
-,O
induced,O
affection,O
of,O
the,O
musculoskeletal,O
system,O
and,O
drug,O
-,O
induced,O
side,O
effects,O
is,O
important,O
for,O
appropriate,O
treatment,O
of,O
SLE,B
patients,O
.,O
Seizure,O
associated,O
with,O
sleep,O
deprivation,O
and,O
sustained,O
-,O
release,O
bupropion,B
.,O
This,O
case,O
report,O
describes,O
a,O
generalized,O
seizure,O
associated,O
with,O
sustained,O
-,O
release,O
bupropion,B
use,O
and,O
sleep,O
deprivation,O
.,O
The,O
subject,O
",",O
a,O
31,O
-,O
year,O
-,O
old,O
female,O
smoker,O
",",O
was,O
participating,O
in,O
a,O
clinical,O
trial,O
evaluating,O
an,O
investigational,O
medication,O
for,O
smoking,O
cessation,O
that,O
used,O
sustained,O
-,O
release,O
bupropion,B
as,O
an,O
active,O
control,O
.,O
After,O
5,O
weeks,O
of,O
bupropion,B
use,O
",",O
the,O
subject,O
experienced,O
a,O
generalized,O
tonic,O
clonic,O
seizure,O
after,O
staying,O
up,O
nearly,O
all,O
night,O
packing,O
and,O
moving,O
to,O
a,O
new,O
residence,O
.,O
The,O
patient,O
had,O
no,O
other,O
risk,O
factors,O
for,O
seizures,O
.,O
We,O
suggest,O
that,O
sleep,O
deprivation,O
may,O
add,O
to,O
the,O
risk,O
of,O
bupropion,B
-,O
associated,O
seizures,O
.,O
Postoperative,O
myalgia,O
after,O
succinylcholine,B
:,O
no,O
evidence,O
for,O
an,O
inflammatory,O
origin,O
.,O
A,O
common,O
side,O
effect,O
associated,O
with,O
succinylcholine,B
is,O
postoperative,O
myalgia,O
.,O
The,O
pathogenesis,O
of,O
this,O
myalgia,B
is,O
still,O
unclear,O
;,O
inflammation,O
has,O
been,O
suggested,O
but,O
without,O
convincing,O
evidence,O
.,O
We,O
designed,O
the,O
present,O
study,O
to,O
investigate,O
whether,O
an,O
inflammatory,O
reaction,O
contributes,O
to,O
this,O
myalgia,B
.,O
The,O
incidence,O
and,O
severity,O
of,O
succinylcholine,B
-,I
associated,I
myalgia,I
was,O
determined,O
in,O
64,O
patients,O
pretreated,O
with,O
saline,B
or,O
dexamethasone,B
before,O
succinylcholine,B
(,O
n,O
=,O
32,O
for,O
each,O
),O
.,O
Incidence,O
and,O
severity,O
of,O
myalgia,B
did,O
not,O
differ,O
significantly,O
between,O
the,O
two,O
groups,O
:,O
15,O
patients,O
in,O
the,O
dexamethasone,B
group,O
complained,O
of,O
myalgia,B
compared,O
with,O
18,O
patients,O
in,O
the,O
saline,B
group,O
",",O
and,O
severe,O
myalgia,B
was,O
reported,O
by,O
five,O
patients,O
and,O
three,O
patients,O
",",O
respectively,O
(,O
not,O
significant,O
),O
.,O
At,O
48,O
h,O
after,O
surgery,O
",",O
12,O
patients,O
in,O
both,O
groups,O
still,O
suffered,O
from,O
myalgia,O
(,O
not,O
significant,O
),O
.,O
In,O
addition,O
",",O
interleukin,B
-,I
6,I
(,O
IL,B
-,I
6,I
),O
as,O
an,O
early,O
marker,O
of,O
inflammation,O
was,O
assessed,O
in,O
a,O
subgroup,O
of,O
10,O
patients,O
pretreated,O
with,O
saline,B
.,O
We,O
found,O
an,O
increase,O
of,O
IL,B
-,I
6,I
for,O
only,O
three,O
patients,O
",",O
but,O
only,O
one,O
patient,O
reported,O
myalgia,O
;,O
no,O
relationship,O
between,O
myalgia,O
and,O
the,O
increase,O
of,O
IL,B
-,I
6,I
was,O
found,O
.,O
In,O
conclusion,O
",",O
there,O
is,O
no,O
evidence,O
for,O
an,O
inflammatory,O
origin,O
of,O
succinylcholine,B
-,O
associated,O
myalgia,O
.,O
IMPLICATIONS,O
:,O
Administration,O
of,O
dexamethasone,B
before,O
succinylcholine,B
was,O
not,O
effective,O
in,O
decreasing,O
the,O
incidence,O
or,O
the,O
severity,O
of,O
succinylcholine,B
-,O
induced,O
postoperative,O
myalgia,O
.,O
Furthermore,O
",",O
there,O
was,O
no,O
significant,O
relationship,O
between,O
postoperative,O
myalgia,O
and,O
time,O
course,O
of,O
interleukin,B
-,O
6,I
concentrations,O
",",O
a,O
marker,O
of,O
inflammation,O
.,O
Pretreatment,O
with,O
dexamethasone,B
is,O
not,O
justified,O
to,O
prevent,O
postoperative,O
myalgia,O
after,O
succinylcholine,B
.,O
Effect,O
of,O
lindane,B
on,O
hepatic,O
and,O
brain,O
cytochrome,B
P450s,I
and,O
influence,O
of,O
P450,B
modulation,O
in,O
lindane,B
induced,O
neurotoxicity,O
.,O
Oral,O
administration,O
of,O
lindane,B
(,O
2,O
.,O
5,O
",",O
5,O
",",O
10,O
and,O
15,O
mg,O
/,O
kg,O
",",O
body,O
weight,O
),O
for,O
5,O
days,O
was,O
found,O
to,O
produce,O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
the,O
activity,O
of,O
P450,B
dependent,O
7,O
-,O
ethoxyresorufin,B
-,O
O,I
-,O
deethylase,O
(,O
EROD,B
),O
",",O
7,O
-,O
pentoxyresorufin,B
-,O
O,I
-,O
dealkylase,O
(,O
PROD,B
),O
and,O
N,B
-,O
nitrosodimethylamine,I
demethylase,O
(,O
NDMA,B
-,O
d,I
),O
in,O
rat,O
brain,O
and,O
liver,O
.,O
A,O
significant,O
increase,O
in,O
the,O
hepatic,B
and,O
brain,B
P450,B
monooxygenases,I
was,O
also,O
observed,O
when,O
the,O
duration,O
of,O
exposure,O
of,O
low,O
dose,O
(,O
2,O
.,O
5,O
mg,O
/,O
kg,O
),O
of,O
lindane,B
was,O
increased,O
from,O
5,O
days,O
to,O
15,O
or,O
21,O
days,O
.,O
As,O
observed,O
with,O
different,O
doses,O
",",O
the,O
magnitude,O
of,O
induction,O
in,O
the,O
activity,O
of,O
P450,B
monooxygenases,I
was,O
several,O
fold,O
higher,O
in,O
liver,B
microsomes,I
when,O
compared,O
with,O
the,O
brain,B
.,O
Western,O
blotting,O
studies,O
have,O
indicated,O
that,O
the,O
increase,O
in,O
the,O
P450,B
enzymes,O
could,O
be,O
due,O
to,O
the,O
increase,O
in,O
the,O
expression,O
of,O
P450,B
1A1,B
/,O
1A2,B
",",O
2B1,B
/,O
2B2,B
and,O
2E+01,B
isoenzymes,O
.,O
In,O
vitro,O
studies,O
using,O
organic,O
inhibitors,O
specific,O
for,O
individual,O
P450,B
isoenzymes,O
and,O
antibody,O
inhibition,O
experiments,O
have,O
further,O
demonstrated,O
that,O
the,O
increase,O
in,O
the,O
activity,O
of,O
PROD,B
",",O
EROD,B
and,O
NDMA,B
-,O
d,O
are,O
due,O
to,O
the,O
increase,O
in,O
the,O
levels,O
of,O
P450,B
2B1,B
/,O
2B2,B
",",O
1A1,B
/,O
1A2,B
and,O
2E+01,B
isoenzymes,O
",",O
respectively,O
.,O
Induction,O
studies,O
have,O
further,O
shown,O
that,O
while,O
pretreatment,O
of,O
3,B
-,I
methylcholanthrene,I
(,O
MC,B
),O
",",O
an,O
inducer,O
of,O
P4501A1,B
/,I
1A2,I
",",O
did,O
not,O
produce,O
any,O
significant,O
effect,O
in,O
the,O
incidence,O
of,O
lindane,B
induced,I
convulsions,I
",",O
pretreatment,O
with,O
phenobarbital,B
(,O
PB,B
),O
",",O
an,O
inducer,O
of,O
P450,B
2B1,I
/,I
2B2,I
or,O
ethanol,B
",",O
an,O
inducer,O
of,O
P450,B
2E+01,I
catalysed,I
reactions,I
",",O
significantly,O
increased,O
the,O
incidence,O
of,O
lindane,B
induced,I
convulsions,I
.,O
Similarly,O
",",O
when,O
the,O
P450,B
-,O
mediated,O
metabolism,O
of,O
lindane,B
was,O
blocked,O
by,O
cobalt,B
chloride,I
incidence,O
of,O
convulsions,O
was,O
increased,O
in,O
animals,O
treated,O
with,O
lindane,B
indicating,O
that,O
lindane,B
per,O
se,O
or,O
its,O
metabolites,O
formed,O
by,O
PB,B
or,O
ethanol,B
inducible,O
P450,B
isoenzymes,I
are,O
involved,O
in,O
its,O
neurobehavioral,O
toxicity,O
.,O
Absolute,O
and,O
attributable,O
risk,O
of,O
venous,B
thromboembolism,I
in,O
women,O
on,O
combined,O
cyproterone,B
acetate,I
and,O
ethinylestradiol,B
.,O
OBJECTIVE,O
:,O
To,O
achieve,O
absolute,O
risk,O
estimates,O
of,O
venous,B
thromboembolism,I
(,O
VTE,B
),O
among,O
women,O
on,O
cyproterone,B
acetate,I
plus,O
ethinylestradiol,B
(,O
CPA,B
/,O
EE,O
),O
",",O
and,O
among,O
women,O
on,O
combined,O
oral,O
contraceptives,O
(,O
COCs,B
),O
.,O
METHODS,O
:,O
From,O
the,O
Danish,O
National,O
Register,O
of,O
Patients,O
(,O
NRP,O
),O
",",O
1996,O
to,O
1998,O
",",O
the,O
records,O
of,O
1,O
.,O
1,O
million,O
Danish,O
women,O
",",O
ages,O
15,O
to,O
44,O
years,O
",",O
were,O
searched,O
for,O
evidence,O
of,O
VTE,B
.,O
COC,B
use,O
was,O
ascertained,O
through,O
mailed,O
questionnaires,O
.,O
Sales,O
statistics,O
of,O
COCs,B
and,O
CPA,B
/,I
EE,I
were,O
provided,O
through,O
Danish,O
Drug,O
Statistics,O
.,O
RESULTS,O
:,O
During,O
the,O
time,O
frame,O
of,O
the,O
study,O
",",O
330,O
women,O
were,O
found,O
to,O
have,O
had,O
VTE,B
while,O
on,O
COCs,B
.,O
Of,O
these,O
women,O
",",O
67,O
were,O
on,O
levonorgestrel,B
-,I
containing,I
COCs,I
.,O
Eleven,O
were,O
on,O
CPA,B
/,I
EE,I
.,O
The,O
corresponding,O
absolute,O
risk,O
of,O
VTE,B
was,O
3,O
.,O
4,O
(,O
range,O
",",O
3,O
.,O
1,O
-,O
3,O
.,O
8,O
),O
per,O
10,O
0,O
women,O
years,O
among,O
the,O
women,O
on,O
COCs,B
",",O
4,O
.,O
2,O
(,O
range,O
",",O
3,O
.,O
2,O
-,O
5,O
.,O
2,O
),O
per,O
10,O
0,O
women,O
years,O
among,O
women,O
on,O
levonorgestrel,B
-,I
containing,I
COCs,I
",",O
and,O
3,O
.,O
1,O
(,O
range,O
",",O
1,O
.,O
3,O
-,O
4,O
.,O
),O
per,O
10,O
0,O
women,O
years,O
among,O
the,O
women,O
on,O
CPA,B
/,I
EE,I
.,O
CONCLUSION,O
:,O
Our,O
results,O
suggest,O
the,O
absolute,O
risk,O
of,O
VTE,B
among,O
Danish,O
women,O
on,O
COCs,O
is,O
similar,O
to,O
that,O
among,O
women,O
taking,O
CPA,B
/,I
EE,I
.,O
Comparison,O
of,O
developmental,O
toxicology,O
of,O
aspirin,B
(,O
acetylsalicylic,B
acid,I
),O
in,O
rats,O
using,O
selected,O
dosing,O
paradigms,O
.,O
BACKGROUND,O
:,O
Analysis,O
of,O
the,O
literature,O
for,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,B
),O
suggests,O
that,O
a,O
low,O
incidence,O
of,O
developmental,O
anomalies,O
occurs,O
in,O
rats,O
given,O
NSAIDs,B
on,O
specific,O
days,O
during,O
organogenesis,O
.,O
Aspirin,B
(,O
acetylsalicylic,B
acid,I
[,O
ASA,B
],O
(,O
),O
",",O
an,O
irreversible,O
cyclooxygenase,B
1,I
and,O
2,I
inhibitor,O
",",O
induces,O
developmental,O
anomalies,O
when,O
administered,O
to,O
Wistar,O
rats,O
on,O
gestational,O
day,O
(,O
GD,B
),O
9,O
",",O
10,O
",",O
or,O
11,O
(,O
Kimmel,O
CA,O
",",O
Wilson,O
JG,O
",",O
Schumacher,O
HJ,O
.,O
Teratology,O
4,O
:,O
15,O
-,O
24,O
",",O
1971,O
),O
.,O
There,O
are,O
no,O
published,O
ASA,B
studies,O
using,O
the,O
multiple,O
dosing,O
paradigm,O
of,O
GDs,B
6,O
to,O
17,O
.,O
Objectives,O
of,O
the,O
current,O
study,O
were,O
to,O
compare,O
results,O
between,O
Sprague,B
-,I
Dawley,I
(,O
SD,B
),O
and,O
Wistar,B
strains,O
when,O
ASA,B
is,O
administered,O
on,O
GD,O
9,O
",",O
10,O
",",O
or,O
11,O
;,O
to,O
compare,O
the,O
malformation,O
patterns,O
following,O
single,O
and,O
multiple,O
dosings,O
during,O
organogenesis,O
in,O
SD,B
rats,O
;,O
and,O
to,O
test,O
the,O
hypothesis,O
that,O
maternal,O
gastrointestinal,O
toxicity,O
confounds,O
the,O
detection,O
of,O
low,O
incidence,O
malformations,O
with,O
ASA,B
when,O
a,O
multiple,O
dosing,O
paradigm,O
is,O
used,O
.,O
METHODS,O
:,O
ASA,B
was,O
administered,O
as,O
a,O
single,O
dose,O
on,O
GD,O
9,O
(,O
0,O
",",O
250,B
",",O
500,B
",",O
or,O
625,B
mg,O
/,O
kg,O
),O
",",O
10,O
(,O
0,O
",",O
500,B
",",O
625,B
",",O
or,O
750,B
mg,O
/,O
kg,O
),O
",",O
or,O
11,O
(,O
0,O
",",O
500,B
",",O
750,B
",",O
or,O
1000,B
mg,O
/,O
kg,O
),O
and,O
from,O
GD,O
6,O
to,O
GD,O
17,O
(,O
0,O
",",O
50,B
",",O
125,B
",",O
or,O
250,B
mg,O
/,O
kg,O
a,O
day,O
),O
in,O
the,O
multiple,O
dose,O
study,O
to,O
SD,O
rats,O
.,O
Animals,O
were,O
killed,O
on,O
GD,O
21,O
",",O
and,O
fetuses,O
were,O
examined,O
viscerally,O
.,O
RESULTS,O
:,O
The,O
literature,O
evaluation,O
suggested,O
that,O
NSAIDs,B
induce,O
ventricular,O
septal,O
defects,O
(,O
VSDs,B
),O
and,O
midline,O
defects,O
(,O
MDs,B
),O
in,O
rats,O
and,O
diaphragmatic,O
hernia,O
(,O
DH,B
),O
",",O
MDs,B
",",O
and,O
VSDs,B
in,O
rabbits,O
(,O
Cook,O
JC,O
et,O
al,O
.,O
",",O
2003,O
);,O
hence,O
",",O
the,O
present,O
study,O
focused,O
on,O
these,O
malformations,O
",",O
even,O
though,O
ASA,B
induces,O
several,O
other,O
low,O
-,O
incidence,O
malformations,O
.,O
In,O
single,O
dose,O
studies,O
",",O
DH,B
",",O
MD,B
",",O
and,O
VSD,B
were,O
induced,O
on,O
GDs,O
9,O
and,O
10,O
.,O
VSD,B
also,O
was,O
noted,O
following,O
treatment,O
on,O
GD,O
11,O
.,O
In,O
contrast,O
",",O
DH,B
and,O
MD,B
were,O
noted,O
in,O
the,O
multiple,O
dose,O
study,O
design,O
only,O
in,O
the,O
high,O
-,O
dose,O
group,O
",",O
and,O
VSD,B
was,O
noted,O
across,O
all,O
dose,O
groups,O
.,O
CONCLUSIONS,O
:,O
High,O
concordance,O
in,O
major,O
developmental,O
anomalies,O
between,O
Wistar,O
and,O
SD,O
rats,O
were,O
noted,O
with,O
the,O
exception,O
of,O
VSD,B
in,O
the,O
SD,O
rats,O
and,O
hydrocephalus,B
in,O
the,O
Wistar,O
rats,O
.,O
Variations,O
and,O
malformations,O
were,O
similar,O
when,O
ASA,B
was,O
administered,O
as,O
a,O
single,O
dose,O
or,O
during,O
the,O
period,O
of,O
organogenesis,O
(,O
GDs,B
6,I
to,I
17,I
),O
.,O
It,O
was,O
also,O
evident,O
that,O
",",O
by,O
titrating,O
the,O
dose,O
to,O
achieve,O
a,O
maximum,O
tolerated,O
dose,O
",",O
malformations,O
that,O
normally,O
occur,O
at,O
low,O
incidence,O
",",O
as,O
reported,O
from,O
previous,O
single,O
dose,O
studies,O
",",O
could,O
also,O
be,O
induced,O
with,O
ASA,B
given,O
at,O
multiple,O
doses,O
.,O
Reversal,O
of,O
central,O
benzodiazepine,B
effects,O
by,O
flumazenil,B
after,O
intravenous,O
conscious,O
sedation,O
with,O
diazepam,B
and,O
opioids,B
:,O
report,O
of,O
a,O
double,O
-,O
blind,O
multicenter,O
study,O
.,O
The,O
Flumazenil,B
in,O
Intravenous,O
Conscious,O
Sedation,O
with,O
Diazepam,B
Multicenter,O
Study,O
Group,O
II,O
.,O
The,O
efficacy,O
and,O
safety,O
of,O
a,O
new,O
benzodiazepine,B
antagonist,O
",",O
flumazenil,B
",",O
were,O
assessed,O
in,O
a,O
double,O
-,O
blind,O
multicenter,O
study,O
.,O
Flumazenil,B
(,O
mean,O
dose,O
",",O
0,O
.,O
76,O
mg,O
),O
or,O
placebo,B
(,O
mean,O
dose,O
",",O
8,O
.,O
9,O
ml,O
),O
was,O
administered,O
intravenously,O
to,O
130,O
and,O
67,O
patients,O
",",O
respectively,O
",",O
who,O
had,O
been,O
given,O
diazepam,B
in,O
conjunction,O
with,O
an,O
opioid,O
(,O
fentanyl,B
",",O
meperidine,B
",",O
or,O
morphine,B
),O
for,O
the,O
induction,O
and,O
maintenance,O
of,O
intravenous,O
conscious,O
sedation,O
for,O
diagnostic,O
or,O
therapeutic,O
surgical,O
procedures,O
.,O
The,O
group,O
assessable,O
for,O
efficacy,O
comprised,O
122,O
patients,O
treated,O
with,O
flumazenil,B
and,O
64,O
patients,O
given,O
placebo,B
.,O
After,O
5,O
minutes,O
",",O
80,O
/,O
115,O
(,O
70,O
%,O
),O
flumazenil,B
-,O
treated,O
patients,O
",",O
compared,O
with,O
21,O
/,O
63,O
(,O
33,O
%,O
),O
placebo,B
-,O
treated,O
patients,O
",",O
were,O
completely,O
awake,O
and,O
alert,O
",",O
as,O
indicated,O
by,O
a,O
score,O
of,O
5,O
on,O
the,O
Observer,O
',O
s,O
Assessment,O
of,O
Alertness,O
/,O
Sedation,O
Scale,O
.,O
Ninety,O
-,O
five,O
percent,O
of,O
patients,O
in,O
each,O
group,O
who,O
attained,O
a,O
score,O
of,O
5,O
at,O
the,O
5,O
-,O
minute,O
assessment,O
showed,O
no,O
loss,O
of,O
alertness,O
throughout,O
the,O
180,O
-,O
minute,O
assessment,O
period,O
.,O
Flumazenil,B
-,I
treated,I
patients,O
also,O
performed,O
significantly,O
better,O
on,O
the,O
Finger,B
-,I
to,I
-,I
Nose,I
Test,I
and,O
the,O
recall,O
of,O
pictures,O
shown,O
at,O
the,O
5,O
-,O
minute,O
assessment,O
.,O
Flumazenil,B
was,O
well,O
tolerated,O
",",O
with,O
no,O
serious,O
adverse,O
effects,O
reported,O
.,O
Thirty,O
-,O
nine,O
(,O
30,O
%,O
),O
of,O
flumazenil,B
-,O
treated,O
patients,O
",",O
compared,O
with,O
17,O
(,O
25,O
%,O
),O
of,O
placebo,B
-,O
treated,O
patients,O
had,O
one,O
or,O
more,O
drug,O
-,O
related,O
adverse,O
experiences,O
.,O
The,O
most,O
common,O
adverse,O
effects,O
were,O
nausea,B
and,O
vomiting,O
in,O
the,O
flumazenil,B
group,O
and,O
nausea,B
and,O
injection,B
-,I
site,I
pain,I
in,O
the,O
placebo,B
group,O
.,O
Flumazenil,B
was,O
found,O
to,O
promptly,O
reverse,O
sedation,O
induced,O
by,O
diazepam,B
in,O
the,O
presence,O
of,O
opioids,B
.,O
Methylphenidate,B
-,I
induced,O
obsessive,O
-,O
compulsive,O
symptoms,O
in,O
an,O
elderly,O
man,O
.,O
An,O
82,O
-,O
year,O
-,O
old,O
man,O
with,O
treatment,O
-,O
resistant,O
depression,O
and,O
early,O
Alzheimer,B
',I
s,I
disease,I
was,O
started,O
on,O
methylphenidate,B
.,O
Significant,O
obsessive,B
-,I
compulsive,I
behavior,O
ensued,O
but,O
diminished,O
over,O
several,O
weeks,O
when,O
methylphenidate,B
was,O
replaced,O
by,O
fluvoxamine,B
.,O
The,O
patient,O
had,O
no,O
prior,O
psychiatric,O
history,O
",",O
but,O
he,O
had,O
a,O
sister,O
with,O
obsessive,B
-,I
compulsive,I
disorder,O
.,O
It,O
appears,O
that,O
methylphenidate,B
precipitated,O
the,O
patient,O
',O
s,O
pathological,O
behavior,O
.,O
Ciprofloxacin,B
-,O
induced,O
acute,O
interstitial,B
nephritis,I
and,O
autoimmune,B
hemolytic,I
anemia,I
.,O
Ciprofloxacin,B
has,O
been,O
associated,O
with,O
several,O
side,O
effects,O
including,O
interstitial,B
nephritis,I
and,O
hemolytic,B
anemia,I
.,O
The,O
combination,O
of,O
both,O
side,O
effects,O
is,O
extremely,O
rare,O
.,O
In,O
this,O
report,O
",",O
we,O
describe,O
a,O
case,O
of,O
ciprofloxacin,B
-,O
induced,O
interstitial,B
nephritis,I
and,O
autoimmune,B
hemolytic,I
anemia,I
.,O
Hemolytic,B
anemia,I
improved,O
after,O
stopping,O
the,O
drug,O
and,O
initiation,O
of,O
steroid,B
therapy,I
.,O
Unfortunately,O
",",O
acute,B
interstitial,I
nephritis,I
was,O
irreversible,O
and,O
the,O
patient,O
developed,O
end,O
-,O
stage,O
renal,B
disease,I
.,O
Potential,O
deleterious,O
effect,O
of,O
furosemide,B
in,O
radiocontrast,B
nephropathy,I
.,O
The,O
purpose,O
of,O
the,O
study,O
was,O
to,O
determine,O
the,O
efficacy,O
of,O
furosemide,B
in,O
addition,O
to,O
intravenous,B
fluids,I
in,O
the,O
prevention,O
of,O
radiocontrast,B
nephropathy,I
.,O
18,O
patients,O
",",O
referred,O
to,O
a,O
radiocontrast,B
study,I
",",O
considered,O
at,O
risk,O
because,O
of,O
preexisting,O
renal,B
insufficiency,I
",",O
were,O
enrolled,O
in,O
a,O
prospective,O
",",O
randomized,O
",",O
controlled,O
trial,O
",",O
performed,O
at,O
the,O
secondary,O
care,O
center,O
of,O
a,O
1,O
",",O
100,O
-,O
bed,O
private,O
university,O
hospital,O
.,O
In,O
addition,O
to,O
fluids,O
",",O
the,O
treatment,O
group,O
received,O
furosemide,B
(,O
mean,O
dose,O
110,O
mg,O
),O
intravenously,O
30,O
min,O
prior,O
to,O
the,O
injection,O
of,O
contrast,B
material,I
.,O
The,O
control,O
group,O
received,O
fluids,O
(,O
mean,O
3,O
liters,O
),O
.,O
Radiological,O
studies,O
were,O
mostly,O
angiographies,O
performed,O
with,O
both,O
ionic,B
and,O
non,B
-,I
contrast,I
material,O
",",O
at,O
an,O
average,O
dose,O
of,O
245,O
ml,O
.,O
Renal,O
function,O
significantly,O
deteriorated,O
in,O
the,O
group,O
pretreated,O
with,O
furosemide,B
(,O
p,O
<,O
0,O
.,O
5,O
by,O
ANOVA,O
),O
",",O
with,O
a,O
rise,O
in,O
serum,O
creatinine,B
from,O
145,O
+,O
/,O
-,O
13,O
to,O
182,O
+,O
/,O
-,O
16,O
mumol,B
/,I
l,I
at,O
24,O
h,O
",",O
while,O
no,O
change,O
occurred,O
in,O
the,O
control,O
group,O
(,O
from,O
141,O
+,O
/,O
-,O
6,O
to,O
142,O
+,O
/,O
-,O
7,O
mumol,B
/,I
l,I
.,O
Renal,B
failure,I
was,O
associated,O
with,O
weight,O
loss,O
in,O
the,O
furosemide,B
-,I
treated,I
group,I
.,O
Furosemide,B
may,O
be,O
deleterious,O
in,O
the,O
prevention,O
of,O
radiocontrast,B
nephropathy,I
.,O
Progestational,B
agents,I
and,O
blood,B
coagulation,I
.,O
VII,O
.,O
Thromboembolic,B
and,I
other,I
complications,I
of,I
oral,I
contraceptive,I
therapy,I
in,I
relationship,I
to,I
pretreatment,I
levels,I
of,I
blood,I
coagulation,I
factors,I
:,O
summary,O
report,O
of,O
a,O
ten,O
-,O
year,O
study,O
.,O
During,O
a,O
ten,O
-,O
year,O
period,O
",",O
348,O
women,O
were,O
studied,O
for,O
a,O
total,O
of,O
5,O
",",O
877,O
patient,O
months,O
in,O
four,O
separate,O
studies,O
relating,O
oral,O
contraceptives,O
to,O
changes,O
in,O
hematologic,O
parameters,O
.,O
Significant,O
increases,O
in,O
certain,O
factors,O
of,O
the,O
blood,B
coagulation,I
and,O
fibrinolysin,B
systems,O
(,O
factors,O
I,B
",",O
II,B
",",O
VII,B
",",O
VIII,B
",",O
IX,B
",",O
and,O
X,B
and,O
plasminogen,B
),O
were,O
observed,O
in,O
the,O
treated,O
groups,O
.,O
Severe,O
complications,O
developed,O
in,O
four,O
patients,O
.,O
All,O
four,O
had,O
an,O
abnormal,O
blood,O
coagulation,O
profile,O
",",O
suggesting,O
hypercoagulability,B
before,O
initiation,O
of,O
therapy,O
.,O
Some,O
of,O
these,O
findings,O
represented,O
the,O
most,O
extreme,O
abnormalities,O
seen,O
in,O
the,O
entire,O
group,O
of,O
patients,O
;,O
some,O
increased,O
further,O
during,O
therapy,O
.,O
One,O
of,O
these,O
patients,O
developed,O
a,O
myocardial,B
infarction,I
before,O
receiving,O
any,O
medication,O
",",O
shortly,O
after,O
the,O
base,O
-,O
line,O
values,O
were,O
obtained,O
.,O
One,O
patient,O
developed,O
retinopathy,B
19,O
months,O
after,O
she,O
began,O
therapy,O
",",O
and,O
another,O
developed,O
thrombophlebitis,B
after,O
27,O
months,O
of,O
therapy,O
.,O
The,O
fourth,O
patient,O
developed,O
thrombophlebitis,B
14,O
days,O
after,O
initiation,O
of,O
contraceptive,O
therapy,O
.,O
All,O
four,O
patients,O
were,O
of,O
the,O
A,B
or,O
AB,B
blood,O
group,O
.,O
Previous,O
studies,O
suggested,O
the,O
possiblility,O
of,O
increased,O
propensity,O
for,O
thromboembolic,O
episodes,O
in,O
patients,O
possessing,O
the,O
A,B
antigen,O
.,O
It,O
appears,O
from,O
these,O
data,O
that,O
hematologic,O
work,O
-,O
ups,O
may,O
be,O
useful,O
in,O
women,O
who,O
are,O
about,O
to,O
start,O
long,O
-,O
term,O
oral,O
contraceptive,O
therapy,O
.,O
Orthostatic,O
hypotension,O
occurs,O
following,O
alpha,B
2,I
-,I
adrenoceptor,I
blockade,O
in,O
chronic,O
prazosin,O
-,O
pretreated,O
conscious,O
spontaneously,O
hypertensive,O
rats,O
.,O
1,O
.,O
Studies,O
were,O
performed,O
to,O
evaluate,O
whether,O
chronic,O
prazosin,O
treatment,O
alters,O
the,O
alpha,B
2,I
-,I
adrenoceptor,I
function,O
for,O
orthostatic,O
control,O
of,O
arterial,O
blood,O
pressure,O
in,O
conscious,O
spontaneously,O
hypertensive,O
rats,O
(,O
SHR,O
),O
.,O
2,O
.,O
Conscious,O
SHR,O
(,O
male,O
300,O
-,O
350,O
g,O
),O
were,O
subjected,O
to,O
90,O
degrees,O
head,O
-,O
up,O
tilts,O
for,O
60,O
s,O
following,O
acute,O
administration,O
of,O
prazosin,B
(,O
0,O
.,O
1,O
mg,O
kg,O
-,O
1,O
i,O
.,O
p,O
.,O
),O
or,O
rauwolscine,B
(,O
3,O
mg,O
kg,O
-,O
1,O
i,O
.,O
v,O
.,O
),O
.,O
Orthostatic,O
hypotension,O
was,O
determined,O
by,O
the,O
average,O
decrease,O
(,O
%,O
),O
in,O
mean,O
arterial,O
pressure,O
(,O
MAP,B
femoral,O
),O
over,O
the,O
60,O
-,O
s,O
tilt,O
period,O
.,O
The,O
basal,O
MAP,O
of,O
conscious,O
SHR,O
was,O
reduced,O
to,O
a,O
similar,O
extent,O
by,O
prazosin,B
(,O
-,O
23,O
%,O
(,O
-,O
),O
-,O
26,O
%,O
MAP,O
),O
and,O
rauwolscine,B
(,O
-,O
16,O
%,O
(,O
-,O
),O
-,O
33,O
%,O
MAP,O
),O
.,O
However,O
",",O
the,O
head,O
-,O
up,O
tilt,O
induced,O
orthostatic,O
hypotension,O
in,O
the,O
SHR,O
treated,O
with,O
prazosin,B
(,O
-,O
16,O
%,O
MAP,O
",",O
n,O
=,O
6,O
),O
",",O
but,O
not,O
in,O
the,O
SHR,O
treated,O
with,O
rauwolscine,B
(,O
less,O
than,O
+,O
2,O
%,O
MAP,O
",",O
n,O
=,O
6,O
),O
.,O
3,O
.,O
Conscious,O
SHR,O
were,O
treated,O
for,O
4,O
days,O
with,O
prazosin,B
at,O
2,O
mg,O
kg,O
-,O
1,O
day,O
-,O
1,O
i,O
.,O
p,O
.,O
for,O
chronic,O
alpha,B
1,I
-,I
adrenoceptor,I
blockade,I
.,O
MAP,O
in,O
conscious,O
SHR,O
after,O
chronic,O
prazosin,B
treatment,O
was,O
14,O
%,O
lower,O
than,O
in,O
the,O
untreated,O
SHR,O
(,O
n,O
=,O
8,O
),O
.,O
Head,O
-,O
up,O
tilts,O
in,O
these,O
rats,O
did,O
not,O
produce,O
orthostatic,O
hypotension,O
when,O
performed,O
either,O
prior,O
to,O
or,O
after,O
acute,O
dosing,O
of,O
prazosin,B
(,O
0,O
.,O
1,O
mg,O
kg,O
-,O
1,O
i,O
.,O
p,O
.,O
),O
.,O
Conversely,O
",",O
administration,O
of,O
rauwolscine,B
(,O
3,B
mg,I
kg,I
-,I
1,I
i,I
.,I
v,I
.,I
),I
in,O
chronic,O
prazosin,B
treated,O
SHR,O
decreased,O
the,O
basal,O
MAP,B
by,O
12,O
-,O
31,O
%,O
(,O
n,O
=,O
4,O
),O
",",O
and,O
subsequent,O
tilts,O
induced,O
further,O
drops,O
of,O
MAP,B
by,O
19,O
-,O
23,O
%,O
in,O
these,O
rats,O
.,O
4,O
.,O
The,O
pressor,O
responses,O
and,O
bradycardia,O
to,O
the,O
alpha,O
1,O
-,O
agonist,O
cirazoline,B
(,O
0,B
.,I
6,O
and,O
2,O
micrograms,O
kg,O
-,O
1,O
i,O
.,O
v,O
.,O
),O
",",O
the,O
alpha,B
2,I
-,I
agonist,I
Abbott,B
-,I
53693,I
(,O
1,O
and,O
3,O
micrograms,O
kg,O
-,O
1,O
i,O
.,O
v,O
.,O
),O
",",O
and,O
noradrenaline,B
(,O
0,O
.,O
1,O
and,O
1,O
.,O
0,O
micrograms,O
kg,O
-,O
1,O
i,O
.,O
v,O
.,O
),O
were,O
determined,O
in,O
conscious,O
SHR,O
with,O
and,O
without,O
chronic,O
prazosin,O
pretreatment,O
.,O
Both,O
the,O
pressor,O
and,O
bradycardia,O
effects,O
of,O
cirazoline,O
were,O
abolished,O
in,O
chronic,O
prazosin,O
treated,O
SHR,O
(,O
n,O
=,O
4,O
),O
as,O
compared,O
to,O
the,O
untreated,O
SHR,O
(,O
n,O
=,O
4,O
),O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
pressor,O
effects,O
of,O
Abbott,B
-,O
53693,I
were,O
similar,O
in,O
both,O
groups,O
of,O
SHR,O
",",O
but,O
the,O
accompanying,O
bradycardia,O
was,O
greater,O
in,O
SHR,O
with,O
chronic,O
prazosin,O
treatment,O
than,O
without,O
such,O
treatment,O
.,O
Furthermore,O
",",O
the,O
bradycardia,O
that,O
accompanied,O
the,O
noradrenaline,B
-,O
induced,O
pressor,O
effect,O
in,O
SHR,O
was,O
similar,O
with,O
and,O
without,O
chronic,O
prazosin,O
treatment,O
despite,O
a,O
47,O
-,O
71,O
%,O
reduction,O
of,O
the,O
pressor,O
effect,O
in,O
chronic,O
alpha,B
1,I
-,I
receptor,I
blocked,I
SHR,I
.,O
Hemolytic,B
-,I
uremic,I
syndrome,I
associated,O
with,O
ingestion,O
of,O
quinine,B
.,O
Hemolytic,B
-,I
uremic,I
syndrome,I
following,O
quinine,B
ingestion,O
is,O
a,O
newly,O
described,O
phenomenon,O
",",O
with,O
just,O
two,O
previous,O
descriptions,O
of,O
4,O
cases,O
in,O
the,O
literature,O
.,O
We,O
describe,O
a,O
5th,O
case,O
.,O
The,O
reaction,O
may,O
be,O
mediated,O
by,O
the,O
presence,O
of,O
antibodies,O
reactive,O
against,O
platelets,O
in,O
the,O
presence,O
of,O
quinine,B
.,O
Treatment,O
has,O
included,O
use,O
of,O
plasma,B
exchange,O
",",O
prednisone,B
",",O
aspirin,B
",",O
and,O
dipyridamole,B
.,O
The,O
patients,O
have,O
all,O
regained,O
some,O
degree,O
of,O
renal,O
function,O
.,O
However,O
",",O
it,O
is,O
unclear,O
whether,O
pharmacological,O
treatment,O
or,O
spontaneous,O
resolution,O
is,O
responsible,O
for,O
the,O
improvement,O
.,O
Quinine,B
-,O
associated,O
hemolytic,O
-,O
uremic,O
syndrome,O
probably,O
occurs,O
more,O
often,O
than,O
is,O
recognized,O
.,O
It,O
is,O
important,O
to,O
recognize,O
this,O
reaction,O
when,O
it,O
occurs,O
and,O
to,O
avoid,O
further,O
quinine,B
exposure,O
",",O
since,O
the,O
reaction,O
seems,O
to,O
be,O
recurrent,O
.,O
Amnestic,O
syndrome,O
associated,O
with,O
propranolol,B
toxicity,O
:,O
a,O
case,O
report,O
.,O
An,O
elderly,O
woman,O
developed,O
an,O
Alzheimer,B
-,I
like,I
subacute,I
dementia,I
as,O
a,O
result,O
of,O
propranolol,B
toxicity,O
.,O
Analysis,O
of,O
the,O
manifestations,O
showed,O
that,O
severe,O
impairment,O
of,O
memory,B
accounted,O
for,O
virtually,O
all,O
of,O
the,O
abnormalities,O
.,O
There,O
is,O
evidence,O
that,O
cerebral,O
reactions,O
to,O
drug,B
toxicity,O
can,O
exhibit,O
patterns,O
that,O
suggest,O
highly,O
selective,O
involvement,O
of,O
functional,O
subdivisions,O
of,O
the,O
brain,O
.,O
Cefotetan,B
-,I
induced,O
immune,B
hemolytic,I
anemia,I
.,O
Immune,O
hemolytic,O
anemia,O
due,O
to,O
a,O
drug,O
-,O
adsorption,O
mechanism,O
has,O
been,O
described,O
primarily,O
in,O
patients,O
receiving,O
penicillins,B
and,O
first,O
-,O
generation,O
cephalosporins,B
.,O
We,O
describe,O
a,O
patient,O
who,O
developed,O
anemia,O
while,O
receiving,O
intravenous,O
cefotetan,B
.,O
Cefotetan,B
-,O
dependent,O
antibodies,O
were,O
detected,O
in,O
the,O
patient,O
',O
s,O
serum,O
and,O
in,O
an,O
eluate,O
prepared,O
from,O
his,O
red,O
blood,O
cells,O
.,O
The,O
eluate,O
also,O
reacted,O
weakly,O
with,O
red,B
blood,I
cells,I
in,O
the,O
absence,O
of,O
cefotetan,B
",",O
suggesting,O
the,O
concomitant,O
formation,O
of,O
warm,B
-,I
reactive,I
autoantibodies,I
.,O
These,O
observations,O
",",O
in,O
conjunction,O
with,O
clinical,O
and,O
laboratory,O
evidence,O
of,O
extravascular,O
hemolysis,O
",",O
are,O
consistent,O
with,O
drug,B
-,I
induced,I
hemolytic,I
anemia,I
",",O
possibly,O
involving,O
both,O
drug,B
-,I
adsorption,I
and,O
autoantibody,B
formation,I
mechanisms,O
.,O
This,O
case,O
emphasizes,O
the,O
need,O
for,O
increased,O
awareness,O
of,O
hemolytic,O
reactions,O
to,O
all,O
cephalosporins,B
.,O
Use,O
of,O
dexamethasone,B
with,O
mesna,O
for,O
the,O
prevention,O
of,O
ifosfamide,B
-,O
induced,O
hemorrhagic,O
cystitis,O
.,O
AIM,O
:,O
Hemorrhagic,O
cystitis,O
(,O
HC,B
),O
is,O
a,O
limiting,O
side,O
-,O
effect,O
of,O
chemotherapy,O
with,O
ifosfamide,B
(,O
IFS,B
),O
.,O
In,O
the,O
study,O
presented,O
here,O
",",O
we,O
investigated,O
the,O
use,O
of,O
dexamethasone,B
in,O
combination,O
with,O
mesna,B
for,O
the,O
prevention,O
of,O
IFS,B
-,O
induced,O
HC,B
.,O
METHODS,O
:,O
Male,O
Wistar,O
rats,O
(,O
150,O
-,O
200,O
g,O
;,O
6,O
rats,O
per,O
group,O
),O
were,O
treated,O
with,O
saline,B
or,O
mesna,B
5,O
min,O
(,O
i,O
.,O
p,O
.,O
),O
before,O
and,O
2,O
and,O
6,O
h,O
after,O
(,O
v,O
.,O
o,O
.,O
),O
administration,O
of,O
IFS,B
.,O
One,O
",",O
two,O
or,O
three,O
doses,O
of,O
mesna,B
were,O
replaced,O
with,O
dexamethasone,B
alone,O
or,O
with,O
dexamethasone,B
plus,O
mesna,B
.,O
Cystitis,O
was,O
evaluated,O
24,O
h,O
after,O
its,O
induction,O
by,O
the,O
changes,O
in,O
bladder,O
wet,O
weight,O
induced,O
by,O
IFS,O
by,O
84,O
.,O
79,O
%,O
and,O
89,O
.,O
13,O
%,O
",",O
respectively,O
.,O
In,O
addition,O
",",O
it,O
almost,O
abolished,O
the,O
macroscopic,O
and,O
microscopic,O
alterations,O
induced,O
by,O
IFS,B
.,O
Moreover,O
",",O
the,O
addition,O
of,O
dexamethasone,B
to,O
the,O
last,O
two,O
doses,O
of,O
mesna,B
was,O
more,O
efficient,O
than,O
three,O
doses,O
of,O
mesna,B
alone,O
when,O
evaluated,O
microscopically,O
.,O
CONCLUSION,O
:,O
Dexamethasone,B
in,O
combination,O
with,O
mesna,B
was,O
efficient,O
in,O
blocking,O
IFS,B
-,O
induced,O
HC,O
.,O
However,O
",",O
the,O
replacement,O
of,O
last,O
two,O
doses,O
of,O
mesna,B
with,O
saline,B
or,O
all,O
of,O
the,O
mesna,B
doses,O
with,O
dexamethasone,B
did,O
not,O
prevent,O
HC,O
.,O
All,O
-,O
trans,B
-,I
retinoic,I
acid,I
-,I
induced,O
erythema,B
nodosum,I
in,O
patients,O
with,O
acute,O
promyelocytic,O
leukemia,O
.,O
Erythema,B
nodosum,I
associated,O
with,O
all,O
-,O
trans,B
-,I
retinoic,I
acid,I
(,I
ATRA,I
),I
for,O
acute,O
promyelocytic,O
leukemia,O
(,O
APL,O
),O
is,O
very,O
rare,O
.,O
We,O
describe,O
four,O
patients,O
with,O
classic,O
APL,B
who,O
developed,O
erythema,B
nodosum,I
during,O
ATRA,O
therapy,O
.,O
Fever,O
and,O
subsequent,O
multiple,O
painful,O
erythematous,B
nodules,I
over,O
extremities,O
developed,O
on,O
D11,O
",",O
D16,O
",",O
D17,O
",",O
and,O
D19,O
",",O
respectively,O
",",O
after,O
ATRA,O
therapy,O
.,O
The,O
skin,O
biopsy,O
taken,O
from,O
each,O
patient,O
was,O
consistent,O
with,O
erythema,B
nodosum,I
.,O
All,O
patients,O
received,O
short,O
course,O
of,O
steroids,B
.,O
Fever,O
subsided,O
rapidly,O
and,O
the,O
skin,O
lesions,O
regressed,O
completely,O
.,O
All,O
patients,O
achieved,O
complete,O
remission,O
without,O
withdrawal,O
of,O
ATRA,B
.,O
ATRA,B
seemed,O
to,O
be,O
the,O
most,O
possible,O
etiology,O
of,O
erythema,O
nodosum,O
in,O
our,O
patients,O
.,O
Short,O
-,O
term,O
use,O
of,O
steroid,B
is,O
very,O
effective,O
in,O
ATRA,B
-,O
induced,O
erythema,O
nodosum,O
.,O
Effect,O
of,O
some,O
convulsants,O
on,O
the,O
protective,O
activity,O
of,O
loreclezole,B
and,O
its,O
combinations,O
with,O
valproate,B
or,O
clonazepam,B
in,O
amygdala,O
-,O
kindled,O
rats,O
.,O
Loreclezole,B
(,O
5,O
mg,O
/,O
kg,O
),O
exerted,O
a,O
significant,O
protective,O
action,O
in,O
amygdala,O
-,O
kindled,O
rats,O
",",O
reducing,O
both,O
seizure,O
and,O
afterdischarge,O
durations,O
.,O
The,O
combinations,O
of,O
loreclezole,B
(,O
2,O
.,O
5,O
mg,O
/,O
kg,O
),O
with,O
valproate,B
",",O
clonazepam,B
",",O
or,O
carbamazepine,B
(,O
applied,O
at,O
their,O
subprotective,O
doses,O
),O
also,O
exhibited,O
antiseizure,O
effect,O
in,O
this,O
test,O
.,O
However,O
",",O
only,O
two,O
first,O
combinations,O
occurred,O
to,O
be,O
of,O
pharmacodynamic,O
nature,O
.,O
Among,O
several,O
chemoconvulsants,O
",",O
bicuculline,B
",",O
N,B
-,I
methyl,I
-,I
D,I
-,I
aspartic,I
acid,I
and,O
BAY,B
k,I
-,I
8644,I
(,O
the,O
opener,O
of,O
L,B
-,I
type,I
calcium,I
channels,I
),O
reversed,O
the,O
protective,O
activity,O
of,O
loreclezole,O
alone,O
and,O
its,O
combination,O
with,O
valproate,B
.,O
On,O
the,O
other,O
hand,O
",",O
bicuculline,B
",",O
aminophylline,B
and,O
BAY,B
k,I
-,I
8644,I
inhibited,O
the,O
anticonvulsive,O
action,O
of,O
loreclezole,O
combined,O
with,O
clonazepam,O
.,O
The,O
results,O
support,O
the,O
hypothesis,O
that,O
the,O
protective,O
activity,O
of,O
loreclezole,O
and,O
its,O
combinations,O
with,O
other,O
antiepileptics,O
may,O
involve,O
potentiation,O
of,O
GABAergic,O
neurotransmission,O
and,O
blockade,O
of,O
L,B
-,I
type,I
of,I
calcium,I
channels,I
.,O
Mitochondrial,B
DNA,I
and,O
its,O
respiratory,O
chain,O
products,O
are,O
defective,O
in,O
doxorubicin,B
nephrosis,O
.,O
BACKGROUND,O
:,O
Doxorubicin,B
induces,O
a,O
self,O
-,O
perpetuating,O
nephropathy,O
characterized,O
by,O
early,O
glomerular,O
and,O
late,O
-,O
onset,O
tubular,O
lesions,O
in,O
rats,O
.,O
We,O
investigated,O
the,O
potential,O
role,O
of,O
mitochondrial,B
injury,O
in,O
the,O
onset,O
of,O
these,O
lesions,O
.,O
METHODS,O
:,O
Rats,O
were,O
treated,O
with,O
intravenous,O
doxorubicin,B
(,O
1,O
mg,O
kg,O
(,O
-,O
1,O
),O
week,O
(,O
-,O
1,O
),O
for,O
7,O
weeks,O
and,O
were,O
sacrificed,O
either,O
1,O
week,O
(,O
',O
short,O
-,O
term,O
',O
),O
or,O
30,O
weeks,O
(,O
',O
long,O
-,O
term,O
',O
),O
following,O
the,O
last,O
dose,O
.,O
Additional,O
rats,O
received,O
a,O
single,O
dose,O
either,O
6,O
days,O
or,O
2,O
h,O
prior,O
to,O
euthanasia,O
.,O
All,O
rats,O
were,O
killed,O
at,O
48,O
weeks,O
of,O
age,O
.,O
Glomerular,B
and,O
tubular,B
injury,O
was,O
monitored,O
and,O
correlated,O
to,O
the,O
activity,O
or,O
expression,O
of,O
respiratory,O
chain,O
components,O
.,O
Finally,O
",",O
we,O
quantified,O
both,O
nuclear,B
and,O
mitochondrial,B
DNA,I
(,O
mtDNA,B
),O
as,O
well,O
as,O
superoxide,B
production,O
and,O
the,O
4834,O
base,O
pair,O
',O
common,O
',O
mtDNA,B
deletion,O
.,O
RESULTS,O
:,O
The,O
',O
long,O
-,O
term,O
',O
group,O
had,O
significant,O
glomerular,B
and,O
tubular,B
lesions,O
",",O
depressed,O
activities,O
of,O
mtDNA,B
-,O
encoded,O
NADH,B
dehydrogenase,I
and,O
cytochrome,B
-,O
c,I
oxidase,I
(,O
COX,B
),O
and,O
increased,O
citrate,B
synthase,I
activity,O
.,O
In,O
addition,O
",",O
expression,O
of,O
the,O
mtDNA,B
-,O
encoded,O
COX,B
subunit,O
I,O
was,O
reduced,O
and,O
mtDNA,B
levels,O
were,O
decreased,O
.,O
In,O
',O
short,O
-,O
term,O
',O
rats,O
",",O
there,O
were,O
fewer,O
tubular,O
lesions,O
",",O
but,O
similar,O
numbers,O
of,O
glomerular,O
lesions,O
activity,O
.,O
Among,O
all,O
animals,O
",",O
glomerular,O
and,O
tubular,O
injury,O
were,O
inversely,O
correlated,O
with,O
mtDNA,B
levels,O
",",O
mtDNA,B
-,O
encoded,O
respiratory,O
chain,O
activities,O
and,O
with,O
the,O
expression,O
of,O
the,O
mtDNA,B
-,O
encoded,O
respiratory,O
chain,O
subunit,O
COX,B
-,O
I,O
.,O
Injury,O
was,O
positively,O
correlated,O
with,O
superoxide,B
production,O
and,O
the,O
activities,O
of,O
nucleus,O
-,O
encoded,O
mitochondrial,B
or,O
cytoplasmic,B
enzymes,O
.,O
Kidneys,O
from,O
the,O
',O
long,O
-,O
term,O
',O
group,O
showed,O
more,O
mtDNA,B
deletions,O
than,O
in,O
',O
short,O
-,O
term,O
',O
animals,O
and,O
these,O
were,O
not,O
observed,O
in,O
the,O
other,O
groups,O
.,O
CONCLUSIONS,O
:,O
These,O
results,O
suggest,O
an,O
important,O
role,O
for,O
quantitative,O
and,O
qualitative,O
mtDNA,B
alterations,O
through,O
the,O
reduction,O
of,O
mtDNA,B
-,O
encoded,O
respiratory,O
chain,O
function,O
and,O
induction,O
of,O
superoxide,B
in,O
doxorubicin,B
-,O
induced,O
renal,O
lesions,O
.,O
A,O
randomized,O
",",O
placebo,B
-,I
controlled,I
",",O
crossover,O
study,O
of,O
ephedrine,B
for,O
SSRI,B
-,I
induced,I
female,O
sexual,O
dysfunction,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
ephedrine,B
",",O
an,O
alpha,B
-,I
and,I
beta,I
-,I
adrenergic,I
agonist,I
previously,O
shown,O
to,O
enhance,O
genital,O
blood,O
flow,O
in,O
women,O
",",O
has,O
beneficial,O
effects,O
in,O
reversing,O
antidepressant,B
-,I
induced,I
sexual,O
dysfunction,O
.,O
Nineteen,O
sexually,O
dysfunctional,O
women,O
receiving,O
either,O
fluoxetine,B
",",O
sertraline,B
",",O
or,O
paroxetine,B
participated,O
in,O
an,O
eight,O
-,O
week,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
",",O
cross,O
-,O
over,O
study,O
of,O
the,O
effects,O
of,O
ephedrine,B
(,O
50,O
mg,O
),O
on,O
self,O
-,O
report,O
measures,O
of,O
sexual,O
desire,O
",",O
arousal,O
",",O
orgasm,O
",",O
and,O
sexual,O
satisfaction,O
.,O
Although,O
there,O
were,O
significant,O
improvements,O
relative,O
to,O
baseline,O
in,O
sexual,O
desire,O
and,O
orgasm,O
intensity,O
/,O
pleasure,O
on,O
50,B
mg,I
ephedrine,I
1,O
-,O
hr,O
prior,O
to,O
sexual,O
activity,O
",",O
significant,O
improvements,O
in,O
these,O
measures,O
",",O
as,O
well,O
as,O
in,O
sexual,O
arousal,O
and,O
orgasmic,O
ability,O
also,O
were,O
noted,O
with,O
placebo,B
.,O
These,O
findings,O
highlight,O
the,O
importance,O
of,O
conducting,O
placebo,B
-,O
controlled,O
trials,O
for,O
this,O
condition,O
.,O
Does,O
hormone,B
therapy,I
for,O
the,O
treatment,O
of,O
breast,B
cancer,I
have,O
a,O
detrimental,O
effect,O
on,O
memory,O
and,O
cognition,O
?,O
A,O
pilot,O
study,O
.,O
This,O
pilot,O
study,O
examines,O
whether,O
hormone,B
therapy,I
for,O
breast,B
cancer,I
affects,O
cognition,O
.,O
Patients,O
participating,O
in,O
a,O
randomised,O
trial,O
of,O
anastrozole,B
",",O
tamoxifen,B
alone,O
or,O
combined,O
(,O
ATAC,B
),O
(,O
n,O
=,O
94,O
),O
and,O
a,O
group,O
of,O
women,O
without,O
breast,B
cancer,I
(,O
n,O
=,O
35,O
),O
completed,O
a,O
battery,O
of,O
neuropsychological,O
measures,O
.,O
Compared,O
with,O
the,O
control,O
group,O
",",O
the,O
patients,O
were,O
impaired,O
on,O
a,O
processing,O
speed,O
task,O
(,O
p,B
=,O
0,O
.,O
32,O
),O
and,O
on,O
a,O
measure,O
of,O
immediate,O
verbal,O
memory,O
(,O
p,B
=,O
0,O
.,O
26,O
),O
after,O
controlling,O
for,O
the,O
use,O
of,O
hormone,B
replacement,I
therapy,I
in,O
both,O
groups,O
.,O
Patient,O
group,O
performance,O
was,O
not,O
significantly,O
related,O
to,O
length,O
of,O
treatment,O
or,O
measures,O
of,O
psychological,O
morbidity,O
.,O
The,O
results,O
showed,O
specific,O
impairments,O
in,O
processing,O
speed,O
and,O
verbal,O
memory,O
in,O
women,O
receiving,O
hormonal,O
therapy,O
for,O
the,O
treatment,O
of,O
breast,O
cancer,O
.,O
Verbal,O
memory,O
may,O
be,O
especially,O
sensitive,O
to,O
changes,O
in,O
oestrogen,B
levels,O
",",O
a,O
finding,O
commonly,O
reported,O
in,O
studies,O
of,O
hormone,O
replacement,O
therapy,O
in,O
healthy,O
women,O
.,O
In,O
view,O
of,O
the,O
increased,O
use,O
of,O
hormone,B
therapies,I
in,O
an,O
adjuvant,O
and,O
preventative,O
setting,O
their,O
impact,O
on,O
cognitive,O
functioning,O
should,O
be,O
investigated,O
more,O
thoroughly,O
.,O
Expression,O
of,O
p300,B
protects,O
cardiac,B
myocytes,I
from,O
apoptosis,O
in,O
vivo,O
.,O
Doxorubicin,B
is,O
an,O
anti,O
-,O
tumor,O
agent,O
that,O
represses,O
cardiac,B
-,O
specific,O
gene,O
expression,O
and,O
induces,O
myocardial,B
cell,I
apoptosis,O
.,O
Doxorubicin,B
depletes,O
cardiac,O
p300,B
",",O
a,O
transcriptional,O
coactivator,O
that,O
is,O
required,O
for,O
the,O
maintenance,O
of,O
the,O
differentiated,O
phenotype,O
of,O
cardiac,O
myocytes,O
.,O
However,O
",",O
the,O
role,O
of,O
p300,B
in,O
protection,O
against,O
doxorubicin,B
-,O
induced,O
apoptosis,O
is,O
unknown,O
.,O
Transgenic,O
mice,O
overexpressing,O
p300,B
in,O
the,O
heart,O
and,O
wild,O
-,O
type,O
mice,O
were,O
subjected,O
to,O
doxorubicin,B
treatment,O
.,O
Compared,O
with,O
wild,B
-,I
type,I
mice,I
",",O
transgenic,B
mice,I
exhibited,O
higher,O
survival,O
rate,O
as,O
well,O
as,O
more,O
preserved,O
left,O
ventricular,O
function,O
and,O
cardiac,O
expression,O
of,O
alpha,B
-,I
sarcomeric,I
actin,I
.,O
Doxorubicin,B
induced,O
myocardial,O
cell,O
apoptosis,O
in,O
wild,B
-,I
type,I
mice,I
but,O
not,O
in,O
transgenic,B
mice,I
.,O
Expression,O
of,O
p300,B
increased,O
the,O
cardiac,O
level,O
of,O
bcl,B
-,I
2,I
and,O
mdm,B
-,I
2,I
",",O
but,O
not,O
that,O
of,O
p53,B
or,O
other,O
members,O
of,O
the,O
bcl,B
-,I
2,I
family,I
.,O
These,O
findings,O
demonstrate,O
that,O
overexpression,O
of,O
p300,B
protects,O
cardiac,O
myocytes,O
from,O
doxorubicin,B
-,I
induced,I
apoptosis,I
and,O
reduces,O
the,O
extent,O
of,O
acute,O
heart,O
failure,O
in,O
adult,O
mice,O
in,O
vivo,O
.,O
Methimazole,B
-,I
induced,I
cholestatic,I
jaundice,I
.,O
Methimazole,B
is,O
a,O
widely,O
used,O
and,O
generally,O
well,O
-,O
tolerated,O
antithyroid,O
agent,O
.,O
A,O
43,O
-,O
year,O
-,O
old,O
woman,O
had,O
severe,O
jaundice,B
and,O
itching,O
1,O
month,O
after,O
receiving,O
methimazole,B
(,O
10,O
mg,O
tid,O
),O
and,O
propranolol,B
(,O
20,O
mg,O
tid,O
),O
for,O
treatment,O
of,O
hyperthyroidism,O
.,O
The,O
patient,O
continued,O
treatment,O
for,O
another,O
4,O
days,O
after,O
the,O
appearance,O
of,O
jaundice,B
until,O
she,O
finished,O
both,O
medications,O
.,O
When,O
seen,O
at,O
the,O
emergency,O
department,O
2,O
weeks,O
later,O
",",O
she,O
still,O
had,O
severe,O
icterus,B
",",O
pruritus,B
",",O
and,O
hyperbilirubinemia,B
",",O
formed,O
mainly,O
of,O
the,O
conjugated,O
fraction,O
.,O
Methimazole,B
-,O
induced,O
cholestasis,O
was,O
diagnosed,O
",",O
and,O
propranolol,B
therapy,O
was,O
resumed,O
.,O
Over,O
the,O
following,O
9,O
days,O
",",O
the,O
symptoms,O
improved,O
and,O
plasma,O
bilirubin,B
levels,O
were,O
normal,O
after,O
12,O
weeks,O
without,O
methimazole,B
.,O
In,O
rare,O
cases,O
within,O
the,O
first,O
few,O
weeks,O
of,O
therapy,O
",",O
this,O
drug,O
can,O
cause,O
severe,O
and,O
reversible,O
cholestatic,O
jaundice,O
.,O
Physicians,O
and,O
patients,O
should,O
be,O
aware,O
of,O
this,O
adverse,O
effect,O
so,O
that,O
",",O
upon,O
occurrence,O
",",O
they,O
can,O
discontinue,O
methimazole,B
therapy,O
and,O
avoid,O
unnecessary,O
invasive,O
procedures,O
.,O
Atrial,O
fibrillation,O
following,O
chemotherapy,O
for,O
stage,O
IIIE,O
diffuse,O
large,O
B,B
-,I
cell,I
gastric,I
lymphoma,I
in,O
a,O
patient,O
with,O
myotonic,O
dystrophy,O
(,O
Steinert,O
',O
s,O
disease,O
),O
.,O
The,O
authors,O
describe,O
the,O
unusual,O
association,O
between,O
diffuse,O
B,B
-,I
cell,I
gastric,I
lymphoma,I
and,O
myotonic,B
dystrophy,I
",",O
the,O
most,O
common,O
form,O
of,O
adult,O
muscular,O
dystrophy,O
",",O
and,O
sudden,O
atrial,B
fibrillation,I
following,O
one,O
cycle,O
of,O
doxorubicin,B
-,I
based,I
chemotherapy,I
in,O
the,O
same,O
patient,O
.,O
Atrial,B
fibrillation,I
or,O
other,O
cardiac,O
arrhythmias,O
are,O
unusual,O
complications,O
in,O
patients,O
treated,O
with,O
chemotherapy,O
.,O
The,O
cardiac,B
toxicity,I
intrinsically,O
associated,O
with,O
the,O
aggressive,O
chemotherapy,O
employed,O
could,O
function,O
as,O
a,O
triggering,O
factor,O
for,O
the,O
arrhythmia,O
in,O
the,O
predisposed,O
myocardium,O
of,O
this,O
patient,O
.,O
Hypersensitivity,B
immune,I
reaction,I
as,O
a,O
mechanism,O
for,O
dilevalol,B
-,I
associated,I
hepatitis,I
.,O
OBJECTIVE,O
:,O
To,O
assess,O
lymphocyte,O
reactivity,O
to,O
dilevalol,B
and,O
to,O
serum,O
containing,O
putative,O
ex,O
vivo,O
dilevalol,I
antigens,I
or,O
metabolites,O
in,O
a,O
case,O
of,O
dilevalol,B
-,I
induced,I
liver,I
injury,I
.,O
PATIENT,O
:,O
A,O
58,O
-,O
year,O
-,O
old,O
woman,O
with,O
a,O
clinical,O
diagnosis,O
of,O
dilevalol,B
-,I
induced,I
liver,I
injury,I
.,O
METHODS,O
:,O
Peripheral,O
blood,O
mononuclear,O
cells,O
collected,O
from,O
the,O
patient,O
were,O
cultured,O
in,O
the,O
presence,O
of,O
a,O
solution,O
of,O
dilevalol,B
and,O
also,O
with,O
sera,O
collected,O
from,O
a,O
volunteer,O
before,O
and,O
after,O
dilevalol,B
intake,O
.,O
A,O
similar,O
protocol,O
was,O
performed,O
with,O
lymphocytes,O
from,O
a,O
healthy,O
subject,O
.,O
RESULTS,O
:,O
No,O
lymphocyte,O
proliferation,O
was,O
observed,O
either,O
in,O
the,O
patient,O
or,O
in,O
the,O
healthy,O
volunteer,O
in,O
the,O
presence,O
of,O
dilevalol,B
solutions,O
.,O
A,O
significant,O
proliferative,O
response,O
to,O
serum,O
collected,O
after,O
dilevalol,B
intake,O
was,O
observed,O
in,O
the,O
case,O
of,O
the,O
patient,O
compared,O
with,O
the,O
proliferative,O
response,O
to,O
the,O
serum,O
collected,O
before,O
the,O
drug,O
intake,O
.,O
No,O
reactivity,O
was,O
found,O
when,O
lymphocytes,O
from,O
the,O
healthy,O
subject,O
were,O
tested,O
under,O
similar,O
conditions,O
.,O
CONCLUSIONS,O
:,O
The,O
methodology,O
used,O
allowed,O
the,O
detection,O
of,O
lymphocyte,O
sensitization,O
to,O
sera,O
containing,O
ex,O
vivo,O
-,O
prepared,O
dilevalol,B
antigens,O
",",O
suggesting,O
the,O
involvement,O
of,O
an,O
immunologic,O
mechanism,O
in,O
dilevalol,B
-,O
induced,O
liver,O
injury,O
.,O
Increased,O
expression,O
and,O
apical,O
targeting,O
of,O
renal,O
ENaC,B
subunits,O
in,O
puromycin,B
aminonucleoside,I
-,I
induced,I
nephrotic,I
syndrome,I
in,O
rats,O
.,O
Nephrotic,O
syndrome,O
is,O
often,O
accompanied,O
by,O
sodium,O
retention,O
and,O
generalized,O
edema,O
.,O
However,O
",",O
the,O
molecular,O
basis,O
for,O
the,O
decreased,O
renal,O
sodium,O
excretion,O
remains,O
undefined,O
.,O
We,O
hypothesized,O
that,O
epithelial,O
Na,B
channel,O
(,O
ENaC,B
),O
subunit,O
dysregulation,O
may,O
be,O
responsible,O
for,O
the,O
increased,O
sodium,B
retention,O
.,O
An,O
experimental,O
group,O
of,O
rats,O
was,O
treated,O
with,O
puromycin,B
aminonucleoside,I
(,O
PAN,B
;,O
180,O
mg,O
/,O
kg,O
iv,O
),O
",",O
whereas,O
the,O
control,O
group,O
received,O
only,O
vehicle,O
.,O
After,O
7,O
days,O
",",O
PAN,B
treatment,O
induced,O
significant,O
proteinuria,B
",",O
hypoalbuminemia,B
",",O
decreased,O
urinary,O
sodium,B
excretion,O
",",O
and,O
extensive,O
ascites,O
.,O
The,O
protein,O
abundance,O
of,O
alpha,B
-,O
ENaC,I
and,O
beta,B
-,O
ENaC,I
was,O
increased,O
in,O
the,O
inner,O
stripe,O
of,O
the,O
outer,O
medulla,O
(,O
ISOM,B
),O
and,O
in,O
the,O
inner,O
medulla,O
(,O
IM,B
),O
but,O
was,O
not,O
altered,O
in,O
the,O
cortex,O
.,O
gamma,B
-,O
ENaC,I
abundance,O
was,O
increased,O
in,O
the,O
cortex,O
",",O
ISOM,B
",",O
and,O
IM,B
.,O
Immunoperoxidase,O
brightfield,O
-,O
and,O
laser,O
-,O
scanning,O
confocal,O
fluorescence,O
microscopy,O
demonstrated,O
increased,O
targeting,O
of,O
alpha,B
-,O
ENaC,I
",",O
beta,B
-,O
ENaC,I
",",O
and,O
gamma,B
-,O
ENaC,I
subunits,O
to,O
the,O
apical,O
plasma,O
membrane,O
in,O
the,O
distal,O
convoluted,O
tubule,O
(,O
DCT2,B
),O
",",O
connecting,O
tubule,O
",",O
and,O
cortical,O
and,O
medullary,O
collecting,O
duct,O
segments,O
.,O
Immunoelectron,O
microscopy,O
further,O
revealed,O
an,O
increased,O
labeling,O
of,O
alpha,B
-,O
ENaC,I
in,O
the,O
apical,O
plasma,O
membrane,O
of,O
cortical,O
collecting,O
duct,O
principal,O
cells,O
of,O
PAN,O
-,O
treated,O
rats,O
",",O
indicating,O
enhanced,O
apical,O
targeting,O
of,O
alpha,B
-,O
ENaC,I
subunits,O
.,O
In,O
contrast,O
",",O
the,O
protein,O
abundances,O
of,O
Na,B
(,O
+,O
)/,O
H,B
(,I
+,I
)/,I
exchanger,O
type,O
3,O
(,O
NHE3,B
),O
",",O
Na,B
(,O
+,O
)-,O
K,B
(,O
+,O
)-,O
-,O
2Cl,I
(,O
-,O
),O
cotransporter,O
(,O
BSC,B
-,O
1,O
),O
",",O
and,O
thiazide,O
-,O
sensitive,O
Na,B
(,O
+,O
)-,O
-,O
Cl,I
(,O
-,O
),O
cotransporter,O
(,O
TSC,B
),O
were,O
decreased,O
.,O
Moreover,O
",",O
the,O
abundance,O
of,O
the,O
alpha,B
(,O
1,O
),O
-,O
subunit,O
of,O
the,O
Na,B
-,O
K,I
-,O
ATPase,I
was,O
decreased,O
in,O
the,O
cortex,O
and,O
ISOM,O
",",O
but,O
it,O
remained,O
unchanged,O
in,O
the,O
IM,O
.,O
In,O
conclusion,O
",",O
the,O
increased,O
or,O
sustained,O
expression,O
of,O
ENaC,B
subunits,O
combined,O
with,O
increased,O
apical,O
targeting,O
in,O
the,O
DCT2,O
",",O
connecting,O
tubule,O
",",O
and,O
collecting,O
duct,O
are,O
likely,O
to,O
play,O
a,O
role,O
in,O
the,O
sodium,O
retention,O
associated,O
with,O
PAN,B
-,O
induced,O
nephrotic,O
syndrome,O
.,O
The,O
decreased,O
abundance,O
of,O
NHE3,B
",",O
BSC,B
-,I
1,I
",",O
TSC,B
",",O
and,O
Na,B
-,I
K,I
-,I
ATPase,I
may,O
play,O
a,O
compensatory,O
role,O
to,O
promote,O
sodium,O
excretion,O
.,O
Pallidal,B
stimulation,O
:,O
an,O
alternative,O
to,O
pallidotomy,O
?,O
A,O
resurgence,O
of,O
interest,O
in,O
the,O
surgical,O
treatment,O
of,O
Parkinson,B
',I
s,I
disease,I
(,O
PD,B
),I
came,O
with,O
the,O
rediscovery,O
of,O
posteroventral,O
pallidotomy,O
by,O
Laitinen,O
in,O
1985,O
.,O
Laitinen,O
's,O
procedure,O
improved,O
most,O
symptoms,O
in,O
drug,B
-,I
resistant,I
PD,I
",",O
which,O
engendered,O
wide,O
interest,O
in,O
the,O
neurosurgical,O
community,O
.,O
Another,O
lesioning,O
procedure,O
",",O
ventrolateral,O
thalamotomy,O
",",O
has,O
become,O
a,O
powerful,O
alternative,O
to,O
stimulate,O
the,O
nucleus,O
ventralis,O
intermedius,O
",",O
producing,O
high,O
long,O
-,O
term,O
success,O
rates,O
and,O
low,O
morbidity,O
rates,O
.,O
Pallidal,B
stimulation,O
has,O
not,O
met,O
with,O
the,O
same,O
success,O
.,O
According,O
to,O
the,O
literature,O
pallidotomy,B
improves,O
the,O
on,O
symptoms,O
of,O
PD,B
",",O
such,O
as,O
dyskinesias,B
",",O
as,O
well,O
as,O
the,O
off,O
symptoms,O
",",O
such,O
as,O
rigidity,B
",",O
bradykinesia,B
",",O
and,O
on,O
-,O
off,O
fluctuations,O
.,O
Pallidal,B
stimulation,O
improves,O
bradykinesia,B
and,O
rigidity,B
to,O
a,O
minor,O
extent,O
;,O
however,O
",",O
its,O
strength,O
seems,O
to,O
be,O
in,O
improving,O
levodopa,B
-,O
induced,O
dyskinesias,B
.,O
Stimulation,O
often,O
produces,O
an,O
improvement,O
in,O
the,O
hyper,B
-,O
or,O
dyskinetic,B
upper,I
limbs,O
",",O
but,O
increases,O
the,O
freezing,B
phenomenon,O
in,O
the,O
lower,B
limbs,O
at,O
the,O
same,O
time,O
.,O
Considering,O
the,O
small,O
increase,O
in,O
the,O
patient,O
',O
s,O
independence,O
",",O
the,O
high,O
costs,O
of,O
bilateral,O
implants,O
",",O
and,O
the,O
difficulty,O
most,O
patients,O
experience,O
in,O
handling,O
the,O
devices,O
",",O
the,O
question,O
arises,O
as,O
to,O
whether,O
bilateral,O
pallidal,B
stimulation,O
is,O
a,O
real,O
alternative,O
to,O
pallidotomy,O
.,O
Effects,O
of,O
the,O
cyclooxygenase,B
-,I
2,I
specific,I
inhibitor,I
valdecoxib,B
versus,O
nonsteroidal,B
antiinflammatory,I
agents,I
and,O
placebo,O
on,O
cardiovascular,O
thrombotic,O
events,O
in,O
patients,O
with,O
arthritis,O
.,O
There,O
have,O
been,O
concerns,O
that,O
the,O
risk,O
of,O
cardiovascular,O
thrombotic,O
events,O
may,O
be,O
higher,O
with,O
cyclooxygenase,B
(,I
COX,I
),I
-,I
2,I
-,I
specific,I
inhibitors,I
than,O
nonselective,B
nonsteroidal,I
antiinflammatory,I
drugs,I
(,I
NSAIDs,I
),I
.,O
We,O
evaluated,O
cardiovascular,O
event,O
data,O
for,O
valdecoxib,B
",",O
a,O
new,O
COX,B
-,I
2,I
-,I
specific,I
inhibitor,I
in,O
approximately,O
8000,O
patients,O
with,O
osteoarthritis,O
and,O
rheumatoid,O
arthritis,O
treated,O
with,O
this,O
agent,O
in,O
randomized,O
clinical,O
trials,O
.,O
The,O
incidence,O
of,O
cardiovascular,O
thrombotic,O
events,O
(,O
cardiac,O
",",O
cerebrovascular,O
and,O
peripheral,O
vascular,O
",",O
or,O
arterial,O
thrombotic,O
),O
was,O
determined,O
by,O
analyzing,O
pooled,O
valdecoxib,B
(,O
10,O
-,O
80,O
mg,O
daily,O
),O
",",O
nonselective,O
NSAID,B
(,O
diclofenac,B
75,O
mg,O
bid,O
",",O
ibuprofen,B
800,O
mg,O
tid,O
",",O
or,O
naproxen,B
500,O
mg,O
bid,O
),O
and,O
placebo,O
data,O
from,O
10,O
randomized,O
osteoarthritis,O
and,O
rheumatoid,O
arthritis,O
trials,O
that,O
were,O
6,O
-,O
52,O
weeks,O
in,O
duration,O
.,O
The,O
incidence,O
rates,O
of,O
events,O
were,O
determined,O
in,O
all,O
patients,O
(,O
n,O
=,O
7934,O
),O
and,O
in,O
users,O
of,O
low,O
-,O
dose,O
(,O
<,O
or,O
=,O
325,O
mg,O
daily,O
),O
aspirin,B
(,O
n,O
=,O
1051,O
),O
and,O
nonusers,O
of,O
aspirin,B
(,O
n,O
=,O
6883,O
),O
.,O
Crude,O
and,O
exposure,O
-,O
adjusted,O
incidences,O
of,O
thrombotic,B
events,O
were,O
similar,O
for,O
valdecoxib,B
",",O
NSAIDs,B
",",O
and,O
placebo,B
.,O
The,O
risk,O
of,O
serious,O
thrombotic,B
events,O
was,O
also,O
similar,O
for,O
each,O
valdecoxib,B
dose,O
.,O
Thrombotic,O
risk,O
was,O
consistently,O
higher,O
for,O
users,O
of,O
aspirin,B
users,O
than,O
nonusers,O
of,O
aspirin,O
(,O
placebo,O
",",O
1,O
.,O
4,O
%,O
vs,O
.,O
0,O
%,O
;,O
valdecoxib,B
",",O
1,O
.,O
7,O
%,O
vs,O
.,O
0,O
.,O
2,O
%,O
;,O
NSAIDs,B
",",O
1,O
.,O
9,O
%,O
vs,O
.,O
0,O
.,O
5,O
%,O
).,O
The,O
rates,O
of,O
events,O
in,O
users,O
of,O
aspirin,B
were,O
similar,O
for,O
all,O
3,O
treatment,O
groups,O
and,O
across,O
valdecoxib,B
doses,O
.,O
Short,O
-,O
and,O
intermediate,O
-,O
term,O
treatment,O
with,O
therapeutic,O
(,O
10,O
or,O
20,O
mg,O
daily,O
),O
and,O
supratherapeutic,O
(,O
40,O
or,O
80,O
mg,O
daily,O
),O
valdecoxib,B
doses,O
was,O
not,O
associated,O
with,O
an,O
increased,O
incidence,O
of,O
thrombotic,O
events,O
relative,O
to,O
nonselective,O
NSAIDs,B
or,O
placebo,O
in,O
osteoarthritis,O
and,O
rheumatoid,O
arthritis,O
patients,O
in,O
controlled,O
clinical,O
trials,O
.,O
Hypersensitivity,B
myocarditis,I
complicating,O
hypertrophic,O
cardiomyopathy,O
heart,O
.,O
The,O
present,O
report,O
describes,O
a,O
case,O
of,O
eosinophilic,B
myocarditis,I
complicating,O
hypertrophic,O
cardiomyopathy,O
.,O
The,O
47,O
-,O
year,O
-,O
old,O
female,O
patient,O
",",O
known,O
to,O
have,O
hypertrophic,O
cardiomyopathy,O
",",O
was,O
admitted,O
with,O
biventricular,O
failure,O
and,O
managed,O
aggressively,O
with,O
dobutamine,B
infusion,O
and,O
other,O
drugs,O
while,O
being,O
assessed,O
for,O
heart,O
transplantation,O
.,O
On,O
transthoracic,O
echocardiogram,O
",",O
she,O
had,O
moderate,O
left,B
ventricular,I
dysfunction,I
with,O
regional,O
variability,O
and,O
moderate,O
mitral,B
regurgitation,I
.,O
The,O
recipient,O
',O
s,O
heart,O
showed,O
the,O
features,O
of,O
apical,B
hypertrophic,I
cardiomyopathy,I
and,O
myocarditis,B
with,O
abundant,O
eosinophils,B
.,O
Myocarditis,B
is,O
rare,O
and,O
eosinophilic,O
myocarditis,B
is,O
rarer,O
.,O
It,O
is,O
likely,O
that,O
the,O
hypersensitivity,O
(,O
eosinophilic,B
),O
myocarditis,O
was,O
related,O
to,O
dobutamine,B
infusion,O
therapy,O
.,O
Eosinophilic,B
myocarditis,O
has,O
been,O
reported,O
with,O
an,O
incidence,O
of,O
2,O
.,O
4,O
%,O
to,O
7,O
.,O
2,O
%,O
in,O
explanted,O
hearts,O
and,O
may,O
be,O
related,O
to,O
multidrug,O
therapy,O
.,O
Time,O
trends,O
in,O
warfarin,B
-,I
associated,I
hemorrhage,O
.,O
The,O
annual,O
incidence,O
of,O
warfarin,B
-,O
related,O
bleeding,O
at,O
Brigham,O
and,O
Women,O
',O
s,O
Hospital,O
increased,O
from,O
0,O
.,O
97,O
/,O
1,O
",",O
0,O
patient,O
admissions,O
in,O
the,O
first,O
time,O
period,O
(,O
January,O
1995,O
to,O
October,O
1998,O
),O
to,O
1,O
.,O
19,O
/,O
1,O
",",O
0,O
patient,O
admissions,O
in,O
the,O
second,O
time,O
period,O
(,O
November,O
1998,O
to,O
August,O
2002,O
),O
of,O
this,O
study,O
.,O
The,O
proportion,O
of,O
patients,O
with,O
major,O
and,O
intracranial,O
bleeding,O
increased,O
from,O
20,O
.,O
2,O
%,O
and,O
1,O
.,O
9,O
%,O
",",O
respectively,O
",",O
in,O
the,O
first,O
time,O
period,O
",",O
to,O
33,O
.,O
3,O
%,O
and,O
7,O
.,O
8,O
%,O
",",O
respectively,O
",",O
in,O
the,O
second,O
.,O
Yohimbine,B
treatment,O
of,O
sexual,O
side,O
effects,O
induced,O
by,O
serotonin,B
reuptake,I
blockers,I
.,O
BACKGROUND,O
:,O
Preclinical,O
and,O
clinical,O
studies,O
suggest,O
that,O
yohimbine,O
facilitates,O
sexual,O
behavior,O
and,O
may,O
be,O
helpful,O
in,O
the,O
treatment,O
of,O
male,O
impotence,O
.,O
A,O
single,O
case,O
report,O
suggests,O
that,O
yohimbine,B
may,O
be,O
used,O
to,O
treat,O
the,O
sexual,O
side,O
effects,O
of,O
clomipramine,B
.,O
This,O
study,O
evaluated,O
yohimbine,B
as,O
a,O
treatment,O
for,O
the,O
sexual,O
side,O
effects,O
caused,O
by,O
serotonin,B
reuptake,I
blockers,I
.,O
METHOD,O
:,O
Six,O
patients,O
with,O
either,O
obsessive,O
compulsive,O
disorder,O
",",O
trichotillomania,B
",",O
anxiety,O
",",O
or,O
affective,O
disorders,O
who,O
suffered,O
sexual,O
side,O
effects,O
after,O
treatment,O
with,O
serotonin,B
reuptake,I
blockers,I
were,O
given,O
yohimbine,B
on,O
a,O
p,O
.,O
r,O
.,O
n,O
.,O
basis,O
in,O
an,O
open,O
clinical,O
trial,O
.,O
Various,O
doses,O
of,O
yohimbine,B
were,O
used,O
to,O
determine,O
the,O
ideal,O
dose,O
for,O
each,O
patient,O
.,O
RESULTS,O
:,O
Five,O
of,O
the,O
six,O
patients,O
experienced,O
improved,O
sexual,O
functioning,O
after,O
taking,O
yohimbine,B
.,O
One,O
patient,O
who,O
failed,O
to,O
comply,O
with,O
yohimbine,B
treatment,O
had,O
no,O
therapeutic,O
effects,O
.,O
Side,O
effects,O
of,O
yohimbine,B
included,O
excessive,O
sweating,O
",",O
increased,O
anxiety,O
",",O
and,O
a,O
wound,O
-,O
up,O
feeling,O
in,O
some,O
patients,O
.,O
CONCLUSION,O
:,O
The,O
results,O
of,O
this,O
study,O
indicate,O
that,O
yohimbine,B
may,O
be,O
an,O
effective,O
treatment,O
for,O
the,O
sexual,O
side,O
effects,O
caused,O
by,O
serotonin,B
reuptake,I
blockers,O
.,O
Future,O
controlled,O
studies,O
are,O
needed,O
to,O
further,O
investigate,O
the,O
effectiveness,O
and,O
safety,O
of,O
yohimbine,B
for,O
this,O
indication,O
.,O
Hemorrhagic,B
cystitis,I
complicating,O
bone,O
marrow,O
transplantation,O
.,O
Hemorrhagic,B
cystitis,I
is,O
a,O
potentially,O
serious,O
complication,O
of,O
high,O
-,O
dose,O
cyclophosphamide,B
therapy,O
administered,O
before,O
bone,O
marrow,O
transplantation,O
.,O
As,O
standard,O
practice,O
at,O
our,O
institution,O
",",O
patients,O
who,O
are,O
scheduled,O
to,O
receive,O
a,O
bone,O
marrow,O
transplant,O
are,O
treated,O
prophylactically,O
with,O
forced,O
hydration,O
and,O
bladder,O
irrigation,O
.,O
In,O
an,O
attempt,O
to,O
obviate,O
the,O
inconvenience,O
of,O
bladder,O
irrigation,O
",",O
we,O
conducted,O
a,O
feasibility,O
trial,O
of,O
uroprophylaxis,O
with,O
mesna,B
",",O
which,O
neutralizes,O
the,O
hepatic,O
metabolite,O
of,O
cyclophosphamide,B
that,O
causes,O
hemorrhagic,O
cystitis,O
.,O
Of,O
97,O
patients,O
who,O
received,O
standard,O
prophylaxis,O
",",O
4,O
had,O
symptomatic,O
hemorrhagic,O
cystitis,O
.,O
In,O
contrast,O
",",O
two,O
of,O
four,O
consecutive,O
patients,O
who,O
received,O
mesna,B
uroprophylaxis,O
before,O
allogeneic,O
bone,O
marrow,O
transplantation,O
had,O
severe,O
hemorrhagic,O
cystitis,O
for,O
at,O
least,O
2,O
weeks,O
.,O
Because,O
of,O
this,O
suboptimal,O
result,O
",",O
we,O
resumed,O
the,O
use,O
of,O
bladder,O
irrigation,O
and,O
forced,O
hydration,O
to,O
minimize,O
the,O
risk,O
of,O
hemorrhagic,O
cystitis,O
.,O
Consensus,O
statement,O
concerning,O
cardiotoxicity,O
occurring,O
during,O
haematopoietic,B
stem,I
cell,I
transplantation,I
in,O
the,O
treatment,O
of,O
autoimmune,O
diseases,O
",",O
with,O
special,O
reference,O
to,O
systemic,O
sclerosis,O
and,O
multiple,O
sclerosis,O
.,O
Autologous,O
haematopoietic,B
stem,I
cell,I
transplantation,I
is,O
now,O
a,O
feasible,O
and,O
effective,O
treatment,O
for,O
selected,O
patients,O
with,O
severe,O
autoimmune,O
diseases,O
.,O
Worldwide,O
",",O
over,O
650,O
patients,O
have,O
been,O
transplanted,O
in,O
the,O
context,O
of,O
phase,O
I,O
and,O
II,O
clinical,O
trials,O
.,O
The,O
results,O
are,O
encouraging,O
enough,O
to,O
begin,O
randomised,O
phase,O
III,O
trials,O
.,O
However,O
",",O
as,O
predicted,O
",",O
significant,O
transplant,O
-,O
related,O
morbidity,O
and,O
mortality,O
have,O
been,O
observed,O
.,O
This,O
is,O
primarily,O
due,O
to,O
complications,O
related,O
to,O
either,O
the,O
stage,O
of,O
the,O
disease,O
at,O
transplant,O
or,O
due,O
to,O
infections,O
.,O
The,O
number,O
of,O
deaths,O
related,O
to,O
cardiac,B
toxicity,I
is,O
low,O
.,O
However,O
",",O
caution,O
is,O
required,O
when,O
cyclophosphamide,B
or,O
anthracyclines,B
such,O
as,O
mitoxantrone,B
are,O
used,O
in,O
patients,O
with,O
a,O
possible,O
underlying,O
heart,B
damage,I
",",O
for,O
example,O
",",O
systemic,O
sclerosis,O
patients,O
.,O
In,O
November,O
2002,O
",",O
a,O
meeting,O
was,O
held,O
in,O
Florence,O
",",O
bringing,O
together,O
a,O
number,O
of,O
experts,O
in,O
various,O
fields,O
",",O
including,O
rheumatology,B
",",O
cardiology,B
",",O
neurology,B
",",O
pharmacology,B
and,O
transplantation,B
medicine,I
.,O
The,O
object,O
of,O
the,O
meeting,O
was,O
to,O
analyse,O
existing,O
data,O
",",O
both,O
published,O
or,O
available,O
",",O
in,O
the,O
European,O
Group,O
for,O
Blood,B
and,I
Marrow,I
Transplantation,I
autoimmune,O
disease,O
database,O
",",O
and,O
to,O
propose,O
a,O
safe,O
approach,O
to,O
such,O
patients,O
.,O
A,O
full,O
cardiological,O
assessment,O
before,O
and,O
during,O
the,O
transplant,O
emerged,O
as,O
the,O
major,O
recommendation,O
.,O
Does,O
supplemental,O
vitamin,B
C,I
increase,O
cardiovascular,O
disease,O
risk,O
in,O
women,O
with,O
diabetes,O
?,O
BACKGROUND,O
:,O
Vitamin,B
C,I
acts,O
as,O
a,O
potent,O
antioxidant,O
;,O
however,O
",",O
it,O
can,O
also,O
be,O
a,O
prooxidant,O
and,O
glycate,O
protein,O
under,O
certain,O
circumstances,O
in,O
vitro,O
.,O
These,O
observations,O
led,O
us,O
to,O
hypothesize,O
that,O
a,O
high,O
intake,O
of,O
vitamin,B
C,I
in,O
diabetic,O
persons,O
might,O
promote,O
atherosclerosis,O
.,O
OBJECTIVE,O
:,O
The,O
objective,O
was,O
to,O
examine,O
the,O
relation,O
between,O
vitamin,B
C,I
intake,O
and,O
mortality,O
from,O
cardiovascular,O
disease,O
.,O
DESIGN,O
:,O
We,O
studied,O
the,O
relation,O
between,O
vitamin,B
C,I
intake,O
and,O
mortality,O
from,O
total,O
cardiovascular,O
disease,O
(,O
n,O
=,O
281,O
),O
",",O
coronary,O
artery,O
disease,O
(,O
n,O
=,O
175,O
),O
",",O
and,O
stroke,O
(,O
n,O
=,O
57,O
),O
in,O
1923,O
postmenopausal,O
women,O
who,O
reported,O
being,O
diabetic,O
at,O
baseline,O
.,O
Diet,O
was,O
assessed,O
with,O
a,O
food,B
-,I
frequency,I
questionnaire,I
at,O
baseline,O
",",O
and,O
subjects,O
initially,O
free,O
of,O
coronary,B
artery,I
disease,I
were,O
prospectively,O
followed,O
for,O
15,O
y,O
.,O
RESULTS,O
:,O
After,O
adjustment,O
for,O
cardiovascular,B
disease,I
risk,I
factors,I
",",O
type,O
of,O
diabetes,B
medication,I
used,O
",",O
duration,O
of,O
diabetes,B
",",O
and,O
intakes,O
of,O
folate,B
",",O
vitamin,B
E,I
",",O
and,O
beta,B
-,I
carotene,I
",",O
the,O
adjusted,O
relative,O
risks,O
of,O
total,O
cardiovascular,B
disease,I
mortality,I
were,O
1,O
.,O
0,O
",",O
0,O
.,O
97,O
",",O
1,O
.,O
11,O
",",O
1,O
.,O
47,O
",",O
and,O
1,O
.,O
84,O
(,O
P,O
for,O
trend,O
<,O
0,O
.,O
1,O
),O
across,O
quintiles,O
of,O
total,O
vitamin,B
C,I
intake,I
from,I
food,I
and,I
supplements,I
.,O
Adjusted,O
relative,O
risks,O
of,O
coronary,O
artery,O
disease,O
were,O
1,O
.,O
0,O
",",O
0,O
.,O
81,O
",",O
0,O
.,O
99,O
",",O
1,O
.,O
26,O
",",O
and,O
1,O
.,O
91,O
(,O
P,O
for,O
trend,O
=,O
0,O
.,O
1,O
),O
and,O
of,O
stroke,O
were,O
1,O
.,O
0,O
",",O
0,O
.,O
52,O
",",O
1,O
.,O
23,O
",",O
2,O
.,O
22,O
",",O
and,O
2,O
.,O
57,O
(,O
P,O
for,O
trend,O
<,O
0,O
.,O
1,O
),O
.,O
When,O
dietary,O
and,O
supplemental,O
vitamin,B
C,I
were,O
analyzed,O
separately,O
",",O
only,O
supplemental,O
vitamin,B
C,I
showed,O
a,O
positive,O
association,O
with,O
mortality,O
endpoints,O
.,O
Vitamin,B
C,I
intake,O
was,O
unrelated,O
to,O
mortality,O
from,O
cardiovascular,O
disease,O
in,O
the,O
nondiabetic,O
subjects,O
at,O
baseline,O
.,O
CONCLUSION,O
:,O
A,O
high,O
vitamin,B
C,I
intake,O
from,O
supplements,O
is,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
cardiovascular,O
disease,O
mortality,O
in,O
postmenopausal,O
women,O
with,O
diabetes,O
.,O
Optical,O
coherence,O
tomography,O
can,O
measure,O
axonal,O
loss,O
in,O
patients,O
with,O
ethambutol,B
-,O
induced,O
optic,O
neuropathy,O
.,O
PURPOSE,O
:,O
To,O
map,O
and,O
identify,O
the,O
pattern,O
",",O
in,O
vivo,O
",",O
of,O
axonal,O
degeneration,O
in,O
ethambutol,B
-,O
induced,O
optic,O
neuropathy,O
using,O
optical,O
coherence,O
tomography,O
(,O
OCT,B
),O
.,O
Ethambutol,B
is,O
an,O
antimycobacterial,O
agent,O
often,O
used,O
to,O
treat,O
tuberculosis,O
.,O
A,O
serious,O
complication,O
of,O
ethambutol,B
is,O
an,O
optic,B
neuropathy,I
that,O
impairs,O
visual,O
acuity,O
",",O
contrast,O
sensitivity,O
",",O
and,O
color,O
vision,O
.,O
However,O
",",O
early,O
on,O
",",O
when,O
the,O
toxic,O
optic,B
neuropathy,I
is,O
mild,O
and,O
partly,O
reversible,O
",",O
the,O
funduscopic,O
findings,O
are,O
often,O
subtle,O
and,O
easy,O
to,O
miss,O
.,O
METHODS,O
:,O
Three,O
subjects,O
with,O
a,O
history,O
of,O
ethambutol,B
(,O
EMB,B
),O
-,O
induced,O
optic,B
neuropathy,I
of,O
short,O
-,O
",",O
intermediate,O
-,O
",",O
and,O
long,O
-,O
term,O
visual,O
deficits,O
were,O
administered,O
a,O
full,O
neuro,O
-,O
ophthalmologic,O
examination,O
including,O
visual,O
acuity,O
",",O
color,O
vision,O
",",O
contrast,O
sensitivity,O
",",O
and,O
fundus,O
examination,O
.,O
In,O
addition,O
",",O
OCT,B
(,O
OCT,B
3000,I
",",O
Humphrey,O
-,O
Zeiss,O
",",O
Dublin,O
",",O
CA,O
),O
was,O
performed,O
on,O
both,O
eyes,O
of,O
each,O
subject,O
using,O
the,O
retinal,B
nerve,I
fiber,I
layer,I
(,O
RNFL,B
),O
analysis,O
protocol,O
.,O
OCT,B
interpolates,O
data,O
from,O
100,O
points,O
around,O
the,O
optic,B
nerve,I
to,O
effectively,O
map,O
out,O
the,O
RNFL,B
.,O
RESULTS,O
:,O
The,O
results,O
were,O
compared,O
to,O
the,O
calculated,O
average,O
RNFL,B
of,O
normal,O
eyes,O
accumulated,O
from,O
four,O
prior,O
studies,O
using,O
OCT,B
",",O
n,O
=,O
661,O
.,O
In,O
all,O
subjects,O
with,O
history,O
of,O
EMB,B
-,O
induced,O
optic,B
neuropathy,I
",",O
there,O
was,O
a,O
mean,O
loss,O
of,O
72,O
%,O
nerve,B
fiber,I
layer,I
thickness,I
in,O
the,O
temporal,O
quadrant,O
(,O
patient,O
A,O
",",O
with,O
eventual,O
recovery,O
of,O
visual,O
acuity,O
and,O
fields,O
",",O
58,O
%,O
loss,O
;,O
patient,O
B,O
",",O
with,O
intermediate,O
visual,O
deficits,O
",",O
68,O
%,O
loss,O
;,O
patient,O
C,O
",",O
with,O
chronic,O
visual,O
deficits,O
",",O
90,O
%,O
loss,O
),O
",",O
with,O
an,O
average,O
mean,O
optic,B
nerve,I
thickness,I
of,O
26,O
+,O
/,O
-,O
16,O
microm,O
There,O
was,O
a,O
combined,O
mean,O
loss,O
of,O
46,O
%,O
of,O
fibers,O
from,O
the,O
superior,O
",",O
inferior,O
",",O
and,O
nasal,O
quadrants,O
in,O
the,O
(,O
six,O
),O
eyes,O
of,O
all,O
three,O
subjects,O
(,O
mean,O
average,O
thickness,O
of,O
55,O
+,O
/,O
-,O
29,O
microm,O
),O
.,O
In,O
both,O
sets,O
(,O
four,O
),O
of,O
eyes,O
of,O
the,O
subjects,O
with,O
persistent,O
visual,O
deficits,O
(,O
patients,O
B,O
and,O
C,O
),O
",",O
there,O
was,O
an,O
average,O
loss,O
of,O
79,O
%,O
of,O
nerve,O
fiber,O
thickness,O
in,O
the,O
temporal,O
quadrant,O
.,O
CONCLUSIONS,O
:,O
The,O
OCT,O
results,O
in,O
these,O
patients,O
with,O
EMB,B
-,O
induced,O
optic,O
neuropathy,O
show,O
considerable,O
loss,O
especially,O
of,O
the,O
temporal,O
fibers,O
.,O
This,O
is,O
consistent,O
with,O
prior,O
histopathological,O
studies,O
that,O
show,O
predominant,O
loss,O
of,O
parvo,B
-,O
cellular,O
axons,O
(,O
or,O
small,O
-,O
caliber,O
axons,O
),O
within,O
the,O
papillo,B
-,O
macular,O
bundle,O
in,O
toxic,O
or,O
hereditary,O
optic,O
neuropathies,O
.,O
OCT,B
can,O
be,O
a,O
valuable,O
tool,O
in,O
the,O
quantitative,O
analysis,O
of,O
optic,B
neuropathies,O
.,O
Additionally,O
",",O
in,O
terms,O
of,O
management,O
of,O
EMB,B
-,I
induced,I
optic,I
neuropathy,I
",",O
it,O
is,O
important,O
to,O
properly,O
manage,O
ethambutol,B
dosing,O
in,O
patients,O
with,O
renal,B
impairment,O
and,O
to,O
achieve,O
proper,O
transition,O
to,O
a,O
maintenance,O
dose,O
once,O
an,O
appropriate,O
loading,O
dose,O
has,O
been,O
reached,O
.,O
Hypoxia,B
in,O
renal,B
disease,I
with,O
proteinuria,B
and,O
/,O
or,O
glomerular,B
hypertension,I
.,O
Despite,O
the,O
increasing,O
need,O
to,O
identify,O
and,O
quantify,O
tissue,O
oxygenation,O
at,O
the,O
cellular,O
level,O
",",O
relatively,O
few,O
methods,O
have,O
been,O
available,O
.,O
In,O
this,O
study,O
",",O
we,O
developed,O
a,O
new,O
hypoxia,B
-,I
responsive,I
reporter,I
vector,I
using,O
a,O
hypoxia,B
-,I
responsive,I
element,I
of,O
the,O
5,O
',O
vascular,B
endothelial,I
growth,I
factor,I
untranslated,I
region,I
and,O
generated,O
a,O
novel,O
hypoxia,B
-,I
sensing,I
transgenic,I
rat,I
.,O
We,O
then,O
applied,O
this,O
animal,O
model,O
to,O
the,O
detection,O
of,O
tubulointerstitial,O
hypoxia,O
in,O
the,O
diseased,O
kidney,O
.,O
With,O
this,O
model,O
",",O
we,O
were,O
able,O
to,O
identify,O
diffuse,O
cortical,O
hypoxia,O
in,O
the,O
puromycin,B
aminonucleoside,I
-,I
induced,O
nephrotic,O
syndrome,O
and,O
focal,O
and,O
segmental,O
hypoxia,O
in,O
the,O
remnant,O
kidney,O
model,O
.,O
Expression,O
of,O
the,O
hypoxia,O
-,O
responsive,O
transgene,O
increased,O
throughout,O
the,O
observation,O
period,O
",",O
reaching,O
2,O
.,O
2,O
-,O
fold,O
at,O
2,O
weeks,O
in,O
the,O
puromycin,B
aminonucleoside,I
model,O
and,O
2,O
.,O
6,O
-,O
fold,O
at,O
4,O
weeks,O
in,O
the,O
remnant,B
kidney,I
model,O
",",O
whereas,O
that,O
of,O
vascular,B
endothelial,I
growth,I
factor,I
showed,O
a,O
mild,O
decrease,O
",",O
reflecting,O
distinct,O
behaviors,O
of,O
the,O
two,O
genes,O
.,O
The,O
degree,O
of,O
hypoxia,O
showed,O
a,O
positive,O
correlation,O
with,O
microscopic,O
tubulointerstitial,O
injury,O
in,O
both,O
models,O
.,O
Finally,O
",",O
we,O
identified,O
the,O
localization,O
of,O
proliferating,O
cell,O
nuclear,B
antigen,I
-,I
positive,O
",",O
ED,B
-,I
1,I
-,I
positive,O
",",O
and,O
terminal,O
dUTP,B
nick,I
-,I
end,I
labeled,I
-,I
positive,O
cells,O
in,O
the,O
hypoxic,O
cortical,O
area,O
in,O
the,O
remnant,O
kidney,O
model,O
.,O
We,O
propose,O
here,O
a,O
possible,O
pathological,O
tie,O
between,O
chronic,O
tubulointerstitial,O
hypoxia,O
and,O
progressive,O
glomerular,O
diseases,O
.,O
Adequate,O
timing,O
of,O
ribavirin,B
reduction,O
in,O
patients,O
with,O
hemolysis,O
during,O
combination,O
therapy,O
of,O
interferon,O
and,O
ribavirin,B
for,O
chronic,O
hepatitis,O
C,O
.,O
BACKGROUND,O
:,O
Hemolytic,O
anemia,O
is,O
one,O
of,O
the,O
major,O
adverse,O
events,O
of,O
the,O
combination,O
therapy,O
of,O
interferon,O
and,O
ribavirin,B
.,O
Because,O
of,O
ribavirin,B
-,O
related,O
hemolytic,O
anemia,O
",",O
dose,O
reduction,O
is,O
a,O
common,O
event,O
in,O
this,O
therapy,O
.,O
In,O
this,O
clinical,O
retrospective,O
cohort,O
study,O
we,O
have,O
examined,O
the,O
suitable,O
timing,O
of,O
ribavirin,B
reduction,O
in,O
patients,O
with,O
hemolysis,O
during,O
combination,O
therapy,O
.,O
METHODS,O
:,O
Thirty,O
-,O
seven,O
of,O
160,O
patients,O
who,O
had,O
HCV,B
-,O
genotype,O
1b,O
",",O
had,O
high,O
virus,O
load,O
",",O
and,O
received,O
24,O
-,O
week,O
combination,O
therapy,O
developed,O
anemia,O
with,O
hemoglobin,B
level,O
<,O
10,O
g,O
/,O
dl,O
or,O
anemia,O
-,O
related,O
signs,O
during,O
therapy,O
.,O
After,O
that,O
",",O
these,O
37,O
patients,O
were,O
reduced,O
one,O
tablet,O
of,O
ribavirin,B
(,O
200,O
mg,O
),O
per,O
day,O
.,O
After,O
reduction,O
of,O
ribavirin,B
",",O
27,O
of,O
37,O
patients,O
could,O
continue,O
combination,O
therapy,O
for,O
a,O
total,O
of,O
24,O
weeks,O
(,O
group,O
A,O
),O
.,O
However,O
",",O
10,O
of,O
37,O
patients,O
with,O
reduction,O
of,O
ribavirin,B
could,O
not,O
continue,O
combination,O
therapy,O
because,O
their,O
<,O
8,O
.,O
5,O
g,O
/,O
dl,O
hemoglobin,B
values,O
decreased,O
to,O
or,O
anemia,B
-,I
related,I
severe,I
side,I
effects,I
occurred,O
(,O
group,O
B,O
),O
.,O
We,O
assessed,O
the,O
final,O
efficacy,O
and,O
safety,O
after,O
reduction,O
of,O
ribavirin,B
in,O
groups,O
A,O
and,O
B,O
.,O
RESULTS,O
:,O
A,O
sustained,O
virological,O
response,O
(,O
SVR,B
),O
was,O
29,O
.,O
6,O
%,O
(,O
8,O
/,O
27,O
),O
in,O
group,O
A,O
and,O
10,O
%,O
(,O
1,O
/,O
10,O
),O
in,O
group,O
B,O
",",O
respectively,O
.,O
A,O
34,O
.,O
4,B
%,O
(,O
12,O
/,O
27,O
),O
of,O
SVR,B
+,O
biological,O
response,O
in,O
group,O
A,O
was,O
higher,O
than,O
10,O
%,O
(,O
1,O
/,O
10,O
),O
in,O
group,O
B,O
(,O
P,O
=,O
0,O
.,O
51,O
),O
",",O
with,O
slight,O
significance,O
.,O
With,O
respect,O
to,O
hemoglobin,B
level,O
at,O
the,O
time,O
of,O
ribavirin,B
reduction,O
",",O
a,O
rate,O
of,O
continuation,O
of,O
therapy,O
in,O
patients,O
with,O
>,O
or,O
=,O
10,O
g,O
/,O
dl,O
hemoglobin,B
was,O
higher,O
than,O
that,O
in,O
patients,O
with,O
<,O
10,O
g,O
/,O
dl,O
(,O
P,O
=,O
0,O
.,O
36,O
),O
.,O
CONCLUSIONS,O
:,O
Reduction,O
of,O
ribavirin,B
at,O
hemoglobin,B
level,O
>,O
or,O
=,O
10,O
g,O
/,O
dl,O
is,O
suitable,O
in,O
terms,O
of,O
efficacy,O
and,O
side,O
effects,O
.,O
Aging,O
process,O
of,O
epithelial,O
cells,O
of,O
the,O
rat,O
prostate,O
lateral,O
lobe,O
in,O
experimental,O
hyperprolactinemia,B
induced,O
by,O
haloperidol,B
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
examine,O
the,O
influence,O
of,O
hyperprolactinemia,B
",",O
induced,O
by,O
haloperidol,B
(,O
HAL,B
),O
on,O
age,O
related,O
morphology,O
and,O
function,O
changes,O
of,O
epithelial,O
cells,O
in,O
rat,O
prostate,O
lateral,O
lobe,O
.,O
The,O
study,O
was,O
performed,O
on,O
sexually,O
mature,O
male,O
rats,O
.,O
Serum,O
concentrations,O
of,O
prolactin,B
(,O
PRL,B
),O
and,O
testosterone,B
(,O
T,B
),O
were,O
measured,O
.,O
Tissue,O
sections,O
were,O
evaluated,O
with,O
light,O
and,O
electron,O
microscopy,O
.,O
Immunohistochemical,O
reactions,O
for,O
Anti,B
-,I
Proliferating,I
Cell,I
Nuclear,I
Antigen,I
(,O
PCNA,B
),O
were,O
performed,O
.,O
In,O
rats,O
of,O
the,O
experimental,O
group,O
",",O
the,O
mean,O
concentration,O
of,O
:,O
PRL,B
was,O
more,O
than,O
twice,O
higher,O
",",O
whereas,O
T,B
concentration,O
was,O
almost,O
twice,O
lower,O
than,O
that,O
in,O
the,O
control,O
group,O
.,O
Light,O
microscopy,O
visualized,O
the,O
following,O
:,O
hypertrophy,O
and,O
epithelium,O
hyperplasia,O
of,O
the,O
glandular,O
ducts,O
",",O
associated,O
with,O
increased,O
PCNA,B
expression,O
.,O
Electron,O
microscopy,O
revealed,O
changes,O
in,O
columnar,O
epithelial,O
cells,O
",",O
concerning,O
organelles,O
",",O
engaged,O
in,O
protein,B
synthesis,I
and,O
secretion,O
.,O
Relation,O
of,O
perfusion,O
defects,O
observed,O
with,O
myocardial,O
contrast,O
echocardiography,O
to,O
the,O
severity,O
of,O
coronary,O
stenosis,O
:,O
correlation,O
with,O
thallium,B
-,I
201,I
single,I
-,I
photon,I
emission,I
tomography,I
.,O
It,O
has,O
been,O
previously,O
shown,O
that,O
myocardial,B
contrast,I
echocardiography,I
is,O
a,O
valuable,O
technique,O
for,O
delineating,O
regions,O
of,O
myocardial,B
underperfusion,I
secondary,O
to,O
coronary,B
occlusion,I
and,O
to,O
critical,O
coronary,B
stenoses,I
in,O
the,O
presence,O
of,O
hyperemic,O
stimulation,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
myocardial,B
contrast,I
echocardiography,I
performed,O
with,O
a,O
stable,O
solution,O
of,O
sonicated,O
albumin,B
could,O
detect,O
regions,O
of,O
myocardial,B
underperfusion,I
resulting,O
from,O
various,O
degrees,O
of,O
coronary,B
stenosis,I
.,O
The,O
perfusion,B
defect,I
produced,O
in,O
16,O
open,O
chest,O
dogs,O
was,O
compared,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
measured,O
by,O
the,O
postmortem,O
dual,O
-,O
perfusion,B
technique,O
and,O
with,O
thallium,B
-,O
201,O
single,O
-,O
photon,O
emission,O
tomography,O
(,O
SPECT,B
),O
.,O
During,O
a,O
transient,O
(,O
20,O
-,O
s,O
),O
coronary,O
occlusion,O
",",O
a,O
perfusion,B
defect,I
was,O
observed,O
with,O
contrast,O
echocardiography,O
in,O
14,O
of,O
the,O
15,O
dogs,O
in,O
which,O
the,O
occlusion,O
was,O
produced,O
.,O
The,O
perfusion,O
defect,O
correlated,O
significantly,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
(,O
r,O
=,O
0,O
.,O
74,O
;,O
p,O
less,O
than,O
0,O
.,O
2,O
),O
.,O
During,O
dipyridamole,B
-,I
induced,I
hyperemia,I
",",O
12,O
of,O
the,O
16,O
dogs,O
with,O
a,O
partial,O
coronary,O
stenosis,O
had,O
a,O
visible,O
area,O
of,O
hypoperfusion,O
by,O
contrast,O
echocardiography,O
.,O
The,O
four,O
dogs,O
without,O
a,O
perfusion,O
defect,O
had,O
a,O
stenosis,O
that,O
resulted,O
in,O
a,O
mild,O
(,O
0,O
%,O
to,O
50,O
%,O
),O
reduction,O
in,O
dipyridamole,B
-,I
induced,I
hyperemia,I
.,O
The,O
size,O
of,O
the,O
perfusion,O
defect,O
during,O
stenosis,O
correlated,O
significantly,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
(,O
r,O
=,O
0,O
.,O
61,O
;,O
p,O
=,O
0,O
.,O
2,O
.,O
Thallium,B
-,I
201,I
SPECT,I
demonstrated,O
a,O
perfusion,O
defect,O
in,O
all,O
14,O
dogs,O
analyzed,O
during,O
dipyridamole,B
-,I
induced,I
hyperemia,I
;,O
the,O
size,O
of,O
the,O
perfusion,O
defect,O
correlated,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
(,O
r,O
=,O
0,O
.,O
58,O
;,O
p,O
less,O
than,O
0,O
.,O
3,O
),O
and,O
with,O
the,O
perfusion,O
defect,O
by,O
contrast,O
echocardiography,O
(,O
r,O
=,O
0,O
.,O
58,O
;,O
p,O
less,O
than,O
0,O
.,O
3,O
),O
.,O
Thus,O
",",O
myocardial,O
contrast,O
echocardiography,O
can,O
be,O
used,O
to,O
visualize,O
and,O
quantitate,O
the,O
amount,O
of,O
jeopardized,O
myocardium,O
during,O
moderate,O
to,O
severe,O
degrees,O
of,O
coronary,O
stenosis,O
.,O
The,O
results,O
obtained,O
show,O
a,O
correlation,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
similar,O
to,O
that,O
obtained,O
with,O
thallium,B
-,I
201,I
SPECT,I
.,O
The,O
activation,O
of,O
spinal,O
N,B
-,I
methyl,I
-,I
D,I
-,I
aspartate,I
receptors,O
may,O
contribute,O
to,O
degeneration,O
of,O
spinal,O
motor,O
neurons,O
induced,O
by,O
neuraxial,O
morphine,O
after,O
a,O
noninjurious,O
interval,O
of,O
spinal,O
cord,O
ischemia,O
.,O
We,O
investigated,O
the,O
relationship,O
between,O
the,O
degeneration,O
of,O
spinal,O
motor,O
neurons,O
and,O
activation,O
of,O
N,B
-,I
methyl,I
-,I
d,I
-,I
aspartate,I
(,O
NMDA,B
),O
receptors,O
after,O
neuraxial,O
morphine,O
following,O
a,O
noninjurious,O
interval,O
of,O
aortic,O
occlusion,O
in,O
rats,O
.,O
Spinal,O
cord,O
ischemia,O
was,O
induced,O
by,O
aortic,O
occlusion,O
for,O
6,O
min,O
with,O
a,O
balloon,O
catheter,O
.,O
In,O
a,O
microdialysis,O
study,O
",",O
10,O
muL,O
of,O
saline,B
(,O
group,O
C,O
;,O
n,O
=,O
8,O
),O
or,O
30,O
mug,O
of,O
morphine,B
(,O
group,O
M,O
;,O
n,O
=,O
8,O
),O
was,O
injected,O
intrathecally,O
(,O
IT,O
),O
0,O
.,O
5,O
h,O
after,O
reflow,O
",",O
and,O
30,O
mug,O
of,O
morphine,B
(,O
group,O
SM,O
;,O
n,O
=,O
8,O
),O
or,O
10,O
muL,O
of,O
saline,B
(,O
group,O
SC,O
;,O
n,O
=,O
8,O
),O
was,O
injected,O
IT,O
0,O
0.89,O
5,O
h,O
after,O
sham,O
operation,O
.,O
Microdialysis,O
samples,O
were,O
collected,O
preischemia,O
",",O
before,O
IT,O
injection,O
",",O
and,O
at,O
2,O
",",O
4,O
",",O
8,O
",",O
24,O
",",O
and,O
48,O
h,O
of,O
reperfusion,O
(,O
after,O
IT,O
injection,O
),O
.,O
Second,O
",",O
we,O
investigated,O
the,O
effect,O
of,O
IT,O
MK,B
-,I
801,I
(,O
30,O
mug,O
),O
on,O
the,O
histopathologic,O
changes,O
in,O
the,O
spinal,O
cord,O
after,O
morphine,B
-,O
induced,O
spastic,O
paraparesis,O
.,O
After,O
IT,O
morphine,B
",",O
the,O
cerebrospinal,O
fluid,O
(,O
CSF,B
),O
glutamate,B
concentration,O
was,O
increased,O
in,O
group,O
M,O
relative,O
to,O
both,O
baseline,O
and,O
group,O
C,O
(,O
P,O
<,O
0,O
.,O
5,O
),O
.,O
This,O
increase,O
persisted,O
for,O
8,O
hrs,O
.,O
IT,O
MK,B
-,I
801,I
significantly,O
reduced,O
the,O
number,O
of,O
dark,O
-,O
stained,O
alpha,B
-,I
motoneurons,I
after,O
morphine,B
-,O
induced,O
spastic,O
paraparesis,O
compared,O
with,O
the,O
saline,O
group,O
.,O
These,O
data,O
indicate,O
that,O
IT,O
morphine,B
induces,O
spastic,O
paraparesis,O
with,O
a,O
concomitant,O
increase,O
in,O
CSF,B
glutamate,O
",",O
which,O
is,O
involved,O
in,O
NMDA,B
receptor,O
activation,O
.,O
We,O
suggest,O
that,O
opioids,O
may,O
be,O
neurotoxic,O
in,O
the,O
setting,O
of,O
spinal,O
cord,O
ischemia,O
via,O
NMDA,B
receptor,O
activation,O
.,O
Acute,O
low,O
back,O
pain,O
during,O
intravenous,O
administration,O
of,O
amiodarone,B
:,O
a,O
report,O
of,O
two,O
cases,O
.,O
Amiodarone,B
represents,O
an,O
effective,O
antiarrhythmic,O
drug,O
for,O
cardioversion,O
of,O
recent,O
-,O
onset,O
atrial,O
fibrillation,O
(,O
AF,B
),O
and,O
maintenance,O
of,O
sinus,O
rhythm,O
.,O
We,O
briefly,O
describe,O
two,O
patients,O
suffering,O
from,O
recent,O
-,O
onset,O
atrial,O
fibrillation,O
",",O
who,O
experienced,O
an,O
acute,O
devastating,O
low,O
back,O
pain,O
a,O
few,O
minutes,O
after,O
initiation,O
of,O
intravenous,O
amiodarone,B
loading,O
.,O
Notably,O
",",O
this,O
side,O
effect,O
has,O
not,O
been,O
ever,O
reported,O
in,O
the,O
medical,O
literature,O
.,O
Clinicians,O
should,O
be,O
aware,O
of,O
this,O
reaction,O
since,O
prompt,O
termination,O
of,O
parenteral,O
administration,O
leads,O
to,O
complete,O
resolution,O
.,O
Quantitative,O
drug,O
levels,O
in,O
stimulant,O
psychosis,O
:,O
relationship,O
to,O
symptom,O
severity,O
",",O
catecholamines,B
and,O
hyperkinesia,O
.,O
To,O
examine,O
the,O
relationship,O
between,O
quantitative,O
stimulant,B
drug,I
levels,O
",",O
catecholamines,B
",",O
and,O
psychotic,O
symptoms,O
",",O
nineteen,O
patients,O
in,O
a,O
psychiatric,O
emergency,O
service,O
with,O
a,O
diagnosis,O
of,O
amphetamine,B
-,I
or,O
cocaine,B
-,I
induced,I
psychosis,I
were,O
interviewed,O
",",O
and,O
plasma,O
and,O
urine,O
were,O
collected,O
for,O
quantitative,O
assays,O
of,O
stimulant,B
drug,I
and,O
catecholamine,B
metabolite,I
levels,O
.,O
Methamphetamine,B
or,O
amphetamine,B
levels,O
were,O
related,O
to,O
several,O
psychopathology,O
scores,O
and,O
the,O
global,O
hyperkinesia,O
rating,O
.,O
HVA,B
levels,O
were,O
related,O
to,O
global,O
hyperkinesia,O
but,O
not,O
to,O
psychopathology,O
ratings,O
.,O
Although,O
many,O
other,O
factors,O
such,O
as,O
sensitization,O
may,O
play,O
a,O
role,O
",",O
intensity,O
of,O
stimulant,O
-,O
induced,O
psychotic,O
symptoms,O
and,O
stereotypies,O
appears,O
to,O
be,O
at,O
least,O
in,O
part,O
dose,O
-,O
related,O
.,O
Pheochromocytoma,B
unmasked,O
by,O
amisulpride,O
and,O
tiapride,O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
the,O
unmasking,O
of,O
pheochromocytoma,B
in,O
a,O
patient,O
treated,O
with,O
amisulpride,O
and,O
tiapride,O
.,O
CASE,O
SUMMARY,O
:,O
A,O
42,O
-,O
year,O
-,O
old,O
white,O
man,O
developed,O
acute,O
hypertension,O
with,O
severe,O
headache,O
and,O
vomiting,O
2,O
hours,O
after,O
the,O
first,O
doses,O
of,O
amisulpride,O
100,O
mg,O
and,O
tiapride,O
100,O
mg,O
.,O
Both,O
drugs,O
were,O
immediately,O
discontinued,O
",",O
and,O
the,O
patient,O
recovered,O
after,O
subsequent,O
nicardipine,B
and,O
verapamil,B
treatment,O
.,O
Abdominal,O
ultrasound,O
showed,O
an,O
adrenal,O
mass,O
",",O
and,O
postoperative,O
histologic,O
examination,O
confirmed,O
the,O
diagnosis,O
of,O
pheochromocytoma,B
.,O
DISCUSSION,O
:,O
Drug,O
-,O
induced,O
symptoms,O
of,O
pheochromocytoma,B
are,O
often,O
associated,O
with,O
the,O
use,O
of,O
substituted,O
benzamide,B
drugs,O
",",O
but,O
the,O
underlying,O
mechanism,O
is,O
unknown,O
.,O
In,O
our,O
case,O
",",O
use,O
of,O
the,O
Naranjo,O
probability,O
scale,O
indicated,O
a,O
possible,O
relationship,O
between,O
the,O
hypertensive,O
crisis,O
and,O
amisulpride,B
and,O
tiapride,B
therapy,O
.,O
CONCLUSIONS,O
:,O
As,O
of,O
March,O
24,O
",",O
2005,O
",",O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
amisulpride,B
-,O
and,O
tiapride,B
-,O
induced,O
hypertensive,O
crisis,O
in,O
a,O
patient,O
with,O
pheochromocytoma,B
.,O
Physicians,O
and,O
other,O
healthcare,O
professionals,O
should,O
be,O
aware,O
of,O
this,O
potential,O
adverse,O
effect,O
of,O
tiapride,B
and,O
amisulpride,B
.,O
Minor,O
neurological,O
dysfunction,O
",",O
cognitive,O
development,O
",",O
and,O
somatic,O
development,O
at,O
the,O
age,O
of,O
3,O
to,O
7,O
years,O
after,O
dexamethasone,B
treatment,O
in,O
very,O
-,O
low,O
birth,O
-,O
weight,O
infants,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
assess,O
minor,O
neurological,O
dysfunction,O
",",O
cognitive,O
development,O
",",O
and,O
somatic,O
development,O
after,O
dexamethasone,B
therapy,O
in,O
very,O
-,O
low,O
-,O
birthweight,O
infants,O
.,O
Thirty,O
-,O
three,O
children,O
after,O
dexamethasone,B
treatment,O
were,O
matched,O
to,O
33,O
children,O
without,O
dexamethasone,B
treatment,O
.,O
Data,O
were,O
assessed,O
at,O
the,O
age,O
of,O
3,O
-,O
7,O
years,O
.,O
Dexamethasone,B
was,O
started,O
between,O
the,O
7th,O
and,O
the,O
28th,O
day,O
of,O
life,O
over,O
7,O
days,O
with,O
a,O
total,O
dose,O
of,O
2,O
.,O
35,O
mg,O
/,O
kg,O
/,O
day,O
.,O
Exclusion,O
criteria,O
were,O
asphyxia,B
",",O
malformations,B
",",O
major,O
surgical,O
interventions,O
",",O
small,O
for,O
gestational,O
age,O
",",O
intraventricular,B
haemorrhage,I
grades,O
III,O
and,O
IV,O
",",O
periventricular,B
leukomalacia,I
",",O
and,O
severe,O
psychomotor,O
retardation,O
.,O
Each,O
child,O
was,O
examined,O
by,O
a,O
neuropediatrician,O
for,O
minor,O
neurological,O
dysfunctions,O
and,O
tested,O
by,O
a,O
psychologist,O
for,O
cognitive,O
development,O
with,O
a,O
Kaufman,B
Assessment,I
Battery,I
for,I
Children,I
and,O
a,O
Draw,B
-,I
a,I
-,I
Man,I
Test,I
.,O
There,O
were,O
no,O
differences,O
in,O
demographic,O
data,O
",",O
growth,O
",",O
and,O
socio,O
-,O
economic,O
status,O
between,O
the,O
two,O
groups,O
.,O
Fine,O
motor,O
skills,O
and,O
gross,O
motor,O
function,O
were,O
significantly,O
better,O
in,O
the,O
control,O
group,O
(,O
p,O
<,O
0,O
.,O
1,O
),O
.,O
In,O
the,O
Draw,O
-,O
a,O
-,O
Man,O
Test,O
",",O
the,O
control,O
group,O
showed,O
better,O
results,O
(,O
p,O
<,O
0,O
.,O
1,O
),O
.,O
There,O
were,O
no,O
differences,O
in,O
development,O
of,O
speech,O
",",O
social,O
development,O
",",O
and,O
the,O
Kaufman,O
Assessment,O
Battery,O
for,O
Children,O
.,O
After,O
dexamethasone,B
treatment,O
",",O
children,O
showed,O
a,O
higher,O
rate,O
of,O
minor,O
neurological,O
dysfunctions,O
.,O
Neurological,O
development,O
was,O
affected,O
even,O
without,O
neurological,O
diagnosis,O
.,O
Further,O
long,O
-,O
term,O
follow,O
-,O
up,O
studies,O
will,O
be,O
necessary,O
to,O
fully,O
evaluate,O
the,O
impact,O
of,O
dexamethasone,B
on,O
neurological,O
and,O
cognitive,O
development,O
.,O
Valproic,B
acid,I
I,O
:,O
time,O
course,O
of,O
lipid,O
peroxidation,O
biomarkers,O
",",O
liver,O
toxicity,O
",",O
and,O
valproic,B
acid,I
metabolite,O
levels,O
in,O
rats,O
.,O
A,O
single,O
dose,O
of,O
valproic,B
acid,I
(,O
VPA,B
),O
",",O
which,O
is,O
a,O
widely,O
used,O
antiepileptic,O
drug,O
",",O
is,O
associated,O
with,O
oxidative,O
stress,O
in,O
rats,O
",",O
as,O
recently,O
demonstrated,O
by,O
elevated,O
levels,O
of,O
15,O
-,O
F,O
(,O
2t,O
),O
-,O
isoprostane,O
(,O
15,O
-,O
F,O
(,O
2t,O
),O
-,O
IsoP,O
.,O
To,O
determine,O
whether,O
there,O
was,O
a,O
temporal,O
relationship,O
between,O
VPA,B
-,O
associated,O
oxidative,O
stress,O
and,O
hepatotoxicity,O
",",O
adult,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
treated,O
ip,O
with,O
VPA,B
(,O
500,O
mg,O
/,O
kg,O
),O
or,O
0,O
.,O
9,O
%,O
saline,O
(,O
vehicle,O
),O
once,O
daily,O
for,O
2,O
",",O
4,O
",",O
7,O
",",O
10,O
",",O
or,O
14,O
days,O
.,O
Oxidative,O
stress,O
was,O
assessed,O
by,O
determining,O
plasma,O
and,O
liver,O
levels,O
of,O
15,B
-,I
F,I
(,I
2t,I
),I
-,I
IsoP,I
",",O
lipid,O
hydroperoxides,O
(,O
LPO,B
),O
",",O
and,O
thiobarbituric,O
acid,O
reactive,O
substances,O
(,O
TBARs,B
),O
.,O
Plasma,B
and,O
liver,B
15,O
-,O
F,O
(,O
2t,O
),O
-,O
IsoP,B
were,O
elevated,O
and,O
reached,O
a,O
plateau,O
after,O
day,O
2,O
of,O
VPA,B
treatment,O
compared,O
to,O
control,O
.,O
Liver,B
LPO,B
levels,O
were,O
not,O
elevated,O
until,O
day,O
7,O
of,O
treatment,O
(,O
1,O
.,O
8,O
-,O
fold,O
versus,O
control,O
",",O
p,O
<,O
0,O
.,O
5,O
.,O
Liver,B
and,O
plasma,B
TBARs,B
were,O
not,O
increased,O
until,O
14,O
days,O
(,O
2,O
-,O
fold,O
vs,O
.,O
control,O
",",O
p,O
<,O
0,O
.,O
5,O
),O
.,O
Liver,B
toxicity,O
was,O
evaluated,O
based,O
on,O
serum,O
levels,O
of,O
alpha,B
-,O
glutathione,I
S,I
-,I
transferase,I
(,O
alpha,B
-,I
GST,I
),O
and,O
by,O
histology,O
.,O
Serum,O
alpha,B
-,I
GST,I
levels,O
were,O
significantly,O
elevated,O
by,O
day,O
4,O
",",O
which,O
corresponded,O
to,O
hepatotoxicity,O
as,O
shown,O
by,O
the,O
increasing,O
incidence,O
of,O
inflammation,O
of,O
the,O
liver,B
capsule,O
",",O
necrosis,O
",",O
and,O
steatosis,O
throughout,O
the,O
study,O
.,O
The,O
liver,O
levels,O
of,O
beta,B
-,I
oxidation,I
metabolites,O
of,O
VPA,B
were,O
decreased,O
by,O
day,O
14,O
",",O
while,O
the,O
levels,O
of,O
4,B
-,I
ene,I
-,I
VPA,I
and,O
(,O
E,B
)-,I
2,I
",",O
4,B
-,I
diene,I
-,I
VPA,I
were,O
not,O
elevated,O
throughout,O
the,O
study,O
.,O
Overall,O
",",O
these,O
findings,O
indicate,O
that,O
VPA,B
treatment,O
results,O
in,O
oxidative,O
stress,O
",",O
as,O
measured,O
by,O
levels,O
of,O
15,B
-,I
F,I
(,I
2t,I
)-,I
-,I
IsoP,I
",",O
which,O
precedes,O
the,O
onset,O
of,O
necrosis,O
",",O
steatosis,O
",",O
and,O
elevated,O
levels,O
of,O
serum,O
alpha,B
-,I
GST,I
.,O
Assessment,O
of,O
perinatal,O
hepatitis,B
B,I
and,O
rubella,B
prevention,O
in,O
New,O
Hampshire,O
delivery,O
hospitals,O
.,O
OBJECTIVE,O
:,O
To,O
evaluate,O
current,O
performance,O
on,O
recommended,O
perinatal,O
hepatitis,B
B,I
and,O
rubella,B
prevention,O
practices,O
in,O
New,O
Hampshire,O
.,O
METHODS,O
:,O
Data,O
were,O
extracted,O
from,O
2021,O
paired,O
mother,O
-,O
infant,O
records,O
for,O
the,O
year,O
2000,O
birth,O
cohort,O
in,O
New,O
Hampshire,O
',O
s,O
25,O
delivery,O
hospitals,O
.,O
Assessment,O
was,O
done,O
on,O
the,O
following,O
:,O
prenatal,O
screening,O
for,O
hepatitis,B
B,I
and,O
rubella,B
",",O
administration,O
of,O
the,O
hepatitis,B
B,I
vaccine,I
birth,I
dose,I
to,O
all,O
infants,O
",",O
administration,O
of,O
hepatitis,B
B,I
immune,I
globulin,I
to,O
infants,O
who,O
were,O
born,O
to,O
hepatitis,B
B,I
surface,I
antigen,I
-,I
positive,I
mothers,O
",",O
rubella,B
immunity,O
",",O
and,O
administration,O
of,O
in,O
-,O
hospital,O
postpartum,O
rubella,B
vaccine,I
to,O
rubella,B
nonimmune,I
women,O
.,O
RESULTS,O
:,O
Prenatal,O
screening,O
rates,O
for,O
hepatitis,B
B,I
(,O
98,O
.,O
8,O
%,O
),O
and,O
rubella,B
(,O
99,O
.,O
4,O
%,O
),O
were,O
high,O
.,O
Hepatitis,B
B,I
vaccine,O
birth,O
dose,O
was,O
administered,O
to,O
76,O
.,O
2,O
%,O
of,O
all,O
infants,O
.,O
All,O
infants,O
who,O
were,O
born,O
to,O
hepatitis,B
B,I
surface,I
antigen,I
-,I
positive,I
mothers,O
also,O
received,O
hepatitis,B
B,I
immune,I
globulin,I
.,O
Multivariate,O
logistic,O
regression,O
showed,O
that,O
the,O
month,O
of,O
delivery,O
and,O
infant,O
birth,O
weight,O
were,O
independent,O
predictors,O
of,O
hepatitis,B
B,I
vaccination,O
.,O
The,O
proportion,O
of,O
infants,O
who,O
were,O
vaccinated,O
in,O
January,O
and,O
February,O
2000,O
(,O
48,O
.,O
5,O
%,O
and,O
67,O
.,O
5,O
%,O
",",O
respectively,O
),O
was,O
less,O
than,O
any,O
other,O
months,O
",",O
whereas,O
the,O
proportion,O
who,O
were,O
vaccinated,O
in,O
December,O
2000,O
(,O
88,O
.,O
2,O
%,O
),O
was,O
the,O
highest,O
.,O
Women,O
who,O
were,O
born,O
between,O
1971,O
and,O
1975,O
had,O
the,O
highest,O
rate,O
of,O
rubella,B
nonimmunity,I
(,I
9,I
.,I
5,O
%,O
),O
.,O
In,O
-,O
hospital,O
postpartum,O
rubella,B
vaccine,O
administration,O
was,O
documented,O
for,O
75,O
.,O
6,O
%,O
of,O
nonimmune,O
women,O
.,O
CONCLUSION,O
:,O
This,O
study,O
documents,O
good,O
compliance,O
in,O
New,O
Hampshire,O
',O
s,O
birthing,O
hospitals,O
with,O
national,O
guidelines,O
for,O
perinatal,O
hepatitis,B
B,I
and,O
rubella,B
prevention,O
and,O
highlights,O
potential,O
areas,O
for,O
improvement,O
.,O
Succinylcholine,B
-,O
induced,O
masseter,B
muscle,I
rigidity,I
during,O
bronchoscopic,O
removal,O
of,O
a,O
tracheal,O
foreign,O
body,O
.,O
Masseter,B
muscle,I
rigidity,I
during,O
general,O
anesthesia,O
is,O
considered,O
an,O
early,O
warning,O
sign,O
of,O
a,O
possible,O
episode,O
of,O
malignant,O
hyperthermia,O
.,O
The,O
decision,O
whether,O
to,O
continue,O
or,O
discontinue,O
the,O
procedure,O
depends,O
on,O
the,O
urgency,O
of,O
the,O
surgery,O
and,O
severity,O
of,O
masseter,B
muscle,I
rigidity,I
.,O
Here,O
",",O
we,O
describe,O
a,O
case,O
of,O
severe,O
masseter,B
muscle,I
rigidity,I
(,O
jaw,B
of,I
steel,I
),O
after,O
succinylcholine,B
(,O
Sch,B
),O
administration,O
during,O
general,O
anesthetic,O
management,O
for,O
rigid,O
bronchoscopic,O
removal,O
of,O
a,O
tracheal,O
foreign,O
body,O
.,O
Anesthesia,O
was,O
continued,O
uneventfully,O
with,O
propofol,B
infusion,O
while,O
all,O
facilities,O
were,O
available,O
to,O
detect,O
and,O
treat,O
malignant,B
hyperthermia,I
.,O
Dexrazoxane,B
protects,O
against,O
myelosuppression,O
from,O
the,O
DNA,B
cleavage,I
-,I
enhancing,O
drugs,O
etoposide,B
and,O
daunorubicin,B
but,O
not,O
doxorubicin,B
.,O
PURPOSE,O
:,O
The,O
anthracyclines,O
daunorubicin,B
and,O
doxorubicin,B
and,O
the,O
epipodophyllotoxin,O
etoposide,B
are,O
potent,O
DNA,B
cleavage,I
-,I
enhancing,O
drugs,O
that,O
are,O
widely,O
used,O
in,O
clinical,O
oncology,O
;,O
however,O
",",O
myelosuppression,O
and,O
cardiac,O
toxicity,O
limit,O
their,O
use,O
.,O
Dexrazoxane,B
(,O
ICRF,B
-,I
187,I
),O
is,O
recommended,O
for,O
protection,O
against,O
anthracycline,B
-,O
induced,O
cardiotoxicity,O
.,O
EXPERIMENTAL,O
DESIGN,O
:,O
Because,O
of,O
their,O
widespread,O
use,O
",",O
the,O
hematologic,O
toxicity,O
following,O
coadministration,O
of,O
dexrazoxane,B
and,O
these,O
three,O
structurally,O
different,O
DNA,O
cleavage,O
enhancers,O
was,O
investigated,O
:,O
Sensitivity,O
of,O
human,O
and,O
murine,O
blood,O
progenitor,O
cells,O
to,O
etoposide,B
",",O
daunorubicin,B
",",O
and,O
doxorubicin,B
+,O
/,O
-,O
dexrazoxane,B
was,O
determined,O
in,O
granulocyte,O
-,O
macrophage,O
colony,O
forming,O
assays,O
.,O
Likewise,O
",",O
in,O
vivo,O
",",O
B6D2F1,O
mice,O
were,O
treated,O
with,O
etoposide,B
",",O
daunorubicin,B
",",O
and,O
doxorubicin,B
",",O
with,O
or,O
without,O
dexrazoxane,B
over,O
a,O
wide,O
range,O
of,O
doses,O
:,O
posttreatment,O
",",O
a,O
full,O
hematologic,O
evaluation,O
was,O
done,O
.,O
RESULTS,O
:,O
Nontoxic,O
doses,O
of,O
dexrazoxane,B
reduced,O
myelosuppression,O
and,O
weight,O
loss,O
from,O
daunorubicin,B
and,O
etoposide,B
in,O
mice,O
and,O
antagonized,O
their,O
antiproliferative,O
effects,O
in,O
the,O
colony,O
assay,O
;,O
however,O
",",O
dexrazoxane,B
neither,O
reduced,O
myelosuppression,O
",",O
weight,O
loss,O
",",O
nor,O
the,O
in,O
vitro,O
cytotoxicity,O
from,O
doxorubicin,B
.,O
CONCLUSION,O
:,O
Although,O
our,O
findings,O
support,O
the,O
observation,O
that,O
dexrazoxane,B
reduces,O
neither,O
hematologic,O
activity,O
nor,O
antitumor,O
activity,O
from,O
doxorubicin,B
clinically,O
",",O
the,O
potent,O
antagonism,O
of,O
daunorubicin,B
activity,O
raises,O
concern,O
;,O
a,O
possible,O
interference,O
with,O
anticancer,O
efficacy,O
certainly,O
would,O
call,O
for,O
renewed,O
attention,O
.,O
Our,O
data,O
also,O
suggest,O
that,O
significant,O
etoposide,B
dose,O
escalation,O
is,O
perhaps,O
possible,O
by,O
the,O
use,O
of,O
dexrazoxane,B
.,O
Clinical,O
trials,O
in,O
patients,O
with,O
brain,O
metastases,O
combining,O
dexrazoxane,B
and,O
high,O
doses,O
of,O
etoposide,B
is,O
ongoing,O
with,O
the,O
aim,O
of,O
improving,O
efficacy,O
without,O
aggravating,O
hematologic,O
toxicity,O
.,O
If,O
successful,O
",",O
this,O
represents,O
an,O
exciting,O
mechanism,O
for,O
pharmacologic,O
regulation,O
of,O
side,O
effects,O
from,O
cytotoxic,O
chemotherapy,O
.,O
Assessment,O
of,O
the,O
onset,O
and,O
persistence,O
of,O
amnesia,O
during,O
procedural,O
sedation,O
with,O
propofol,B
.,O
OBJECTIVES,O
:,O
To,O
assess,O
patients,O
',O
ability,O
to,O
repeat,O
and,O
recall,O
words,O
presented,O
to,O
them,O
while,O
undergoing,O
procedural,O
sedation,O
with,O
propofol,B
",",O
and,O
correlate,O
their,O
recall,O
with,O
their,O
level,O
of,O
awareness,O
as,O
measured,O
by,O
bispectral,O
index,O
(,O
BIS,B
),O
monitoring,O
.,O
METHODS,O
:,O
This,O
was,O
a,O
prospective,O
",",O
single,O
-,O
intervention,O
study,O
of,O
consenting,O
adult,O
patients,O
undergoing,O
procedural,O
sedation,O
with,O
propofol,B
between,O
December,O
28,O
",",O
2002,O
",",O
and,O
October,O
31,O
",",O
2003,O
.,O
BIS,O
monitoring,O
was,O
initiated,O
starting,O
3,O
minutes,O
before,O
the,O
procedure,O
and,O
continuing,O
until,O
the,O
patient,O
had,O
regained,O
baseline,O
mental,O
status,O
.,O
At,O
1,O
-,O
minute,O
intervals,O
during,O
the,O
procedural,O
sedation,O
",",O
until,O
the,O
patient,O
regained,O
baseline,O
mental,O
status,O
at,O
the,O
end,O
of,O
the,O
procedure,O
",",O
a,O
word,O
from,O
a,O
standardized,O
list,O
was,O
read,O
aloud,O
",",O
and,O
the,O
patient,O
was,O
asked,O
to,O
immediately,O
repeat,O
the,O
word,O
to,O
the,O
investigator,O
.,O
The,O
BIS,O
score,O
at,O
the,O
time,O
the,O
word,O
was,O
read,O
and,O
the,O
patient,O
',O
s,O
ability,O
to,O
repeat,O
the,O
word,O
were,O
recorded,O
.,O
After,O
the,O
procedure,O
",",O
the,O
patient,O
was,O
asked,O
to,O
state,O
all,O
of,O
the,O
words,O
from,O
the,O
list,O
that,O
he,O
or,O
she,O
could,O
recall,O
",",O
and,O
to,O
identify,O
the,O
last,O
word,O
recalled,O
from,O
prior,O
to,O
the,O
start,O
of,O
the,O
procedure,O
and,O
the,O
first,O
word,O
recalled,O
from,O
after,O
the,O
procedure,O
was,O
completed,O
.,O
RESULTS,O
:,O
Seventy,O
-,O
five,O
consenting,O
patients,O
were,O
enrolled,O
;,O
one,O
patient,O
was,O
excluded,O
from,O
data,O
analysis,O
for,O
a,O
protocol,O
violation,O
.,O
No,O
serious,O
adverse,O
events,O
were,O
noted,O
during,O
the,O
procedural,O
sedations,O
.,O
The,O
mean,O
(,O
+,O
/,O
-,O
standard,O
deviation,O
),O
time,O
of,O
data,O
collection,O
was,O
16,O
.,O
4,O
minutes,O
(,O
+,O
/,O
-,O
7,O
.,O
1,O
;,O
range,O
5,O
to,O
34,O
minutes,O
),O
.,O
The,O
mean,O
initial,O
(,O
preprocedure,O
),O
BIS,B
score,O
was,O
97,O
.,O
1,O
(,O
+,O
/,O
-,O
2,O
.,O
3,O
;,O
range,O
92,O
to,O
99,O
),O
.,O
The,O
mean,O
lowest,O
BIS,B
score,O
occurring,O
during,O
these,O
procedural,O
sedations,O
was,O
66,O
.,O
9,O
(,O
+,O
/,O
-,O
14,O
.,O
4,O
;,O
range,O
33,O
to,O
91,O
.,O
),O
.,O
The,O
mean,O
lowest,O
BIS,O
score,O
corresponding,O
to,O
the,O
ability,O
of,O
the,O
patient,O
to,O
immediately,O
repeat,O
words,O
read,O
from,O
the,O
list,O
was,O
77,O
.,O
1,O
(,O
95,O
%,O
CI,O
=,O
74,O
.,O
3,O
to,O
80,O
.,O
0,O
),O
.,O
The,O
mean,O
highest,O
BIS,O
score,O
corresponding,O
to,O
the,O
inability,O
to,O
repeat,O
words,O
was,O
81,O
.,O
5,O
(,O
95,O
%,O
CI,O
=,O
78,O
.,O
1,O
to,O
84,O
8,O
),O
.,O
The,O
mean,O
BIS,B
score,O
corresponding,O
to,O
the,O
last,O
word,O
recalled,O
from,O
prior,O
to,O
the,O
initiation,O
of,O
the,O
sedation,O
was,O
96,O
0.7,O
(,O
+,O
/,O
-,O
2,O
.,O
4,O
;,O
range,O
84,O
to,O
98,O
).36,O
The,O
mean,O
BIS,B
score,O
corresponding,O
to,O
the,O
first,O
word,O
recalled,O
after,O
the,O
procedure,O
was,O
completed,O
was,O
91,O
0.2,O
(,O
95,O
%,O
CI,O
=,O
88,O
0.1,O
to,O
94,O
0.3,O
).65,O
All,O
patients,O
recalled,O
at,O
least,O
one,O
word,O
that,O
had,O
been,O
read,O
to,O
them,O
during,O
the,O
protocol,O
.,O
The,O
mean,O
lowest,O
BIS,B
score,O
for,O
any,O
recalled,O
word,O
was,O
91,O
.,O
5,O
(,O
+,O
/,O
-,O
11,O
.,O
1,O
;,O
range,O
79,O
to,O
98,O
.,O
",",O
and,O
no,O
words,O
were,O
recalled,O
when,O
the,O
corresponding,O
BIS,B
score,O
was,O
less,O
than,O
90,O
.,O
CONCLUSIONS,O
:,O
There,O
is,O
a,O
range,O
of,O
BIS,B
scores,O
during,O
which,O
sedated,O
patients,O
are,O
able,O
to,O
repeat,O
words,O
read,O
to,O
them,O
but,O
are,O
not,O
able,O
to,O
subsequently,O
recall,O
these,O
words,O
.,O
Furthermore,O
",",O
patients,O
had,O
no,O
recall,O
of,O
words,O
repeated,O
prior,O
to,O
procedural,O
sedation,O
in,O
BIS,O
ranges,O
associated,O
with,O
recall,O
after,O
procedural,O
sedation,O
",",O
suggestive,O
of,O
retrograde,O
amnesia,O
.,O
Amiodarone,B
pulmonary,O
toxicity,O
.,O
Amiodarone,B
is,O
an,O
effective,O
antiarrhythmic,O
agent,O
whose,O
utility,O
is,O
limited,O
by,O
many,O
side,O
-,O
effects,O
",",O
the,O
most,O
problematic,O
being,O
pneumonitis,B
.,O
The,O
pulmonary,O
toxicity,O
of,O
amiodarone,B
is,O
thought,O
to,O
result,O
from,O
direct,O
injury,O
related,O
to,O
the,O
intracellular,O
accumulation,O
of,O
phospholipid,B
and,O
T,B
cell,I
-,I
mediated,I
hypersensitivity,I
pneumonitis,I
.,O
The,O
clinical,O
and,O
radiographic,O
features,O
of,O
amiodarone,B
-,O
induced,O
pulmonary,O
toxicity,O
are,O
characteristic,O
but,O
nonspecific,O
.,O
The,O
diagnosis,O
depends,O
on,O
exclusion,O
of,O
other,O
entities,O
",",O
such,O
as,O
heart,B
failure,I
",",O
infection,B
",",O
and,O
malignancy,B
.,O
While,O
withdrawal,O
of,O
amiodarone,B
leads,O
to,O
clinical,O
improvement,O
in,O
majority,O
of,O
cases,O
",",O
this,O
is,O
not,O
always,O
possible,O
or,O
advisable,O
.,O
Dose,O
reduction,O
or,O
concomitant,O
steroid,O
therapy,O
may,O
have,O
a,O
role,O
in,O
selected,O
patients,O
.,O
Two,O
prodrugs,O
of,O
potent,O
and,O
selective,O
GluR5,B
kainate,I
receptor,I
antagonists,I
actives,O
in,O
three,O
animal,O
models,O
of,O
pain,O
.,O
Amino,O
acids,O
5,O
and,O
7,O
",",O
two,O
potent,O
and,O
selective,O
competitive,O
GluR5,B
KA,I
receptor,I
antagonists,I
",",O
exhibited,O
high,O
GluR5,B
receptor,I
affinity,O
over,O
other,O
glutamate,B
receptors,I
.,O
Their,O
ester,O
prodrugs,O
6,O
and,O
8,O
were,O
orally,O
active,O
in,O
three,O
models,O
of,O
pain,O
:,O
reversal,O
of,O
formalin,B
-,I
induced,I
paw,I
licking,I
",",O
carrageenan,B
-,I
induced,I
thermal,I
hyperalgesia,I
",",O
and,O
capsaicin,B
-,I
induced,I
mechanical,I
hyperalgesia,I
.,O
Possible,O
azithromycin,B
-,O
associated,O
hiccups,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
persistent,O
hiccups,O
associated,O
by,O
azithromycin,B
therapy,O
.,O
CASE,O
SUMMARY,O
:,O
A,O
76,O
-,O
year,O
-,O
old,O
man,O
presented,O
with,O
persistent,O
hiccups,O
after,O
beginning,O
azithromycin,B
for,O
the,O
treatment,O
of,O
pharyngitis,O
.,O
Hiccups,O
were,O
persistent,O
and,O
exhausting,O
.,O
Discontinuation,O
of,O
azithromycin,B
and,O
therapy,O
with,O
baclofen,B
finally,O
resolved,O
hiccups,O
.,O
No,O
organic,O
cause,O
of,O
hiccups,O
was,O
identified,O
despite,O
extensive,O
investigation,O
.,O
DISCUSSION,O
:,O
Pharmacotherapeutic,O
agents,O
have,O
been,O
uncommonly,O
associated,O
with,O
hiccups,O
.,O
Corticosteroids,B
(,O
dexamethasone,B
and,O
methylprednisolone,B
),O
",",O
benzodiazepines,B
(,O
midazolam,B
),O
and,O
general,O
anaesthesia,O
have,O
been,O
the,O
specific,O
agents,O
mentioned,O
most,O
frequently,O
in,O
the,O
literature,O
as,O
being,O
associated,O
with,O
the,O
development,O
of,O
hiccups,O
.,O
Few,O
cases,O
of,O
drug,B
-,O
induced,O
hiccups,O
have,O
been,O
reported,O
related,O
to,O
macrolide,B
antimicrobials,O
.,O
Using,O
the,O
Naranjo,O
adverse,O
effect,O
reaction,O
probability,O
scale,O
this,O
event,O
could,O
be,O
classified,O
as,O
possible,O
(,O
score,O
5,O
points,O
),O
",",O
mostly,O
because,O
of,O
the,O
close,O
temporal,O
sequence,O
",",O
previous,O
reports,O
on,O
this,O
reaction,O
with,O
other,O
macrolides,B
and,O
the,O
absence,O
of,O
any,O
alternative,O
explanation,O
for,O
hiccups,O
.,O
Our,O
hypothesis,O
is,O
that,O
a,O
vagal,O
mechanism,O
mediated,O
by,O
azithromycin,B
could,O
be,O
the,O
pathogenesis,O
of,O
hiccups,O
in,O
our,O
patient,O
.,O
CONCLUSIONS,O
:,O
Diagnosis,O
of,O
drug,O
-,O
induced,O
hiccups,O
is,O
difficult,O
and,O
often,O
achieved,O
only,O
by,O
a,O
process,O
of,O
elimination,O
.,O
However,O
",",O
macrolide,B
antimicrobials,O
have,O
been,O
reported,O
to,O
be,O
associated,O
with,O
hiccups,O
and,O
vagal,O
mechanism,O
could,O
explain,O
the,O
development,O
of,O
this,O
side,O
-,O
effect,O
.,O
Calcium,B
carbonate,I
toxicity,I
:,O
the,O
updated,O
milk,O
-,O
alkali,O
syndrome,O
;,O
report,O
of,O
3,O
cases,O
and,O
review,O
of,O
the,O
literature,O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
3,O
patients,O
with,O
calcium,B
carbonate,I
-,I
induced,I
hypercalcemia,I
and,O
gain,O
insights,O
into,O
the,O
cause,O
and,O
management,O
of,O
the,O
milk,O
-,O
alkali,O
syndrome,O
.,O
METHODS,O
:,O
We,O
report,O
the,O
clinical,O
and,O
laboratory,O
data,O
in,O
3,O
patients,O
who,O
presented,O
with,O
severe,O
hypercalcemia,I
(,O
corrected,O
serum,O
calcium,B
>,O
or,O
=,O
14,O
mg,O
/,O
dL,O
and,O
review,O
the,O
pertinent,O
literature,O
on,O
milk,O
-,O
alkali,O
syndrome,O
.,O
RESULTS,O
:,O
The,O
3,O
patients,O
had,O
acute,O
renal,B
insufficiency,O
",",O
relative,O
metabolic,O
alkalosis,O
",",O
and,O
low,O
parathyroid,B
hormone,I
(,O
PTH,B
),O
",",O
PTH,B
-,O
related,O
peptide,O
",",O
and,O
1,O
",",O
25,O
-,O
dihydroxyvitamin,B
D,I
concentrations,O
.,O
No,O
malignant,O
lesion,O
was,O
found,O
.,O
Treatment,O
included,O
aggressive,O
hydration,O
and,O
varied,O
amounts,O
of,O
furosemide,B
.,O
The,O
2,O
patients,O
with,O
the,O
higher,O
serum,O
calcium,B
concentrations,O
received,O
pamidronate,B
intravenously,O
(,O
60,O
and,O
30,O
mg,O
",",O
respectively,O
),O
",",O
which,O
caused,O
severe,O
hypocalcemia,B
.,O
Of,O
the,O
3,O
patients,O
",",O
2,O
were,O
ingesting,O
acceptable,O
doses,O
of,O
elemental,O
calcium,B
(,O
1,O
g,O
and,O
2,O
g,O
daily,O
",",O
respectively,O
),O
in,O
the,O
form,O
of,O
calcium,B
carbonate,I
.,O
In,O
addition,O
to,O
our,O
highlighted,O
cases,O
",",O
we,O
review,O
the,O
history,O
",",O
classification,O
",",O
pathophysiologic,O
features,O
",",O
and,O
treatment,O
of,O
milk,B
-,I
alkali,I
syndrome,I
and,O
summarize,O
the,O
cases,O
reported,O
from,O
early,O
1995,O
to,O
November,O
2003,O
.,O
CONCLUSION,O
:,O
Milk,B
-,I
alkali,I
syndrome,I
may,O
be,O
a,O
common,O
cause,O
of,O
unexplained,O
hypercalcemia,O
and,O
can,O
be,O
precipitated,O
by,O
small,O
amounts,O
of,O
orally,O
ingested,O
calcium,B
carbonate,I
in,O
susceptible,O
persons,O
.,O
Treatment,O
with,O
hydration,O
",",O
furosemide,B
",",O
and,O
discontinuation,O
of,O
the,O
calcium,B
and,O
vitamin,B
D,I
source,O
is,O
adequate,O
.,O
Pamidronate,B
treatment,O
is,O
associated,O
with,O
considerable,O
risk,O
for,O
hypocalcemia,O
",",O
even,O
in,O
cases,O
of,O
initially,O
severe,O
hypercalcemia,O
.,O
Warfarin,B
-,I
induced,I
leukocytoclastic,I
vasculitis,I
.,O
Skin,O
reactions,O
associated,O
with,O
oral,O
coumarin,B
-,I
derived,I
anticoagulants,I
are,O
an,O
uncommon,O
occurrence,O
.,O
Leukocytoclastic,B
vasculitis,I
(,O
LV,B
),O
is,O
primarily,O
a,O
cutaneous,O
small,O
vessel,O
vasculitis,O
",",O
though,O
systemic,O
involvement,O
may,O
be,O
encountered,O
.,O
We,O
report,O
4,O
patients,O
with,O
late,O
-,O
onset,O
LV,B
probably,O
due,O
to,O
warfarin,B
.,O
All,O
4,O
patients,O
presented,O
with,O
skin,O
eruptions,O
that,O
developed,O
after,O
receiving,O
warfarin,B
for,O
several,O
years,O
.,O
The,O
results,O
of,O
skin,O
lesion,O
biopsies,O
were,O
available,O
in,O
3,O
patients,O
",",O
confirming,O
LV,B
Cutaneous,I
lesions,I
resolved,O
in,O
all,O
patients,O
after,O
warfarin,B
was,O
discontinued,O
.,O
In,O
2,O
of,O
the,O
4,O
patients,O
",",O
rechallenge,O
with,O
warfarin,B
led,O
to,O
recurrence,O
of,O
the,O
lesions,O
.,O
LV,B
may,O
be,O
a,O
late,O
-,O
onset,O
adverse,O
reaction,O
associated,O
with,O
warfarin,B
therapy,O
.,O
Cocaine,B
-,O
induced,O
brainstem,O
seizures,O
and,O
behavior,O
.,O
A,O
variety,O
of,O
abnormal,O
sensory,O
/,O
motor,O
behaviors,O
associated,O
with,O
electrical,O
discharges,O
recorded,O
from,O
the,O
bilateral,O
brainstem,O
were,O
induced,O
in,O
adult,O
WKY,O
rats,O
by,O
mechanical,O
(,O
electrode,O
implants,O
),O
and,O
DC,O
electrical,O
current,O
stimulations,O
and,O
by,O
acute,O
and,O
chronic,O
administration,O
of,O
cocaine,B
.,O
The,O
electrode,O
implant,O
implicated,O
one,O
side,O
or,O
the,O
other,O
of,O
the,O
reticular,O
system,O
of,O
the,O
brainstem,O
but,O
subjects,O
were,O
not,O
incapacitated,O
by,O
the,O
stimulations,O
.,O
Cocaine,B
(,O
40,O
mg,O
/,O
kg,O
),O
was,O
injected,O
subcutaneously,O
for,O
an,O
acute,O
experiment,O
and,O
subsequent,O
20,O
mg,O
/,O
kg,O
doses,O
twice,O
daily,O
for,O
3,O
days,O
in,O
a,O
chronic,O
study,O
.,O
Cocaine,B
generated,O
more,O
abnormal,O
behaviors,O
in,O
the,O
brainstem,B
perturbation,O
group,O
",",O
especially,O
the,O
electrically,O
perturbated,O
subjects,O
.,O
The,O
abnormal,O
behaviors,O
were,O
yawning,O
",",O
retrocollis,O
",",O
hyperactivity,O
",",O
hypersensitivity,O
",",O
beating,O
O,O
drum,O
O,O
behavior,O
",",O
squealing,O
",",O
head,O
bobbing,O
",",O
circling,O
",",O
sniffing,O
",",O
abnormal,O
posturing,O
",",O
and,O
facial,O
twitching,O
.,O
Shifts,O
in,O
the,O
power,O
frequency,O
spectra,O
of,O
the,O
discharge,O
patterns,O
were,O
noted,O
between,O
quiet,O
and,O
pacing,O
behavioral,O
states,O
.,O
Hypersensitivity,O
to,O
various,O
auditory,B
",",O
tactile,B
",",O
and,O
visual,B
stimulation,O
was,O
present,O
and,O
shifts,O
in,O
the,O
brainstem,B
ambient,I
power,I
spectral,I
frequency,I
occurred,O
in,O
response,O
to,O
tactile,B
stimulation,O
.,O
These,O
findings,O
suggest,O
that,O
the,O
brainstem,O
generates,O
and,O
propagates,O
pathological,O
discharges,O
that,O
can,O
be,O
elicited,O
by,O
mechanical,O
and,O
DC,B
electrical,I
perturbation,I
.,O
Cocaine,B
was,O
found,O
to,O
activate,O
the,O
discharge,O
system,O
and,O
thus,O
induce,O
abnormal,O
behaviors,O
that,O
are,O
generated,O
at,O
the,O
discharge,O
site,O
and,O
at,O
distant,O
sites,O
to,O
which,O
the,O
discharge,O
propagates,O
.,O
Cognitive,O
functions,O
may,O
also,O
be,O
involved,O
since,O
dopaminergic,B
and,O
serotonergic,B
cellular,O
elements,O
at,O
the,O
brainstem,O
level,O
are,O
also,O
implicated,O
.,O
rTMS,O
of,O
supplementary,O
motor,O
area,O
modulates,O
therapy,O
-,O
induced,O
dyskinesias,O
in,O
Parkinson,O
disease,O
.,O
The,O
neural,O
mechanisms,O
and,O
circuitry,O
involved,O
in,O
levodopa,B
-,O
induced,O
dyskinesia,O
are,O
unclear,O
.,O
Using,O
repetitive,O
transcranial,O
magnetic,O
stimulation,O
(,O
rTMS,B
),O
over,O
the,O
supplementary,O
motor,O
area,O
(,O
SMA,B
),O
in,O
a,O
group,O
of,O
patients,O
with,O
advanced,O
Parkinson,B
disease,I
",",O
the,O
authors,O
investigated,O
whether,O
modulation,O
of,O
SMA,B
excitability,O
may,O
result,O
in,O
a,O
modification,O
of,O
a,O
dyskinetic,O
state,O
induced,O
by,O
continuous,O
apomorphine,B
infusion,O
.,O
rTMS,O
at,O
1,O
Hz,O
was,O
observed,O
to,O
markedly,O
reduce,O
drug,B
-,O
induced,O
dyskinesias,O
",",O
whereas,O
5,B
-,I
Hz,I
rTMS,I
induced,O
a,O
slight,O
but,O
not,O
significant,O
increase,O
.,O
Intracavitary,O
chemotherapy,B
(,O
paclitaxel,B
/,O
carboplatin,B
liquid,O
crystalline,O
cubic,O
phases,O
),O
for,O
recurrent,O
glioblastoma,B
-,O
-,O
clinical,O
observations,O
.,O
Human,O
malignant,O
brain,O
tumors,O
have,O
a,O
poor,O
prognosis,O
in,O
spite,O
of,O
surgery,O
and,O
radiation,O
therapy,O
.,O
Cubic,B
phases,I
consist,O
of,O
curved,O
biocontinuous,O
lipid,B
bilayers,I
",",O
separating,O
two,O
congruent,O
networks,O
of,O
water,B
channels,I
.,O
Used,O
as,O
a,O
host,O
for,O
cytotoxic,O
drugs,O
",",O
the,O
gel,B
-,I
like,I
matrix,I
can,O
easily,O
be,O
applied,O
to,O
the,O
walls,O
of,O
a,O
surgical,O
resection,O
cavity,O
.,O
For,O
human,O
glioblastoma,B
recurrences,I
",",O
the,O
feasibility,O
",",O
safety,O
",",O
and,O
short,O
-,O
term,O
effects,O
of,O
a,O
surgical,O
intracavitary,O
application,O
of,O
paclitaxel,B
and,O
carboplatin,B
encapsulated,O
by,O
liquid,B
crystalline,I
cubic,I
phases,I
are,O
examined,O
in,O
a,O
pilot,O
study,O
.,O
A,O
total,O
of,O
12,O
patients,O
with,O
a,O
recurrence,O
of,O
a,O
glioblastoma,B
multiforme,I
underwent,O
re,O
-,O
resection,O
and,O
received,O
an,O
intracavitary,O
application,O
of,O
paclitaxel,B
and,O
carboplatin,B
cubic,O
phases,O
in,O
different,O
dosages,O
.,O
Six,O
of,O
the,O
patients,O
received,O
more,O
than,O
15,O
mg,O
paclitaxel,B
and,O
suffered,O
from,O
moderate,O
to,O
severe,O
brain,O
edema,O
",",O
while,O
the,O
remaining,O
patients,O
received,O
only,O
a,O
total,O
of,O
15,O
mg,O
paclitaxel,B
.,O
In,O
the,O
latter,O
group,O
",",O
brain,B
edema,I
was,O
markedly,O
reduced,O
and,O
dealt,O
medically,O
.,O
Intracavitary,O
chemotherapy,O
in,O
recurrent,O
glioblastoma,B
using,O
cubic,O
phases,O
is,O
feasible,O
and,O
safe,O
",",O
yet,O
the,O
clinical,O
benefit,O
remains,O
to,O
be,O
examined,O
in,O
a,O
clinical,O
phase,O
II,O
study,O
.,O
Lamotrigine,B
associated,O
with,O
exacerbation,O
or,O
de,O
novo,O
myoclonus,O
in,O
idiopathic,O
generalized,O
epilepsies,O
.,O
Five,O
patients,O
with,O
idiopathic,B
generalized,I
epilepsies,I
(,O
IGE,B
),O
treated,O
with,O
lamotrigine,B
(,O
LTG,B
),O
experienced,O
exacerbation,O
or,O
de,O
novo,O
appearance,O
of,O
myoclonic,B
jerks,I
(,O
MJ,B
),O
.,O
In,O
three,O
patients,O
",",O
LTG,B
exacerbated,O
MJ,B
in,O
a,O
dose,O
-,O
dependent,O
manner,O
with,O
early,O
aggravation,O
during,O
titration,O
.,O
MJ,B
disappeared,O
when,O
LTG,B
dose,O
was,O
decreased,O
by,O
25,O
to,O
50,O
%,O
.,O
In,O
two,O
patients,O
",",O
LTG,B
exacerbated,O
MJ,B
in,O
a,O
delayed,O
but,O
more,O
severe,O
manner,O
",",O
with,O
myoclonic,B
status,O
that,O
only,O
ceased,O
after,O
LTG,B
withdrawal,O
.,O
Absence,O
of,O
acute,O
cerebral,O
vasoconstriction,O
after,O
cocaine,B
-,O
associated,O
subarachnoid,O
hemorrhage,O
.,O
INTRODUCTION,O
:,O
Cocaine,B
use,O
has,O
been,O
associated,O
with,O
neurovascular,O
complications,O
",",O
including,O
arterial,O
vasoconstriction,O
and,O
vasculitis,O
.,O
However,O
",",O
there,O
are,O
few,O
studies,O
of,O
angiographic,O
effects,O
of,O
cocaine,B
on,O
human,O
cerebral,O
arteries,O
.,O
Information,O
on,O
these,O
effects,O
could,O
be,O
obtained,O
from,O
angiograms,O
of,O
patients,O
with,O
cocaine,B
-,O
associated,O
subarachnoid,O
hemorrhage,O
(,O
SAH,O
),O
who,O
underwent,O
angiography,O
shortly,O
after,O
cocaine,B
use,O
.,O
METHODS,O
:,O
We,O
screened,O
patients,O
with,O
SAH,O
retrospectively,O
and,O
identified,O
those,O
with,O
positive,O
urine,O
toxicology,O
for,O
cocaine,B
or,O
its,O
metabolites,O
.,O
Quantitative,O
arterial,B
diameter,I
measurements,O
from,O
angiograms,O
of,O
these,O
patients,O
were,O
compared,O
to,O
measurements,O
from,O
control,O
patients,O
with,O
SAH,O
who,O
were,O
matched,O
for,O
factors,O
known,O
to,O
influence,O
arterial,B
diameter,I
.,O
Qualitative,O
comparisons,O
of,O
small,O
artery,B
changes,O
also,O
were,O
made,O
.,O
RESULTS,O
:,O
Thirteen,O
patients,O
with,O
positive,O
cocaine,B
toxicology,I
were,O
compared,O
to,O
26,O
controls,O
.,O
There,O
were,O
no,O
significant,O
differences,O
between,O
groups,O
in,O
the,O
mean,O
diameters,O
of,O
the,O
intradural,O
internal,B
carotid,I
",",O
sphenoidal,O
segment,O
of,O
the,O
middle,B
cerebral,I
",",O
precommunicating,O
segment,O
of,O
the,O
anterior,B
cerebral,I
",",O
or,O
basilar,B
arteries,I
(,O
p,O
greater,O
than,O
0,O
.,O
5,O
for,O
all,O
comparisons,O
",",O
unpaired,O
t,O
-,O
tests,O
.,O
There,O
also,O
were,O
no,O
significant,O
differences,O
between,O
groups,O
when,O
expressing,O
diameters,O
as,O
the,O
sum,O
of,O
the,O
precommunicating,O
segment,O
of,O
the,O
anterior,B
cerebral,I
+,O
sphenoidal,O
segment,O
of,O
the,O
middle,B
cerebral,I
+,O
supraclinoid,O
internal,B
carotid,I
artery,I
+,O
basilar,B
artery,I
divided,O
by,O
the,O
diameter,O
of,O
the,O
petrous,O
internal,B
carotid,I
artery,I
(,O
p,O
greater,O
than,O
0,O
5,O
",",O
unpaired,O
t,O
-,O
tests,O
.,O
),O
.,O
Qualitative,O
assessments,O
showed,O
two,O
arterial,O
irregularities,O
in,O
the,O
distal,O
vasculature,O
in,O
each,O
group,O
.,O
CONCLUSION,O
:,O
No,O
quantitative,O
evidence,O
for,O
narrowing,O
of,O
large,O
cerebral,O
arteries,O
or,O
qualitative,O
angiographic,O
evidence,O
for,O
distal,O
narrowing,O
or,O
vasculitis,O
could,O
be,O
found,O
in,O
patients,O
who,O
underwent,O
angiography,O
after,O
aneurysmal,O
SAH,O
associated,O
with,O
cocaine,B
use,O
.,O
Methamphetamine,B
causes,O
alterations,O
in,O
the,O
MAP,B
kinase,I
-,I
related,I
pathways,I
in,O
the,O
brains,O
of,O
mice,O
that,O
display,O
increased,O
aggressiveness,O
.,O
Aggressive,O
behaviors,O
have,O
been,O
reported,O
in,O
patients,O
who,O
suffer,O
from,O
some,O
psychiatric,O
disorders,O
",",O
and,O
are,O
common,O
in,O
methamphetamine,B
(,O
METH,B
),O
abusers,O
.,O
Herein,O
",",O
we,O
report,O
that,O
multiple,O
(,O
but,O
not,O
single,O
),O
injections,O
of,O
METH,B
significantly,O
increased,O
aggressiveness,O
in,O
male,O
CD,O
-,O
1,O
mice,O
.,O
This,O
increase,O
in,O
aggressiveness,O
was,O
not,O
secondary,O
to,O
METH,B
-,O
induced,O
hyperactivity,O
.,O
Analysis,O
of,O
protein,O
expression,O
using,O
antibody,O
microarrays,O
and,O
Western,O
blotting,O
revealed,O
differential,O
changes,O
in,O
MAP,B
kinase,I
-,I
related,I
pathways,I
after,O
multiple,O
and,O
single,O
METH,B
injections,O
.,O
There,O
were,O
statistically,O
significant,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
decreases,O
in,O
MEK1,B
",",O
Erk2p,B
",",O
GSK3alpha,B
",",O
14,B
-,I
3,I
-,I
3e,I
",",O
and,O
MEK7,B
in,O
the,O
striata,O
of,O
mice,O
after,O
multiple,O
injections,O
of,O
METH,B
.,O
MEK1,B
was,O
significantly,O
decreased,O
also,O
after,O
a,O
single,O
injection,O
of,O
METH,B
",",O
but,O
to,O
a,O
much,O
lesser,O
degree,O
than,O
after,O
multiple,O
injections,O
of,O
METH,B
.,O
In,O
the,O
frontal,O
cortex,O
",",O
there,O
was,O
a,O
statistically,O
significant,O
decrease,O
in,O
GSK3alpha,B
after,O
multiple,O
(,O
but,O
not,O
single,O
),O
injections,O
of,O
METH,B
.,O
These,O
findings,O
suggest,O
that,O
alterations,O
in,O
MAP,B
kinase,I
-,I
related,I
pathways,I
in,O
the,O
prefronto,B
-,I
striatal,I
circuitries,I
might,O
be,O
involved,O
in,O
the,O
manifestation,O
of,O
aggressive,O
behaviors,O
in,O
mice,O
.,O
Amisulpride,B
related,O
tic,B
-,I
like,I
symptoms,I
in,O
an,O
adolescent,O
schizophrenic,O
.,O
Tic,B
disorders,I
can,O
be,O
effectively,O
treated,O
by,O
atypical,B
antipsychotics,I
such,O
as,O
risperidone,B
",",O
olanzapine,B
and,O
ziprasidone,B
.,O
However,O
",",O
there,O
are,O
two,O
case,O
reports,O
that,O
show,O
tic,B
-,I
like,I
symptoms,O
",",O
including,O
motor,O
and,O
phonic,O
variants,O
",",O
occurring,O
during,O
treatment,O
with,O
quetiapine,B
or,O
clozapine,B
.,O
We,O
present,O
a,O
15,O
-,O
year,O
-,O
old,O
girl,O
schizophrenic,O
who,O
developed,O
frequent,O
involuntary,O
eye,O
-,O
blinking,O
movements,O
after,O
5,O
months,O
of,O
amisulpride,B
treatment,O
(,O
1000,O
mg,O
per,O
day,O
),O
.,O
The,O
tic,O
-,O
like,O
symptoms,O
resolved,O
completely,O
after,O
we,O
reduced,O
the,O
dose,O
of,O
amisulpride,B
down,O
to,O
800,O
mg,O
per,O
day,O
.,O
However,O
",",O
her,O
psychosis,O
recurred,O
after,O
the,O
dose,O
reduction,O
.,O
We,O
then,O
placed,O
her,O
on,O
an,O
additional,O
100,O
mg,O
per,O
day,O
of,O
quetiapine,B
.,O
She,O
has,O
been,O
in,O
complete,O
remission,O
under,O
the,O
combined,O
medications,O
for,O
more,O
than,O
one,O
year,O
and,O
maintains,O
a,O
fair,O
role,O
function,O
.,O
No,O
more,O
tic,O
-,O
like,O
symptoms,O
or,O
other,O
side,O
effects,O
have,O
been,O
reported,O
.,O
Together,O
with,O
previously,O
reported,O
cases,O
",",O
our,O
patient,O
suggests,O
that,O
tic,O
-,O
like,O
symptoms,O
might,O
occur,O
in,O
certain,O
vulnerable,O
individuals,O
during,O
treatment,O
with,O
atypical,O
antipsychotics,O
such,O
as,O
quetiapine,B
",",O
clozapine,B
",",O
or,O
amisulpride,B
.,O
Chloroquine,B
related,O
complete,O
heart,O
block,O
with,O
blindness,O
:,O
case,O
report,O
.,O
A,O
27,O
-,O
year,O
old,O
African,O
woman,O
with,O
history,O
of,O
regular,O
chloroquine,B
ingestion,O
presented,O
with,O
progressive,O
deterioration,O
of,O
vision,O
",",O
easy,O
fatiguability,O
",",O
dyspnoea,O
",",O
dizziness,O
progressing,O
to,O
syncopal,O
attacks,O
.,O
Ophthalmological,O
assessment,O
revealed,O
features,O
of,O
chloroquine,B
retinopathy,O
",",O
cardiac,O
assessment,O
revealed,O
features,O
of,O
heart,O
failure,O
and,O
a,O
complete,O
heart,O
block,O
with,O
right,O
bundle,O
branch,O
block,O
pattern,O
.,O
The,O
heart,B
block,I
was,O
treated,O
by,O
pacemaker,O
insertion,O
and,O
the,O
heart,B
failure,I
resolved,O
spontaneously,O
following,O
chloroquine,B
discontinuation,O
.,O
She,O
however,O
remains,O
blind,O
.,O
Effects,O
of,O
suprofen,B
on,O
the,O
isolated,O
perfused,O
rat,O
kidney,O
.,O
Although,O
suprofen,B
has,O
been,O
associated,O
with,O
the,O
development,O
of,O
acute,O
renal,B
failure,I
in,O
greater,O
than,O
100,O
subjects,O
",",O
the,O
mechanism,O
of,O
damage,O
remains,O
unclear,O
.,O
The,O
direct,O
nephrotoxic,O
effects,O
of,O
a,O
single,O
dose,O
of,O
15,O
mg,O
of,O
suprofen,B
were,O
compared,O
in,O
the,O
recirculating,O
isolated,O
rat,O
kidney,O
perfused,O
with,O
cell,O
-,O
free,O
buffer,O
with,O
or,O
without,O
the,O
addition,O
of,O
5,O
mg,O
/,O
dL,O
of,O
uric,B
acid,I
.,O
There,O
were,O
no,O
significant,O
differences,O
in,O
renal,O
sodium,O
excretion,O
",",O
oxygen,O
consumption,O
",",O
or,O
urinary,O
flow,O
rates,O
in,O
kidneys,O
perfused,O
with,O
suprofen,B
compared,O
with,O
the,O
drug,O
-,O
free,O
control,O
groups,O
.,O
In,O
contrast,O
",",O
a,O
significant,O
decline,O
in,O
glomerular,B
filtration,I
rate,I
was,O
found,O
after,O
the,O
introduction,O
of,O
suprofen,B
to,O
the,O
kidney,B
perfused,O
with,O
uric,B
acid,I
;,O
no,O
changes,O
were,O
found,O
with,O
suprofen,B
in,O
the,O
absence,O
of,O
uric,B
acid,I
.,O
A,O
significant,O
decrease,O
in,O
the,O
baseline,O
excretion,O
rate,O
of,O
uric,B
acid,I
was,O
found,O
in,O
rats,O
given,O
suprofen,B
",",O
compared,O
with,O
drug,O
-,O
free,O
controls,O
.,O
However,O
",",O
the,O
fractional,O
excretion,O
of,O
uric,B
acid,I
was,O
unchanged,O
between,O
the,O
groups,O
over,O
the,O
experimental,O
period,O
.,O
In,O
summary,O
",",O
suprofen,O
causes,O
acute,O
declines,O
in,O
renal,O
function,O
",",O
most,O
likely,O
by,O
directly,O
altering,O
the,O
intrarenal,O
distribution,O
of,O
uric,B
acid,I
.,O
Microinjection,O
of,O
ritanserin,O
into,O
the,O
CA1,O
region,O
of,O
hippocampus,O
improves,O
scopolamine,B
-,O
induced,O
amnesia,O
in,O
adult,O
male,O
rats,O
.,O
The,O
effect,O
of,O
ritanserin,B
(,O
5,O
-,O
HT2,B
antagonist,O
),O
on,O
scopolamine,B
(,O
muscarinic,B
cholinergic,I
antagonist,O
),O
-,O
induced,O
amnesia,O
in,O
Morris,O
water,O
maze,O
(,O
MWM,O
),O
was,O
investigated,O
.,O
Rats,O
were,O
divided,O
into,O
eight,O
groups,O
and,O
bilaterally,O
cannulated,O
into,O
CA1,O
region,O
of,O
the,O
hippocampus,O
.,O
One,O
week,O
later,O
",",O
they,O
received,O
repeatedly,O
vehicles,O
(,O
saline,B
",",O
DMSO,B
",",O
saline,B
+,O
DMSO,B
),O
",",O
scopolamine,B
(,O
2,O
microg,O
/,O
0,O
0.0,O
5,O
microl,O
saline,B
/,O
side,O
;,O
30,O
min,O
before,O
training,O
),O
",",O
ritanserin,B
(,O
2,O
",",O
4,O
and,O
8,O
microg,O
/,O
0,O
.,O
5,O
DMSO,B
20,O
scopolamine,B
30,O
ritanserin,O
injection,O
+,O
4,O
DMSO,B
through,O
cannulae,O
each,O
day,O
Animals,O
were,O
tested,O
for,O
four,O
consecutive,O
days,O
(,O
4,O
trial,O
/,O
day,O
),O
in,O
MWM,O
during,O
which,O
the,O
position,O
of,O
hidden,O
platform,O
was,O
unchanged,O
In,O
the,O
fifth,O
day,O
",",O
the,O
platform,O
was,O
elevated,O
above,O
the,O
water,O
surface,O
in,O
another,O
position,O
to,O
evaluate,O
the,O
function,O
of,O
motor,O
",",O
motivational,O
and,O
visual,O
systems,O
.,O
The,O
results,O
showed,O
a,O
significant,O
increase,O
in,O
escape,O
latencies,O
and,O
traveled,O
distances,O
to,O
find,O
platform,O
in,O
scopolamine,B
-,I
treated,I
group,O
as,O
compared,O
to,O
saline,B
group,O
.,O
Ritanserin,B
-,O
treated,O
rats,O
(,O
4,B
microg,I
/,I
0,I
.,I
5,I
microl,I
/,I
side,I
),O
showed,O
a,O
significant,O
decrease,O
in,O
the,O
mentioned,O
parameters,O
as,O
compared,O
to,O
DMSO,B
-,O
treated,O
group,O
.,O
However,O
",",O
scopolamine,B
and,O
ritanserin,B
co,O
-,O
administration,O
resulted,O
in,O
a,O
significant,O
decrease,O
in,O
escape,O
latencies,O
and,O
traveled,O
distances,O
as,O
compared,O
to,O
the,O
scopolamine,B
-,O
treated,O
rats,O
.,O
Our,O
findings,O
show,O
that,O
microinjection,O
of,O
ritanserin,B
into,O
the,O
CA1,B
region,O
of,O
the,O
hippocampus,O
improves,O
the,O
scopolamine,B
-,I
induced,I
amnesia,I
.,O
PTU,B
-,I
associated,I
vasculitis,I
in,O
a,O
girl,O
with,O
Turner,B
Syndrome,I
and,O
Graves,B
',I
disease,I
.,O
Palpable,O
purpura,O
is,O
a,O
concerning,O
clinical,O
finding,O
in,O
pediatric,O
patients,O
and,O
can,O
have,O
many,O
causes,O
",",O
including,O
infectious,O
and,O
autoimmune,O
processes,O
.,O
A,O
rare,O
cause,O
",",O
drug,B
-,O
induced,O
vasculitis,O
",",O
may,O
result,O
from,O
the,O
production,O
of,O
antineutrophil,B
cytoplasmic,I
antibodies,I
(,O
ANCAs,B
),O
in,O
response,O
to,O
a,O
medication,O
.,O
We,O
report,O
a,O
girl,O
with,O
Turner,O
syndrome,O
and,O
Graves,O
',O
disease,O
who,O
presented,O
with,O
palpable,O
purpuric,O
lesions,O
.,O
The,O
diagnosis,O
of,O
propylthiouracil,B
(,O
PTU,B
),O
-,O
associated,O
vasculitis,O
was,O
made,O
by,O
observation,O
of,O
consistent,O
clinical,O
features,O
",",O
the,O
detection,O
of,O
elevated,O
ANA,B
and,O
ANCA,B
in,O
the,O
blood,O
",",O
and,O
the,O
observed,O
clinical,O
resolution,O
of,O
symptoms,O
following,O
withdrawal,O
of,O
PTU,B
.,O
Subsequent,O
treatment,O
of,O
persistent,O
hyperthyroidism,B
with,O
radioablation,O
did,O
not,O
result,O
in,O
an,O
exacerbation,O
of,O
the,O
vasculitis,B
",",O
a,O
complication,O
described,O
in,O
prior,O
case,O
reports,O
.,O
Daidzein,B
activates,O
choline,B
acetyltransferase,I
from,O
MC,B
-,I
IXC,I
cells,O
and,O
improves,O
drug,O
-,O
induced,O
amnesia,O
.,O
The,O
choline,B
acetyltransferase,I
(,O
ChAT,B
),O
activator,O
",",O
which,O
enhances,O
cholinergic,O
transmission,O
via,O
an,O
augmentation,O
of,O
the,O
enzymatic,O
production,O
of,O
acetylcholine,B
(,O
ACh,B
),O
",",O
is,O
an,O
important,O
factor,O
in,O
the,O
treatment,O
of,O
Alzheimer,B
',O
s,O
disease,O
(,O
AD,B
),O
.,O
Methanolic,B
extracts,O
from,O
Pueraria,B
thunbergiana,I
exhibited,O
an,O
activation,O
effect,O
(,O
46,O
%,O
),O
on,O
ChAT,B
in,O
vitro,O
.,O
Via,O
the,O
sequential,O
isolation,O
of,O
Pueraria,B
thunbergiana,I
",",O
the,O
active,O
component,O
was,O
ultimately,O
identified,O
as,O
daidzein,B
(,O
4,O
',O
",",O
7,O
-,O
dihydroxy,O
-,O
isoflavone,O
),O
.,O
In,O
order,O
to,O
investigate,O
the,O
effects,O
of,O
daidzein,B
from,O
Pueraria,B
thunbergiana,I
on,O
scopolamine,B
-,O
induced,O
impairments,O
of,O
learning,O
and,O
memory,O
",",O
we,O
conducted,O
a,O
series,O
of,O
in,O
vivo,O
tests,O
.,O
Administration,O
of,O
daidzein,B
(,O
4,O
.,O
5,O
mg,O
/,O
kg,O
body,O
weight,O
),O
to,O
mice,O
was,O
shown,O
significantly,O
to,O
reverse,O
scopolamine,B
-,O
induced,O
amnesia,O
",",O
according,O
to,O
the,O
results,O
of,O
a,O
Y,O
-,O
maze,O
test,O
.,O
Injections,O
of,O
scopolamine,B
into,O
mice,O
resulted,O
in,O
impaired,O
performance,O
on,O
Y,O
-,O
maze,O
tests,O
(,O
a,O
37,O
%,O
decreases,O
in,O
alternation,O
behavior,O
),O
.,O
By,O
way,O
of,O
contrast,O
",",O
mice,O
treated,O
with,O
daidzein,B
prior,O
to,O
the,O
scopolamine,B
injections,O
were,O
noticeably,O
protected,O
from,O
this,O
performance,O
impairment,O
(,O
an,O
approximately,O
12,O
%,O
-,O
21,O
%,O
decrease,O
in,O
alternation,O
behavior,O
),O
.,O
These,O
results,O
indicate,O
that,O
daidzein,B
might,O
play,O
a,O
role,O
in,O
acetylcholine,B
biosynthesis,O
as,O
a,O
ChAT,B
activator,O
",",O
and,O
that,O
it,O
also,O
ameliorates,O
scopolamine,B
-,O
induced,O
amnesia,O
.,O
Urinary,O
symptoms,O
and,O
quality,O
of,O
life,O
changes,O
in,O
Thai,O
women,O
with,O
overactive,O
bladder,O
after,O
tolterodine,B
treatment,O
.,O
OBJECTIVES,O
:,O
To,O
study,O
the,O
urinary,O
symptoms,O
and,O
quality,O
of,O
life,O
changes,O
in,O
Thai,O
women,O
with,O
overactive,O
bladder,O
(,O
OAB,B
),O
after,O
tolterodine,B
treatment,O
.,O
MATERIAL,O
AND,O
METHOD,O
:,O
Thirty,O
women,O
(,O
aged,O
30,O
-,O
77,O
years,O
),O
diagnosed,O
as,O
having,O
OAB,B
at,O
the,O
Gynecology,O
Clinic,O
",",O
King,O
Chulalongkorn,O
Memorial,O
Hospital,O
from,O
January,O
to,O
April,O
2004,O
were,O
included,O
in,O
the,O
present,O
study,O
.,O
Tolterodine,B
2,O
mg,O
",",O
twice,O
daily,O
was,O
given,O
.,O
After,O
8,O
weeks,O
treatment,O
",",O
changes,O
in,O
micturition,O
diary,O
variables,O
and,O
tolerability,O
were,O
determined,O
.,O
Short,O
form,O
36,O
(,O
SF36,B
),O
questionaires,O
(,O
Thai,O
version,O
),O
were,O
given,O
before,O
and,O
after,O
8,O
weeks,O
of,O
treatment,O
.,O
RESULTS,O
:,O
At,O
8,O
weeks,O
",",O
all,O
micturition,O
per,O
day,O
decreased,O
from,O
16,O
.,O
7,O
+,O
/,O
-,O
5,O
.,O
3,O
to,O
6,O
.,O
7,O
+,O
/,O
-,O
2,O
.,O
4,O
times,O
per,O
day,O
.,O
The,O
number,O
of,O
nocturia,O
episodes,O
decreased,O
from,O
5,O
.,O
4,O
+,O
/,O
-,O
4,O
.,O
2,O
to,O
1,O
.,O
1,O
+,O
/,O
-,O
1,O
.,O
0,O
times,O
per,O
night,O
.,O
The,O
most,O
common,O
side,O
effect,O
was,O
dry,B
month,I
in,O
5,O
cases,O
(,O
16,O
.,O
7,O
%,O
),O
with,O
2,O
cases,O
reporting,O
a,O
moderate,O
degree,O
and,O
1,O
case,O
with,O
severe,O
degree,O
.,O
Only,O
one,O
case,O
(,O
3,O
.,O
3,O
%,O
),O
withdrew,O
from,O
the,O
present,O
study,O
due,O
to,O
a,O
severe,O
dry,O
mouth,O
.,O
The,O
SF,O
-,O
36,O
scores,O
changed,O
significantly,O
in,O
the,O
domains,O
of,O
physical,O
functioning,O
",",O
role,O
function,O
emotional,O
",",O
social,O
function,O
and,O
mental,O
heath,O
.,O
CONCLUSION,O
:,O
Tolterodine,B
was,O
well,O
tolerated,O
and,O
its,O
effects,O
improved,O
the,O
quality,O
of,O
life,O
in,O
Thai,O
women,O
with,O
OAB,B
.,O
Remifentanil,B
pretreatment,O
reduces,O
myoclonus,O
after,O
etomidate,B
.,O
STUDY,O
OBJECTIVE,O
:,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
compare,O
the,O
effect,O
of,O
pretreatment,O
with,O
remifentanil,B
1,O
microg,O
/,O
kg,O
and,O
the,O
effect,O
of,O
gender,O
on,O
the,O
incidence,O
of,O
myoclonus,O
after,O
anesthesia,O
induction,O
with,O
etomidate,B
.,O
DESIGN,O
:,O
This,O
was,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
study,O
.,O
SETTING,O
:,O
The,O
study,O
was,O
conducted,O
at,O
a,O
university,O
hospital,O
.,O
PATIENTS,O
:,O
Sixty,O
patients,O
were,O
pretreated,O
in,O
a,O
randomized,O
double,O
-,O
blinded,O
fashion,O
with,O
remifentanil,B
1,O
microg,O
/,O
kg,O
or,O
placebo,B
.,O
Two,O
minutes,O
after,O
remifentanil,B
or,O
placebo,B
injection,O
",",O
etomidate,B
0,O
.,O
3,O
mg,O
/,O
kg,O
was,O
given,O
.,O
MEASUREMENTS,O
:,O
Myoclonus,O
was,O
recorded,O
with,O
a,O
scale,O
of,O
0,O
to,O
3,O
.,O
The,O
grade,O
of,O
sedation,O
(,O
none,O
",",O
mild,O
",",O
moderate,O
",",O
severe,O
),O
",",O
nausea,O
",",O
pruritus,O
",",O
and,O
apnea,O
were,O
recorded,O
after,O
injection,O
of,O
both,O
drugs,O
.,O
MAIN,O
RESULTS,O
:,O
The,O
incidence,O
of,O
myoclonus,O
was,O
significantly,O
lower,O
in,O
the,O
remifentanil,B
group,O
(,O
6,O
.,O
7,O
%,O
),O
than,O
in,O
the,O
placebo,B
group,O
(,O
70,O
%,O
),O
(,O
P,O
<,O
0,O
.,O
1,O
),O
.,O
None,O
of,O
the,O
patients,O
experienced,O
sedation,O
",",O
apnea,O
",",O
nausea,O
",",O
or,O
pruritus,O
after,O
injection,O
of,O
both,O
drugs,O
.,O
In,O
the,O
placebo,O
group,O
",",O
male,O
patients,O
were,O
associated,O
with,O
significantly,O
increased,O
incidence,O
of,O
myoclonus,B
after,O
etomidate,O
administration,O
.,O
CONCLUSION,O
:,O
Pretreatment,O
with,O
remifentanil,B
1,O
microg,O
/,O
kg,O
reduced,O
myoclonus,B
after,O
etomidate,O
induction,O
without,O
side,O
effects,O
such,O
as,O
sedation,O
",",O
apnea,B
",",O
nausea,B
",",O
or,O
pruritus,B
.,O
Men,O
experience,O
increased,O
incidence,O
of,O
myoclonus,B
than,O
women,O
after,O
etomidate,O
administration,O
.,O
Memory,O
function,O
and,O
serotonin,B
transporter,O
promoter,O
gene,O
polymorphism,O
in,O
ecstasy,B
(,O
MDMA,I
),O
users,O
.,O
Although,O
3,O
",",O
4,B
-,I
methylenedioxymethamphetamine,I
(,O
MDMA,I
or,O
ecstasy,I
),O
has,O
been,O
shown,O
to,O
damage,O
brain,O
serotonin,B
(,O
5,B
-,I
HT,I
),O
neurons,O
in,O
animals,O
and,O
possibly,O
humans,O
",",O
little,O
is,O
known,O
about,O
the,O
long,O
-,O
term,O
consequences,O
of,O
MDMA,B
-,O
induced,O
5,B
-,I
HT,I
neurotoxic,I
lesions,O
on,O
functions,O
in,O
which,O
5,B
-,I
-,I
HT,I
is,O
involved,O
",",O
such,O
as,O
cognitive,O
function,O
.,O
Because,O
5,B
-,I
HT,I
transporters,O
play,O
a,O
key,O
element,O
in,O
the,O
regulation,O
of,O
synaptic,O
5,B
-,I
HT,I
transmission,O
it,O
may,O
be,O
important,O
to,O
control,O
for,O
the,O
potential,O
covariance,O
effect,O
of,O
a,O
polymorphism,O
in,O
the,O
5,B
-,I
HT,I
transporter,O
promoter,O
gene,O
region,O
(,O
5,B
-,I
HTTLPR,I
),O
when,O
studying,O
the,O
effects,O
of,O
MDMA,B
as,O
well,O
as,O
cognitive,O
functioning,O
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
investigate,O
the,O
effects,O
of,O
moderate,O
and,O
heavy,O
MDMA,B
use,O
on,O
cognitive,O
function,O
",",O
as,O
well,O
as,O
the,O
effects,O
of,O
long,O
-,O
term,O
abstention,O
from,O
MDMA,B
",",O
in,O
subjects,O
genotyped,O
for,O
5,O
-,O
HTTLPR,B
.,O
A,O
second,O
aim,O
of,O
the,O
study,O
was,O
to,O
determine,O
whether,O
these,O
effects,O
differ,O
for,O
females,O
and,O
males,O
.,O
Fifteen,O
moderate,O
MDMA,B
users,O
(,O
<,O
55,O
lifetime,O
tablets,O
),O
",",O
22,O
heavy,O
MDMA,B
+,O
users,O
(,O
>,O
55,O
lifetime,O
tablets,O
),O
",",O
16,O
ex,O
-,O
MDMA,B
+,O
users,O
(,O
last,O
tablet,O
>,O
1,O
year,O
ago,O
),O
and,O
13,O
controls,O
were,O
compared,O
on,O
a,O
battery,O
of,O
neuropsychological,O
tests,O
.,O
DNA,B
from,O
peripheral,O
nuclear,O
blood,O
cells,O
was,O
genotyped,O
for,O
5,B
-,I
HTTLPR,I
using,O
standard,O
polymerase,O
chain,O
reaction,O
methods,O
.,O
A,O
significant,O
group,O
effect,O
was,O
observed,O
only,O
on,O
memory,B
function,I
tasks,O
(,O
p,O
=,O
0,O
.,O
4,O
),O
but,O
not,O
on,O
reaction,O
times,O
(,O
p,O
=,O
0,O
.,O
61,O
),O
or,O
attention,O
/,O
executive,O
functioning,O
(,O
p,O
=,O
0,O
.,O
59,O
),O
.,O
Heavy,O
and,O
ex,B
-,I
MDMA,I
+,I
users,O
performed,O
significantly,O
poorer,O
on,O
memory,B
tasks,O
than,O
controls,O
.,O
In,O
contrast,O
",",O
no,O
evidence,O
of,O
memory,B
impairment,I
was,O
observed,O
in,O
moderate,O
MDMA,B
users,O
.,O
No,O
significant,O
effect,O
of,O
5,B
-,I
HTTLPR,I
or,O
gender,O
was,O
observed,O
.,O
While,O
the,O
use,O
of,O
MDMA,B
in,O
quantities,O
that,O
may,O
be,O
considered,O
moderate,O
is,O
not,O
associated,O
with,O
impaired,O
memory,O
functioning,O
",",O
heavy,O
use,O
of,O
MDMA,B
use,O
may,O
lead,O
to,O
long,O
lasting,O
memory,O
impairments,O
.,O
No,O
effect,O
of,O
5,B
-,I
HTTLPR,I
or,O
gender,O
on,O
memory,O
function,O
or,O
MDMA,B
use,O
was,O
observed,O
.,O
Role,O
of,O
mangiferin,B
on,O
biochemical,O
alterations,O
and,O
antioxidant,O
status,O
in,O
isoproterenol,B
-,O
induced,O
myocardial,O
infarction,O
in,O
rats,O
.,O
The,O
current,O
study,O
dealt,O
with,O
the,O
protective,O
role,O
of,O
mangiferin,B
",",O
a,O
polyphenol,O
from,O
Mangifera,B
indica,I
Linn,I
.,O
(,O
Anacardiaceae,B
),O
",",O
on,O
isoproterenol,B
(,O
ISPH,B
),O
-,O
induced,O
myocardial,O
infarction,O
(,O
MI,B
),O
in,O
rats,O
through,O
its,O
antioxidative,O
mechanism,O
.,O
Subcutaneous,O
injection,O
of,O
ISPH,B
(,O
200,O
mg,O
/,O
kg,O
body,O
weight,O
in,O
1,O
ml,O
saline,O
),O
to,O
rats,O
for,O
2,O
consecutive,O
days,O
caused,O
myocardial,O
damage,O
in,O
rat,O
heart,O
",",O
which,O
was,O
determined,O
by,O
the,O
increased,O
activity,O
of,O
serum,O
lactate,B
dehydrogenase,I
(,O
LDH,B
),O
and,O
creatine,B
phosphokinase,I
isoenzymes,I
(,O
CK,B
-,I
MB,I
),O
",",O
increased,O
uric,B
acid,I
level,I
and,O
reduced,O
plasma,O
iron,B
binding,I
capacity,I
.,O
The,O
protective,O
role,O
of,O
mangiferin,B
was,O
analyzed,O
by,O
triphenyl,B
tetrazolium,I
chloride,I
(,O
TTC,B
),O
test,O
used,O
for,O
macroscopic,O
enzyme,O
mapping,O
assay,O
of,O
the,O
ischemic,O
myocardium,O
.,O
The,O
heart,O
tissue,O
antioxidant,O
enzymes,O
such,O
as,O
superoxide,B
dismutase,I
",",O
catalase,B
",",O
glutathione,B
peroxidase,I
",",O
glutathione,B
transferase,I
and,O
glutathione,B
reductase,I
activities,O
",",O
non,O
-,O
enzymic,O
antioxidants,O
such,O
as,O
cerruloplasmin,B
",",O
Vitamin,B
C,I
",",O
Vitamin,B
E,I
and,O
glutathione,B
levels,O
were,O
altered,O
in,O
MI,O
rats,O
.,O
Upon,O
pretreatment,O
with,O
mangiferin,B
(,O
100,O
mg,O
/,O
kg,O
body,O
weight,O
suspended,O
in,O
2,O
ml,O
of,O
dimethyl,B
sulphoxide,I
),O
given,O
intraperitoneally,O
for,O
28,O
days,O
to,O
MI,O
rats,O
protected,O
the,O
above,O
-,O
mentioned,O
parameters,O
to,O
fall,O
from,O
the,O
normal,O
levels,O
.,O
Activities,O
of,O
heart,O
tissue,O
enzymic,O
antioxidants,O
and,O
serum,O
non,O
-,O
enzymic,O
antioxidants,O
levels,O
rose,O
significantly,O
upon,O
mangiferin,B
administration,O
as,O
compared,O
to,O
ISPH,O
-,O
induced,O
MI,O
rats,O
.,O
From,O
the,O
present,O
study,O
it,O
is,O
concluded,O
that,O
mangiferin,B
exerts,O
a,O
beneficial,O
effect,O
against,O
ISPH,B
-,O
induced,O
MI,O
due,O
to,O
its,O
antioxidant,O
potential,O
",",O
which,O
regulated,O
the,O
tissues,O
defense,O
system,O
against,O
cardiac,O
damage,O
.,O
Cardiovascular,O
risk,O
with,O
cyclooxygenase,B
inhibitors,O
:,O
general,O
problem,O
with,O
substance,O
specific,O
differences,O
?,O
Randomised,O
clinical,O
trials,O
and,O
observational,O
studies,O
have,O
shown,O
an,O
increased,O
risk,O
of,O
myocardial,O
infarction,O
",",O
stroke,O
",",O
hypertension,O
and,O
heart,O
failure,O
during,O
treatment,O
with,O
cyclooxygenase,B
inhibitors,O
.,O
Adverse,O
cardiovascular,B
effects,I
occurred,O
mainly,O
",",O
but,O
not,O
exclusively,O
",",O
in,O
patients,O
with,O
concomitant,O
risk,O
factors,O
.,O
Cyclooxygenase,B
inhibitors,I
cause,O
complex,O
changes,O
in,O
renal,B
",",O
vascular,B
and,O
cardiac,B
prostanoid,I
profiles,I
thereby,O
increasing,O
vascular,B
resistance,I
and,O
fluid,O
retention,O
.,O
The,O
incidence,O
of,O
cardiovascular,B
adverse,I
events,I
tends,O
to,O
increase,O
with,O
the,O
daily,O
dose,O
and,O
total,O
exposure,O
time,O
.,O
A,O
comparison,O
of,O
individual,O
selective,O
and,O
unselective,O
cyclooxygenase,B
inhibitors,O
suggests,O
substance,O
-,O
specific,O
differences,O
",",O
which,O
may,O
depend,O
on,O
differences,O
in,O
pharmacokinetic,O
parameters,O
or,O
inhibitory,O
potency,O
and,O
may,O
be,O
contributed,O
by,O
prostaglandin,B
-,I
independent,I
effects,O
.,O
Diagnostic,O
markers,O
such,O
as,O
N,B
-,I
terminal,I
pro,I
brain,I
natriuretic,I
peptide,I
(,I
NT,I
-,I
proBNP,I
),I
or,O
high,O
-,O
sensitive,O
C,B
-,I
reactive,I
protein,I
might,O
help,O
in,O
the,O
early,O
identification,O
of,O
patients,O
at,O
risk,O
",",O
thus,O
avoiding,O
the,O
occurrence,O
of,O
serious,O
cardiovascular,O
toxicity,O
.,O
Pilocarpine,B
seizures,O
cause,O
age,O
-,O
dependent,O
impairment,O
in,O
auditory,O
location,O
discrimination,O
.,O
Children,O
who,O
have,O
status,O
epilepticus,O
have,O
continuous,O
or,O
rapidly,O
repeating,O
seizures,O
that,O
may,O
be,O
life,O
-,O
threatening,O
and,O
may,O
cause,O
life,O
-,O
long,O
changes,O
in,O
brain,O
and,O
behavior,O
.,O
The,O
extent,O
to,O
which,O
status,O
epilepticus,O
causes,O
deficits,O
in,O
auditory,O
discrimination,O
is,O
unknown,O
.,O
A,O
naturalistic,O
auditory,O
location,O
discrimination,O
method,O
was,O
used,O
to,O
evaluate,O
this,O
question,O
using,O
an,O
animal,O
model,O
of,O
status,O
epilepticus,O
.,O
Male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
injected,O
with,O
saline,B
on,O
postnatal,O
day,O
(,O
P,B
),O
20,O
",",O
or,O
a,O
convulsant,O
dose,O
of,O
pilocarpine,B
on,O
P20,O
or,O
P45,O
.,O
Pilocarpine,B
on,O
either,O
day,O
induced,O
status,O
epilepticus,O
;,O
status,O
epilepticus,O
at,O
P45,O
resulted,O
in,O
CA3,B
cell,O
loss,O
and,O
spontaneous,O
seizures,O
",",O
whereas,O
P20,O
rats,O
had,O
no,O
cell,O
loss,O
or,O
spontaneous,O
seizures,O
.,O
Mature,O
rats,O
were,O
trained,O
with,O
sound,B
-,O
source,I
location,I
and,O
sound,B
-,O
silence,I
discriminations,O
.,O
Control,O
(,O
saline,B
P20,I
),O
rats,O
acquired,O
both,O
discriminations,O
immediately,O
.,O
In,O
status,O
epilepticus,O
(,O
P20,I
),O
rats,O
",",O
acquisition,O
of,O
the,O
sound,B
-,O
source,I
location,I
discrimination,O
was,O
moderately,O
impaired,O
.,O
Status,O
epilepticus,O
(,O
P45,I
),O
rats,O
failed,O
to,O
acquire,O
either,O
sound,B
-,O
source,I
location,I
or,O
sound,B
-,O
silence,I
discriminations,O
.,O
Status,O
epilepticus,O
in,O
rat,O
causes,O
an,O
age,O
-,O
dependent,O
",",O
long,O
-,O
term,O
impairment,O
in,O
auditory,O
discrimination,O
.,O
This,O
impairment,O
may,O
explain,O
one,O
cause,O
of,O
impaired,O
auditory,O
location,O
discrimination,O
in,O
humans,O
.,O
Nerve,B
growth,I
factor,I
and,O
prostaglandins,B
in,O
the,O
urine,O
of,O
female,O
patients,O
with,O
overactive,O
bladder,O
.,O
PURPOSE,O
:,O
NGF,B
and,O
PGs,B
in,O
the,O
bladder,O
can,O
be,O
affected,O
by,O
pathological,O
changes,O
in,O
the,O
bladder,O
and,O
these,O
changes,O
can,O
be,O
detected,O
in,O
urine,O
.,O
We,O
investigated,O
changes,O
in,O
urinary,O
NGF,B
and,O
PGs,B
in,O
women,O
with,O
OAB,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
The,O
study,O
groups,O
included,O
65,O
women,O
with,O
OAB,O
and,O
20,O
without,O
bladder,O
symptoms,O
who,O
served,O
as,O
controls,O
.,O
Evaluation,O
included,O
patient,O
history,O
",",O
urinalysis,O
",",O
a,O
voiding,O
diary,O
and,O
urodynamic,O
studies,O
.,O
Urine,O
samples,O
were,O
collected,O
.,O
NGF,B
",",O
PGE2,B
",",O
PGF2alpha,B
and,O
PGI2,B
were,O
measured,O
using,O
enzyme,O
-,O
linked,O
immunosorbent,O
assay,O
and,O
compared,O
between,O
the,O
groups,O
.,O
In,O
addition,O
",",O
correlations,O
between,O
urinary,O
NGF,B
and,O
PG,B
",",O
and,O
urodynamic,O
parameters,O
in,O
patients,O
with,O
OAB,O
were,O
examined,O
.,O
RESULTS,O
:,O
Urinary,O
NGF,B
",",O
PGE2,B
and,O
PGF2alpha,B
were,O
significantly,O
increased,O
in,O
patients,O
with,O
OAB,O
compared,O
with,O
controls,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
.,O
However,O
",",O
urinary,O
PGI2,B
was,O
not,O
different,O
between,O
controls,O
and,O
patients,O
with,O
OAB,O
.,O
In,O
patients,O
with,O
OAB,O
urinary,O
PGE2,B
positively,O
correlated,O
with,O
volume,O
at,O
first,O
desire,O
to,O
void,O
and,O
maximum,O
cystometric,O
capacity,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
.,O
Urinary,O
NGF,B
",",O
PGF2alpha,B
and,O
PGI2,B
did,O
not,O
correlate,O
with,O
urodynamic,O
parameters,O
in,O
patients,O
with,O
OAB,O
.,O
CONCLUSIONS,O
:,O
NGF,B
and,O
PGs,B
have,O
important,O
roles,O
in,O
the,O
development,O
of,O
OAB,O
symptoms,O
in,O
female,O
patients,O
.,O
Urinary,O
levels,O
of,O
these,O
factors,O
may,O
be,O
used,O
as,O
markers,O
to,O
evaluate,O
OAB,O
symptoms,O
.,O
Definition,O
and,O
management,O
of,O
anemia,O
in,O
patients,O
infected,O
with,O
hepatitis,B
C,I
virus,I
.,O
Chronic,O
infection,O
with,O
hepatitis,B
C,I
virus,I
(,O
HCV,B
),I
can,O
progress,O
to,O
cirrhosis,O
",",O
hepatocellular,O
carcinoma,O
",",O
and,O
end,O
-,O
stage,O
liver,O
disease,O
.,O
The,O
current,O
best,O
treatment,O
for,O
HCV,B
infection,O
is,O
combination,O
therapy,O
with,O
pegylated,O
interferon,B
and,O
ribavirin,B
.,O
Although,O
this,O
regimen,O
produces,O
sustained,O
virologic,O
responses,O
(,O
SVRs,O
),O
in,O
approximately,O
50,O
%,O
of,O
patients,O
",",O
it,O
can,O
be,O
associated,O
with,O
a,O
potentially,O
dose,O
-,O
limiting,O
hemolytic,O
anemia,O
.,O
Hemoglobin,B
concentrations,O
decrease,O
mainly,O
as,O
a,O
result,O
of,O
ribavirin,B
-,O
induced,O
hemolysis,O
",",O
and,O
this,O
anemia,O
can,O
be,O
problematic,O
in,O
patients,O
with,O
HCV,B
infection,O
",",O
especially,O
those,O
who,O
have,O
comorbid,O
renal,O
or,O
cardiovascular,O
disorders,O
.,O
In,O
general,O
",",O
anemia,B
can,O
increase,O
the,O
risk,O
of,O
morbidity,O
and,O
mortality,O
",",O
and,O
may,O
have,O
negative,O
effects,O
on,O
cerebral,O
function,O
and,O
quality,O
of,O
life,O
.,O
Although,O
ribavirin,B
-,O
associated,O
anemia,B
can,O
be,O
reversed,O
by,O
dose,O
reduction,O
or,O
discontinuation,O
",",O
this,O
approach,O
compromises,O
outcomes,O
by,O
significantly,O
decreasing,O
SVR,O
rates,O
.,O
Recombinant,B
human,I
erythropoietin,I
has,O
been,O
used,O
to,O
manage,O
ribavirin,B
-,O
associated,O
anemia,O
but,O
has,O
other,O
potential,O
disadvantages,O
.,O
Viramidine,B
",",O
a,O
liver,B
-,O
targeting,O
prodrug,O
of,O
ribavirin,B
",",O
has,O
the,O
potential,O
to,O
maintain,O
the,O
virologic,O
efficacy,O
of,O
ribavirin,B
while,O
decreasing,O
the,O
risk,O
of,O
hemolytic,O
anemia,O
in,O
patients,O
with,O
chronic,O
hepatitis,B
C,I
.,O
Impact,O
of,O
alcohol,B
exposure,O
after,O
pregnancy,O
recognition,O
on,O
ultrasonographic,O
fetal,O
growth,O
measures,O
.,O
BACKGROUND,O
:,O
More,O
than,O
3,O
decades,O
after,O
Jones,O
and,O
Smith,O
(,O
1973,O
),O
reported,O
on,O
the,O
devastation,O
caused,O
by,O
alcohol,B
exposure,O
on,O
fetal,O
development,O
",",O
the,O
rates,O
of,O
heavy,O
drinking,O
during,O
pregnancy,O
remain,O
relatively,O
unchanged,O
.,O
Early,O
identification,O
of,O
fetal,B
alcohol,I
exposure,I
and,O
maternal,O
abstinence,O
led,O
to,O
better,O
infant,O
outcomes,O
.,O
This,O
study,O
examined,O
the,O
utility,O
of,O
biometry,O
for,O
detecting,O
alcohol,B
-,I
related,I
fetal,I
growth,I
impairment,I
.,O
METHODS,O
:,O
We,O
obtained,O
fetal,B
ultrasound,I
measures,O
from,O
routine,O
ultrasound,I
examinations,O
for,O
167,O
pregnant,O
hazardous,O
drinkers,O
who,O
were,O
enrolled,O
in,O
a,O
brief,O
alcohol,B
intervention,I
study,O
.,O
The,O
fetal,O
measures,O
for,O
women,O
who,O
quit,O
after,O
learning,O
of,O
their,O
pregnancies,O
were,O
compared,O
with,O
measures,O
for,O
women,O
who,O
continued,O
some,O
drinking,O
throughout,O
the,O
course,O
of,O
their,O
pregnancies,O
.,O
Because,O
intensity,O
of,O
alcohol,B
consumption,O
is,O
associated,O
with,O
poorer,O
fetal,O
outcomes,O
",",O
separate,O
analyses,O
were,O
conducted,O
for,O
the,O
heavy,O
(,O
average,O
of,O
>,O
or,O
=,O
5,O
drinks,O
per,O
drinking,O
day,O
),O
alcohol,B
consumers,O
.,O
Fetal,O
measures,O
from,O
the,O
heavy,O
-,O
exposed,O
fetuses,O
were,O
also,O
compared,O
with,O
measures,O
from,O
a,O
nondrinking,O
group,O
that,O
was,O
representative,O
of,O
normal,O
",",O
uncomplicated,O
pregnancies,O
from,O
our,O
clinics,O
.,O
Analyses,O
of,O
covariance,O
were,O
used,O
to,O
determine,O
whether,O
there,O
were,O
differences,O
between,O
groups,O
after,O
controlling,O
for,O
influences,O
of,O
gestational,O
age,O
and,O
drug,O
abuse,O
.,O
RESULTS,O
:,O
Nearly,O
half,O
of,O
the,O
pregnant,O
drinkers,O
abstained,O
after,O
learning,O
of,O
their,O
pregnancies,O
.,O
When,O
women,O
reportedly,O
quit,O
drinking,O
early,O
in,O
their,O
pregnancies,O
",",O
fetal,O
growth,O
measures,O
were,O
not,O
significantly,O
different,O
from,O
a,O
non,O
-,O
alcohol,B
-,I
exposed,I
group,O
",",O
regardless,O
of,O
prior,O
drinking,O
patterns,O
.,O
Any,O
alcohol,B
consumption,O
postpregnancy,O
recognition,O
among,O
the,O
heavy,O
drinkers,O
resulted,O
in,O
reduced,O
cerebellar,B
growth,O
as,O
well,O
as,O
decreased,O
cranial,B
to,I
body,I
growth,O
in,O
comparison,O
with,O
women,O
who,O
either,O
quit,O
drinking,O
or,O
who,O
were,O
nondrinkers,O
.,O
Amphetamine,B
abuse,O
was,O
predictive,O
of,O
larger,O
cranial,B
to,O
body,O
growth,O
ratios,O
.,O
CONCLUSIONS,O
:,O
Alterations,O
in,O
fetal,O
biometric,O
measurements,O
were,O
observed,O
among,O
the,O
heavy,O
drinkers,O
only,O
when,O
they,O
continued,O
drinking,O
after,O
becoming,O
aware,O
of,O
their,O
pregnancies,O
.,O
Although,O
the,O
reliance,O
on,O
self,O
-,O
reported,O
drinking,O
is,O
a,O
limitation,O
in,O
this,O
study,O
",",O
these,O
findings,O
support,O
the,O
benefits,O
of,O
early,O
abstinence,O
and,O
the,O
potential,O
for,O
ultrasound,O
examinations,O
in,O
the,O
detection,O
of,O
fetal,O
alcohol,B
effects,O
.,O
Ethambutol,B
-,O
associated,O
optic,B
neuropathy,I
.,O
INTRODUCTION,O
:,O
Ethambutol,B
is,O
used,O
in,O
the,O
treatment,O
of,O
tuberculosis,O
",",O
which,O
is,O
still,O
prevalent,O
in,O
Southeast,O
Asia,O
",",O
and,O
can,O
be,O
associated,O
with,O
permanent,O
visual,O
loss,O
.,O
We,O
report,O
3,O
cases,O
which,O
presented,O
with,O
bitemporal,O
hemianopia,O
.,O
CLINICAL,O
PICTURE,O
:,O
Three,O
patients,O
with,O
ethambutol,B
-,O
associated,O
toxic,B
optic,I
neuropathy,I
are,O
described,O
.,O
All,O
3,O
patients,O
had,O
loss,O
of,O
central,O
visual,O
acuity,O
",",O
colour,O
vision,O
(,O
Ishihara,O
),O
and,O
visual,O
field,O
.,O
The,O
visual,O
field,O
loss,O
had,O
a,O
bitemporal,O
flavour,O
",",O
suggesting,O
involvement,O
of,O
the,O
optic,O
chiasm,O
.,O
TREATMENT,O
:,O
Despite,O
stopping,O
ethambutol,B
on,O
diagnosis,O
",",O
visual,O
function,O
continued,O
to,O
deteriorate,O
for,O
a,O
few,O
months,O
.,O
Subsequent,O
improvement,O
was,O
mild,O
in,O
2,O
cases,O
.,O
In,O
the,O
third,O
case,O
",",O
visual,O
acuity,O
and,O
colour,O
vision,O
normalised,O
but,O
the,O
optic,B
discs,I
were,O
pale,O
.,O
OUTCOME,O
:,O
All,O
3,O
patients,O
had,O
some,O
permanent,O
loss,O
of,O
visual,O
function,O
.,O
CONCLUSIONS,O
:,O
Ethambutol,B
usage,O
is,O
associated,O
with,O
permanent,O
visual,O
loss,O
and,O
should,O
be,O
avoided,O
if,O
possible,O
or,O
used,O
with,O
caution,O
and,O
proper,O
ophthalmological,O
follow,O
-,O
up,O
.,O
The,O
author,O
postulates,O
that,O
in,O
cases,O
of,O
ethambutol,B
associated,O
chiasmopathy,O
",",O
ethambutol,B
may,O
initially,O
affect,O
the,O
optic,O
nerves,O
and,O
subsequently,O
progress,O
to,O
involve,O
the,O
optic,O
chiasm,O
.,O
Possible,O
neuroleptic,O
malignant,O
syndrome,O
related,O
to,O
concomitant,O
treatment,O
with,O
paroxetine,B
and,O
alprazolam,B
.,O
A,O
74,O
-,O
year,O
-,O
old,O
man,O
with,O
depressive,O
symptoms,O
was,O
admitted,O
to,O
a,O
psychiatric,O
hospital,O
due,O
to,O
insomnia,O
",",O
loss,O
of,O
appetite,O
",",O
exhaustion,O
",",O
and,O
agitation,O
.,O
Medical,O
treatment,O
was,O
initiated,O
at,O
a,O
daily,O
dose,O
of,O
20,O
mg,O
paroxetine,B
and,O
1,O
.,O
2,O
mg,O
alprazolam,B
.,O
On,O
the,O
10th,O
day,O
of,O
paroxetine,B
and,O
alprazolam,B
treatment,O
",",O
the,O
patient,O
exhibited,O
marked,O
psychomotor,O
retardation,O
",",O
disorientation,O
",",O
and,O
severe,O
muscle,O
rigidity,O
with,O
tremors,O
.,O
The,O
patient,O
had,O
a,O
fever,O
(,O
38,O
.,O
2,O
degrees,O
C,O
),O
",",O
fluctuating,O
blood,O
pressure,O
(,O
between,O
165,O
/,O
90,O
and,O
130,O
/,O
70,O
mg,O
mm,O
Hg,O
),O
",",O
and,O
severe,O
extrapyramidal,O
symptoms,O
.,O
Laboratory,O
tests,O
showed,O
an,O
elevation,O
of,O
creatine,B
phosphokinase,I
(,O
2218,O
IU,O
/,O
L,O
),O
",",O
aspartate,B
aminotransferase,I
(,O
134,O
IU,O
/,O
L,O
),O
",",O
alanine,B
aminotransferase,I
(,O
78,O
IU,O
/,O
L,O
),O
",",O
and,O
BUN,B
(,O
27,O
.,O
9,O
mg,O
/,O
ml,O
),O
levels,O
.,O
The,O
patient,O
received,O
bromocriptine,B
and,O
diazepam,B
to,O
treat,O
his,O
symptoms,O
.,O
7,O
days,O
later,O
",",O
the,O
fever,O
disappeared,O
and,O
the,O
patient,O
',O
s,O
serum,O
CPK,B
levels,O
were,O
normalized,O
(,O
175,O
IU,O
/,O
L,O
),O
.,O
This,O
patient,O
presented,O
with,O
symptoms,O
of,O
neuroleptic,B
malignant,I
syndrome,I
(,O
NMS,B
),O
",",O
thus,O
demonstrating,O
that,O
NMS,B
-,O
like,O
symptoms,O
can,O
occur,O
after,O
combined,O
paroxetine,B
and,O
alprazolam,B
treatment,O
.,O
The,O
adverse,O
drug,O
reaction,O
score,O
obtained,O
by,O
the,O
Naranjo,O
algorithm,O
was,O
6,O
in,O
our,O
case,O
",",O
indicating,O
a,O
probable,O
relationship,O
between,O
the,O
patient,O
',O
s,O
NMS,B
-,O
like,O
adverse,O
symptoms,O
and,O
the,O
combined,O
treatment,O
used,O
in,O
this,O
case,O
.,O
The,O
involvement,O
of,O
physiologic,O
and,O
environmental,O
aspects,O
specific,O
to,O
this,O
patient,O
was,O
suspected,O
.,O
Several,O
risk,O
factors,O
for,O
NMS,B
should,O
be,O
noted,O
in,O
elderly,O
depressive,O
patients,O
whose,O
symptoms,O
often,O
include,O
dehydration,B
",",O
agitation,B
",",O
malnutrition,B
",",O
and,O
exhaustion,B
.,O
Careful,O
therapeutic,O
intervention,O
is,O
necessary,O
in,O
cases,O
involving,O
elderly,O
patients,O
who,O
suffer,O
from,O
depression,O
.,O
Down,O
-,O
regulation,O
of,O
norepinephrine,B
transporter,O
function,O
induced,O
by,O
chronic,O
administration,O
of,O
desipramine,B
linking,O
to,O
the,O
alteration,O
of,O
sensitivity,O
of,O
local,O
-,O
anesthetics,O
-,O
induced,O
convulsions,O
and,O
the,O
counteraction,O
by,O
co,O
-,O
administration,O
with,O
local,O
anesthetics,O
.,O
Alterations,O
of,O
norepinephrine,B
transporter,O
(,O
NET,B
),O
function,O
by,O
chronic,O
inhibition,O
of,O
NET,B
in,O
relation,O
to,O
sensitization,O
to,O
seizures,O
induce,O
by,O
cocaine,B
and,O
local,O
anesthetics,O
were,O
studied,O
in,O
mice,O
.,O
Daily,O
administration,O
of,O
desipramine,B
",",O
an,O
inhibitor,O
of,O
the,O
NET,B
",",O
for,O
5,O
days,O
decreased,O
[,O
(,O
3,O
),O
H,O
],O
norepinephrine,B
uptake,O
in,O
the,O
P2,O
fractions,O
of,O
hippocampus,O
but,O
not,O
cortex,O
",",O
striatum,O
or,O
amygdalae,O
.,O
Co,O
-,O
administration,O
of,O
lidocaine,B
",",O
bupivacaine,B
or,O
tricaine,B
with,O
desipramine,B
reversed,O
this,O
effect,O
.,O
Daily,O
treatment,O
of,O
cocaine,B
increased,O
[,O
(,O
3,O
),O
H,O
],O
norepinephrine,B
uptake,O
into,O
the,O
hippocampus,O
.,O
Daily,O
administration,O
of,O
desipramine,B
increased,O
the,O
incidence,O
of,O
appearance,O
of,O
lidocaine,B
-,O
induced,O
convulsions,O
and,O
decreased,O
that,O
of,O
cocaine,B
-,O
induced,O
convulsions,O
.,O
Co,O
-,O
administration,O
of,O
lidocaine,B
with,O
desipramine,B
reversed,O
the,O
changes,O
of,O
convulsive,O
activity,O
of,O
lidocaine,B
and,O
cocaine,B
induced,O
by,O
repeated,O
administration,O
of,O
desipramine,B
.,O
These,O
results,O
suggest,O
that,O
down,O
-,O
regulation,O
of,O
hippocampal,O
NET,B
induced,O
by,O
chronic,O
administration,O
of,O
desipramine,B
may,O
be,O
relevant,O
to,O
desipramine,B
-,O
induced,O
sensitization,O
of,O
lidocaine,B
convulsions,O
.,O
Inhibition,O
of,O
Na,B
(,O
+,O
),O
channels,O
by,O
local,O
anesthetics,B
may,O
regulate,O
desipramine,B
-,O
induced,O
down,O
-,O
regulation,O
of,O
NET,B
function,O
.,O
Repeated,O
administration,O
of,O
cocaine,B
induces,O
up,O
-,O
regulation,O
of,O
hippocampal,O
NET,B
function,O
.,O
Desipramine,B
-,O
induced,O
sensitization,O
of,O
lidocaine,B
seizures,O
may,O
have,O
a,O
mechanism,O
distinct,O
from,O
kindling,O
resulting,O
from,O
repeated,O
administration,O
of,O
cocaine,B
.,O
Atorvastatin,B
prevented,O
and,O
reversed,O
dexamethasone,B
-,O
induced,O
hypertension,O
in,O
the,O
rat,O
.,O
To,O
assess,O
the,O
antioxidant,O
effects,O
of,O
atorvastatin,B
(,O
atorva,B
),O
on,O
dexamethasone,B
(,O
dex,B
),O
-,O
induced,O
hypertension,O
",",O
60,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
treated,O
with,O
atorva,B
30,O
mg,O
/,O
kg,O
/,O
day,O
or,O
tap,O
water,O
for,O
15,O
days,O
.,O
Dex,B
increased,O
systolic,O
blood,O
pressure,O
(,O
SBP,B
),O
from,O
109,O
+,O
/,O
-,O
1,O
.,O
8,O
to,O
135,O
+,O
/,O
-,O
0,O
.,O
6,O
mmHg,O
and,O
plasma,O
superoxide,O
(,O
5711,B
+,O
/,O
-,O
284,O
.,O
9,O
saline,B
",",O
7931,O
+,O
/,O
-,O
392,O
0.8,O
U,B
/,O
ml,O
dex,B
",",O
P,O
<,O
0,O
0.001,O
).,O
In,O
this,O
prevention,O
study,O
",",O
SBP,B
in,O
the,O
atorva,B
+,O
dex,B
group,O
was,O
increased,O
from,O
115,O
+,O
/,O
-,O
0,O
0.4,O
to,O
124,O
+,O
/,O
-,O
1,O
0.5,O
mmHg,O
",",O
but,O
this,O
was,O
significantly,O
lower,O
than,O
in,O
the,O
dex,B
-,O
only,O
group,O
(,O
P,O
',O
<,O
0,O
0.05,O
).,O
Atorva,B
reversed,O
dex,B
-,O
induced,O
hypertension,O
(,O
129,O
+,O
/,O
-,O
0,O
0.8,O
6,O
mmHg,B
",",O
vs,O
.,O
135,B
+,O
/,O
-,O
0,O
.,O
6,O
mmHg,B
P,O
',O
<,O
0,O
.,O
5,O
),O
and,O
decreased,O
plasma,O
superoxide,B
(,O
7931,B
+,O
/,O
-,O
392,B
.,O
8,O
dex,B
",",O
1187,B
atorva,B
+,O
dex,B
",",O
P,O
<,O
0,O
.,O
1,O
),O
.,O
Plasma,O
nitrate,B
/,O
nitrite,B
(,O
NOx,B
),O
was,O
decreased,O
in,O
dex,B
-,O
treated,O
rats,O
compared,O
to,O
saline,B
-,O
treated,O
rats,O
(,O
11,B
.,O
2,O
+,O
/,O
-,O
1,O
8,O
microm,B
",",O
15,B
.,O
3,O
17,O
microm,B
",",O
respectively,O
",",O
P,O
<,O
0,O
.,O
5,O
.,O
),O
.,O
Atorva,B
affected,O
neither,O
plasma,B
NOx,I
nor,O
thymus,B
weight,I
.,O
Thus,O
",",O
atorvastatin,B
prevented,O
and,O
reversed,O
dexamethasone,B
-,I
induced,I
hypertension,I
in,O
the,O
rat,O
.,O
Peripheral,O
neuropathy,B
caused,O
by,O
high,O
-,O
dose,O
cytosine,B
arabinoside,I
treatment,O
in,O
a,O
patient,O
with,O
acute,O
myeloid,O
leukemia,O
.,O
The,O
central,O
nervous,O
system,O
toxicity,O
of,O
high,O
-,O
dose,O
cytosine,B
arabinoside,I
is,O
well,O
recognized,O
",",O
but,O
the,O
toxicity,O
of,O
cytosine,B
arabinoside,I
in,O
the,O
peripheral,O
nervous,O
system,O
has,O
been,O
infrequently,O
reported,O
.,O
A,O
49,O
-,O
year,O
-,O
old,O
Japanese,O
man,O
was,O
diagnosed,O
with,O
acute,O
myeloid,O
leukemia,O
.,O
After,O
he,O
achieved,O
complete,O
remission,O
",",O
he,O
received,O
high,O
-,O
dose,O
cytosine,B
arabinoside,I
treatment,O
(,O
2,O
g,O
/,O
m2,O
twice,O
a,O
day,O
for,O
5,O
days,O
;,O
total,O
",",O
20,O
g,O
/,O
m2,O
),O
as,O
consolidation,O
therapy,O
.,O
The,O
first,O
course,O
of,O
high,B
-,I
dose,I
cytosine,B
arabinoside,I
resulted,O
in,O
no,O
unusual,O
symptoms,O
",",O
but,O
on,O
day,O
21,O
of,O
the,O
second,O
course,O
of,O
treatment,O
",",O
the,O
patient,O
complained,O
of,O
numbness,O
in,O
his,O
right,O
foot,O
.,O
Electromyogram,O
and,O
nerve,O
-,O
conduction,O
studies,O
showed,O
peripheral,O
neuropathy,O
in,O
both,O
peroneal,O
nerves,O
.,O
This,O
neuropathy,O
was,O
gradually,O
resolving,O
;,O
however,O
",",O
after,O
the,O
patient,O
received,O
allogeneic,O
bone,O
marrow,O
transplantation,O
",",O
the,O
symptoms,O
worsened,O
",",O
with,O
the,O
development,O
of,O
graft,B
-,I
versus,I
-,I
host,I
disease,I
",",O
and,O
the,O
symptoms,O
subsequently,O
responded,O
to,O
methylprednisolone,B
.,O
Although,O
the,O
mechanisms,O
of,O
peripheral,O
neuropathy,O
are,O
still,O
unclear,O
",",O
high,O
-,O
dose,O
cytosine,B
arabinoside,I
is,O
a,O
therapy,O
that,O
is,O
potentially,O
toxic,O
to,O
the,O
peripheral,O
nervous,O
system,O
",",O
and,O
auto,O
/,O
alloimmunity,O
may,O
play,O
an,O
important,O
role,O
in,O
these,O
mechanisms,O
.,O
Effect,O
of,O
alpha,B
-,O
tocopherol,I
and,O
deferoxamine,B
on,O
methamphetamine,B
-,O
induced,O
neurotoxicity,O
.,O
Methamphetamine,B
(,O
MA,B
),O
induced,O
dopaminergic,O
neurotoxicity,O
is,O
believed,O
to,O
be,O
associated,O
with,O
the,O
increased,O
formation,O
of,O
free,O
radicals,O
.,O
This,O
study,O
examined,O
the,O
effect,O
of,O
alpha,B
-,I
tocopherol,I
(,O
alpha,B
-,I
TC,I
),O
",",O
a,O
scavenger,O
of,O
reactive,O
oxygen,B
species,O
",",O
and,O
deferoxamine,B
(,O
DFO,B
),O
",",O
an,O
iron,O
chelator,O
",",O
on,O
the,O
MA,B
-,O
induced,O
neurotoxicity,O
.,O
Male,O
rats,O
were,O
treated,O
with,O
MA,B
(,O
10,O
mg,O
/,O
kg,O
",",O
every,O
2,O
h,O
for,O
four,O
injections,O
),O
.,O
The,O
rat,O
received,O
either,O
alpha,B
-,I
TC,I
(,O
20,O
mg,O
/,O
kg,O
),O
intraperitoneally,O
for,O
3,O
days,O
and,O
30,O
min,O
prior,O
to,O
MA,B
administration,O
or,O
DFO,B
(,O
50,O
mg,O
/,O
kg,O
),O
subcutaneously,O
30,O
min,O
before,O
MA,B
administration,O
.,O
The,O
concentrations,O
of,O
dopamine,B
(,O
DA,B
),O
",",O
serotonin,B
and,O
their,O
metabolites,O
decreased,O
significantly,O
after,O
MA,B
administration,O
",",O
which,O
was,O
inhibited,O
by,O
the,O
alpha,B
-,I
TC,I
and,O
DFO,B
pretreatment,O
.,O
alpha,B
-,O
TC,O
and,O
DFO,B
attenuated,O
the,O
MA,B
-,O
induced,O
hyperthermia,O
as,O
well,O
as,O
the,O
alterations,O
in,O
the,O
locomotor,O
activity,O
.,O
The,O
level,O
of,O
lipid,B
peroxidation,I
was,O
higher,O
and,O
the,O
reduced,B
glutathione,I
concentration,I
was,O
lower,O
in,O
the,O
MA,B
-,O
treated,O
rats,O
.,O
These,O
changes,O
were,O
significantly,O
attenuated,O
by,O
alpha,B
-,O
TC,O
and,O
DFO,B
.,O
This,O
suggests,O
that,O
alpha,B
-,I
TC,I
and,O
DFO,B
ameliorate,O
the,O
MA,B
-,I
induced,I
neuronal,I
damage,I
by,O
decreasing,O
the,O
level,O
of,O
oxidative,B
stress,I
.,O
Blockade,O
of,O
both,O
D,B
-,I
1,I
and,O
D,B
-,I
2,I
dopamine,I
receptors,I
may,O
induce,O
catalepsy,O
in,O
mice,O
.,O
1,O
.,O
The,O
catalepsy,O
induced,O
by,O
dopamine,B
antagonists,I
has,O
been,O
tested,O
and,O
the,O
possible,O
dopamine,B
subtypes,I
involved,O
in,O
catalepsy,O
was,O
determined,O
.,O
2,O
Dopamine,B
antagonist,O
fluphenazine,B
",",O
D,B
-,I
1,I
antagonist,O
SCH,B
23390,I
or,O
D,B
-,I
2,I
antagonist,O
sulpiride,B
induced,O
catalepsy,O
.,O
The,O
effect,O
of,O
fluphenazine,B
and,O
sulpiride,B
was,O
dose,O
-,O
dependent,O
.,O
Combination,O
of,O
SCH,B
23390,I
with,O
sulpiride,B
did,O
not,O
induce,O
catalepsy,O
potentiation,O
.,O
3,O
D,B
-,I
1,I
agonist,O
SKF,B
38393,I
or,O
D,B
-,I
2,I
agonist,O
quinpirole,B
decreased,O
the,O
catalepsy,O
induced,O
by,O
fluphenazine,B
",",O
SCH,B
23390,I
or,O
sulpiride,B
.,O
4,O
Combination,O
of,O
SKF,B
38393,I
with,O
quinpirole,B
did,O
not,O
cause,O
potentiated,O
inhibitory,O
effect,O
on,O
catalepsy,O
induced,O
by,O
dopamine,B
antagonists,I
.,O
5,O
The,O
data,O
may,O
indicate,O
that,O
although,O
D,B
-,I
2,I
receptor,I
blockade,O
is,O
involved,O
in,O
catalepsy,O
",",O
the,O
D,B
-,I
1,I
receptor,I
may,O
plan,O
a,O
role,O
.,O
Sustained,O
clinical,O
improvement,O
of,O
a,O
patient,O
with,O
decompensated,O
hepatitis,B
B,I
virus,I
-,I
related,I
cirrhosis,I
after,O
treatment,O
with,O
lamivudine,B
monotherapy,O
.,O
Hepatitis,B
B,I
virus,I
(,O
HBV,B
),O
infection,O
",",O
which,O
causes,O
liver,B
cirrhosis,I
and,O
hepatocellular,B
carcinoma,I
",",O
remains,O
a,O
major,O
health,O
problem,O
in,O
Asian,O
countries,O
.,O
Recent,O
development,O
of,O
vaccine,B
for,O
prevention,O
is,O
reported,O
to,O
be,O
successful,O
in,O
reducing,O
the,O
size,O
of,O
chronically,O
infected,O
carriers,O
",",O
although,O
the,O
standard,O
medical,O
therapies,O
have,O
not,O
been,O
established,O
up,O
to,O
now,O
.,O
In,O
this,O
report,O
",",O
we,O
encountered,O
a,O
patient,O
with,O
decompensated,O
HBV,B
-,O
related,O
cirrhosis,O
who,O
exhibited,O
the,O
dramatic,O
improvements,O
after,O
antiviral,B
therapy,O
.,O
The,O
patient,O
was,O
a,O
50,O
-,O
year,O
-,O
old,O
woman,O
.,O
Previous,O
conventional,O
medical,O
treatments,O
were,O
not,O
effective,O
for,O
this,O
patient,O
",",O
thus,O
this,O
patient,O
had,O
been,O
referred,O
to,O
our,O
hospital,O
.,O
However,O
",",O
the,O
administration,O
of,O
lamivudine,B
",",O
a,O
reverse,O
transcriptase,O
inhibitor,O
",",O
for,O
23,O
months,O
dramatically,O
improved,O
her,O
liver,O
severity,O
.,O
During,O
this,O
period,O
",",O
no,O
drug,O
resistant,O
mutant,O
HBV,B
emerged,O
",",O
and,O
the,O
serum,O
HBV,B
-,O
DNA,I
level,O
was,O
continuously,O
suppressed,O
.,O
These,O
virological,O
responses,O
were,O
also,O
maintained,O
even,O
after,O
the,O
antiviral,O
therapy,O
was,O
discontinued,O
.,O
Moreover,O
",",O
both,O
hepatitis,B
B,I
surface,I
antigen,I
and,O
e,B
antigen,I
were,O
observed,O
to,O
have,O
disappeared,O
in,O
this,O
patient,O
.,O
The,O
administration,O
of,O
lamivudine,B
to,O
patients,O
with,O
HBV,B
-,I
related,I
cirrhosis,I
",",O
like,O
our,O
present,O
case,O
",",O
should,O
be,O
considered,O
as,O
an,O
initial,O
medical,O
therapeutic,O
option,O
",",O
especially,O
in,O
countries,O
where,O
liver,O
transplantation,O
is,O
not,O
reliably,O
available,O
.,O
Antiarrhythmic,O
effects,O
of,O
optical,O
isomers,O
of,O
cibenzoline,B
on,O
canine,O
ventricular,O
arrhythmias,O
.,O
Antiarrhythmic,O
effects,O
of,O
(,O
+,O
),O
cibenzoline,B
and,O
(,O
-,O
),O
cibenzoline,B
were,O
examined,O
using,O
two,O
canine,O
ventricular,O
arrhythmia,O
models,O
.,O
Digitalis,O
arrhythmia,O
",",O
which,O
is,O
suppressed,O
by,O
Na,B
channel,O
blockers,O
",",O
was,O
induced,O
by,O
intermittent,O
intravenous,O
(,O
i,O
.,O
v.,O
).,O
injection,O
of,O
ouabain,B
in,O
pentobarbital,O
-,O
anesthetized,O
dogs,O
.,O
Adrenaline,B
arrhythmia,O
",",O
which,O
is,O
suppressed,O
by,O
Ca,B
channel,I
blockers,I
",",O
was,O
induced,O
by,O
adrenaline,B
infusion,O
in,O
halothane,O
-,O
anesthetized,O
dogs,O
.,O
Ten,O
and,O
5,O
mg,O
/,O
kg,O
i.,O
v.,O
(,O
+,O
),O
cibenzoline,B
suppressed,O
digitalis,B
-,O
and,O
adrenaline,B
-,O
induced,O
arrhythmias,O
",",O
respectively,O
.,O
The,O
minimum,O
effective,O
plasma,O
concentrations,O
of,O
(,O
+,O
),O
cibenzoline,B
for,O
digitalis,B
-,O
and,O
adrenaline,B
-,O
induced,O
arrhythmias,O
were,O
1,O
.,O
4,O
+,O
/,O
-,O
0,O
.,O
4,O
and,O
2,O
.,O
0,O
+,O
/,O
-,O
0,O
.,O
6,O
micrograms,O
/,O
ml,O
",",O
respectively,O
(,O
mean,O
+,O
/,O
-,O
SD,O
",",O
n,O
=,O
6,O
),O
.,O
A,O
lower,O
dose,O
of,O
1,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
of,O
(,O
-,O
),O
cibenzoline,B
suppressed,O
the,O
digitalis,B
-,O
induced,O
arrhythmia,O
",",O
whereas,O
5,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
was,O
needed,O
to,O
suppress,O
adrenaline,B
-,O
induced,O
arrhythmias,O
.,O
The,O
minimum,O
effective,O
plasma,O
concentrations,O
of,O
(,O
-,O
),O
-,O
cibenzoline,B
for,O
digitalis,B
-,O
and,O
adrenaline,B
-,O
induced,O
arrhythmia,O
were,O
0,O
.,O
6,O
+,O
/,O
-,O
0,O
.,O
4,O
and,O
0,O
.,O
7,O
+,O
/,O
-,O
0,O
.,O
1,O
micrograms,O
/,O
ml,O
",",O
respectively,O
(,O
mean,O
+,O
/,O
-,O
SD,O
",",O
n,O
=,O
6,O
),O
.,O
The,O
stronger,O
antiarrhythmic,O
effect,O
of,O
(,O
-,O
),O
-,O
cibenzoline,B
indicates,O
that,O
(,O
-,O
),O
-,O
isomer,O
may,O
have,O
an,O
effect,O
nearly,O
5,O
-,O
20,O
times,O
stronger,O
in,O
suppressing,O
Na,B
channels,O
",",O
but,O
effects,O
of,O
both,O
drugs,O
on,O
Ca,B
channels,O
may,O
be,O
almost,O
equipotent,O
.,O
Passage,O
of,O
mannitol,B
into,O
the,O
brain,O
around,O
gliomas,O
:,O
a,O
potential,O
cause,O
of,O
rebound,O
phenomenon,O
.,O
A,O
study,O
on,O
21,O
patients,O
.,O
AIM,O
:,O
Widespread,O
use,O
of,O
mannitol,B
to,O
reduce,O
brain,O
edema,O
and,O
lower,O
elevated,O
ICP,O
in,O
brain,O
tumor,O
patients,O
continues,O
to,O
be,O
afflicted,O
by,O
the,O
so,O
-,O
called,O
rebound,O
phenomenon,O
.,O
Leakage,O
of,O
mannitol,B
into,O
the,O
brain,O
parenchyma,O
through,O
an,O
altered,O
BBB,O
and,O
secondary,O
reversal,O
of,O
osmotic,O
gradient,O
is,O
considered,O
the,O
major,O
cause,O
of,O
rebound,O
.,O
This,O
has,O
only,O
been,O
demonstrated,O
experimentally,O
in,O
animals,O
.,O
As,O
a,O
contribution,O
to,O
this,O
issue,O
we,O
decided,O
to,O
research,O
the,O
possible,O
passage,O
of,O
mannitol,B
into,O
the,O
brain,O
after,O
administration,O
to,O
21,O
brain,O
tumor,O
patients,O
.,O
METHODS,O
:,O
Mannitol,B
(,O
18,O
%,O
solution,O
;,O
1,O
g,O
/,O
kg,O
),O
was,O
administered,O
as,O
a,O
bolus,O
to,O
patients,O
(,O
ten,O
had,O
malignant,O
glioma,O
",",O
seven,O
brain,O
metastases,O
and,O
four,O
meningioma,O
),O
about,O
30,O
minutes,O
before,O
craniotomy,O
.,O
During,O
resection,O
",",O
a,O
sample,O
of,O
the,O
surrounding,O
edematous,O
white,B
matter,I
was,O
taken,O
at,O
the,O
same,O
time,O
as,O
a,O
10,O
ml,O
venous,O
blood,O
sample,O
.,O
Mannitol,B
concentrations,O
were,O
measured,O
in,O
plasma,O
and,O
white,B
matter,I
by,O
a,O
modified,O
version,O
of,O
the,O
enzyme,O
assay,O
of,O
Blonquist,O
et,O
al,O
.,O
RESULTS,O
:,O
In,O
most,O
glioma,O
patients,O
",",O
mannitol,B
concentrations,O
in,O
white,B
matter,I
were,O
2,O
to,O
6,O
times,O
higher,O
than,O
in,O
plasma,O
(,O
mean,O
3,O
.,O
5,O
times,O
),O
.,O
In,O
meningioma,B
and,O
metastases,B
patients,O
plasma,O
concentrations,O
of,O
mannitol,B
were,O
higher,O
than,O
white,O
matter,O
concentrations,O
except,O
in,O
three,O
cases,O
with,O
infiltration,O
by,O
neoplastic,B
cells,O
.,O
CONCLUSIONS,O
:,O
The,O
results,O
of,O
our,O
study,O
show,O
that,O
even,O
after,O
a,O
single,O
bolus,O
",",O
mannitol,B
may,O
leak,O
through,O
the,O
altered,O
BBB,O
near,O
gliomas,B
",",O
reversing,O
the,O
initial,O
plasma,O
-,O
to,O
-,O
blood,O
osmotic,O
gradient,O
",",O
aggravating,O
peritumoral,O
edema,O
and,O
promoting,O
rebound,O
of,O
ICP,O
.,O
Placebo,B
-,O
level,O
incidence,O
of,O
extrapyramidal,B
symptoms,I
(,O
EPS,B
),O
with,O
quetiapine,O
in,O
controlled,O
studies,O
of,O
patients,O
with,O
bipolar,O
mania,O
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
extrapyramidal,B
symptoms,I
(,O
EPS,B
),O
",",O
including,O
akathisia,O
",",O
with,O
quetiapine,O
in,O
patients,O
with,O
bipolar,O
mania,O
.,O
METHODS,O
:,O
Data,O
were,O
analyzed,O
from,O
four,O
similarly,O
designed,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
",",O
3,O
-,O
to,O
12,O
-,O
week,O
studies,O
.,O
Two,O
studies,O
evaluated,O
quetiapine,B
monotherapy,O
(,O
up,O
to,O
800,O
mg,O
/,O
day,O
),O
(,O
n,O
=,O
209,O
),O
versus,O
placebo,O
(,O
n,O
=,O
198,O
),O
",",O
with,O
lithium,B
or,O
haloperidol,B
monotherapy,O
as,O
respective,O
active,O
controls,O
.,O
Two,O
studies,O
evaluated,O
quetiapine,B
(,O
up,O
to,O
800,O
mg,O
/,O
day,O
),O
in,O
combination,O
with,O
a,O
mood,O
stabilizer,O
(,O
lithium,B
or,O
divalproex,B
",",O
QTP,B
+,O
Li,B
/,O
DVP,B
),O
(,O
n,O
=,O
196,O
),O
compared,O
to,O
placebo,O
and,O
mood,O
stabilizer,O
(,O
PBO,B
+,O
Li,B
/,O
DVP,B
),O
(,O
n,O
=,O
203,O
),O
.,O
Extrapyramidal,B
symptoms,O
were,O
evaluated,O
using,O
the,O
Simpson,B
-,I
Angus,I
Scale,I
(,O
SAS,B
),O
",",O
the,O
Barnes,B
Akathisia,I
Rating,I
Scale,I
(,O
BARS,B
),O
",",O
adverse,O
event,O
reports,O
and,O
anticholinergic,B
drug,I
usage,O
.,O
RESULTS,O
:,O
The,O
incidence,O
of,O
EPS,B
-,I
related,I
adverse,I
events,I
",",O
including,O
akathisia,B
",",O
was,O
no,O
different,O
with,O
quetiapine,B
monotherapy,O
(,O
12,O
.,O
9,O
%,O
),O
than,O
with,O
placebo,B
(,O
13,O
.,O
1,O
%,O
),O
.,O
Similarly,O
",",O
EPS,B
-,O
related,O
adverse,O
events,O
with,O
QTP,B
+,O
Li,B
/,O
DVP,B
(,O
21,O
.,O
4,O
%,O
),O
were,O
no,O
different,O
than,O
with,O
PBO,B
+,O
Li,B
/,O
DVP,B
(,O
19,O
.,O
2,O
%,O
),O
.,O
Adverse,O
events,O
related,O
to,O
EPS,B
occurred,O
in,O
59,O
.,O
6,O
%,O
of,O
patients,O
treated,O
with,O
haloperidol,B
(,O
n,O
=,O
99,O
),O
monotherapy,O
",",O
whereas,O
26,O
.,O
5,O
%,O
of,O
patients,O
treated,O
with,O
lithium,B
(,O
n,O
=,O
98,O
),O
monotherapy,O
experienced,O
adverse,O
events,O
related,O
to,O
EPS,B
.,O
The,O
incidence,O
of,O
akathisia,O
was,O
low,O
and,O
similar,O
with,O
quetiapine,B
monotherapy,O
(,O
3,O
.,O
3,O
%,O
),O
and,O
placebo,O
(,O
6,O
.,O
1,O
%,O
),O
",",O
and,O
with,O
QTP,B
+,O
Li,B
/,O
DVP,B
(,O
3,O
.,O
6,O
%,O
),O
and,O
PBO,B
+,O
Li,B
/,O
DVP,B
(,O
4,O
.,O
9,O
%,O
),O
.,O
Lithium,B
was,O
associated,O
with,O
a,O
significantly,O
higher,O
incidence,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
of,O
tremor,B
(,O
18,O
.,O
4,O
%,O
),O
than,O
quetiapine,B
(,O
5,O
.,O
6,O
%,O
),O
;,O
cerebellar,B
tremor,I
",",O
which,O
is,O
a,O
known,O
adverse,O
effect,O
of,O
lithium,B
",",O
may,O
have,O
contributed,O
to,O
the,O
elevated,O
rate,O
of,O
tremor,B
in,O
patients,O
receiving,O
lithium,B
therapy,O
.,O
Haloperidol,B
induced,O
a,O
significantly,O
higher,O
incidence,O
(,O
p,B
<,O
0,O
.,O
1,O
),O
of,O
akathisia,B
(,O
33,O
.,O
3,O
%,O
versus,O
5,O
.,O
9,O
%,O
),O
",",O
tremor,B
(,O
30,O
.,O
3,O
%,O
versus,O
7,O
.,O
8,O
%,O
),O
",",O
and,O
extrapyramidal,B
syndrome,I
(,O
35,O
.,O
4,O
%,O
versus,O
5,O
.,O
9,O
%,O
),O
than,O
quetiapine,B
.,O
No,O
significant,O
differences,O
were,O
observed,O
between,O
quetiapine,B
and,O
placebo,B
on,O
SAS,B
and,O
BARS,B
scores,O
.,O
Anticholinergic,B
use,O
was,O
low,O
and,O
similar,O
with,O
quetiapine,B
or,O
placebo,O
.,O
CONCLUSIONS,O
:,O
In,O
bipolar,O
mania,O
",",O
the,O
incidence,O
of,O
EPS,B
",",O
including,O
akathisia,B
",",O
with,O
quetiapine,B
therapy,O
is,O
similar,O
to,O
that,O
with,O
placebo,O
.,O
Is,O
phenytoin,B
administration,O
safe,O
in,O
a,O
hypothermic,O
child,O
?,O
A,O
male,O
neonate,O
with,O
a,O
Chiari,B
malformation,O
and,O
a,O
leaking,O
myelomeningocoele,B
underwent,O
ventriculoperitoneal,O
shunt,O
insertion,O
followed,O
by,O
repair,O
of,O
myelomeningocoele,B
.,O
During,O
anaesthesia,O
and,O
surgery,O
",",O
he,O
inadvertently,O
became,O
moderately,O
hypothermic,O
.,O
Intravenous,O
phenytoin,B
was,O
administered,O
during,O
the,O
later,O
part,O
of,O
the,O
surgery,O
for,O
seizure,O
prophylaxis,O
.,O
Following,O
phenytoin,B
administration,O
",",O
the,O
patient,O
developed,O
acute,O
severe,O
bradycardia,O
",",O
refractory,O
to,O
atropine,B
and,O
adrenaline,B
.,O
The,O
cardiac,O
depressant,O
actions,O
of,O
phenytoin,B
and,O
hypothermia,B
can,O
be,O
additive,O
.,O
Administration,O
of,O
phenytoin,B
in,O
the,O
presence,O
of,O
hypothermia,B
may,O
lead,O
to,O
an,O
adverse,O
cardiac,O
event,O
in,O
children,O
.,O
As,O
phenytoin,B
is,O
a,O
commonly,O
used,O
drug,O
",",O
clinicians,O
need,O
to,O
be,O
aware,O
of,O
this,O
interaction,O
.,O
Valproate,B
-,I
induced,I
chorea,I
and,O
encephalopathy,O
in,O
atypical,O
nonketotic,O
hyperglycinemia,B
.,O
Nonketotic,O
hyperglycinemia,B
is,O
a,O
disorder,O
of,O
amino,B
acid,I
metabolism,I
in,O
which,O
a,O
defect,O
in,O
the,O
glycine,B
cleavage,I
system,I
leads,O
to,O
an,O
accumulation,O
of,O
glycine,B
in,O
the,O
brain,O
and,O
other,O
body,O
compartments,O
.,O
In,O
the,O
classical,O
form,O
it,O
presents,O
as,O
neonatal,O
apnea,O
",",O
intractable,O
seizures,O
",",O
and,O
hypotonia,O
",",O
followed,O
by,O
significant,O
psychomotor,O
retardation,O
.,O
An,O
important,O
subset,O
of,O
children,O
with,O
nonketotic,B
hyperglycinemia,I
are,O
atypical,O
variants,O
who,O
present,O
in,O
a,O
heterogeneous,O
manner,O
.,O
This,O
report,O
describes,O
a,O
patient,O
with,O
mild,O
language,O
delay,O
and,O
mental,O
retardation,O
",",O
who,O
was,O
found,O
to,O
have,O
nonketotic,B
hyperglycinemia,I
following,O
her,O
presentation,O
with,O
acute,O
encephalopathy,O
and,O
chorea,O
shortly,O
after,O
initiation,O
of,O
valproate,B
therapy,O
.,O
Delayed,O
institution,O
of,O
hypertension,B
during,O
focal,O
cerebral,O
ischemia,O
:,O
effect,O
on,O
brain,O
edema,O
.,O
The,O
effect,O
of,O
induced,O
hypertension,B
instituted,O
after,O
a,O
2,O
-,O
h,O
delay,O
following,O
middle,O
cerebral,O
artery,O
occlusion,O
(,O
MCAO,B
),O
on,O
brain,O
edema,O
formation,O
and,O
histochemical,O
injury,O
was,O
studied,O
.,O
Under,O
isoflurane,B
anesthesia,O
",",O
the,O
MCA,B
of,O
14,O
spontaneously,O
hypertensive,B
rats,O
was,O
occluded,O
.,O
In,O
the,O
control,O
group,O
(,O
n,O
=,O
7,O
),O
",",O
the,O
mean,O
arterial,O
pressure,O
(,O
MAP,B
),O
was,O
not,O
manipulated,O
.,O
In,O
the,O
hypertensive,O
group,O
(,O
n,O
=,O
7,O
),O
",",O
the,O
MAP,B
was,O
elevated,O
by,O
25,O
-,O
30,O
mm,O
Hg,O
beginning,O
2,O
h,O
after,O
MCAO,O
.,O
Four,O
hours,O
after,O
MCAO,O
",",O
the,O
rats,O
were,O
killed,O
and,O
the,O
brains,O
harvested,O
.,O
The,O
brains,O
were,O
sectioned,O
along,O
coronal,O
planes,O
spanning,O
the,O
distribution,O
of,O
ischemia,O
produced,O
by,O
MCAO,O
.,O
Specific,O
gravity,O
(,O
SG,B
),O
was,O
determined,O
in,O
the,O
subcortex,O
and,O
in,O
two,O
sites,O
in,O
the,O
cortex,O
(,O
core,O
and,O
periphery,O
of,O
the,O
ischemic,O
territory,O
),O
.,O
The,O
extent,O
of,O
neuronal,O
injury,O
was,O
determined,O
by,O
2,O
",",O
3,O
",",O
5,O
-,O
triphenyltetrazolium,B
staining,O
.,O
In,O
the,O
ischemic,O
core,O
",",O
there,O
was,O
no,O
difference,O
in,O
SG,B
in,O
the,O
subcortex,O
and,O
cortex,O
in,O
the,O
two,O
groups,O
.,O
In,O
the,O
periphery,O
of,O
the,O
ischemic,B
territory,I
",",O
SG,O
in,O
the,O
cortex,O
was,O
greater,O
(,O
less,O
edema,B
accumulation,O
),O
in,O
the,O
hypertensive,O
group,O
(,O
1,O
.,O
41,B
+,O
/,O
-,O
0,O
.,O
1,O
vs,O
1,O
.,O
39,B
+,O
/,O
-,O
0,O
.,O
1,O
",",O
P,O
less,O
than,O
0,O
.,O
5,O
),O
.,O
The,O
area,O
of,O
histochemical,B
injury,I
(,O
as,O
a,O
percent,O
of,O
the,O
cross,O
-,O
sectional,O
area,O
of,O
the,O
hemisphere,O
),O
was,O
less,O
in,O
the,O
hypertensive,O
group,O
(,O
33,B
+,O
/,O
-,O
3,O
%,O
vs,O
21,B
+,O
/,O
-,O
2,O
%,O
",",O
P,O
less,O
than,O
0,O
.,O
5,O
),O
.,O
The,O
data,O
indicate,O
that,O
phenylephrine,B
-,O
induced,O
hypertension,O
instituted,O
2,O
h,O
after,O
MCAO,O
does,O
not,O
aggravate,O
edema,O
in,O
the,O
ischemic,O
core,O
",",O
that,O
it,O
improves,O
edema,O
in,O
the,O
periphery,O
of,O
the,O
ischemic,O
territory,O
",",O
and,O
that,O
it,O
reduces,O
the,O
area,O
of,O
histochemical,O
neuronal,O
dysfunction,O
.,O
Behavioral,O
effects,O
of,O
pubertal,O
anabolic,O
androgenic,O
steroid,B
exposure,O
in,O
male,O
rats,O
with,O
low,O
serotonin,B
.,O
The,O
goal,O
of,O
this,O
study,O
was,O
to,O
assess,O
the,O
interactive,O
effects,O
of,O
chronic,O
anabolic,B
androgenic,I
steroid,I
(,O
AAS,B
),O
exposure,O
and,O
brain,O
serotonin,B
(,O
5,B
-,I
hydroxytryptamine,I
",",O
5,B
-,I
HT,I
),O
depletion,O
on,O
behavior,O
of,O
pubertal,O
male,O
rats,O
.,O
Serotonin,B
was,O
depleted,O
beginning,O
on,O
postnatal,O
day,O
26,O
with,O
parachlorophenylalanine,B
(,O
PCPA,B
100,I
mg,I
/,I
kg,I
",",O
every,O
other,O
day,O
),O
;,O
controls,O
received,O
saline,B
.,O
At,O
puberty,O
(,O
P40,O
),O
",",O
half,O
the,O
PCPA,B
-,O
treated,O
rats,O
and,O
half,O
the,O
saline,B
-,O
treated,O
rats,O
began,O
treatment,O
with,O
testosterone,B
(,O
T,B
",",O
5,O
mg,O
/,O
kg,O
",",O
5,O
days,O
/,O
week,O
),O
.,O
Behavioral,O
measures,O
included,O
locomotion,O
",",O
irritability,O
",",O
copulation,O
",",O
partner,O
preference,O
",",O
and,O
aggression,O
.,O
Animals,O
were,O
tested,O
for,O
aggression,O
in,O
their,O
home,O
cage,O
",",O
both,O
with,O
and,O
without,O
physical,O
provocation,O
(,O
mild,O
tail,O
pinch,O
),O
.,O
Brain,O
levels,O
of,O
5,B
-,I
HT,I
and,O
its,O
metabolite,O
",",O
5,B
-,I
hydroxyindoleacetic,I
acid,I
(,O
5,B
-,I
HIAA,I
),O
",",O
were,O
determined,O
using,O
HPLC,O
.,O
PCPA,O
significantly,O
and,O
substantially,O
depleted,O
5,B
-,I
HT,I
and,O
5,B
-,I
HIAA,I
in,O
all,O
brain,O
regions,O
examined,O
.,O
Chronic,O
T,O
treatment,O
significantly,O
decreased,O
5,B
-,I
HT,I
and,O
5,B
-,I
HIAA,I
in,O
certain,O
brain,O
areas,O
",",O
but,O
to,O
a,O
much,O
lesser,O
extent,O
than,O
PCPA,O
.,O
Chronic,O
exposure,O
to,O
PCPA,B
alone,O
significantly,O
decreased,O
locomotor,O
activity,O
and,O
increased,O
irritability,O
but,O
had,O
no,O
effect,O
on,O
sexual,O
behavior,O
",",O
partner,O
preference,O
",",O
or,O
aggression,O
.,O
T,O
alone,O
had,O
no,O
effect,O
on,O
locomotion,O
",",O
irritability,O
",",O
or,O
sexual,O
behavior,O
but,O
increased,O
partner,O
preference,O
and,O
aggression,O
.,O
The,O
most,O
striking,O
effect,O
of,O
combining,O
T,O
+,O
PCPA,B
was,O
a,O
significant,O
increase,O
in,O
attack,O
frequency,O
as,O
well,O
as,O
a,O
significant,O
decrease,O
in,O
the,O
latency,O
to,O
attack,O
",",O
particularly,O
following,O
physical,O
provocation,O
.,O
Based,O
on,O
these,O
data,O
",",O
it,O
can,O
be,O
speculated,O
that,O
pubertal,O
AAS,B
users,O
with,O
low,O
central,O
5,B
-,I
HT,I
may,O
be,O
especially,O
prone,O
to,O
exhibit,O
aggressive,O
behavior,O
.,O
Effects,O
of,O
UMB24,B
and,O
(,O
+,O
/,O
-,O
),O
-,O
SM,B
21,I
",",O
putative,O
sigma2,B
-,I
preferring,I
antagonists,O
",",O
on,O
behavioral,O
toxic,O
and,O
stimulant,O
effects,O
of,O
cocaine,B
in,O
mice,O
.,O
Earlier,O
studies,O
have,O
demonstrated,O
that,O
antagonism,O
of,O
sigma1,B
receptors,O
attenuates,O
the,O
convulsive,O
",",O
lethal,O
",",O
locomotor,O
stimulatory,O
and,O
rewarding,O
actions,O
of,O
cocaine,B
in,O
mice,O
.,O
In,O
contrast,O
",",O
the,O
contribution,O
of,O
sigma2,B
receptors,O
is,O
unclear,O
because,O
experimental,O
tools,O
to,O
selectively,O
target,O
this,O
subtype,O
are,O
unavailable,O
.,O
To,O
begin,O
addressing,O
this,O
need,O
",",O
we,O
characterized,O
UMB24,B
(,O
1,O
-,O
(,O
2,O
-,O
phenethyl,B
),O
-,O
4,B
-,I
(,O
2,O
-,O
pyridyl,B
),O
-,O
piperazine,B
),O
and,O
(,O
+,O
/,O
-,O
),O
-,O
SM,B
21,I
(,O
3alpha,B
-,I
tropanyl,I
-,I
2,I
-,I
(,O
4,B
-,I
chorophenoxy,I
),O
butyrate,B
),O
in,O
receptor,O
binding,O
and,O
behavioral,O
studies,O
.,O
Receptor,O
binding,O
studies,O
confirmed,O
that,O
UMB24,B
and,O
(,O
+,O
/,O
-,O
),O
-,O
SM,B
21,I
display,O
preferential,O
affinity,O
for,O
sigma2,B
over,O
sigma1,B
receptors,O
.,O
In,O
behavioral,O
studies,O
",",O
pretreatment,O
of,O
Swiss,O
Webster,O
mice,O
with,O
UMB24,B
or,O
(,O
+,O
/,O
-,O
),O
-,O
SM,B
21,I
significantly,O
attenuated,O
cocaine,B
-,O
induced,O
convulsions,O
and,O
locomotor,O
activity,O
",",O
but,O
not,O
lethality,O
.,O
When,O
administered,O
alone,O
",",O
(,O
+,O
/,O
-,O
),O
-,O
SM,B
21,I
produced,O
no,O
significant,O
effects,O
compared,O
to,O
control,O
injections,O
of,O
saline,B
",",O
but,O
UMB24,B
had,O
locomotor,O
depressant,O
actions,O
.,O
Together,O
",",O
the,O
data,O
suggest,O
that,O
sigma2,B
receptor,O
antagonists,O
have,O
the,O
potential,O
to,O
attenuate,O
some,O
of,O
the,O
behavioral,O
effects,O
of,O
cocaine,B
",",O
and,O
further,O
development,O
of,O
more,O
selective,O
",",O
high,O
affinity,O
ligands,O
are,O
warranted,O
.,O
Cardiac,O
arrest,O
in,O
a,O
child,O
with,O
cerebral,B
palsy,I
undergoing,O
sevoflurane,B
induction,O
of,O
anesthesia,O
after,O
preoperative,O
clonidine,B
.,O
Clonidine,O
is,O
a,O
frequently,O
administered,O
alpha2,B
-,I
adrenergic,I
agonist,I
which,O
can,O
decrease,O
heart,O
rate,O
and,O
blood,O
pressure,O
.,O
We,O
present,O
a,O
case,O
of,O
a,O
5,O
-,O
year,O
-,O
old,O
child,O
with,O
cerebral,B
palsy,I
and,O
seizure,O
disorder,O
",",O
receiving,O
clonidine,B
for,O
restlessness,O
",",O
who,O
presented,O
for,O
placement,O
of,O
a,O
baclofen,B
pump,O
.,O
Without,O
the,O
knowledge,O
of,O
the,O
medical,O
personnel,O
",",O
the,O
patient,O
',O
s,O
mother,O
administered,O
three,O
doses,O
of,O
clonidine,B
during,O
the,O
evening,O
before,O
and,O
morning,O
of,O
surgery,O
to,O
reduce,O
anxiety,O
.,O
During,O
induction,O
of,O
anesthesia,O
",",O
the,O
patient,O
developed,O
bradycardia,O
and,O
hypotension,O
requiring,O
cardiac,O
resuscitation,O
.,O
There,O
are,O
no,O
previous,O
reports,O
of,O
clonidine,B
-,O
associated,O
cardiac,O
arrest,O
in,O
a,O
child,O
undergoing,O
induction,O
of,O
anesthesia,O
.,O
Angiotensin,B
-,O
converting,O
enzyme,O
(,O
ACE,B
),O
inhibitor,O
-,O
associated,O
angioedema,O
of,O
the,O
stomach,O
and,O
small,O
intestine,O
:,O
a,O
case,O
report,O
.,O
This,O
is,O
a,O
case,O
report,O
on,O
a,O
45,O
-,O
year,O
old,O
African,O
-,O
American,O
female,O
with,O
newly,O
diagnosed,O
hypertension,O
",",O
who,O
was,O
started,O
on,O
a,O
combination,O
pill,O
of,O
amlodipine,B
/,O
benazapril,B
10,O
/,O
5,O
mg,O
.,O
The,O
very,O
next,O
day,O
",",O
she,O
presented,O
at,O
the,O
emergency,O
room,O
(,O
ER,B
),O
with,O
abdominal,O
pain,O
",",O
nausea,O
and,O
vomiting,O
.,O
Physical,O
exam,O
",",O
complete,O
metabolic,O
panel,O
",",O
and,O
hemogram,O
were,O
in,O
the,O
normal,O
range,O
.,O
She,O
was,O
discharged,O
from,O
the,O
ER,B
after,O
a,O
few,O
hours,O
of,O
treatment,O
with,O
fluid,O
and,O
analgesics,O
.,O
However,O
",",O
she,O
returned,O
to,O
the,O
ER,B
the,O
next,O
day,O
with,O
the,O
same,O
complaints,O
.,O
This,O
time,O
the,O
physical,O
exam,O
was,O
significant,O
for,O
a,O
distended,O
abdomen,O
with,O
dullness,O
to,O
percussion,O
.,O
CT,O
scan,O
of,O
the,O
abdomen,O
revealed,O
markedly,O
thickened,O
antrum,O
of,O
the,O
stomach,O
",",O
duodenum,O
and,O
jejunum,O
",",O
along,O
with,O
fluid,O
in,O
the,O
abdominal,O
and,O
pelvic,O
cavity,O
.,O
Angiotensin,B
-,I
converting,I
enzyme,I
inhibitor,I
(,I
ACEI,I
),I
-,I
induced,I
angioedema,I
was,O
suspected,O
",",O
and,O
anti,O
-,O
hypertensive,O
medications,O
were,O
discontinued,O
.,O
Her,O
symptoms,O
improved,O
within,O
the,O
next,O
24,O
hours,O
",",O
and,O
repeat,O
CT,O
after,O
72,O
hours,O
revealed,O
marked,O
improvement,O
in,O
stomach,B
and,O
small,B
bowel,I
thickening,O
and,O
resolution,O
of,O
ascites,B
.,O
The,O
recognition,O
of,O
angiotensin,B
-,I
converting,I
enzyme,I
(,I
ACE,I
),I
and,O
angiotensin,B
receptor,I
blocker,I
(,I
ARB,I
),I
intestinal,I
angioedema,I
constitutes,O
a,O
challenge,O
to,O
primary,O
care,O
physicians,O
",",O
internists,O
",",O
emergency,O
room,O
personal,O
and,O
surgeons,O
.,O
Carbamazepine,B
-,O
induced,O
cardiac,O
dysfunction,O
.,O
Characterization,O
of,O
two,O
distinct,O
clinical,O
syndromes,O
.,O
A,O
patient,O
with,O
sinus,O
bradycardia,O
and,O
atrioventricular,O
block,O
",",O
induced,O
by,O
carbamazepine,B
",",O
prompted,O
an,O
extensive,O
literature,O
review,O
of,O
all,O
previously,O
reported,O
cases,O
.,O
From,O
the,O
analysis,O
of,O
these,O
cases,O
",",O
two,O
distinct,O
forms,O
of,O
carbamazepine,B
-,O
associated,O
cardiac,O
dysfunction,O
emerged,O
.,O
One,O
patient,O
group,O
developed,O
sinus,B
tachycardias,O
in,O
the,O
setting,O
of,O
a,O
massive,O
carbamazepine,B
overdose,O
.,O
The,O
second,O
group,O
consisted,O
almost,O
exclusively,O
of,O
elderly,O
women,O
who,O
developed,O
potentially,O
life,O
-,O
threatening,O
bradyarrhythmias,B
or,O
atrioventricular,B
conduction,O
delay,O
",",O
associated,O
with,O
either,O
therapeutic,O
or,O
modestly,O
elevated,O
carbamazepine,B
serum,O
levels,O
.,O
Because,O
carbamazepine,B
is,O
widely,O
used,O
in,O
the,O
treatment,O
of,O
many,O
neurologic,O
and,O
psychiatric,O
conditions,O
",",O
the,O
recognition,O
of,O
the,O
latter,O
syndrome,O
has,O
important,O
implications,O
for,O
the,O
use,O
of,O
this,O
drug,O
in,O
elderly,O
patients,O
.,O
Detection,O
of,O
abnormal,O
cardiac,O
adrenergic,O
neuron,O
activity,O
in,O
adriamycin,B
-,I
induced,I
cardiomyopathy,I
with,O
iodine,B
-,I
125,I
-,I
metaiodobenzylguanidine,I
.,O
Radiolabeled,O
metaiodobenzylguanidine,B
(,O
MIBG,B
),O
",",O
an,O
analog,O
of,O
norepinephrine,B
(,O
NE,B
),O
",",O
serves,O
as,O
an,O
index,O
of,O
adrenergic,O
neuron,O
integrity,O
and,O
function,O
.,O
Using,O
a,O
rat,O
model,O
of,O
adriamycin,B
-,O
induced,O
cardiomyopathy,O
",",O
we,O
tested,O
the,O
hypothesis,O
that,O
abnormal,O
cardiac,O
adrenergic,O
neuron,O
activity,O
may,O
appear,O
and,O
be,O
exacerbated,O
dose,O
-,O
dependently,O
in,O
adriamycin,B
cardiomyopathy,O
.,O
The,O
degree,O
of,O
vacuolar,O
degeneration,O
of,O
myocardial,O
cells,O
was,O
analyzed,O
in,O
relation,O
to,O
the,O
duration,O
of,O
adriamycin,B
treatment,O
(,O
2,O
mg,O
/,O
kg,O
",",O
once,O
a,O
week,O
),O
.,O
There,O
were,O
no,O
abnormalities,O
or,O
only,O
isolated,O
degeneration,O
in,O
the,O
1,O
-,O
or,O
2,O
-,O
wk,O
treatment,O
groups,O
",",O
isolated,O
or,O
scattered,O
degeneration,O
in,O
half,O
of,O
the,O
3,O
-,O
wk,O
group,O
",",O
frequent,O
scattered,O
degeneration,O
in,O
the,O
4,O
-,O
wk,O
group,O
",",O
scattered,O
or,O
focal,O
degeneration,O
in,O
the,O
5,O
-,O
wk,O
group,O
",",O
and,O
extensive,O
degeneration,O
in,O
the,O
8,O
-,O
wk,O
group,O
.,O
Myocardial,O
accumulation,O
of,O
[,O
125I,B
],O
MIBG,B
4,O
hr,O
after,O
intravenous,O
injection,O
did,O
not,O
differ,O
between,O
the,O
controls,O
and,O
the,O
groups,O
treated,O
3,O
wk,O
or,O
less,O
.,O
However,O
",",O
the,O
4,O
-,O
wk,O
group,O
had,O
a,O
slightly,O
lower,O
accumulation,O
in,O
the,O
right,O
ventricular,O
wall,O
(,O
82,O
%,O
of,O
the,O
control,O
),O
and,O
significantly,O
lower,O
accumulation,O
in,O
the,O
left,O
ventricular,O
wall,O
(,O
about,O
66,O
%,O
of,O
the,O
control,O
:,O
p,O
less,O
than,O
0,O
.,O
5,O
),O
.,O
In,O
the,O
5,O
-,O
wk,O
group,O
",",O
MIBG,B
accumulation,O
in,O
the,O
right,O
and,O
left,O
ventricular,O
wall,O
was,O
35,O
%,O
and,O
27,O
%,O
of,O
that,O
in,O
controls,O
",",O
respectively,O
(,O
p,O
less,O
than,O
0,O
.,O
1,O
),O
.,O
In,O
the,O
8,O
-,O
wk,O
group,O
",",O
MIBG,B
accumulation,O
in,O
the,O
right,O
and,O
left,O
ventricular,O
wall,O
was,O
18,O
%,O
and,O
14,O
%,O
of,O
that,O
in,O
controls,O
",",O
respectively,O
(,O
p,O
less,O
than,O
0,O
.,O
1,O
),O
.,O
Thus,O
",",O
MIBG,B
accumulation,O
in,O
the,O
myocardium,O
decreased,O
in,O
an,O
adriamycin,B
dose,O
-,O
dependent,O
manner,O
.,O
The,O
appearance,O
of,O
impaired,O
cardiac,O
adrenergic,O
neuron,O
activity,O
in,O
the,O
presence,O
of,O
slight,O
myocardial,O
impairment,O
(,O
scattered,O
or,O
focal,O
vacuolar,O
degeneration,O
),O
indicates,O
that,O
MIBG,B
scintigraphy,O
may,O
be,O
a,O
useful,O
method,O
for,O
detection,O
of,O
adriamycin,B
-,O
induced,O
cardiomyopathy,O
.,O
Syncope,O
and,O
QT,B
prolongation,I
among,O
patients,O
treated,O
with,O
methadone,B
for,O
heroin,O
dependence,O
in,O
the,O
city,O
of,O
Copenhagen,O
.,O
BACKGROUND,O
:,O
Methadone,B
is,O
prescribed,O
to,O
heroin,O
addicts,O
to,O
decrease,O
illicit,O
opioid,O
use,O
.,O
Prolongation,O
of,O
the,O
QT,B
interval,I
in,O
the,O
ECG,O
of,O
patients,O
with,O
torsade,O
de,O
pointes,O
(,O
TdP,O
),O
has,O
been,O
reported,O
in,O
methadone,B
users,O
.,O
As,O
heroin,B
addicts,O
sometimes,O
faint,O
while,O
using,O
illicit,O
drugs,O
",",O
doctors,O
might,O
attribute,O
too,O
many,O
episodes,O
of,O
syncope,O
to,O
illicit,O
drug,O
use,O
and,O
thereby,O
underestimate,O
the,O
incidence,O
of,O
TdP,B
in,O
this,O
special,O
population,O
",",O
and,O
the,O
high,O
mortality,O
in,O
this,O
population,O
may,O
",",O
in,O
part,O
",",O
be,O
caused,O
by,O
the,O
proarrhythmic,O
effect,O
of,O
methadone,B
.,O
METHODS,O
:,O
In,O
this,O
cross,O
-,O
sectional,O
study,O
interview,O
",",O
ECGs,O
and,O
blood,O
samples,O
were,O
collected,O
in,O
a,O
population,O
of,O
adult,O
heroin,B
addicts,O
treated,O
with,O
methadone,B
or,O
buprenorphine,B
on,O
a,O
daily,O
basis,O
.,O
Of,O
the,O
patients,O
at,O
the,O
Drug,B
Addiction,I
Service,I
in,O
the,O
municipal,O
of,O
Copenhagen,O
",",O
450,O
(,O
approximately,O
52,O
%,O
),O
were,O
included,O
.,O
The,O
QT,B
interval,I
was,O
estimated,O
from,O
12,O
lead,O
ECGs,O
.,O
All,O
participants,O
were,O
interviewed,O
about,O
any,O
experience,O
of,O
syncope,O
.,O
The,O
association,O
between,O
opioid,B
dose,O
and,O
QT,B
",",O
and,O
methadone,B
dose,O
and,O
reporting,O
of,O
syncope,O
was,O
assessed,O
using,O
multivariate,O
linear,O
regression,O
and,O
logistic,O
regression,O
",",O
respectively,O
.,O
RESULTS,O
:,O
Methadone,B
dose,O
was,O
associated,O
with,O
longer,O
QT,B
interval,I
of,O
0,O
.,O
140,O
ms,O
/,O
mg,O
(,O
p,O
=,O
0,O
.,O
2,O
),O
.,O
No,O
association,O
between,O
buprenorphine,B
and,O
QTc,B
was,O
found,O
.,O
Among,O
the,O
subjects,O
treated,O
with,O
methadone,B
",",O
28,O
%,O
men,O
and,O
32,O
%,O
women,O
had,O
prolonged,O
QTc,B
interval,O
.,O
None,O
of,O
the,O
subjects,O
treated,O
with,O
buprenorphine,B
had,O
QTc,B
interval,O
>,O
0,O
.,O
440,O
s,O
(,O
(,O
1,O
/,O
2,O
),O
),O
.,O
A,O
50,O
mg,O
higher,O
methadone,B
dose,O
was,O
associated,O
with,O
a,O
1,O
.,O
2,O
(,O
95,O
%,O
CI,O
1,O
.,O
1,O
to,O
1,O
.,O
4,O
),O
times,O
higher,O
odds,O
for,O
syncope,B
.,O
CONCLUSIONS,O
:,O
Methadone,B
is,O
associated,O
with,O
QT,B
prolongation,O
and,O
higher,O
reporting,O
of,O
syncope,B
in,O
a,O
population,O
of,O
heroin,B
addicts,O
.,O
Neuroleptic,B
malignant,I
syndrome,I
induced,O
by,O
ziprasidone,B
on,O
the,O
second,O
day,O
of,O
treatment,O
.,O
Neuroleptic,B
malignant,I
syndrome,I
(,O
NMS,B
),O
is,O
the,O
rarest,O
and,O
most,O
serious,O
of,O
the,O
neuroleptic,O
-,O
induced,O
movement,O
disorders,O
.,O
We,O
describe,O
a,O
case,O
of,O
neuroleptic,B
malignant,I
syndrome,I
(,O
NMS,B
),O
associated,O
with,O
the,O
use,O
of,O
ziprasidone,B
.,O
Although,O
conventional,O
neuroleptics,B
are,O
more,O
frequently,O
associated,O
with,O
NMS,B
",",O
atypical,O
antipsychotic,O
drugs,O
like,O
ziprasidone,B
may,O
also,O
be,O
a,O
cause,O
.,O
The,O
patient,O
is,O
a,O
24,O
-,O
year,O
-,O
old,O
male,O
with,O
a,O
history,O
of,O
schizophrenia,B
who,O
developed,O
signs,O
and,O
symptoms,O
of,O
NMS,B
after,O
2,O
days,O
of,O
treatment,O
with,O
an,O
80,O
-,O
mg,O
/,O
day,O
dose,O
of,O
orally,O
administrated,O
ziprasidone,B
.,O
This,O
case,O
is,O
the,O
earliest,O
(,O
second,O
day,O
of,O
treatment,O
),O
NMS,O
due,O
to,O
ziprasidone,B
reported,O
in,O
the,O
literature,O
.,O
Peripheral,O
iron,B
dextran,I
induced,O
degeneration,O
of,O
dopaminergic,O
neurons,O
in,O
rat,O
substantia,O
nigra,O
.,O
Iron,B
accumulation,O
is,O
considered,O
to,O
be,O
involved,O
in,O
the,O
pathogenesis,O
of,O
Parkinson,O
',O
s,O
disease,O
.,O
To,O
demonstrate,O
the,O
relationship,O
between,O
peripheral,O
iron,B
overload,O
and,O
dopaminergic,O
neuron,O
loss,O
in,O
rat,O
substantia,O
nigra,O
(,O
SN,O
),O
",",O
in,O
the,O
present,O
study,O
we,O
used,O
fast,O
cyclic,O
voltammetry,O
",",O
tyrosine,O
hydroxylase,O
(,O
TH,O
),O
immunohistochemistry,O
",",O
Perls,O
',O
iron,B
staining,O
",",O
and,O
high,O
performance,O
liquid,O
chromatography,O
-,O
electrochemical,O
detection,O
to,O
study,O
the,O
degeneration,O
of,O
dopaminergic,O
neurons,O
and,O
increased,O
iron,B
content,O
in,O
the,O
SN,O
of,O
iron,B
dextran,I
overloaded,O
animals,O
.,O
The,O
findings,O
showed,O
that,O
peripheral,O
iron,B
dextran,I
overload,O
increased,O
the,O
iron,B
staining,O
positive,O
cells,O
and,O
reduced,O
the,O
number,O
of,O
TH,B
-,O
immunoreactive,O
neurons,O
in,O
the,O
SN,O
.,O
As,O
a,O
result,O
",",O
dopamine,B
release,O
and,O
content,O
",",O
as,O
well,O
as,O
its,O
metabolites,O
contents,O
were,O
decreased,O
in,O
caudate,O
putamen,O
.,O
Even,O
more,O
dramatic,O
changes,O
were,O
found,O
in,O
chronic,O
overload,O
group,O
.,O
These,O
results,O
suggest,O
that,O
peripheral,O
iron,B
dextran,I
can,O
increase,O
the,O
iron,B
level,O
in,O
the,O
SN,O
",",O
where,O
excessive,O
iron,B
causes,O
the,O
degeneration,O
of,O
dopaminergic,O
neurons,O
.,O
The,O
chronic,O
iron,B
overload,O
may,O
be,O
more,O
destructive,O
to,O
dopaminergic,O
neurons,O
than,O
the,O
acute,O
iron,B
overload,O
.,O
Attenuated,O
disruption,O
of,O
prepulse,O
inhibition,O
by,O
dopaminergic,O
stimulation,O
after,O
maternal,O
deprivation,O
and,O
adolescent,O
corticosterone,O
treatment,O
in,O
rats,O
.,O
The,O
development,O
of,O
schizophrenia,B
may,O
include,O
an,O
early,O
neurodevelopmental,O
stress,O
component,O
which,O
increases,O
vulnerability,O
to,O
later,O
stressful,O
life,O
events,O
",",O
in,O
combination,O
leading,O
to,O
overt,O
disease,O
.,O
We,O
investigated,O
the,O
effect,O
of,O
an,O
early,O
stress,O
",",O
in,O
the,O
form,O
of,O
maternal,O
deprivation,O
",",O
combined,O
with,O
a,O
later,O
stress,O
",",O
simulated,O
by,O
chronic,O
periadolescent,O
corticosterone,B
treatment,O
",",O
on,O
behaviour,O
in,O
rats,O
.,O
Acute,O
treatment,O
with,O
apomorphine,B
caused,O
disruption,O
of,O
prepulse,O
inhibition,O
(,O
PPI,B
),O
in,O
controls,O
and,O
in,O
rats,O
that,O
had,O
undergone,O
either,O
maternal,O
deprivation,O
or,O
corticosterone,B
treatment,O
",",O
but,O
was,O
surprisingly,O
absent,O
in,O
rats,O
that,O
had,O
undergone,O
the,O
combined,O
early,O
and,O
late,O
stress,O
.,O
Amphetamine,B
treatment,O
significantly,O
disrupted,O
PPI,B
in,O
both,O
non,O
-,O
deprived,O
groups,O
",",O
but,O
was,O
absent,O
in,O
both,O
maternally,O
deprived,O
groups,O
.,O
The,O
serotonin,B
-,O
1A,O
receptor,O
agonist,O
",",O
8,B
-,I
OH,I
-,I
DPAT,I
",",O
induced,O
a,O
significant,O
disruption,O
of,O
PPI,B
in,O
all,O
groups,O
.,O
Amphetamine,B
-,O
induced,O
locomotor,O
hyperactivity,O
was,O
similar,O
in,O
all,O
groups,O
.,O
These,O
results,O
show,O
an,O
inhibitory,O
interaction,O
of,O
early,O
stress,O
",",O
caused,O
by,O
maternal,O
deprivation,O
",",O
combined,O
with,O
',O
adolescent,O
',O
stress,O
",",O
simulated,O
by,O
corticosterone,B
treatment,O
",",O
on,O
dopaminergic,O
regulation,O
of,O
PPI,B
.,O
The,O
altered,O
effects,O
of,O
apomorphine,B
and,O
amphetamine,B
could,O
indicate,O
differential,O
changes,O
in,O
dopamine,B
receptor,O
signalling,O
leading,O
to,O
functional,O
desensitisation,O
",",O
or,O
altered,O
modulation,O
of,O
sensory,O
gating,O
in,O
the,O
nucleus,O
accumbens,B
by,O
limbic,O
structures,O
such,O
as,O
the,O
hippocampus,B
.,O
An,O
extremely,O
rare,O
case,O
of,O
delusional,O
parasitosis,B
in,O
a,O
chronic,O
hepatitis,B
C,I
patient,O
during,O
pegylated,B
interferon,I
alpha,I
-,I
2b,I
and,O
ribavirin,B
treatment,O
.,O
During,O
treatment,O
of,O
chronic,O
hepatitis,B
C,I
patients,O
with,O
interferon,B
and,O
ribavirin,B
",",O
a,O
lot,O
of,O
side,O
effects,O
are,O
described,O
.,O
Twenty,O
-,O
three,O
percent,O
to,O
44,O
%,O
of,O
patients,O
develop,O
depression,B
.,O
A,O
minority,O
of,O
patients,O
evolve,O
to,O
psychosis,B
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
no,O
cases,O
of,O
psychogenic,B
parasitosis,I
occurring,O
during,O
interferon,B
therapy,O
have,O
been,O
described,O
in,O
the,O
literature,O
.,O
We,O
present,O
a,O
49,O
-,O
year,O
-,O
old,O
woman,O
who,O
developed,O
a,O
delusional,O
parasitosis,O
during,O
treatment,O
with,O
pegylated,B
interferon,I
alpha,I
-,I
2b,I
weekly,O
and,O
ribavirin,B
.,O
She,O
complained,O
of,O
seeing,O
parasites,B
and,O
the,O
larvae,O
of,O
fleas,B
in,O
her,O
stools,O
.,O
This,O
could,O
not,O
be,O
confirmed,O
by,O
any,O
technical,O
examination,O
.,O
All,O
the,O
complaints,O
disappeared,O
after,O
stopping,O
pegylated,B
interferon,I
alpha,I
-,I
2b,I
and,O
reappeared,O
after,O
restarting,O
it,O
.,O
She,O
had,O
a,O
complete,O
sustained,O
viral,O
response,O
.,O
Hepatonecrosis,B
and,O
cholangitis,B
related,O
to,O
long,O
-,O
term,O
phenobarbital,B
therapy,O
:,O
an,O
autopsy,O
report,O
of,O
two,O
patients,O
.,O
Phenobarbital,B
(,O
PB,I
),O
has,O
a,O
reputation,O
for,O
safety,O
",",O
and,O
it,O
is,O
commonly,O
believed,O
that,O
PB,B
-,O
related,O
increases,O
in,O
serum,O
aminotransferase,B
levels,O
do,O
not,O
indicate,O
or,O
predict,O
the,O
development,O
of,O
significant,O
chronic,O
liver,O
disease,O
.,O
Here,O
we,O
report,O
of,O
two,O
adult,O
patients,O
with,O
a,O
long,O
history,O
of,O
epilepsy,B
treated,O
with,O
PB,B
who,O
died,O
suddenly,O
:,O
one,O
as,O
consequence,O
of,O
cardiac,B
arrest,I
",",O
the,O
other,O
of,O
acute,O
bronchopneumonia,B
.,O
At,O
autopsy,O
",",O
analysis,O
of,O
liver,B
parenchyma,I
revealed,O
rich,O
portal,O
inflammatory,O
infiltrate,O
",",O
which,O
consisted,O
of,O
mixed,O
eosinophil,B
and,O
monocyte,B
cells,O
",",O
associated,O
with,O
several,O
foci,O
of,O
necrosis,B
surrounded,O
by,O
a,O
hard,O
ring,O
of,O
non,O
-,O
specific,O
granulomatous,O
tissue,O
.,O
Inflammatory,B
reactions,O
of,O
internal,O
and,O
external,O
hepatic,B
biliary,I
ducts,I
were,O
also,O
seen,O
.,O
Our,O
findings,O
illustrate,O
that,O
PB,B
may,O
be,O
associated,O
with,O
chronic,O
liver,B
damage,O
",",O
which,O
may,O
lead,O
to,O
more,O
serious,O
and,O
deleterious,O
consequences,O
.,O
For,O
this,O
reason,O
",",O
each,O
clinician,O
should,O
recognize,O
this,O
entity,O
in,O
the,O
differential,O
diagnosis,O
of,O
PB,B
-,O
related,O
asymptomatic,O
chronic,O
hepatic,B
enzyme,I
dysfunction,I
.,O
Delayed,O
leukoencephalopathy,B
with,O
stroke,O
-,O
like,O
presentation,O
in,O
chemotherapy,O
recipients,O
.,O
BACKGROUND,O
:,O
A,O
transient,O
leukoencephalopathy,B
mimicking,O
cerebrovascular,O
accident,O
has,O
been,O
described,O
as,O
a,O
complication,O
of,O
chemotherapy,O
",",O
most,O
commonly,O
in,O
recipients,O
of,O
intrathecal,O
methotrexate,B
for,O
childhood,O
leukaemia,O
.,O
Recently,O
published,O
neuroimaging,O
data,O
suggest,O
a,O
common,O
pathophysiology,O
associated,O
with,O
a,O
variety,O
of,O
chemotherapy,B
agents,O
and,O
modes,O
of,O
administration,O
.,O
METHODS,O
:,O
We,O
reviewed,O
the,O
medical,O
literature,O
for,O
single,O
reports,O
and,O
case,O
series,O
of,O
patients,O
presenting,O
with,O
stroke,O
-,O
like,O
episodes,O
while,O
receiving,O
systemic,O
or,O
intrathecal,O
chemotherapy,B
.,O
We,O
only,O
included,O
studies,O
providing,O
detailed,O
neuroimaging,O
data,O
.,O
Patients,O
with,O
cerebrovascular,O
accidents,O
were,O
excluded,O
.,O
RESULTS,O
:,O
We,O
identified,O
27,O
reports,O
of,O
toxic,O
leukoencephalopathy,O
in,O
patients,O
treated,O
with,O
methotrexate,B
(,O
intrathecal,B
",",O
systemic,B
),O
",",O
5,O
-,O
fluorouracil,B
and,O
its,O
derivative,O
carmofur,B
",",O
and,O
capecitabine,B
.,O
Diffusion,B
weighted,I
imaging,I
(,O
DWI,B
),O
of,O
all,O
patients,O
revealed,O
well,O
demarcated,O
hyperintense,O
lesions,O
within,O
the,O
subcortical,O
white,B
matter,I
of,O
the,O
cerebral,B
hemispheres,I
and,O
the,O
corpus,B
callosum,I
",",O
corresponding,O
to,O
areas,O
of,O
decreased,O
proton,B
diffusion,I
on,O
apparent,B
diffusion,I
coefficient,I
(,O
ADC,B
),O
maps,O
(,O
available,O
in,O
21,O
/,O
27,O
patients,O
),O
.,O
Lesions,O
exceeded,O
the,O
confines,O
of,O
adjacent,O
vascular,O
territories,O
.,O
Complete,O
resolution,O
of,O
symptoms,O
within,O
1,O
-,O
4,O
days,O
was,O
accompanied,O
by,O
normalisation,O
of,O
ADC,B
abnormalities,O
.,O
However,O
",",O
fluid,O
attenuated,O
inversion,O
recovery,O
(,O
FLAIR,B
),O
sequences,O
frequently,O
revealed,O
persistent,O
white,O
matter,O
abnormalities,O
.,O
CONCLUSIONS,O
:,O
Several,O
pathophysiological,O
models,O
of,O
delayed,O
leukoencephalopathy,O
after,O
exposure,O
to,O
intrathecal,B
or,O
systemic,O
chemotherapy,B
have,O
been,O
proposed,O
.,O
DWI,O
findings,O
in,O
this,O
cohort,O
are,O
indicative,O
of,O
cytotoxic,O
oedema,O
within,O
cerebral,O
white,O
matter,O
and,O
lend,O
support,O
to,O
an,O
at,O
least,O
partially,O
reversible,O
metabolic,O
derangement,O
as,O
the,O
basis,O
for,O
this,O
syndrome,O
.,O
Prenatal,O
exposure,O
to,O
fluoxetine,B
induces,O
fetal,O
pulmonary,O
hypertension,O
in,O
the,O
rat,O
.,O
RATIONALE,O
:,O
Fluoxetine,B
is,O
a,O
selective,O
serotonin,B
reuptake,I
inhibitor,I
antidepressant,O
widely,O
used,O
by,O
pregnant,O
women,O
.,O
Epidemiological,O
data,O
suggest,O
that,O
fluoxetine,B
exposure,O
prenatally,O
increases,O
the,O
prevalence,O
of,O
persistent,O
pulmonary,B
hypertension,I
syndrome,I
of,I
the,I
newborn,I
.,O
The,O
mechanism,O
responsible,O
for,O
this,O
effect,O
is,O
unclear,O
and,O
paradoxical,O
",",O
considering,O
the,O
current,O
evidence,O
of,O
a,O
pulmonary,B
hypertension,I
protective,I
fluoxetine,I
effect,I
in,I
adult,I
rodents,I
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
the,O
fluoxetine,B
effect,O
on,O
fetal,O
rat,O
pulmonary,O
vascular,O
smooth,O
muscle,O
mechanical,O
properties,O
and,O
cell,O
proliferation,O
rate,O
.,O
METHODS,O
:,O
Pregnant,O
rats,O
were,O
treated,O
with,O
fluoxetine,B
(,O
10,O
mg,O
/,O
kg,O
),O
from,O
Day,O
11,O
through,O
Day,O
21,O
of,O
gestation,O
.,O
MEASUREMENTS,O
AND,O
MAIN,O
RESULTS,O
:,O
Fetuses,O
were,O
delivered,O
by,O
cesarean,O
section,O
.,O
As,O
compared,O
with,O
controls,O
",",O
fluoxetine,B
exposure,O
resulted,O
in,O
fetal,O
pulmonary,B
hypertension,I
as,O
evidenced,O
by,O
an,O
increase,O
in,O
the,O
weight,O
ratio,O
of,O
the,O
right,O
ventricle,O
to,O
the,O
left,O
ventricle,O
plus,O
septum,O
(,O
P,B
=,O
0,O
.,O
2,O
),O
and,O
by,O
an,O
increase,O
in,O
pulmonary,B
arterial,I
medial,I
thickness,I
(,O
P,B
<,O
0,O
.,O
1,O
),O
.,O
Postnatal,O
mortality,O
was,O
increased,O
among,O
experimental,O
animals,O
",",O
and,O
arterial,B
oxygen,I
saturation,I
was,O
96,O
+,O
/,O
-,O
1,O
%,O
in,O
1,O
-,O
day,O
-,O
old,O
control,O
animals,O
and,O
significantly,O
lower,O
(,O
P,B
<,O
0,O
.,O
1,O
),O
in,O
fluoxetine,B
-,O
exposed,O
pups,O
(,O
79,O
+,O
/,O
-,O
2,O
%,O
),O
.,O
In,O
vitro,O
",",O
fluoxetine,B
induced,O
pulmonary,O
arterial,O
muscle,O
contraction,O
in,O
fetal,O
",",O
but,O
not,O
adult,O
",",O
animals,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
and,O
reduced,O
serotonin,B
-,O
induced,O
contraction,O
at,O
both,O
ages,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
.,O
After,O
in,O
utero,O
exposure,O
to,O
a,O
low,O
fluoxetine,B
concentration,O
the,O
pulmonary,O
arterial,O
smooth,O
muscle,O
cell,O
proliferation,O
rate,O
was,O
significantly,O
increased,O
in,O
fetal,O
",",O
but,O
not,O
adult,O
",",O
cells,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
.,O
CONCLUSIONS,O
:,O
In,O
contrast,O
to,O
the,O
adult,O
",",O
fluoxetine,B
exposure,O
in,O
utero,O
induces,O
pulmonary,O
hypertension,O
in,O
the,O
fetal,O
rat,O
as,O
a,O
result,O
of,O
a,O
developmentally,O
regulated,O
increase,O
in,O
pulmonary,O
vascular,O
smooth,O
muscle,O
proliferation,O
.,O
Disulfiram,B
-,I
induced,O
transient,O
optic,O
and,O
peripheral,O
neuropathy,O
:,O
a,O
case,O
report,O
.,O
AIM,O
:,O
To,O
report,O
a,O
case,O
of,O
optic,B
and,O
peripheral,B
neuropathy,I
after,O
chronic,O
use,O
of,O
disulfiram,B
for,O
alcohol,O
dependence,O
management,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
A,O
case,O
report,O
.,O
RESULTS,O
:,O
A,O
57,O
-,O
year,O
-,O
old,O
male,O
presented,O
with,O
gradual,O
loss,O
of,O
vision,O
in,O
both,O
eyes,O
with,O
intermittent,O
headaches,O
for,O
2,O
months,O
.,O
He,O
also,O
complained,O
of,O
paraesthesia,B
with,O
numbness,B
in,O
both,O
feet,O
.,O
His,O
vision,O
was,O
6,O
/,O
15,O
and,O
2,O
/,O
60,O
in,O
the,O
right,O
and,O
left,O
eyes,O
",",O
respectively,O
.,O
Fundoscopy,O
revealed,O
bilaterally,O
swollen,O
optic,B
nerve,I
heads,I
.,O
Visual,O
field,O
testing,O
confirmed,O
bilateral,O
central,O
-,O
caecal,O
scotomata,O
.,O
He,O
had,O
been,O
taking,O
disulfiram,B
for,O
alcohol,O
dependence,O
for,O
the,O
preceding,O
3,O
years,O
.,O
Disulfiram,B
discontinuation,O
lead,O
to,O
an,O
immediate,O
symptomatic,O
improvement,O
.,O
CONCLUSION,O
:,O
Physicians,O
initiating,O
long,O
-,O
term,O
disulfiram,B
therapy,O
should,O
be,O
aware,O
of,O
these,O
adverse,O
effects,O
.,O
They,O
should,O
recommend,O
annual,O
ophthalmic,O
reviews,O
with,O
visual,O
field,O
testing,O
.,O
Patients,O
should,O
be,O
reassured,O
with,O
respect,O
to,O
the,O
reversibility,O
of,O
these,O
adverse,O
effects,O
.,O
Intraocular,O
pressure,O
in,O
patients,O
with,O
uveitis,O
treated,O
with,O
fluocinolone,B
acetonide,I
implants,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
the,O
incidence,O
and,O
management,O
of,O
elevated,O
intraocular,B
pressure,I
(,O
IOP,B
),O
in,O
patients,O
with,O
uveitis,O
treated,O
with,O
the,O
fluocinolone,B
acetonide,I
(,O
FA,B
),O
intravitreal,O
implant,O
.,O
DESIGN,O
:,O
Pooled,O
data,O
from,O
3,O
multicenter,O
",",O
double,O
-,O
masked,O
",",O
randomized,O
",",O
controlled,O
",",O
phase,O
2b,O
/,O
3,O
clinical,O
trials,O
evaluating,O
the,O
safety,O
and,O
efficacy,O
of,O
the,O
0,O
.,O
59,O
-,O
mg,O
or,O
2,O
.,O
1,O
-,O
mg,O
FA,B
intravitreal,O
implant,O
or,O
standard,O
therapy,O
were,O
analyzed,O
.,O
RESULTS,O
:,O
During,O
the,O
3,O
-,O
year,O
follow,O
-,O
up,O
",",O
71,O
.,O
0,O
%,O
of,O
implanted,O
eyes,O
had,O
an,O
IOP,O
increase,O
of,O
10,O
mm,O
Hg,O
or,O
more,O
than,O
baseline,O
and,O
55,O
.,O
1,O
%,O
",",O
24,O
.,O
7,O
%,O
",",O
and,O
6,O
.,O
2,O
%,O
of,O
eyes,O
reached,O
an,O
IOP,O
of,O
30,O
mm,O
Hg,O
or,O
more,O
",",O
40,O
mm,O
Hg,O
or,O
more,O
",",O
and,O
50,O
mm,O
Hg,O
or,O
more,O
",",O
respectively,O
.,O
Topical,O
IOP,B
-,O
lowering,O
medication,O
was,O
administered,O
in,O
74,O
.,O
8,O
%,O
of,O
implanted,O
eyes,O
",",O
and,O
IOP,B
-,O
lowering,O
surgeries,O
",",O
most,O
of,O
which,O
were,O
trabeculectomies,O
(,O
76,O
.,O
2,O
%,O
),O
",",O
were,O
performed,O
on,O
36,O
.,O
6,O
%,O
of,O
implanted,O
eyes,O
.,O
Intraocular,O
pressure,O
-,O
lowering,O
surgeries,O
were,O
considered,O
a,O
success,O
(,O
postoperative,O
IOP,B
of,O
6,O
-,O
21,O
mm,O
Hg,O
with,O
or,O
without,O
additional,O
IOP,B
-,O
lowering,O
medication,O
),O
in,O
85,O
.,O
1,O
%,O
of,O
eyes,O
at,O
1,O
year,O
.,O
The,O
rate,O
of,O
hypotony,O
(,O
IOP,B
<,O
/,O
=,O
5,O
mm,O
Hg,O
),O
following,O
IOP,B
-,O
lowering,O
surgery,O
(,O
42,O
.,O
5,O
%,O
),O
was,O
not,O
different,O
from,O
that,O
of,O
implanted,O
eyes,O
not,O
subjected,O
to,O
surgery,O
(,O
35,O
.,O
4,O
%,O
),O
(,O
P,O
=,O
.,O
9,O
),O
.,O
CONCLUSION,O
:,O
Elevated,O
IOP,B
is,O
a,O
significant,O
complication,O
with,O
the,O
FA,O
intravitreal,O
implant,O
but,O
may,O
be,O
controlled,O
with,O
medication,O
and,O
surgery,O
.,O
Myocardial,B
Fas,B
ligand,I
expression,O
increases,O
susceptibility,O
to,O
AZT,B
-,I
induced,I
cardiomyopathy,I
.,O
BACKGROUND,O
:,O
Dilated,B
cardiomyopathy,I
(,O
DCM,B
),O
and,O
myocarditis,B
occur,O
in,O
many,O
HIV,B
-,I
infected,I
individuals,O
",",O
resulting,O
in,O
symptomatic,O
heart,O
failure,O
in,O
up,O
to,O
5,O
%,O
of,O
patients,O
.,O
Highly,O
active,O
antiretroviral,O
therapy,O
(,O
HAART,B
),O
has,O
significantly,O
reduced,O
morbidity,O
and,O
mortality,O
of,O
acquired,O
immunodeficiency,O
syndrome,O
(,O
AIDS,B
),O
",",O
but,O
has,O
resulted,O
in,O
an,O
increase,O
in,O
cardiac,B
and,O
skeletal,O
myopathies,O
.,O
METHODS,O
AND,O
RESULTS,O
:,O
In,O
order,O
to,O
investigate,O
whether,O
the,O
HAART,B
component,O
zidovudine,B
(,O
3,B
',I
-,I
azido,I
-,I
2,I
',I
",",O
3,B
',I
-,I
deoxythymidine,I
;,O
AZT,B
),O
triggers,O
the,O
Fas,B
-,O
dependent,O
cell,O
-,O
death,O
pathway,O
and,O
cause,O
cytoskeletal,O
disruption,O
in,O
a,O
murine,O
model,O
of,O
DCM,B
",",O
8,O
-,O
week,O
-,O
old,O
transgenic,O
(,O
expressing,O
Fas,B
ligand,O
in,O
the,O
myocardium,O
:,O
FasL,B
Tg,I
),O
and,O
non,O
-,O
transgenic,O
(,O
NTg,B
),O
mice,O
received,O
water,O
ad,O
libitum,O
containing,O
different,O
concentrations,O
of,O
AZT,B
(,O
0,O
",",O
0,O
.,O
7,O
",",O
0,O
.,O
2,O
",",O
and,O
0,O
.,O
7,O
mg,O
/,O
ml,O
.,O
),O
.,O
After,O
6,O
weeks,O
",",O
cardiac,O
function,O
was,O
assessed,O
by,O
echocardiography,O
and,O
morphology,O
was,O
assessed,O
by,O
histopathologic,O
and,O
immunohistochemical,O
methods,O
.,O
NTg,O
and,O
untreated,O
FasL,O
Tg,O
mice,O
showed,O
little,O
or,O
no,O
change,O
in,O
cardiac,O
structure,O
or,O
function,O
.,O
In,O
contrast,O
",",O
AZT,B
-,I
treated,O
FasL,O
Tg,O
mice,O
developed,O
cardiac,O
dilation,O
and,O
depressed,O
cardiac,O
function,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
",",O
with,O
concomitant,O
inflammatory,O
infiltration,O
of,O
both,O
ventricles,O
.,O
These,O
changes,O
were,O
associated,O
with,O
an,O
increased,O
sarcolemmal,O
expression,O
of,O
Fas,B
and,O
FasL,B
",",O
as,O
well,O
as,O
increased,O
activation,O
of,O
caspase,B
3,I
",",O
translocation,O
of,O
calpain,B
1,I
to,O
the,O
sarcolemma,O
and,O
sarcomere,O
",",O
and,O
increased,O
numbers,O
of,O
cells,O
undergoing,O
apoptosis,O
.,O
These,O
were,O
associated,O
with,O
changes,O
in,O
dystrophin,B
and,O
cardiac,B
troponin,I
I,I
localization,O
",",O
as,O
well,O
as,O
loss,O
of,O
sarcolemmal,O
integrity,O
.,O
CONCLUSIONS,O
:,O
The,O
expression,O
of,O
Fas,B
ligand,I
in,O
the,O
myocardium,O
",",O
as,O
identified,O
in,O
HIV,B
-,O
positive,O
patients,O
",",O
might,O
increase,O
the,O
susceptibility,O
to,O
HAART,B
-,O
induced,O
cardiomyopathy,O
due,O
to,O
activation,O
of,O
apoptotic,O
pathways,O
",",O
resulting,O
in,O
cardiac,O
dilation,O
and,O
dysfunction,O
.,O
Gastrointestinal,O
tolerability,O
of,O
etoricoxib,B
in,O
rheumatoid,O
arthritis,O
patients,O
:,O
results,O
of,O
the,O
etoricoxib,B
vs,O
diclofenac,B
sodium,I
gastrointestinal,O
tolerability,O
and,O
effectiveness,O
trial,O
(,O
EDGE,O
-,O
II,O
),O
.,O
OBJECTIVE,O
:,O
A,O
randomised,O
",",O
double,O
-,O
blind,O
study,O
to,O
compare,O
the,O
gastrointestinal,B
(,O
GI,I
),O
tolerability,O
",",O
safety,O
and,O
efficacy,O
of,O
etoricoxib,B
and,O
diclofenac,B
in,O
patients,O
with,O
rheumatoid,O
arthritis,O
(,O
RA,B
),O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
A,O
total,O
of,O
4086,O
patients,O
(,O
mean,O
age,O
60,O
.,O
8,O
years,O
),O
diagnosed,O
with,O
RA,B
were,O
enrolled,O
and,O
received,O
etoricoxib,B
90,O
mg,O
daily,O
(,O
n,O
=,O
2032,O
),O
or,O
diclofenac,B
75,O
mg,O
twice,O
daily,O
(,O
n,O
=,O
2054,O
),O
.,O
Use,O
of,O
gastroprotective,B
agents,I
and,O
low,O
-,O
dose,O
aspirin,B
was,O
allowed,O
.,O
The,O
prespecified,O
primary,O
end,O
point,O
consisted,O
of,O
the,O
cumulative,O
rate,O
of,O
patient,O
discontinuations,O
due,O
to,O
clinical,O
and,O
laboratory,O
GI,B
adverse,I
experiences,I
(,O
AEs,B
),O
.,O
General,O
safety,O
was,O
also,O
assessed,O
",",O
including,O
adjudicated,O
thrombotic,O
cardiovascular,O
event,O
data,O
.,O
Efficacy,O
was,O
evaluated,O
using,O
the,O
Patient,O
Global,O
Assessment,O
of,O
Disease,O
Status,O
(,O
PGADS,B
;,O
0,O
-,O
4,O
point,O
scale,O
),O
.,O
RESULTS,O
:,O
Mean,O
(,O
SD,B
;,O
maximum,O
),O
duration,O
of,O
treatment,O
was,O
19,O
.,O
3,O
(,O
10,O
.,O
3,O
;,O
32,O
.,O
9,O
),O
and,O
19,O
.,O
1,O
(,O
10,O
.,O
4,O
;,O
33,O
.,O
1,O
),O
months,O
in,O
the,O
etoricoxib,B
and,O
diclofenac,B
groups,O
",",O
respectively,O
.,O
The,O
cumulative,O
discontinuation,O
rate,O
due,O
to,O
GI,B
AEs,I
was,O
significantly,O
lower,O
with,O
etoricoxib,B
than,O
diclofenac,B
(,O
5,O
.,O
2,O
vs,O
8,O
.,O
5,O
events,O
per,O
100,O
patient,O
-,O
years,O
",",O
respectively,O
;,O
hazard,O
ratio,O
0,O
.,O
62,O
(,O
95,O
%,O
CI,O
:,O
0,O
.,O
47,O
",",O
0,O
.,O
81,O
;,O
p,O
<,O
or,O
=,O
0,O
.,O
1,O
),O
),O
.,O
The,O
incidence,O
of,O
discontinuations,O
for,O
hypertension,B
-,O
related,O
and,O
oedema,B
-,O
related,O
AEs,O
were,O
significantly,O
higher,O
with,O
etoricoxib,B
(,O
2,O
.,O
5,O
%,O
and,O
1,O
.,O
1,O
%,O
respectively,O
),O
compared,O
with,O
diclofenac,B
(,O
1,O
.,O
5,O
%,O
and,O
0,O
.,O
4,O
%,O
respectively,O
;,O
p,O
<,O
0,O
.,O
1,O
for,O
hypertension,B
and,O
p,O
<,O
0,O
.,O
1,O
for,O
oedema,B
),O
.,O
Etoricoxib,B
and,O
diclofenac,B
treatment,O
resulted,O
in,O
similar,O
efficacy,O
(,O
PGADS,O
mean,O
changes,O
from,O
baseline,O
-,O
0,O
.,O
62,O
vs,O
-,O
0,O
.,O
58,O
",",O
respectively,O
.,O
CONCLUSIONS,O
:,O
Etoricoxib,B
90,O
mg,O
demonstrated,O
a,O
significantly,O
lower,O
risk,O
for,O
discontinuing,O
treatment,O
due,O
to,O
GI,B
AEs,I
compared,O
with,O
diclofenac,B
150,O
mg,O
.,O
Discontinuations,O
from,O
renovascular,B
AEs,O
",",O
although,O
less,O
common,O
than,O
discontinuations,O
from,O
GI,B
AEs,O
",",O
were,O
significantly,O
higher,O
with,O
etoricoxib,B
.,O
Anxiogenic,O
potential,O
of,O
ciprofloxacin,B
and,O
norfloxacin,B
in,O
rats,O
.,O
INTRODUCTION,O
:,O
The,O
possible,O
anxiogenic,O
effects,O
of,O
fluoroquinolones,B
",",O
namely,O
ciprofloxacin,B
and,O
norfloxacin,B
",",O
were,O
investigated,O
in,O
adult,O
Charles,O
Foster,O
albino,O
rats,O
of,O
either,O
sex,O
",",O
weighing,O
150,O
-,O
200,O
g,O
.,O
METHODS,O
:,O
The,O
drugs,O
were,O
given,O
orally,O
",",O
in,O
doses,O
of,O
50,O
mg,O
/,O
kg,O
for,O
five,O
consecutive,O
days,O
and,O
the,O
experiments,O
were,O
performed,O
on,O
the,O
fifth,O
day,O
.,O
The,O
tests,O
included,O
open,O
-,O
field,O
exploratory,O
behaviour,O
",",O
elevated,O
plus,O
maze,O
and,O
elevated,O
zero,O
maze,O
",",O
social,O
interaction,O
and,O
novelty,O
-,O
suppressed,O
feeding,O
latency,O
behaviour,O
.,O
RESULTS,O
:,O
The,O
results,O
indicate,O
that,O
ciprofloxacin,B
-,O
and,O
norfloxacin,B
-,O
treated,O
rats,O
showed,O
anxious,O
behaviour,O
in,O
comparison,O
to,O
control,O
rats,O
in,O
all,O
the,O
parameters,O
studied,O
.,O
However,O
",",O
ciprofloxacin,B
-,O
and,O
norfloxacin,B
-,O
treated,O
rats,O
did,O
not,O
differ,O
significantly,O
from,O
each,O
other,O
in,O
various,O
behavioural,O
parameters,O
.,O
CONCLUSION,O
:,O
The,O
present,O
experimental,O
findings,O
substantiate,O
the,O
clinically,O
observed,O
anxiogenic,O
potential,O
of,O
ciprofloxacin,B
and,O
norfloxacin,B
.,O
Reduction,O
of,O
pain,O
during,O
induction,O
with,O
target,O
-,O
controlled,O
propofol,B
and,O
remifentanil,B
.,O
BACKGROUND,O
:,O
Pain,O
on,O
injection,O
of,O
propofol,B
is,O
unpleasant,O
.,O
We,O
hypothesized,O
that,O
propofol,B
infusion,O
pain,O
might,O
be,O
prevented,O
by,O
infusing,O
remifentanil,B
before,O
starting,O
the,O
propofol,B
infusion,O
in,O
a,O
clinical,O
setting,O
where,O
target,O
-,O
controlled,O
infusions,O
(,O
TCI,O
),O
of,O
both,O
drugs,O
were,O
used,O
.,O
A,O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
was,O
performed,O
to,O
determine,O
the,O
effect,O
-,O
site,O
concentration,O
(,O
Ce,B
),O
of,O
remifentanil,B
to,O
prevent,O
the,O
pain,O
without,O
producing,O
complications,O
.,O
METHODS,O
:,O
A,O
total,O
of,O
128,O
patients,O
undergoing,O
general,O
surgery,O
were,O
randomly,O
allocated,O
to,O
receive,O
normal,O
saline,B
(,O
control,O
),O
or,O
remifentanil,B
to,O
a,O
target,O
Ce,B
of,O
2,O
ng,O
ml,O
(,O
-,O
1,O
),O
(,O
R2,B
),O
",",O
4,O
ng,O
ml,O
(,O
-,O
1,O
),O
(,O
R4,B
),O
",",O
or,O
6,O
ng,O
ml,O
(,O
-,O
1,O
),O
(,O
R6,B
),O
administered,O
via,O
TCI,O
.,O
After,O
the,O
target,O
Ce,B
was,O
achieved,O
",",O
the,O
infusion,O
of,O
propofol,B
was,O
started,O
.,O
Remifentanil,B
-,O
related,O
complications,O
were,O
assessed,O
during,O
the,O
remifentanil,B
infusion,O
",",O
and,O
pain,O
caused,O
by,O
propofol,B
was,O
evaluated,O
using,O
a,O
four,O
-,O
point,O
scale,O
during,O
the,O
propofol,B
infusion,O
.,O
RESULTS,O
:,O
The,O
incidence,O
of,O
pain,O
was,O
significantly,O
lower,O
in,O
Groups,O
R4,O
and,O
R6,O
than,O
in,O
the,O
control,O
and,O
R2,O
groups,O
(,O
12,O
/,O
32,O
and,O
6,O
/,O
31,O
vs,O
26,O
/,O
31,O
and,O
25,O
/,O
32,O
",",O
respectively,O
",",O
P,O
<,O
0,O
.,O
1,O
),O
.,O
Pain,O
was,O
less,O
severe,O
in,O
Groups,O
R4,O
and,O
R6,O
than,O
in,O
the,O
control,O
and,O
R2,O
groups,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
.,O
However,O
",",O
both,O
incidence,O
and,O
severity,O
of,O
pain,O
were,O
not,O
different,O
between,O
Groups,O
R4,O
and,O
R6,O
.,O
No,O
significant,O
complications,O
were,O
observed,O
during,O
the,O
study,O
.,O
CONCLUSIONS,O
:,O
During,O
induction,O
of,O
anaesthesia,O
with,O
TCI,O
of,O
propofol,B
and,O
remifentanil,B
",",O
a,O
significant,O
reduction,O
in,O
propofol,B
infusion,O
pain,O
was,O
achieved,O
without,O
significant,O
complications,O
by,O
prior,O
administration,O
of,O
remifentanil,B
at,O
a,O
target,O
Ce,O
of,O
4,O
ng,O
ml,O
(,O
-,O
1,O
),O
.,O
Dexmedetomidine,B
and,O
cardiac,O
protection,O
for,O
non,O
-,O
cardiac,O
surgery,O
:,O
a,O
meta,O
-,O
analysis,O
of,O
randomised,O
controlled,O
trials,O
.,O
We,O
conducted,O
a,O
systematic,O
review,O
of,O
the,O
effects,O
of,O
dexmedetomidine,B
on,O
cardiac,O
outcomes,O
following,O
non,O
-,O
cardiac,O
surgery,O
.,O
We,O
included,O
prospective,O
",",O
randomised,O
peri,O
-,O
operative,O
studies,O
of,O
dexmedetomidine,B
that,O
reported,O
mortality,O
",",O
cardiac,O
morbidity,O
or,O
adverse,O
drug,O
events,O
.,O
A,O
PubMed,O
Central,O
and,O
EMBASE,O
search,O
was,O
conducted,O
up,O
to,O
July,O
2007,O
.,O
The,O
reference,O
lists,O
of,O
identified,O
papers,O
were,O
examined,O
for,O
further,O
trials,O
.,O
Of,O
425,O
studies,O
identified,O
",",O
20,O
were,O
included,O
in,O
the,O
meta,O
-,O
analysis,O
(,O
840,O
patients,O
),O
.,O
Dexmedetomidine,B
was,O
associated,O
with,O
a,O
trend,O
towards,O
improved,O
cardiac,O
outcomes,O
;,O
all,O
-,O
cause,O
mortality,O
(,O
OR,O
0,O
.,O
27,O
",",O
95,O
%,O
CI,O
0,O
.,O
1,O
-,O
7,O
.,O
13,O
",",O
p,O
=,O
0,O
.,O
44,O
.,O
),O
",",O
non,O
-,O
fatal,O
myocardial,B
infarction,I
(,O
OR,O
0,O
.,O
26,O
",",O
95,O
%,O
CI,O
0,O
.,O
4,O
-,O
1,O
.,O
60,O
",",O
p,O
=,O
0,O
.,O
14,O
.,O
),O
",",O
and,O
myocardial,B
ischaemia,I
(,O
OR,O
0,O
.,O
65,O
",",O
95,O
%,O
CI,O
0,O
.,O
26,O
-,O
1,O
.,O
63,O
",",O
p,O
=,O
0,O
.,O
36,O
),O
.,O
Peri,O
-,O
operative,O
hypotension,O
(,O
26,O
%,O
",",O
OR,O
3,O
.,O
80,O
",",O
95,O
%,O
CI,O
1,O
.,O
91,O
-,O
7,O
.,O
54,O
",",O
p,O
=,O
0,O
.,O
1,O
),O
and,O
bradycardia,O
(,O
17,O
%,O
",",O
OR,O
5,O
45,O
",",O
95,O
%,O
CI,O
2,O
.,O
98,O
-,O
9,O
.,O
95,O
",",O
p,O
<,O
0,O
.,O
1,O
),O
were,O
significantly,O
increased,O
.,O
An,O
anticholinergic,O
did,O
not,O
reduce,O
the,O
incidence,O
of,O
bradycardia,O
(,O
p,O
=,O
0,O
.,O
43,O
),O
.,O
A,O
randomised,O
placebo,O
-,O
controlled,O
trial,O
of,O
dexmedetomidine,O
is,O
warranted,O
.,O
Myocardial,O
infarction,O
in,O
pregnancy,O
associated,O
with,O
clomiphene,B
citrate,I
for,O
ovulation,O
induction,O
:,O
a,O
case,O
report,O
.,O
BACKGROUND,O
:,O
Clomiphene,B
citrate,I
(,O
CC,B
),O
is,O
commonly,O
prescribed,O
for,O
ovulation,O
induction,O
.,O
It,O
is,O
considered,O
safe,O
",",O
with,O
minimal,O
side,O
effects,O
.,O
Thromboembolism,O
is,O
a,O
rare,O
but,O
life,O
-,O
threatening,O
complication,O
that,O
has,O
been,O
reported,O
after,O
ovulation,O
induction,O
with,O
CC,B
.,O
Spontaneous,O
coronary,B
thrombosis,I
or,O
thromboembolism,O
with,O
subsequent,O
clot,O
lysis,O
has,O
been,O
suggested,O
as,O
one,O
of,O
the,O
most,O
common,O
causes,O
of,O
myocardial,B
infarction,I
(,O
MI,B
),O
during,O
pregnancy,O
",",O
with,O
a,O
subsequently,O
normal,O
coronary,B
angiogram,I
.,O
CASE,O
:,O
A,O
33,O
-,O
year,O
-,O
old,O
woman,O
with,O
a,O
5,O
-,O
week,O
gestation,O
had,O
recently,O
received,O
CC,B
for,O
ovulation,O
induction,O
and,O
presented,O
with,O
chest,O
pain,O
.,O
An,O
electrocardiogram,O
showed,O
a,O
lateral,O
and,O
anterior,O
wall,O
myocardial,O
infarction,O
.,O
Cardiac,O
enzymes,O
showed,O
a,O
peak,O
rise,O
in,O
troponin,B
I,I
to,O
9,O
.,O
10,O
ng,O
/,O
mL,O
.,O
An,O
initial,O
exercise,O
stress,O
test,O
was,O
normal,O
.,O
At,O
the,O
time,O
of,O
admission,O
",",O
the,O
patient,O
was,O
at,O
high,O
risk,O
of,O
radiation,B
injury,O
to,O
the,O
fetus,O
",",O
so,O
a,O
coronary,B
angiogram,I
was,O
postponed,O
until,O
the,O
second,O
trimester,O
.,O
It,O
showed,O
normal,O
coronary,B
vessels,O
.,O
CONCLUSION,O
:,O
This,O
appears,O
to,O
be,O
the,O
first,O
reported,O
case,O
documenting,O
a,O
possible,O
association,O
between,O
CC,B
and,O
myocardial,B
infarction,O
.,O
Thrombosis,B
might,O
be,O
a,O
rare,O
but,O
hazardous,O
complication,O
of,O
CC,B
.,O
Given,O
this,O
life,O
-,O
threatening,O
complication,O
",",O
appropriate,O
prophylactic,O
measures,O
should,O
be,O
used,O
in,O
high,O
-,O
risk,O
woman,O
undergoing,O
ovarian,O
stimulation,O
.,O
Reverse,O
or,O
inverted,O
left,O
ventricular,O
apical,O
ballooning,O
syndrome,O
(,O
reverse,O
Takotsubo,B
cardiomyopathy,I
),O
in,O
a,O
young,O
woman,O
in,O
the,O
setting,O
of,O
amphetamine,B
use,O
.,O
Transient,O
left,O
ventricular,O
apical,O
ballooning,O
syndrome,O
was,O
first,O
described,O
in,O
Japan,O
as,O
Takotsubo,B
cardiomyopathy,O
.,O
This,O
syndrome,O
has,O
been,O
identified,O
in,O
many,O
other,O
countries,O
.,O
Many,O
variations,O
of,O
this,O
syndrome,O
have,O
been,O
recently,O
described,O
in,O
the,O
literature,O
.,O
One,O
of,O
the,O
rarest,O
is,O
the,O
reverse,O
type,O
of,O
this,O
syndrome,O
",",O
with,O
hyperdynamic,O
apex,O
and,O
complete,O
akinesia,O
of,O
the,O
base,O
(,O
as,O
opposed,O
to,O
the,O
classic,O
apical,O
ballooning,O
),O
.,O
In,O
this,O
article,O
",",O
we,O
report,O
an,O
interesting,O
case,O
of,O
a,O
young,O
woman,O
who,O
presented,O
with,O
this,O
rare,O
type,O
of,O
reverse,O
apical,O
ballooning,O
syndrome,O
occurring,O
after,O
amphetamine,B
use,O
.,O
This,O
report,O
is,O
followed,O
by,O
review,O
of,O
the,O
literature,O
.,O
Results,O
of,O
a,O
comparative,O
",",O
phase,O
III,O
",",O
12,O
-,O
week,O
",",O
multicenter,O
",",O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
assessment,O
of,O
the,O
efficacy,O
and,O
tolerability,O
of,O
a,O
fixed,O
-,O
dose,O
combination,O
of,O
telmisartan,B
and,O
amlodipine,B
versus,O
amlodipine,B
monotherapy,O
in,O
Indian,O
adults,O
with,O
stage,O
II,O
hypertension,O
.,O
OBJECTIVE,O
:,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
efficacy,O
and,O
tolerability,O
of,O
a,O
new,O
fixed,O
-,O
dose,O
combination,O
(,O
FDC,O
),O
of,O
telmisartan,B
40,O
mg,O
+,O
amlodipine,B
5,O
mg,O
(,O
T,O
+,O
A,O
),O
compared,O
with,O
amlodipine,B
5,O
-,O
mg,O
monotherapy,O
(,O
A,O
),O
in,O
adult,O
Indian,O
patients,O
with,O
stage,O
II,O
hypertension,O
.,O
METHODS,O
:,O
This,O
comparative,O
",",O
Phase,O
III,O
",",O
12,O
-,O
week,O
",",O
multicenter,O
",",O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
study,O
was,O
conducted,O
in,O
Indian,O
patients,O
aged,O
18,O
to,O
65,O
years,O
with,O
established,O
stage,O
II,O
hypertension,O
.,O
Patients,O
were,O
treated,O
with,O
oral,O
FDC,B
of,O
T,B
+,O
A,B
or,O
A,B
QD,O
before,O
breakfast,O
for,O
12,O
weeks,O
;,O
blood,O
pressure,O
(,O
BP,B
),O
and,O
heart,O
rate,O
were,O
measured,O
in,O
the,O
sitting,O
position,O
.,O
Primary,O
efficacy,O
end,O
points,O
were,O
reduction,O
in,O
clinical,O
systolic,B
BP,I
(,O
SBP,B
),O
/,O
diastolic,B
BP,I
(,O
DBP,B
),O
from,O
baseline,O
to,O
study,O
end,O
and,O
number,O
of,O
responders,O
(,O
ie,O
",",O
patients,O
who,O
achieved,O
target,O
SBP,B
/,O
DBP,B
<,O
130,O
/,O
<,O
80,O
mm,O
Hg,O
),O
at,O
end,O
of,O
study,O
.,O
Tolerability,O
was,O
assessed,O
by,O
treatment,O
-,O
emergent,O
adverse,O
events,O
",",O
identified,O
using,O
physical,O
examination,O
",",O
laboratory,O
analysis,O
",",O
and,O
electrocardiography,O
.,O
RESULTS,O
:,O
A,O
total,O
of,O
210,O
patients,O
were,O
enrolled,O
in,O
the,O
study,O
;,O
203,O
patients,O
(,O
143,O
men,O
",",O
60,O
women,O
),O
completed,O
the,O
study,O
while,O
7,O
were,O
lost,O
to,O
follow,O
-,O
up,O
(,O
4,O
patients,O
in,O
the,O
T,B
+,I
A,I
group,I
and,O
3,O
in,O
the,O
A,B
group,I
),O
and,O
considered,O
with,O
-,O
drawn,O
.,O
At,O
study,O
end,O
",",O
statistically,O
significant,O
percentage,O
reductions,O
from,O
baseline,O
within,O
groups,O
and,O
between,O
groups,O
were,O
observed,O
in,O
SBP,B
(,O
T,B
+,I
A,I
[,O
-,O
27,O
.,O
4,O
%,O
],O
;,O
A,B
[,O
-,O
16,O
.,O
6,O
%,O
],O
and,O
DBP,B
(,O
T,B
+,I
A,I
[,O
-,O
20,O
.,O
1,O
%,O
],O
;,O
A,B
[,O
-,O
13,O
.,O
3,O
%,O
],O
(,O
all,O
",",O
P,O
<,O
0,O
.,O
5,O
),O
.,O
Response,O
rates,O
were,O
87,O
.,O
3,O
%,O
(,O
89,O
/,O
102,O
),O
in,O
the,O
T,B
+,I
A,I
group,O
and,O
69,O
.,O
3,O
%,O
(,O
70,O
/,O
101,O
),O
in,O
the,O
A,B
group,O
(,O
P,O
<,O
0,O
.,O
5,O
),O
.,O
The,O
prevalences,O
of,O
adverse,O
events,O
were,O
not,O
significantly,O
different,O
between,O
the,O
2,O
treatment,O
groups,O
(,O
T,B
+,O
A,O
",",O
16,O
.,O
0,O
%,O
[,O
17,O
/,O
106,O
],O
;,O
A,B
",",O
15,O
.,O
4,O
%,O
[,O
16,O
/,O
104,O
],O
),O
.,O
Peripheral,O
edema,O
was,O
reported,O
in,O
8,O
.,O
5,O
%,O
patients,O
(,O
9,O
/,O
106,O
),O
in,O
the,O
T,B
+,O
A,O
group,O
compared,O
with,O
13,O
.,O
5,O
%,O
(,O
14,O
/,O
104,O
),O
in,O
the,O
A,O
group,O
",",O
and,O
cough,O
was,O
reported,O
in,O
3,O
.,O
8,O
%,O
patients,O
(,O
4,O
/,O
106,O
),O
in,O
the,O
T,O
+,O
A,O
group,O
and,O
1,O
.,O
0,O
%,O
(,O
1,O
/,O
104,O
),O
patients,O
in,O
the,O
A,O
group,O
;,O
these,O
differences,O
did,O
not,O
reach,O
statistical,O
significance,O
.,O
The,O
incidences,O
of,O
headache,O
",",O
dizziness,O
",",O
and,O
diarrhea,O
were,O
similar,O
between,O
the,O
2,O
groups,O
.,O
CONCLUSIONS,O
:,O
Among,O
these,O
Indian,O
patients,O
with,O
stage,O
II,O
hypertension,O
",",O
the,O
FDC,B
of,O
T,B
+,O
A,B
was,O
found,O
to,O
be,O
significantly,O
more,O
effective,O
",",O
with,O
regard,O
to,O
BP,O
reductions,O
",",O
than,O
A,B
",",O
and,O
both,O
treatments,O
were,O
well,O
tolerated,O
.,O
Increased,O
mental,O
slowing,O
associated,O
with,O
the,O
APOE,B
epsilon4,I
allele,O
after,O
trihexyphenidyl,B
oral,O
anticholinergic,O
challenge,O
in,O
healthy,O
elderly,O
.,O
OBJECTIVES,O
:,O
The,O
objectives,O
of,O
this,O
study,O
were,O
to,O
examine,O
the,O
relationship,O
between,O
APOE,B
epsilon4,I
and,O
subjective,O
effects,O
of,O
trihexyphenidyl,B
on,O
measures,O
reflecting,O
sedation,O
and,O
confusion,O
and,O
to,O
investigate,O
the,O
relationship,O
between,O
trihexyphenidyl,B
-,O
induced,O
subjective,O
effects,O
and,O
objective,O
memory,O
performance,O
.,O
METHODS,O
:,O
This,O
study,O
comprised,O
24,O
cognitively,O
intact,O
",",O
health,O
elderly,O
adults,O
(,O
12,O
APOE,B
epsilon4,I
carriers,O
),O
at,O
an,O
outpatient,O
geriatric,O
psychiatry,O
research,O
clinic,O
.,O
This,O
was,O
a,O
randomized,O
",",O
double,O
blind,O
",",O
placebo,O
-,O
controlled,O
",",O
three,O
-,O
way,O
",",O
crossover,O
experimental,O
design,O
.,O
All,O
participants,O
received,O
1,O
.,O
0,O
mg,O
or,O
2,O
.,O
0,O
mg,O
trihexyphenidyl,B
or,O
placebo,O
administered,O
in,O
counterbalanced,O
sequences,O
over,O
a,O
period,O
of,O
three,O
consecutive,O
weeks,O
.,O
Bond,O
and,O
Lader,O
',O
s,O
visual,O
analog,O
scales,O
and,O
alternate,O
versions,O
of,O
the,O
Buschke,O
Selective,O
Reminding,O
Test,O
were,O
administered,O
in,O
a,O
repeated,O
measures,O
design,O
at,O
baseline,O
",",O
1,O
",",O
2,O
.,O
5,O
",",O
and,O
5,O
hours,O
postdrug,O
administration,O
.,O
RESULTS,O
:,O
A,O
2,O
.,O
0,O
-,O
mg,O
oral,O
dose,O
of,O
trihexyphenidyl,B
resulted,O
in,O
increased,O
subjective,O
ratings,O
of,O
mental,O
slowness,O
in,O
carriers,O
of,O
the,O
APOE,B
epsilon4,I
allele,I
only,O
.,O
Drug,O
effects,O
as,O
determined,O
by,O
difference,O
scores,O
between,O
2,O
.,O
0,O
mg,O
trihexyphenidyl,B
and,O
placebo,O
on,O
ratings,O
of,O
mental,O
slowness,O
significantly,O
correlated,O
with,O
total,O
and,O
delayed,O
recall,O
on,O
the,O
Buschke,O
Selective,O
Reminding,O
Test,O
in,O
carriers,O
of,O
the,O
APOE,B
epsilon4,I
allele,I
only,O
.,O
However,O
",",O
no,O
significant,O
effects,O
were,O
found,O
with,O
other,O
visual,O
analog,O
scales,O
reflecting,O
subjective,O
sedation,O
and,O
clear,O
-,O
headedness,O
.,O
CONCLUSION,O
:,O
The,O
epsilon4,B
allele,O
in,O
healthy,O
elderly,O
was,O
associated,O
with,O
increased,O
subjective,O
mental,O
slowing,O
after,O
trihexyphenidyl,B
anticholinergic,O
challenge,O
.,O
An,O
evaluation,O
of,O
amikacin,B
nephrotoxicity,O
in,O
the,O
hematology,O
/,O
oncology,O
population,O
.,O
Amikacin,B
is,O
an,O
aminoglycoside,B
commonly,O
used,O
to,O
provide,O
empirical,O
double,O
gram,O
-,O
negative,O
treatment,O
for,O
febrile,O
neutropenia,O
and,O
other,O
suspected,O
infections,O
.,O
Strategies,O
of,O
extended,O
-,O
interval,O
and,O
conventional,O
dosing,O
have,O
been,O
utilized,O
extensively,O
in,O
the,O
general,O
medical,O
population,O
;,O
however,O
",",O
data,O
are,O
lacking,O
to,O
support,O
a,O
dosing,O
strategy,O
in,O
the,O
hematology,O
/,O
oncology,O
population,O
.,O
To,O
evaluate,O
amikacin,B
-,O
associated,O
nephrotoxicity,O
in,O
an,O
adult,O
hematology,O
/,O
oncology,O
population,O
",",O
a,O
prospective,O
",",O
randomized,O
",",O
open,O
-,O
label,O
trial,O
was,O
conducted,O
at,O
a,O
university,O
-,O
affiliated,O
medical,O
center,O
.,O
Forty,O
patients,O
with,O
a,O
diagnosis,O
consistent,O
with,O
a,O
hematologic,O
/,O
oncologic,O
disorder,O
that,O
required,O
treatment,O
with,O
an,O
aminoglycoside,O
were,O
randomized,O
to,O
either,O
conventional,O
or,O
extended,O
-,O
interval,O
amikacin,B
.,O
The,O
occurrence,O
of,O
nephrotoxicity,O
by,O
means,O
of,O
an,O
increase,O
in,O
serum,O
creatinine,B
and,O
evaluation,O
of,O
efficacy,O
via,O
amikacin,B
serum,O
concentrations,O
with,O
respective,O
pathogens,O
were,O
assessed,O
.,O
The,O
occurrence,O
of,O
nephrotoxicity,O
was,O
similar,O
between,O
the,O
conventional,O
and,O
extended,O
-,O
interval,O
groups,O
",",O
at,O
10,O
%,O
and,O
5,O
%,O
",",O
respectively,O
(,O
P,O
=,O
1,O
.,O
0,O
),O
.,O
Six,O
patients,O
in,O
the,O
conventional,O
group,O
had,O
a,O
positive,O
culture,O
",",O
compared,O
with,O
none,O
in,O
the,O
extended,O
-,O
interval,O
group,O
(,O
P,O
=,O
0,O
.,O
2,O
),O
.,O
The,O
occurrence,O
of,O
nephrotoxicity,O
was,O
similar,O
between,O
the,O
two,O
dosing,O
regimens,O
",",O
but,O
the,O
distribution,O
of,O
risk,O
factors,O
was,O
variable,O
between,O
the,O
two,O
groups,O
.,O
Efficacy,O
could,O
not,O
be,O
assessed,O
.,O
High,O
dose,O
dexmedetomidine,B
as,O
the,O
sole,O
sedative,O
for,O
pediatric,O
MRI,O
.,O
OBJECTIVE,O
:,O
This,O
large,O
-,O
scale,O
retrospective,O
review,O
evaluates,O
the,O
sedation,O
profile,O
of,O
dexmedetomidine,B
.,O
AIM,O
:,O
To,O
determine,O
the,O
hemodynamic,O
responses,O
",",O
efficacy,O
and,O
adverse,O
events,O
associated,O
with,O
the,O
use,O
of,O
high,O
dose,O
dexmedetomidine,B
as,O
the,O
sole,O
sedative,O
for,O
magnetic,O
resonance,O
imaging,O
(,O
MRI,O
),O
studies,O
.,O
BACKGROUND,O
:,O
Dexmedetomidine,B
has,O
been,O
used,O
at,O
our,O
institution,O
since,O
2005,O
to,O
provide,O
sedation,O
for,O
pediatric,O
radiological,O
imaging,O
studies,O
.,O
Over,O
time,O
",",O
an,O
effective,O
protocol,O
utilizing,O
high,O
dose,O
dexmedetomidine,B
as,O
the,O
sole,O
sedative,O
agent,O
has,O
evolved,O
.,O
METHODS,O
/,O
MATERIALS,O
:,O
As,O
part,O
of,O
the,O
ongoing,O
Quality,O
Assurance,O
process,O
",",O
data,O
on,O
all,O
sedations,O
are,O
reviewed,O
monthly,O
and,O
protocols,O
modified,O
as,O
needed,O
.,O
Data,O
were,O
analyzed,O
from,O
all,O
747,O
consecutive,O
patients,O
who,O
received,O
dexmedetomidine,B
for,O
MRI,O
sedation,O
from,O
April,O
2005,O
to,O
April,O
2007,O
.,O
RESULTS,O
:,O
Since,O
2005,O
",",O
the,O
10,O
-,O
min,O
loading,O
dose,O
of,O
our,O
dexmedetomidine,B
protocol,O
increased,O
from,O
2,O
to,O
3,O
microg,B
.,O
kg,O
(,O
-,O
1,O
),O
",",O
and,O
the,O
infusion,O
rate,O
increased,O
from,O
1,O
to,O
1,O
.,O
5,O
to,O
2,O
microg,B
.,O
kg,O
(,O
-,O
1,O
),O
.,O
h,O
(,O
-,O
1,O
),O
.,O
The,O
current,O
sedation,O
protocol,O
progressively,O
increased,O
the,O
rate,O
of,O
successful,O
sedation,O
(,O
able,O
to,O
complete,O
the,O
imaging,O
study,O
),O
when,O
using,O
dexmedetomidine,B
alone,O
from,O
91,O
.,O
8,O
%,O
to,O
97,O
.,O
6,O
%,O
(,O
P,O
=,O
0,O
.,O
9,O
),O
",",O
reducing,O
the,O
requirement,O
for,O
adjuvant,O
pentobarbital,B
in,O
the,O
event,O
of,O
sedation,O
failure,O
with,O
dexmedetomidine,B
alone,O
and,O
decreased,O
the,O
mean,O
recovery,O
time,O
by,O
10,O
min,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
.,O
Although,O
dexmedetomidine,B
sedation,O
was,O
associated,O
with,O
a,O
16,O
%,O
incidence,O
of,O
bradycardia,O
",",O
all,O
concomitant,O
mean,O
arterial,O
blood,O
pressures,O
were,O
within,O
20,O
%,O
of,O
age,O
-,O
adjusted,O
normal,O
range,O
and,O
oxygen,B
saturations,O
were,O
95,O
%,O
or,O
higher,O
.,O
CONCLUSION,O
:,O
Dexmedetomidine,B
in,O
high,O
doses,O
provides,O
adequate,O
sedation,O
for,O
pediatric,O
MRI,O
studies,O
.,O
While,O
use,O
of,O
high,O
dose,O
dexmedetomidine,B
is,O
associated,O
with,O
decreases,O
in,O
heart,B
rate,I
and,O
blood,B
pressure,I
outside,O
the,O
established,O
',O
awake,O
',O
norms,O
",",O
this,O
deviation,O
is,O
generally,O
within,O
20,O
%,O
of,O
norms,O
",",O
and,O
is,O
not,O
associated,O
with,O
adverse,O
sequelae,O
.,O
Dexmedetomidine,B
is,O
useful,O
as,O
the,O
sole,O
sedative,O
for,O
pediatric,O
MRI,O
.,O
Hepatotoxicity,O
associated,O
with,O
sulfasalazine,B
in,O
inflammatory,O
arthritis,O
:,O
A,O
case,O
series,O
from,O
a,O
local,O
surveillance,O
of,O
serious,O
adverse,O
events,O
.,O
BACKGROUND,O
:,O
Spontaneous,O
reporting,O
systems,O
for,O
adverse,O
drug,O
reactions,O
(,O
A,O
DRs,O
),O
are,O
handicapped,O
by,O
under,O
-,O
reporting,O
and,O
limited,O
detail,O
on,O
individual,O
cases,O
.,O
We,O
report,O
an,O
investigation,O
from,O
a,O
local,O
surveillance,O
for,O
serious,O
adverse,O
drug,O
reactions,O
associated,O
with,O
disease,O
modifying,O
anti,O
-,O
rheumatic,O
drugs,O
that,O
was,O
triggered,O
by,O
the,O
occurrence,O
of,O
liver,O
failure,O
in,O
two,O
of,O
our,O
patients,O
.,O
METHODS,O
:,O
Serious,O
ADR,O
reports,O
have,O
been,O
solicited,O
from,O
local,O
clinicians,O
by,O
regular,O
postcards,O
over,O
the,O
past,O
seven,O
years,O
.,O
Patients,O
',O
",",O
who,O
had,O
hepatotoxicity,B
on,O
sulfasalazine,B
and,O
met,O
a,O
definition,O
of,O
a,O
serious,O
ADR,O
",",O
were,O
identified,O
.,O
Two,O
clinicians,O
reviewed,O
structured,O
case,O
reports,O
and,O
assessed,O
causality,O
by,O
consensus,O
and,O
by,O
using,O
a,O
causality,O
assessment,O
instrument,O
.,O
The,O
likely,O
frequency,O
of,O
hepatotoxicity,B
with,O
sulfasalazine,B
was,O
estimated,O
by,O
making,O
a,O
series,O
of,O
conservative,O
assumptions,O
.,O
RESULTS,O
:,O
Ten,O
cases,O
were,O
identified,O
:,O
eight,O
occurred,O
during,O
surveillance,O
.,O
Eight,O
patients,O
were,O
hospitalised,O
",",O
two,O
in,O
hepatic,O
failure,O
-,O
one,O
died,O
after,O
a,O
liver,O
transplant,O
.,O
All,O
but,O
one,O
event,O
occurred,O
within,O
6,O
weeks,O
of,O
treatment,O
.,O
Seven,O
patients,O
had,O
a,O
skin,B
rash,I
",",O
three,O
eosinophilia,B
and,O
one,O
interstitial,B
nephritis,I
.,O
Five,O
patients,O
were,O
of,O
Black,B
British,I
of,I
African,I
or,I
Caribbean,I
descent,I
.,O
Liver,B
enzymes,I
showed,O
a,O
hepatocellular,B
pattern,I
in,O
four,O
cases,O
and,O
a,O
mixed,B
pattern,I
in,O
six,O
.,O
Drug,B
-,I
related,I
hepatotoxicity,I
was,O
judged,O
probable,O
or,O
highly,O
probable,O
in,O
8,O
patients,O
.,O
The,O
likely,O
frequency,O
of,O
serious,O
hepatotoxicity,O
with,O
sulfasalazine,B
was,O
estimated,O
at,O
0,O
.,O
4,O
%,O
of,O
treated,O
patients,O
.,O
CONCLUSION,O
:,O
Serious,O
hepatotoxicity,O
associated,O
with,O
sulfasalazine,B
appears,O
to,O
be,O
under,O
-,O
appreciated,O
and,O
intensive,O
monitoring,O
and,O
vigilance,O
in,O
the,O
first,O
6,O
weeks,O
of,O
treatment,O
is,O
especially,O
important,O
.,O
Complete,O
atrioventricular,B
block,I
secondary,O
to,O
lithium,B
therapy,O
.,O
Sinus,O
node,O
dysfunction,O
has,O
been,O
reported,O
most,O
frequently,O
among,O
the,O
adverse,O
cardiovascular,O
effects,O
of,O
lithium,B
.,O
In,O
the,O
present,O
case,O
",",O
complete,O
atrioventricular,B
(,O
AV,O
),O
block,I
with,O
syncopal,O
attacks,O
developed,O
secondary,O
to,O
lithium,B
therapy,O
",",O
necessitating,O
permanent,O
pacemaker,O
implantation,O
.,O
Serum,O
lithium,B
levels,O
remained,O
under,O
or,O
within,O
the,O
therapeutic,O
range,O
during,O
the,O
syncopal,O
attacks,O
.,O
Lithium,B
should,O
be,O
used,O
with,O
extreme,O
caution,O
",",O
especially,O
in,O
patients,O
with,O
mild,O
disturbance,O
of,O
AV,O
conduction,O
.,O
Exaggerated,O
expression,O
of,O
inflammatory,O
mediators,O
in,O
vasoactive,O
intestinal,O
polypeptide,O
knockout,O
(,O
VIP,B
-,I
/,I
-,I
),I
mice,O
with,O
cyclophosphamide,B
(,O
CYP,B
),O
-,O
induced,O
cystitis,O
.,O
Vasoactive,B
intestinal,I
polypeptide,I
(,O
VIP,B
),O
is,O
an,O
immunomodulatory,O
neuropeptide,O
distributed,O
in,O
micturition,O
pathways,O
.,O
VIP,B
(,O
-,O
/,O
-,O
),O
mice,O
exhibit,O
altered,O
bladder,O
function,O
and,O
neurochemical,O
properties,O
in,O
micturition,O
pathways,O
after,O
cyclophosphamide,B
(,O
CYP,B
),O
-,O
induced,O
cystitis,O
.,O
Given,O
VIP,B
',O
s,O
role,O
as,O
an,O
anti,O
-,O
inflammatory,O
mediator,O
",",O
we,O
hypothesized,O
that,O
VIP,B
(,O
-,O
/,O
-,O
),O
mice,O
would,O
exhibit,O
enhanced,O
inflammatory,O
mediator,O
expression,O
after,O
cystitis,O
.,O
A,O
mouse,O
inflammatory,O
cytokine,B
and,O
receptor,O
RT2,B
profiler,O
array,O
was,O
used,O
to,O
determine,O
regulated,O
transcripts,O
in,O
the,O
urinary,O
bladder,O
of,O
wild,O
type,O
(,O
WT,O
),O
and,O
VIP,O
(,O
-,O
/,O
-,O
),O
mice,O
with,O
or,O
without,O
CYP,B
-,O
induced,O
cystitis,O
(,O
150,O
mg,O
/,O
kg,O
;,O
i,O
.,O
p,O
;,O
48,O
h,O
),O
.,O
Four,O
binary,O
comparisons,O
were,O
made,O
:,O
WT,O
control,O
versus,O
CYP,B
treatment,O
(,O
48,O
h,O
),O
",",O
VIP,O
(,O
-,O
/,O
-,O
),O
control,O
versus,O
CYP,B
treatment,O
(,O
48,O
h,O
),O
",",O
WT,O
control,O
versus,O
VIP,O
(,O
-,O
/,O
-,O
),control_94
",",O
and,O
WT,O
with,O
CYP,B
treatment,O
(,O
48,O
h,O
),O
versus,O
VIP,O
(,O
-,O
/,O
-,O
),with_112
CYP,B
treatment,O
(,O
48,O
h,O
),O
The,O
genes,O
presented,O
represent,O
(,O
1,O
),O
greater,O
than,O
1,O
.,O
5,O
-,O
fold,O
change,O
in,O
either,O
direction,O
and,O
(,O
2,O
),O
the,O
p,O
value,O
is,O
less,O
than,O
0,O
.,O
5,O
for,O
the,O
comparison,O
being,O
made,O
.,O
Several,O
regulated,O
genes,O
were,O
validated,O
using,O
enzyme,O
-,O
linked,O
immunoassays,O
including,O
IL,B
-,O
1beta,I
and,O
CXCL1,B
.,O
CYP,B
treatment,O
significantly,O
(,O
p,O
<,O
or,O
=,O
0,O
.,O
1,O
),O
increased,O
expression,O
of,O
CXCL1,B
and,O
IL,B
-,I
1beta,I
in,O
the,O
urinary,O
bladder,O
of,O
WT,O
and,O
VIP,O
(,O
-,O
/,O
-,O
),O
mice,O
",",O
but,O
expression,O
in,O
VIP,O
(,O
-,O
/,O
-,O
),O
mice,O
with,O
CYP,O
treatment,O
was,O
significantly,O
(,O
p,O
<,O
or,O
=,O
0,O
.,O
1,O
),O
greater,O
(,O
4,O
.,O
2,O
-,O
to,O
13,O
-,O
fold,O
increase,O
),O
than,O
that,O
observed,O
in,O
WT,O
urinary,O
bladder,O
(,O
3,O
.,O
6,O
-,O
to,O
5,O
-,O
fold,O
increase,O
),O
.,O
The,O
data,O
suggest,O
that,O
in,O
VIP,B
(,O
-,O
/,O
-,O
),O
mice,O
with,O
bladder,O
inflammation,O
",",O
inflammatory,O
mediators,O
are,O
increased,O
above,O
that,O
observed,O
in,O
WT,O
with,O
CYP,B
.,O
This,O
shift,O
in,O
balance,O
may,O
contribute,O
to,O
increased,O
bladder,O
dysfunction,O
in,O
VIP,B
(,O
-,O
/,O
-,O
),O
mice,O
with,O
bladder,O
inflammation,O
and,O
altered,O
neurochemical,O
expression,O
in,O
micturition,O
pathways,O
.,O
Debrisoquine,B
phenotype,O
and,O
the,O
pharmacokinetics,O
and,O
beta,B
-,I
2,I
receptor,I
pharmacodynamics,O
of,O
metoprolol,B
and,O
its,O
enantiomers,O
.,O
The,O
metabolism,O
of,O
the,O
cardioselective,O
beta,B
-,I
blocker,I
metoprolol,B
is,O
under,O
genetic,O
control,O
of,O
the,O
debrisoquine,B
/,I
sparteine,I
type,I
.,O
The,O
two,O
metabolic,O
phenotypes,O
",",O
extensive,O
(,O
EM,B
),O
and,O
poor,O
metabolizers,O
(,O
PM,B
),O
",",O
show,O
different,O
stereoselective,O
metabolism,O
",",O
resulting,O
in,O
apparently,O
higher,O
beta,B
-,I
1,I
adrenoceptor,I
antagonistic,I
potency,I
of,O
racemic,O
metoprolol,B
in,O
EMs,O
.,O
We,O
investigated,O
if,O
the,O
latter,O
also,O
applies,O
to,O
the,O
beta,B
-,I
2,I
adrenoceptor,I
antagonism,O
by,O
metoprolol,B
.,O
The,O
drug,O
effect,O
studied,O
was,O
the,O
antagonism,O
by,O
metoprolol,B
of,O
terbutaline,B
-,I
induced,O
hypokalemia,O
.,O
By,O
using,O
pharmacokinetic,O
pharmacodynamic,O
modeling,O
the,O
pharmacodynamics,O
of,O
racemic,B
metoprolol,I
and,O
the,O
active,O
S,B
-,I
isomer,I
",",O
were,O
quantitated,O
in,O
EMs,O
and,O
PMs,O
in,O
terms,O
of,O
IC50,O
values,O
",",O
representing,O
metoprolol,B
plasma,O
concentrations,O
resulting,O
in,O
half,O
-,O
maximum,O
receptor,O
occupancy,O
.,O
Six,O
EMs,O
received,O
0,O
.,O
5,O
mg,O
of,O
terbutaline,B
s,O
.,O
c,O
.,O
on,O
two,O
different,O
occasions,O
:,O
1,O
),O
1,O
hr,O
after,O
administration,O
of,O
a,O
placebo,O
and,O
2,O
),O
1,O
hr,O
after,O
150,O
mg,O
of,O
metoprolol,B
p,O
.,O
o,O
.,O
Five,O
PMs,O
were,O
studied,O
according,O
to,O
the,O
same,O
protocol,O
",",O
except,O
for,O
a,O
higher,O
terbutaline,B
dose,O
(,O
0,O
.,O
75,O
mg,O
),O
on,O
day,O
2,O
.,O
Blood,O
samples,O
for,O
the,O
analysis,O
of,O
plasma,O
potassium,B
",",O
terbutaline,B
",",O
metoprolol,B
(,O
racemic,O
",",O
R,O
-,O
and,O
S,O
-,O
isomer,O
),O
",",O
and,O
alpha,O
-,O
hydroxymetoprolol,B
concentrations,O
were,O
taken,O
at,O
regular,O
time,O
intervals,O
",",O
during,O
8,O
hr,O
after,O
metoprolol,B
.,O
In,O
PMs,O
",",O
metoprolol,B
increased,O
the,O
terbutaline,B
area,I
under,I
the,I
plasma,I
concentration,I
vs,I
.,O
time,O
curve,O
(,O
+,O
67,O
%,O
),O
.,O
Higher,O
metoprolol,B
/,O
alpha,B
-,I
hydroxymetoprolol,I
ratios,O
in,O
PMs,O
were,O
predictive,O
for,O
higher,O
R,B
-,I
/,I
S,I
-,I
isomer,I
ratios,O
of,O
unchanged,O
drug,O
.,O
There,O
was,O
a,O
difference,O
in,O
metoprolol,B
potency,O
with,O
higher,O
racemic,B
metoprolol,I
IC50,O
values,O
in,O
PMs,O
(,O
72,O
+,O
/,O
-,O
7,O
ng,O
.,O
ml,O
-,O
1,O
)-3,O
than,O
EMs,O
(,O
42,B
+,O
/,O
-,O
8,O
ng,O
.,O
ml,O
-,O
1,O
",",O
P,O
less,O
than,O
.,O
1,O
).,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
The,O
hemodynamics,O
of,O
oxytocin,B
and,O
other,O
vasoactive,O
agents,O
during,O
neuraxial,O
anesthesia,O
for,O
cesarean,O
delivery,O
:,O
findings,O
in,O
six,O
cases,O
.,O
Oxytocin,B
is,O
a,O
commonly,O
used,O
uterotonic,O
that,O
can,O
cause,O
significant,O
and,O
even,O
fatal,O
hypotension,O
",",O
particularly,O
when,O
given,O
as,O
a,O
bolus,O
.,O
The,O
resulting,O
hypotension,O
can,O
be,O
produced,O
by,O
a,O
decrease,O
in,O
systemic,O
vascular,O
resistance,O
or,O
cardiac,O
output,O
through,O
a,O
decrease,O
in,O
venous,O
return,O
.,O
Parturients,O
with,O
normal,O
volume,O
status,O
",",O
heart,O
valves,O
and,O
pulmonary,O
vasculature,O
most,O
often,O
respond,O
to,O
this,O
hypotension,O
with,O
a,O
compensatory,O
increase,O
in,O
heart,O
rate,O
and,O
stroke,O
volume,O
.,O
Oxytocin,B
-,O
induced,O
hypotension,O
at,O
cesarean,O
delivery,O
may,O
be,O
incorrectly,O
attributed,O
to,O
blood,O
loss,O
.,O
Pulse,O
power,O
analysis,O
(,O
also,O
called,O
pulse,O
contour,O
analysis,O
(,O
),O
of,O
an,O
arterial,O
pressure,O
wave,O
form,O
allows,O
continuous,O
evaluation,O
of,O
systemic,O
vascular,O
resistance,O
and,O
cardiac,O
output,O
in,O
real,O
time,O
",",O
thereby,O
elucidating,O
the,O
causative,O
factors,O
behind,O
changes,O
in,O
blood,O
pressure,O
.,O
Pulse,O
power,O
analysis,O
was,O
conducted,O
in,O
six,O
cases,O
of,O
cesarean,B
delivery,I
performed,O
under,O
neuraxial,O
anesthesia,O
.,O
Hypotension,O
in,O
response,O
to,O
oxytocin,B
was,O
associated,O
with,O
a,O
decrease,O
in,O
systemic,O
vascular,O
resistance,O
and,O
a,O
compensatory,O
increase,O
in,O
stroke,O
volume,O
",",O
heart,O
rate,O
and,O
cardiac,O
output,O
.,O
Pulse,O
power,O
analysis,O
may,O
be,O
helpful,O
in,O
determining,O
the,O
etiology,O
of,O
and,O
treating,O
hypotension,O
during,O
cesarean,B
delivery,I
under,O
neuraxial,O
anesthesia,O
.,O
Protective,O
effects,O
of,O
antithrombin,B
on,O
puromycin,B
aminonucleoside,I
nephrosis,I
in,O
rats,O
.,O
We,O
investigated,O
the,O
effects,O
of,O
antithrombin,B
",",O
a,O
plasma,O
inhibitor,O
of,O
coagulation,O
factors,O
",",O
in,O
rats,O
with,O
puromycin,B
aminonucleoside,I
-,I
induced,I
nephrosis,I
",",O
which,O
is,O
an,O
experimental,O
model,O
of,O
human,O
nephrotic,O
syndrome,O
.,O
Antithrombin,B
(,O
50,O
or,O
500,O
IU,O
/,O
kg,O
/,O
i,O
.,O
v.,O
).,O
was,O
administered,O
to,O
rats,O
once,O
a,O
day,O
for,O
10,O
days,O
immediately,O
after,O
the,O
injection,O
of,O
puromycin,B
aminonucleoside,I
(,O
50,O
mg,O
/,O
kg,O
/,O
i.,O
v.,O
).,O
Treatment,O
with,O
antithrombin,O
attenuated,O
the,O
puromycin,B
aminonucleoside,I
-,O
induced,O
hematological,O
abnormalities,O
.,O
Puromycin,B
aminonucleoside,I
-,O
induced,O
renal,O
dysfunction,O
and,O
hyperlipidemia,O
were,O
also,O
suppressed,O
.,O
Histopathological,O
examination,O
revealed,O
severe,O
renal,B
damage,O
such,O
as,O
proteinaceous,O
casts,O
in,O
tubuli,B
and,O
tubular,O
expansion,O
in,O
the,O
kidney,B
of,O
control,O
rats,O
",",O
while,O
an,O
improvement,O
of,O
the,O
damage,O
was,O
seen,O
in,O
antithrombin,B
-,O
treated,O
rats,O
.,O
In,O
addition,O
",",O
antithrombin,B
treatment,O
markedly,O
suppressed,O
puromycin,B
aminonucleoside,I
-,I
induced,O
apoptosis,O
of,O
renal,B
tubular,O
epithelial,O
cells,O
.,O
Furthermore,O
",",O
puromycin,B
aminonucleoside,I
-,I
induced,O
increases,O
in,O
renal,O
cytokine,O
content,O
were,O
also,O
decreased,O
.,O
These,O
findings,O
suggest,O
that,O
thrombin,B
plays,O
an,O
important,O
role,O
in,O
the,O
pathogenesis,O
of,O
puromycin,B
aminonucleoside,I
-,I
induced,O
nephrotic,O
syndrome,O
.,O
Treatment,O
with,O
antithrombin,B
may,O
be,O
clinically,O
effective,O
in,O
patients,O
with,O
nephrotic,O
syndrome,O
.,O
Heparin,B
-,O
induced,O
thrombocytopenia,O
after,O
liver,O
transplantation,O
.,O
BACKGROUND,O
:,O
Unfractionated,B
heparin,O
sodium,O
(,O
UFH,B
),O
or,O
low,B
-,I
molecular,I
weight,I
heparin,I
(,O
LMWH,B
),O
is,O
used,O
in,O
anticoagulant,O
protocols,O
at,O
several,O
institutions,O
to,O
prevent,O
thrombosis,O
after,O
liver,O
transplantation,O
.,O
Heparin,B
-,O
induced,O
thrombocytopenia,O
(,O
HIT,B
),O
is,O
an,O
adverse,O
immune,O
-,O
mediated,O
reaction,O
to,O
heparin,O
",",O
resulting,O
in,O
platelet,O
count,O
decreases,O
of,O
more,O
than,O
50,O
%,O
.,O
The,O
frequencies,O
of,O
HIT,B
after,O
liver,O
transplantation,O
and,O
platelet,O
factor,O
4,B
/,I
heparin,I
-,I
reactive,I
antibody,I
(,O
HIT,B
antibody,I
),O
positivity,O
in,O
liver,O
transplantation,O
patients,O
",",O
however,O
",",O
are,O
unknown,O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
The,O
32,O
men,O
and,O
20,O
women,O
underwent,O
living,O
donor,O
liver,O
transplantation,O
.,O
We,O
started,O
LMWH,B
(,O
25,O
IU,O
/,O
kg,O
/,O
h,O
),O
on,O
postoperative,O
day,O
(,O
POD,O
),O
1,O
",",O
switching,O
to,O
UFH,B
(,O
5000,O
U,O
/,O
d,O
),O
on,O
POD,O
2,O
or,O
3,O
.,O
The,O
dose,O
of,O
UFH,B
was,O
changed,O
according,O
to,O
the,O
activated,O
clotting,O
time,O
level,O
.,O
HIT,B
antibody,I
levels,O
were,O
measured,O
the,O
day,O
before,O
surgery,O
and,O
on,O
POD,O
7,O
and,O
14,O
.,O
Platelet,B
count,O
was,O
measured,O
daily,O
for,O
3,O
weeks,O
.,O
RESULTS,O
:,O
The,O
average,O
platelet,B
counts,O
preoperatively,O
",",O
and,O
on,O
POD,O
7,O
",",O
14,O
",",O
and,O
21,O
were,O
65,O
",",O
88,O
",",O
149,O
",",O
and,O
169,O
x,O
10,O
(,O
9,O
),O
/,O
L,O
",",O
respectively,O
.,O
Two,O
patients,O
developed,O
hepatic,B
artery,I
thrombosis,I
on,O
POD,O
11,O
and,O
19,O
",",O
respectively,O
",",O
although,O
they,O
were,O
HIT,B
antibody,I
-,I
negative,I
and,O
their,O
platelet,O
counts,O
were,O
stable,O
.,O
In,O
2,O
other,O
patients,O
",",O
the,O
platelet,O
count,O
decreased,O
suddenly,O
from,O
107,O
x,O
10,O
(,O
9,O
),O
/,O
L,O
on,O
POD,O
4,O
to,O
65,O
x,O
10,O
(,O
9,O
),O
/,O
L,O
on,O
POD,O
6,O
and,O
from,O
76,O
x,O
10,O
(,O
9,O
),O
/,O
L,O
on,O
POD,O
7,O
to,O
33,O
x,O
10,O
(,O
9,O
),O
/,O
L,O
on,O
POD,O
9,O
",",O
respectively,O
.,O
The,O
heparin,B
-,O
induced,O
platelet,O
aggregation,O
test,O
was,O
negative,O
in,O
these,O
patients,O
.,O
The,O
percentage,O
of,O
HIT,B
antibody,I
-,I
positive,O
patients,O
was,O
0,O
.,O
5,O
%,O
preoperatively,O
",",O
5,O
.,O
6,O
%,O
on,O
POD,O
7,O
",",O
and,O
5,O
.,O
6,O
%,O
on,O
POD,O
14,O
.,O
None,O
of,O
the,O
subjects,O
/,O
patients,O
developed,O
UFH,B
-,I
related,I
HIT,I
.,O
CONCLUSIONS,O
:,O
In,O
our,O
series,O
",",O
the,O
occurrence,O
of,O
HIT,B
after,O
liver,O
transplantation,O
was,O
uncommon,O
.,O
Doxorubicin,B
cardiomyopathy,O
-,O
induced,O
inflammation,O
and,O
apoptosis,O
are,O
attenuated,O
by,O
gene,O
deletion,O
of,O
the,O
kinin,B
B1,I
receptor,I
.,O
Clinical,O
use,O
of,O
the,O
anthracycline,B
doxorubicin,I
(,O
DOX,B
),O
is,O
limited,O
by,O
its,O
cardiotoxic,O
effects,O
",",O
which,O
are,O
attributed,O
to,O
the,O
induction,O
of,O
apoptosis,O
.,O
To,O
elucidate,O
the,O
possible,O
role,O
of,O
the,O
kinin,B
B1,I
receptor,I
(,O
B1R,B
),O
during,O
the,O
development,O
of,O
DOX,B
cardiomyopathy,O
",",O
we,O
studied,O
B1R,B
knockout,O
mice,O
(,O
B1R,B
(,O
-,O
/,O
-,O
),O
),O
by,O
investigating,O
cardiac,O
inflammation,O
and,O
apoptosis,O
after,O
induction,O
of,O
DOX,B
-,O
induced,O
cardiomyopathy,O
.,O
DOX,B
control,O
mice,O
showed,O
cardiac,O
dysfunction,O
measured,O
by,O
pressure,O
-,O
volume,O
loops,O
in,O
vivo,O
.,O
This,O
was,O
associated,O
with,O
a,O
reduced,O
activation,O
state,O
of,O
AKT,B
",",O
as,O
well,O
as,O
an,O
increased,O
bax,B
/,I
bcl2,I
ratio,O
in,O
Western,O
blots,O
",",O
indicating,O
cardiac,O
apoptosis,O
.,O
Furthermore,O
",",O
mRNA,O
levels,O
of,O
the,O
proinflammatory,O
cytokine,O
interleukin,B
6,I
were,O
increased,O
in,O
the,O
cardiac,O
tissue,O
.,O
In,O
DOX,B
B1R,B
(,O
-,O
/,O
-,O
),O
mice,O
",",O
cardiac,O
dysfunction,O
was,O
improved,O
compared,O
to,O
DOX,B
control,O
mice,O
",",O
which,O
was,O
associated,O
with,O
normalization,O
of,O
the,O
bax,B
/,I
bcl,I
-,I
2,I
ratio,O
and,O
interleukin,B
6,I
",",O
as,O
well,O
as,O
AKT,B
activation,O
state,O
.,O
These,O
findings,O
suggest,O
that,O
B1R,B
is,O
detrimental,O
in,O
DOX,B
cardiomyopathy,O
in,O
that,O
it,O
mediates,O
the,O
inflammatory,O
response,O
and,O
apoptosis,O
.,O
These,O
insights,O
might,O
have,O
useful,O
implications,O
for,O
future,O
studies,O
utilizing,O
B1R,B
antagonists,O
for,O
treatment,O
of,O
human,O
DOX,B
cardiomyopathy,O
.,O
Detailed,O
spectral,O
profile,O
analysis,O
of,O
penicillin,B
-,O
induced,O
epileptiform,O
activity,O
in,O
anesthetized,O
rats,O
.,O
Penicillin,B
model,O
is,O
a,O
widely,O
used,O
experimental,O
model,O
for,O
epilepsy,O
research,O
.,O
In,O
the,O
present,O
study,O
we,O
aimed,O
to,O
portray,O
a,O
detailed,O
spectral,O
analysis,O
of,O
penicillin,B
-,O
induced,O
epileptiform,O
activity,O
in,O
comparison,O
with,O
basal,O
brain,O
activity,O
in,O
anesthetized,O
Wistar,O
rats,O
.,O
Male,O
Wistar,O
rats,O
were,O
anesthetized,O
with,O
i,O
.,O
p,O
.,O
urethane,B
and,O
connected,O
to,O
an,O
electrocorticogram,O
setup,O
.,O
After,O
a,O
short,O
period,O
of,O
basal,O
activity,O
recording,O
epileptic,O
focus,O
was,O
induced,O
by,O
injecting,O
400IU,O
/,O
2,O
microl,O
penicillin,B
-,O
G,I
potassium,I
into,O
the,O
left,O
lateral,O
ventricle,O
while,O
the,O
cortical,O
activity,O
was,O
continuously,O
recorded,O
.,O
Basal,O
activity,O
",",O
latent,O
period,O
and,O
the,O
penicillin,B
-,O
induced,O
epileptiform,O
activity,O
periods,O
were,O
then,O
analyzed,O
using,O
both,O
conventional,O
methods,O
and,O
spectral,O
analysis,O
.,O
Spectral,O
analyses,O
were,O
conducted,O
by,O
dividing,O
the,O
whole,O
spectrum,O
into,O
different,O
frequency,O
bands,O
including,O
delta,B
",",O
theta,B
(,O
slow,I
and,I
fast,I
),O
",",O
alpha,B
-,O
sigma,I
",",O
beta,B
(,O
1,I
and,I
2,I
),O
and,O
gamma,B
(,O
1,I
and,I
2,I
),O
bands,O
.,O
Our,O
results,O
show,O
that,O
the,O
most,O
affected,O
frequency,O
bands,O
were,O
delta,B
",",O
theta,B
",",O
beta,B
-,I
2,I
and,O
gamma,B
-,I
2,I
bands,O
during,O
the,O
epileptiform,O
activity,O
and,O
there,O
were,O
marked,O
differences,O
in,O
terms,O
of,O
spectral,O
densities,O
between,O
three,O
investigated,O
episodes,O
(,O
basal,O
activity,O
",",O
latent,O
period,O
and,O
epileptiform,O
activity,O
),O
.,O
Our,O
results,O
may,O
help,O
to,O
analyze,O
novel,O
data,O
obtained,O
using,O
similar,O
experimental,O
models,O
and,O
the,O
simple,O
analysis,O
method,O
described,O
here,O
can,O
be,O
used,O
in,O
similar,O
studies,O
to,O
investigate,O
the,O
basic,O
neuronal,O
mechanism,O
of,O
this,O
or,O
other,O
types,O
of,O
experimental,O
epilepsies,O
.,O
High,O
fat,O
diet,O
-,O
fed,O
obese,O
rats,O
are,O
highly,O
sensitive,O
to,O
doxorubicin,B
-,I
induced,I
cardiotoxicity,I
.,O
Often,O
",",O
chemotherapy,O
by,O
doxorubicin,B
(,O
Adriamycin,B
),O
is,O
limited,O
due,O
to,O
life,O
threatening,O
cardiotoxicity,O
in,O
patients,O
during,O
and,O
posttherapy,O
.,O
Recently,O
",",O
we,O
have,O
shown,O
that,O
moderate,O
diet,O
restriction,O
remarkably,O
protects,O
against,O
doxorubicin,B
-,O
induced,O
cardiotoxicity,O
.,O
This,O
cardioprotection,O
is,O
accompanied,O
by,O
decreased,O
cardiac,O
oxidative,O
stress,O
and,O
triglycerides,B
and,O
increased,O
cardiac,O
fatty,O
-,O
acid,O
oxidation,O
",",O
ATP,B
synthesis,O
",",O
and,O
upregulated,O
JAK,B
/,I
STAT3,I
pathway,O
.,O
In,O
the,O
current,O
study,O
",",O
we,O
investigated,O
whether,O
a,O
physiological,O
intervention,O
by,O
feeding,O
40,O
%,O
high,O
fat,O
diet,O
(,O
HFD,B
),O
",",O
which,O
induces,O
obesity,O
in,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
(,O
250,O
-,O
275,O
g,O
),O
",",O
sensitizes,O
to,O
doxorubicin,B
-,I
induced,I
cardiotoxicity,I
. A,O
LD,O
(,O
10,O
),O
dose,O
(,O
8,O
mg,O
doxorubicin,B
/,O
kg,O
",",O
ip,O
),O
administered,O
on,O
day,O
43,O
of,O
the,O
HFD,B
feeding,O
regimen,O
led,O
to,O
higher,O
cardiotoxicity,O
",",O
cardiac,O
dysfunction,O
",",O
lipid,O
peroxidation,O
",",O
and,O
80,O
%,O
mortality,O
in,O
the,O
obese,O
(,O
OB,B
),O
rats,O
in,O
the,O
absence,O
of,O
any,O
significant,O
renal,O
or,O
hepatic,O
toxicity,O
.,O
Doxorubicin,B
toxicokinetics,O
studies,O
revealed,O
no,O
change,O
in,O
accumulation,O
of,O
doxorubicin,B
and,O
doxorubicinol,B
(,O
toxic,I
metabolite,I
),O
in,O
the,O
normal,O
diet,O
-,O
fed,O
(,O
ND,O
),O
and,O
OB,O
hearts,O
.,O
Mechanistic,O
studies,O
revealed,O
that,O
OB,O
rats,O
are,O
sensitized,O
due,O
to,O
:,O
(,O
1,O
),O
higher,O
oxyradical,O
stress,O
leading,O
to,O
upregulation,O
of,O
uncoupling,O
proteins,O
2,O
and,O
3,O
",",O
(,O
2,O
),O
downregulation,O
of,O
cardiac,O
peroxisome,O
proliferators,O
activated,O
receptor,O
-,O
alpha,O
",",O
(,O
3,O
),O
decreased,O
plasma,O
adiponectin,B
levels,O
",",O
(,O
4,O
),O
decreased,O
cardiac,O
fatty,O
-,O
acid,O
oxidation,O
(,O
666,O
.,O
9,O
+,O
/,O
-,O
14,B
.,O
0,O
nmol,O
/,O
min,O
/,O
g,O
heart,O
in,O
ND,O
versus,O
400,B
.,O
2,O
+,O
/,O
-,O
11,B
.,O
8,O
nmol,O
/,O
min,O
/,O
g,O
heart,O
in,O
OB,O
.,O
),O
",",O
(,O
5,O
),O
decreased,O
mitochondrial,O
AMP,B
-,O
alpha2,B
protein,O
kinase,O
",",O
and,O
(,O
6,O
),O
86,O
%,O
drop,O
in,O
cardiac,O
ATP,B
levels,O
accompanied,O
by,O
decreased,O
ATP,B
/,O
ADP,B
ratio,O
after,O
doxorubicin,O
administration,O
.,O
Decreased,O
cardiac,O
erythropoietin,O
and,O
increased,O
SOCS3,O
further,O
downregulated,O
the,O
cardioprotective,O
JAK,B
/,O
STAT3,B
pathway,O
.,O
In,O
conclusion,O
",",O
HFD,B
-,O
induced,O
obese,O
rats,O
are,O
highly,O
sensitized,O
to,O
doxorubicin,B
-,O
induced,O
cardiotoxicity,O
by,O
substantially,O
downregulating,O
cardiac,O
mitochondrial,O
ATP,B
generation,O
",",O
increasing,O
oxidative,O
stress,O
and,O
downregulating,O
the,O
JAK,B
/,I
STAT3,I
pathway,O
.,O
Isoproterenol,B
induces,O
primary,O
loss,O
of,O
dystrophin,B
in,O
rat,O
hearts,O
:,O
correlation,O
with,O
myocardial,O
injury,O
.,O
The,O
mechanism,O
of,O
isoproterenol,B
-,O
induced,O
myocardial,O
damage,O
is,O
unknown,O
",",O
but,O
a,O
mismatch,O
of,O
oxygen,O
supply,O
vs,O
.,O
demand,O
following,O
coronary,O
hypotension,O
and,O
myocardial,O
hyperactivity,O
is,O
the,O
best,O
explanation,O
for,O
the,O
complex,O
morphological,O
alterations,O
observed,O
.,O
Severe,O
alterations,O
in,O
the,O
structural,O
integrity,O
of,O
the,O
sarcolemma,O
of,O
cardiomyocytes,O
have,O
been,O
demonstrated,O
to,O
be,O
caused,O
by,O
isoproterenol,B
.,O
Taking,O
into,O
account,O
that,O
the,O
sarcolemmal,O
integrity,O
is,O
stabilized,O
by,O
the,O
dystrophin,B
-,I
glycoprotein,I
complex,I
(,O
DGC,B
),O
that,O
connects,O
actin,B
and,O
laminin,B
in,O
contractile,O
machinery,O
and,O
extracellular,O
matrix,O
and,O
by,O
integrins,B
",",O
this,O
study,O
tests,O
the,O
hypothesis,O
that,O
isoproterenol,B
affects,O
sarcolemmal,O
stability,O
through,O
changes,O
in,O
the,O
DGC,B
and,O
integrins,B
.,O
We,O
found,O
different,O
sensitivity,O
of,O
the,O
DGC,B
and,O
integrin,B
to,O
isoproterenol,B
subcutaneous,O
administration,O
.,O
Immunofluorescent,O
staining,O
revealed,O
that,O
dystrophin,B
is,O
the,O
most,O
sensitive,O
among,O
the,O
structures,O
connecting,O
the,O
actin,B
in,O
the,O
cardiomyocyte,O
cytoskeleton,O
and,O
the,O
extracellular,O
matrix,O
.,O
The,O
sarcomeric,O
actin,B
dissolution,O
occurred,O
after,O
the,O
reduction,O
or,O
loss,O
of,O
dystrophin,B
.,O
Subsequently,O
",",O
after,O
lysis,O
of,O
myofilaments,O
",",O
gamma,B
-,O
sarcoglycan,I
",",O
beta,B
-,O
dystroglycan,I
",",O
beta1,B
-,O
integrin,I
",",O
and,O
laminin,B
alpha,I
-,O
2,I
expressions,O
were,O
reduced,O
followed,O
by,O
their,O
breakdown,O
",",O
as,O
epiphenomena,O
of,O
the,O
myocytolytic,O
process,O
.,O
In,O
conclusion,O
",",O
administration,O
of,O
isoproterenol,B
to,O
rats,O
results,O
in,O
primary,O
loss,O
of,O
dystrophin,B
",",O
the,O
most,O
sensitive,O
among,O
the,O
structural,O
proteins,O
that,O
form,O
the,O
DGC,O
that,O
connects,O
the,O
extracellular,O
matrix,O
and,O
the,O
cytoskeleton,O
in,O
cardiomyocyte,O
.,O
These,O
changes,O
",",O
related,O
to,O
ischaemic,O
injury,O
",",O
explain,O
the,O
severe,O
alterations,O
in,O
the,O
structural,O
integrity,O
of,O
the,O
sarcolemma,B
of,O
cardiomyocytes,O
and,O
hence,O
severe,O
and,O
irreversible,O
injury,O
induced,O
by,O
isoproterenol,B
.,O
Etiologic,O
factors,O
in,O
the,O
pathogenesis,O
of,O
liver,B
tumors,O
associated,O
with,O
oral,O
contraceptives,O
.,O
Within,O
the,O
last,O
several,O
years,O
",",O
previously,O
rare,O
liver,B
tumors,O
have,O
been,O
seen,O
in,O
young,O
women,O
using,O
oral,O
contraceptive,O
steroids,O
.,O
The,O
Registry,O
for,O
Liver,B
Tumors,I
Associated,O
with,O
Oral,B
Contraceptives,I
at,O
the,O
University,O
of,O
California,O
",",O
Irvine,O
",",O
has,O
clearly,O
identified,O
27,O
cases,O
.,O
The,O
recent,O
literature,O
contains,O
44,O
case,O
reports,O
.,O
Common,O
to,O
these,O
71,O
cases,O
has,O
been,O
a,O
histopathologic,O
diagnosis,O
of,O
focal,O
nodular,O
hyperplasia,B
",",O
adenoma,B
",",O
hamartoma,B
",",O
and,O
hepatoma,B
.,O
Significant,O
statistical,O
etiologic,O
factors,O
include,O
prolonged,O
uninterrupted,O
usage,O
of,O
oral,B
contraceptive,I
steroids,I
.,O
Eight,O
deaths,O
and,O
liver,B
rupture,O
in,O
18,O
patients,O
attest,O
to,O
the,O
seriousness,O
of,O
this,O
new,O
potentially,O
lethal,O
adverse,O
phenomenon,O
.,O
Ifosfamide,B
continuous,O
infusion,O
without,O
mesna,B
.,O
A,O
phase,O
I,O
trial,O
of,O
a,O
14,O
-,O
day,O
cycle,O
.,O
Twenty,O
patients,O
received,O
27,O
courses,O
of,O
ifosfamide,B
administered,O
as,O
a,O
24,O
-,O
hour,O
continuous,O
infusion,O
for,O
14,O
days,O
without,O
Mesna,O
.,O
The,O
goal,O
of,O
the,O
study,O
was,O
to,O
deliver,O
a,O
dose,O
rate,O
and,O
total,O
cumulative,O
dose,O
of,O
ifosfamide,B
that,O
would,O
be,O
comparable,O
to,O
standard,O
bolus,O
or,O
short,O
-,O
term,O
infusions,O
administered,O
with,O
Mesna,O
.,O
Dose,O
escalations,O
proceeded,O
from,O
200,O
to,O
300,O
",",O
400,O
",",O
450,O
",",O
500,O
",",O
and,O
550,O
mg,O
/,O
m2,O
/,O
d,O
.,O
Four,O
patients,O
developed,O
transient,O
microscopic,O
hematuria,O
at,O
400,O
",",O
450,O
",",O
and,O
500,O
mg,O
/,O
m2,O
/,O
d,O
.,O
There,O
were,O
no,O
instances,O
of,O
macroscopic,O
hematuria,O
.,O
At,O
550,O
mg,O
/,O
m2,O
/,O
d,O
",",O
three,O
patients,O
experienced,O
nonurologic,O
toxicity,O
;,O
confusion,B
(,O
1,O
),O
",",O
nausea,B
(,O
1,O
),O
",",O
and,O
Grade,O
2,O
leukopenia,B
(,O
1,O
),O
.,O
The,O
recommended,O
dose,O
of,O
500,B
mg,I
/,I
m2,I
/,I
d,I
delivers,O
a,O
total,O
dose,O
of,O
7,B
g,I
/,I
m2,I
per,O
cycle,O
",",O
which,O
is,O
comparable,O
to,O
that,O
delivered,O
in,O
clinical,O
practice,O
for,O
bolus,O
or,O
short,O
-,O
term,O
infusion,O
.,O
Because,O
few,O
patients,O
received,O
multiple,O
courses,O
over,O
time,O
",",O
the,O
cumulative,O
effects,O
are,O
indeterminate,O
in,O
the,O
present,O
trial,O
.,O
The,O
frequency,O
and,O
predictability,O
of,O
hematuria,B
are,O
not,O
precise,O
",",O
and,O
at,O
least,O
daily,O
monitoring,O
by,O
urine,O
Hematest,O
is,O
essential,O
",",O
adding,O
Mesna,B
to,O
the,O
infusate,O
in,O
patients,O
with,O
persistent,O
hematuria,B
.,O
The,O
protracted,O
infusion,O
schedule,O
for,O
ifosfamide,B
permits,O
convenient,O
outpatient,O
administration,O
without,O
Mesna,B
and,O
reduces,O
the,O
drug,O
cost,O
of,O
clinical,O
usage,O
of,O
this,O
agent,O
by,O
up,O
to,O
890,O
per,O
cycle,O
.,O
Clinical,O
activity,O
was,O
demonstrated,O
in,O
a,O
single,O
patient,O
",",O
but,O
a,O
comparative,O
trial,O
of,O
standard,O
bolus,O
schedules,O
with,O
the,O
protracted,O
infusion,O
schedule,O
will,O
be,O
necessary,O
to,O
determine,O
if,O
the,O
clinical,O
effectiveness,O
of,O
the,O
drug,O
is,O
maintained,O
.,O
A,O
case,O
of,O
ventricular,O
tachycardia,O
related,O
to,O
caffeine,B
pretreatment,O
.,O
Suboptimal,O
seizure,O
duration,O
is,O
commonly,O
encountered,O
in,O
electroconvulsive,O
therapy,O
practice,O
",",O
especially,O
in,O
older,O
patients,O
with,O
higher,O
seizure,O
thresholds,O
.,O
Intravenous,O
caffeine,B
is,O
commonly,O
used,O
to,O
improve,O
seizure,O
duration,O
and,O
quality,O
in,O
such,O
patients,O
and,O
is,O
generally,O
well,O
tolerated,O
aside,O
from,O
occasional,O
reports,O
of,O
relatively,O
benign,O
ventricular,O
ectopy,O
.,O
We,O
describe,O
a,O
patient,O
with,O
no,O
previous,O
history,O
of,O
cardiac,B
disease,I
or,O
arrhythmia,B
who,O
developed,O
sustained,O
bigeminy,O
and,O
2,O
brief,O
runs,O
of,O
ventricular,B
tachycardia,I
after,O
caffeine,B
administration,O
.,O
Although,O
intravenous,O
caffeine,B
is,O
generally,O
well,O
tolerated,O
",",O
the,O
clinician,O
should,O
be,O
aware,O
of,O
the,O
potential,O
for,O
unpredictable,O
and,O
serious,O
ventricular,B
arrhythmias,I
.,O
Fatal,O
haemopericardium,O
and,O
gastrointestinal,O
haemorrhage,O
due,O
to,O
possible,O
interaction,O
of,O
cranberry,B
juice,I
with,O
warfarin,O
.,O
We,O
report,O
a,O
case,O
of,O
fatal,O
internal,O
haemorrhage,O
in,O
an,O
elderly,O
man,O
who,O
consumed,O
only,O
cranberry,B
juice,I
for,O
two,O
weeks,O
while,O
maintaining,O
his,O
usual,O
dosage,O
of,O
warfarin,O
.,O
We,O
propose,O
that,O
naturally,O
occurring,O
compounds,O
such,O
as,O
flavonoids,B
",",O
which,O
are,O
present,O
in,O
fruit,O
juices,O
",",O
may,O
increase,O
the,O
potency,O
of,O
warfarin,O
by,O
competing,O
for,O
the,O
enzymes,O
that,O
normally,O
inactivate,O
warfarin,O
.,O
While,O
traditionally,O
regarded,O
as,O
foodstuffs,O
",",O
consumption,O
of,O
fruit,B
juices,I
should,O
be,O
considered,O
when,O
patients,O
develop,O
adverse,O
drug,B
reactions,O
.,O
Effect,O
of,O
increasing,O
intraperitoneal,O
infusion,O
rates,O
on,O
bupropion,B
hydrochloride,I
-,I
induced,O
seizures,O
in,O
mice,O
.,O
BACKGROUND,O
:,O
It,O
is,O
not,O
known,O
if,O
there,O
is,O
a,O
relationship,O
between,O
input,O
rate,O
and,O
incidence,O
of,O
bupropion,B
-,I
induced,O
seizures,O
.,O
This,O
is,O
important,O
",",O
since,O
different,O
controlled,O
release,O
formulations,O
of,O
bupropion,B
release,O
the,O
active,O
drug,O
at,O
different,O
rates,O
.,O
METHODS,O
:,O
We,O
investigated,O
the,O
effect,O
of,O
varying,O
the,O
intraperitoneal,O
infusion,O
rates,O
of,O
bupropion,B
HCl,I
120,I
mg,I
/,I
kg,I
",",O
a,O
known,O
convulsive,O
dose,O
50,O
(,O
CD50,O
),O
",",O
on,O
the,O
incidence,O
and,O
severity,O
of,O
bupropion,B
-,O
induced,O
convulsions,O
in,O
the,O
Swiss,O
albino,O
mice,O
.,O
A,O
total,O
of,O
69,O
mice,O
",",O
approximately,O
7,O
weeks,O
of,O
age,O
",",O
and,O
weighing,O
21,O
.,O
0,O
to,O
29,O
.,O
1,O
g,O
were,O
randomly,O
assigned,O
to,O
bupropion,B
HCl,I
120,O
mg,O
/,O
kg,O
treatment,O
by,O
intraperitoneal,O
(,O
IP,B
),O
administration,O
in,O
7,O
groups,O
(,O
9,O
to,O
10,O
animals,O
per,O
group,O
),O
.,O
Bupropion,B
HCl,I
was,O
infused,O
through,O
a,O
surgically,O
implanted,O
IP,B
dosing,O
catheter,O
with,O
infusions,O
in,O
each,O
group,O
of,O
0,O
min,O
",",O
15,O
min,O
",",O
30,O
min,O
",",O
60,O
min,O
",",O
90,O
min,O
",",O
120,O
min,O
",",O
and,O
240,O
min,O
.,O
The,O
number,O
",",O
time,O
of,O
onset,O
",",O
duration,O
and,O
the,O
intensity,O
of,O
the,O
convulsions,O
or,O
absence,O
of,O
convulsions,O
were,O
recorded,O
.,O
RESULTS,O
:,O
The,O
results,O
showed,O
that,O
IP,O
administration,O
of,O
bupropion,B
HCl,I
120,O
mg,O
/,O
kg,O
by,O
bolus,O
injection,O
induced,O
convulsions,O
in,O
6,O
out,O
of,O
10,O
mice,O
(,O
60,O
%,O
of,O
convulsing,O
mice,O
),O
in,O
group,O
1,O
.,O
Logistic,O
regression,O
analysis,O
revealed,O
that,O
infusion,O
time,O
was,O
significant,O
(,O
p,O
=,O
0,O
.,O
4,O
;,O
odds,O
ratio,O
=,O
0,O
.,O
974,B
),O
and,O
increasing,O
the,O
IP,O
infusion,O
time,O
of,O
bupropion,B
HCl,I
120,I
mg,I
/,I
kg,I
was,O
associated,O
with,O
a,O
91,B
%,I
reduced,I
odds,I
of,I
convulsions,I
at,I
infusion,I
times,I
of,I
15,I
to,I
90,I
min,I
compared,I
to,I
bolus,I
injection,I
.,O
Further,O
increase,O
in,O
infusion,O
time,O
resulted,O
in,O
further,O
reduction,O
in,O
the,O
odds,O
of,O
convulsions,O
to,O
99,B
.,O
8,O
%,O
reduction,O
at,O
240,O
min,O
.,O
CONCLUSION,O
:,O
In,O
conclusion,O
",",O
the,O
demonstration,O
of,O
an,O
inverse,O
relationship,O
between,O
infusion,O
time,O
of,O
a,O
fixed,O
and,O
convulsive,O
dose,O
of,O
bupropion,B
and,O
the,O
risk,O
of,O
convulsions,O
in,O
a,O
prospective,O
study,O
is,O
novel,O
.,O
Graft,O
-,O
versus,O
-,O
host,O
disease,O
prophylaxis,O
with,O
everolimus,B
and,O
tacrolimus,B
is,O
associated,O
with,O
a,O
high,O
incidence,O
of,O
sinusoidal,B
obstruction,I
syndrome,I
and,O
microangiopathy,O
:,O
results,O
of,O
the,O
EVTAC,O
trial,O
.,O
A,O
calcineurin,B
inhibitor,I
combined,O
with,O
methotrexate,B
is,O
the,O
standard,O
prophylaxis,O
for,O
graft,O
-,O
versus,O
-,O
host,O
disease,O
(,O
GVHD,B
),O
after,O
allogeneic,O
hematopoietic,O
stem,O
cell,O
transplantation,O
(,O
HSCT,B
),O
.,O
Everolimus,B
",",O
a,O
derivative,O
of,O
sirolimus,B
",",O
seems,O
to,O
mediate,O
antileukemia,O
effects,O
.,O
We,O
report,O
on,O
a,O
combination,O
of,O
everolimus,B
and,O
tacrolimus,B
in,O
24,O
patients,O
(,O
median,O
age,O
",",O
62,O
years,O
),O
with,O
either,O
myelodysplastic,B
syndrome,I
(,O
MDS,B
;,O
n,O
=,O
17,O
),O
or,O
acute,B
myeloid,I
leukemia,I
(,O
AML,B
;,O
n,O
=,O
7,O
),O
undergoing,O
intensive,O
conditioning,O
followed,O
by,O
HSCT,B
from,O
related,O
(,O
n,O
=,O
4,O
),O
or,O
unrelated,O
(,O
n,O
=,O
20,O
),O
donors,O
.,O
All,O
patients,O
engrafted,O
",",O
and,O
only,O
1,O
patient,O
experienced,O
grade,O
IV,O
mucositis,B
.,O
Nine,O
patients,O
(,O
37,O
%,O
),O
developed,O
acute,O
grade,O
II,O
-,O
IV,O
GVHD,B
",",O
and,O
11,O
of,O
17,O
evaluable,O
patients,O
(,O
64,O
%,O
),O
developed,O
chronic,O
extensive,O
GVHD,B
.,O
Transplantation,O
-,O
associated,O
microangiopathy,B
(,O
TMA,B
),O
occurred,O
in,O
7,O
patients,O
(,O
29,O
%,O
),O
",",O
with,O
2,O
cases,O
of,O
acute,O
renal,O
failure,O
.,O
The,O
study,O
was,O
terminated,O
prematurely,O
because,O
an,O
additional,O
6,O
patients,O
(,O
25,O
%,O
),O
developed,O
sinusoidal,B
obstruction,I
syndrome,I
(,O
SOS,B
),O
",",O
which,O
was,O
fatal,O
in,O
2,O
cases,O
.,O
With,O
a,O
median,O
follow,O
-,O
up,O
of,O
26,O
months,O
",",O
the,O
2,O
-,O
year,O
overall,O
survival,O
rate,O
was,O
47,O
%,O
.,O
Although,O
this,O
new,O
combination,O
appears,O
to,O
be,O
effective,O
as,O
a,O
prophylactic,O
regimen,O
for,O
acute,O
GVHD,O
",",O
the,O
incidence,O
of,O
TMA,B
and,O
SOS,B
is,O
considerably,O
higher,O
than,O
seen,O
with,O
other,O
regimens,O
.,O
Longitudinal,O
assessment,O
of,O
air,O
conduction,O
audiograms,O
in,O
a,O
phase,O
III,O
clinical,O
trial,O
of,O
difluoromethylornithine,B
and,O
sulindac,B
for,O
prevention,O
of,O
sporadic,O
colorectal,O
adenomas,O
.,O
A,O
phase,O
III,O
clinical,O
trial,O
assessed,O
the,O
recurrence,O
of,O
adenomatous,O
polyps,O
after,O
treatment,O
for,O
36,O
months,O
with,O
difluoromethylornithine,B
(,O
DFMO,I
),O
plus,O
sulindac,B
or,O
matched,O
placebos,O
.,O
Temporary,O
hearing,O
loss,O
is,O
a,O
known,O
toxicity,O
of,O
treatment,O
with,O
DFMO,B
",",O
thus,O
a,O
comprehensive,O
approach,O
was,O
developed,O
to,O
analyze,O
serial,O
air,O
conduction,O
audiograms,O
.,O
The,O
generalized,O
estimating,O
equation,O
method,O
estimated,O
the,O
mean,O
difference,O
between,O
treatment,O
arms,O
with,O
regard,O
to,O
change,O
in,O
air,O
conduction,O
pure,O
tone,O
thresholds,O
while,O
accounting,O
for,O
within,O
-,O
subject,O
correlation,O
due,O
to,O
repeated,O
measurements,O
at,O
frequencies,O
.,O
Based,O
on,O
290,O
subjects,O
",",O
there,O
was,O
an,O
average,O
difference,O
of,O
0,O
.,O
50,O
dB,O
between,O
subjects,O
treated,O
with,O
DFMO,B
plus,O
sulindac,B
compared,O
with,O
those,O
treated,O
with,O
placebo,B
(,O
95,O
%,O
confidence,O
interval,O
",",O
-,O
0,O
.,O
64,O
to,O
1,O
.,O
63,O
dB,O
;,O
P,O
=,O
0,O
.,O
39,O
),O
",",O
adjusted,O
for,O
baseline,O
values,O
",",O
age,O
",",O
and,O
frequencies,O
.,O
In,O
the,O
normal,O
speech,O
range,O
of,O
500,O
to,O
3,O
",",O
0,O
Hz,O
",",O
an,O
estimated,O
difference,O
of,O
0,O
.,O
99,O
dB,O
(,O
-,O
0,O
.,O
17,O
to,O
2,O
.,O
14,O
dB,O
;,O
P,O
=,O
0,O
.,O
9,O
),O
was,O
detected,O
.,O
Dose,O
intensity,O
did,O
not,O
add,O
information,O
to,O
models,O
.,O
There,O
were,O
14,O
of,O
151,O
(,O
9,O
.,O
3,O
%,O
),O
in,O
the,O
DFMO,O
plus,O
sulindac,O
group,O
and,O
4,O
of,O
139,O
(,O
2,O
.,O
9,O
%,O
),O
in,O
the,O
placebo,O
group,O
who,O
experienced,O
at,O
least,O
15,O
dB,O
hearing,O
reduction,O
from,O
baseline,O
in,O
2,O
or,O
more,O
consecutive,O
frequencies,O
across,O
the,O
entire,O
range,O
tested,O
(,O
P,O
=,O
0,O
.,O
2,O
),O
.,O
Follow,O
-,O
up,O
air,O
conduction,O
done,O
at,O
least,O
6,O
months,O
after,O
end,O
of,O
treatment,O
showed,O
an,O
adjusted,O
mean,O
difference,O
in,O
hearing,O
thresholds,O
of,O
1,O
.,O
8,O
dB,O
(,O
-,O
0,O
.,O
81,O
to,O
2,O
.,O
96,O
dB,O
;,O
P,O
=,O
0,O
.,O
26,O
),O
between,O
treatment,O
arms,O
.,O
There,O
was,O
no,O
significant,O
difference,O
in,O
the,O
proportion,O
of,O
subjects,O
in,O
the,O
DFMO,B
plus,O
sulindac,B
group,O
who,O
experienced,O
clinically,O
significant,O
hearing,O
loss,O
compared,O
with,O
the,O
placebo,B
group,O
.,O
The,O
estimated,O
attributable,O
risk,O
of,O
ototoxicity,B
from,O
exposure,O
to,O
the,O
drug,O
is,O
8,O
.,O
4,O
%,O
(,O
95,O
%,O
confidence,O
interval,O
",",O
-,O
2,O
.,O
0,O
%,O
to,O
18,O
.,O
8,O
%,O
;,O
P,O
=,O
0,O
.,O
12,O
.,O
There,O
is,O
a,O
<,O
2,O
dB,O
difference,O
in,O
mean,O
threshold,O
for,O
patients,O
treated,O
with,O
DFMO,B
plus,O
sulindac,B
compared,O
with,O
those,O
treated,O
with,O
placebo,O
.,O
Proteinase,B
3,I
-,I
antineutrophil,I
cytoplasmic,I
antibody,I
-,I
(,I
PR3,I
-,I
ANCA,I
),I
positive,O
necrotizing,O
glomerulonephritis,O
after,O
restarting,O
sulphasalazine,B
treatment,O
.,O
A,O
59,O
-,O
year,O
-,O
old,O
woman,O
with,O
ulcerative,B
colitis,I
developed,O
red,O
eyes,O
",",O
pleural,O
effusion,O
",",O
eosinophilia,O
and,O
urinary,O
abnormalities,O
after,O
restarting,O
of,O
sulphasalazine,B
treatment,O
.,O
Light,O
microscopy,O
of,O
a,O
kidney,O
biopsy,O
revealed,O
segmental,O
necrotizing,O
glomerulonephritis,O
without,O
deposition,O
of,O
immunoglobulin,O
or,O
complement,O
.,O
Proteinase,B
3,I
-,O
antineutrophil,O
cytoplasmic,O
antibody,O
(,O
PR3,B
-,O
ANCA,O
),O
titer,O
was,O
elevated,O
at,O
183,O
ELISA,O
units,O
(,O
EU,B
),O
in,O
sera,O
(,O
normal,O
range,O
less,O
than,O
10,O
EU,B
),O
",",O
myeloperoxidase,O
-,O
ANCA,O
was,O
negative,O
.,O
PR3,B
-,O
ANCA,O
titer,O
was,O
250,O
and,O
1,O
",",O
70,O
EU,B
in,O
pleural,O
effusions,O
on,O
right,O
and,O
left,O
side,O
",",O
respectively,O
.,O
Although,O
cessation,O
of,O
sulphasalazine,B
treatment,O
resulted,O
in,O
improvements,O
in,O
fever,O
",",O
red,O
eyes,O
",",O
chest,O
pain,O
",",O
titer,O
of,O
C,B
-,I
reactive,I
protein,I
and,O
volume,O
of,O
the,O
pleural,O
effusions,O
",",O
we,O
initiated,O
steroid,O
therapy,O
",",O
because,O
PR3,B
-,O
ANCA,O
titer,O
rose,O
to,O
320,O
EU,B
",",O
eosinophil,O
count,O
increased,O
to,O
1,O
",",O
100,O
cells,O
/,O
microl,O
",",O
and,O
the,O
pleural,O
effusion,O
remained,O
.,O
One,O
month,O
after,O
steroid,B
therapy,O
",",O
the,O
pleural,B
effusion,I
disappeared,O
",",O
and,O
PR3,B
-,O
ANCA,I
titer,O
normalized,O
3,O
months,O
later,O
.,O
This,O
case,O
suggests,O
that,O
sulphasalazine,B
can,O
induce,O
PR3,B
-,O
ANCA,I
-,O
positive,O
necrotizing,O
glomerulonephritis,O
.,O
Comparison,O
of,O
unilateral,O
pallidotomy,O
and,O
subthalamotomy,O
findings,O
in,O
advanced,O
idiopathic,O
Parkinson,O
',O
s,O
disease,O
.,O
A,O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
pilot,O
study,O
to,O
compare,O
the,O
results,O
of,O
stereotactic,O
unilateral,O
pallidotomy,B
and,O
subthalamotomy,B
in,O
advanced,O
idiopathic,O
Parkinson,B
',O
s,O
disease,O
(,O
PD,B
),O
refractory,O
to,O
medical,O
treatment,O
was,O
designed,O
.,O
Ten,O
consecutive,O
patients,O
(,O
mean,O
age,O
",",O
58,O
.,O
4,O
+,O
/,O
-,O
6,O
years,O
;,O
7,O
men,O
",",O
3,O
women,O
),O
with,O
similar,O
characteristics,O
at,O
the,O
duration,O
of,O
disease,O
(,O
mean,O
disease,O
time,O
",",O
8,O
.,O
4,O
+,O
/,O
-,O
3,O
.,O
5,O
years,O
),O
",",O
disabling,O
motor,O
fluctuations,O
(,O
Hoehn,B
,I
Yahr,I
stage,O
3,O
-,O
5,O
in,O
off,O
-,O
drug,O
phases,O
),O
and,O
levodopa,B
-,O
induced,O
dyskinesias,O
were,O
selected,O
.,O
All,O
patients,O
had,O
bilateral,O
symptoms,O
and,O
their,O
levodopa,B
equivalent,O
dosing,O
were,O
analysed,O
.,O
Six,O
patients,O
were,O
operated,O
on,O
in,O
the,O
globus,B
pallidus,I
interna,I
(,O
GPi,B
),O
and,O
four,O
in,O
the,O
subthalamic,B
nucleus,I
(,O
STN,B
),O
.,O
Clinical,O
evaluation,O
included,O
the,O
use,O
of,O
the,O
Unified,B
Parkinson,I
',I
s,I
Disease,I
Rating,I
Scale,I
(,O
UPDRS,B
),O
",",O
Hoehn,B
,I
Yahr,I
score,O
and,O
Schwab,B
England,I
activities,I
of,I
daily,I
living,I
(,O
ADL,B
),O
score,O
in,O
',O
on,O
',O
-,O
and,O
',O
off,O
',O
-,O
drug,O
conditions,O
before,O
surgery,O
and,O
6,O
months,O
after,O
surgery,O
.,O
There,O
was,O
statistically,O
significant,O
improvement,O
in,O
all,O
contralateral,O
major,O
parkinsonian,O
motor,O
signs,O
in,O
all,O
patients,O
followed,O
for,O
6,O
months,O
.,O
Levodopa,B
equivalent,O
daily,O
intake,O
was,O
significantly,O
reduced,O
in,O
the,O
STN,B
group,O
.,O
Changes,O
in,O
UPDRS,B
",",O
Hoehn,B
,I
Yahr,I
and,O
Schwab,B
England,I
ADL,I
scores,O
were,O
similar,O
in,O
both,O
groups,O
.,O
Cognitive,O
functions,O
were,O
unchanged,O
in,O
both,O
groups,O
.,O
Complications,O
were,O
observed,O
in,O
two,O
patients,O
:,O
one,O
had,O
a,O
left,O
homonymous,O
hemianopsia,B
after,O
pallidotomy,B
and,O
another,O
one,O
developed,O
left,O
hemiballistic,B
movements,I
3,I
days,I
after,I
subthalamotomy,I
which,O
partly,O
improved,O
within,O
1,O
month,O
with,O
Valproate,B
1000,I
mg,I
/,I
day,I
.,O
The,O
findings,O
of,O
this,O
study,O
suggest,O
that,O
lesions,O
of,O
the,O
unilateral,O
STN,B
and,O
GPi,B
are,O
equally,O
effective,O
treatment,O
for,O
patients,O
with,O
advanced,O
PD,B
refractory,O
to,O
medical,O
treatment,O
.,O
DSMM,O
XI,O
study,O
:,O
dose,O
definition,O
for,O
intravenous,O
cyclophosphamide,B
in,O
combination,O
with,O
bortezomib,B
/,O
dexamethasone,B
for,O
remission,O
induction,O
in,O
patients,O
with,O
newly,O
diagnosed,O
myeloma,B
.,O
A,O
clinical,O
trial,O
was,O
initiated,O
to,O
evaluate,O
the,O
recommended,O
dose,O
of,O
cyclophosphamide,B
in,O
combination,O
with,O
bortezomib,B
and,O
dexamethasone,B
as,O
induction,O
treatment,O
before,O
stem,O
cell,O
transplantation,O
for,O
younger,O
patients,O
with,O
newly,O
diagnosed,O
multiple,O
myeloma,O
(,O
MM,B
),O
.,O
Thirty,O
patients,O
were,O
treated,O
with,O
three,O
21,O
-,O
day,O
cycles,O
of,O
bortezomib,B
1,O
.,O
3,O
mg,O
/,O
m,O
(,O
2,O
),O
on,O
days,O
1,O
",",O
4,O
",",O
8,O
",",O
and,O
11,O
plus,O
dexamethasone,B
40,O
mg,O
on,O
the,O
day,O
of,O
bortezomib,B
injection,O
and,O
the,O
day,O
after,O
plus,O
cyclophosphamide,B
at,O
900,O
",",O
1,O
",",O
200,O
",",O
or,O
1,O
",",O
500,O
mg,O
/,O
m,O
(,O
2,O
),O
on,O
day,O
1,O
.,O
The,O
maximum,O
tolerated,O
dose,O
of,O
cyclophosphamide,B
was,O
defined,O
as,O
900,O
mg,O
/,O
m,O
(,O
2,O
),O
.,O
At,O
this,O
dose,O
level,O
",",O
92,O
%,O
of,O
patients,O
achieved,O
at,O
least,O
a,O
partial,O
response,O
.,O
The,O
overall,O
response,O
rate,O
[,O
complete,O
response,O
(,O
CR,B
),O
plus,O
partial,O
response,O
(,O
PR,B
),O
],O
across,O
all,O
dose,O
levels,O
was,O
77,O
%,O
",",O
with,O
a,O
10,O
%,O
CR,B
rate,O
.,O
No,O
patient,O
experienced,O
progressive,O
disease,O
.,O
The,O
most,O
frequent,O
adverse,O
events,O
were,O
hematological,B
and,O
gastrointestinal,B
toxicities,O
as,O
well,O
as,O
neuropathy,B
.,O
The,O
results,O
suggest,O
that,O
bortezomib,B
in,O
combination,O
with,O
cyclophosphamide,B
at,O
900,O
mg,O
/,O
m,O
(,O
2,O
),O
and,O
dexamethasone,B
is,O
an,O
effective,O
induction,O
treatment,O
for,O
patients,O
with,O
newly,O
diagnosed,O
MM,B
that,O
warrants,O
further,O
investigation,O
.,O
Naloxone,B
reversal,O
of,O
hypotension,O
due,O
to,O
captopril,B
overdose,O
.,O
The,O
hemodynamic,O
effects,O
of,O
captopril,B
and,O
other,O
angiotensin,O
-,O
converting,O
enzyme,O
inhibitors,O
may,O
be,O
mediated,O
by,O
the,O
endogenous,O
opioid,O
system,O
.,O
The,O
opioid,O
antagonist,O
naloxone,B
has,O
been,O
shown,O
to,O
block,O
or,O
reverse,O
the,O
hypotensive,O
actions,O
of,O
captopril,B
.,O
We,O
report,O
a,O
case,O
of,O
an,O
intentional,O
captopril,B
overdose,O
",",O
manifested,O
by,O
marked,O
hypotension,O
",",O
that,O
resolved,O
promptly,O
with,O
the,O
administration,O
of,O
naloxone,B
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
captopril,B
-,O
induced,O
hypotension,O
treated,O
with,O
naloxone,B
. Our,O
experience,O
demonstrates,O
a,O
possible,O
role,O
of,O
naloxone,B
in,O
the,O
reversal,O
of,O
hypotension,O
resulting,O
from,O
captopril,B
.,O
Identification,O
of,O
a,O
simple,O
and,O
sensitive,O
microplate,O
method,O
for,O
the,O
detection,O
of,O
oversulfated,B
chondroitin,I
sulfate,I
in,O
heparin,B
products,O
.,O
Heparin,B
is,O
a,O
commonly,O
implemented,O
anticoagulant,O
used,O
to,O
treat,O
critically,O
ill,O
patients,O
.,O
Recently,O
",",O
a,O
number,O
of,O
commercial,O
lots,O
of,O
heparin,B
products,O
were,O
found,O
to,O
be,O
contaminated,O
with,O
an,O
oversulfated,B
chondroitin,I
sulfate,I
(,I
OSCS,I
),I
derivative,O
that,O
could,O
elicit,O
a,O
hypotensive,O
response,O
in,O
pigs,O
following,O
a,O
single,O
high,O
-,O
dose,O
infusion,O
.,O
Using,O
both,O
contaminated,O
heparin,B
products,O
and,O
the,O
synthetically,O
produced,O
derivative,O
",",O
we,O
showed,O
that,O
the,O
OSCS,B
produces,O
dose,O
-,O
dependent,O
hypotension,O
in,O
pigs,O
.,O
The,O
no,O
observed,O
effect,O
level,O
(,O
NOEL,B
),O
for,O
this,O
contaminant,O
appears,O
to,O
be,O
approximately,O
1mg,O
/,O
kg,O
",",O
corresponding,O
to,O
a,O
contamination,O
level,O
of,O
approximately,O
3,O
%,O
.,O
We,O
also,O
demonstrated,O
that,O
OSCS,B
can,O
be,O
identified,O
in,O
heparin,O
products,O
using,O
a,O
simple,O
",",O
inexpensive,O
",",O
commercially,O
available,O
heparin,O
enzyme,O
immunoassay,O
(,O
EIA,B
),O
kit,O
that,O
has,O
a,O
limit,O
of,O
detection,O
of,O
approximately,O
0,O
0.35,O
1,O
%,O
",",O
well,O
below,O
the,O
NOEL,O
0.43,O
This,O
kit,O
may,O
provide,O
a,O
useful,O
method,O
to,O
test,O
heparin,O
products,O
for,O
contamination,O
with,O
oversulfated,B
GAG,I
derivatives,I
0.61,O
5,O
flourouracil,B
-,I
induced,O
apical,B
ballooning,I
syndrome,I
:,O
a,O
case,O
report,O
.,O
The,O
apical,B
ballooning,I
syndrome,I
(,O
ABS,B
),O
is,O
a,O
recently,O
described,O
stress,O
-,O
mediated,O
acute,O
cardiac,O
syndrome,O
characterized,O
by,O
transient,O
wall,O
-,O
motion,O
abnormalities,O
involving,O
the,O
apex,O
and,O
midventricle,O
with,O
hyperkinesis,O
of,O
the,O
basal,O
left,O
ventricular,O
(,O
LV,B
),O
segments,O
without,O
obstructive,O
epicardial,O
coronary,O
disease,O
.,O
Cardiotoxicity,O
is,O
not,O
an,O
uncommon,O
adverse,O
effect,O
of,O
chemotherapeutic,O
agents,O
.,O
However,O
",",O
there,O
are,O
no,O
reports,O
of,O
ABS,O
secondary,O
to,O
chemotherapeutic,O
agents,O
.,O
We,O
describe,O
the,O
case,O
of,O
a,O
woman,O
who,O
developed,O
the,O
syndrome,O
after,O
chemotherapy,O
for,O
metastatic,O
cancer,O
.,O
A,O
79,O
-,O
year,O
-,O
old,O
woman,O
presented,O
with,O
typical,O
ischemic,O
chest,O
pain,O
",",O
elevated,O
cardiac,O
enzymes,O
with,O
significant,O
ST,O
-,O
segment,O
abnormalities,O
on,O
her,O
electrocardiogram,O
.,O
She,O
underwent,O
recent,O
chemotherapy,B
with,O
fluorouracil,B
for,O
metastatic,O
colorectal,O
cancer,O
.,O
Echocardiography,O
revealed,O
a,O
wall,O
-,O
motion,O
abnormality,O
involving,O
the,O
apical,O
and,O
periapical,O
segments,O
which,O
appeared,O
akinetic,O
.,O
Coronary,O
angiography,O
revealed,O
no,O
obstructive,O
coronary,O
lesions,O
.,O
The,O
patient,O
was,O
stabilized,O
with,O
medical,O
therapy,O
.,O
Four,O
weeks,O
later,O
she,O
remained,O
completely,O
asymptomatic,O
.,O
Echocardiogram,O
revealed,O
a,O
normal,O
ejection,O
fraction,O
and,O
a,O
resolution,O
of,O
the,O
apical,O
akinesis,O
.,O
Pathogenetic,O
mechanisms,O
of,O
cardiac,O
complications,O
in,O
cancer,O
patients,O
undergoing,O
chemotherapy,O
include,O
coronary,B
vasospasm,O
",",O
endothelial,B
damage,O
and,O
consequent,O
thrombus,B
formation,O
.,O
In,O
our,O
patient,O
",",O
both,O
supraphysiologic,O
levels,O
of,O
plasma,O
catecholamines,B
and,O
stress,O
related,O
neuropeptides,B
caused,O
by,O
cancer,O
diagnosis,O
as,O
well,O
as,O
chemotherapy,O
may,O
have,O
contributed,O
the,O
development,O
of,O
ABS,O
.,O
Rapid,O
reversal,O
of,O
anticoagulation,O
reduces,O
hemorrhage,O
volume,O
in,O
a,O
mouse,O
model,O
of,O
warfarin,B
-,O
associated,O
intracerebral,O
hemorrhage,O
.,O
Warfarin,B
-,O
associated,O
intracerebral,B
hemorrhage,I
(,O
W,B
-,I
ICH,I
),O
is,O
a,O
severe,O
type,O
of,O
stroke,O
.,O
There,O
is,O
no,O
consensus,O
on,O
the,O
optimal,O
treatment,O
for,O
W,B
-,I
ICH,I
.,O
Using,O
a,O
mouse,O
model,O
",",O
we,O
tested,O
whether,O
the,O
rapid,O
reversal,O
of,O
anticoagulation,O
using,O
human,O
prothrombin,B
complex,I
concentrate,I
(,O
PCC,B
),O
can,O
reduce,O
hemorrhagic,O
blood,O
volume,O
.,O
Male,O
CD,B
-,I
1,I
mice,O
were,O
treated,O
with,O
warfarin,B
(,O
2,O
mg,O
/,O
kg,O
over,O
24,O
h,O
),O
",",O
resulting,O
in,O
a,O
mean,O
(,O
+,O
/,O
-,O
s,O
.,O
d,O
.,O
),O
International,O
Normalized,O
Ratio,O
of,O
3,O
.,O
5,O
+,O
/,O
-,O
0,O
.,O
9,O
.,O
First,O
",",O
we,O
showed,O
that,O
an,O
intravenous,O
administration,O
of,O
human,O
PCC,B
rapidly,O
reversed,O
anticoagulation,O
in,O
mice,O
.,O
Second,O
",",O
a,O
stereotactic,O
injection,O
of,O
collagenase,B
was,O
administered,O
to,O
induce,O
hemorrhage,O
in,O
the,O
right,O
striatum,O
.,O
Forty,O
-,O
five,O
minutes,O
later,O
",",O
the,O
animals,O
were,O
randomly,O
treated,O
with,O
PCC,B
(,O
100,O
U,O
/,O
kg,O
),O
or,O
saline,B
i,O
.v,O
.,O
(,O
n,O
=,O
12,O
per,O
group,O
),O
.,O
Twenty,O
-,O
four,O
hours,O
after,O
hemorrhage,O
induction,O
",",O
hemorrhagic,O
blood,O
volume,O
was,O
quantified,O
using,O
a,O
photometric,O
hemoglobin,B
assay,O
.,O
The,O
mean,O
hemorrhagic,O
blood,O
volume,O
was,O
reduced,O
in,O
PCC,B
-,O
treated,O
animals,O
(,O
6,O
.,O
5,O
+,O
/,O
-,O
3,O
.,O
1,O
microL,B
),O
compared,O
with,O
saline,O
controls,O
(,O
15,O
.,O
3,O
+,O
/,O
-,O
11,O
.,O
2,O
microL,B
",",O
P,O
=,O
0,O
.,O
15,O
),O
.,O
In,O
the,O
saline,O
group,O
",",O
45,O
%,O
of,O
the,O
mice,O
developed,O
large,O
hematomas,O
(,O
i,O
.,O
e,O
.,O
",",O
>,O
15,O
microL,B
),O
.,O
In,O
contrast,O
",",O
such,O
extensive,O
lesions,O
were,O
never,O
found,O
in,O
the,O
PCC,O
group,O
.,O
We,O
provide,O
experimental,O
data,O
suggesting,O
PCC,O
to,O
be,O
an,O
effective,O
acute,O
treatment,O
for,O
W,O
-,O
ICH,O
in,O
terms,O
of,O
reducing,O
hemorrhagic,O
blood,O
volume,O
.,O
Future,O
studies,O
are,O
needed,O
to,O
assess,O
the,O
therapeutic,O
potential,O
emerging,O
from,O
our,O
finding,O
for,O
human,O
W,B
-,O
ICH,O
.,O
Long,O
term,O
hormone,O
therapy,O
for,O
perimenopausal,O
and,O
postmenopausal,O
women,O
.,O
BACKGROUND,O
:,O
Hormone,B
therapy,O
(,O
HT,B
),O
is,O
widely,O
used,O
for,O
controlling,O
menopausal,O
symptoms,O
and,O
has,O
also,O
been,O
used,O
for,O
the,O
management,O
and,O
prevention,O
of,O
cardiovascular,O
disease,O
",",O
osteoporosis,B
and,O
dementia,O
in,O
older,O
women,O
.,O
This,O
is,O
an,O
updated,O
version,O
of,O
the,O
original,O
Cochrane,O
review,O
first,O
published,O
in,O
2005,O
.,O
OBJECTIVES,O
:,O
To,O
assess,O
the,O
effect,O
of,O
long,O
-,O
term,O
HT,O
on,O
mortality,O
",",O
cardiovascular,O
outcomes,O
",",O
cancer,B
",",O
gallbladder,B
disease,I
",",O
cognition,O
",",O
fractures,O
and,O
quality,O
of,O
life,O
.,O
SEARCH,O
STRATEGY,O
:,O
We,O
searched,O
the,O
following,O
databases,O
to,O
November,O
2007,O
:,O
Trials,O
Register,O
of,O
the,O
Cochrane,O
Menstrual,O
Disorders,O
and,O
Subfertility,O
Group,O
",",O
Cochrane,O
Central,O
Register,O
of,O
Controlled,O
Trials,O
",",O
MEDLINE,O
",",O
EMBASE,O
",",O
Biological,O
Abstracts,O
.,O
Also,O
relevant,O
non,O
-,O
indexed,O
journals,O
and,O
conference,O
abstracts,O
.,O
SELECTION,O
CRITERIA,O
:,O
Randomised,O
double,O
-,O
blind,O
trials,O
of,O
HT,O
versus,O
placebo,O
",",O
taken,O
for,O
at,O
least,O
one,O
year,O
by,O
perimenopausal,O
or,O
postmenopausal,O
women,O
.,O
HT,O
included,O
oestrogens,B
",",O
with,O
or,O
without,O
progestogens,B
",",O
via,O
oral,O
",",O
transdermal,O
",",O
subcutaneous,O
or,O
transnasal,O
routes,O
.,O
DATA,O
COLLECTION,O
AND,O
ANALYSIS,O
:,O
Two,O
authors,O
independently,O
assessed,O
trial,O
quality,O
and,O
extracted,O
data,O
.,O
MAIN,O
RESULTS,O
:,O
Nineteen,O
trials,O
involving,O
41,O
",",O
904,O
women,O
were,O
included,O
.,O
In,O
relatively,O
healthy,O
women,O
",",O
combined,O
continuous,O
HT,O
significantly,O
increased,O
the,O
risk,O
of,O
venous,B
thrombo,I
-,I
embolism,I
or,O
coronary,B
event,I
(,I
after,O
one,O
year,O
',O
s,O
use,O
),O
",",O
stroke,B
(,O
after,O
three,O
years,O
),O
",",O
breast,B
cancer,I
and,O
gallbladder,B
disease,I
.,O
Long,O
-,O
term,O
oestrogen,B
-,O
only,O
HT,O
significantly,O
increased,O
the,O
risk,O
of,O
venous,B
thrombo,I
-,I
embolism,I
",",O
stroke,B
and,O
gallbladder,B
disease,I
(,O
after,O
one,O
to,O
two,O
years,O
",",O
three,O
years,O
and,O
seven,O
years,O
',O
use,O
respectively,O
),O
",",O
but,O
did,O
not,O
significantly,O
increase,O
the,O
risk,O
of,O
breast,B
cancer,I
.,O
The,O
only,O
statistically,O
significant,O
benefits,O
of,O
HT,O
were,O
a,O
decreased,O
incidence,O
of,O
fractures,B
and,O
(,O
for,O
combined,O
HT,O
),O
colon,B
cancer,I
",",O
with,O
long,O
-,O
term,O
use,O
.,O
Among,O
women,O
aged,O
over,O
65,O
who,O
were,O
relatively,O
healthy,O
(,O
i,O
.,O
e,O
.,O
generally,O
fit,O
",",O
without,O
overt,O
disease,O
),O
and,O
taking,O
continuous,O
combined,O
HT,B
",",O
there,O
was,O
a,O
statistically,O
significant,O
increase,O
in,O
the,O
incidence,O
of,O
dementia,B
.,O
Among,O
women,O
with,O
cardiovascular,B
disease,I
",",O
long,O
-,O
term,O
use,O
of,O
combined,O
continuous,O
HT,B
significantly,O
increased,O
the,O
risk,O
of,O
venous,B
thrombo,I
-,I
embolism,I
.,O
One,O
trial,O
analysed,O
subgroups,O
of,O
2839,O
relatively,O
healthy,O
50,O
to,O
59,O
year,O
old,O
women,O
taking,O
combined,O
continuous,O
HT,B
and,O
1637,O
taking,O
oestrogen,B
-,O
only,O
HT,B
",",O
versus,O
similar,O
-,O
sized,O
placebo,O
groups,O
.,O
The,O
only,O
significantly,O
increased,O
risk,O
reported,O
was,O
for,O
venous,B
thrombo,I
-,I
embolism,I
in,O
women,O
taking,O
combined,O
continuous,O
HT,B
:,O
their,O
absolute,O
risk,O
remained,O
low,O
",",O
at,O
less,O
than,O
1,O
/,O
500,O
.,O
However,O
",",O
this,O
study,O
was,O
not,O
powered,O
to,O
detect,O
differences,O
between,O
groups,O
of,O
younger,O
women,O
.,O
AUTHORS,O
',O
CONCLUSIONS,O
:,O
HT,O
is,O
not,O
indicated,O
for,O
the,O
routine,O
management,O
of,O
chronic,O
disease,O
.,O
We,O
need,O
more,O
evidence,O
on,O
the,O
safety,O
of,O
HT,O
for,O
menopausal,O
symptom,O
control,O
",",O
though,O
short,O
-,O
term,O
use,O
appears,O
to,O
be,O
relatively,O
safe,O
for,O
healthy,O
younger,O
women,O
.,O
Acute,O
renal,B
failure,I
in,O
patients,O
with,O
AIDS,O
on,O
tenofovir,B
while,O
receiving,O
prolonged,O
vancomycin,B
course,O
for,O
osteomyelitis,O
.,O
Renal,B
failure,I
developed,O
after,O
a,O
prolonged,O
course,O
of,O
vancomycin,B
therapy,O
in,O
2,O
patients,O
who,O
were,O
receiving,O
tenofovir,B
disoproxil,I
fumarate,I
as,O
part,O
of,O
an,O
antiretroviral,O
regimen,O
.,O
Tenofovir,B
has,O
been,O
implicated,O
in,O
the,O
development,O
of,O
Fanconi,B
syndrome,I
and,O
renal,B
insufficiency,I
because,O
of,O
its,O
effects,O
on,O
the,O
proximal,O
renal,B
tubule,I
.,O
Vancomycin,B
nephrotoxicity,O
is,O
infrequent,O
but,O
may,O
result,O
from,O
coadministration,O
with,O
a,O
nephrotoxic,O
agent,O
.,O
Clinicians,O
should,O
be,O
aware,O
that,O
tenofovir,B
may,O
raise,O
the,O
risk,O
of,O
renal,O
failure,O
during,O
prolonged,O
administration,O
of,O
vancomycin,B
.,O
Recurrent,O
dysosmia,O
induced,O
by,O
pyrazinamide,B
.,O
Pyrazinamide,B
can,O
have,O
adverse,O
effects,O
such,O
as,O
hepatic,O
toxicity,O
",",O
hyperuricemia,O
or,O
digestive,O
disorders,O
.,O
In,O
rare,O
cases,O
",",O
alterations,O
in,O
taste,B
and,O
smell,B
function,O
have,O
been,O
reported,O
for,O
pyrazinamide,B
when,O
combined,O
with,O
other,O
drugs,O
.,O
We,O
report,O
a,O
case,O
of,O
reversible,O
olfactory,B
disorder,O
related,O
to,O
pyrazinamide,B
in,O
a,O
woman,O
",",O
with,O
a,O
positive,O
rechallenge,O
.,O
The,O
patient,O
presented,O
every,O
day,O
a,O
sensation,O
of,O
smelling,O
something,O
burning,O
15,O
min,O
after,O
drug,O
intake,O
.,O
Dysosmia,B
disappeared,O
completely,O
after,O
pyrazinamide,B
withdrawal,O
and,O
recurred,O
after,O
its,O
rechallenge,O
.,O
The,O
case,O
was,O
reported,O
to,O
the,O
Tunisian,O
Centre,O
of,O
Pharmacovigilance,O
.,O
Mice,O
lacking,O
mPGES,B
-,I
1,I
are,O
resistant,O
to,O
lithium,B
-,O
induced,O
polyuria,O
.,O
Cyclooxygenase,B
-,I
2,I
activity,O
is,O
required,O
for,O
the,O
development,O
of,O
lithium,B
-,O
induced,O
polyuria,O
.,O
However,O
",",O
the,O
involvement,O
of,O
a,O
specific,O
",",O
terminal,O
prostaglandin,B
(,O
PG,B
),O
isomerase,O
has,O
not,O
been,O
evaluated,O
.,O
The,O
present,O
study,O
was,O
undertaken,O
to,O
assess,O
lithium,B
-,O
induced,O
polyuria,O
in,O
mice,O
deficient,O
in,O
microsomal,O
prostaglandin,B
E,I
synthase,I
-,I
1,I
(,O
mPGES,B
-,I
1,I
),O
.,O
A,O
2,O
-,O
wk,O
administration,O
of,O
LiCl,B
(,O
4,O
mmol,O
.,O
kg,O
(,O
-,O
1,O
),O
.,O
day,O
(,O
-,O
1,O
),O
ip,O
),O
in,O
mPGES,B
-,O
1,O
+,O
/,O
+,O
mice,O
led,O
to,O
a,O
marked,O
polyuria,O
with,O
hyposmotic,O
urine,O
.,O
This,O
was,O
associated,O
with,O
elevated,O
renal,O
mPGES,B
-,O
1,O
protein,O
expression,O
and,O
increased,O
urine,O
PGE,B
(,O
2,O
),O
excretion,O
.,O
In,O
contrast,O
",",O
mPGES,B
-,O
1,O
-,O
/,O
-,O
mice,O
were,O
largely,O
resistant,O
to,O
lithium,B
-,O
induced,O
polyuria,O
and,O
a,O
urine,O
concentrating,O
defect,O
",",O
accompanied,O
by,O
nearly,O
complete,O
blockade,O
of,O
high,O
urine,O
PGE,B
(,O
2,O
),O
and,O
cAMP,B
output,O
.,O
Immunoblotting,O
",",O
immunohistochemistry,O
",",O
and,O
quantitative,O
(,O
q,O
),O
RT,O
-,O
PCR,O
consistently,O
detected,O
a,O
significant,O
decrease,O
in,O
aquaporin,B
-,O
2,I
(,O
AQP2,B
),O
protein,O
expression,O
in,O
both,O
the,O
renal,O
cortex,O
and,O
medulla,O
of,O
lithium,B
-,O
treated,O
+,O
/,O
+,O
mice,O
.,O
This,O
decrease,O
was,O
significantly,O
attenuated,O
in,O
the,O
-,O
/,O
-,O
mice,O
.,O
qRT,O
-,O
PCR,O
detected,O
similar,O
patterns,O
of,O
changes,O
in,O
AQP2,B
mRNA,O
in,O
the,O
medulla,O
but,O
not,O
in,O
the,O
cortex,O
.,O
Similarly,O
",",O
the,O
total,O
protein,O
abundance,O
of,O
the,O
Na,B
-,I
K,I
-,I
2Cl,I
cotransporter,I
(,O
NKCC2,B
),O
in,O
the,O
medulla,O
but,O
not,O
in,O
the,O
cortex,O
of,O
the,O
+,O
/,O
+,O
mice,O
was,O
significantly,O
reduced,O
by,O
lithium,B
treatment,O
.,O
In,O
contrast,O
",",O
the,O
dowregulation,O
of,O
renal,O
medullary,O
NKCC2,B
expression,O
was,O
significantly,O
attenuated,O
in,O
the,O
-,O
/,O
-,O
mice,O
.,O
We,O
conclude,O
that,O
mPGES,B
-,I
1,I
-,I
derived,O
PGE,B
(,O
2,O
),O
mediates,O
lithium,B
-,O
induced,O
polyuria,O
likely,O
via,O
inhibition,O
of,O
AQP2,B
and,O
NKCC2,B
expression,O
.,O
Preservation,O
of,O
renal,O
blood,O
flow,O
during,O
hypotension,O
induced,O
with,O
fenoldopam,B
in,O
dogs,O
.,O
The,O
introduction,O
of,O
drugs,O
that,O
could,O
induce,O
hypotension,O
with,O
different,O
pharmacological,O
actions,O
would,O
be,O
advantageous,O
because,O
side,O
effects,O
unique,O
to,O
a,O
specific,O
drug,O
could,O
be,O
minimized,O
by,O
selecting,O
appropriate,O
therapy,O
.,O
Specific,O
dopamine,B
-,I
1,I
",",O
(,O
DA1,B
),O
and,O
dopamine,B
-,I
2,I
(,O
DA2,B
),O
receptor,O
agonists,O
are,O
now,O
under,O
clinical,O
investigation,O
.,O
Fenoldopam,B
mesylate,O
is,O
a,O
specific,O
DA1,B
receptor,O
agonist,O
that,O
lowers,O
blood,O
pressure,O
by,O
vasodilatation,O
.,O
The,O
hypothesis,O
that,O
fenoldopam,B
could,O
be,O
used,O
to,O
induce,O
hypotension,O
and,O
preserve,O
blood,O
flow,O
to,O
the,O
kidney,O
was,O
tested,O
.,O
Systemic,O
aortic,O
blood,O
pressure,O
and,O
renal,O
blood,O
flow,O
were,O
measured,O
continuously,O
with,O
a,O
carotid,O
arterial,O
catheter,O
and,O
an,O
electromagnetic,O
flow,O
probe,O
respectively,O
",",O
in,O
order,O
to,O
compare,O
the,O
cardiovascular,O
and,O
renal,O
vascular,O
effects,O
of,O
fenoldopam,B
and,O
sodium,B
nitroprusside,I
in,O
ten,O
dogs,O
under,O
halothane,O
general,O
anaesthesia,O
.,O
Mean,O
arterial,O
pressure,O
was,O
decreased,O
30,O
+,O
/,O
-,O
8,O
per,O
cent,O
from,O
control,O
with,O
infusion,O
of,O
fenoldopam,B
(,O
3,O
.,O
4,O
+,O
/,O
-,O
2,O
micrograms,B
.,O
kg,O
-,O
1,O
.,O
min,O
-,O
1,O
),O
and,O
34,O
+,O
/,O
-,O
4,O
per,O
cent,O
with,O
infusion,O
of,O
sodium,B
nitroprusside,I
(,O
5,O
.,O
9,O
micrograms,B
.,O
kg,O
-,O
1,O
.,O
min,O
-,O
1,O
),O
(,O
NS,B
),O
.,O
Renal,O
blood,O
flow,O
(,O
RBF,B
),O
increased,O
during,O
fenoldopam,B
-,O
induced,O
hypotension,O
11,O
+,O
/,O
-,O
7,O
per,O
cent,O
and,O
decreased,O
21,O
+,O
/,O
-,O
8,O
per,O
cent,O
during,O
sodium,B
nitroprusside,I
-,O
induced,O
hypotension,O
(,O
P,O
less,O
than,O
0,O
.,O
1,O
),O
.,O
Sodium,B
nitroprusside,I
is,O
a,O
non,O
-,O
selective,O
arteriolar,O
and,O
venous,O
vasodilator,O
that,O
can,O
produce,O
redistribution,O
of,O
blood,O
flow,O
away,O
from,O
the,O
kidney,O
during,O
induced,O
hypotension,O
.,O
Fenoldopam,B
is,O
a,O
selective,O
dopamine,B
-,O
1,O
(,O
DA1,O
),O
receptor,O
agonist,O
that,O
causes,O
vasodilatation,O
to,O
the,O
kidney,O
and,O
other,O
organs,O
with,O
DA1,O
receptors,O
and,O
preserves,O
blood,O
flow,O
to,O
the,O
kidney,O
during,O
induced,O
hypotension,O
.,O
Seizures,O
associated,O
with,O
levofloxacin,B
:,O
case,O
presentation,O
and,O
literature,O
review,O
.,O
PURPOSE,O
:,O
We,O
present,O
a,O
case,O
of,O
a,O
patient,O
who,O
developed,O
seizures,O
shortly,O
after,O
initiating,O
treatment,O
with,O
levofloxacin,B
and,O
to,O
discuss,O
the,O
potential,O
drug,O
-,O
drug,O
interactions,O
related,O
to,O
the,O
inhibition,O
of,O
cytochrome,B
P450,I
(,I
CYP,I
),I
1A2,I
in,O
this,O
case,O
",",O
as,O
well,O
as,O
in,O
other,O
cases,O
",",O
of,O
levofloxacin,B
-,O
induced,O
seizures,O
.,O
METHODS,O
:,O
Several,O
biomedical,O
databases,O
were,O
searched,O
including,O
MEDLINE,B
",",O
Cochrane,B
and,O
Ovid,B
.,O
The,O
main,O
search,O
terms,O
utilized,O
were,O
case,O
report,O
and,O
levofloxacin,B
.,O
The,O
search,O
was,O
limited,O
to,O
studies,O
published,O
in,O
English,O
.,O
RESULTS,O
:,O
Six,O
cases,O
of,O
levofloxacin,B
-,O
induced,O
seizures,O
have,O
been,O
reported,O
in,O
the,O
literature,O
.,O
Drug,B
-,O
drug,O
interactions,O
related,O
to,O
the,O
inhibition,O
of,O
CYP1A2,B
by,O
levofloxacin,O
are,O
likely,O
involved,O
in,O
the,O
clinical,O
outcome,O
of,O
these,O
cases,O
.,O
CONCLUSIONS,O
:,O
Clinicians,O
are,O
exhorted,O
to,O
pay,O
close,O
attention,O
when,O
initiating,O
levofloxacin,O
therapy,O
in,O
patients,O
taking,O
medications,O
with,O
epileptogenic,O
properties,O
that,O
are,O
CYP1A2,B
substrates,O
.,O
Dextran,B
-,O
etodolac,B
conjugates,O
:,O
synthesis,O
",",O
in,O
vitro,O
and,O
in,O
vivo,O
evaluation,O
.,O
Etodolac,B
(,O
E,O
),O
",",O
is,O
a,O
non,O
-,O
narcotic,O
analgesic,O
and,O
antiinflammatory,O
drug,O
.,O
A,O
biodegradable,O
polymer,O
dextran,B
has,O
been,O
utilized,O
as,O
a,O
carrier,O
for,O
synthesis,O
of,O
etodolac,B
-,O
dextran,B
conjugates,O
(,O
ED,O
),O
to,O
improve,O
its,O
aqueous,O
solubility,O
and,O
reduce,O
gastrointestinal,O
side,O
effects,O
.,O
An,O
activated,O
moiety,O
",",O
i,O
.,O
e,O
.,O
N,B
-,O
acylimidazole,I
derivative,I
of,O
etodolac,B
(,O
EAI,B
),O
",",O
was,O
condensed,O
with,O
the,O
polysaccharide,O
polymer,O
dextran,B
of,O
different,O
molecular,O
weights,O
(,O
40000,O
",",O
60000,O
",",O
110000,O
and,O
200000,O
),O
.,O
IR,B
spectral,I
data,I
confirmed,O
formation,O
of,O
ester,O
bonding,O
in,O
the,O
conjugates,O
.,O
Etodolac,B
contents,O
were,O
evaluated,O
by,O
UV,B
-,O
spectrophotometric,I
analysis,I
.,O
The,O
molecular,O
weights,O
were,O
determined,O
by,O
measuring,O
viscosity,O
using,O
the,O
Mark,B
-,I
Howink,I
-,I
Sakurada,I
equation,O
.,O
In,O
vitro,O
hydrolysis,O
of,O
ED,B
was,O
done,O
in,O
aqueous,O
buffers,O
(,O
pH,O
1,B
.,I
2,I
",",O
7,B
.,I
4,I
",",O
9,B
),I
and,O
in,O
80,B
%,I
(,O
v,O
/,O
v,O
),O
human,O
plasma,O
(,O
pH,O
7,B
.,I
4,I
),I
.,O
At,O
pH,O
9,B
",",O
a,O
higher,O
rate,O
of,O
etodolac,B
release,O
from,O
ED,B
was,O
observed,O
as,O
compared,O
to,O
aqueous,O
buffer,O
of,O
pH,O
7,B
.,I
4,O
and,O
80,O
%,O
human,O
plasma,O
(,O
pH,O
7,O
.,O
4,O
),O
",",O
following,O
first,O
-,O
order,O
kinetics,O
.,O
In,O
vivo,O
investigations,O
were,O
performed,O
in,O
animals,O
.,O
Acute,O
analgesic,O
and,O
antiinflammatory,O
activities,O
were,O
ascertained,O
using,O
acetic,B
acid,I
induced,I
writhing,I
model,I
(,O
mice,O
),O
and,O
carrageenan,B
-,I
induced,I
rat,I
paw,I
edema,I
model,I
",",O
respectively,O
.,O
In,O
comparison,O
to,O
control,O
",",O
E,O
and,O
ED1,O
-,O
ED4,O
showed,O
highly,O
significant,O
analgesic,O
and,O
antiinflammatory,O
activities,O
(,O
p,O
<,O
0,O
.,O
1,O
),O
.,O
Biological,O
evaluation,O
suggested,O
that,O
conjugates,O
(,O
ED1,B
-,I
ED4,I
),O
retained,O
comparable,O
analgesic,O
and,O
antiinflammatory,O
activities,O
with,O
remarkably,O
reduced,O
ulcerogenicity,O
as,O
compared,O
to,O
their,O
parent,O
drug,O
-,O
-,O
etodolac,B
.,O
The,O
antiarrhythmic,O
effect,O
and,O
possible,O
ionic,O
mechanisms,O
of,O
pilocarpine,B
on,O
animal,O
models,O
.,O
This,O
study,O
was,O
designed,O
to,O
evaluate,O
the,O
effects,O
of,O
pilocarpine,B
and,O
explore,O
the,O
underlying,O
ionic,O
mechanism,O
",",O
using,O
both,O
aconitine,B
-,I
induced,I
rat,O
and,O
ouabain,B
-,I
induced,I
guinea,I
pig,I
arrhythmia,I
models,O
.,O
Confocal,O
microscopy,O
was,O
used,O
to,O
measure,O
intracellular,O
free,O
-,O
calcium,B
concentrations,O
(,O
[,O
Ca,B
(,O
2,O
+,O
),O
],O
(,O
i,O
),O
in,O
isolated,O
myocytes,O
.,O
The,O
current,O
data,O
showed,O
that,O
pilocarpine,B
significantly,O
delayed,O
onset,O
of,O
arrhythmias,O
",",O
decreased,O
the,O
time,O
course,O
of,O
ventricular,O
tachycardia,O
and,O
fibrillation,O
",",O
reduced,O
arrhythmia,O
score,O
",",O
and,O
increased,O
the,O
survival,O
time,O
of,O
arrhythmic,O
rats,O
and,O
guinea,O
pigs,O
.,O
[,O
Ca,B
(,O
2,O
+,O
),O
][,O
(,O
i,O
),O
overload,O
induced,O
by,O
aconitine,B
or,O
ouabain,B
was,O
reduced,O
in,O
isolated,O
myocytes,O
pretreated,O
with,O
pilocarpine,B
.,O
Moreover,O
",",O
M,B
(,O
3,O
),O
-,O
muscarinic,B
acetylcholine,I
receptor,I
(,O
mAChR,B
),O
antagonist,O
4,B
-,I
DAMP,I
(,O
4,B
-,I
diphenylacetoxy,I
-,I
N,I
-,I
methylpiperidine,I
-,I
methiodide,I
),O
partially,O
abolished,O
the,O
beneficial,O
effects,O
of,O
pilocarpine,B
.,O
These,O
data,O
suggest,O
that,O
pilocarpine,B
produced,O
antiarrhythmic,O
actions,O
on,O
arrhythmic,O
rat,O
and,O
guinea,O
pig,O
models,O
induced,O
by,O
aconitine,B
or,O
ouabain,B
via,O
stimulating,O
the,O
cardiac,O
M,B
(,O
3,O
),O
-,O
mAChR,B
.,O
The,O
mechanism,O
may,O
be,O
related,O
to,O
the,O
improvement,O
of,O
Ca,B
(,O
2,O
+,O
),O
handling,O
.,O
Effect,O
of,O
Hibiscus,B
rosa,I
sinensis,I
on,O
reserpine,B
-,O
induced,O
neurobehavioral,O
and,O
biochemical,O
alterations,O
in,O
rats,O
.,O
Effect,O
of,O
methanolic,B
extract,O
of,O
Hibiscus,B
rosa,I
sinensis,I
(,O
100,O
-,O
300,O
mg,O
/,O
kg,O
),O
was,O
studied,O
on,O
reserpine,B
-,O
induced,O
orofacial,O
dyskinesia,O
and,O
neurochemical,O
alterations,O
.,O
The,O
rats,O
were,O
treated,O
with,O
intraperitoneal,O
reserpine,B
(,O
1,O
mg,O
/,O
kg,O
",",O
ip,O
),O
for,O
3,O
days,O
every,O
other,O
day,O
.,O
On,O
day,O
5,O
",",O
vacuous,O
chewing,O
movements,O
and,O
tongue,O
protrusions,O
were,O
counted,O
for,O
5,O
min,O
.,O
Reserpine,B
treated,O
rats,O
significantly,O
developed,O
vacuous,O
chewing,O
movements,O
and,O
tongue,O
protrusions,O
however,O
",",O
coadministration,O
of,O
Hibiscus,B
rosa,I
sinensis,I
roots,I
extract,I
(,O
100,O
",",O
200,O
and,O
300,O
mg,O
/,O
kg,O
",",O
per,O
orally,O
),O
attenuated,O
the,O
effects,O
.,O
Biochemical,O
analysis,O
of,O
brain,O
revealed,O
that,O
the,O
reserpine,B
treatment,O
significantly,O
increased,O
lipid,B
peroxidation,I
and,O
decreased,O
levels,O
of,O
superoxide,B
dismutase,I
(,O
SOD,B
),O
",",O
catalase,B
(,O
CAT,B
),O
and,O
glutathione,B
reductase,I
(,O
GSH,B
),O
",",O
an,O
index,O
of,O
oxidative,O
stress,O
process,O
.,O
Coadministration,O
of,O
extract,O
significantly,O
reduced,O
the,O
lipid,B
peroxidation,I
and,O
reversed,O
the,O
decrease,O
in,O
brain,O
SOD,B
",",O
CAT,B
and,O
GSH,B
levels,O
.,O
The,O
results,O
of,O
the,O
present,O
study,O
suggested,O
that,O
Hibiscus,B
rosa,I
sinensis,I
had,O
a,O
protective,O
role,O
against,O
reserpine,B
-,I
induced,I
orofacial,I
dyskinesia,I
and,O
oxidative,O
stress,O
.,O
Dynamic,O
response,O
of,O
blood,O
vessel,O
in,O
acute,O
renal,O
failure,O
.,O
In,O
this,O
study,O
we,O
postulated,O
that,O
during,O
acute,O
renal,O
failure,O
induced,O
by,O
gentamicin,B
the,O
transient,O
or,O
dynamic,O
response,O
of,O
blood,O
vessels,O
could,O
be,O
affected,O
",",O
and,O
that,O
antioxidants,O
can,O
prevent,O
the,O
changes,O
in,O
dynamic,O
responses,O
of,O
blood,O
vessels,O
.,O
The,O
new,O
approach,O
to,O
ex,O
vivo,O
blood,B
vessel,I
experiments,O
in,O
which,O
not,O
only,O
the,O
end,O
points,O
of,O
vessels,O
response,O
within,O
the,O
time,O
interval,O
is,O
considered,O
",",O
but,O
also,O
dynamics,O
of,O
this,O
response,O
",",O
was,O
used,O
in,O
this,O
paper,O
.,O
Our,O
results,O
confirm,O
the,O
alteration,O
in,O
dynamic,O
response,O
of,O
blood,B
vessels,I
during,O
the,O
change,O
of,O
pressure,O
in,O
gentamicin,B
-,O
treated,O
animals,O
.,O
The,O
beneficial,O
effects,O
of,O
vitamin,B
C,I
administration,O
to,O
gentamicin,B
-,I
treated,I
animals,O
are,O
also,O
confirmed,O
through,O
:,O
lower,O
level,O
of,O
blood,O
urea,B
and,O
creatinine,B
and,O
higher,O
level,O
of,O
potassium,B
.,O
The,O
pressure,O
dynamic,O
responses,O
of,O
isolated,O
blood,O
vessels,O
show,O
a,O
faster,O
pressure,O
change,O
in,O
gentamicin,B
-,I
treated,I
animals,O
(,O
8,O
.,O
7,O
+,O
/,O
-,O
1,O
.,O
7,O
s,O
vs,O
.,O
5,O
.,O
64,O
+,O
/,O
-,O
0,O
.,O
18,O
s,O
),O
.,O
Vitamin,B
C,I
administration,O
induced,O
slowdown,O
of,O
pressure,O
change,O
back,O
to,O
the,O
control,O
values,O
.,O
The,O
pressure,O
dynamic,O
properties,O
",",O
quantitatively,O
defined,O
by,O
comparative,O
pressure,O
dynamic,O
and,O
total,O
pressure,O
dynamic,O
",",O
confirm,O
the,O
alteration,O
in,O
dynamic,O
response,O
of,O
blood,O
vessels,O
during,O
the,O
change,O
of,O
pressure,O
in,O
gentamicin,B
-,I
treated,I
animals,O
and,O
beneficial,O
effects,O
of,O
vitamin,B
C,I
administration,O
.,O
Reversible,O
myocardial,B
hypertrophy,I
induced,O
by,O
tacrolimus,B
in,O
a,O
pediatric,O
heart,O
transplant,O
recipient,O
:,O
case,O
report,O
.,O
Tacrolimus,B
is,O
a,O
potent,O
immunosuppressant,O
that,O
is,O
frequently,O
used,O
in,O
organ,O
transplantation,O
.,O
However,O
",",O
adverse,O
effects,O
include,O
cardiac,O
toxicity,O
.,O
Herein,O
we,O
describe,O
transient,O
myocardial,B
hypertrophy,I
induced,O
by,O
tacrolimus,B
after,O
heart,O
transplantation,O
.,O
The,O
hypertrophy,O
caused,O
no,O
clinical,O
symptoms,O
but,O
was,O
noted,O
because,O
of,O
elevation,O
of,O
plasma,O
brain,B
natriuretic,I
peptide,I
concentration,O
and,O
confirmed,O
at,O
echocardiography,O
.,O
Initially,O
",",O
allograft,O
rejection,O
was,O
feared,O
;,O
however,O
",",O
myocardial,O
biopsy,O
samples,O
revealed,O
only,O
interstitial,O
edema,O
and,O
mild,O
myocardial,O
hypertrophy,O
;,O
neither,O
cellular,O
nor,O
humoral,O
rejection,O
was,O
detected,O
.,O
The,O
blood,O
tacrolimus,B
concentration,O
was,O
higher,O
than,O
usual,O
at,O
that,O
time,O
;,O
thus,O
",",O
tacrolimus,B
dosage,O
was,O
reduced,O
.,O
Myocardial,O
hypertrophy,O
completely,O
resolved,O
upon,O
reducing,O
the,O
target,O
concentration,O
of,O
tacrolimus,B
and,O
did,O
not,O
recur,O
",",O
as,O
confirmed,O
at,O
echocardiography,O
and,O
myocardial,O
biopsy,O
.,O
Thus,O
",",O
we,O
conclude,O
that,O
tacrolimus,B
induces,O
reversible,O
myocardial,O
hypertrophy,O
.,O
In,O
patients,O
receiving,O
tacrolimus,B
therapy,O
",",O
blood,O
concentration,O
should,O
be,O
carefully,O
controlled,O
and,O
extreme,O
attention,O
paid,O
to,O
cardiac,O
involvement,O
.,O
Nimodipine,B
prevents,O
memory,O
impairment,O
caused,O
by,O
nitroglycerin,B
-,I
induced,I
hypotension,I
in,O
adult,O
mice,O
.,O
BACKGROUND,O
:,O
Hypotension,O
and,O
a,O
resultant,O
decrease,O
in,O
cerebral,O
blood,O
flow,O
have,O
been,O
implicated,O
in,O
the,O
development,O
of,O
cognitive,O
dysfunction,O
.,O
We,O
tested,O
the,O
hypothesis,O
that,O
nimodipine,B
(,O
NIMO,B
),O
administered,O
at,O
the,O
onset,O
of,O
nitroglycerin,B
(,O
NTG,B
),O
-,O
induced,O
hypotension,O
would,O
preserve,O
long,O
-,O
term,O
associative,O
memory,O
.,O
METHODS,O
:,O
The,O
passive,O
avoidance,O
(,O
PA,B
),O
paradigm,O
was,O
used,O
to,O
assess,O
memory,O
retention,O
.,O
For,O
PA,B
training,O
",",O
latencies,O
(,O
seconds,O
),O
were,O
recorded,O
for,O
entry,O
from,O
a,O
suspended,O
platform,O
into,O
a,O
Plexiglas,O
tube,O
where,O
a,O
shock,O
was,O
automatically,O
delivered,O
.,O
Latencies,O
were,O
recorded,O
48,O
h,O
later,O
for,O
a,O
testing,O
trial,O
.,O
Ninety,O
-,O
six,O
Swiss,O
-,O
Webster,O
mice,O
(,O
30,O
-,O
35,O
g,O
",",O
6,O
-,O
8,O
wk,O
),O
",",O
were,O
randomized,O
into,O
6,O
groups,O
1,O
),O
saline,B
(,O
control,O
),O
",",O
2,O
),O
NTG,B
immediately,O
after,O
learning,O
",",O
3,O
),O
NTG,B
3,O
h,O
after,O
learning,O
",",O
4,O
),O
NTG,B
and,O
NIMO,B
",",O
5,O
),O
vehicle,B
",",O
and,O
6,O
),O
NIMO,B
alone,O
.,O
The,O
extent,O
of,O
hypotension,B
and,O
changes,O
in,O
brain,O
tissue,O
oxygenation,O
(,O
PbtO,B
(,O
2,O
),O
and,O
in,O
cerebral,O
blood,O
flow,O
were,O
studied,O
in,O
a,O
separate,O
group,O
of,O
animals,O
.,O
RESULTS,O
:,O
All,O
groups,O
exhibited,O
similar,O
training,O
latencies,O
(,O
17,O
.,O
0,O
+,O
/,O
-,O
4,O
.,O
6,O
s,O
),O
.,O
Mice,O
subjected,O
to,O
hypotensive,O
episodes,O
showed,O
a,O
significant,O
decrease,O
in,O
latency,O
time,O
(,O
178,O
+,O
/,O
-,O
156,O
s,O
),O
compared,O
with,O
those,O
injected,O
with,O
saline,B
",",O
NTG,B
+,O
NIMO,B
",",O
or,O
delayed,O
NTG,B
(,O
580,O
+,O
/,O
-,O
81,O
s,O
",",O
557,O
+,O
/,O
-,O
67,O
s,O
",",O
and,O
493,O
+,O
/,O
-,O
146,O
s,O
",",O
respectively,O
.,O
A,O
Kruskal,B
-,I
Wallis,I
1,O
-,O
way,O
analysis,O
of,O
variance,O
indicated,O
a,O
significant,O
difference,O
among,O
the,O
4,O
treatment,O
groups,O
(,O
H,B
=,O
15,O
.,O
34,O
;,O
P,B
<,O
0,O
.,O
1,O
),O
.,O
In,O
a,O
separate,O
group,O
of,O
mice,O
not,O
subjected,O
to,O
behavioral,O
studies,O
",",O
the,O
same,O
dose,O
of,O
NTG,B
(,O
n,O
=,O
3,O
),O
and,O
NTG,B
+,O
NIMO,B
(,O
n,O
=,O
3,O
),O
caused,O
mean,O
arterial,O
blood,O
pressure,O
to,O
decrease,O
from,O
85,O
.,O
9,O
+,O
/,O
-,O
3,O
.,O
8,O
mm,O
Hg,B
sem,O
to,O
31,O
.,O
6,O
+,O
/,O
-,O
0,O
.,O
8,O
mm,O
Hg,B
sem,O
and,O
from,O
86,O
.,O
2,O
+,O
/,O
-,O
3,O
.,O
7,O
mm,O
Hg,B
sem,O
to,O
32,O
.,O
6,O
+,O
/,O
-,O
0,O
.,O
2,O
mm,O
Hg,B
sem,O
",",O
respectively,O
.,O
Mean,O
arterial,O
blood,O
pressure,O
in,O
mice,O
treated,O
with,O
NIMO,B
alone,O
decreased,O
from,O
88,O
.,O
1,O
+,O
/,O
-,O
3,O
.,O
8,O
mm,O
Hg,B
to,O
80,O
.,O
0,O
+,O
/,O
-,O
2,O
.,O
9,O
mm,O
Hg,B
.,O
The,O
intergroup,O
difference,O
was,O
statistically,O
significant,O
(,O
P,B
<,O
0,O
.,O
5,O
),O
.,O
PbtO,B
(,O
2,O
),O
decreased,O
from,O
51,O
.,O
7,O
+,O
/,O
-,O
4,O
.,O
5,O
mm,O
Hg,O
sem,O
to,O
33,O
.,O
8,O
+,O
/,O
-,O
5,O
mm,O
Hg,O
sem,O
in,O
the,O
NTG,B
group,O
and,O
from,O
38,O
.,O
6,O
+,O
/,O
-,O
6,O
mm,O
Hg,O
sem,O
to,O
25,O
.,O
4,O
+,O
/,O
-,O
2,O
mm,O
Hg,O
sem,O
in,O
the,O
NTG,B
+,I
NIMO,I
groups,O
",",O
respectively,O
.,O
There,O
were,O
no,O
significant,O
differences,O
among,O
groups,O
.,O
CONCLUSION,O
:,O
In,O
a,O
PA,B
retention,O
paradigm,O
",",O
the,O
injection,O
of,O
NTG,B
immediately,O
after,O
learning,O
produced,O
a,O
significant,O
impairment,O
of,O
long,O
-,O
term,O
associative,O
memory,O
in,O
mice,O
",",O
whereas,O
delayed,O
induced,O
hypotension,O
had,O
no,O
effect,O
.,O
NIMO,B
attenuated,O
the,O
disruption,O
in,O
consolidation,O
of,O
long,O
-,O
term,O
memory,O
caused,O
by,O
NTG,B
but,O
did,O
not,O
improve,O
latency,O
in,O
the,O
absence,O
of,O
hypotension,O
.,O
The,O
observed,O
effect,O
of,O
NIMO,B
may,O
have,O
been,O
attributable,O
to,O
the,O
preservation,O
of,O
calcium,B
homeostasis,O
during,O
hypotension,O
",",O
because,O
there,O
were,O
no,O
differences,O
in,O
the,O
PbtO,B
(,O
2,O
),O
indices,O
among,O
groups,O
.,O
Metabotropic,B
glutamate,I
7,I
receptor,I
subtype,I
modulates,O
motor,O
symptoms,O
in,O
rodent,O
models,O
of,O
Parkinson,B
',I
s,I
disease,I
.,O
Metabotropic,B
glutamate,I
(,I
mGlu,I
),I
receptors,I
modulate,O
synaptic,O
transmission,O
in,O
the,O
central,O
nervous,O
system,O
and,O
represent,O
promising,O
therapeutic,O
targets,O
for,O
symptomatic,O
treatment,O
of,O
Parkinson,B
',I
s,I
disease,I
(,I
PD,I
),I
.,O
Among,O
the,O
eight,O
mGlu,B
receptor,O
subtypes,O
",",O
mGlu7,B
receptor,O
is,O
prominently,O
expressed,O
in,O
the,O
basal,O
ganglia,O
",",O
but,O
its,O
role,O
in,O
restoring,O
motor,O
function,O
in,O
animal,O
models,O
of,O
PD,B
is,O
not,O
known,O
.,O
The,O
effects,O
of,O
N,B
",",O
N,B
',I
-,I
dibenzhydrylethane,I
-,I
1,I
",",I
2,I
-,I
diamine,I
dihydrochloride,I
(,I
AMN082,B
),I
",",O
the,O
first,O
selective,O
allosteric,O
activator,O
of,O
mGlu7,B
receptors,O
",",O
were,O
thus,O
tested,O
in,O
different,O
rodent,O
models,O
of,O
PD,B
.,O
Here,O
",",O
we,O
show,O
that,O
oral,O
(,O
5,B
mg,I
/,I
kg,I
),O
or,O
intrastriatal,O
administration,O
(,O
0,B
.,I
1,I
and,I
0,I
.,I
5,I
nmol,I
),O
of,O
AMN082,B
reverses,O
haloperidol,B
-,I
induced,I
catalepsy,I
in,O
rats,O
.,O
AMN082,B
(,O
2,B
.,I
5,I
and,I
5,I
mg,I
/,I
kg,I
),O
reduces,O
apomorphine,B
-,I
induced,I
rotations,I
in,O
unilateral,O
6,B
-,I
hydroxydopamine,I
(,I
6,I
-,I
OHDA,I
),I
-,I
lesioned,I
rats,O
.,O
In,O
a,O
more,O
complex,O
task,O
commonly,O
used,O
to,O
evaluate,O
major,O
akinetic,O
symptoms,O
of,O
PD,O
patients,O
",",O
5,B
mg,I
/,I
kg,I
AMN082,B
reverses,O
the,O
increased,O
reaction,O
time,O
to,O
respond,O
a,O
cue,O
of,O
bilateral,O
6,B
-,I
OHDA,I
-,I
lesioned,I
rats,O
.,O
In,O
addition,O
",",O
AMN082,B
reduces,O
the,O
duration,O
of,O
haloperidol,B
-,O
induced,O
catalepsy,O
in,O
a,O
mGlu7,B
receptor,O
-,O
dependent,O
manner,O
in,O
wild,O
-,O
type,O
but,O
not,O
mGlu7,B
receptor,O
knockout,O
mice,O
.,O
Higher,O
doses,O
of,O
AMN082,B
(,O
10,O
and,O
20,O
mg,O
/,O
kg,O
p,O
.,O
o,O
.,O
),O
have,O
no,O
effect,O
on,O
the,O
same,O
models,O
of,O
PD,B
.,O
Overall,O
these,O
findings,O
suggest,O
that,O
mGlu7,B
receptor,O
activation,O
can,O
reverse,O
motor,O
dysfunction,O
associated,O
with,O
reduced,O
dopamine,B
activity,O
.,O
Selective,O
ligands,O
of,O
mGlu7,B
receptor,I
subtypes,I
may,O
thus,O
be,O
considered,O
as,O
promising,O
compounds,O
for,O
the,O
development,O
of,O
antiparkinsonian,O
therapeutic,O
strategies,O
.,O
Sorafenib,B
-,I
induced,I
acute,I
myocardial,I
infarction,I
due,O
to,O
coronary,B
artery,I
spasm,I
.,O
A,O
65,O
-,O
year,O
-,O
old,O
man,O
with,O
advanced,O
renal,B
cell,I
carcinoma,I
was,O
admitted,O
due,O
to,O
continuing,O
chest,O
pain,O
at,O
rest,O
.,O
Two,O
weeks,O
before,O
his,O
admission,O
",",O
sorafenib,B
had,O
been,O
started,O
.,O
He,O
was,O
diagnosed,O
with,O
non,B
-,I
ST,I
-,I
elevation,I
myocardial,I
infarction,I
by,O
laboratory,O
data,O
and,O
electrocardiogram,O
.,O
Enhanced,O
heart,O
magnetic,O
resonance,O
imaging,O
also,O
showed,O
subendocardial,O
infarction,O
.,O
However,O
",",O
there,O
was,O
no,O
stenosis,O
in,O
coronary,O
arteries,O
on,O
angiography,O
.,O
Coronary,B
artery,I
spasm,I
was,O
induced,O
by,O
a,O
provocative,O
test,O
.,O
Cessation,O
of,O
sorafenib,B
and,O
administration,O
of,O
Ca,B
-,I
channel,I
blocker,I
and,O
nitrates,B
ameliorated,O
his,O
symptoms,O
",",O
but,O
relapse,O
occurred,O
after,O
resumption,O
of,O
sorafenib,B
.,O
Addition,O
of,O
oral,O
nicorandil,B
reduced,O
his,O
symptoms,O
and,O
maintained,O
stable,O
angina,O
status,O
.,O
We,O
report,O
the,O
first,O
case,O
of,O
sorafenib,B
-,I
induced,O
coronary,B
artery,I
spasm,I
.,O
Sorafenib,B
is,O
a,O
multikinase,O
inhibitor,O
that,O
targets,O
signaling,O
pathways,O
necessary,O
for,O
cellular,O
proliferation,O
and,O
survival,O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
Rho,O
/,O
ROCK,O
pathway,O
has,O
an,O
important,O
role,O
in,O
the,O
pathogenesis,O
of,O
coronary,B
artery,I
spasm,I
.,O
Our,O
report,O
may,O
show,O
an,O
adverse,O
effect,O
on,O
the,O
Rho,B
/,I
ROCK,I
pathway,O
by,O
sorafenib,B
use,O
.,O
A,O
novel,O
animal,O
model,O
to,O
evaluate,O
the,O
ability,O
of,O
a,O
drug,O
delivery,O
system,O
to,O
promote,O
the,O
passage,O
through,O
the,O
BBB,B
.,O
The,O
purpose,O
of,O
this,O
investigation,O
was,O
to,O
explore,O
the,O
potentiality,O
of,O
a,O
novel,O
animal,O
model,O
to,O
be,O
used,O
for,O
the,O
in,O
vivo,O
evaluation,O
of,O
the,O
ability,O
of,O
a,O
drug,O
delivery,O
system,O
to,O
promote,O
the,O
passage,O
through,O
the,O
blood,O
-,O
brain,O
barrier,O
(,O
BBB,I
),O
and,O
/,O
or,O
to,O
improve,O
the,O
brain,O
localization,O
of,O
a,O
bioactive,O
compound,O
.,O
A,O
Tween,B
80,I
-,I
coated,O
poly,B
-,I
L,I
-,I
lactid,I
acid,I
nanoparticles,O
was,O
used,O
as,O
a,O
model,O
of,O
colloidal,O
drug,O
delivery,O
system,O
",",O
able,O
to,O
trespass,O
the,O
BBB,B
.,O
Tacrine,B
",",O
administered,O
in,O
LiCl,B
pre,O
-,O
treated,O
rats,O
",",O
induces,O
electrocorticographic,O
seizures,O
and,O
delayed,O
hippocampal,O
damage,O
.,O
The,O
toxic,O
effects,O
of,O
tacrine,B
-,O
loaded,O
poly,B
-,I
L,I
-,I
lactid,I
acid,I
nanoparticles,O
(,O
5mg,O
/,O
kg,O
),O
",",O
a,O
saline,O
solution,O
of,O
tacrine,B
(,O
5mg,O
/,O
kg,O
),O
and,O
an,O
empty,O
colloidal,O
nanoparticle,O
suspension,O
were,O
compared,O
following,O
i,O
.,O
p,O
.,O
administration,O
in,O
LiCl,B
-,O
pre,O
-,O
treated,O
Wistar,O
rats,O
.,O
All,O
the,O
animals,O
treated,O
with,O
tacrine,B
-,O
loaded,O
nanoparticles,O
showed,O
an,O
earlier,O
outcome,O
of,O
CNS,O
adverse,O
symptoms,O
",",O
i,O
.,O
e,O
.,O
epileptic,O
onset,O
",",O
with,O
respect,O
to,O
those,O
animals,O
treated,O
with,O
the,O
free,O
compound,O
(,O
10,O
min,O
vs,O
.,O
22,O
min,O
respectively,O
),O
.,O
In,O
addition,O
",",O
tacrine,B
-,O
loaded,O
nanoparticles,O
administration,O
induced,O
damage,O
of,O
neuronal,O
cells,O
in,O
CA1,B
field,O
of,O
the,O
hippocampus,O
in,O
all,O
treated,O
animals,O
",",O
while,O
the,O
saline,B
solution,O
of,O
tacrine,B
only,O
in,O
60,O
%,O
of,O
animals,O
.,O
Empty,O
nanoparticles,B
provided,O
similar,O
results,O
to,O
control,O
(,O
saline,B
-,I
treated,I
),O
group,O
of,O
animals,O
.,O
In,O
conclusion,O
",",O
the,O
evaluation,O
of,O
time,O
-,O
to,O
-,O
onset,O
of,O
symptoms,O
and,O
the,O
severity,O
of,O
neurodegenerative,O
processes,O
induced,O
by,O
the,O
tacrine,B
-,I
lithium,I
model,O
of,O
epilepsy,O
in,O
the,O
rat,O
",",O
could,O
be,O
used,O
to,O
evaluate,O
preliminarily,O
the,O
capability,O
of,O
a,O
drug,O
delivery,O
system,O
to,O
trespass,O
(,O
or,O
not,O
),O
the,O
BBB,B
in,O
vivo,O
.,O
High,O
-,O
dose,O
tranexamic,B
Acid,I
is,O
associated,O
with,O
nonischemic,O
clinical,O
seizures,O
in,O
cardiac,O
surgical,O
patients,O
.,O
BACKGROUND,O
:,O
In,O
2,O
separate,O
centers,O
",",O
we,O
observed,O
a,O
notable,O
increase,O
in,O
the,O
incidence,O
of,O
postoperative,O
convulsive,O
seizures,O
from,O
1,O
.,O
3,O
%,O
to,O
3,O
.,O
8,O
%,O
in,O
patients,O
having,O
undergone,O
major,O
cardiac,O
surgical,O
procedures,O
.,O
These,O
events,O
were,O
temporally,O
coincident,O
with,O
the,O
initial,O
use,O
of,O
high,O
-,O
dose,O
tranexamic,B
acid,I
(,O
TXA,B
),O
therapy,O
after,O
withdrawal,O
of,O
aprotinin,O
from,O
general,O
clinical,O
usage,O
.,O
The,O
purpose,O
of,O
this,O
review,O
was,O
to,O
perform,O
a,O
retrospective,O
analysis,O
to,O
examine,O
whether,O
there,O
was,O
a,O
relation,O
between,O
TXA,B
usage,O
and,O
seizures,O
after,O
cardiac,O
surgery,O
.,O
METHODS,O
:,O
An,O
in,O
-,O
depth,O
chart,O
review,O
was,O
undertaken,O
in,O
all,O
24,O
patients,O
who,O
developed,O
perioperative,O
seizures,O
.,O
Electroencephalographic,O
activity,O
was,O
recorded,O
in,O
11,O
of,O
these,O
patients,O
",",O
and,O
all,O
patients,O
had,O
a,O
formal,O
neurological,O
evaluation,O
and,O
brain,O
imaging,O
studies,O
.,O
RESULTS,O
:,O
Twenty,O
-,O
one,O
of,O
the,O
24,O
patients,O
did,O
not,O
have,O
evidence,O
of,O
new,O
cerebral,O
ischemic,O
injury,O
",",O
but,O
seizures,O
were,O
likely,O
due,O
to,O
ischemic,O
brain,O
injury,O
in,O
3,O
patients,O
.,O
All,O
patients,O
with,O
seizures,O
did,O
not,O
have,O
permanent,O
neurological,O
abnormalities,O
.,O
All,O
24,O
patients,O
with,O
seizures,O
received,O
high,O
doses,O
of,O
TXA,B
intraoperatively,O
ranging,O
from,O
61,O
to,O
259,O
mg,O
/,O
kg,O
",",O
had,O
a,O
mean,O
age,O
of,O
69,O
.,O
9,O
years,O
",",O
and,O
21,O
of,O
24,O
had,O
undergone,O
open,O
chamber,O
rather,O
than,O
coronary,O
bypass,O
procedures,O
.,O
All,O
but,O
one,O
patient,O
were,O
managed,O
using,O
cardiopulmonary,O
bypass,O
.,O
No,O
evidence,O
of,O
brain,B
ischemic,I
",",O
metabolic,B
",",O
or,O
hyperthermia,B
-,I
induced,I
causes,O
for,O
their,O
seizures,O
was,O
apparent,O
.,O
CONCLUSION,O
:,O
Our,O
results,O
suggest,O
that,O
use,O
of,O
high,O
-,O
dose,O
TXA,B
in,O
older,O
patients,O
in,O
conjunction,O
with,O
cardiopulmonary,O
bypass,O
and,O
open,O
-,O
chamber,O
cardiac,O
surgery,O
is,O
associated,O
with,O
clinical,O
seizures,O
in,O
susceptible,O
patients,O
.,O
Electrocardiographic,O
changes,O
and,O
cardiac,O
arrhythmias,O
in,O
patients,O
receiving,O
psychotropic,O
drugs,O
.,O
Eight,O
patients,O
had,O
cardiac,O
manifestations,O
that,O
were,O
life,O
-,O
threatening,O
in,O
five,O
while,O
taking,O
psychotropic,O
drugs,O
",",O
either,O
phenothiazines,B
or,O
tricyclic,B
antidepressants,I
.,O
Although,O
most,O
patients,O
were,O
receiving,O
several,O
drugs,O
",",O
Mellaril,B
(,O
thioridazine,I
),O
appeared,O
to,O
be,O
responsible,O
for,O
five,O
cases,O
of,O
ventricular,O
tachycardia,O
",",O
one,O
of,O
which,O
was,O
fatal,O
in,O
a,O
35,O
year,O
old,O
woman,O
.,O
Supraventricular,O
tachycardia,O
developed,O
in,O
one,O
patient,O
receiving,O
Thorazine,B
(,O
chlorpromazine,B
),O
.,O
Aventyl,B
(,O
nortriptyline,B
),O
and,O
Elavil,B
(,O
amitriptyline,B
),O
each,O
produced,O
left,O
bundle,O
branch,O
block,O
in,O
a,O
73,O
year,O
old,O
woman,O
.,O
Electrocardiographic,O
T,B
and,O
U,B
wave,I
abnormalities,O
were,O
present,O
in,O
most,O
patients,O
.,O
The,O
ventricular,B
arrhythmias,I
responded,O
to,O
intravenous,O
administration,O
of,O
lidocaine,B
and,O
to,O
direct,O
current,O
electric,O
shock,O
;,O
ventricular,B
pacing,I
was,O
required,O
in,O
some,O
instances,O
and,O
intravenous,O
administration,O
of,O
propranolol,B
combined,O
with,O
ventricular,B
pacing,I
in,O
one,O
.,O
The,O
tachyarrhythmias,O
generally,O
subsided,O
within,O
48,O
hours,O
after,O
administration,O
of,O
the,O
drugs,O
was,O
stopped,O
.,O
Five,O
of,O
the,O
eight,O
patients,O
were,O
50,O
years,O
of,O
age,O
or,O
younger,O
;,O
only,O
one,O
clearly,O
had,O
antecedent,O
heart,O
disease,O
.,O
Major,O
cardiac,O
arrhythmias,O
are,O
a,O
potential,O
hazard,O
in,O
patients,O
without,O
heart,O
disease,O
who,O
are,O
receiving,O
customary,O
therapeutic,O
doses,O
of,O
psychotropic,O
drugs,O
.,O
A,O
prospective,O
clinical,O
trial,O
is,O
suggested,O
to,O
quantify,O
the,O
risk,O
of,O
cardiac,O
complications,O
to,O
patients,O
receiving,O
phenothiazines,B
or,O
tricyclic,B
antidepressant,I
drugs,O
.,O
Sensitivity,O
of,O
erythroid,O
progenitor,O
colonies,O
to,O
erythropoietin,B
in,O
azidothymidine,B
treated,O
immunodeficient,O
mice,O
.,O
The,O
anaemia,O
induced,O
by,O
3,B
',I
-,I
azido,I
-,I
3,I
',I
dideoxythymidine,I
(,I
AZT,I
),I
is,O
poorly,O
understood,O
.,O
We,O
have,O
used,O
a,O
murine,O
model,O
of,O
AIDS,O
",",O
infection,O
of,O
female,O
C57BL,O
/,O
6,O
mice,O
with,O
LP,B
-,I
BM5,I
murine,I
leukaemia,I
(,O
MuLV,B
),O
virus,O
",",O
to,O
determine,O
if,O
AZT,B
-,O
induced,O
anaemia,O
is,O
due,O
",",O
in,O
part,O
",",O
to,O
decreased,O
responsiveness,O
of,O
erythropoietic,O
precursors,O
(,O
BFU,B
-,I
e,I
),O
to,O
erythropoietin,B
(,O
EPO,B
),O
.,O
Mice,O
in,O
the,O
early,O
stage,O
of,O
LP,B
-,I
BM5,I
MuLV,I
disease,I
were,O
given,O
AZT,B
in,O
their,O
drinking,O
water,O
at,O
1,O
.,O
0,O
and,O
2,O
.,O
5,O
mg,O
/,O
ml,O
.,O
AZT,B
produced,O
anaemia,O
in,O
both,O
groups,O
",",O
in,O
a,O
dose,O
-,O
dependent,O
fashion,O
.,O
Despite,O
the,O
anaemia,O
",",O
the,O
number,O
of,O
splenic,O
and,O
bone,O
marrow,O
BFU,O
-,O
e,O
in,O
AZT,B
treated,O
mice,O
increased,O
up,O
to,O
five,O
-,O
fold,O
over,O
levels,O
observed,O
in,O
infected,O
untreated,O
animals,O
after,O
15,O
d,O
of,O
treatment,O
.,O
Colony,O
formation,O
by,O
splenic,O
and,O
bone,O
marrow,O
BFUe,O
was,O
stimulated,O
at,O
lower,O
concentrations,O
of,O
EPO,B
in,O
mice,O
receiving,O
AZT,B
for,O
15,O
d,O
than,O
for,O
infected,O
",",O
untreated,O
mice,O
.,O
By,O
day,O
30,O
",",O
sensitivity,O
of,O
both,O
splenic,B
and,O
bone,B
marrow,I
BFU,I
-,I
e,I
of,O
treated,O
animals,O
returned,O
to,O
that,O
observed,O
from,O
cells,O
of,O
infected,O
untreated,O
animals,O
.,O
The,O
mean,O
plasma,O
levels,O
of,O
EPO,B
observed,O
in,O
AZT,B
treated,O
mice,O
were,O
appropriate,O
for,O
the,O
degree,O
of,O
anaemia,O
observed,O
when,O
compared,O
with,O
phenylhydrazine,B
(,I
PHZ,I
),I
treated,O
mice,O
.,O
The,O
numbers,O
of,O
BFU,B
-,I
e,I
and,O
the,O
percentage,O
of,O
bone,O
marrow,O
erythroblasts,B
observed,O
were,O
comparable,O
in,O
AZT,B
and,O
PHZ,B
treated,O
mice,O
with,O
similar,O
degrees,O
of,O
anaemia,O
.,O
However,O
",",O
reticulocytosis,O
was,O
inappropriate,O
for,O
the,O
degree,O
of,O
anaemia,O
observed,O
in,O
AZT,B
treated,O
infected,O
mice,O
.,O
AZT,B
-,O
induced,O
peripheral,O
anaemia,O
in,O
the,O
face,O
of,O
increased,O
numbers,O
of,O
BFU,B
-,I
e,I
and,O
increased,O
levels,O
of,O
plasma,O
EPO,B
suggest,O
a,O
lesion,O
in,O
terminal,O
differentiation,O
.,O
Sedation,O
depth,O
during,O
spinal,O
anesthesia,O
and,O
the,O
development,O
of,O
postoperative,O
delirium,O
in,O
elderly,O
patients,O
undergoing,O
hip,O
fracture,O
repair,O
.,O
OBJECTIVE,O
:,O
To,O
determine,O
whether,O
limiting,O
intraoperative,O
sedation,O
depth,O
during,O
spinal,O
anesthesia,O
for,O
hip,O
fracture,O
repair,O
in,O
elderly,O
patients,O
can,O
decrease,O
the,O
prevalence,O
of,O
postoperative,O
delirium,O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
We,O
performed,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
controlled,O
trial,O
at,O
an,O
academic,O
medical,O
center,O
of,O
elderly,O
patients,O
(,O
>,O
or,O
=,O
65,O
years,O
),O
without,O
preoperative,O
delirium,O
or,O
severe,O
dementia,O
who,O
underwent,O
hip,O
fracture,O
repair,O
under,O
spinal,O
anesthesia,O
with,O
propofol,B
sedation,O
.,O
Sedation,O
depth,O
was,O
titrated,O
using,O
processed,O
electroencephalography,O
with,O
the,O
bispectral,O
index,O
(,O
BIS,B
),O
",",O
and,O
patients,O
were,O
randomized,O
to,O
receive,O
either,O
deep,O
(,O
BIS,B
",",O
approximately,O
50,O
),O
or,O
light,O
(,O
BIS,B
",",O
>,O
or,O
=,O
80,O
),O
sedation,O
.,O
Postoperative,O
delirium,O
was,O
assessed,O
as,O
defined,O
by,O
Diagnostic,B
and,I
Statistical,I
Manual,I
of,I
Mental,I
Disorders,I
(,I
Third,I
Edition,I
Revised,I
),I
criteria,O
using,O
the,O
Confusion,B
Assessment,I
Method,I
beginning,O
at,O
any,O
time,O
from,O
the,O
second,O
day,O
after,O
surgery,O
.,O
RESULTS,O
:,O
From,O
April,O
2,O
",",O
2005,O
",",O
through,O
October,O
30,O
",",O
2008,O
",",O
a,O
total,O
of,O
114,O
patients,O
were,O
randomized,O
.,O
The,O
prevalence,O
of,O
postoperative,O
delirium,O
was,O
significantly,O
lower,O
in,O
the,O
light,O
sedation,O
group,O
(,O
11,O
/,O
57,O
[,O
19,O
%,O
].,O
vs,O
23,O
/,O
57,O
[,O
40,O
%,O
].,O
in,O
the,O
deep,O
sedation,O
group,O
;,O
P,O
=,O
.,O
2,O
),O
",",O
indicating,O
that,O
1,O
incident,O
of,O
delirium,O
will,O
be,O
prevented,O
for,O
every,O
4,O
.,O
7,O
patients,O
treated,O
with,O
light,O
sedation,O
.,O
The,O
mean,O
+,O
/,O
-,O
SD,O
number,O
of,O
days,O
of,O
delirium,O
during,O
hospitalization,O
was,O
lower,O
in,O
the,O
light,O
sedation,O
group,O
than,O
in,O
the,O
deep,O
sedation,O
group,O
(,O
0,O
.,O
5,O
+,O
/,O
-,O
1,O
.,O
5,O
days,O
vs,O
1,O
.,O
4,O
+,O
/,O
-,O
4,O
.,O
0,O
days,O
;,O
P,O
=,O
.,O
1,O
),O
.,O
CONCLUSION,O
:,O
The,O
use,O
of,O
light,O
propofol,B
sedation,O
decreased,O
the,O
prevalence,O
of,O
postoperative,O
delirium,O
by,O
50,O
%,O
compared,O
with,O
deep,O
sedation,O
.,O
Limiting,O
depth,O
of,O
sedation,O
during,O
spinal,O
anesthesia,O
is,O
a,O
simple,O
",",O
safe,O
",",O
and,O
cost,O
-,O
effective,O
intervention,O
for,O
preventing,O
postoperative,O
delirium,O
in,O
elderly,O
patients,O
that,O
could,O
be,O
widely,O
and,O
readily,O
adopted,O
.,O
The,O
protective,O
role,O
of,O
Nrf2,B
in,O
streptozotocin,B
-,I
induced,I
diabetic,I
nephropathy,I
.,O
OBJECTIVE,O
:,O
Diabetic,O
nephropathy,O
is,O
one,O
of,O
the,O
major,O
causes,O
of,O
renal,O
failure,O
",",O
which,O
is,O
accompanied,O
by,O
the,O
production,O
of,O
reactive,O
oxygen,O
species,O
(,O
ROS,B
),O
.,O
Nrf2,B
is,O
the,O
primary,O
transcription,O
factor,O
that,O
controls,O
the,O
antioxidant,O
response,O
essential,O
for,O
maintaining,O
cellular,O
redox,O
homeostasis,O
.,O
Here,O
",",O
we,O
report,O
our,O
findings,O
demonstrating,O
a,O
protective,O
role,O
of,O
Nrf2,B
against,O
diabetic,O
nephropathy,O
.,O
RESEARCH,O
DESIGN,O
AND,O
METHODS,O
:,O
We,O
explore,O
the,O
protective,O
role,O
of,O
Nrf2,B
against,O
diabetic,O
nephropathy,O
using,O
human,O
kidney,O
biopsy,O
tissues,O
from,O
diabetic,O
nephropathy,O
patients,O
",",O
a,O
streptozotocin,B
-,I
induced,O
diabetic,O
nephropathy,O
model,O
in,O
Nrf2,B
(,O
-,O
/,O
-,O
),O
mice,O
",",O
and,O
cultured,O
human,O
mesangial,O
cells,O
.,O
RESULTS,O
:,O
The,O
glomeruli,O
of,O
human,O
diabetic,B
nephropathy,I
patients,O
were,O
under,O
oxidative,O
stress,O
and,O
had,O
elevated,O
Nrf2,B
levels,O
.,O
In,O
the,O
animal,O
study,O
",",O
Nrf2,B
was,O
demonstrated,O
to,O
be,O
crucial,O
in,O
ameliorating,O
streptozotocin,B
-,I
induced,I
renal,I
damage,O
.,O
This,O
is,O
evident,O
by,O
Nrf2,B
(,O
-,O
/,O
-,O
),O
mice,O
having,O
higher,O
ROS,B
production,O
and,O
suffering,O
from,O
greater,O
oxidative,O
DNA,B
damage,O
and,O
renal,I
injury,O
compared,O
with,O
Nrf2,B
(,O
+,O
/,O
+,O
),O
mice,O
.,O
Mechanistic,O
studies,O
in,O
both,O
in,O
vivo,O
and,O
in,O
vitro,O
systems,O
showed,O
that,O
the,O
Nrf2,B
-,O
mediated,O
protection,O
against,O
diabetic,O
nephropathy,O
is,O
",",O
at,O
least,O
",",O
partially,O
through,O
inhibition,O
of,O
transforming,B
growth,I
factor,I
-,I
beta1,I
(,O
TGF,B
-,I
beta1,I
),O
and,O
reduction,O
of,O
extracellular,O
matrix,O
production,O
.,O
In,O
human,O
renal,O
mesangial,O
cells,O
",",O
high,O
glucose,B
induced,O
ROS,B
production,O
and,O
activated,O
expression,O
of,O
Nrf2,B
and,O
its,O
downstream,O
genes,O
.,O
Furthermore,O
",",O
activation,O
or,O
overexpression,O
of,O
Nrf2,B
inhibited,O
the,O
promoter,O
activity,O
of,O
TGF,B
-,O
beta1,I
in,O
a,O
dose,O
-,O
dependent,O
manner,O
",",O
whereas,O
knockdown,O
of,O
Nrf2,B
by,O
siRNA,B
enhanced,O
TGF,B
-,O
beta1,I
transcription,O
and,O
fibronectin,B
production,O
.,O
CONCLUSIONS,O
:,O
This,O
work,O
clearly,O
indicates,O
a,O
protective,O
role,O
of,O
Nrf2,B
in,O
diabetic,O
nephropathy,O
",",O
suggesting,O
that,O
dietary,O
or,O
therapeutic,O
activation,O
of,O
Nrf2,B
could,O
be,O
used,O
as,O
a,O
strategy,O
to,O
prevent,O
or,O
slow,O
down,O
the,O
progression,O
of,O
diabetic,O
nephropathy,O
.,O
Metformin,B
prevents,O
experimental,O
gentamicin,B
-,O
induced,O
nephropathy,O
by,O
a,O
mitochondria,B
-,O
dependent,O
pathway,O
.,O
The,O
antidiabetic,O
drug,O
metformin,B
can,O
diminish,O
apoptosis,O
induced,O
by,O
oxidative,O
stress,O
in,O
endothelial,O
cells,O
and,O
prevent,O
vascular,O
dysfunction,O
even,O
in,O
nondiabetic,O
patients,O
.,O
Here,O
we,O
tested,O
whether,O
it,O
has,O
a,O
beneficial,O
effect,O
in,O
a,O
rat,O
model,O
of,O
gentamicin,B
toxicity,O
.,O
Mitochondrial,B
analysis,O
",",O
respiration,O
intensity,O
",",O
levels,O
of,O
reactive,B
oxygen,I
species,I
",",O
permeability,O
transition,O
",",O
and,O
cytochrome,B
c,I
release,O
were,O
assessed,O
3,O
and,O
6,O
days,O
after,O
gentamicin,B
administration,O
.,O
Metformin,B
treatment,O
fully,O
blocked,O
gentamicin,B
-,O
mediated,O
acute,O
renal,O
failure,O
.,O
This,O
was,O
accompanied,O
by,O
a,O
lower,O
activity,O
of,O
N,B
-,O
acetyl,I
-,I
beta,I
-,I
D,I
-,I
glucosaminidase,I
",",O
together,O
with,O
a,O
decrease,O
of,O
lipid,B
peroxidation,I
and,O
increase,O
of,O
antioxidant,B
systems,I
.,O
Metformin,B
also,O
protected,O
the,O
kidney,O
from,O
histological,O
damage,O
6,O
days,O
after,O
gentamicin,O
administration,O
.,O
These,O
in,O
vivo,O
markers,O
of,O
kidney,O
dysfunction,O
and,O
their,O
correction,O
by,O
metformin,B
were,O
complemented,O
by,O
in,O
vitro,O
studies,O
of,O
mitochondrial,O
function,O
.,O
We,O
found,O
that,O
gentamicin,O
treatment,O
depleted,O
respiratory,O
components,O
(,O
cytochrome,B
c,I
",",O
NADH,B
),O
",",O
probably,O
due,O
to,O
the,O
opening,O
of,O
mitochondrial,O
transition,O
pores,O
.,O
These,O
injuries,O
",",O
partly,O
mediated,O
by,O
a,O
rise,O
in,O
reactive,B
oxygen,I
species,I
from,O
the,O
electron,O
transfer,O
chain,O
",",O
were,O
significantly,O
decreased,O
by,O
metformin,B
.,O
Thus,O
",",O
our,O
study,O
suggests,O
that,O
pleiotropic,O
effects,O
of,O
metformin,B
can,O
lessen,O
gentamicin,O
nephrotoxicity,O
and,O
improve,O
mitochondrial,O
homeostasis,O
.,O
Risk,O
of,O
nephropathy,O
after,O
consumption,O
of,O
nonionic,B
contrast,I
media,I
by,O
children,O
undergoing,O
cardiac,O
angiography,O
:,O
a,O
prospective,O
study,O
.,O
Despite,O
increasing,O
reports,O
on,O
nonionic,B
contrast,I
media,I
-,I
induced,O
nephropathy,O
(,O
CIN,B
),O
in,O
hospitalized,O
adult,O
patients,O
during,O
cardiac,O
procedures,O
",",O
the,O
studies,O
in,O
pediatrics,O
are,O
limited,O
",",O
with,O
even,O
less,O
focus,O
on,O
possible,O
predisposing,O
factors,O
and,O
preventive,O
measures,O
for,O
patients,O
undergoing,O
cardiac,O
angiography,O
.,O
This,O
prospective,O
study,O
determined,O
the,O
incidence,O
of,O
CIN,B
for,O
two,O
nonionic,O
contrast,O
media,O
(,O
CM,B
),O
",",O
iopromide,B
and,O
iohexol,B
",",O
among,O
80,O
patients,O
younger,O
than,O
18,O
years,O
and,O
compared,O
the,O
rates,O
for,O
this,O
complication,O
in,O
relation,O
to,O
the,O
type,O
and,O
dosage,O
of,O
CM,B
and,O
the,O
presence,O
of,O
cyanosis,O
.,O
The,O
80,O
patients,O
in,O
the,O
study,O
consecutively,O
received,O
either,O
iopromide,B
(,O
group,O
A,O
",",O
n,O
=,O
40,O
),O
or,O
iohexol,B
(,O
group,O
B,O
",",O
n,O
=,O
40,O
),O
.,O
Serum,O
sodium,B
(,O
Na,B
),O
",",O
potassium,B
(,O
K,B
),O
",",O
and,O
creatinine,B
(,O
Cr,B
),O
were,O
measured,O
24,O
h,O
before,O
angiography,O
as,O
baseline,O
values,O
",",O
then,O
measured,O
again,O
at,O
12,O
-,O
",",O
24,O
-,O
",",O
and,O
48,O
-,O
h,O
intervals,O
after,O
CM,O
use,O
.,O
Urine,O
samples,O
for,O
Na,B
and,O
Cr,B
also,O
were,O
checked,O
at,O
the,O
same,O
intervals,O
.,O
Risk,O
of,O
renal,O
failure,O
",",O
Injury,O
to,O
the,O
kidney,O
",",O
Failure,O
of,O
kidney,O
function,O
",",O
Loss,O
of,O
kidney,O
function,O
",",O
and,O
End,O
-,O
stage,O
renal,O
damage,O
(,O
RIFLE,O
criteria,O
),O
were,O
used,O
to,O
define,O
CIN,O
and,O
its,O
incidence,O
in,O
the,O
study,O
population,O
.,O
Accordingly,O
",",O
among,O
the,O
15,O
CIN,B
patients,O
(,O
18,O
.,O
75,O
%,O
),O
",",O
7,O
.,O
5,O
%,O
of,O
the,O
patients,O
in,O
group,O
A,O
had,O
increased,O
risk,O
and,O
3,O
.,O
75,O
%,O
had,O
renal,O
injury,O
",",O
whereas,O
5,O
%,O
of,O
group,O
B,O
had,O
increased,O
risk,O
and,O
2,O
.,O
5,O
%,O
had,O
renal,O
injury,O
.,O
Whereas,O
33,O
.,O
3,O
%,O
of,O
the,O
patients,O
with,O
CIN,B
were,O
among,O
those,O
who,O
received,O
the,O
proper,O
dosage,O
of,O
CM,B
",",O
the,O
percentage,O
increased,O
to,O
66,O
.,O
6,O
%,O
among,O
those,O
who,O
received,O
larger,O
doses,O
",",O
with,O
a,O
significant,O
difference,O
in,O
the,O
incidence,O
of,O
CIN,B
related,O
to,O
the,O
different,O
dosages,O
of,O
CM,B
(,O
p,O
=,O
0,O
.,O
14,O
),O
.,O
Among,O
the,O
15,O
patients,O
with,O
CIN,B
",",O
6,O
had,O
cyanotic,O
congenital,O
heart,O
diseases,O
",",O
but,O
the,O
incidence,O
did,O
not,O
differ,O
significantly,O
from,O
that,O
for,O
the,O
noncyanotic,O
patients,O
(,O
p,O
=,O
0,O
.,O
243,O
),O
.,O
Although,O
clinically,O
silent,O
",",O
CIN,B
is,O
not,O
rare,O
in,O
pediatrics,O
.,O
The,O
incidence,O
depends,O
on,O
dosage,O
but,O
not,O
on,O
the,O
type,O
of,O
consumed,O
nonionic,B
CM,I
",",O
nor,O
on,O
the,O
presence,O
of,O
cyanosis,O
",",O
and,O
although,O
CIN,B
usually,O
is,O
reversible,O
",",O
more,O
concern,O
is,O
needed,O
for,O
the,O
prevention,O
of,O
such,O
a,O
complication,O
in,O
children,O
.,O
Renal,B
function,O
and,O
hemodynamics,O
during,O
prolonged,O
isoflurane,B
-,O
induced,O
hypotension,O
in,O
humans,O
.,O
The,O
effect,O
of,O
isoflurane,B
-,O
induced,O
hypotension,O
on,O
glomerular,O
function,O
and,O
renal,O
blood,O
flow,O
was,O
investigated,O
in,O
20,O
human,O
subjects,O
.,O
Glomerular,O
filtration,O
rate,O
(,O
GFR,B
),O
and,O
effective,O
renal,O
plasma,O
flow,O
(,O
ERPF,B
),O
were,O
measured,O
by,O
inulin,B
and,O
para,B
-,I
aminohippurate,I
(,O
PAH,B
),O
clearance,O
",",O
respectively,O
.,O
Anesthesia,O
was,O
maintained,O
with,O
fentanyl,B
",",O
nitrous,B
oxide,I
",",O
oxygen,B
",",O
and,O
isoflurane,B
.,O
Hypotension,O
was,O
induced,O
for,O
236,O
.,O
9,O
+,O
/,O
-,O
15,O
.,O
1,O
min,O
by,O
increasing,O
the,O
isoflurane,B
inspired,I
concentration,I
to,O
maintain,O
a,O
mean,O
arterial,O
pressure,O
of,O
59,O
.,O
8,O
+,O
/,O
-,O
0,O
.,O
4,O
mmHg,O
.,O
GFR,B
and,O
ERPF,B
decreased,O
with,O
the,O
induction,O
of,O
anesthesia,O
but,O
not,O
significantly,O
more,O
during,O
hypotension,O
.,O
Postoperatively,O
",",O
ERPF,B
returned,O
to,O
preoperative,O
values,O
",",O
whereas,O
GFR,B
was,O
higher,O
than,O
preoperative,O
values,O
.,O
Renal,B
vascular,I
resistance,I
increased,O
during,O
anesthesia,O
but,O
decreased,O
when,O
hypotension,B
was,O
induced,O
",",O
allowing,O
the,O
maintenance,O
of,O
renal,B
blood,I
flow,I
.,O
We,O
conclude,O
that,O
renal,B
compensatory,I
mechanisms,I
are,O
preserved,O
during,O
isoflurane,B
-,I
induced,I
hypotension,I
and,O
that,O
renal,B
function,I
and,I
hemodynamics,I
quickly,O
return,O
to,O
normal,O
when,O
normotension,B
is,O
resumed,O
.,O
Brainstem,B
dysgenesis,O
in,O
an,O
infant,O
prenatally,O
exposed,O
to,O
cocaine,B
.,O
Many,O
authors,O
described,O
the,O
effects,O
on,O
the,O
fetus,O
of,O
maternal,O
cocaine,B
abuse,O
during,O
pregnancy,O
.,O
Vasoconstriction,O
appears,O
to,O
be,O
the,O
common,O
mechanism,O
of,O
action,O
leading,O
to,O
a,O
wide,O
range,O
of,O
fetal,O
anomalies,O
.,O
We,O
report,O
on,O
an,O
infant,O
with,O
multiple,O
cranial,O
-,O
nerve,O
involvement,O
attributable,O
to,O
brainstem,B
dysgenesis,O
",",O
born,O
to,O
a,O
cocaine,B
-,O
addicted,O
mother,O
.,O
A,O
cross,O
-,O
sectional,O
evaluation,O
of,O
the,O
effect,O
of,O
risperidone,B
and,O
selective,O
serotonin,B
reuptake,I
inhibitors,I
on,O
bone,B
mineral,I
density,I
in,O
boys,O
.,O
OBJECTIVE,O
:,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
effect,O
of,O
risperidone,B
-,O
induced,O
hyperprolactinemia,O
on,O
trabecular,O
bone,B
mineral,I
density,I
(,O
BMD,O
),O
in,O
children,O
and,O
adolescents,O
.,O
METHOD,O
:,O
Medically,O
healthy,O
7,O
-,O
to,O
17,O
-,O
year,O
-,O
old,O
males,O
chronically,O
treated,O
",",O
in,O
a,O
naturalistic,O
setting,O
",",O
with,O
risperidone,B
were,O
recruited,O
for,O
this,O
cross,O
-,O
sectional,O
study,O
through,O
child,O
psychiatry,O
outpatient,O
clinics,O
between,O
November,O
2005,O
and,O
June,O
2007,O
.,O
Anthropometric,O
measurements,O
and,O
laboratory,O
testing,O
were,O
conducted,O
.,O
The,O
clinical,O
diagnoses,O
were,O
based,O
on,O
chart,O
review,O
",",O
and,O
developmental,O
and,O
treatment,O
history,O
was,O
obtained,O
from,O
the,O
medical,O
record,O
.,O
Volumetric,O
BMD,B
of,O
the,O
ultradistal,O
radius,O
was,O
measured,O
using,O
peripheral,O
quantitative,O
computed,O
tomography,O
",",O
and,O
areal,O
BMD,B
of,O
the,O
lumbar,O
spine,O
was,O
estimated,O
using,O
dual,O
-,O
energy,O
x,O
-,O
ray,O
absorptiometry,O
.,O
RESULTS,O
:,O
Hyperprolactinemia,B
was,O
present,O
in,O
49,O
%,O
of,O
83,O
boys,O
(,O
n,O
=,O
41,O
),O
treated,O
with,O
risperidone,B
for,O
a,O
mean,O
of,O
2,O
.,O
9,O
years,O
.,O
Serum,O
testosterone,B
concentration,O
increased,O
with,O
pubertal,O
status,O
but,O
was,O
not,O
affected,O
by,O
hyperprolactinemia,B
.,O
As,O
expected,O
",",O
bone,O
mineral,O
content,O
and,O
BMD,B
increased,O
with,O
sexual,O
maturity,O
.,O
After,O
adjusting,O
for,O
the,O
stage,O
of,O
sexual,O
development,O
and,O
height,O
and,O
BMI,O
z,O
scores,O
",",O
serum,O
prolactin,B
was,O
negatively,O
associated,O
with,O
trabecular,O
volumetric,O
BMD,B
at,O
the,O
ultradistal,O
radius,O
(,O
P,O
<,O
.,O
3,O
),O
.,O
Controlling,O
for,O
relevant,O
covariates,O
",",O
we,O
also,O
found,O
treatment,O
with,O
selective,O
serotonin,B
reuptake,I
inhibitors,I
(,O
SSRIs,B
),O
to,O
be,O
associated,O
with,O
lower,O
trabecular,O
BMD,B
at,O
the,O
radius,O
(,O
P,O
=,O
.,O
3,O
),O
and,O
BMD,B
z,I
score,I
at,O
the,O
lumbar,O
spine,O
(,O
P,O
<,O
.,O
5,O
),O
.,O
These,O
findings,O
became,O
more,O
marked,O
when,O
the,O
analysis,O
was,O
restricted,O
to,O
non,O
-,O
Hispanic,O
white,O
patients,O
.,O
Of,O
13,O
documented,O
fractures,O
",",O
3,O
occurred,O
after,O
risperidone,B
and,O
SSRIs,B
were,O
started,O
",",O
and,O
none,O
occurred,O
in,O
patients,O
with,O
hyperprolactinemia,B
.,O
CONCLUSIONS,O
:,O
This,O
is,O
the,O
first,O
study,O
to,O
link,O
risperidone,B
-,O
induced,O
hyperprolactinemia,I
and,O
SSRI,B
treatment,O
to,O
lower,O
BMD,B
in,O
children,O
and,O
adolescents,O
.,O
Future,O
research,O
should,O
evaluate,O
the,O
longitudinal,O
course,O
of,O
this,O
adverse,O
event,O
to,O
determine,O
its,O
temporal,O
stability,O
and,O
whether,O
a,O
higher,O
fracture,O
rate,O
ensues,O
.,O
Fear,O
-,O
potentiated,O
startle,O
",",O
but,O
not,O
light,O
-,O
enhanced,O
startle,O
",",O
is,O
enhanced,O
by,O
anxiogenic,O
drugs,O
.,O
RATIONALE,O
AND,O
OBJECTIVES,O
:,O
The,O
light,O
-,O
enhanced,O
startle,O
paradigm,O
(,O
LES,B
),O
is,O
suggested,O
to,O
model,O
anxiety,O
",",O
because,O
of,O
the,O
non,O
-,O
specific,O
cue,O
and,O
the,O
long,O
-,O
term,O
effect,O
.,O
In,O
contrast,O
",",O
the,O
fear,B
-,I
potentiated,I
startle,I
(,O
FPS,B
),O
is,O
suggested,O
to,O
model,O
conditioned,O
fear,O
.,O
However,O
",",O
the,O
pharmacological,O
profiles,O
of,O
these,O
two,O
paradigms,O
are,O
very,O
similar,O
.,O
The,O
present,O
study,O
investigated,O
the,O
effects,O
of,O
putative,O
anxiogenic,O
drugs,O
on,O
LES,B
and,O
FPS,B
and,O
aimed,O
at,O
determining,O
the,O
sensitivity,O
of,O
LES,B
for,O
anxiogenic,O
drugs,O
and,O
to,O
potentially,O
showing,O
a,O
pharmacological,O
differentiation,O
between,O
these,O
two,O
paradigms,O
.,O
METHODS,O
:,O
Male,O
Wistar,O
rats,O
received,O
each,O
dose,O
of,O
the,O
alpha,B
(,O
2,O
),O
adrenoceptor,O
antagonist,O
yohimbine,B
(,O
0,O
.,O
25,O
-,O
1,O
.,O
0mg,O
/,O
kg,O
),O
",",O
the,O
5,B
-,I
HT,I
(,O
2C,O
),O
receptor,O
agonist,O
m,B
-,I
chlorophenylpiperazine,I
(,O
mCPP,B
",",O
0,O
.,O
5,O
-,O
2,O
.,O
0mg,O
/,O
kg,O
),O
or,O
the,O
GABA,B
(,O
A,O
),O
inverse,O
receptor,O
agonist,O
pentylenetetrazole,B
(,O
PTZ,B
",",O
3,O
-,O
30mg,O
/,O
kg,O
),O
and,O
were,O
subsequently,O
tested,O
in,O
either,O
LES,O
or,O
FPS,O
.,O
RESULTS,O
:,O
None,O
of,O
the,O
drugs,O
enhanced,O
LES,O
",",O
whereas,O
mCPP,O
increased,O
percentage,O
FPS,O
and,O
yohimbine,O
increased,O
absolute,O
FPS,O
values,O
.,O
Furthermore,O
",",O
yohimbine,O
increased,O
baseline,O
startle,O
amplitude,O
in,O
the,O
LES,O
",",O
while,O
mCPP,O
suppressed,O
baseline,O
startle,O
in,O
both,O
the,O
LES,O
and,O
FPS,O
and,O
PTZ,O
suppressed,O
baseline,O
startle,O
in,O
the,O
FPS,O
.,O
CONCLUSIONS,O
:,O
In,O
contrast,O
to,O
findings,O
in,O
the,O
FPS,O
paradigm,O
",",O
none,O
of,O
the,O
drugs,O
were,O
able,O
to,O
exacerbate,O
the,O
LES,O
response,O
.,O
Thus,O
",",O
a,O
clear,O
pharmacological,O
differentiation,O
was,O
found,O
between,O
LES,O
and,O
FPS,O
.,O
Rosaceiform,O
dermatitis,O
associated,O
with,O
topical,O
tacrolimus,B
treatment,O
.,O
We,O
describe,O
herein,O
3,O
patients,O
who,O
developed,O
rosacea,B
-,I
like,I
dermatitis,I
eruptions,O
while,O
using,O
0,O
.,O
3,O
%,O
or,O
0,O
.,O
1,O
%,O
tacrolimus,B
ointment,O
for,O
facial,O
dermatitis,O
.,O
Skin,O
biopsy,O
specimens,O
showed,O
telangiectasia,O
and,O
noncaseating,O
epithelioid,O
granulomatous,O
tissue,O
formation,O
in,O
the,O
papillary,O
to,O
mid,O
dermis,O
.,O
Continuous,O
topical,O
use,O
of,O
immunomodulators,O
such,O
as,O
tacrolimus,B
or,O
pimecrolimus,B
should,O
be,O
regarded,O
as,O
a,O
potential,O
cause,O
of,O
rosaceiform,O
dermatitis,O
",",O
although,O
many,O
cases,O
have,O
not,O
been,O
reported,O
.,O
Coenzyme,B
Q10,I
treatment,O
ameliorates,O
acute,O
cisplatin,B
nephrotoxicity,O
in,O
mice,O
.,O
The,O
nephroprotective,O
effect,O
of,O
coenzyme,B
Q10,I
was,O
investigated,O
in,O
mice,O
with,O
acute,O
renal,O
injury,O
induced,O
by,O
a,O
single,O
i,O
.,O
p,O
injection,O
of,O
cisplatin,B
(,O
5,O
mg,O
/,O
kg,O
),O
.,O
Coenzyme,B
Q10,I
treatment,O
(,O
10,O
mg,O
/,O
kg,O
/,O
day,O
",",O
i,O
.,O
p,O
.,O
),O
was,O
applied,O
for,O
6,O
consecutive,O
days,O
",",O
starting,O
1,O
day,O
before,O
cisplatin,O
administration,O
.,O
Coenzyme,B
Q10,I
significantly,O
reduced,O
blood,O
urea,B
nitrogen,I
and,O
serum,O
creatinine,B
levels,O
which,O
were,O
increased,O
by,O
cisplatin,B
.,O
Coenzyme,B
Q10,I
significantly,O
compensated,O
deficits,O
in,O
the,O
antioxidant,O
defense,O
mechanisms,O
(,O
reduced,O
glutathione,B
level,O
and,O
superoxide,B
dismutase,I
activity,O
),O
",",O
suppressed,O
lipid,O
peroxidation,O
",",O
decreased,O
the,O
elevations,O
of,O
tumor,O
necrosis,O
factor,O
-,O
alpha,O
",",O
nitric,B
oxide,I
and,O
platinum,B
ion,I
concentration,O
",",O
and,O
attenuated,O
the,O
reductions,O
of,O
selenium,B
and,O
zinc,B
ions,I
in,O
renal,O
tissue,O
resulted,O
from,O
cisplatin,B
administration,O
.,O
Also,O
",",O
histopathological,O
renal,B
tissue,I
damage,O
mediated,O
by,O
cisplatin,B
was,O
ameliorated,O
by,O
coenzyme,B
Q10,I
treatment,O
.,O
Immunohistochemical,O
analysis,O
revealed,O
that,O
coenzyme,B
Q10,I
significantly,O
decreased,O
the,O
cisplatin,B
-,O
induced,O
overexpression,O
of,O
inducible,B
nitric,I
oxide,I
synthase,I
",",O
nuclear,B
factor,I
-,I
kappaB,I
",",O
caspase,B
-,I
3,I
and,O
p53,B
in,O
renal,B
tissue,I
.,O
It,O
was,O
concluded,O
that,O
coenzyme,B
Q10,I
represents,O
a,O
potential,O
therapeutic,O
option,O
to,O
protect,O
against,O
acute,O
cisplatin,B
nephrotoxicity,O
commonly,O
encountered,O
in,O
clinical,O
practice,O
.,O
Reversible,O
cholestasis,O
with,O
bile,O
duct,O
injury,O
following,O
azathioprine,B
therapy,O
.,O
A,O
case,O
report,O
.,O
A,O
67,O
-,O
year,O
-,O
old,O
patient,O
",",O
with,O
primary,O
polymyositis,O
and,O
without,O
previous,O
evidence,O
of,O
liver,O
disease,O
",",O
developed,O
clinical,O
and,O
biochemical,O
features,O
of,O
severe,O
cholestasis,O
3,O
months,O
after,O
initiation,O
of,O
azathioprine,B
therapy,O
.,O
Liver,B
biopsy,O
showed,O
cholestasis,B
with,O
both,O
cytological,O
and,O
architectural,O
alterations,O
of,O
interlobular,O
bile,B
ducts,O
.,O
Azathioprine,B
withdrawal,O
resulted,O
after,O
7,O
weeks,O
in,O
the,O
resolution,O
of,O
clinical,O
and,O
biochemical,O
abnormalities,O
.,O
It,O
is,O
believed,O
that,O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
reversible,O
azathioprine,B
-,I
induced,O
cholestasis,B
associated,O
with,O
histological,O
evidence,O
of,O
bile,B
duct,I
injury,O
.,O
Dopamine,B
is,O
not,O
essential,O
for,O
the,O
development,O
of,O
methamphetamine,B
-,O
induced,O
neurotoxicity,O
.,O
It,O
is,O
widely,O
believed,O
that,O
dopamine,B
(,O
DA,B
),O
mediates,O
methamphetamine,B
(,O
METH,B
),O
-,O
induced,O
toxicity,O
to,O
brain,O
dopaminergic,O
neurons,O
",",O
because,O
drugs,O
that,O
interfere,O
with,O
DA,B
neurotransmission,O
decrease,O
toxicity,O
",",O
whereas,O
drugs,O
that,O
increase,O
DA,B
neurotransmission,O
enhance,O
toxicity,O
.,O
However,O
",",O
temperature,O
effects,O
of,O
drugs,O
that,O
have,O
been,O
used,O
to,O
manipulate,O
brain,O
DA,B
neurotransmission,O
confound,O
interpretation,O
of,O
the,O
data,O
.,O
Here,O
we,O
show,O
that,O
the,O
recently,O
reported,O
ability,O
of,O
L,B
-,I
dihydroxyphenylalanine,I
to,O
reverse,O
the,O
protective,O
effect,O
of,O
alpha,B
-,I
methyl,I
-,I
para,I
-,I
tyrosine,I
on,O
METH,B
-,I
induced,I
DA,I
neurotoxicity,O
is,O
also,O
confounded,O
by,O
drug,O
effects,O
on,O
body,O
temperature,O
.,O
Further,O
",",O
we,O
show,O
that,O
mice,O
genetically,O
engineered,O
to,O
be,O
deficient,O
in,O
brain,O
DA,B
develop,O
METH,B
neurotoxicity,O
",",O
as,O
long,O
as,O
the,O
thermic,O
effects,O
of,O
METH,B
are,O
preserved,O
.,O
In,O
addition,O
",",O
we,O
demonstrate,O
that,O
mice,O
genetically,O
engineered,O
to,O
have,O
unilateral,O
brain,O
DA,B
deficits,O
develop,O
METH,B
-,O
induced,O
dopaminergic,O
deficits,O
that,O
are,O
of,O
comparable,O
magnitude,O
on,O
both,O
sides,O
of,O
the,O
brain,O
.,O
Taken,O
together,O
",",O
these,O
findings,O
demonstrate,O
that,O
DA,B
is,O
not,O
essential,O
for,O
the,O
development,O
of,O
METH,B
-,I
induced,I
dopaminergic,I
neurotoxicity,I
and,O
suggest,O
that,O
mechanisms,O
independent,O
of,O
DA,B
warrant,O
more,O
intense,O
investigation,O
.,O
Swallowing,O
-,O
induced,O
atrial,O
tachyarrhythmia,O
triggered,O
by,O
salbutamol,B
:,O
case,O
report,O
and,O
review,O
of,O
the,O
literature,O
.,O
CASE,O
:,O
A,O
49,O
-,O
year,O
-,O
-,O
old,O
patient,O
experienced,O
chest,O
discomfort,O
while,O
swallowing,O
.,O
On,O
electrocardiogram,O
",",O
episodes,O
of,O
atrial,O
tachyarrhythmia,O
were,O
recorded,O
immediately,O
after,O
swallowing,O
;,O
24,O
-,O
hour,O
Holter,O
monitoring,O
recorded,O
several,O
events,O
.,O
The,O
arrhythmia,O
resolved,O
after,O
therapy,O
with,O
atenolol,B
",",O
but,O
recurred,O
a,O
year,O
later,O
.,O
The,O
patient,O
noticed,O
that,O
before,O
these,O
episodes,O
he,O
had,O
been,O
using,O
an,O
inhalator,O
of,O
salbutamol,B
.,O
After,O
stopping,O
the,O
beta,B
-,I
agonist,I
",",O
and,O
after,O
a,O
week,O
with,O
the,O
atenolol,B
",",O
the,O
arrhythmia,O
disappeared,O
.,O
DISCUSSION,O
:,O
Swallowing,O
-,O
induced,O
atrial,O
tachyarrhythmia,O
(,O
SIAT,B
),O
is,O
a,O
rare,O
phenomenon,O
.,O
Fewer,O
than,O
50,O
cases,O
of,O
SIAT,B
have,O
been,O
described,O
in,O
the,O
literature,O
.,O
This,O
article,O
summarizes,O
all,O
the,O
cases,O
published,O
",",O
creating,O
a,O
comprehensive,O
review,O
of,O
the,O
current,O
knowledge,O
and,O
approach,O
to,O
SIAT,B
.,O
It,O
discusses,O
demographics,O
",",O
clinical,O
characteristics,O
and,O
types,O
of,O
arrhythmia,O
",",O
postulated,O
mechanisms,O
of,O
SIAT,B
",",O
and,O
different,O
treatment,O
possibilities,O
such,O
as,O
medications,B
",",O
surgery,O
",",O
and,O
radiofrequency,B
catheter,I
ablation,I
(,I
RFCA,I
),I
.,O
CONCLUSION,O
:,O
Salbutamol,B
is,O
presented,O
here,O
as,O
a,O
possible,O
trigger,O
for,O
SIAT,O
.,O
Although,O
it,O
is,O
difficult,O
to,O
define,O
causality,O
in,O
a,O
case,O
report,O
",",O
it,O
is,O
logical,O
to,O
think,O
that,O
a,O
beta,O
-,O
agonist,O
like,O
salbutamol,B
(,O
known,O
to,O
induce,O
tachycardia,O
),O
may,O
be,O
the,O
trigger,O
of,O
adrenergic,O
reflexes,O
originating,O
in,O
the,O
esophagus,O
while,O
swallowing,O
and,O
that,O
a,O
beta,O
-,O
blocker,O
such,O
as,O
atenolol,B
(,O
that,O
blocks,O
the,O
adrenergic,O
activity,O
),O
may,O
relieve,O
it,O
.,O
The,O
ability,O
of,O
insulin,B
treatment,O
to,O
reverse,O
or,O
prevent,O
the,O
changes,O
in,O
urinary,O
bladder,O
function,O
caused,O
by,O
streptozotocin,B
-,O
induced,O
diabetes,O
mellitus,O
.,O
1,O
.,O
The,O
effects,O
of,O
insulin,B
treatment,O
on,O
in,O
vivo,O
and,O
in,O
vitro,O
urinary,O
bladder,O
function,O
in,O
streptozotocin,B
-,O
diabetic,O
rats,O
were,O
investigated,O
.,O
2,O
.,O
Diabetes,O
of,O
2,O
months,O
duration,O
resulted,O
in,O
decreases,O
in,O
body,O
weight,O
and,O
increases,O
in,O
fluid,O
consumption,O
",",O
urine,O
volume,O
",",O
frequency,O
of,O
micturition,O
",",O
and,O
average,O
volume,O
per,O
micturition,O
;,O
effects,O
which,O
were,O
prevented,O
by,O
insulin,B
treatment,O
.,O
3,O
Insulin,B
treatment,O
also,O
prevented,O
the,O
increases,O
in,O
contractile,O
responses,O
of,O
bladder,O
body,O
strips,O
from,O
diabetic,O
rats,O
to,O
nerve,O
stimulation,O
",",O
ATP,B
",",O
and,O
bethanechol,B
.,O
4,O
Diabetes,O
of,O
4,O
months,O
duration,O
also,O
resulted,O
in,O
decreases,O
in,O
body,O
weight,O
",",O
and,O
increases,O
in,O
fluid,O
consumption,O
",",O
urine,O
volume,O
",",O
frequency,O
of,O
micturition,O
",",O
and,O
average,O
volume,O
per,O
micturition,O
",",O
effects,O
which,O
were,O
reversed,O
by,O
insulin,B
treatment,O
for,O
the,O
final,O
2,O
months,O
of,O
the,O
study,O
.,O
5,O
Insulin,B
treatment,O
reversed,O
the,O
increases,O
in,O
contractile,O
responses,O
of,O
bladder,O
body,O
strips,O
from,O
diabetic,O
rats,O
to,O
nerve,O
stimulation,O
",",O
ATP,B
",",O
and,O
bethanechol,B
.,O
6,O
The,O
data,O
indicate,O
that,O
the,O
effects,O
of,O
streptozotocin,B
-,I
induced,I
diabetes,I
on,O
urinary,O
bladder,O
function,O
are,O
both,O
prevented,O
and,O
reversed,O
by,O
insulin,B
treatment,O
.,O
Glutamatergic,B
neurotransmission,O
mediated,O
by,O
NMDA,B
receptors,O
in,O
the,O
inferior,O
colliculus,O
can,O
modulate,O
haloperidol,B
-,O
induced,O
catalepsy,O
.,O
The,O
inferior,O
colliculus,O
(,O
IC,B
),O
is,O
primarily,O
involved,O
in,O
the,O
processing,O
of,O
auditory,O
information,O
",",O
but,O
it,O
is,O
distinguished,O
from,O
other,O
auditory,O
nuclei,O
in,O
the,O
brainstem,O
by,O
its,O
connections,O
with,O
structures,O
of,O
the,O
motor,O
system,O
.,O
Functional,O
evidence,O
relating,O
the,O
IC,B
to,O
motor,O
behavior,O
derives,O
from,O
experiments,O
showing,O
that,O
activation,O
of,O
the,O
IC,B
by,O
electrical,O
stimulation,O
or,O
excitatory,B
amino,I
acid,I
microinjection,I
causes,O
freezing,O
",",O
escape,O
-,O
like,O
behavior,O
",",O
and,O
immobility,O
.,O
However,O
",",O
the,O
nature,O
of,O
this,O
immobility,O
is,O
still,O
unclear,O
.,O
The,O
present,O
study,O
examined,O
the,O
influence,O
of,O
excitatory,B
amino,I
acid,I
-,I
mediated,I
mechanisms,I
in,O
the,O
IC,B
on,O
the,O
catalepsy,O
induced,O
by,O
the,O
dopamine,B
receptor,I
blocker,I
haloperidol,I
administered,O
systemically,O
(,O
1,O
or,O
0,O
.,O
5,O
mg,O
/,O
kg,O
),O
in,O
rats,O
.,O
Haloperidol,B
-,O
induced,O
catalepsy,O
was,O
challenged,O
with,O
prior,O
intracollicular,O
microinjections,O
of,O
glutamate,B
NMDA,B
receptor,O
antagonists,O
",",O
MK,B
-,O
801,I
(,O
15,O
or,O
30,O
mmol,O
/,O
0,O
.,O
5,O
microl,O
),O
and,O
AP7,B
(,O
10,O
or,O
20,O
nmol,O
/,O
0,O
.,O
NMDA,B
receptor,O
agonist,O
N,B
-,I
methyl,I
-,I
d,I
-,I
aspartate,I
(,I
NMDA,I
",",I
20,I
or,I
30,I
nmol,I
/,I
0,I
.,I
5,O
microl,O
),O
.,O
The,O
results,O
showed,O
that,O
intracollicular,O
microinjection,O
of,O
MK,B
-,O
801,B
and,O
AP7,B
previous,O
to,O
systemic,O
injections,O
of,O
haloperidol,B
significantly,O
attenuated,O
the,O
catalepsy,O
",",O
as,O
indicated,O
by,O
a,O
reduced,O
latency,O
to,O
step,O
down,O
from,O
a,O
horizontal,O
bar,O
.,O
Accordingly,O
",",O
intracollicular,O
microinjection,O
of,O
NMDA,B
increased,O
the,O
latency,O
to,O
step,O
down,O
the,O
bar,O
.,O
These,O
findings,O
suggest,O
that,O
glutamate,B
-,O
mediated,O
mechanisms,O
in,O
the,O
neural,O
circuits,O
at,O
the,O
IC,O
level,O
influence,O
haloperidol,B
-,O
induced,O
catalepsy,O
and,O
participate,O
in,O
the,O
regulation,O
of,O
motor,O
activity,O
.,O
Severe,O
congestive,O
heart,O
failure,O
patient,O
on,O
amiodarone,B
presenting,O
with,O
myxedemic,O
coma,O
:,O
a,O
case,O
report,O
.,O
This,O
is,O
a,O
case,O
report,O
of,O
myxedema,O
coma,O
secondary,O
to,O
amiodarone,B
-,O
induced,O
hypothyroidism,O
in,O
a,O
patient,O
with,O
severe,O
congestive,O
heart,O
failure,O
(,O
CHF,O
),O
.,O
To,O
our,O
knowledge,O
and,O
after,O
reviewing,O
the,O
literature,O
there,O
is,O
one,O
case,O
report,O
of,O
myxedema,B
coma,I
during,O
long,O
term,O
amiodarone,B
therapy,O
.,O
Myxedema,B
coma,I
is,O
a,O
life,O
threatening,O
condition,O
that,O
carries,O
a,O
mortality,O
reaching,O
as,O
high,O
as,O
20,O
%,O
with,O
treatment,O
.,O
The,O
condition,O
is,O
treated,O
with,O
intravenous,O
thyroxine,B
(,O
T4,B
),O
or,O
intravenous,O
tri,B
-,I
iodo,I
-,I
thyronine,I
(,O
T3,B
),O
.,O
Patients,O
with,O
CHF,O
on,O
amiodarone,B
may,O
suffer,O
serious,O
morbidity,O
and,O
mortality,O
from,O
hypothyroidism,O
",",O
and,O
thus,O
may,O
deserve,O
closer,O
follow,O
up,O
for,O
thyroid,O
stimulating,O
hormone,O
(,O
TSH,B
),O
levels,O
.,O
This,O
case,O
report,O
carries,O
an,O
important,O
clinical,O
application,O
given,O
the,O
frequent,O
usage,O
of,O
amiodarone,B
among,O
CHF,O
patients,O
.,O
The,O
myriad,O
clinical,O
presentation,O
of,O
myxedema,B
coma,I
and,O
its,O
serious,O
morbidity,O
and,O
mortality,O
stresses,O
the,O
need,O
to,O
suspect,O
this,O
clinical,O
syndrome,O
among,O
CHF,B
patients,O
presenting,O
with,O
hypotension,O
",",O
weakness,O
or,O
other,O
unexplained,O
symptoms,O
.,O
Effects,O
of,O
active,O
constituents,O
of,O
Crocus,B
sativus,I
L,I
.,O
",",O
crocin,B
on,O
streptozocin,B
-,I
induced,I
model,I
of,I
sporadic,I
Alzheimer,B
',I
s,I
disease,I
in,O
male,O
rats,O
.,O
BACKGROUND,O
:,O
The,O
involvement,O
of,O
water,B
-,I
soluble,I
carotenoids,I
",",O
crocins,B
",",O
as,O
the,O
main,O
and,O
active,O
components,O
of,O
Crocus,B
sativus,I
L,I
.,O
extract,O
in,O
learning,O
and,O
memory,O
processes,O
has,O
been,O
proposed,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
effect,O
of,O
crocins,B
on,O
sporadic,O
Alzheimer,B
',I
s,I
disease,I
induced,O
by,O
intracerebroventricular,O
(,O
icv,B
),I
streptozocin,I
(,I
STZ,I
),I
in,O
male,O
rats,O
was,O
investigated,O
.,O
METHODS,O
:,O
Male,O
adult,O
Wistar,O
rats,O
(,O
n,O
=,O
90,O
and,O
260,O
-,O
290,O
g,O
):,O
were,O
divided,O
into,O
1,O
",",O
control,O
;,O
2,O
and,O
3,O
",",O
crocins,B
(,O
15,O
and,O
30,O
mg,O
/,O
kg,O
):,O
;,O
4,O
",",O
STZ,B
;,O
5,O
and,O
6,O
",",O
STZ,B
+,O
crocins,B
(,O
15,O
and,O
30,O
mg,O
/,O
kg,O
):,O
groups,O
.,O
In,O
Alzheimer,B
',O
s,O
disease,O
groups,O
",",O
rats,O
were,O
injected,O
with,O
STZ,B
-,O
icv,O
bilaterally,O
(,O
3,O
mg,O
/,O
kg,O
):,O
in,O
first,O
day,O
and,O
3,O
days,O
later,O
",",O
a,O
similar,O
STZ,B
-,O
icv,O
application,O
was,O
repeated,O
.,O
In,O
STZ,B
+,O
crocin,B
animal,O
groups,O
",",O
crocin,B
was,O
applied,O
in,O
doses,O
of,O
15,O
and,O
30,O
mg,O
/,O
kg,O
",",O
i,O
.,O
p,O
.,O
",",O
one,O
day,O
pre,O
-,O
surgery,O
and,O
continued,O
for,O
three,O
weeks,O
.,O
Prescription,O
of,O
crocin,B
in,O
each,O
dose,O
was,O
repeated,O
once,O
for,O
two,O
days,O
.,O
However,O
",",O
the,O
learning,O
and,O
memory,O
performance,O
was,O
assessed,O
using,O
passive,O
avoidance,O
paradigm,O
",",O
and,O
for,O
spatial,O
cognition,O
evaluation,O
",",O
Y,O
-,O
maze,O
task,O
was,O
used,O
.,O
RESULTS,O
:,O
It,O
was,O
found,O
out,O
that,O
crocin,B
(,O
30,O
mg,O
/,O
kg,O
),O
treated,O
STZ,B
-,O
injected,O
rats,O
show,O
higher,O
correct,O
choices,O
and,O
lower,O
errors,O
in,O
Y,O
-,O
maze,O
than,O
vehicle,O
-,O
treated,O
STZ,B
-,O
injected,O
rats,O
.,O
In,O
addition,O
",",O
crocin,B
in,O
the,O
mentioned,O
dose,O
could,O
significantly,O
attenuated,O
learning,O
and,O
memory,O
impairment,O
in,O
treated,O
STZ,B
-,O
injected,O
group,O
in,O
passive,O
avoidance,O
test,O
.,O
CONCLUSION,O
:,O
Therefore,O
",",O
these,O
results,O
demonstrate,O
the,O
effectiveness,O
of,O
crocin,B
(,O
30,O
mg,O
/,O
kg,O
),O
in,O
antagonizing,O
the,O
cognitive,O
deficits,O
caused,O
by,O
STZ,B
-,O
icv,O
in,O
rats,O
and,O
its,O
potential,O
in,O
the,O
treatment,O
of,O
neurodegenerative,O
diseases,O
such,O
as,O
Alzheimer,B
',O
s,O
disease,O
.,O
Serotonin,B
6,I
receptor,I
gene,I
is,O
associated,O
with,O
methamphetamine,B
-,O
induced,O
psychosis,O
in,O
a,O
Japanese,O
population,O
.,O
BACKGROUND,O
:,O
Altered,O
serotonergic,O
neural,O
transmission,O
is,O
hypothesized,O
to,O
be,O
a,O
susceptibility,O
factor,O
for,O
psychotic,O
disorders,O
such,O
as,O
schizophrenia,O
.,O
The,O
serotonin,B
6,I
(,I
5,I
-,I
HT6,I
),I
receptor,O
is,O
therapeutically,O
targeted,O
by,O
several,O
second,O
generation,O
antipsychotics,O
",",O
such,O
as,O
clozapine,B
and,O
olanzapine,B
",",O
and,O
d,B
-,I
amphetamine,I
-,I
induced,I
hyperactivity,O
in,O
rats,O
is,O
corrected,O
with,O
the,O
use,O
of,O
a,O
selective,O
5,B
-,I
HT6,I
receptor,O
antagonist,O
.,O
In,O
addition,O
",",O
the,O
disrupted,O
prepulse,O
inhibition,O
induced,O
by,O
d,B
-,I
amphetamine,I
or,O
phencyclidine,B
was,O
restored,O
by,O
5,B
-,I
HT6,I
receptor,I
antagonist,I
in,O
an,O
animal,O
study,O
using,O
rats,O
.,O
These,O
animal,O
models,O
were,O
considered,O
to,O
reflect,O
the,O
positive,O
symptoms,O
of,O
schizophrenia,B
",",O
and,O
the,O
above,O
evidence,O
suggests,O
that,O
altered,O
5,B
-,I
HT6,I
receptors,I
are,O
involved,O
in,O
the,O
pathophysiology,O
of,O
psychotic,O
disorders,O
.,O
The,O
symptoms,O
of,O
methamphetamine,B
(,O
METH,B
),O
-,O
induced,O
psychosis,O
are,O
similar,O
to,O
those,O
of,O
paranoid,O
type,O
schizophrenia,O
.,O
Therefore,O
",",O
we,O
conducted,O
an,O
analysis,O
of,O
the,O
association,O
of,O
the,O
5,O
-,O
HT6,B
gene,O
(,O
HTR6,B
),O
with,O
METH,B
-,O
induced,O
psychosis,O
.,O
METHOD,O
:,O
Using,O
five,O
tagging,O
SNPs,O
(,O
rs6693503,B
",",O
rs1805054,B
",",O
rs4912138,B
",",O
rs3790757,B
and,O
rs9659997,B
),O
",",O
we,O
conducted,O
a,O
genetic,O
association,O
analysis,O
of,O
case,O
-,O
control,O
samples,O
(,O
197,O
METH,B
-,O
induced,O
psychosis,O
patients,O
and,O
337,O
controls,O
),O
in,O
the,O
Japanese,O
population,O
.,O
The,O
age,O
and,O
sex,O
of,O
the,O
control,O
subjects,O
did,O
not,O
differ,O
from,O
those,O
of,O
the,O
methamphetamine,B
dependence,I
patients,I
.,O
RESULTS,O
:,O
rs6693503,O
was,O
associated,O
with,O
METH,B
-,I
induced,I
psychosis,I
patients,I
in,O
the,O
allele,O
/,O
genotype,O
-,O
wise,O
analysis,O
.,O
Moreover,O
",",O
this,O
association,O
remained,O
significant,O
after,O
Bonferroni,O
correction,O
.,O
In,O
the,O
haplotype,O
-,O
wise,O
analysis,O
",",O
we,O
detected,O
an,O
association,O
between,O
two,O
markers,O
(,O
rs6693503,B
and,O
rs1805054,B
),O
and,O
three,O
markers,O
(,O
rs6693503,B
",",O
rs1805054,B
and,O
rs4912138,B
),O
in,O
HTR6,B
and,O
METH,B
-,O
induced,O
psychosis,O
patients,O
",",O
respectively,O
.,O
CONCLUSION,O
:,O
HTR6,B
may,O
play,O
an,O
important,O
role,O
in,O
the,O
pathophysiology,O
of,O
METH,B
-,O
induced,O
psychosis,O
in,O
the,O
Japanese,O
population,O
.,O
Neural,O
correlates,O
of,O
S,B
-,I
ketamine,I
induced,O
psychosis,O
during,O
overt,O
continuous,O
verbal,O
fluency,O
.,O
The,O
glutamatergic,O
N,B
-,I
methyl,I
-,I
D,I
-,I
aspartate,I
(,O
NMDA,B
),O
receptor,O
has,O
been,O
implicated,O
in,O
the,O
pathophysiology,O
of,O
schizophrenia,O
.,O
Administered,O
to,O
healthy,O
volunteers,O
",",O
a,O
subanesthetic,O
dose,O
of,O
the,O
non,O
-,O
competitive,O
NMDA,B
receptor,O
antagonist,O
ketamine,I
leads,O
to,O
psychopathological,O
symptoms,O
similar,O
to,O
those,O
observed,O
in,O
schizophrenia,O
.,O
In,O
patients,O
with,O
schizophrenia,B
",",O
ketamine,B
exacerbates,O
the,O
core,O
symptoms,O
of,O
illness,O
",",O
supporting,O
the,O
hypothesis,O
of,O
a,O
glutamatergic,O
dysfunction,O
.,O
In,O
a,O
counterbalanced,O
",",O
placebo,O
-,O
controlled,O
",",O
double,O
-,O
blind,O
study,O
design,O
",",O
healthy,O
subjects,O
were,O
administered,O
a,O
continuous,O
subanesthetic,O
S,B
-,O
ketamine,B
infusion,O
while,O
differences,O
in,O
BOLD,B
responses,O
measured,O
with,O
fMRI,B
were,O
detected,O
.,O
During,O
the,O
scanning,O
period,O
",",O
subjects,O
performed,O
continuous,O
overt,O
verbal,O
fluency,O
tasks,O
(,O
phonological,B
",",O
lexical,B
and,O
semantic,B
),O
.,O
Ketamine,B
-,O
induced,O
psychopathological,O
symptoms,O
were,O
assessed,O
with,O
the,O
Positive,B
and,I
Negative,I
Syndrome,I
Scale,I
(,O
PANSS,B
),O
.,O
Ketamine,B
elicited,O
psychosis,O
like,O
psychopathology,O
.,O
Post,O
-,O
hoc,O
t,O
-,O
tests,O
revealed,O
significant,O
differences,O
between,O
placebo,O
and,O
ketamine,B
for,O
the,O
amounts,O
of,O
words,O
generated,O
during,O
lexical,B
and,O
semantic,B
verbal,O
fluency,O
",",O
while,O
the,O
phonological,B
domain,O
remained,O
unaffected,O
.,O
Ketamine,B
led,O
to,O
enhanced,O
cortical,O
activations,O
in,O
supramarginal,B
and,O
frontal,B
brain,O
regions,O
for,O
phonological,B
and,O
lexical,O
verbal,O
fluency,O
",",O
but,O
not,O
for,O
semantic,B
verbal,O
fluency,O
.,O
Ketamine,B
induces,O
activation,O
changes,O
in,O
healthy,O
subjects,O
similar,O
to,O
those,O
observed,O
in,O
patients,O
with,O
schizophrenia,B
",",O
particularly,O
in,O
frontal,B
and,O
temporal,B
brain,O
regions,O
.,O
Our,O
results,O
provide,O
further,O
support,O
for,O
the,O
hypothesis,O
of,O
an,O
NMDA,B
receptor,I
dysfunction,O
in,O
the,O
pathophysiology,O
of,O
schizophrenia,O
.,O
Long,O
-,O
term,O
prognosis,O
for,O
transplant,O
-,O
free,O
survivors,O
of,O
paracetamol,B
-,I
induced,I
acute,I
liver,I
failure,I
.,O
BACKGROUND,O
:,O
The,O
prognosis,O
for,O
transplant,O
-,O
free,O
survivors,O
of,O
paracetamol,B
-,I
induced,I
acute,I
liver,I
failure,I
remains,O
unknown,O
.,O
AIM,O
:,O
To,O
examine,O
whether,O
paracetamol,B
-,O
induced,O
acute,O
liver,O
failure,O
increases,O
long,O
-,O
term,O
mortality,O
.,O
METHODS,O
:,O
We,O
followed,O
up,O
all,O
transplant,O
-,O
free,O
survivors,O
of,O
paracetamol,B
-,O
induced,O
acute,O
liver,O
injury,O
",",O
hospitalized,O
in,O
a,O
Danish,O
national,O
referral,O
centre,O
during,O
1984,O
-,O
2004,O
.,O
We,O
compared,O
age,O
-,O
specific,O
mortality,O
rates,O
from,O
1,O
year,O
post,O
-,O
discharge,O
through,O
2008,O
between,O
those,O
in,O
whom,O
the,O
liver,O
injury,O
led,O
to,O
an,O
acute,O
liver,O
failure,O
and,O
those,O
in,O
whom,O
it,O
did,O
not,O
.,O
RESULTS,O
:,O
We,O
included,O
641,O
patients,O
.,O
On,O
average,O
",",O
age,O
-,O
specific,O
mortality,O
rates,O
were,O
slightly,O
higher,O
for,O
the,O
101,O
patients,O
whose,O
paracetamol,B
-,O
induced,O
liver,B
injury,O
had,O
caused,O
an,O
acute,O
liver,B
failure,I
(,O
adjusted,O
mortality,O
rate,O
ratio,O
=,O
1,O
.,O
70,O
",",O
95,O
%,O
CI,O
1,O
.,O
2,O
-,O
2,O
.,O
85,O
),O
",",O
but,O
the,O
association,O
was,O
age,O
-,O
dependent,O
",",O
and,O
no,O
survivors,O
of,O
acute,O
liver,B
failure,I
died,O
of,O
liver,B
disease,I
",",O
whereas,O
suicides,O
were,O
frequent,O
in,O
both,O
groups,O
.,O
These,O
observations,O
speak,O
against,O
long,O
-,O
term,O
effects,O
of,O
acute,O
liver,B
failure,I
.,O
More,O
likely,O
",",O
the,O
elevated,O
mortality,O
rate,O
ratio,O
resulted,O
from,O
incomplete,O
adjustment,O
for,O
the,O
greater,O
prevalence,O
of,O
substance,O
abuse,O
among,O
survivors,O
of,O
acute,O
liver,B
failure,I
.,O
CONCLUSIONS,O
:,O
Paracetamol,B
-,I
induced,I
acute,I
liver,I
failure,I
did,O
not,O
affect,O
long,O
-,O
term,O
mortality,O
.,O
Clinical,O
follow,O
-,O
up,O
may,O
be,O
justified,O
by,O
the,O
cause,O
of,O
the,O
liver,B
failure,I
",",O
but,O
not,O
by,O
the,O
liver,B
failure,I
itself,O
.,O
In,O
vivo,O
characterization,O
of,O
a,O
dual,O
adenosine,B
A2A,I
/,O
A1,I
receptor,I
antagonist,I
in,O
animal,O
models,O
of,O
Parkinson,B
',O
s,O
disease,I
.,O
The,O
in,O
vivo,O
characterization,O
of,O
a,O
dual,O
adenosine,B
A,I
(,O
2A,I
),O
/,O
A,I
(,O
1,I
),O
receptor,I
antagonist,I
in,O
several,O
animal,O
models,O
of,O
Parkinson,B
',O
s,O
disease,I
is,O
described,O
.,O
Discovery,O
and,O
scale,O
-,O
up,O
syntheses,O
of,O
compound,O
1,B
are,O
described,O
in,O
detail,O
",",O
highlighting,O
optimization,O
steps,O
that,O
increased,O
the,O
overall,O
yield,O
of,O
1,B
from,O
10,O
.,O
0,O
%,O
to,O
30,O
.,O
5,O
%,O
.,O
Compound,O
1,B
is,O
a,O
potent,O
A,B
(,O
2A,O
),O
/,O
A,B
(,O
1,O
),O
receptor,O
antagonist,O
in,O
vitro,O
(,O
A,B
(,O
2A,O
),O
K,B
(,O
i,O
),O
=,O
4,O
.,O
1,O
nM,O
;,O
A,B
(,O
1,O
),O
K,B
(,O
i,O
),O
=,O
17,O
.,O
0,O
nM,O
),O
that,O
has,O
excellent,O
activity,O
",",O
after,O
oral,O
administration,O
",",O
across,O
a,O
number,O
of,O
animal,O
models,O
of,O
Parkinson,B
',O
s,O
disease,O
including,O
mouse,O
and,O
rat,O
models,O
of,O
haloperidol,B
-,O
induced,O
catalepsy,O
",",O
mouse,O
model,O
of,O
reserpine,B
-,O
induced,O
akinesia,O
",",O
rat,O
6,O
-,O
hydroxydopamine,B
(,O
6,O
-,O
OHDA,O
),O
lesion,O
model,O
of,O
drug,O
-,O
induced,O
rotation,O
",",O
and,O
MPTP,B
-,O
treated,O
non,O
-,O
human,O
primate,O
model,O
.,O
Effects,O
of,O
the,O
hippocampal,B
deep,I
brain,I
stimulation,I
on,O
cortical,B
epileptic,I
discharges,I
in,O
penicillin,B
-,I
induced,I
epilepsy,I
model,I
in,I
rats,I
.,O
AIM,O
:,O
Experimental,O
and,O
clinical,O
studies,O
have,O
revealed,O
that,O
hippocampal,B
DBS,I
can,O
control,O
epileptic,I
activity,I
",",O
but,O
the,O
mechanism,O
of,O
action,O
is,O
obscure,O
and,O
optimal,O
stimulation,O
parameters,O
are,O
not,O
clearly,O
defined,O
.,O
The,O
aim,O
was,O
to,O
evaluate,O
the,O
effects,O
of,O
high,O
frequency,O
hippocampal,O
stimulation,O
on,O
cortical,O
epileptic,O
activity,O
in,O
penicillin,B
-,I
induced,I
epilepsy,I
model,O
.,O
MATERIAL,O
AND,O
METHODS,O
:,O
Twenty,O
-,O
five,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
implanted,O
DBS,O
electrodes,O
.,O
In,O
group,O
-,O
1,O
(,O
n,O
=,O
10,O
),O
hippocampal,O
DBS,O
was,O
off,O
and,O
in,O
the,O
group,O
-,O
2,O
(,O
n,O
=,O
10,O
),O
hippocampal,O
DBS,O
was,O
on,O
(,O
185,O
Hz,O
",",O
0,O
.,O
5V,B
",",O
1V,B
",",O
2V,B
",",O
and,O
5V,B
for,O
60,O
sec,O
),O
following,O
penicillin,B
G,I
injection,O
intracortically,O
.,O
In,O
the,O
control,O
group,O
hippocampal,O
DBS,O
was,O
on,O
following,O
8,O
l,O
saline,B
injection,O
intracortically,O
.,O
EEG,O
recordings,O
were,O
obtained,O
before,O
and,O
15,O
minutes,O
following,O
penicillin,B
-,I
G,I
injection,O
",",O
and,O
at,O
10th,O
minutes,O
following,O
each,O
stimulus,O
for,O
analysis,O
in,O
terms,O
of,O
frequency,O
",",O
amplitude,O
",",O
and,O
power,O
spectrum,O
.,O
RESULTS,O
:,O
High,O
frequency,O
hippocampal,O
DBS,O
suppressed,O
the,O
acute,O
penicillin,B
-,O
induced,O
cortical,O
epileptic,O
activity,O
independent,O
from,O
stimulus,O
intensity,O
.,O
In,O
the,O
control,O
group,O
",",O
hippocampal,O
stimulation,O
alone,O
lead,O
only,O
to,O
diffuse,O
slowing,O
of,O
cerebral,O
bioelectrical,O
activity,O
at,O
5V,O
stimulation,O
.,O
CONCLUSION,O
:,O
Our,O
results,O
revealed,O
that,O
continuous,O
high,O
frequency,O
stimulation,O
of,O
the,O
hippampus,O
suppressed,O
acute,O
cortical,O
epileptic,O
activity,O
effectively,O
without,O
causing,O
secondary,O
epileptic,O
discharges,O
.,O
These,O
results,O
are,O
important,O
in,O
terms,O
of,O
defining,O
the,O
optimal,O
parameters,O
of,O
hippocampal,O
DBS,O
in,O
patients,O
with,O
epilepsy,O
.,O
CCNU,B
(,O
lomustine,I
),O
toxicity,O
in,O
dogs,O
:,O
a,O
retrospective,O
study,O
(,O
2002,O
-,O
7,O
),O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
the,O
incidence,O
of,O
haematological,O
",",O
renal,O
",",O
hepatic,O
and,O
gastrointestinal,O
toxicities,O
in,O
tumour,O
-,O
bearing,O
dogs,O
receiving,O
1,O
-,O
(,O
2,O
-,O
chloroethyl,B
),O
-,O
3,O
-,O
cyclohexyl,B
-,O
1,O
-,O
nitrosourea,I
(,O
CCNU,B
),O
.,O
DESIGN,O
:,O
The,O
medical,O
records,O
of,O
206,O
dogs,O
that,O
were,O
treated,O
with,O
CCNU,B
at,O
the,O
Melbourne,O
Veterinary,O
Specialist,O
Centre,O
between,O
February,O
2002,O
and,O
December,O
2007,O
were,O
retrospectively,O
evaluated,O
.,O
RESULTS,O
:,O
Of,O
the,O
206,O
dogs,O
treated,O
with,O
CCNU,B
",",O
185,O
met,O
the,O
inclusion,O
criteria,O
for,O
at,O
least,O
one,O
class,O
of,O
toxicity,O
.,O
CCNU,B
was,O
used,O
most,O
commonly,O
in,O
the,O
treatment,O
of,O
lymphoma,B
",",O
mast,B
cell,I
tumour,I
",",O
brain,B
tumour,I
",",O
histiocytic,B
tumours,I
and,O
epitheliotropic,B
lymphoma,I
.,O
Throughout,O
treatment,O
",",O
56,O
.,O
9,O
%,O
of,O
dogs,O
experienced,O
neutropenia,B
",",O
34,O
.,O
2,O
%,O
experienced,O
anaemia,B
and,O
14,O
.,O
2,O
%,O
experienced,O
thrombocytopenia,B
.,O
Gastrointestinal,B
toxicosis,I
was,O
detected,O
in,O
37,O
.,O
8,O
%,O
of,O
dogs,O
",",O
the,O
most,O
common,O
sign,O
of,O
which,O
was,O
vomiting,B
(,O
24,O
.,O
3,O
%,O
),O
.,O
Potential,O
renal,B
toxicity,I
and,O
elevated,O
alanine,B
transaminase,I
(,O
ALT,B
),O
concentration,O
were,O
reported,O
in,O
12,O
.,O
2,O
%,O
and,O
48,O
.,O
8,O
%,O
of,O
dogs,O
",",O
respectively,O
.,O
The,O
incidence,O
of,O
hepatic,B
failure,I
was,O
1,O
.,O
2,O
%,O
.,O
CONCLUSIONS,O
:,O
CCNU,B
-,I
associated,I
toxicity,I
in,O
dogs,O
is,O
common,O
",",O
but,O
is,O
usually,O
not,O
life,O
threatening,O
.,O
Central,B
vein,I
thrombosis,I
and,O
topical,O
dipivalyl,B
epinephrine,I
.,O
A,O
report,O
is,O
given,O
on,O
an,O
83,O
-,O
year,O
-,O
old,O
female,O
who,O
acquired,O
central,B
vein,I
thrombosis,I
in,O
her,O
seeing,O
eye,O
one,O
day,O
after,O
having,O
started,O
topical,O
medication,O
with,O
dipivalyl,B
epinephrine,I
for,O
advanced,O
glaucoma,O
discovered,O
in,O
the,O
other,O
eye,O
.,O
From,O
present,O
knowledge,O
about,O
the,O
effects,O
of,O
adrenergic,O
eye,O
drops,O
on,O
ocular,O
blood,O
circulation,O
",",O
it,O
is,O
difficult,O
to,O
suggest,O
an,O
association,O
between,O
the,O
two,O
events,O
",",O
which,O
may,O
be,O
coincidental,O
only,O
.,O
Benzylacyclouridine,B
reverses,O
azidothymidine,B
-,I
induced,O
marrow,O
suppression,O
without,O
impairment,O
of,O
anti,O
-,O
human,O
immunodeficiency,O
virus,O
activity,O
.,O
Increased,O
extracellular,O
concentrations,O
of,O
uridine,B
(,O
Urd,B
),O
have,O
been,O
reported,O
to,O
reduce,O
",",O
in,O
vitro,O
",",O
azidothymidine,B
(,O
AZT,B
),O
-,O
induced,O
inhibition,O
of,O
human,O
granulocyte,O
-,O
macrophage,O
progenitor,O
cells,O
without,O
impairment,O
of,O
its,O
antihuman,O
immunodeficiency,O
virus,O
(,O
HIV,B
),O
activity,O
.,O
Because,O
of,O
the,O
clinical,O
toxicities,O
associated,O
with,O
chronic,O
Urd,B
administration,O
",",O
the,O
ability,O
of,O
benzylacyclouridine,B
(,O
BAU,B
),O
to,O
effect,O
",",O
in,O
vivo,O
",",O
AZT,B
-,O
induced,O
anemia,O
and,O
leukopenia,O
was,O
assessed,O
.,O
This,O
agent,O
inhibits,O
Urd,B
catabolism,O
and,O
",",O
in,O
vivo,O
",",O
increases,O
the,O
plasma,O
concentration,O
of,O
Urd,B
in,O
a,O
dose,O
-,O
dependent,O
manner,O
",",O
without,O
Urd,B
-,O
related,O
toxicity,O
.,O
In,O
mice,O
rendered,O
anemic,O
and,O
leukopenic,O
by,O
the,O
administration,O
of,O
AZT,B
for,O
28,O
days,O
in,O
drinking,O
water,O
(,O
1,O
.,O
5,O
mg,O
/,O
mL,O
),O
",",O
the,O
continued,O
administration,O
of,O
AZT,B
plus,O
daily,O
BAU,B
(,O
300,O
mg,O
/,O
kg,O
",",O
orally,O
),O
partially,O
reversed,O
AZT,B
-,O
induced,O
anemia,O
and,O
leukopenia,O
(,O
P,O
less,O
than,O
.,O
5,O
),O
",",O
increased,O
peripheral,O
reticulocytes,O
(,O
to,O
4,O
.,O
9,O
%,O
",",O
P,O
less,O
than,O
.,O
1,O
.,O
),O
",",O
increased,O
cellularity,O
in,O
the,O
marrow,O
",",O
and,O
improved,O
megaloblastosis,O
.,O
When,O
coadministered,O
with,O
AZT,B
from,O
the,O
onset,O
of,O
drug,O
administration,O
",",O
BAU,B
reduced,O
AZT,B
-,O
induced,O
marrow,O
toxicity,O
.,O
In,O
vitro,O
",",O
at,O
a,O
concentration,O
of,O
100,O
mumol,O
/,O
L,O
",",O
BAU,B
possesses,O
minimal,O
anti,O
-,O
HIV,B
activity,O
and,O
has,O
no,O
effect,O
on,O
the,O
ability,O
of,O
AZT,B
to,O
reverse,O
the,O
HIV,B
-,O
induced,O
cytopathic,O
effect,O
in,O
MT4,O
cells,O
.,O
The,O
clinical,O
and,O
biochemical,O
implications,O
of,O
these,O
findings,O
are,O
discussed,O
.,O
Lethal,O
anuria,B
complicating,O
high,O
dose,O
ifosfamide,B
chemotherapy,O
in,O
a,O
breast,O
cancer,O
patient,O
with,O
an,O
impaired,O
renal,O
function,O
.,O
A,O
sixty,O
-,O
year,O
-,O
old,O
woman,O
with,O
advanced,O
breast,O
cancer,O
",",O
previously,O
treated,O
with,O
cisplatin,B
",",O
developed,O
an,O
irreversible,O
lethal,O
renal,O
failure,O
with,O
anuria,B
",",O
the,O
day,O
after,O
5,O
g,O
/,O
m2,O
bolus,O
ifosfamide,B
.,O
Postrenal,O
failure,O
was,O
excluded,O
by,O
echography,O
.,O
A,O
prerenal,O
component,O
could,O
have,O
contributed,O
to,O
renal,O
failure,O
because,O
of,O
a,O
transient,O
hypotension,O
",",O
due,O
to,O
an,O
increasing,O
ascitis,O
",",O
occurring,O
just,O
before,O
anuria,O
.,O
However,O
",",O
correction,O
of,O
the,O
hemodynamic,O
parameters,O
did,O
not,O
improve,O
renal,O
function,O
.,O
Ifosfamide,B
is,O
a,O
known,O
nephrotoxic,O
drug,O
with,O
demonstrated,O
tubulopathies,O
.,O
We,O
strongly,O
suspect,O
that,O
this,O
lethal,O
anuria,O
was,O
mainly,O
due,O
to,O
ifosfamide,B
",",O
occurring,O
in,O
a,O
patient,O
having,O
received,O
previous,O
cisplatin,B
chemotherapy,O
and,O
with,O
poor,O
kidney,O
perfusion,O
due,O
to,O
transient,O
hypotension,O
.,O
We,O
recommend,O
careful,O
use,O
of,O
ifosfamide,B
in,O
patients,O
pretreated,O
with,O
nephrotoxic,O
chemotherapy,O
and,O
inadequate,O
renal,O
perfusion,O
.,O
Nociceptive,O
effects,O
induced,O
by,O
intrathecal,O
administration,O
of,O
prostaglandin,B
D2,I
",",O
E2,B
",",O
or,O
F2,B
alpha,I
to,O
conscious,O
mice,O
.,O
The,O
effects,O
of,O
intrathecal,O
administration,O
of,O
prostaglandins,B
on,O
pain,O
responses,O
in,O
conscious,O
mice,O
were,O
evaluated,O
by,O
using,O
hot,O
plate,O
and,O
acetic,O
acid,O
writhing,O
tests,O
.,O
Prostaglandin,B
D2,I
(,O
0,O
.,O
5,O
-,O
3,O
ng,O
/,O
mouse,O
),O
had,O
a,O
hyperalgesic,O
action,O
on,O
the,O
response,O
to,O
a,O
hot,O
plate,O
during,O
a,O
3,O
-,O
60,O
min,O
period,O
after,O
injection,O
.,O
Prostaglandin,B
E2,I
showed,O
a,O
hyperalgesic,O
effect,O
at,O
doses,O
of,O
1,O
pg,O
to,O
10,O
ng,O
/,O
mouse,O
",",O
but,O
the,O
effect,O
lasted,O
shorter,O
(,O
3,O
-,O
30,O
min,O
),O
than,O
that,O
of,O
prostaglandin,B
D2,I
.,O
Similar,O
results,O
were,O
obtained,O
by,O
acetic,B
acid,I
writhing,I
tests,I
.,O
The,O
hyperalgesic,O
effect,O
of,O
prostaglandin,B
D2,I
was,O
blocked,O
by,O
simultaneous,O
injection,O
of,O
a,O
substance,O
P,O
antagonist,O
(,O
greater,O
than,O
or,O
equal,O
to,O
100,O
ng,O
),O
but,O
not,O
by,O
AH6809,B
",",O
a,O
prostanoid,O
EP1,O
-,O
receptor,O
antagonist,O
.,O
Conversely,O
",",O
prostaglandin,B
E2,I
-,I
induced,O
hyperalgesia,O
was,O
blocked,O
by,O
AH6809,B
(,O
greater,O
than,O
or,O
equal,O
to,O
500,O
ng,O
),O
but,O
not,O
by,O
the,O
substance,O
P,O
antagonist,O
.,O
Prostaglandin,B
F2,I
alpha,I
had,O
little,O
effect,O
on,O
pain,O
responses,O
.,O
These,O
results,O
demonstrate,O
that,O
both,O
prostaglandin,B
D2,I
and,O
prostaglandin,B
E2,I
exert,O
hyperalgesia,O
in,O
the,O
spinal,O
cord,O
",",O
but,O
in,O
different,O
ways,O
.,O
D,B
-,I
penicillamine,I
in,O
the,O
treatment,O
of,O
localized,O
scleroderma,O
.,O
Localized,B
scleroderma,I
has,O
no,O
recognized,O
internal,O
organ,O
involvement,O
but,O
may,O
be,O
disfiguring,O
and,O
disabling,O
when,O
the,O
cutaneous,O
lesions,O
are,O
extensive,O
or,O
affect,O
children,O
.,O
There,O
is,O
no,O
accepted,O
or,O
proven,O
treatment,O
for,O
localized,B
scleroderma,I
.,O
Case,O
reports,O
of,O
11,O
patients,O
with,O
severe,O
",",O
extensive,B
localized,I
scleroderma,I
who,O
were,O
treated,O
with,O
D,B
-,I
penicillamine,I
are,O
summarized,O
in,O
this,O
article,O
.,O
This,O
drug,O
was,O
judged,O
to,O
have,O
a,O
favorable,O
effect,O
on,O
the,O
disease,O
course,O
in,O
7,O
(,O
64,O
%,O
),O
of,O
11,O
patients,O
.,O
Improvement,O
began,O
within,O
3,O
to,O
6,O
months,O
and,O
consisted,O
of,O
cessation,O
of,O
active,O
cutaneous,O
lesions,O
in,O
all,O
7,O
patients,O
",",O
skin,O
softening,O
in,O
5,O
",",O
and,O
more,O
normal,O
growth,O
of,O
the,O
affected,O
limb,O
in,O
2,O
of,O
3,O
children,O
.,O
Joint,O
stiffness,O
and,O
contractures,O
also,O
improved,O
.,O
The,O
dose,O
of,O
D,B
-,I
penicillamine,I
associated,O
with,O
a,O
favorable,O
response,O
was,O
as,O
low,O
as,O
2,O
to,O
5,O
mg,O
/,O
kg,O
per,O
day,O
given,O
over,O
a,O
period,O
ranging,O
from,O
15,O
to,O
53,O
months,O
.,O
D,B
-,I
Penicillamine,I
caused,O
nephrotic,O
syndrome,O
in,O
1,O
patient,O
and,O
milder,O
reversible,O
proteinuria,O
in,O
3,O
other,O
patients,O
;,O
none,O
developed,O
renal,O
insufficiency,O
.,O
These,O
data,O
suggest,O
that,O
D,B
-,I
penicillamine,I
may,O
be,O
effective,O
in,O
severe,O
cases,O
of,O
localized,O
scleroderma,O
.,O
Cerebral,B
sinus,I
thrombosis,I
as,O
a,O
potential,O
hazard,O
of,O
antifibrinolytic,O
treatment,O
in,O
menorrhagia,O
.,O
We,O
describe,O
a,O
42,O
-,O
year,O
-,O
old,O
woman,O
who,O
developed,O
superior,B
sagittal,I
and,O
left,B
transverse,I
sinus,I
thrombosis,I
associated,O
with,O
prolonged,O
epsilon,B
-,I
aminocaproic,I
acid,I
therapy,O
for,O
menorrhagia,O
.,O
This,O
antifibrinolytic,O
agent,O
has,O
been,O
used,O
in,O
women,O
with,O
menorrhagia,O
to,O
promote,O
clotting,O
and,O
reduce,O
blood,O
loss,O
.,O
Although,O
increased,O
risk,O
of,O
thromboembolic,O
disease,O
has,O
been,O
reported,O
during,O
treatment,O
with,O
epsilon,B
-,I
aminocaproic,I
acid,I
",",O
cerebral,B
sinus,I
thrombosis,I
has,O
not,O
been,O
previously,O
described,O
.,O
Careful,O
use,O
of,O
epsilon,B
-,I
aminocaproic,I
acid,I
therapy,O
is,O
recommended,O
.,O
Seizure,O
activity,O
with,O
imipenem,B
therapy,O
:,O
incidence,O
and,O
risk,O
factors,O
.,O
Two,O
elderly,O
patients,O
with,O
a,O
history,O
of,O
either,O
cerebral,O
vascular,O
accident,O
(,O
CVA,B
),O
or,O
head,O
trauma,O
and,O
no,O
evidence,O
of,O
renal,O
disease,O
developed,O
seizures,O
while,O
receiving,O
maximum,O
doses,O
of,O
imipenem,B
/,O
cilastatin,B
.,O
Neither,O
patient,O
had,O
reported,O
previous,O
seizures,O
or,O
seizure,O
-,O
like,O
activity,O
nor,O
was,O
receiving,O
anticonvulsant,O
agents,O
.,O
All,O
seizures,O
were,O
controlled,O
with,O
therapeutic,O
doses,O
of,O
phenytoin,B
.,O
Both,O
patients,O
had,O
received,O
maximum,O
doses,O
of,O
other,O
beta,O
-,O
lactam,O
antibiotics,O
without,O
evidence,O
of,O
seizure,O
activity,O
.,O
Midline,O
B3,O
serotonin,O
nerves,O
in,O
rat,O
medulla,O
are,O
involved,O
in,O
hypotensive,O
effect,O
of,O
methyldopa,B
.,O
Previous,O
experiments,O
in,O
this,O
laboratory,O
have,O
shown,O
that,O
microinjection,O
of,O
methyldopa,B
onto,O
the,O
ventrolateral,O
cells,O
of,O
the,O
B3,O
serotonin,B
neurons,O
in,O
the,O
medulla,O
elicits,O
a,O
hypotensive,O
response,O
mediated,O
by,O
a,O
projection,O
descending,O
into,O
the,O
spinal,B
cord,I
.,O
The,O
present,O
experiments,O
were,O
designed,O
to,O
investigate,O
the,O
role,O
of,O
the,O
midline,O
cells,O
of,O
the,O
B3,O
serotonin,B
neurons,O
in,O
the,O
medulla,O
",",O
coinciding,O
with,O
the,O
raphe,O
magnus,O
.,O
In,O
spontaneously,O
hypertensive,O
",",O
stroke,O
-,O
prone,O
rats,O
",",O
microinjection,O
of,O
methyldopa,B
into,O
the,O
area,O
of,O
the,O
midline,O
B3,O
serotonin,O
cell,O
group,O
in,O
the,O
ventral,O
medulla,O
caused,O
a,O
potent,O
hypotension,O
of,O
30,O
-,O
40,O
mm,O
Hg,O
",",O
which,O
was,O
maximal,O
2,O
-,O
3,O
h,O
after,O
administration,O
and,O
was,O
abolished,O
by,O
the,O
serotonin,O
neurotoxin,O
5,B
",",O
7,I
-,I
dihydroxytryptamine,I
(,I
5,I
",",I
7,I
-,I
DHT,I
),I
injected,O
intracerebroventricularly,O
.,O
However,O
",",O
intraspinal,O
injection,O
of,O
5,B
",",O
7,I
-,I
DHT,I
to,O
produce,O
a,O
more,O
selective,O
lesion,O
of,O
only,O
descending,O
serotonin,B
projections,O
in,O
the,O
spinal,O
cord,O
did,O
not,O
affect,O
this,O
hypotension,O
.,O
Further,O
",",O
5,B
",",O
7,I
-,I
DHT,I
lesion,O
of,O
serotonin,B
nerves,O
travelling,O
in,O
the,O
median,O
forebrain,O
bundle,O
",",O
one,O
of,O
the,O
main,O
ascending,O
pathways,O
from,O
the,O
B3,O
serotonin,B
cells,O
",",O
did,O
not,O
affect,O
the,O
fall,O
in,O
blood,O
pressure,O
associated,O
with,O
a,O
midline,O
B3,O
serotonin,B
methyldopa,O
injection,O
.,O
It,O
is,O
concluded,O
therefore,O
that,O
",",O
unlike,O
the,O
ventrolateral,O
B3,O
cells,O
which,O
mediate,O
a,O
methyldopa,B
-,O
induced,O
hypotension,O
via,O
descending,O
projections,O
",",O
the,O
midline,O
serotonin,B
B3,O
cells,O
in,O
the,O
medulla,O
contribute,O
to,O
the,O
hypotensive,O
action,O
of,O
methyldopa,B
",",O
either,O
by,O
way,O
of,O
an,O
ascending,O
projection,O
which,O
does,O
not,O
pass,O
through,O
the,O
median,O
forebrain,O
bundle,O
",",O
or,O
through,O
a,O
projection,O
restricted,O
to,O
the,O
caudal,O
brainstem,O
.,O
Antiarrhythmic,O
plasma,O
concentrations,O
of,O
cibenzoline,B
on,O
canine,O
ventricular,O
arrhythmias,O
.,O
Using,O
two,O
-,O
stage,O
coronary,O
ligation,O
-,O
",",O
digitalis,B
-,O
",",O
and,O
adrenaline,B
-,O
induced,O
canine,O
ventricular,O
arrhythmias,O
",",O
antiarrhythmic,O
effects,O
of,O
cibenzoline,B
were,O
examined,O
and,O
the,O
minimum,O
effective,O
plasma,O
concentration,O
for,O
each,O
arrhythmia,O
model,O
was,O
determined,O
.,O
Cibenzoline,B
suppressed,O
all,O
the,O
arrhythmias,O
",",O
and,O
the,O
minimum,O
effective,O
plasma,O
concentrations,O
for,O
arrhythmias,O
induced,O
by,O
24,O
-,O
h,O
coronary,O
ligation,O
",",O
48,O
-,O
h,O
coronary,O
ligation,O
",",O
digitalis,B
",",O
and,O
adrenaline,B
were,O
1,O
.,O
9,O
+,O
/,O
-,O
0,O
.,O
9,O
(,O
by,O
8,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
",",O
1,O
.,O
6,O
+,O
/,O
-,O
0,O
.,O
5,O
(,O
by,O
8,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
",",O
0,O
.,O
6,O
+,O
/,O
-,O
0,O
2,O
(,O
by,O
2,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
),O
",",O
and,O
3,O
.,O
5,O
+,O
/,O
-,O
1,O
.,O
3,O
(,O
by,O
5,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
),O
micrograms,O
/,O
ml,O
",",O
respectively,O
(,O
mean,O
+,O
/,O
-,O
SDM,O
",",O
n,O
=,O
6,O
-,O
7,O
),O
.,O
The,O
concentration,O
for,O
adrenaline,B
-,O
induced,O
arrhythmia,O
was,O
significantly,O
higher,O
than,O
those,O
for,O
the,O
other,O
types,O
of,O
arrhythmias,O
.,O
This,O
pharmacological,O
profile,O
is,O
similar,O
to,O
those,O
of,O
mexiletine,B
and,O
tocainide,B
",",O
and,O
all,O
three,O
drugs,O
have,O
central,O
nervous,O
system,O
(,O
CNS,B
),O
stimulant,O
action,O
.,O
Because,O
cibenzoline,B
had,O
only,O
weak,O
hypotensive,O
and,O
sinus,B
node,I
depressive,I
effects,O
and,O
was,O
found,O
to,O
be,O
orally,O
active,O
when,O
given,O
to,O
coronary,O
ligation,O
arrhythmia,O
dogs,O
",",O
its,O
clinical,O
usefulness,O
is,O
expected,O
.,O
Continuous,O
ambulatory,O
ECG,B
monitoring,O
during,O
fluorouracil,B
therapy,O
:,O
a,O
prospective,O
study,O
.,O
Although,O
there,O
have,O
been,O
anecdotal,O
reports,O
of,O
cardiac,O
toxicity,O
associated,O
with,O
fluorouracil,B
(,I
5,I
-,I
FU,I
),I
therapy,O
",",O
this,O
phenomenon,O
has,O
not,O
been,O
studied,O
in,O
a,O
systematic,O
fashion,O
.,O
We,O
prospectively,O
performed,O
continuous,O
ambulatory,O
ECG,O
monitoring,O
on,O
25,O
patients,O
undergoing,O
5,B
-,I
FU,I
infusion,I
for,O
treatment,O
of,O
solid,O
tumors,O
in,O
order,O
to,O
assess,O
the,O
incidence,O
of,O
ischemic,O
ST,O
changes,O
.,O
Patients,O
were,O
monitored,O
for,O
23,O
+,O
/,O
-,O
4,O
hours,O
before,O
5,B
-,I
FU,I
infusion,I
",",O
and,O
98,O
+,O
/,O
-,O
9,O
hours,O
during,O
5,B
-,I
FU,I
infusion,I
.,O
Anginal,B
episodes,O
were,O
rare,O
:,O
only,O
one,O
patient,O
had,O
angina,B
(,O
during,O
5,B
-,I
FU,I
infusion,I
),O
.,O
However,O
",",O
asymptomatic,O
ST,B
changes,O
(,O
greater,O
than,O
or,O
equal,O
to,O
1,O
mm,O
ST,B
deviation,O
),O
were,O
common,O
:,O
six,O
of,O
25,O
patients,O
(,O
24,O
%,O
),O
had,O
ST,B
changes,O
before,O
5,B
-,I
FU,I
infusion,I
v,O
17,O
(,O
68,O
%,O
),O
during,O
5,B
-,I
FU,I
infusion,I
(,O
P,O
less,O
than,O
.,O
2,O
),O
.,O
The,O
incidence,O
of,O
ischemic,B
episodes,O
per,O
patient,O
per,O
hour,O
was,O
0,O
.,O
5,O
+,O
/,O
-,O
0,O
.,O
2,O
prior,O
to,O
5,B
-,I
FU,I
infusion,O
v,O
0,O
.,O
13,O
+,O
/,O
-,O
0,O
.,O
3,O
during,O
5,B
-,I
FU,I
infusion,O
(,O
P,O
less,O
than,O
.,O
1,O
),O
;,O
the,O
duration,O
of,O
ECG,B
changes,O
was,O
0,O
.,O
6,O
+,O
/,O
-,O
0,O
.,O
3,O
minutes,O
per,O
patient,O
per,O
hour,O
before,O
5,B
-,I
FU,I
v,O
1,O
.,O
9,O
+,O
/,O
-,O
0,O
.,O
5,O
minutes,O
per,O
patient,O
per,O
hour,O
during,O
5,B
-,I
FU,I
(,O
P,O
less,O
than,O
.,O
1,O
),O
.,O
ECG,O
changes,O
were,O
more,O
common,O
among,O
patients,O
with,O
known,O
coronary,B
artery,I
disease,I
.,O
There,O
were,O
two,O
cases,O
of,O
sudden,O
death,O
",",O
both,O
of,O
which,O
occurred,O
at,O
the,O
end,O
of,O
the,O
chemotherapy,O
course,O
.,O
We,O
conclude,O
that,O
5,O
-,O
FU,B
infusion,O
is,O
associated,O
with,O
a,O
significant,O
increase,O
in,O
silent,O
ST,B
segment,I
deviation,I
suggestive,O
of,O
ischemia,O
",",O
particularly,O
among,O
patients,O
with,O
coronary,B
artery,I
disease,I
.,O
The,O
mechanism,O
and,O
clinical,O
significance,O
of,O
these,O
ECG,O
changes,O
remain,O
to,O
be,O
determined,O
.,O
Nature,O
",",O
time,O
course,O
and,O
dose,O
dependence,O
of,O
zidovudine,B
-,O
related,O
side,O
effects,O
:,O
results,O
from,O
the,O
Multicenter,O
Canadian,O
Azidothymidine,B
Trial,O
.,O
To,O
characterize,O
the,O
nature,O
",",O
time,O
course,O
and,O
dose,O
dependency,O
of,O
zidovudine,B
-,O
related,O
side,O
effects,O
",",O
we,O
undertook,O
a,O
multicenter,O
",",O
prospective,O
",",O
dose,O
-,O
range,O
finding,O
study,O
.,O
Our,O
study,O
group,O
consisted,O
of,O
74,O
HIV,B
-,O
positive,O
homosexual,O
men,O
belonging,O
to,O
groups,O
II,O
B,O
",",O
III,O
and,O
IV,O
C2,O
from,O
the,O
Centers,O
for,O
Disease,O
Control,O
(,O
CDC,B
),O
classification,O
of,O
HIV,B
disease,O
.,O
Following,O
a,O
3,O
-,O
week,O
observation,O
period,O
",",O
volunteers,O
were,O
treated,O
with,O
zidovudine,B
600,O
mg,O
/,O
day,O
for,O
18,O
weeks,O
",",O
900,O
mg,O
/,O
day,O
for,O
9,O
weeks,O
and,O
1200,O
mg,O
/,O
day,O
for,O
9,O
weeks,O
",",O
followed,O
by,O
a,O
washout,O
period,O
of,O
6,O
weeks,O
after,O
which,O
they,O
were,O
re,O
-,O
started,O
on,O
1200,O
mg,O
/,O
day,O
or,O
the,O
highest,O
tolerated,O
dose,O
at,O
8,O
-,O
hourly,O
intervals,O
.,O
Subjects,O
were,O
randomly,O
assigned,O
to,O
4,O
-,O
hourly,O
or,O
8,O
-,O
hourly,O
regimens,O
within,O
CDC,B
groups,O
while,O
taking,O
600,B
and,O
1200,B
mg,I
/,I
day,I
.,O
Clinical,O
and,O
laboratory,O
evaluations,O
were,O
performed,O
at,O
3,O
-,O
week,O
intervals,O
.,O
Symptomatic,O
adverse,O
effects,O
were,O
present,O
in,O
96,B
%,I
of,O
subjects,O
",",O
most,O
commonly,O
nausea,B
(,O
64,B
%,I
),I
",",O
fatigue,B
(,O
55,B
%,I
),I
and,O
headache,B
(,O
49,B
%,I
),I
.,O
These,O
were,O
generally,O
self,O
-,O
limited,O
",",O
reappearing,O
briefly,O
at,O
each,O
dose,O
increment,O
.,O
A,O
decrease,O
in,O
hemoglobin,B
occurred,O
shortly,O
after,O
initiation,O
of,O
therapy,O
.,O
This,O
was,O
not,O
dose,O
dependent,O
and,O
reversed,O
rapidly,O
upon,O
discontinuation,O
of,O
treatment,O
.,O
A,O
red,B
blood,I
cell,I
count,I
decrease,O
",",O
a,O
mean,O
cell,O
volume,O
increase,O
and,O
a,O
granulocyte,B
count,I
decrease,O
developed,O
early,O
in,O
a,O
dose,O
-,O
independent,O
fashion,O
",",O
reverting,O
at,O
least,O
partially,O
during,O
the,O
washout,O
phase,O
.,O
The,O
decrease,O
in,O
reticulocyte,B
count,O
was,O
dose,O
related,O
between,O
600,O
and,O
900,O
mg,O
/,O
day,O
with,O
no,O
further,O
change,O
when,O
the,O
dose,O
was,O
escalated,O
to,O
1200,O
mg,O
/,O
day,O
.,O
Bone,B
marrow,I
changes,O
occurred,O
rapidly,O
as,O
demonstrated,O
by,O
megaloblastosis,B
in,O
95,O
%,O
of,O
65,O
specimens,O
at,O
week,O
18,O
.,O
(,O
ABSTRACT,B
TRUNCATED,I
AT,I
250,I
WORDS,I
),O
National,B
project,I
on,I
the,I
prevention,I
of,I
mother,I
-,I
to,I
-,I
infant,I
infection,I
by,I
hepatitis,B
B,I
virus,I
in,I
Japan,I
.,O
In,O
Japan,O
",",O
a,O
nationwide,O
prevention,O
program,O
against,O
mother,O
-,O
to,O
-,O
infant,O
infection,O
by,O
hepatitis,B
B,I
virus,I
(,O
HBV,B
),O
started,O
in,O
1985,O
.,O
This,O
program,O
consists,O
of,O
double,O
screenings,O
of,O
pregnant,O
women,O
and,O
prophylactic,O
treatment,O
to,O
the,O
infants,O
born,O
to,O
both,O
hepatitis,B
B,I
surface,I
antigen,I
(,O
HBsAg,B
),O
and,O
hepatitis,B
B,I
e,I
antigen,I
(,O
HBeAg,B
),O
positive,O
mothers,O
.,O
These,O
infants,O
are,O
treated,O
with,O
two,O
injections,O
of,O
hepatitis,B
B,I
immune,I
globulin,I
(,O
HBIG,B
),O
and,O
at,O
least,O
three,O
injections,O
of,O
plasma,B
derived,I
hepatitis,B
B,I
vaccine,I
.,O
We,O
sent,O
questionnaires,O
about,O
the,O
numbers,O
of,O
each,O
procedure,O
or,O
examination,O
during,O
nine,O
months,O
of,O
investigation,O
period,O
to,O
each,O
local,O
government,O
in,O
1986,O
and,O
1987,O
.,O
93,O
.,O
4,O
%,O
pregnant,O
women,O
had,O
the,O
chance,O
to,O
be,O
examined,O
for,O
HBsAg,B
",",O
and,O
the,O
positive,O
rate,O
was,O
1,O
.,O
4,O
to,O
1,O
.,O
5,O
%,O
.,O
The,O
HBeAg,B
positive,O
rate,O
in,O
HBsAg,B
positive,O
was,O
23,O
to,O
26,O
%,O
.,O
The,O
HBsAg,B
positive,O
rate,O
in,O
neonates,O
and,O
in,O
infants,O
before,O
two,O
months,O
were,O
3,O
%,O
and,O
2,O
%,O
respectively,O
.,O
Some,O
problems,O
may,O
arise,O
",",O
because,O
27,O
to,O
30,O
%,O
of,O
infants,O
need,O
the,O
fourth,O
vaccination,O
in,O
some,O
restricted,O
areas,O
.,O
Involvement,O
of,O
the,O
mu,B
-,O
opiate,O
receptor,O
in,O
peripheral,O
analgesia,O
.,O
The,O
intradermal,O
injection,O
of,O
mu,B
(,O
morphine,B
",",O
Tyr,B
-,O
D,I
-,I
Ala,I
-,I
Gly,I
-,I
NMe,I
-,I
Phe,I
-,I
Gly,I
-,I
ol,I
and,O
morphiceptin,B
),O
",",O
kappa,B
(,O
trans,B
-,I
3,I
",",I
4,I
-,I
dichloro,I
-,I
N,I
-,I
methyl,I
-,I
N,I
[,I
2,I
-,I
(,I
1,I
-,I
pyrrolidinyl,I
),I
cyclohexyl,I
],I
benzeneactemide,I
),O
and,O
delta,B
(,O
[,O
D,I
-,I
Pen2,I
0.72,I
5,O
],O
-,O
enkephalin,B
and,O
[,O
D,B
-,I
Ser2,I
],I
-,I
[,I
Leu,I
],I
enkephalin,I
-,O
Thr,O
selective,O
opioid,O
-,O
agonists,O
",",O
by,O
themselves,O
",",O
did,O
not,O
significantly,O
affect,O
the,O
mechanical,O
nociceptive,O
threshold,O
in,O
the,O
hindpaw,O
of,O
the,O
rat,O
.,O
Intradermal,O
injection,O
of,O
mu,B
",",O
but,O
not,O
delta,B
or,O
kappa,B
opioid,I
-,I
agonists,I
",",O
however,O
",",O
produced,O
dose,O
-,O
dependent,O
inhibition,O
of,O
prostaglandin,B
E2,I
-,I
induced,I
hyperalgesia,I
.,O
The,O
analgesic,O
effect,O
of,O
the,O
mu,B
-,O
agonist,O
morphine,B
was,O
dose,O
-,O
dependently,O
antagonized,O
by,O
naloxone,B
and,O
prevented,O
by,O
co,O
-,O
injection,O
of,O
pertussis,B
toxin,I
.,O
Morphine,B
did,O
not,O
",",O
however,O
",",O
alter,O
the,O
hyperalgesia,O
induced,O
by,O
8,O
-,O
bromo,B
cyclic,I
adenosine,I
monophosphate,I
.,O
We,O
conclude,O
that,O
the,O
analgesic,O
action,O
of,O
opioids,B
on,O
the,O
peripheral,O
terminals,O
of,O
primary,O
afferents,O
is,O
via,O
a,O
binding,O
site,O
with,O
characteristics,O
of,O
the,O
mu,B
-,O
opioid,I
receptor,I
and,O
that,O
this,O
action,O
is,O
mediated,O
by,O
inhibition,O
of,O
the,O
cyclic,B
adenosine,I
monophosphate,I
second,I
messenger,I
system,I
.,O
Involvement,O
of,O
locus,B
coeruleus,I
and,O
noradrenergic,B
neurotransmission,I
in,O
fentanyl,B
-,O
induced,O
muscular,O
rigidity,O
in,O
the,O
rat,O
.,O
Whereas,O
muscular,O
rigidity,O
is,O
a,O
well,O
-,O
known,O
side,O
effect,O
that,O
is,O
associated,O
with,O
high,O
-,O
dose,O
fentanyl,B
anesthesia,O
",",O
a,O
paucity,O
of,O
information,O
exists,O
with,O
regard,O
to,O
its,O
underlying,O
mechanism,O
(,O
s,O
),O
.,O
We,O
investigated,O
in,O
this,O
study,O
the,O
possible,O
engagement,O
of,O
locus,B
coeruleus,I
of,I
the,I
pons,I
in,O
this,O
phenomenon,O
",",O
using,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
anesthetized,O
with,O
ketamine,B
.,O
Under,O
proper,O
control,O
of,O
respiration,O
",",O
body,O
temperature,O
and,O
end,O
-,O
tidal,O
CO2,B
",",O
intravenous,O
administration,O
of,O
fentanyl,B
(,O
50,O
or,O
100,O
micrograms,O
/,O
kg,O
),O
consistently,O
promoted,O
an,O
increase,O
in,O
electromyographic,O
activity,O
recorded,O
from,O
the,O
gastrocnemius,B
and,O
abdominal,B
rectus,I
muscles,O
.,O
Such,O
an,O
induced,O
muscular,O
rigidity,O
by,O
the,O
narcotic,B
agent,O
was,O
significantly,O
antagonized,O
or,O
even,O
reduced,O
by,O
prior,O
electrolytic,O
lesions,O
of,O
the,O
locus,O
coeruleus,O
or,O
pretreatment,O
with,O
the,O
alpha,B
-,I
adrenoceptor,I
blocker,O
",",O
prazosin,B
.,O
Microinjection,O
of,O
fentanyl,B
(,O
2,O
.,O
5,O
micrograms,O
/,O
50,O
nl,O
),O
directly,O
into,O
this,O
pontine,O
nucleus,O
",",O
on,O
the,O
other,O
hand,O
",",O
elicited,O
discernible,O
electromyographic,O
excitation,O
.,O
It,O
is,O
speculated,O
that,O
the,O
induction,O
of,O
muscular,O
rigidity,O
by,O
fentanyl,B
may,O
involve,O
the,O
coerulospinal,O
noradrenergic,O
fibers,O
to,O
the,O
spinal,O
motoneurons,O
.,O
Dexmedetomidine,B
",",O
acting,O
through,O
central,O
alpha,B
-,I
2,I
adrenoceptors,I
",",O
prevents,O
opiate,O
-,O
induced,O
muscle,O
rigidity,O
in,O
the,O
rat,O
.,O
The,O
highly,O
-,O
selective,O
alpha,B
-,I
2,I
adrenergic,I
agonist,O
dexmedetomidine,B
(,O
D,B
-,I
MED,I
),O
is,O
capable,O
of,O
inducing,O
muscle,O
flaccidity,O
and,O
anesthesia,O
in,O
rats,O
and,O
dogs,O
.,O
Intense,O
generalized,O
muscle,O
rigidity,O
is,O
an,O
undesirable,O
side,O
effect,O
of,O
potent,O
opiate,B
agonists,O
.,O
Although,O
the,O
neurochemistry,O
of,O
opiate,B
-,O
induced,O
rigidity,O
has,O
yet,O
to,O
be,O
fully,O
elucidated,O
",",O
recent,O
work,O
suggests,O
a,O
role,O
for,O
a,O
central,O
adrenergic,B
mechanism,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
authors,O
determined,O
if,O
treatment,O
with,O
D,B
-,I
MED,I
prevents,O
the,O
muscle,O
rigidity,O
caused,O
by,O
high,O
-,O
dose,O
alfentanil,B
anesthesia,O
in,O
the,O
rat,O
.,O
Animals,O
(,O
n,O
=,O
42,O
),O
were,O
treated,O
intraperitoneally,O
with,O
one,O
of,O
the,O
following,O
six,O
regimens,O
:,O
1,O
),O
L,B
-,I
MED,I
(,O
the,O
inactive,O
L,B
-,I
isomer,I
of,O
medetomidine,B
),O
",",O
30,O
micrograms,O
/,O
kg,O
;,O
2,O
),O
D,B
-,I
MED,I
",",O
10,O
micrograms,O
/,O
kg,O
;,O
3,O
),O
D,B
-,I
MED,I
",",O
30,O
micrograms,O
/,O
kg,O
;,O
4,O
),O
D,B
-,I
MED,I
[,O
30,O
micrograms,O
/,O
kg,O
],O
and,O
the,O
central,O
-,O
acting,O
alpha,B
-,I
2,I
antagonist,I
",",O
idazoxan,B
[,O
10,O
mg,O
/,O
kg,O
],O
;,O
5,O
),O
D,B
-,I
MED,I
[,O
30,O
micrograms,O
/,O
kg,O
],O
and,O
the,O
peripheral,O
-,O
acting,O
alpha,B
-,I
2,I
antagonist,I
DG,B
-,I
5128,I
[,O
10,O
mg,O
/,O
kg,O
],O
",",O
or,O
;,O
6,O
),O
saline,B
Baseline,O
electromyographic,O
activity,O
was,O
recorded,O
from,O
the,O
gastrocnemius,B
muscle,I
before,O
and,O
after,O
drug,O
treatment,O
.,O
Each,O
rat,O
was,O
then,O
injected,O
with,O
alfentanil,B
(,O
ALF,B
",",O
0,O
.,O
5,O
mg,O
/,O
kg,O
sc,O
),O
.,O
ALF,B
injection,O
resulted,O
in,O
a,O
marked,O
increase,O
in,O
hindlimb,O
EMG,B
activity,O
in,O
the,O
L,O
-,O
MED,O
treatment,O
group,O
which,O
was,O
indistinguishable,O
from,O
that,O
seen,O
in,O
animals,O
treated,O
with,O
saline,B
.,O
In,O
contrast,O
",",O
D,B
-,I
MED,I
prevented,O
alfentanil,B
-,O
induced,O
muscle,O
rigidity,O
in,O
a,O
dose,O
-,O
dependent,O
fashion,O
.,O
The,O
small,O
EMG,B
values,O
obtained,O
in,O
the,O
high,O
-,O
dose,O
D,B
-,I
MED,I
group,O
were,O
comparable,O
with,O
those,O
recorded,O
in,O
earlier,O
studies,O
from,O
control,O
animals,O
not,O
given,O
any,O
opiate,O
.,O
The,O
high,O
-,O
dose,O
D,B
-,I
MED,I
animals,O
were,O
flaccid,O
",",O
akinetic,O
",",O
and,O
lacked,O
a,O
startle,O
response,O
during,O
the,O
entire,O
experimental,O
period,O
.,O
Some,O
central,O
effects,O
of,O
repeated,O
treatment,O
with,O
fluvoxamine,B
.,O
We,O
investigated,O
the,O
effect,O
of,O
repeated,O
treatment,O
with,O
fluvoxamine,B
",",O
a,O
selective,O
serotonin,B
uptake,I
inhibitor,I
",",O
on,O
behavioral,O
effects,O
of,O
dopaminomimetics,B
and,O
methoxamine,B
and,O
on,O
the,O
animal,O
behavior,O
in,O
the,O
behavioral,O
despair,O
test,O
.,O
A,O
repeated,O
treatment,O
with,O
fluvoxamine,B
(,O
twice,O
daily,O
for,O
14,O
days,O
),O
potentiated,O
in,O
mice,O
and,O
in,O
rats,O
(,O
weaker,O
),O
the,O
amphetamine,B
-,O
induced,O
hyperactivity,O
.,O
The,O
hyperactivity,O
induced,O
by,O
nomifensine,B
in,O
mice,O
remained,O
unaffected,O
by,O
fluvoxamine,B
.,O
The,O
stimulation,O
of,O
locomotor,O
activity,O
by,O
intracerebroventricularly,O
administered,O
methoxamine,B
was,O
not,O
affected,O
by,O
repeated,O
treatment,O
with,O
fluvoxamine,B
.,O
Given,O
three,O
times,O
fluvoxamine,B
had,O
no,O
effect,O
on,O
the,O
immobilization,O
time,O
in,O
the,O
behavioral,O
despair,O
test,O
in,O
rats,O
.,O
The,O
results,O
indicate,O
that,O
fluvoxamine,B
given,O
repeatedly,O
acts,O
differently,O
than,O
citalopram,B
",",O
another,O
selective,O
serotonin,B
uptake,I
inhibitor,I
",",O
and,O
differs,O
also,O
from,O
other,O
antidepressant,B
drugs,O
.,O
Protective,O
effect,O
of,O
a,O
specific,O
platelet,B
-,I
activating,I
factor,I
antagonist,O
",",O
BN,B
52021,I
",",O
on,O
bupivacaine,B
-,I
induced,I
cardiovascular,I
impairments,I
in,O
rats,O
.,O
Administration,O
of,O
the,O
local,O
anaesthetic,O
bupivacaine,B
(,O
1,O
.,O
5,O
or,O
2,O
mg,O
/,O
kg,O
",",O
i,O
.,O
v,O
.,O
),O
to,O
rats,O
elicited,O
a,O
marked,O
decrease,O
of,O
mean,O
arterial,O
blood,O
pressure,O
(,O
MBP,B
),O
and,O
heart,O
rate,O
(,O
HR,B
),O
leading,O
to,O
death,O
(,O
in,O
67,O
%,O
or,O
90,O
%,O
of,O
animals,O
respectively,O
.,O
Intravenous,O
injection,O
of,O
the,O
specific,O
platelet,O
-,O
activating,O
factor,O
(,O
PAF,B
),O
antagonist,O
BN,B
52021,I
(,O
10,O
mg,O
/,O
kg,O
),O
",",O
30,O
min,O
before,O
bupivacaine,O
administration,O
(,O
2,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
),O
suppressed,O
both,O
the,O
decrease,O
of,O
MBP,B
and,O
HR,B
.,O
In,O
contrast,O
",",O
doses,O
of,O
1,O
mg,O
/,O
kg,O
BN,B
52021,I
given,O
30,O
min,O
before,O
or,O
10,O
mg,O
/,O
kg,O
administered,O
5,O
min,O
before,O
i,O
.,O
v.,O
injection,O
of,O
bupivacaine,B
were,O
ineffective,O
.,O
When,O
BN,B
52021,I
(,O
20,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
),O
was,O
injected,O
immediately,O
after,O
bupivacaine,B
(,O
2,O
mg,O
/,O
kg,O
),O
",",O
a,O
partial,O
reversion,O
of,O
the,O
decrease,O
of,O
MBP,B
and,O
HR,B
was,O
observed,O
",",O
whereas,O
the,O
dose,O
of,O
10,O
mg,O
/,O
kg,O
was,O
ineffective,O
.,O
A,O
partial,O
recovery,O
of,O
bupivacaine,B
-,O
induced,O
ECG,B
alterations,O
was,O
observed,O
after,O
pretreatment,O
of,O
the,O
rats,O
with,O
BN,B
52021,I
.,O
Since,O
the,O
administration,O
of,O
BN,B
52021,I
",",O
at,O
all,O
doses,O
studied,O
",",O
did,O
not,O
alter,O
MBP,B
and,O
HR,B
at,O
the,O
doses,O
used,O
",",O
the,O
bulk,O
of,O
these,O
results,O
clearly,O
demonstrate,O
a,O
protective,O
action,O
of,O
BN,B
52021,I
",",O
a,O
specific,O
antagonist,O
of,O
PAF,B
",",O
against,O
bupivacaine,O
-,O
induced,O
cardiovascular,O
toxicity,O
.,O
Thus,O
",",O
consistent,O
with,O
its,O
direct,O
effect,O
on,O
heart,O
",",O
PAF,B
appears,O
to,O
be,O
implicated,O
in,O
bupivacaine,O
-,O
induced,O
cardiovascular,O
alterations,O
.,O
The,O
epidemiology,O
of,O
the,O
acute,O
flank,O
pain,O
syndrome,O
from,O
suprofen,B
.,O
Suprofen,B
",",O
a,O
new,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
",",O
was,O
marketed,O
in,O
early,O
1986,O
as,O
an,O
analgesic,O
agent,O
.,O
Until,O
physicians,O
began,O
reporting,O
an,O
unusual,O
acute,O
flank,O
pain,O
syndrome,O
to,O
the,O
spontaneous,O
reporting,O
system,O
",",O
700,O
",",O
0,O
persons,O
used,O
the,O
drug,O
in,O
the,O
United,O
States,O
.,O
Through,O
August,O
1986,O
",",O
a,O
total,O
of,O
163,O
cases,O
of,O
this,O
syndrome,O
were,O
reported,O
.,O
To,O
elucidate,O
the,O
epidemiology,O
of,O
the,O
syndrome,O
",",O
a,O
case,O
-,O
control,O
study,O
was,O
performed,O
",",O
comparing,O
62,O
of,O
the,O
case,O
patients,O
who,O
had,O
been,O
reported,O
to,O
the,O
spontaneous,O
reporting,O
system,O
to,O
185,O
suprofen,B
-,I
exposed,O
control,O
subjects,O
who,O
did,O
not,O
have,O
the,O
syndrome,O
.,O
Case,O
patients,O
were,O
more,O
likely,O
to,O
be,O
men,O
(,O
odds,O
ratio,O
",",O
3,O
.,O
8,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
1,O
.,O
2,O
-,O
12,O
.,O
1,O
),O
",",O
suffer,O
from,O
hay,B
fever,I
and,O
asthma,B
(,O
odds,O
ratio,O
",",O
3,O
.,O
4,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
1,O
.,O
0,O
-,O
11,O
.,O
9,O
),O
;,O
to,O
participate,O
in,O
regular,O
exercise,O
(,O
odds,O
ratio,O
",",O
5,O
.,O
9,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
1,O
.,O
1,O
-,O
30,O
.,O
7,O
),O
",",O
especially,O
in,O
the,O
use,O
of,O
Nautilus,B
equipment,O
(,O
p,O
=,O
0,O
.,O
2,O
),O
;,O
and,O
to,O
use,O
alcohol,B
(,O
odds,O
ratio,O
",",O
4,B
.,O
4,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
1,O
.,O
-,O
17,O
.,O
5,O
),O
.,O
Possible,O
risk,O
factors,O
included,O
young,O
age,O
",",O
concurrent,O
use,O
of,O
other,O
analgesic,O
agents,O
(,O
especially,O
ibuprofen,B
),O
",",O
preexisting,O
renal,O
disease,O
",",O
a,O
history,O
of,O
kidney,O
stones,O
",",O
a,O
history,O
of,O
gout,B
",",O
a,O
recent,O
increase,O
in,O
activity,O
",",O
a,O
recent,O
increase,O
in,O
sun,O
exposure,O
",",O
and,O
residence,O
in,O
the,O
Sunbelt,B
.,O
These,O
were,O
findings,O
that,O
were,O
suggestive,O
but,O
did,O
not,O
reach,O
conventional,O
statistical,O
significance,O
.,O
These,O
findings,O
are,O
consistent,O
with,O
the,O
postulated,O
mechanism,O
for,O
this,O
unusual,O
syndrome,O
:,O
acute,O
diffuse,O
crystallization,O
of,O
uric,B
acid,I
in,O
renal,O
tubules,O
.,O
Phlorizin,B
-,I
induced,I
glycosuria,I
does,O
not,O
prevent,O
gentamicin,B
nephrotoxicity,I
in,O
rats,O
.,O
Because,O
rats,O
with,O
streptozotocin,B
-,I
induced,I
diabetes,I
mellitus,I
(,O
DM,B
),O
have,O
a,O
high,O
solute,O
diuresis,O
(,O
glycosuria,B
of,O
10,O
to,O
12,O
g,O
/,O
day,O
),O
",",O
we,O
have,O
suggested,O
that,O
this,O
may,O
in,O
part,O
be,O
responsible,O
for,O
their,O
resistance,O
to,O
gentamicin,B
-,I
induced,I
acute,I
renal,I
failure,I
(,O
ARF,B
),O
.,O
The,O
protection,O
from,O
gentamicin,B
nephrotoxicity,I
was,O
studied,O
in,O
non,O
-,O
diabetic,O
rats,O
with,O
chronic,O
solute,O
diuresis,O
induced,O
by,O
blockage,O
of,O
tubular,O
glucose,B
reabsorption,I
with,O
phlorizin,B
(,O
P,B
),O
.,O
DM,B
rats,O
with,O
mild,O
glycosuria,O
(,O
similar,O
in,O
degree,O
to,O
that,O
of,O
the,O
P,B
treated,O
animals,O
),O
were,O
also,O
studied,O
.,O
Unanesthetized,O
adult,O
female,O
",",O
Sprague,O
-,O
Dawley,O
rats,O
were,O
divided,O
in,O
four,O
groups,O
and,O
studied,O
for,O
15,O
days,O
.,O
Group,O
1,O
(,O
P,B
alone,O
),O
received,O
P,B
",",O
360,O
mg,O
/,O
day,O
",",O
for,O
15,O
days,O
;,O
Group,O
II,O
(,O
P,B
+,O
gentamicin,B
),O
;,O
Group,O
III,O
(,O
gentamicin,B
alone,O
),O
and,O
Group,O
IV,O
(,O
mild,O
DM,B
+,O
gentamicin,B
),O
.,O
Nephrotoxic,O
doses,O
(,O
40,O
mg,B
/,O
kg,O
body,O
wt,O
/,O
day,O
),O
of,O
gentamicin,B
were,O
injected,O
during,O
the,O
last,O
nine,O
days,O
of,O
study,O
to,O
the,O
animals,O
of,O
groups,O
II,O
to,O
IV,O
.,O
In,O
Group,O
I,O
",",O
P,O
induced,O
a,O
moderate,O
and,O
stable,O
glycosuria,O
(,O
3,O
.,O
9,O
+,O
/,O
-,O
0,O
.,O
1,O
g,O
/,O
day,O
",",O
SE,O
),O
",",O
and,O
no,O
functional,O
or,O
morphologic,O
evidence,O
of,O
renal,O
dysfunction,O
(,O
baseline,O
CCr,B
2,O
.,O
1,O
+,O
/,O
-,O
0,O
.,O
1,O
ml,O
/,O
min,O
",",O
undetectable,O
lysozymuria,O
),O
or,O
damage,O
(,O
tubular,O
necrosis,O
score,O
[,O
maximum,O
4,O
](23,O
",",O
zero,O
).26,O
In,O
Group,O
II,O
",",O
P,O
did,O
not,O
prevent,O
gentamicin,B
-,O
ARF,O
(,O
maximal,O
decrease,O
in,O
CCr,O
at,O
day,O
9,O
0.46,O
89,O
%,O
",",O
less,O
than,O
0,O
0.53,O
1,O
;,O
peak,O
lysozymuria,O
",",O
1863,O
+,O
/,O
-,O
321,O
micrograms,O
/,O
day,O
;,O
and,O
tubular,O
necrosis,O
score,O
",",O
3,O
0.74,O
9,O
+,O
/,O
-,O
0,O
.,O
1,O
.,O
),O
.,O
These,O
values,O
were,O
not,O
different,O
from,O
those,O
of,O
Group,O
III,O
:,O
maximal,O
decrease,O
in,O
CCr,B
73,O
%,O
(,O
P,O
less,O
than,O
0,O
.,O
1,O
),O
;,O
lysozymuria,B
",",O
2147,O
+,O
/,O
-,O
701,O
micrograms,O
/,O
day,O
;,O
tubular,O
necrosis,O
score,O
",",O
3,O
.,O
8,O
+,O
/,O
-,O
0,O
.,O
1,O
.,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Catalepsy,O
induced,O
by,O
combinations,O
of,O
ketamine,B
and,O
morphine,B
:,O
potentiation,O
",",O
antagonism,O
",",O
tolerance,O
and,O
cross,O
-,O
tolerance,O
in,O
the,O
rat,O
.,O
Previous,O
studies,O
demonstrated,O
that,O
both,O
ketamine,B
and,O
morphine,B
induced,O
analgesia,O
and,O
catalepsy,O
in,O
the,O
rat,O
.,O
Pre,O
-,O
treatment,O
with,O
ketamine,B
produced,O
cross,O
-,O
tolerance,O
to,O
morphine,B
",",O
whereas,O
pretreatment,O
with,O
morphine,B
did,O
not,O
induce,O
cross,O
-,O
tolerance,O
to,O
ketamine,B
but,O
rather,O
augmented,O
the,O
cataleptic,O
response,O
;,O
this,O
augmentation,O
was,O
attributed,O
to,O
residual,O
morphine,B
in,O
the,O
brain,O
.,O
The,O
present,O
studies,O
explored,O
the,O
duration,O
of,O
the,O
loss,O
of,O
righting,O
reflex,O
induced,O
by,O
sub,O
-,O
effective,O
doses,O
of,O
ketamine,B
and,O
morphine,B
",",O
administered,O
simultaneously,O
.,O
There,O
was,O
mutual,O
potentiation,O
between,O
sub,O
-,O
effective,O
doses,O
of,O
ketamine,B
and,O
morphine,B
",",O
but,O
sub,O
-,O
effective,O
doses,O
of,O
ketamine,B
partly,O
antagonized,O
fully,O
-,O
effective,O
doses,O
of,O
morphine,B
.,O
Latency,O
to,O
the,O
loss,O
of,O
righting,O
reflex,O
",",O
rigidity,O
and,O
behavior,O
on,O
recovery,O
",",O
reflected,O
the,O
relative,O
predominance,O
of,O
ketamine,B
or,O
morphine,B
in,O
each,O
combination,O
.,O
Naloxone,B
inhibited,O
the,O
induced,O
cataleptic,O
effects,O
.,O
The,O
degree,O
and,O
time,O
course,O
of,O
development,O
of,O
tolerance,O
to,O
daily,O
administration,O
of,O
sub,O
-,O
effective,O
dose,O
combinations,O
of,O
ketamine,B
and,O
morphine,B
were,O
similar,O
.,O
Rats,O
",",O
tolerant,O
to,O
ketamine,B
-,O
dominant,O
combinations,O
",",O
were,O
cross,O
-,O
tolerant,O
to,O
both,O
drugs,O
",",O
while,O
those,O
tolerant,O
to,O
morphine,B
-,O
dominant,O
combinations,O
were,O
cross,O
-,O
tolerant,O
to,O
morphine,B
but,O
showed,O
either,O
no,O
cross,O
-,O
tolerance,O
or,O
an,O
augmented,O
response,O
to,O
ketamine,B
.,O
While,O
the,O
mutual,O
potentiation,O
",",O
antagonism,O
and,O
tolerance,O
suggest,O
common,O
mechanisms,O
for,O
the,O
induced,O
catalepsy,O
",",O
differences,O
in,O
latency,O
",",O
rigidity,O
and,O
behavior,O
",",O
asymmetry,O
of,O
cross,O
-,O
tolerance,O
and,O
a,O
widely,O
-,O
different,O
ID50,O
for,O
naloxone,B
would,O
argue,O
against,O
an,O
action,O
at,O
a,O
single,O
opioid,O
site,O
.,O
Hydrocortisone,B
-,O
induced,O
hypertension,O
in,O
humans,O
:,O
pressor,O
responsiveness,O
and,O
sympathetic,O
function,O
.,O
Oral,O
hydrocortisone,B
increases,O
blood,O
pressure,O
and,O
enhances,O
pressor,O
responsiveness,O
in,O
normal,O
human,O
subjects,O
.,O
We,O
studied,O
the,O
effects,O
of,O
1,O
week,O
of,O
oral,O
hydrocortisone,B
(,O
200,O
mg,O
/,O
day,O
),O
on,O
blood,O
pressure,O
",",O
cardiac,O
output,O
",",O
total,O
peripheral,O
resistance,O
",",O
forearm,O
vascular,O
resistance,O
",",O
and,O
norepinephrine,B
spillover,O
to,O
plasma,O
in,O
eight,O
healthy,O
male,O
volunteers,O
.,O
Although,O
diastolic,O
blood,O
pressure,O
remained,O
unchanged,O
",",O
systolic,O
blood,O
pressure,O
increased,O
from,O
119,O
to,O
135,O
mm,O
Hg,O
(,O
SED,B
+,I
/,I
-,I
3,I
.,O
4,O
",",O
p,O
less,O
than,O
0,O
.,O
1,O
(,O
",",O
associated,O
with,O
an,O
increased,O
cardiac,O
output,O
(,O
5,O
.,O
85,O
-,O
7,O
.,O
73,O
l,O
/,O
min,O
",",O
SED,B
+,I
/,I
-,I
0,I
.,O
46,O
",",O
p,O
less,O
than,O
0,O
.,O
1,O
(,O
"),",O
.,O
Total,O
peripheral,O
vascular,O
resistance,O
fell,O
from,O
15,O
.,O
1,O
to,O
12,O
.,O
2,O
mm,B
Hg,I
/,I
l,I
/,I
min,O
(,O
SED,B
+,I
/,I
-,I
1,I
.,O
3,O
",",O
p,O
less,O
than,O
0,O
.,O
5,O
.,O
Resting,O
forearm,O
vascular,O
resistance,O
remained,O
unchanged,O
",",O
but,O
the,O
reflex,O
response,O
to,O
the,O
cold,O
pressor,O
test,O
was,O
accentuated,O
",",O
the,O
rise,O
in,O
resistance,O
increasing,O
from,O
10,O
.,O
5,O
mm,B
Hg,I
/,I
ml,I
/,I
100,I
ml,I
/,I
min,O
(,O
R,O
units,O
),O
before,O
treatment,O
to,O
32,O
.,O
6,O
R,O
units,O
after,O
treatment,O
(,O
SED,B
+,I
/,I
-,I
6,I
4,O
",",O
p,O
less,O
than,O
0,O
.,O
25,O
),O
.,O
The,O
rise,O
in,O
forearm,O
vascular,O
resistance,O
accompanying,O
intra,O
-,O
arterial,O
norepinephrine,B
(,O
25,O
",",O
50,O
",",O
and,O
100,O
ng,O
/,O
min,O
),O
was,O
also,O
significantly,O
greater,O
after,O
hydrocortisone,B
",",O
increasing,O
from,O
an,O
average,O
of,O
14,O
.,O
9,O
+,O
/,O
-,O
2,O
R,O
units,O
before,O
treatment,O
to,O
35,O
.,O
1,O
+,O
/,O
-,O
5,O
R,O
units,O
after,O
hydrocortisone,B
(,O
SED,O
+,O
/,O
-,O
6,O
.,O
0,O
",",O
p,O
less,O
than,O
0,O
.,O
5,O
),O
.,O
A,O
shift,O
to,O
the,O
left,O
in,O
the,O
dose,O
-,O
response,O
relation,O
and,O
fall,O
in,O
threshold,O
suggested,O
increased,O
sensitivity,O
to,O
norepinephrine,B
after,O
treatment,O
.,O
Measurement,O
of,O
resting,O
norepinephrine,B
spillover,O
rate,O
to,O
plasma,O
and,O
norepinephrine,B
uptake,O
indicated,O
that,O
overall,O
resting,O
sympathetic,O
nervous,O
system,O
activity,O
was,O
not,O
increased,O
.,O
The,O
rise,O
in,O
resting,O
blood,B
pressure,I
with,O
hydrocortisone,B
is,O
associated,O
with,O
an,O
increased,O
cardiac,O
output,O
(,O
presumably,O
due,O
to,O
increased,O
blood,B
volume,I
),O
.,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Neuromuscular,O
blockade,O
with,O
magnesium,B
sulfate,I
and,O
nifedipine,B
.,O
A,O
patient,O
who,O
received,O
tocolysis,O
with,O
nifedipine,B
developed,O
neuromuscular,O
blockade,O
after,O
500,O
mg,O
of,O
magnesium,B
sulfate,I
was,O
administered,O
.,O
This,O
reaction,O
demonstrates,O
that,O
nifedipine,B
can,O
seriously,O
potentiate,O
the,O
toxicity,O
of,O
magnesium,B
.,O
Caution,O
should,O
be,O
exercised,O
when,O
these,O
two,O
tocolytics,O
are,O
combined,O
.,O
Chronic,O
carbamazepine,B
inhibits,O
the,O
development,O
of,O
local,O
anesthetic,O
seizures,O
kindled,O
by,O
cocaine,B
and,O
lidocaine,B
.,O
The,O
effects,O
of,O
carbamazepine,B
(,O
CBZ,O
),O
treatment,O
on,O
local,O
anesthetic,O
-,O
kindled,O
seizures,O
and,O
lethality,O
were,O
evaluated,O
in,O
different,O
stages,O
of,O
the,O
kindling,O
process,O
and,O
under,O
different,O
methods,O
of,O
CBZ,O
administration,O
.,O
Chronic,O
oral,O
CBZ,B
inhibited,O
the,O
development,O
of,O
both,O
lidocaine,B
-,O
and,O
cocaine,B
-,O
induced,O
seizures,O
",",O
but,O
had,O
little,O
effect,O
on,O
the,O
fully,O
developed,O
local,O
anesthetic,O
seizures,O
.,O
Chronic,O
CBZ,B
also,O
decreased,O
the,O
incidence,O
of,O
seizure,O
-,O
related,O
mortality,O
in,O
the,O
cocaine,B
-,O
injected,O
rats,O
.,O
Acute,O
CBZ,B
over,O
a,O
range,O
of,O
doses,O
(,O
15,O
-,O
50,O
mg,O
/,O
kg,O
),O
had,O
no,O
effect,O
on,O
completed,O
lidocaine,B
-,O
kindled,O
or,O
acute,O
cocaine,B
-,O
induced,O
seizures,O
.,O
Repeated,O
i,O
.,O
p,O
.,O
injection,O
of,O
CBZ,B
(,O
15,O
mg,O
/,O
kg,O
),O
also,O
was,O
without,O
effect,O
on,O
the,O
development,O
of,O
lidocaine,B
-,O
or,O
cocaine,B
-,O
kindled,O
seizures,O
.,O
The,O
differential,O
effects,O
of,O
CBZ,B
depending,O
upon,O
stage,O
of,O
seizure,O
development,O
suggest,O
that,O
distinct,O
mechanisms,O
underlie,O
the,O
development,O
versus,O
maintenance,O
of,O
local,O
anesthetic,O
-,O
kindled,O
seizures,O
.,O
The,O
effectiveness,O
of,O
chronic,O
but,O
not,O
repeated,O
",",O
intermittent,O
injections,O
of,O
CBZ,B
suggests,O
that,O
different,O
biochemical,O
consequences,O
result,O
from,O
the,O
different,O
treatment,O
regimens,O
.,O
The,O
possible,O
utility,O
of,O
chronic,O
CBZ,B
in,O
preventing,O
the,O
development,O
of,O
toxic,O
side,O
effects,O
in,O
human,O
cocaine,B
users,O
is,O
suggested,O
by,O
these,O
data,O
",",O
but,O
remains,O
to,O
be,O
directly,O
evaluated,O
.,O
Magnetic,O
resonance,O
imaging,O
of,O
cerebral,O
venous,O
thrombosis,O
secondary,O
to,O
low,O
-,O
dose,O
birth,O
control,O
pills,O
.,O
The,O
clinical,O
and,O
radiographic,O
features,O
of,O
cerebral,O
deep,O
venous,O
thrombosis,O
in,O
a,O
21,O
-,O
year,O
-,O
old,O
white,O
woman,O
are,O
presented,O
.,O
This,O
nulliparous,O
patient,O
presented,O
with,O
relatively,O
mild,O
clinical,O
symptoms,O
and,O
progressing,O
mental,O
status,O
changes,O
.,O
The,O
only,O
known,O
risk,O
factor,O
was,O
low,O
-,O
dose,O
oral,O
contraceptive,O
pills,O
.,O
The,O
magnetic,O
resonance,O
image,O
(,O
MRI,B
),O
showed,O
increased,O
signal,O
intensity,O
from,O
the,O
internal,O
cerebral,O
veins,O
",",O
vein,O
of,O
Galen,B
",",O
and,O
straight,O
sinus,O
.,O
The,O
diagnosis,O
was,O
confirmed,O
by,O
arterial,O
angiography,O
.,O
Beta,B
-,I
2,I
-,I
adrenoceptor,I
-,I
mediated,I
hypokalemia,I
and,O
its,O
abolishment,O
by,O
oxprenolol,B
.,O
The,O
time,O
course,O
and,O
concentration,O
-,O
effect,O
relationship,O
of,O
terbutaline,B
-,O
induced,O
hypokalemia,O
was,O
studied,O
",",O
using,O
computer,O
-,O
aided,O
pharmacokinetic,O
-,O
dynamic,O
modeling,O
.,O
Subsequently,O
we,O
investigated,O
the,O
efficacy,O
of,O
oxprenolol,B
in,O
antagonizing,O
such,O
hypokalemia,O
",",O
together,O
with,O
the,O
pharmacokinetic,O
interaction,O
between,O
both,O
drugs,O
.,O
Six,O
healthy,O
subjects,O
were,O
given,O
a,O
0,O
.,O
5,O
mg,O
subcutaneous,O
dose,O
of,O
terbutaline,B
on,O
two,O
occasions,O
:,O
1,O
hour,O
after,O
oral,O
administration,O
of,O
a,O
placebo,B
and,O
1,O
hour,O
after,O
80,O
mg,O
oxprenolol,B
orally,O
.,O
In,O
the,O
7,O
-,O
hour,O
period,O
after,O
terbutaline,B
administration,O
",",O
plasma,O
samples,O
were,O
taken,O
for,O
determination,O
of,O
plasma,O
potassium,B
levels,O
and,O
drug,O
concentrations,O
.,O
The,O
sigmoid,O
Emax,O
model,O
offered,O
a,O
good,O
description,O
of,O
the,O
relation,O
between,O
terbutaline,B
concentrations,O
and,O
potassium,B
effects,O
.,O
Oxprenolol,B
caused,O
decreases,O
of,O
65,O
%,O
and,O
56,O
%,O
of,O
terbutaline,B
volume,O
of,O
distribution,O
and,O
clearance,O
",",O
respectively,O
",",O
and,O
an,O
increase,O
of,O
130,O
%,O
of,O
its,O
AUC,O
.,O
In,O
spite,O
of,O
higher,O
terbutaline,B
concentrations,O
after,O
oxprenolol,B
pretreatment,O
",",O
the,O
hypokalemia,O
was,O
almost,O
completely,O
antagonized,O
by,O
the,O
beta,O
2,O
-,O
blocking,O
action,O
.,O
A,O
dystonia,B
-,O
like,O
syndrome,O
after,O
neuropeptide,B
(,O
MSH,B
/,O
ACTH,B
),O
stimulation,O
of,O
the,O
rat,O
locus,O
ceruleus,O
.,O
The,O
movement,O
disorder,O
investigated,O
in,O
these,O
studies,O
has,O
some,O
features,O
in,O
common,O
with,O
human,O
idiopathic,O
dystonia,B
",",O
and,O
information,O
obtained,O
in,O
these,O
studies,O
may,O
be,O
of,O
potential,O
clinical,O
benefit,O
.,O
The,O
present,O
experimental,O
results,O
indicated,O
that,O
peptidergic,B
stimulation,O
of,O
the,O
LC,O
resulted,O
in,O
a,O
NE,B
-,O
mediated,O
inhibition,O
of,O
cerebellar,O
Purkinje,B
cells,O
located,O
at,O
terminals,O
of,O
the,O
ceruleo,O
-,O
cerebellar,O
pathway,O
.,O
However,O
",",O
it,O
is,O
not,O
certain,O
as,O
to,O
the,O
following,O
:,O
(,O
a,O
),O
what,O
receptors,O
were,O
stimulated,O
by,O
the,O
ACTH,B
N,I
-,I
terminal,I
fragments,I
at,O
the,O
LC,B
that,O
resulted,O
in,O
this,O
disorder,O
;,O
(,O
b,O
),O
whether,O
NE,B
",",O
released,O
onto,O
Purkinje,B
cell,I
synapses,I
located,O
at,O
terminals,O
of,O
the,O
ceruleo,B
-,I
cerebellar,I
pathway,I
",",O
did,O
indeed,O
cause,O
the,O
long,O
-,O
term,O
depression,O
at,O
Purkinje,B
cell,I
synapses,I
(,O
previously,O
described,O
by,O
others,O
),O
that,O
resulted,O
in,O
the,O
long,O
duration,O
of,O
the,O
movement,O
disorder,O
;,O
(,O
c,O
),O
whether,O
the,O
inhibition,O
of,O
inhibitory,O
Purkinje,B
cells,I
resulted,O
in,O
disinhibition,O
or,O
increased,O
excitability,O
of,O
the,O
unilateral,O
cerebellar,O
fastigial,O
or,O
interpositus,O
nuclei,O
",",O
the,O
output,O
targets,O
of,O
the,O
Purkinje,B
cell,I
axons,I
",",O
that,O
may,O
have,O
been,O
an,O
important,O
contributing,O
factor,O
to,O
this,O
disorder,O
.,O
These,O
questions,O
are,O
currently,O
being,O
investigated,O
.,O
Enhanced,O
stimulus,O
-,O
induced,O
neurotransmitter,O
overflow,O
in,O
epinephrine,B
-,O
induced,O
hypertensive,O
rats,O
is,O
not,O
mediated,O
by,O
prejunctional,O
beta,B
-,I
adrenoceptor,I
activation,O
.,O
The,O
present,O
study,O
examines,O
the,O
effect,O
of,O
6,O
-,O
day,O
epinephrine,B
treatment,O
(,O
100,O
micrograms,O
/,O
kg,O
per,O
h,O
",",O
s,O
.,O
c,O
.,O
),O
on,O
stimulus,O
-,O
induced,O
(,O
1,O
Hz,O
),O
endogenous,O
neurotransmitter,O
overflow,O
from,O
the,O
isolated,O
perfused,O
kidney,O
of,O
vehicle,O
-,O
and,O
epinephrine,B
-,O
treated,O
rats,O
.,O
Renal,O
catecholamine,O
stores,O
and,O
stimulus,O
-,O
induced,O
overflow,O
in,O
the,O
vehicle,O
-,O
treated,O
group,O
consisted,O
of,O
norepinephrine,B
only,O
.,O
However,O
",",O
epinephrine,B
treatment,O
resulted,O
in,O
the,O
incorporation,O
of,O
epinephrine,B
into,O
renal,O
catecholamine,O
stores,O
such,O
that,O
approximately,O
40,O
%,O
of,O
the,O
catecholamine,O
present,O
was,O
epinephrine,B
while,O
the,O
norepinephrine,B
content,O
was,O
reduced,O
by,O
a,O
similar,O
degree,O
.,O
Total,O
tissue,O
catecholamine,B
content,O
of,O
the,O
kidney,O
on,O
a,O
molar,O
basis,O
was,O
unchanged,O
.,O
Stimulus,O
-,O
induced,O
fractional,O
overflow,O
of,O
neurotransmitter,O
from,O
the,O
epinephrine,B
-,O
treated,O
kidneys,O
was,O
approximately,O
twice,O
normal,O
and,O
consisted,O
of,O
both,O
norepinephrine,B
and,O
epinephrine,B
in,O
proportions,O
similar,O
to,O
those,O
found,O
in,O
the,O
kidney,O
.,O
This,O
difference,O
in,O
fractional,O
overflow,O
between,O
groups,O
was,O
not,O
affected,O
by,O
neuronal,O
and,O
extraneuronal,O
uptake,O
blockade,O
.,O
Propranolol,O
had,O
no,O
effect,O
on,O
stimulus,O
-,O
induced,O
overflow,O
in,O
either,O
group,O
.,O
Phentolamine,O
increased,O
stimulus,O
-,O
induced,O
overflow,O
in,O
both,O
groups,O
although,O
the,O
increment,O
in,O
overflow,O
was,O
greater,O
in,O
the,O
epinephrine,B
-,I
treated,O
group,O
.,O
In,O
conclusion,O
",",O
chronic,O
epinephrine,B
treatment,O
results,O
in,O
enhanced,O
fractional,O
neurotransmitter,O
overflow,O
.,O
However,O
",",O
neither,O
alterations,O
in,O
prejunctional,O
beta,B
-,I
adrenoceptor,I
influences,O
nor,O
alterations,O
in,O
neuronal,O
and,O
extraneuronal,O
uptake,O
mechanisms,O
appear,O
to,O
be,O
responsible,O
for,O
this,O
alteration,O
.,O
Furthermore,O
",",O
data,O
obtained,O
with,O
phentolamine,B
alone,O
do,O
not,O
suggest,O
alpha,B
-,I
adrenoceptor,I
desensitization,O
as,O
the,O
cause,O
of,O
the,O
enhanced,O
neurotransmitter,O
overflow,O
after,O
epinephrine,B
treatment,O
.,O
GABA,B
involvement,O
in,O
naloxone,B
induced,O
reversal,O
of,O
respiratory,O
paralysis,O
produced,O
by,O
thiopental,B
.,O
No,O
agent,O
is,O
yet,O
available,O
to,O
reverse,O
respiratory,O
paralysis,O
produced,O
by,O
CNS,B
depressants,O
",",O
such,O
as,O
general,O
anesthetics,O
.,O
In,O
this,O
study,O
naloxone,B
reversed,O
respiratory,O
paralysis,O
induced,O
by,O
thiopental,B
in,O
rats,O
.,O
25,O
mg,O
/,O
kg,O
",",O
i,O
.,O
v,O
.,O
thiopental,B
produced,O
anesthesia,O
without,O
altering,O
respiratory,O
rate,O
",",O
increased,O
GABA,B
",",O
decreased,O
glutamate,B
",",O
and,O
had,O
no,O
effect,O
on,O
aspartate,B
or,O
glycine,B
levels,O
compared,O
to,O
controls,O
in,O
rat,O
cortex,O
and,O
brain,O
stem,O
.,O
Pretreatment,O
of,O
rats,O
with,O
thiosemicarbazide,B
for,O
30,O
minutes,O
abolished,O
the,O
anesthetic,O
action,O
as,O
well,O
as,O
the,O
respiratory,O
depressant,O
action,O
of,O
thiopental,B
.,O
50,O
mg,O
/,O
kg,O
",",O
i,O
.,O
v,O
.,O
thiopental,B
produced,O
respiratory,O
arrest,O
with,O
further,O
increase,O
in,O
GABA,B
and,O
decrease,O
in,O
glutamate,B
again,O
in,O
cortex,O
and,O
brain,O
stem,O
without,O
affecting,O
any,O
of,O
the,O
amino,O
acids,O
studied,O
in,O
four,O
regions,O
of,O
rat,O
brain,O
.,O
Naloxone,B
(,O
2,O
.,O
5,O
mg,O
/,O
kg,O
",",O
i,O
.,O
v,O
.,O
),O
reversed,O
respiratory,O
paralysis,O
",",O
glutamate,B
and,O
GABA,B
levels,O
to,O
control,O
values,O
in,O
brain,O
stem,O
and,O
cortex,O
with,O
no,O
changes,O
in,O
caudate,O
or,O
cerebellum,O
.,O
These,O
data,O
suggest,O
naloxone,B
reverses,O
respiratory,O
paralysis,O
produced,O
by,O
thiopental,B
and,O
involves,O
GABA,B
in,O
its,O
action,O
.,O
Diazepam,B
facilitates,O
reflex,O
bradycardia,O
in,O
conscious,O
rats,O
.,O
The,O
effects,O
of,O
diazepam,B
on,O
cardiovascular,O
function,O
were,O
assessed,O
in,O
conscious,O
rats,O
.,O
Intravenous,O
administration,O
of,O
diazepam,B
(,O
1,O
-,O
30,O
mg,O
kg,O
-,O
1,O
),O
produced,O
a,O
dose,O
-,O
dependent,O
decrease,O
in,O
both,O
the,O
mean,O
arterial,O
pressure,O
and,O
the,O
heart,O
rate,O
.,O
Also,O
",",O
reflex,O
bradycardia,O
was,O
produced,O
in,O
rats,O
by,O
intravenous,O
infusion,O
of,O
adrenaline,B
(,O
1,O
.,O
25,O
-,O
2,O
.,O
5,O
micrograms,O
kg,O
-,O
1,O
),O
.,O
Intravenous,O
pretreatment,O
of,O
the,O
rats,O
with,O
diazepam,B
",",O
although,O
causing,O
no,O
change,O
in,O
the,O
adrenaline,B
-,O
induced,O
pressor,O
effect,O
",",O
did,O
enhance,O
the,O
adrenaline,B
-,O
induced,O
reflex,O
bradycardia,O
.,O
However,O
",",O
the,O
diazepam,B
enhancement,O
of,O
adrenaline,B
-,O
induced,O
reflex,O
bradycardia,O
was,O
antagonized,O
by,O
pretreatment,O
of,O
rats,O
with,O
an,O
intravenous,O
dose,O
of,O
picrotoxin,B
(,O
an,O
agent,O
blocks,O
chloride,B
channels,O
by,O
binding,O
to,O
sites,O
associated,O
with,O
the,O
benzodiazepine,B
-,I
GABA,I
-,I
chloride,I
channel,I
macromolecular,I
complex,I
),O
.,O
The,O
data,O
indicate,O
that,O
diazepam,B
acts,O
through,O
the,O
benzodiazepine,B
-,I
GABA,B
-,I
chloride,I
channel,I
macromolecular,I
complex,I
within,O
the,O
central,O
nervous,O
system,O
to,O
facilitate,O
reflex,O
bradycardia,O
mediated,O
through,O
baroreceptor,O
reflexes,O
in,O
response,O
to,O
an,O
acute,O
increase,O
in,O
arterial,O
pressure,O
.,O
Initial,O
potassium,B
loss,O
and,O
hypokalaemia,O
during,O
chlorthalidone,B
administration,O
in,O
patients,O
with,O
essential,O
hypertension,O
:,O
the,O
influence,O
of,O
dietary,O
sodium,O
restriction,O
.,O
To,O
investigate,O
the,O
initial,O
potassium,B
loss,O
and,O
development,O
of,O
hypokalaemia,O
during,O
the,O
administration,O
of,O
an,O
oral,O
diuretic,O
",",O
metabolic,O
balance,O
studies,O
were,O
performed,O
in,O
ten,O
patients,O
with,O
essential,O
hypertension,O
who,O
had,O
shown,O
hypokalaemia,O
under,O
prior,O
oral,O
diuretic,O
treatment,O
.,O
Chlorthalidone,B
(,O
50,O
mg,O
daily,O
),O
was,O
given,O
for,O
14,O
days,O
.,O
Six,O
patients,O
received,O
a,O
normal,O
-,O
sodium,B
diet,O
and,O
four,O
a,O
low,O
-,O
sodium,B
(,O
17,O
mmol,O
/,O
day,O
),O
diet,O
.,O
All,O
patients,O
had,O
a,O
normal,O
initial,O
total,O
body,O
potassium,B
(,O
40K,O
),O
.,O
The,O
electrolyte,O
balances,O
",",O
weight,O
",",O
bromide,B
space,O
",",O
plasma,O
renin,O
activity,O
",",O
and,O
aldosterone,B
secretion,O
rate,O
were,O
measured,O
.,O
In,O
both,O
groups,O
a,O
potassium,B
deficit,O
developed,O
",",O
with,O
proportionally,O
larger,O
losses,O
from,O
the,O
extracellular,O
than,O
from,O
the,O
intracellular,O
compartment,O
.,O
In,O
the,O
normal,O
-,O
sodium,B
group,O
the,O
highest,O
mean,O
potassium,B
deficit,O
was,O
176,O
mmol,O
on,O
day,O
9,O
",",O
after,O
which,O
some,O
potassium,B
was,O
regained,O
;,O
in,O
the,O
low,O
-,O
sodium,B
group,O
the,O
highest,O
deficit,O
was,O
276,O
mmol,O
on,O
day,O
13,O
.,O
The,O
normal,O
-,O
sodium,B
group,O
showed,O
an,O
immediate,O
but,O
temporary,O
rise,O
of,O
the,O
renin,B
and,O
aldosterone,B
levels,O
;,O
in,O
the,O
low,O
-,O
sodium,B
group,O
renin,B
and,O
aldosterone,B
increased,O
more,O
slowly,O
but,O
remained,O
elevated,O
.,O
It,O
is,O
concluded,O
that,O
dietary,O
sodium,B
restriction,O
increases,O
diuretic,O
-,O
induced,O
potassium,B
loss,O
",",O
presumably,O
by,O
an,O
increased,O
activity,O
of,O
the,O
renin,B
-,I
angiotensin,I
-,I
aldosterone,I
system,O
",",O
while,O
sodium,B
delivery,O
to,O
the,O
distal,O
renal,O
tubules,O
remains,O
sufficiently,O
high,O
to,O
allow,O
increased,O
potassium,B
secretion,O
.,O
Reversal,O
of,O
neuroleptic,O
-,O
induced,O
catalepsy,O
by,O
novel,O
aryl,B
-,I
piperazine,I
anxiolytic,I
drugs,O
.,O
The,O
novel,O
anxiolytic,O
drug,O
",",O
buspirone,B
",",O
reverses,O
catalepsy,O
induced,O
by,O
haloperidol,O
.,O
A,O
series,O
of,O
aryl,O
-,O
piperazine,O
analogues,O
of,O
buspirone,O
and,O
other,O
5,B
-,I
hydroxytryptaminergic,I
agonists,O
were,O
tested,O
for,O
their,O
ability,O
to,O
reverse,O
haloperidol,O
induced,O
catalepsy,O
.,O
Those,O
drugs,O
with,O
strong,O
affinity,O
for,O
5,B
-,I
hydroxytryptamine1a,I
receptors,O
were,O
able,O
to,O
reverse,O
catalepsy,O
.,O
Drugs,O
with,O
affinity,O
for,O
other,O
5,B
-,I
HT,I
receptors,O
or,O
weak,O
affinity,O
were,O
ineffective,O
.,O
However,O
",",O
inhibition,O
of,O
postsynaptic,O
5,B
-,I
HT,I
receptors,O
neither,O
inhibited,O
nor,O
potentiated,O
reversal,O
of,O
catalepsy,O
and,O
leaves,O
open,O
the,O
question,O
as,O
to,O
the,O
site,O
or,O
mechanism,O
for,O
this,O
effect,O
.,O
Glycopyrronium,B
requirements,O
for,O
antagonism,O
of,O
the,O
muscarinic,O
side,O
effects,O
of,O
edrophonium,B
.,O
We,O
have,O
compared,O
",",O
in,O
60,O
adult,O
patients,O
",",O
the,O
cardiovascular,O
effects,O
of,O
glycopyrronium,B
5,O
micrograms,O
kg,O
-,O
1,O
and,O
10,O
micrograms,O
kg,O
-,O
1,O
given,O
either,O
simultaneously,O
or,O
1,O
min,O
before,O
edrophonium,B
1,O
mg,O
kg,O
-,O
1,O
.,O
Significant,O
differences,O
between,O
the,O
four,O
groups,O
were,O
detected,O
(,O
P,O
less,O
than,O
0,O
.,O
1,O
),O
.,O
Both,O
groups,O
receiving,O
10,O
micrograms,O
kg,O
-,O
1,O
showed,O
increases,O
in,O
heart,O
rate,O
of,O
up,O
to,O
30,O
beat,O
min,O
-,O
1,O
(,O
95,O
%,O
confidence,O
limits,O
28,O
-,O
32,O
beat,O
min,O
-,O
1,O
.,O
Use,O
of,O
glycopyrronium,B
5,O
micrograms,O
kg,O
-,O
1,O
provided,O
greater,O
cardiovascular,O
stability,O
and,O
",",O
given,O
1,O
min,O
before,O
the,O
edrophonium,O
",",O
was,O
sufficient,O
to,O
minimize,O
early,O
",",O
edrophonium,O
-,O
induced,O
bradycardias,O
.,O
This,O
low,O
dose,O
of,O
glycopyrronium,B
provided,O
good,O
control,O
of,O
oropharyngeal,O
secretions,O
.,O
Selective,O
injection,O
of,O
iopentol,B
",",O
iohexol,B
and,O
metrizoate,B
into,O
the,O
left,O
coronary,O
artery,O
of,O
the,O
dog,O
.,O
Induction,O
of,O
ventricular,O
fibrillation,O
and,O
decrease,O
of,O
aortic,O
pressure,O
.,O
In,O
twenty,O
beagle,O
dogs,O
selective,O
injections,O
were,O
made,O
into,O
the,O
left,O
coronary,O
artery,O
with,O
iopentol,B
",",O
iohexol,B
and,O
metrizoate,B
in,O
doses,O
of,O
4,O
ml,O
",",O
8,O
ml,O
and,O
16,O
ml,O
.,O
Thirty,O
-,O
six,O
iopentol,B
injections,O
",",O
35,O
iohexol,B
injections,O
and,O
37,O
metrizoate,B
injections,O
were,O
made,O
.,O
Frequencies,O
of,O
ventricular,O
fibrillation,O
were,O
significantly,O
lower,O
(,O
p,O
less,O
than,O
0,O
.,O
5,O
),O
after,O
iopentol,B
(,O
0,O
%,O
),O
and,O
iohexol,B
(,O
3,O
%,O
),O
than,O
after,O
metrizoate,B
(,O
22,O
%,O
),O
.,O
Iopentol,B
and,O
iohexol,B
also,O
produced,O
significantly,O
less,O
decrease,O
in,O
aortic,O
blood,O
pressure,O
than,O
metrizoate,B
at,O
the,O
different,O
doses,O
.,O
Thyroid,B
function,O
and,O
urine,O
-,O
concentrating,O
ability,O
during,O
lithium,B
treatment,O
.,O
It,O
has,O
been,O
suggested,O
that,O
adenylate,B
cyclase,I
inhibition,O
may,O
be,O
important,O
in,O
the,O
development,O
of,O
both,O
nephrogenic,B
diabetes,I
insipidus,I
and,O
hypothyroidism,B
during,O
lithium,O
treatment,O
.,O
We,O
measured,O
serum,O
thyroxine,B
and,O
urine,O
-,O
concentrating,O
ability,O
(,O
Umax,B
),O
in,O
response,O
to,O
desmopressin,B
(,O
DDAVP,B
),O
in,O
85,O
patients,O
receiving,O
lithium,O
.,O
Hypothyroidism,B
developed,O
in,O
eight,O
patients,O
while,O
they,O
were,O
taking,O
lithium,B
.,O
Impaired,O
Umax,O
was,O
found,O
in,O
both,O
euthyroid,O
and,O
hypothyroid,B
patients,O
while,O
some,O
hypothyroid,B
patients,O
concentrated,O
their,O
urine,O
well,O
.,O
It,O
is,O
concluded,O
that,O
the,O
dominant,O
mechanisms,O
by,O
which,O
lithium,B
exerts,O
these,O
two,O
effects,O
are,O
different,O
.,O
Remodelling,O
of,O
nerve,O
structure,O
in,O
experimental,O
isoniazid,B
neuropathy,O
in,O
the,O
rat,O
.,O
The,O
neuropathy,O
caused,O
by,O
a,O
single,O
dose,O
of,O
isoniazid,B
in,O
rats,O
was,O
studied,O
with,O
a,O
computer,O
-,O
assisted,O
morphometric,O
method,O
.,O
Scatter,O
diagrams,O
of,O
the,O
g,O
ratio,O
(,O
quotient,O
fibre,O
diameter,O
/,O
axon,O
diameter,O
),O
define,O
regenerating,O
fibres,O
as,O
a,O
distinct,O
population,O
",",O
distinguishable,O
from,O
the,O
surviving,O
fibres,O
by,O
reduced,O
sheath,O
thickness,O
and,O
reduced,O
axon,O
calibre,O
.,O
There,O
was,O
also,O
evidence,O
of,O
a,O
subtle,O
direct,O
toxic,O
effect,O
on,O
the,O
entire,O
fibre,O
population,O
",",O
causing,O
axon,O
shrinkage,O
masked,O
by,O
readjustment,O
of,O
the,O
myelin,B
sheath,I
.,O
Multicenter,O
",",O
double,O
-,O
blind,O
",",O
multiple,O
-,O
dose,O
",",O
parallel,O
-,O
groups,O
efficacy,O
and,O
safety,O
trial,O
of,O
azelastine,B
",",O
chlorpheniramine,B
",",O
and,O
placebo,B
in,O
the,O
treatment,O
of,O
spring,O
allergic,O
rhinitis,O
.,O
Azelastine,B
",",O
a,O
novel,O
antiallergic,O
medication,O
",",O
was,O
compared,O
with,O
chlorpheniramine,B
maleate,I
and,O
placebo,O
for,O
efficacy,O
and,O
safety,O
in,O
the,O
treatment,O
of,O
spring,O
allergic,O
rhinitis,O
in,O
a,O
multicenter,O
",",O
double,O
-,O
blind,O
",",O
multiple,O
-,O
dose,O
",",O
parallel,O
-,O
groups,O
study,O
.,O
One,O
hundred,O
fifty,O
-,O
five,O
subjects,O
participated,O
.,O
Subjects,O
ranged,O
in,O
age,O
from,O
18,O
to,O
60,O
years,O
of,O
age,O
and,O
had,O
at,O
least,O
a,O
2,O
-,O
year,O
history,O
of,O
spring,O
allergic,O
rhinitis,O
",",O
confirmed,O
by,O
positive,O
skin,O
test,O
to,O
spring,O
aeroallergens,O
.,O
Medications,O
were,O
given,O
four,O
times,O
daily,O
;,O
the,O
azelastine,B
groups,O
received,O
0,O
.,O
5,O
",",O
1,O
.,O
0,O
",",O
or,O
2,O
.,O
0,O
mg,O
in,O
the,O
morning,O
and,O
evening,O
with,O
placebo,O
early,O
late,O
afternoon,O
;,O
the,O
chlorpheniramine,B
group,O
received,O
4,O
.,O
0,O
mg,O
four,O
times,O
daily,O
.,O
Daily,O
subject,O
symptom,O
cards,O
were,O
completed,O
during,O
a,O
screening,O
period,O
to,O
assess,O
pretreatment,O
symptoms,O
and,O
during,O
a,O
4,O
-,O
week,O
treatment,O
period,O
while,O
subjects,O
received,O
study,O
medications,O
.,O
Individual,O
symptoms,O
",",O
total,O
symptoms,O
",",O
and,O
major,O
symptoms,O
were,O
compared,O
to,O
determine,O
efficacy,O
of,O
medication,O
.,O
Elicited,O
",",O
volunteered,O
",",O
and,O
observed,O
adverse,O
experiences,O
were,O
recorded,O
for,O
each,O
subject,O
and,O
compared,O
among,O
groups,O
.,O
Vital,O
signs,O
",",O
body,O
weights,O
",",O
serum,B
chemistry,I
values,I
",",O
complete,O
blood,O
cell,O
counts,O
",",O
urine,O
studies,O
",",O
and,O
electrocardiograms,O
were,O
obtained,O
for,O
each,O
subject,O
and,O
compared,O
among,O
groups,O
.,O
Symptoms,O
relief,O
in,O
the,O
group,O
receiving,O
the,O
highest,O
concentration,O
of,O
azelastine,B
(,O
2,O
.,O
0,O
mg,O
twice,O
daily,O
),O
was,O
statistically,O
greater,O
than,O
in,O
the,O
placebo,O
group,O
during,O
all,O
weeks,O
of,O
the,O
study,O
.,O
Lower,O
doses,O
of,O
azelastine,B
were,O
statistically,O
more,O
effective,O
than,O
placebo,O
only,O
during,O
portions,O
of,O
the,O
first,O
3,O
weeks,O
of,O
the,O
study,O
.,O
In,O
contrast,O
",",O
although,O
the,O
chlorpheniramine,B
group,O
did,O
have,O
fewer,O
symptoms,O
than,O
the,O
placebo,B
group,O
during,O
the,O
study,O
",",O
the,O
difference,O
never,O
reached,O
statistical,O
significance,O
during,O
any,O
week,O
of,O
the,O
study,O
.,O
There,O
were,O
no,O
serious,O
side,O
effects,O
in,O
any,O
of,O
the,O
treatment,O
groups,O
.,O
Drowsiness,O
and,O
altered,O
taste,O
perception,O
were,O
increased,O
significantly,O
over,O
placebo,B
only,O
in,O
the,O
high,O
-,O
dose,O
azelastine,B
group,O
.,O
Azelastine,B
appears,O
to,O
be,O
a,O
safe,O
",",O
efficacious,O
medication,O
for,O
seasonal,O
allergic,O
rhinitis,O
.,O
Toxicity,B
due,O
to,O
remission,O
inducing,O
drugs,O
in,O
rheumatoid,O
arthritis,O
.,O
Association,O
with,O
HLA,B
-,I
B35,I
and,O
Cw4,B
antigens,O
.,O
Twenty,O
-,O
five,O
patients,O
with,O
rheumatoid,O
arthritis,O
(,O
RA,O
),O
who,O
developed,O
toxicity,B
while,O
taking,O
remission,O
inducing,O
drugs,O
and,O
30,O
without,O
toxicity,B
were,O
studied,O
for,O
possible,O
associations,O
with,O
class,O
I,O
and,O
II,O
HLA,B
antigens,O
.,O
A,O
strong,O
association,O
has,O
been,O
found,O
between,O
nephritis,B
and,O
dermatitis,B
due,O
to,O
Tiopronin,B
(,O
a,O
D,B
-,I
Penicillamine,I
like,I
compound,I
),O
and,O
class,O
I,O
antigens,O
B35,B
-,I
Cw4,I
",",O
and,O
between,O
dermatitis,B
due,O
to,O
gold,B
thiosulphate,I
and,O
B35,B
.,O
Compared,O
to,O
healthy,O
controls,O
a,O
lower,O
DR5,B
frequency,O
was,O
observed,O
in,O
patients,O
with,O
RA,O
except,O
for,O
the,O
Tiopronin,B
related,I
nephritis,I
group,I
.,O
Transient,O
contralateral,O
rotation,O
following,O
unilateral,O
substantia,B
nigra,I
lesion,O
reflects,O
susceptibility,O
of,O
the,O
nigrostriatal,B
system,O
to,O
exhaustion,O
by,O
amphetamine,B
.,O
Following,O
unilateral,O
6,O
-,O
OHDA,B
induced,O
SN,B
lesion,O
",",O
a,O
transient,O
period,O
of,O
contralateral,O
rotation,O
has,O
been,O
reported,O
to,O
precede,O
the,O
predominant,O
ipsilateral,O
circling,O
.,O
In,O
order,O
to,O
clarify,O
the,O
nature,O
of,O
this,O
initial,O
contralateral,O
rotation,O
we,O
examined,O
the,O
effect,O
of,O
the,O
duration,O
of,O
recovery,O
period,O
after,O
the,O
lesion,O
",",O
on,O
amphetamine,B
-,I
induced,I
rotational,I
behavior,I
.,O
Three,O
days,O
post,O
lesion,O
",",O
most,O
rats,O
circled,O
predominantly,O
contralaterally,O
to,O
the,O
lesion,O
.,O
Such,O
contralateral,O
rotation,O
may,O
result,O
from,O
either,O
degeneration,O
-,O
induced,O
breakdown,O
of,O
the,O
DA,B
pool,I
",",O
or,O
lesion,O
-,O
induced,O
increase,O
of,O
DA,B
turnover,I
in,O
the,O
spared,O
neurons,O
.,O
A,O
substantial,O
degree,O
of,O
contralateral,O
preference,O
was,O
still,O
evident,O
when,O
amphetamine,B
was,O
administered,O
for,O
the,O
first,O
time,O
24,O
days,O
after,O
lesioning,O
",",O
indicating,O
involvement,O
of,O
spared,O
cells,O
in,O
the,O
contralateral,O
rotation,O
.,O
However,O
",",O
regardless,O
of,O
the,O
duration,O
of,O
recovery,O
(,O
and,O
irrespective,O
of,O
either,O
lesion,O
volume,O
",",O
amphetamine,B
dose,O
",",O
or,O
post,O
-,O
lesion,O
motor,O
exercise,O
),O
",",O
amphetamine,B
-,O
induced,O
rotation,O
tended,O
to,O
become,O
gradually,O
more,O
ipsilateral,O
as,O
the,O
observation,O
session,O
progressed,O
",",O
and,O
all,O
rats,O
circled,O
ipsilaterally,O
to,O
the,O
lesion,O
in,O
response,O
to,O
further,O
amphetamine,B
injections,O
.,O
These,O
findings,O
suggest,O
that,O
amphetamine,B
has,O
an,O
irreversible,O
effect,O
on,O
the,O
post,O
-,O
lesion,O
DA,B
pool,O
contributing,O
to,O
contralateral,O
rotation,O
.,O
Mitomycin,B
C,I
associated,O
hemolytic,O
uremic,O
syndrome,O
.,O
Mitomycin,B
C,I
associated,O
Hemolytic,B
Uremic,I
Syndrome,I
(,O
HUS,I
),O
is,O
a,O
potentially,O
fatal,O
but,O
uncommon,O
condition,O
that,O
is,O
not,O
yet,O
widely,O
recognised,O
.,O
It,O
consists,O
of,O
microangiopathic,B
hemolytic,I
anemia,I
",",O
thrombocytopenia,B
and,O
progressive,O
renal,B
failure,I
associated,O
with,O
mitomycin,B
C,I
treatment,O
and,O
affects,O
about,O
10,O
%,O
of,O
patients,O
treated,O
with,O
this,O
agent,O
.,O
The,O
renal,B
failure,I
usually,O
develops,O
about,O
8,O
-,O
10,O
mth,O
after,O
start,O
of,O
mitomycin,B
C,I
treatment,O
and,O
the,O
mortality,O
is,O
approximately,O
60,O
%,O
from,O
renal,B
failure,I
or,O
pulmonary,B
edema,I
.,O
Renal,O
lesions,O
are,O
similar,O
to,O
those,O
seen,O
in,O
idiopathic,O
HUS,O
and,O
include,O
arteriolar,O
fibrin,B
thrombi,O
",",O
expanded,O
subendothelial,O
zones,O
in,O
glomerular,O
capillary,O
walls,O
",",O
ischemic,O
wrinkling,O
of,O
glomerular,O
basement,O
membranes,O
and,O
mesangiolysis,O
.,O
The,O
mechanism,O
of,O
action,O
is,O
postulated,O
as,O
mitomycin,B
C,I
-,I
induced,O
endothelial,O
cell,O
damage,O
.,O
We,O
describe,O
the,O
clinical,O
course,O
and,O
pathological,O
findings,O
in,O
a,O
65,O
yr,O
-,O
old,O
man,O
with,O
gastric,B
adenocarcinoma,I
who,O
developed,O
renal,B
failure,I
and,O
thrombocytopenia,B
while,O
on,O
treatment,O
with,O
mitomycin,B
C,I
and,O
died,O
in,O
pulmonary,B
edema,I
.,O
Ketanserin,B
pretreatment,O
reverses,O
alfentanil,B
-,O
induced,O
muscle,O
rigidity,O
.,O
Systemic,O
pretreatment,O
with,O
ketanserin,B
",",O
a,O
relatively,O
specific,O
type,O
-,O
2,O
serotonin,O
receptor,O
antagonist,O
",",O
significantly,O
attenuated,O
the,O
muscle,O
rigidity,O
produced,O
in,O
rats,O
by,O
the,O
potent,O
short,O
-,O
acting,O
opiate,O
agonist,O
alfentanil,B
.,O
Following,O
placement,O
of,O
subcutaneous,O
electrodes,O
in,O
each,O
animal,O
',O
s,O
left,O
gastrocnemius,O
muscle,O
",",O
rigidity,O
was,O
assessed,O
by,O
analyzing,O
root,O
-,O
mean,O
-,O
square,O
electromyographic,O
activity,O
.,O
Intraperitoneal,O
ketanserin,B
administration,O
at,O
doses,O
of,O
0,O
.,O
63,O
and,O
2,O
.,O
5,O
mg,O
/,O
kg,O
prevented,O
the,O
alfentanil,B
-,O
induced,O
increase,O
in,O
electromyographic,O
activity,O
compared,O
with,O
animals,O
pretreated,O
saline,B
.,O
Chlordiazepoxide,B
at,O
doses,O
up,O
to,O
10,O
mg,O
/,O
kg,O
failed,O
to,O
significantly,O
influence,O
the,O
rigidity,O
produced,O
by,O
alfentanil,O
.,O
Despite,O
the,O
absence,O
of,O
rigidity,O
",",O
animals,O
that,O
received,O
ketanserin,B
(,O
greater,O
than,O
0,O
.,O
31,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
followed,O
by,O
alfentanil,O
were,O
motionless,O
",",O
flaccid,O
",",O
and,O
less,O
responsive,O
to,O
external,O
stimuli,O
than,O
were,O
animals,O
receiving,O
alfentanil,O
alone,O
.,O
Rats,O
that,O
received,O
ketanserin,B
and,O
alfentanil,B
exhibited,O
less,O
rearing,O
and,O
exploratory,O
behavior,O
at,O
the,O
end,O
of,O
the,O
60,O
-,O
min,O
recording,O
period,O
than,O
did,O
animals,O
that,O
received,O
ketanserin,B
alone,O
.,O
These,O
results,O
",",O
in,O
combination,O
with,O
previous,O
work,O
",",O
suggest,O
that,O
muscle,O
rigidity,O
",",O
a,O
clinically,O
relevant,O
side,O
-,O
effect,O
of,O
parenteral,O
narcotic,O
administration,O
",",O
may,O
be,O
partly,O
mediated,O
via,O
serotonergic,O
pathways,O
.,O
Pretreatment,O
with,O
type,B
-,I
2,I
serotonin,I
antagonists,I
may,O
be,O
clinically,O
useful,O
in,O
attenuating,O
opiate,B
-,I
induced,I
rigidity,I
",",O
although,O
further,O
studies,O
will,O
be,O
necessary,O
to,O
assess,O
the,O
interaction,O
of,O
possibly,O
enhanced,O
CNS,B
",",O
cardiovascular,B
",",O
and,O
respiratory,B
depression,I
.,O
Antagonism,O
of,O
diazepam,B
-,I
induced,I
sedative,I
effects,I
by,O
Ro15,B
-,I
1788,I
in,O
patients,O
after,O
surgery,O
under,O
lumbar,O
epidural,O
block,O
.,O
A,O
double,O
-,O
blind,O
placebo,B
-,O
controlled,O
investigation,O
of,O
efficacy,O
and,O
safety,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
assess,O
the,O
efficacy,O
of,O
Ro15,B
-,I
1788,I
and,O
a,O
placebo,B
in,O
reversing,O
diazepam,B
-,O
induced,O
effects,O
after,O
surgery,O
under,O
epidural,O
block,O
",",O
and,O
to,O
evaluate,O
the,O
local,O
tolerance,O
and,O
general,O
safety,O
of,O
Ro15,B
-,I
1788,I
.,O
Fifty,O
-,O
seven,O
patients,O
were,O
sedated,O
with,O
diazepam,B
for,O
surgery,O
under,O
epidural,O
anaesthesia,O
.,O
Antagonism,O
of,O
diazepam,B
-,O
induced,O
effects,O
by,O
Ro15,B
-,O
1788,I
was,O
investigated,O
postoperatively,O
in,O
a,O
double,O
-,O
blind,O
placebo,O
-,O
controlled,O
trial,O
.,O
The,O
patient,O
',O
s,O
subjective,O
assessment,O
of,O
mood,O
rating,O
",",O
an,O
objective,O
test,O
of,O
performance,O
",",O
a,O
test,O
for,O
amnesia,O
",",O
and,O
vital,O
signs,O
were,O
recorded,O
for,O
up,O
to,O
300,O
min,O
after,O
administration,O
of,O
the,O
trial,O
drug,O
.,O
No,O
significant,O
differences,O
between,O
the,O
two,O
groups,O
were,O
observed,O
for,O
mood,O
rating,O
",",O
amnesia,O
",",O
or,O
vital,O
signs,O
.,O
The,O
Ro15,B
-,I
1788,I
group,O
showed,O
a,O
significant,O
improvement,O
in,O
the,O
performance,O
test,O
up,O
to,O
120,O
min,O
after,O
administration,O
of,O
the,O
drug,O
.,O
There,O
was,O
no,O
evidence,O
of,O
reaction,O
at,O
the,O
injection,O
site,O
.,O
Chorea,B
associated,O
with,O
oral,O
contraception,O
.,O
Three,O
patients,O
developed,O
chorea,O
while,O
receiving,O
oral,B
contraceptives,I
.,O
Two,O
were,O
young,O
patients,O
whose,O
chorea,O
developed,O
long,O
after,O
treatment,O
had,O
been,O
started,O
and,O
disappeared,O
soon,O
after,O
it,O
had,O
been,O
discontinued,O
.,O
The,O
third,O
patient,O
had,O
acute,O
amphetamine,B
-,I
induced,I
chorea,O
after,O
prolonged,O
oral,B
contraception,I
.,O
Prolonged,O
administration,O
of,O
female,B
sex,I
hormones,I
is,O
a,O
possible,O
cause,O
of,O
chorea,O
in,O
women,O
who,O
have,O
not,O
previously,O
had,O
chorea,O
or,O
rheumatic,O
fever,O
.,O
Co,O
-,O
carcinogenic,O
effect,O
of,O
retinyl,B
acetate,I
on,O
forestomach,O
carcinogenesis,O
of,O
male,B
F344,I
rats,I
induced,O
with,O
butylated,B
hydroxyanisole,I
.,O
The,O
potential,O
modifying,O
effect,O
of,O
retinyl,B
acetate,I
(,O
RA,B
),O
on,O
butylated,B
hydroxyanisole,I
(,O
BHA,B
),O
-,O
induced,O
rat,B
forestomach,I
tumorigenesis,I
was,O
examined,O
.,O
Male,O
F344,O
rats,O
",",O
5,O
weeks,O
of,O
age,O
",",O
were,O
maintained,O
on,O
diet,O
containing,O
1,O
%,O
or,O
2,O
%,O
BHA,B
by,O
weight,O
and,O
simultaneously,O
on,O
drinking,O
water,O
supplemented,O
with,O
RA,B
at,O
various,O
concentrations,O
(,O
w,O
/,O
v,O
),O
for,O
52,O
weeks,O
.,O
In,O
groups,O
given,O
2,O
%,O
BHA,B
",",O
although,O
marked,O
hyperplastic,O
changes,O
of,O
the,O
forestomach,O
epithelium,O
were,O
observed,O
in,O
all,O
animals,O
",",O
co,O
-,O
administration,O
of,O
0,O
.,O
25,O
%,O
RA,B
significantly,O
(,O
P,O
less,O
than,O
0,O
.,O
5,O
),O
increased,O
the,O
incidence,O
of,O
forestomach,B
tumors,O
(,O
squamous,B
cell,I
papilloma,I
and,O
carcinoma,I
),O
to,O
60,O
%,O
(,O
9,O
/,O
15,O
",",O
2,O
rats,O
with,O
carcinoma,I
),O
from,O
15,O
%,O
(,O
3,O
/,O
20,O
",",O
one,O
rat,O
with,O
carcinoma,I
),O
in,O
the,O
group,O
given,O
RA,B
-,O
free,O
water,O
.,O
In,O
rats,O
given,O
1,O
%,O
BHA,B
",",O
RA,B
co,O
-,O
administered,O
at,O
a,O
dose,O
of,O
0,O
.,O
5,O
",",O
0,O
.,O
1,O
",",O
0,O
.,O
2,O
or,O
0,O
.,O
25,O
%,O
showed,O
a,O
dose,O
-,O
dependent,O
enhancing,O
effect,O
on,O
the,O
development,O
of,O
the,O
BHA,B
-,O
induced,O
epithelial,O
hyperplasia,O
.,O
Tumors,O
",",O
all,O
papillomas,O
",",O
were,O
induced,O
in,O
3,O
rats,O
(,O
17,O
%,O
),O
with,O
0,O
.,O
25,O
%,O
RA,B
and,O
in,O
one,O
rat,O
(,O
10,O
%,O
),O
with,O
0,O
.,O
5,O
%,O
RA,B
co,O
-,O
administration,O
.,O
RA,B
alone,O
did,O
not,O
induce,O
hyperplastic,O
changes,O
in,O
the,O
forestomach,O
.,O
These,O
findings,O
indicate,O
that,O
RA,B
acted,O
as,O
a,O
co,O
-,O
carcinogen,O
in,O
the,O
BHA,B
forestomach,O
carcinogenesis,O
of,O
the,O
rat,O
.,O
A,O
prospective,O
study,O
on,O
the,O
dose,O
dependency,O
of,O
cardiotoxicity,O
induced,O
by,O
mitomycin,B
C,I
.,O
Since,O
1975,O
mitomycin,B
C,I
(,O
MMC,B
),O
has,O
been,O
suggested,O
to,O
be,O
cardiotoxic,O
",",O
especially,O
when,O
combined,O
with,O
or,O
given,O
following,O
doxorubicin,B
.,O
Data,O
on,O
dose,O
dependency,O
or,O
incidence,O
concerning,O
this,O
side,O
effect,O
were,O
not,O
known,O
.,O
We,O
have,O
initiated,O
a,O
prospective,O
study,O
to,O
obtain,O
some,O
more,O
data,O
on,O
these,O
subjects,O
.,O
Forty,O
-,O
four,O
MMC,B
-,O
treated,O
patients,O
were,O
studied,O
",",O
37,O
of,O
them,O
could,O
be,O
evaluated,O
.,O
All,O
patients,O
were,O
studied,O
by,O
repeated,O
physical,O
examinations,O
",",O
chest,O
X,B
-,I
rays,I
",",O
electro,B
-,I
and,I
echocardiography,I
and,I
radionuclide,B
left,I
ventricular,I
ejection,I
fraction,I
(,I
EF,I
),I
determinations,I
.,O
The,O
results,O
were,O
evaluated,O
per,O
cumulative,O
dose,O
level,O
.,O
One,O
of,O
the,O
patients,O
developed,O
cardiac,B
failure,I
after,O
30,O
mg,O
m,O
-,O
2,O
MMC,B
and,O
only,O
150,O
mg,O
m,O
-,O
2,O
doxorubicin,B
.,O
The,O
cardiac,B
failure,I
was,O
predicted,O
by,O
a,O
drop,O
in,O
EF,B
determined,O
during,O
a,O
cold,O
pressor,O
test,O
.,O
None,O
of,O
the,O
other,O
patients,O
developed,O
clinical,O
cardiotoxicity,B
",",O
nor,O
did,O
the,O
studied,O
parameters,O
change,O
.,O
The,O
literature,O
on,O
this,O
subject,O
was,O
also,O
reviewed,O
.,O
Based,O
on,O
the,O
combined,O
data,O
from,O
the,O
present,O
study,O
and,O
the,O
literature,O
",",O
we,O
suggest,O
that,O
MMC,B
-,O
related,O
cardiotoxicity,O
is,O
dose,O
dependent,O
",",O
occurring,O
at,O
cumulative,O
dose,O
levels,O
of,O
30,O
mg,O
m,O
-,O
2,O
or,O
more,O
",",O
mainly,O
in,O
patients,O
also,O
(,O
previously,O
or,O
simultaneously,O
),O
treated,O
with,O
doxorubicin,B
.,O
The,O
incidence,O
is,O
likely,O
to,O
be,O
less,O
than,O
10,O
%,O
even,O
for,O
this,O
risk,O
group,O
.,O
Reversible,O
cerebral,O
lesions,O
associated,O
with,O
tiazofurin,B
usage,O
:,O
MR,O
demonstration,O
.,O
Tiazofurin,B
is,O
an,O
experimental,O
chemotherapeutic,O
agent,O
currently,O
undergoing,O
clinical,O
evaluation,O
.,O
We,O
report,O
our,O
results,O
with,O
magnetic,O
resonance,O
(,O
MR,O
),O
in,O
demonstrating,O
reversible,O
cerebral,O
abnormalities,O
concurrent,O
with,O
the,O
use,O
of,O
this,O
drug,O
.,O
The,O
abnormalities,O
on,O
MR,B
were,O
correlated,O
with,O
findings,O
on,O
CT,B
as,O
well,O
as,O
with,O
cerebral,B
angiography,I
.,O
The,O
utility,O
of,O
MR,B
in,O
the,O
evaluation,O
of,O
patients,O
receiving,O
this,O
new,O
agent,O
is,O
illustrated,O
.,O
Receptor,O
mechanisms,O
of,O
nicotine,B
-,O
induced,O
locomotor,O
hyperactivity,O
in,O
chronic,O
nicotine,B
-,O
treated,O
rats,O
.,O
Rats,O
were,O
pretreated,O
with,O
saline,B
or,O
nicotine,B
(,O
1,O
.,O
5,O
mg,O
/,O
kg,O
per,O
day,O
),O
by,O
subcutaneously,O
implanting,O
each,O
animal,O
with,O
an,O
Alzet,B
osmotic,I
mini,I
-,I
pump,I
which,O
continuously,O
released,O
saline,B
or,O
nicotine,B
for,O
1,O
",",O
5,O
and,O
14,O
days,O
.,O
At,O
the,O
end,O
of,O
each,O
pretreatment,O
period,O
",",O
animals,O
were,O
used,O
for,O
(,O
i,O
),O
determining,O
their,O
locomotor,O
response,O
to,O
acutely,O
injected,O
nicotine,B
(,O
0,O
.,O
2,O
mg,O
/,O
kg,O
",",O
s,O
.,O
c,O
.,O
),O
and,O
(,O
ii,O
),O
measuring,O
the,O
density,O
of,O
L,B
-,O
[,O
3H,B
],O
nicotine,B
and,O
[,O
3H,B
],O
spiperone,B
binding,O
sites,O
in,O
the,O
striatum,O
.,O
We,O
observed,O
no,O
changes,O
in,O
nicotine,B
-,O
induced,O
locomotor,O
response,O
",",O
striatal,O
L,B
-,O
[,O
3H,B
],O
nicotine,B
and,O
[,O
3H,B
],O
spiperone,B
binding,O
in,O
the,O
animals,O
pretreated,O
with,O
nicotine,B
for,O
1,O
day,O
.,O
In,O
rats,O
which,O
were,O
pretreated,O
with,O
nicotine,B
for,O
5,O
days,O
",",O
there,O
was,O
a,O
significant,O
increase,O
in,O
the,O
nicotine,B
-,O
stimulated,O
locomotor,O
response,O
which,O
was,O
associated,O
with,O
an,O
increase,O
in,O
the,O
number,O
of,O
L,B
-,I
[,O
3H,B
],O
nicotine,B
binding,O
sites,O
and,O
also,O
with,O
an,O
elevated,O
dopamine,B
(,O
DA,I
),O
level,O
in,O
the,O
striatum,O
.,O
The,O
number,O
of,O
striatal,O
[,O
3H,B
],O
spiperone,I
binding,O
sites,O
was,O
not,O
affected,O
.,O
In,O
animals,O
pretreated,O
with,O
nicotine,B
for,O
14,O
days,O
",",O
the,O
nicotine,B
-,O
induced,O
locomotor,O
response,O
remained,O
to,O
be,O
potentiated,O
.,O
However,O
",",O
this,O
response,O
was,O
correlated,O
with,O
an,O
elevated,O
number,O
of,O
striatal,O
[,O
3H,B
],O
spiperone,I
binding,O
sites,O
",",O
whereas,O
the,O
number,O
of,O
striatal,O
L,B
-,O
[,O
3H,B
],O
nicotine,I
binding,O
sites,O
and,O
the,O
striatal,O
DA,B
level,O
were,O
normal,O
.,O
These,O
results,O
suggest,O
that,O
chronic,O
nicotine,B
-,O
treated,O
rats,O
develop,O
locomotor,O
hyperactivity,O
in,O
response,O
to,O
nicotine,B
initially,O
due,O
to,O
increases,O
of,O
both,O
the,O
density,O
of,O
nicotinic,B
receptors,O
and,O
DA,B
concentration,O
",",O
followed,O
by,O
inducing,O
DA,B
receptor,O
supersensitivity,O
in,O
the,O
striatum,O
.,O
Amelioration,O
of,O
bendrofluazide,B
-,O
induced,O
hypokalemia,O
by,O
timolol,B
.,O
The,O
beta,B
adrenergic,I
blocking,I
drug,I
",",O
timolol,B
",",O
tended,O
to,O
correct,O
the,O
hypokalemia,O
of,O
short,O
-,O
term,O
bendrofluazide,O
treatment,O
in,O
6,O
healthy,O
male,O
subjects,O
and,O
although,O
the,O
effect,O
was,O
small,O
it,O
was,O
significant,O
.,O
Timolol,B
also,O
reduced,O
the,O
rise,O
in,O
plasma,O
aldosterone,B
and,O
urine,O
potassium,B
excretion,O
following,O
bendrofluazide,O
and,O
increased,O
the,O
urine,O
sodium,B
/,O
potassium,B
ratio,O
.,O
There,O
was,O
no,O
evidence,O
of,O
a,O
shift,O
of,O
potassium,B
from,O
the,O
intracellular,O
to,O
the,O
extracellular,O
space,O
.,O
St,O
.,O
Anthony,O
',O
s,O
fire,O
",",O
then,O
and,O
now,O
:,O
a,O
case,O
report,O
and,O
historical,O
review,O
.,O
A,O
rare,O
case,O
of,O
morbid,O
vasospasm,O
",",O
together,O
with,O
striking,O
angiographic,O
findings,O
",",O
is,O
described,O
secondary,O
to,O
the,O
ingestion,O
of,O
methysergide,B
by,O
a,O
48,O
-,O
year,O
-,O
old,O
woman,O
.,O
A,O
brief,O
review,O
of,O
the,O
literature,O
on,O
similar,O
cases,O
is,O
presented,O
.,O
A,O
discussion,O
of,O
the,O
history,O
of,O
ergot,B
includes,O
its,O
original,O
discovery,O
",",O
the,O
epidemics,O
of,O
gangrene,O
that,O
it,O
has,O
caused,O
through,O
the,O
ages,O
and,O
its,O
past,O
and,O
present,O
role,O
in,O
the,O
management,O
of,O
migraine,O
headache,O
.,O
Despite,O
the,O
advent,O
of,O
calcium,B
channel,I
blockers,I
and,O
beta,B
-,I
adrenergic,I
antagonists,I
",",O
ergot,B
preparations,O
continue,O
to,O
play,O
a,O
major,O
role,O
in,O
migraine,O
therapy,O
",",O
so,O
that,O
the,O
danger,O
of,O
St,O
.,O
Anthony,O
',O
s,O
fire,O
persists,O
.,O
Cardiac,O
transplantation,O
:,O
improved,O
quality,O
of,O
survival,O
with,O
a,O
modified,O
immunosuppressive,O
protocol,O
.,O
The,O
effects,O
on,O
renal,O
function,O
on,O
two,O
different,O
immunosuppressive,O
protocols,O
were,O
evaluated,O
retrospectively,O
in,O
two,O
subsequent,O
groups,O
of,O
heart,O
transplant,O
recipients,O
.,O
In,O
group,O
I,O
",",O
cyclosporine,B
was,O
given,O
before,O
the,O
procedure,O
at,O
a,O
loading,O
dose,O
of,O
17,O
.,O
5,O
mg,O
/,O
kg,O
and,O
then,O
continued,O
after,O
the,O
procedure,O
to,O
keep,O
a,O
whole,O
blood,O
level,O
about,O
1000,O
ng,O
/,O
ml,O
.,O
In,O
group,O
II,O
",",O
cyclosporine,B
was,O
started,O
only,O
after,O
the,O
procedure,O
at,O
a,O
lower,O
dosage,O
and,O
was,O
complemented,O
by,O
azathioprine,B
",",O
which,O
was,O
used,O
for,O
the,O
first,O
postoperative,O
week,O
.,O
Group,O
II,O
showed,O
a,O
better,O
perioperative,O
renal,O
function,O
as,O
determined,O
by,O
serum,O
blood,O
urea,B
nitrogen,I
and,O
serum,O
creatinine,B
levels,O
.,O
Group,O
II,O
also,O
showed,O
a,O
significant,O
decrease,O
of,O
chronic,O
nephrotoxicity,O
secondary,O
to,O
long,O
-,O
term,O
therapy,O
with,O
cyclosporine,B
.,O
Despite,O
this,O
improvement,O
in,O
late,O
renal,O
function,O
",",O
group,O
II,O
still,O
shows,O
a,O
slow,O
rise,O
in,O
serum,O
creatinine,B
.,O
We,O
think,O
that,O
even,O
these,O
lower,O
dosages,O
of,O
cyclosporine,B
can,O
cause,O
chronic,O
nephrotoxicity,O
and,O
that,O
further,O
modification,O
of,O
the,O
immunosuppressive,O
regimen,O
is,O
required,O
to,O
completely,O
abolish,O
this,O
toxic,O
side,O
effect,O
.,O
Ethopropazine,B
and,O
benztropine,B
in,O
neuroleptic,O
-,O
induced,O
parkinsonism,O
.,O
In,O
a,O
12,O
-,O
week,O
controlled,O
study,O
ethopropazine,B
was,O
compared,O
to,O
benztropine,B
in,O
the,O
treatment,O
of,O
parkinsonism,O
induced,O
by,O
fluphenazine,O
enanthate,O
in,O
60,O
schizophrenic,O
outpatients,O
.,O
Ethopropazine,B
and,O
benztropine,B
were,O
found,O
to,O
be,O
equally,O
effective,O
in,O
controlling,O
parkinsonian,O
symptoms,O
and,O
were,O
as,O
efficacious,O
as,O
procyclidine,O
",",O
their,O
previous,O
antiparkinsonian,O
drug,O
.,O
However,O
",",O
benztropine,B
treated,O
patients,O
had,O
a,O
significant,O
increase,O
in,O
tardive,B
dyskinesia,I
compared,O
to,O
their,O
condition,O
during,O
procyclindine,B
treatment,O
",",O
and,O
significantly,O
more,O
anxiety,O
and,O
depression,O
than,O
ethopropazine,B
treated,O
patients,O
.,O
This,O
suggests,O
that,O
benztropine,B
is,O
not,O
the,O
anticholinergic,O
drug,O
of,O
choice,O
in,O
the,O
treatment,O
of,O
neuroleptic,O
-,O
induced,O
parkinsonian,O
symptoms,O
",",O
because,O
of,O
its,O
more,O
toxic,O
central,O
and,O
peripheral,O
atropinic,O
effect,O
.,O
Quinidine,B
phenylethylbarbiturate,I
-,I
induced,O
fulminant,O
hepatitis,O
in,O
a,O
pregnant,O
woman,O
.,O
A,O
case,O
report,O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
19,O
-,O
year,O
-,O
old,O
Laotian,O
patient,O
affected,O
by,O
fulminant,O
hepatitis,O
during,O
the,O
third,O
trimester,O
of,O
her,O
pregnancy,O
after,O
a,O
1,O
-,O
month,O
administration,O
of,O
quinidine,B
phenylethylbarbiturate,I
.,O
After,O
delivery,O
",",O
the,O
patient,O
underwent,O
orthotopic,O
liver,B
transplantation,I
.,O
The,O
patient,O
was,O
in,O
good,O
condition,O
16,O
months,O
after,O
liver,B
transplantation,I
.,O
Quinidine,B
itself,O
or,O
phenylethylbarbiturate,B
may,O
be,O
responsible,O
for,O
fulminant,O
hepatitis,O
in,O
this,O
patient,O
.,O
Mechanisms,O
of,O
myocardial,O
ischemia,O
induced,O
by,O
epinephrine,B
:,O
comparison,O
with,O
exercise,O
-,O
induced,O
ischemia,O
.,O
The,O
role,O
of,O
epinephrine,B
in,O
eliciting,O
myocardial,O
ischemia,O
was,O
examined,O
in,O
patients,O
with,O
coronary,O
artery,O
disease,O
.,O
Objective,O
signs,O
of,O
ischemia,O
and,O
factors,O
increasing,O
myocardial,O
oxygen,O
consumption,O
were,O
compared,O
during,O
epinephrine,B
infusion,O
and,O
supine,O
bicycle,O
exercise,O
.,O
Both,O
epinephrine,B
and,O
exercise,O
produced,O
myocardial,O
ischemia,O
as,O
evidenced,O
by,O
ST,B
segment,I
depression,I
and,O
angina,O
.,O
However,O
",",O
the,O
mechanisms,O
of,O
myocardial,O
ischemia,O
induced,O
by,O
epinephrine,B
were,O
significantly,O
different,O
from,O
those,O
of,O
exercise,O
.,O
Exercise,O
-,O
induced,O
myocardial,O
ischemia,O
was,O
marked,O
predominantly,O
by,O
increased,O
heart,O
rate,O
and,O
rate,O
-,O
pressure,O
product,O
with,O
a,O
minor,O
contribution,O
of,O
end,O
-,O
diastolic,O
volume,O
",",O
while,O
epinephrine,B
-,O
induced,O
ischemia,O
was,O
characterized,O
by,O
a,O
marked,O
increase,O
in,O
contractility,O
and,O
a,O
less,O
pronounced,O
increase,O
in,O
heart,O
rate,O
and,O
rate,O
-,O
pressure,O
product,O
.,O
These,O
findings,O
indicate,O
that,O
ischemia,O
produced,O
by,O
epinephrine,B
",",O
as,O
may,O
occur,O
during,O
states,O
of,O
emotional,O
distress,O
",",O
has,O
a,O
mechanism,O
distinct,O
from,O
that,O
due,O
to,O
physical,O
exertion,O
.,O
Recent,O
preclinical,O
and,O
clinical,O
studies,O
with,O
the,O
thymidylate,B
synthase,I
inhibitor,O
N10,B
-,I
propargyl,I
-,I
5,I
",",I
8,I
-,I
dideazafolic,I
acid,I
(,I
CB,I
3717,I
),I
.,O
CB,B
3717,I
",",O
N10,B
-,I
propargyl,I
-,I
5,I
",",O
8,I
-,I
dideazafolic,I
acid,I
",",O
is,O
a,O
tight,O
-,O
binding,O
inhibitor,O
of,O
thymidylate,B
synthase,I
(,I
TS,I
),O
whose,O
cytotoxicity,O
is,O
mediated,O
solely,O
through,O
the,O
inhibition,O
of,O
this,O
enzyme,O
.,O
Recent,O
preclinical,O
studies,O
have,O
focused,O
on,O
the,O
intracellular,O
formation,O
of,O
CB,B
3717,I
polyglutamates,I
.,O
Following,O
a,O
12,O
-,O
hour,O
exposure,O
of,O
L1210,O
cells,O
to,O
50,O
microM,O
[,O
3H,O
],O
CB,B
3717,I
",",O
30,O
%,O
of,O
the,O
extractable,O
radioactivity,O
could,O
be,O
accounted,O
for,O
as,O
CB,B
3717,I
tetra,I
-,I
and,I
pentaglutamate,I
",",O
as,O
determined,O
by,O
high,O
-,O
pressure,O
liquid,O
chromatography,O
(,O
HPLC,O
),O
analyses,O
.,O
As,O
inhibitors,O
of,O
isolated,O
L1210,B
TS,O
",",O
CB,B
3717,I
di,O
-,O
",",O
tri,O
-,O
",",O
tetra,O
-,O
",",O
and,O
pentaglutamate,O
are,O
26,O
-,O
",",O
87,O
-,O
",",O
119,O
-,O
",",O
and,O
114,O
-,O
fold,O
more,O
potent,O
than,O
CB,B
3717,I
",",O
respectively,O
",",O
and,O
their,O
formation,O
may,O
",",O
therefore,O
",",O
be,O
an,O
important,O
determinant,O
of,O
CB,B
3717,I
cytotoxicity,O
.,O
In,O
early,O
clinical,O
studies,O
with,O
CB,B
3717,I
",",O
activity,O
has,O
been,O
seen,O
in,O
breast,O
cancer,O
",",O
ovarian,O
cancer,O
",",O
hepatoma,O
",",O
and,O
mesothelioma,O
.,O
Toxicities,O
included,O
hepatotoxicity,B
",",O
malaise,O
",",O
and,O
dose,O
-,O
limiting,O
nephrotoxicity,B
.,O
This,O
latter,O
effect,O
is,O
thought,O
to,O
be,O
due,O
to,O
drug,O
precipitation,O
within,O
the,O
renal,O
tubule,O
as,O
a,O
result,O
of,O
the,O
poor,O
solubility,O
of,O
CB,B
3717,I
under,O
acidic,O
conditions,O
.,O
In,O
an,O
attempt,O
to,O
overcome,O
this,O
problem,O
",",O
a,O
clinical,O
trial,O
of,O
CB,B
3717,I
administered,O
with,O
alkaline,O
diuresis,O
is,O
under,O
way,O
.,O
Preliminary,O
results,O
at,O
400,B
and,O
500,B
mg,I
/,I
m2,I
suggest,O
that,O
a,O
reduction,O
in,O
nephrotoxicity,B
may,O
have,O
been,O
achieved,O
with,O
only,O
1,O
instance,O
of,O
renal,B
toxicity,I
in,O
10,O
patients,O
.,O
Hepatotoxicity,B
and,O
malaise,O
are,O
again,O
the,O
most,O
frequent,O
side,O
effects,O
.,O
Evidence,O
of,O
antitumor,B
activity,I
has,O
been,O
seen,O
in,O
3,O
patients,O
.,O
Pharmacokinetic,B
investigations,I
have,O
shown,O
that,O
alkaline,B
diuresis,I
does,O
not,O
alter,O
CB,B
3717,I
plasma,I
levels,I
or,O
urinary,B
excretion,I
and,O
that,O
satisfactory,O
urinary,B
alkalinization,I
can,O
be,O
readily,O
achieved,O
.,O
Type,O
B,O
hepatitis,B
after,O
needle,O
-,O
stick,O
exposure,O
:,O
prevention,O
with,O
hepatitis,B
B,I
immune,I
globulin,I
.,O
Final,O
report,O
of,O
the,O
Veterans,O
Administration,O
Cooperative,O
Study,O
.,O
Hepatitis,B
B,I
immune,I
globulin,I
(,O
HBIG,B
),O
and,O
immune,O
serum,O
globulin,O
(,O
ISG,B
),O
were,O
examined,O
in,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
trial,O
to,O
assess,O
their,O
relative,O
efficacies,O
in,O
preventing,O
type,O
B,I
hepatitis,I
after,O
needle,O
-,O
stick,O
exposure,O
to,O
hepatitis,B
B,I
surface,I
antigen,I
(,O
HBsAG,B
),O
-,O
positive,O
donors,O
.,O
Clinical,O
hepatitis,B
developed,O
in,O
1,O
.,O
4,O
%,O
of,O
HBIG,O
and,O
in,O
5,O
.,O
9,O
%,O
of,O
ISG,O
recipients,O
(,O
P,O
=,O
0,O
.,O
16,O
),O
",",O
and,O
seroconversion,O
(,O
anti,B
-,I
HBs,I
),O
occurred,O
in,O
5,O
.,O
6,O
%,O
and,O
20,O
.,O
7,O
%,O
of,O
them,O
respectively,O
(,O
P,O
less,O
than,O
0,O
.,O
1,O
),O
.,O
Mild,O
and,O
transient,O
side,O
-,O
effects,O
were,O
noted,O
in,O
3,O
.,O
0,O
%,O
of,O
ISG,O
and,O
in,O
3,O
.,O
2,O
%,O
of,O
HBIG,O
recipients,O
.,O
Available,O
donor,O
sera,O
were,O
examined,O
for,O
DNA,B
polymerase,I
(,O
DNAP,B
),O
and,O
e,O
antigen,O
and,O
antibody,O
(,O
HBeAg,B
;,O
anti,O
-,O
HBE,O
),O
.,O
Both,O
DNAP,B
and,O
HBeAg,B
showed,O
a,O
highly,O
statistically,O
significant,O
correlation,O
with,O
the,O
infectivity,O
of,O
HBsAg,B
-,O
positive,O
donors,O
.,O
Hepatitis,B
B,I
immune,I
globulin,I
remained,O
significantly,O
superior,O
to,O
ISG,B
in,O
preventing,O
type,O
B,I
hepatitis,I
even,O
when,O
the,O
analysis,O
was,O
confined,O
to,O
these,O
two,O
high,O
-,O
risk,O
subgroups,O
.,O
The,O
efficacy,O
of,O
ISG,B
in,O
preventing,O
type,O
B,O
hepatitis,O
cannot,O
be,O
ascertained,O
because,O
a,O
TRUE,O
placebo,O
group,O
was,O
not,O
included,O
.,O
Production,O
of,O
autochthonous,O
prostate,B
cancer,I
in,O
Lobund,O
-,O
Wistar,O
rats,O
by,O
treatments,O
with,O
N,B
-,I
nitroso,I
-,I
N,I
-,I
methylurea,I
and,O
testosterone,O
.,O
More,O
than,O
50,O
%,O
of,O
Lobund,O
-,O
Wistar,O
(,O
L,O
-,O
W,O
),O
strain,O
rats,O
developed,O
large,O
",",O
palpable,O
prostate,B
adenocarcinomas,I
(,O
PAs,B
),O
following,O
treatments,O
with,O
N,B
-,I
nitroso,I
-,I
N,I
-,I
methylurea,I
(,O
CAS,O
:,O
684,O
-,O
93,O
-,O
5,O
),O
and,O
testosterone,O
propionate,O
[,O
(,O
TP,B
),O
CAS,O
:,O
57,O
-,O
85,O
-,O
2,O
],O
",",O
and,O
most,O
of,O
the,O
tumor,O
-,O
bearing,O
rats,O
manifested,O
metastatic,O
lesions,O
.,O
The,O
incubation,O
periods,O
averaged,O
10,O
.,O
6,O
months,O
.,O
Within,O
the,O
same,O
timeframe,O
",",O
no,O
L,O
-,O
W,O
rat,O
developed,O
a,O
similar,O
palpable,O
PA,O
when,O
treated,O
only,O
with,O
TP,B
.,O
In,O
L,O
-,O
W,O
rats,O
",",O
TP,B
acted,O
as,O
a,O
tumor,O
enhancement,O
agent,O
",",O
with,O
primary,O
emphasis,O
on,O
the,O
development,O
of,O
prostate,B
cancer,I
.,O
Relative,O
efficacy,O
and,O
toxicity,O
of,O
netilmicin,B
and,O
tobramycin,B
in,O
oncology,O
patients,O
.,O
We,O
prospectively,O
compared,O
the,O
efficacy,O
and,O
safety,O
of,O
netilmicin,B
sulfate,I
or,O
tobramycin,B
sulfate,I
in,O
conjunction,O
with,O
piperacillin,O
sodium,O
in,O
118,O
immunocompromised,O
patients,O
with,O
presumed,O
severe,O
infections,O
.,O
The,O
two,O
treatment,O
regimens,O
were,O
equally,O
efficacious,O
.,O
Nephrotoxicity,O
occurred,O
in,O
a,O
similar,O
proportion,O
in,O
patients,O
treated,O
with,O
netilmicin,B
and,O
tobramycin,B
(,O
17,O
%,O
vs,O
11,O
%,O
),O
.,O
Ototoxicity,O
occurred,O
in,O
four,O
(,O
9,O
.,O
5,O
%,O
),O
of,O
42,O
netilmicin,B
and,O
piperacillin,B
and,O
in,O
12,O
(,O
22,O
%,O
),O
of,O
54,O
tobramycin,B
and,O
piperacillin,B
-,O
treated,O
patients,O
.,O
Of,O
those,O
evaluated,O
with,O
posttherapy,O
audiograms,O
",",O
three,O
of,O
four,O
netilmicin,B
and,O
piperacillin,B
-,O
treated,O
patients,O
had,O
auditory,O
thresholds,O
return,O
to,O
baseline,O
compared,O
with,O
one,O
of,O
nine,O
tobramycin,B
and,O
piperacillin,B
-,O
treated,O
patients,O
.,O
The,O
number,O
of,O
greater,O
than,O
or,O
equal,O
to,O
15,O
-,O
dB,O
increases,O
in,O
auditory,O
threshold,O
as,O
a,O
proportion,O
of,O
total,O
greater,O
than,O
or,O
equal,O
to,O
15,O
-,O
dB,O
changes,O
(,O
increases,O
and,O
decreases,O
),O
was,O
significantly,O
lower,O
in,O
netilmicin,B
and,O
piperacillin,B
-,O
vs,O
tobramycin,B
and,O
piperacillin,B
-,O
treated,O
patients,O
(,O
18,O
of,O
78,O
vs,O
67,O
of,O
115,O
),O
.,O
We,O
conclude,O
that,O
aminoglycoside,B
-,I
associated,O
ototoxicity,O
was,O
less,O
severe,O
and,O
more,O
often,O
reversible,O
with,O
netilmicin,B
than,O
with,O
tobramycin,B
.,O
Urinary,O
enzymes,O
and,O
protein,O
patterns,O
as,O
indicators,O
of,O
injury,O
to,O
different,O
regions,O
of,O
the,O
kidney,O
.,O
Acute,O
experimental,O
models,O
of,O
renal,O
damage,O
to,O
the,O
proximal,O
tubular,O
",",O
glomerular,O
",",O
and,O
papillary,O
regions,O
of,O
the,O
rat,O
were,O
produced,O
by,O
administration,O
of,O
hexachloro,B
-,I
1,I
:,I
3,I
-,I
butadiene,I
(,I
HCBD,I
),I
",",O
puromycin,B
aminonucleoside,I
(,I
PAN,I
),I
",",O
and,O
2,B
-,I
bromoethylamine,I
(,I
BEA,I
),I
",",O
respectively,O
.,O
Several,O
routine,O
indicators,O
of,O
nephrotoxicity,O
",",O
the,O
enzymes,O
alkaline,B
phosphatase,I
and,O
N,B
-,I
acetyl,I
-,I
beta,I
-,I
glucosaminidase,I
",",O
and,O
the,O
molecular,O
weight,O
of,O
protein,O
excretion,O
were,O
determined,O
on,O
urine,O
samples,O
.,O
Tubular,O
damage,O
produced,O
by,O
HCBD,B
or,O
BEA,B
was,O
discriminated,O
both,O
quantitatively,O
and,O
qualitatively,O
from,O
glomerular,O
damage,O
produced,O
by,O
PAN,B
.,O
The,O
latter,O
was,O
characterized,O
by,O
a,O
pronounced,O
increase,O
in,O
protein,B
excretion,O
",",O
especially,O
proteins,O
with,O
molecular,O
weight,O
greater,O
than,O
40,O
",",O
0,O
Da,O
.,O
In,O
contrast,O
",",O
protein,B
excretion,O
in,O
tubular,O
damage,O
was,O
raised,O
only,O
slightly,O
and,O
characterized,O
by,O
excretion,O
of,O
proteins,O
of,O
a,O
wide,O
range,O
of,O
molecular,O
weights,O
.,O
Proximal,O
tubular,O
damage,O
caused,O
by,O
HCBD,B
and,O
papillary,O
damage,O
caused,O
by,O
BEA,B
were,O
distinguished,O
both,O
by,O
conventional,O
urinalysis,O
(,O
volume,O
and,O
specific,O
gravity,O
),O
and,O
by,O
measurement,O
of,O
the,O
two,O
urinary,O
enzymes,O
.,O
Alkaline,B
phosphatase,I
and,O
glucose,B
were,O
markedly,O
and,O
transiently,O
elevated,O
in,O
proximal,O
tubular,O
damage,O
and,O
N,B
-,I
acetyl,I
-,I
beta,I
-,I
glucosaminidase,I
showed,O
a,O
sustained,O
elevation,O
in,O
papillary,O
damage,O
.,O
It,O
is,O
concluded,O
that,O
both,O
selective,O
urinary,O
enzymes,O
and,O
the,O
molecular,O
weight,O
pattern,O
of,O
urinary,O
proteins,O
can,O
be,O
used,O
to,O
provide,O
diagnostic,O
information,O
about,O
the,O
possible,O
site,O
of,O
renal,O
damage,O
.,O
A,O
catch,O
in,O
the,O
Reye,B
.,O
Twenty,O
-,O
six,O
cases,O
of,O
Reye,B
syndrome,O
from,O
The,O
Children,O
',O
s,O
Hospital,O
",",O
Camperdown,O
",",O
Australia,O
",",O
occurring,O
between,O
1973,O
and,O
1982,O
were,O
reviewed,O
.,O
Of,O
these,O
",",O
20,O
cases,O
met,O
the,O
US,O
Public,O
Health,O
Service,O
Centers,O
for,O
Disease,O
Control,O
criteria,O
for,O
the,O
diagnosis,O
of,O
Reye,B
syndrome,I
.,O
Aspirin,B
or,O
salicylate,B
ingestion,O
had,O
occurred,O
in,O
only,O
one,O
of,O
the,O
20,O
cases,O
(,O
5,O
%,O
),O
",",O
and,O
paracetamol,B
(,O
acetaminophen,I
),O
had,O
been,O
administered,O
in,O
only,O
six,O
of,O
the,O
cases,O
(,O
30,O
%,O
),O
.,O
Pathologic,O
confirmation,O
of,O
the,O
diagnosis,O
of,O
Reye,B
syndrome,I
was,O
accomplished,O
in,O
90,O
%,O
of,O
the,O
cases,O
.,O
The,O
incidence,O
of,O
Reye,B
syndrome,I
in,O
New,O
South,O
Wales,O
",",O
Australia,O
",",O
is,O
estimated,O
from,O
this,O
study,O
to,O
be,O
approximately,O
nine,O
cases,O
per,O
1,O
million,O
children,O
compared,O
with,O
recent,O
US,O
data,O
of,O
ten,O
to,O
20,O
cases,O
per,O
1,O
million,O
children,O
and,O
three,O
to,O
seven,O
cases,O
per,O
1,O
million,O
children,O
in,O
Great,O
Britain,O
.,O
The,O
mortality,O
for,O
these,O
Reye,B
syndrome,I
cases,O
in,O
Australia,O
was,O
45,O
%,O
as,O
compared,O
with,O
a,O
32,O
%,O
case,O
-,O
fatality,O
rate,O
in,O
the,O
United,O
States,O
.,O
In,O
Australia,O
",",O
the,O
pediatric,O
usage,O
of,O
aspirin,B
has,O
been,O
extremely,O
low,O
for,O
the,O
past,O
25,O
years,O
(,O
less,O
than,O
1,O
%,O
of,O
total,O
dosage,O
units,O
sold,O
),O
",",O
with,O
paracetamol,B
(,O
acetaminophen,I
),O
dominating,O
the,O
pediatric,O
analgesic,O
and,O
antipyretic,O
market,O
.,O
Reye,B
syndrome,I
may,O
be,O
disappearing,O
from,O
Australia,O
despite,O
a,O
total,O
lack,O
of,O
association,O
with,O
salicylates,B
or,O
aspirin,B
ingestion,O
",",O
since,O
there,O
were,O
no,O
cases,O
found,O
at,O
The,O
Children,O
',O
s,O
Hospital,O
in,O
1983,O
",",O
1984,O
",",O
or,O
1985,O
.,O
Postpartum,O
psychosis,O
induced,O
by,O
bromocriptine,B
.,O
Two,O
multigravida,O
patients,O
with,O
no,O
prior,O
psychiatric,O
history,O
were,O
seen,O
with,O
postpartum,O
psychosis,O
",",O
having,O
received,O
bromocriptine,B
for,O
inhibition,O
of,O
lactation,O
.,O
Bromocriptine,B
given,O
in,O
high,O
doses,O
has,O
been,O
associated,O
with,O
psychosis,O
in,O
patients,O
receiving,O
the,O
drug,O
for,O
Parkinson,B
',I
s,I
disease,I
.,O
These,O
cases,O
demonstrate,O
that,O
bromocriptine,B
may,O
cause,O
psychosis,O
even,O
when,O
given,O
in,O
low,O
doses,O
.,O
Hyperglycemic,B
acidotic,I
coma,I
and,I
death,I
in,I
Kearns,I
-,I
Sayre,I
syndrome,I
.,O
This,O
paper,O
presents,O
the,O
clinical,O
and,O
metabolic,O
findings,O
in,O
two,O
young,O
boys,O
with,O
long,O
-,O
standing,O
Kearns,B
-,I
Sayre,I
syndrome,I
.,O
Following,O
short,O
exposure,O
to,O
oral,O
prednisone,B
",",O
both,O
boys,O
developed,O
lethargy,O
",",O
increasing,O
somnolence,O
",",O
polydipsia,O
",",O
polyphagia,O
",",O
and,O
polyuria,O
.,O
Both,O
presented,O
in,O
the,O
emergency,O
room,O
with,O
profound,O
coma,O
",",O
hypotension,O
",",O
severe,O
hyperglycemia,B
",",O
and,O
acidosis,B
.,O
Nonketotic,O
lactic,B
acidosis,I
was,O
present,O
in,O
one,O
and,O
ketosis,B
without,O
a,O
known,O
serum,O
lactate,O
level,O
was,O
present,O
in,O
the,O
other,O
.,O
Respiratory,O
failure,O
rapidly,O
ensued,O
and,O
both,O
patients,O
expired,O
in,O
spite,O
of,O
efforts,O
at,O
resuscitation,O
.,O
We,O
believe,O
these,O
two,O
cases,O
represent,O
a,O
newly,O
described,O
and,O
catastrophic,O
metabolic,B
-,I
endocrine,I
failure,O
in,O
the,O
Kearns,O
-,O
Sayre,O
syndrome,O
.,O
Experimental,O
cyclosporine,B
nephrotoxicity,O
:,O
risk,O
of,O
concomitant,O
chemotherapy,O
.,O
The,O
role,O
of,O
cyclosporine,B
(,O
CSA,B
),O
alone,O
or,O
in,O
combination,O
with,O
various,O
chemotherapeutics,O
in,O
the,O
development,O
of,O
renal,O
toxicity,O
was,O
evaluated,O
in,O
rats,O
.,O
Administration,O
of,O
20,O
mg,O
/,O
kg,O
/,O
day,O
CSA,B
for,O
4,O
weeks,O
caused,O
renal,O
functional,O
and,O
structural,O
changes,O
similar,O
to,O
those,O
reported,O
in,O
man,O
.,O
The,O
combined,O
administration,O
of,O
CSA,B
and,O
various,O
chemotherapeutic,O
drugs,O
with,O
a,O
nephrotoxic,O
potential,O
",",O
such,O
as,O
gentamicin,B
(,O
at,O
therapeutic,O
doses,O
),O
",",O
amphothericin,B
B,I
and,O
ketoconazole,B
",",O
which,O
are,O
frequently,O
used,O
in,O
immunosuppressed,O
patients,O
",",O
did,O
not,O
aggravate,O
the,O
CSA,B
induced,O
toxicity,O
in,O
the,O
rat,O
model,O
.,O
Gentamicin,B
at,O
toxic,O
doses,O
",",O
however,O
",",O
increased,O
CSA,B
nephrotoxicity,O
.,O
Thus,O
",",O
the,O
nephrotoxicity,O
induced,O
by,O
CSA,B
has,O
a,O
different,O
pathogenetic,O
mechanism,O
.,O
Diuretics,B
",",O
potassium,B
and,O
arrhythmias,O
in,O
hypertensive,O
coronary,O
disease,O
.,O
It,O
has,O
been,O
proposed,O
that,O
modest,O
changes,O
in,O
plasma,O
potassium,B
can,O
alter,O
the,O
tendency,O
towards,O
cardiac,O
arrhythmias,O
.,O
If,O
this,O
were,O
so,O
",",O
patients,O
with,O
coronary,B
artery,I
disease,I
might,O
be,O
especially,O
susceptible,O
.,O
Thus,O
",",O
myocardial,O
electrical,O
excitability,O
was,O
measured,O
in,O
patients,O
with,O
mild,O
essential,O
hypertension,O
and,O
known,O
coronary,B
artery,I
disease,I
after,O
8,O
weeks,O
of,O
treatment,O
with,O
a,O
potassium,B
-,I
conserving,I
diuretic,I
(,O
amiloride,B
),O
and,O
a,O
similar,O
period,O
on,O
a,O
potassium,B
-,I
losing,I
diuretic,I
(,O
chlorthalidone,B
),O
in,O
a,O
randomised,O
study,O
.,O
Plasma,B
potassium,B
concentrations,O
were,O
on,O
average,O
1,O
mmol,O
/,O
L,O
lower,O
during,O
the,O
chlorthalidone,B
phase,O
compared,O
to,O
amiloride,B
therapy,O
.,O
Blood,B
pressure,O
and,O
volume,O
states,O
as,O
assessed,O
by,O
bodyweight,O
",",O
plasma,B
renin,B
and,O
noradrenaline,B
(,O
norepinephrine,O
),O
concentrations,O
were,O
similar,O
on,O
the,O
2,O
regimens,O
.,O
Compared,O
to,O
amiloride,B
treatment,O
",",O
the,O
chlorthalidone,B
phase,O
was,O
associated,O
with,O
an,O
increased,O
frequency,O
of,O
ventricular,B
ectopic,I
beats,O
(,O
24,O
-,O
hour,O
Holter,O
monitoring,O
),O
and,O
a,O
higher,O
Lown,B
grading,O
",",O
increased,O
upslope,O
and,O
duration,O
of,O
the,O
monophasic,O
action,O
potential,O
",",O
prolonged,O
ventricular,B
effective,I
refractory,I
period,O
",",O
and,O
increased,O
electrical,O
instability,O
during,O
programmed,O
ventricular,B
stimulation,O
.,O
The,O
above,O
results,O
indicate,O
that,O
because,O
potassium,B
-,O
losing,O
diuretic,O
therapy,O
can,O
increase,O
myocardial,O
electrical,O
excitability,O
in,O
patients,O
with,O
ischaemic,O
heart,O
disease,O
",",O
even,O
minor,O
falls,O
in,O
plasma,O
potassium,B
concentrations,O
are,O
probably,O
best,O
avoided,O
in,O
such,O
patients,O
.,O
Transketolase,O
abnormality,O
in,O
tolazamide,B
-,O
induced,O
Wernicke,B
',O
s,O
encephalopathy,O
.,O
We,O
studied,O
a,O
thiamine,B
-,O
dependent,O
enzyme,O
",",O
transketolase,O
",",O
from,O
fibroblasts,O
of,O
a,O
diabetic,O
patient,O
who,O
developed,O
Wernicke,O
',O
s,O
encephalopathy,O
when,O
treated,O
with,O
tolazamide,O
",",O
in,O
order,O
to,O
delineate,O
if,O
this,O
patient,O
also,O
had,O
transketolase,O
abnormality,O
[,O
high,O
Km,O
for,O
thiamine,B
pyrophosphate,I
(,I
TPP,I
),I
"],",O
as,O
previously,O
reported,O
in,O
postalcoholic,O
Wernicke,O
-,O
Korsakoff,O
syndrome,O
.,O
In,O
addition,O
to,O
this,O
patient,O
",",O
we,O
also,O
studied,O
this,O
enzyme,O
from,O
three,O
diabetic,O
kindreds,O
without,O
any,O
history,O
of,O
Wernicke,O
',O
s,O
encephalopathy,O
and,O
from,O
four,O
normal,O
controls,O
.,O
We,O
found,O
that,O
the,O
above,O
-,O
mentioned,O
patient,O
and,O
one,O
of,O
the,O
diabetic,O
kindreds,O
with,O
no,O
history,O
of,O
Wernicke,O
',O
s,O
encephalopathy,O
had,O
abnormal,O
transketolase,O
as,O
determined,O
by,O
its,O
Km,O
for,O
TPP,B
.,O
These,O
data,O
suggest,O
a,O
similarity,O
between,O
postalcoholic,O
Wernicke,B
-,I
Korsakoff,I
syndrome,I
and,O
the,O
patient,O
with,O
tolazamide,B
-,I
induced,I
Wernicke,I
',I
s,I
encephalopathy,I
from,O
the,O
standpoint,O
of,O
transketolase,O
abnormality,O
.,O
Bradycardia,O
due,O
to,O
trihexyphenidyl,B
hydrochloride,I
.,O
A,O
chronic,O
schizophrenic,O
patient,O
was,O
treated,O
with,O
an,O
anticholinergic,O
drug,O
",",O
trihexyphenidyl,B
hydrochloride,I
.,O
The,O
patient,O
developed,O
",",O
paradoxically,O
",",O
sinus,O
bradycardia,O
.,O
The,O
reaction,O
was,O
specific,O
to,O
trihexyphenidyl,B
and,O
not,O
to,O
other,O
anticholinergic,O
drugs,O
.,O
This,O
antidyskinetic,O
drug,O
is,O
widely,O
used,O
in,O
clinical,O
psychiatric,O
practice,O
and,O
physicians,O
should,O
be,O
aware,O
of,O
this,O
side,O
effect,O
.,O
Post,O
-,O
operative,O
rigidity,O
after,O
fentanyl,B
administration,O
.,O
A,O
case,O
of,O
thoraco,B
-,I
abdominal,I
rigidity,I
leading,O
to,O
respiratory,O
failure,O
is,O
described,O
in,O
the,O
post,O
-,O
operative,O
period,O
in,O
an,O
elderly,O
patient,O
who,O
received,O
a,O
moderate,O
dose,O
of,O
fentanyl,B
.,O
This,O
was,O
successfully,O
reversed,O
by,O
naloxone,B
.,O
The,O
mechanisms,O
possibly,O
implicated,O
in,O
this,O
accident,O
are,O
discussed,O
.,O
Anti,O
-,O
carcinogenic,O
action,O
of,O
phenobarbital,B
given,O
simultaneously,O
with,O
diethylnitrosamine,B
in,O
the,O
rat,O
.,O
The,O
present,O
work,O
has,O
been,O
planned,O
in,O
order,O
to,O
elucidate,O
the,O
effect,O
of,O
phenobarbital,B
(,O
PB,B
:,O
15,O
mg,O
per,O
rat,O
of,O
ingested,O
dose,O
),O
on,O
carcinogenesis,O
when,O
it,O
is,O
administered,O
simultaneously,O
with,O
diethylnitrosamine,B
(,O
DEN,B
:,O
10,O
mg,O
/,O
kg,O
/,O
day,O
),O
.,O
Wistar,O
rats,O
(,O
180,O
g,O
),O
were,O
treated,O
by,O
DEN,B
alone,O
or,O
by,O
DEN,B
+,O
PB,B
during,O
2,O
",",O
4,O
and,O
6,O
weeks,O
according,O
to,O
our,O
schedule,O
for,O
hepatocarcinogenesis,O
.,O
After,O
the,O
end,O
of,O
the,O
treatment,O
",",O
the,O
number,O
and,O
the,O
size,O
of,O
induced,O
PAS,B
positive,O
preneoplastic,O
foci,O
was,O
significantly,O
reduced,O
when,O
PB,B
was,O
given,O
simultaneously,O
with,O
DEN,B
for,O
4,O
and,O
6,O
weeks,O
.,O
The,O
mitotic,O
inhibition,O
and,O
the,O
production,O
of,O
micronuclei,O
normally,O
observed,O
after,O
partial,O
hepatectomy,O
in,O
DEN,B
treated,O
rats,O
were,O
also,O
significantly,O
decreased,O
in,O
DEN,B
+,O
PB,B
treated,O
rats,O
.,O
When,O
the,O
treatment,O
last,O
only,O
2,O
weeks,O
",",O
the,O
presence,O
of,O
PB,B
did,O
not,O
change,O
significantly,O
the,O
last,O
parameters,O
.,O
In,O
DEN,B
+,O
PB,B
treated,O
rats,O
",",O
the,O
survival,O
was,O
prolonged,O
and,O
the,O
tumor,O
incidence,O
decreased,O
as,O
compared,O
with,O
the,O
results,O
obtained,O
by,O
DEN,B
alone,O
.,O
It,O
is,O
concluded,O
that,O
PB,B
",",O
which,O
promotes,O
carcinogenesis,O
when,O
administered,O
after,O
the,O
DEN,B
treatment,O
",",O
reduces,O
the,O
carcinogen,O
effect,O
when,O
given,O
simultaneously,O
with,O
DEN,B
.,O
This,O
',O
anti,B
-,I
carcinogen,I
',O
effect,O
acts,O
on,O
the,O
initiation,O
as,O
well,O
as,O
on,O
the,O
promotion,O
of,O
the,O
precancerous,O
lesions,O
.,O
Biochemical,O
investigations,O
are,O
in,O
progress,O
to,O
obtain,O
more,O
information,O
about,O
this,O
',O
paradoxical,O
',O
PB,B
effect,O
.,O
Bilateral,O
optic,B
neuropathy,I
due,O
to,O
combined,O
ethambutol,B
and,O
isoniazid,B
treatment,O
.,O
The,O
case,O
of,O
a,O
40,O
-,O
year,O
-,O
old,O
patient,O
who,O
underwent,O
an,O
unsuccessful,O
cadaver,O
kidney,B
transplantation,O
and,O
was,O
treated,O
with,O
ethambutol,B
and,O
isoniazid,B
is,O
reported,O
.,O
A,O
bilateral,O
retrobulbar,O
neuropathy,O
with,O
an,O
unusual,O
central,O
bitemporal,O
hemianopic,O
scotoma,O
was,O
found,O
.,O
Ethambutol,B
was,O
stopped,O
and,O
only,O
small,O
improvement,O
of,O
the,O
visual,O
acuity,O
followed,O
.,O
Isoniazid,B
was,O
discontinued,O
later,O
",",O
followed,O
by,O
a,O
dramatic,O
improvement,O
in,O
the,O
visual,O
acuity,O
.,O
The,O
hazards,O
of,O
optic,O
nerve,O
toxicity,O
due,O
to,O
ethambutol,B
are,O
known,O
.,O
We,O
emphasize,O
the,O
potential,O
danger,O
in,O
the,O
use,O
of,O
ethambutol,B
and,O
isoniazid,B
.,O
A,O
prospective,O
study,O
of,O
adverse,O
reactions,O
associated,O
with,O
vancomycin,B
therapy,O
.,O
A,O
prospective,O
evaluation,O
of,O
the,O
efficacy,O
and,O
safety,O
of,O
vancomycin,B
was,O
conducted,O
in,O
54,O
consecutive,O
patients,O
over,O
a,O
16,O
-,O
month,O
period,O
.,O
Vancomycin,B
was,O
curative,O
in,O
95,O
%,O
of,O
43,O
patients,O
with,O
proven,O
infection,O
.,O
Drugs,O
were,O
ceased,O
in,O
six,O
patients,O
because,O
of,O
adverse,O
reactions,O
;,O
in,O
three,O
of,O
these,O
vancomycin,B
was,O
considered,O
the,O
likely,O
cause,O
.,O
Reactions,O
included,O
thrombophlebitis,B
(,O
20,O
of,O
54,O
patients,O
),O
",",O
rash,B
(,O
4,O
of,O
54,O
),O
",",O
nephrotoxicity,B
(,O
4,O
of,O
50,O
),O
",",O
proteinuria,B
(,O
1,O
of,O
50,O
),O
and,O
ototoxicity,B
(,O
1,O
of,O
11,O
patients,O
tested,O
by,O
audiometry,O
),O
.,O
Thrombophlebitis,B
occurred,O
only,O
with,O
infusion,O
through,O
peripheral,O
cannulae,O
;,O
nephrotoxicity,B
and,O
ototoxicity,B
were,O
confined,O
to,O
patients,O
receiving,O
an,O
aminoglycoside,B
plus,O
vancomycin,B
.,O
We,O
conclude,O
that,O
vancomycin,B
",",O
administered,O
appropriately,O
",",O
constitutes,O
safe,O
",",O
effective,O
therapy,O
for,O
infections,O
caused,O
by,O
susceptible,O
bacteria,O
.,O
Factors,O
associated,O
with,O
nephrotoxicity,O
and,O
clinical,O
outcome,O
in,O
patients,O
receiving,O
amikacin,B
.,O
Data,O
from,O
60,O
patients,O
treated,O
with,O
amikacin,B
were,O
analyzed,O
for,O
factors,O
associated,O
with,O
nephrotoxicity,O
.,O
In,O
42,O
of,O
these,O
patients,O
",",O
data,O
were,O
examined,O
for,O
factors,O
associated,O
with,O
clinical,O
outcome,O
.,O
Variables,O
evaluated,O
included,O
patient,O
weight,O
",",O
age,O
",",O
sex,O
",",O
serum,B
creatinine,I
level,I
",",O
creatinine,B
clearance,I
",",O
duration,O
of,O
therapy,O
",",O
total,O
dose,O
",",O
mean,O
daily,O
dose,O
",",O
organism,O
minimum,O
inhibitory,O
concentration,O
(,O
MIC,B
),O
",",O
mean,O
peak,O
levels,O
",",O
mean,O
trough,O
levels,O
",",O
mean,O
area,O
under,O
the,O
serum,B
concentration,I
-,I
time,I
curve,I
(,I
AUC,I
),O
",",O
total,O
AUC,O
",",O
mean,O
AUC,O
greater,O
than,O
MIC,O
",",O
total,O
AUC,O
greater,O
than,O
MIC,O
",",O
mean,O
Schumacher,O
',O
s,O
intensity,O
factor,O
(,O
IF,B
),O
",",O
total,O
IF,O
",",O
In,O
(,O
mean,O
maximum,O
concentration,O
[,O
Cmax,O
],O
/,O
MIC,O
),O
.,O
Model,B
-,O
dependent,O
pharmacokinetic,O
parameters,O
were,O
calculated,O
by,O
computer,O
based,O
on,O
a,O
one,O
-,O
compartment,O
model,O
.,O
When,O
the,O
parameters,O
were,O
examined,O
individually,O
",",O
duration,O
of,O
therapy,O
and,O
total,O
AUC,B
correlated,O
significantly,O
(,O
P,O
less,O
than,O
.,O
5,O
),O
with,O
nephrotoxicity,B
.,O
In,O
contrast,O
",",O
a,O
stepwise,O
discriminant,O
function,O
analysis,O
identified,O
only,O
duration,O
of,O
therapy,O
(,O
P,O
less,O
than,O
1,O
),O
as,O
an,O
important,O
factor,O
.,O
Based,O
on,O
this,O
model,O
and,O
on,O
Bayes,O
',O
theorem,O
",",O
the,O
predictive,O
accuracy,O
of,O
identifying,O
nephrotoxic,B
patients,O
increased,O
from,O
0,O
.,O
17,O
to,O
0,O
.,O
39,O
.,O
When,O
examined,O
individually,O
",",O
mean,O
IF,O
",",O
MIC,B
",",O
total,O
dose,O
",",O
mean,O
daily,O
dose,O
",",O
and,O
ln,O
(,O
mean,O
Cmax,O
/,O
MIC,B
),O
correlated,O
significantly,O
(,O
P,O
less,O
than,O
.,O
5,O
),O
with,O
cure,O
.,O
In,O
contrast,O
",",O
a,O
simultaneous,O
multivariable,O
analysis,O
identified,O
IF,B
",",O
MIC,B
",",O
and,O
total,O
dose,O
according,O
to,O
one,O
model,O
and,O
ln,O
(,O
mean,O
Cmax,B
/,O
MIC,B
),O
according,O
to,O
a,O
second,O
statistical,O
model,O
of,O
parameters,O
selected,O
to,O
have,O
the,O
greatest,O
prospective,O
value,O
.,O
Based,O
on,O
Bayes,B
',O
theorem,O
and,O
the,O
first,O
model,O
",",O
the,O
predictive,O
accuracy,O
of,O
identifying,O
patients,O
not,O
cured,O
increased,O
from,O
0,O
.,O
19,O
to,O
0,O
.,O
83,O
.,O
For,O
the,O
second,O
model,O
",",O
the,O
predictive,O
accuracy,O
increased,O
from,O
0,O
.,O
19,O
to,O
0,O
.,O
50,O
.,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Cardiac,O
toxicity,O
of,O
5,B
-,I
fluorouracil,I
.,O
Report,O
of,O
a,O
case,O
of,O
spontaneous,O
angina,O
.,O
We,O
report,O
a,O
case,O
of,O
a,O
patient,O
with,O
colon,O
carcinoma,O
and,O
liver,O
metastasis,O
who,O
presented,O
chest,O
pain,O
after,O
5,B
-,I
fluorouracil,I
(,O
5,B
-,I
FU,I
),O
administration,O
.,O
Clinical,O
electrocardiographic,O
evolution,O
was,O
similar,O
to,O
that,O
observed,O
in,O
Prinzmetal,O
',O
s,O
angina,O
",",O
and,O
chest,O
pain,O
promptly,O
resolved,O
with,O
nifedipine,B
.,O
These,O
data,O
suggest,O
that,O
coronary,O
spasm,O
may,O
be,O
the,O
cause,O
of,O
cardiotoxicity,O
due,O
to,O
5,B
-,I
FU,I
",",O
and,O
that,O
calcium,B
antagonists,O
may,O
probably,O
be,O
used,O
in,O
the,O
prevention,O
or,O
treatment,O
of,O
5,B
-,I
FU,I
cardiotoxicity,O
.,O
Dose,O
-,O
related,O
beneficial,O
and,O
adverse,O
effects,O
of,O
dietary,O
corticosterone,B
on,O
organophosphorus,O
-,O
induced,O
delayed,O
neuropathy,O
in,O
chickens,O
.,O
Tri,O
-,O
ortho,B
-,I
tolyl,I
phosphate,I
(,O
TOTP,B
),O
",",O
360,O
mg,O
/,O
kg,O
",",O
po,O
",",O
and,O
0,O
",",O
0,O
',O
-,O
diisopropyl,B
phosphorofluoridate,I
(,O
DFP,B
),O
",",O
1,O
mg,O
/,O
kg,O
sc,O
",",O
were,O
administered,O
to,O
adult,O
White,O
Leghorn,O
chickens,O
24,O
hr,O
after,O
they,O
were,O
placed,O
on,O
diets,O
containing,O
0,O
to,O
300,O
ppm,O
corticosterone,B
.,O
Supplemented,O
diets,O
were,O
continued,O
until,O
clinical,O
signs,O
and,O
lesions,O
of,O
delayed,O
neuropathy,O
appeared,O
.,O
Although,O
low,O
concentrations,O
(,O
less,O
than,O
or,O
equal,O
to,O
50,O
ppm,O
),O
of,O
corticosterone,B
had,O
beneficial,O
effects,O
on,O
TOTP,B
-,O
induced,O
neuropathy,O
",",O
greater,O
than,O
or,O
equal,O
to,O
200,O
ppm,O
exacerbated,O
clinical,O
signs,O
in,O
chickens,O
given,O
either,O
TOTP,B
or,O
DFP,B
.,O
Neurotoxic,B
esterase,I
activities,O
24,O
hr,O
after,O
TOTP,B
or,O
DFP,B
were,O
less,O
than,O
20,O
%,O
of,O
values,O
measured,O
in,O
chickens,O
not,O
given,O
organophosphorous,O
compounds,O
.,O
Chickens,O
given,O
200,O
ppm,O
corticosterone,B
without,O
TOTP,B
or,O
DFP,B
had,O
significantly,O
elevated,O
activity,O
of,O
plasma,O
cholinesterase,B
and,O
significantly,O
inhibited,O
activity,O
of,O
liver,O
carboxylesterase,B
.,O
Degenerating,O
myelinated,O
fibers,O
were,O
also,O
evident,O
in,O
distal,O
levels,O
of,O
the,O
peripheral,O
nerves,O
of,O
chickens,O
given,O
TOTP,B
or,O
DFP,B
.,O
Hepatotoxicity,O
of,O
amiodarone,B
.,O
Amiodarone,B
has,O
proved,O
very,O
effective,O
in,O
the,O
treatment,O
of,O
otherwise,O
resistant,O
cardiac,O
tachyarrhythmias,O
.,O
The,O
use,O
of,O
amiodarone,B
has,O
",",O
however,O
",",O
been,O
limited,O
due,O
to,O
its,O
serious,O
side,O
-,O
effects,O
.,O
A,O
patient,O
with,O
cholestatic,B
hepatitis,I
due,O
to,O
amiodarone,B
treatment,O
is,O
presented,O
below,O
and,O
a,O
review,O
of,O
the,O
hepatotoxicity,O
of,O
amiodarone,B
is,O
given,O
.,O
It,O
is,O
concluded,O
that,O
solid,O
evidence,O
exists,O
of,O
hepatic,O
injury,O
due,O
to,O
amiodarone,B
treatment,O
",",O
including,O
steatosis,O
",",O
alterations,O
resembling,O
alcoholic,O
hepatitis,O
",",O
cholestatic,B
hepatitis,I
and,O
micronodular,O
cirrhosis,O
of,O
the,O
liver,O
.,O
Patients,O
receiving,O
amiodarone,B
should,O
be,O
regularly,O
screened,O
with,O
respect,O
to,O
hepatic,O
enzyme,O
levels,O
.,O
Therapy,O
should,O
be,O
discontinued,O
on,O
the,O
suspicion,O
of,O
cholestatic,O
injury,O
or,O
hepatomegaly,O
.,O
Promotional,O
effects,O
of,O
testosterone,B
and,O
dietary,O
fat,O
on,O
prostate,O
carcinogenesis,O
in,O
genetically,O
susceptible,O
rats,O
.,O
Germfree,O
(,O
GF,O
),O
Lobund,O
strain,O
Wistar,O
(,O
LW,O
),O
rats,O
",",O
fed,O
vegetable,O
diet,O
L,O
-,O
485,O
",",O
have,O
developed,O
prostate,O
adenocarcinomas,O
spontaneously,O
(,O
10,O
%,O
incidence,O
),O
at,O
average,O
age,O
34,O
months,O
.,O
Conventional,O
LW,O
rats,O
",",O
implanted,O
with,O
testosterone,B
at,O
age,O
4,O
months,O
",",O
developed,O
a,O
higher,O
incidence,O
of,O
prostate,B
cancer,I
after,O
an,O
average,O
interval,O
of,O
14,O
months,O
:,O
24,O
%,O
had,O
developed,O
gross,O
tumors,O
",",O
and,O
40,O
%,O
when,O
it,O
included,O
microscopic,O
tumors,O
.,O
Preliminary,O
results,O
indicate,O
that,O
testosterone,B
-,O
treated,O
LW,O
rats,O
that,O
were,O
fed,O
the,O
same,O
diet,O
",",O
which,O
was,O
supplemented,O
with,O
corn,B
oil,I
up,O
to,O
20,O
%,O
fat,O
",",O
developed,O
prostate,B
cancer,I
after,O
intervals,O
of,O
6,O
-,O
12,O
months,O
.,O
Aged,O
GF,O
Sprague,B
-,I
Dawley,I
(,O
SD,I
),O
rats,O
have,O
not,O
developed,O
prostate,B
cancer,I
spontaneously,O
.,O
Conventional,O
SD,I
rats,O
fed,O
diet,O
L,B
-,I
485,I
and,O
treated,O
with,O
testosterone,B
developed,O
only,O
prostatitis,B
.,O
Experimental,O
designs,O
should,O
consider,O
genetic,O
susceptibility,O
as,O
a,O
basic,O
prerequisite,O
for,O
studies,O
on,O
experimental,O
prostate,B
cancer,I
.,O
Time,O
course,O
alterations,O
of,O
QTC,B
interval,O
due,O
to,O
hypaque,B
76,O
.,O
Sequential,O
measurement,O
of,O
QT,B
interval,O
during,O
left,O
ventricular,O
angiography,O
was,O
made,O
30,O
seconds,O
and,O
one,O
",",O
three,O
",",O
five,O
and,O
ten,O
minutes,O
after,O
injection,O
of,O
hypaque,B
76,O
.,O
The,O
subjects,O
were,O
ten,O
patients,O
found,O
to,O
have,O
normal,O
left,O
ventricles,O
and,O
coronary,O
arteries,O
.,O
Significant,O
QTC,B
prolongation,O
occurred,O
in,O
30,O
seconds,O
to,O
one,O
minute,O
in,O
association,O
with,O
marked,O
hypotension,O
and,O
elevation,O
of,O
cardiac,O
output,O
.,O
Rat,O
extraocular,O
muscle,O
regeneration,O
.,O
Repair,O
of,O
local,O
anesthetic,O
-,O
induced,O
damage,O
.,O
Local,O
anesthetics,O
that,O
are,O
commonly,O
used,O
in,O
ophthalmic,O
surgery,O
(,O
0,O
.,O
75,O
%,O
bupivacaine,B
hydrochloride,I
",",O
2,O
.,O
0,O
mepivacaine,B
hydrochloride,I
",",O
and,O
2,O
.,O
0,O
lidocaine,B
hydrochloride,I
plus,O
1,O
:,O
100,O
",",O
0,O
epinephrine,B
),O
were,O
injected,O
into,O
the,O
retrobulbar,O
area,O
of,O
rat,O
eyes,O
.,O
Controls,O
were,O
injected,O
with,O
physiological,O
saline,B
.,O
All,O
three,O
anesthetics,O
produced,O
massive,O
degeneration,O
of,O
the,O
extraocular,O
muscles,O
.,O
Muscle,O
degeneration,O
is,O
followed,O
by,O
regeneration,O
of,O
the,O
damaged,O
muscle,O
fibers,O
.,O
In,O
addition,O
to,O
muscle,B
damage,I
",",O
severe,O
damage,B
was,O
also,O
seen,O
in,O
harderian,B
glands,I
",",O
especially,O
after,O
exposure,O
to,O
mepivacaine,B
and,O
lidocaine,B
plus,O
epinephrine,B
.,O
With,O
these,O
findings,O
in,O
rats,O
",",O
it,O
is,O
hypothesized,O
that,O
the,O
temporary,O
diplopia,O
sometimes,O
seen,O
in,O
patients,O
after,O
ophthalmic,O
surgery,O
might,O
be,O
due,O
to,O
anesthetic,B
-,I
induced,I
damage,I
to,O
the,O
extraocular,B
muscles,I
.,O
Gentamicin,B
nephropathy,O
in,O
a,O
neonate,O
.,O
The,O
clinical,O
and,O
autopsy,O
findings,O
in,O
a,O
premature,O
baby,O
who,O
died,O
of,O
acute,O
renal,O
failure,O
after,O
therapy,O
with,O
gentamicin,B
(,O
5,O
mg,O
/,O
kg,O
/,O
day,O
),O
and,O
penicillin,O
are,O
presented,O
.,O
The,O
serum,O
gentamicin,B
concentration,O
had,O
reached,O
toxic,O
levels,O
when,O
anuria,O
developed,O
.,O
Numerous,O
periodic,O
acid,B
Schiff,I
(,O
PAS,B
),O
positive,O
",",O
diastase,B
resistant,O
cytoplasmic,O
inclusion,O
bodies,O
which,O
appeared,O
as,O
myelin,O
figures,O
in,O
cytosegresomes,O
under,O
the,O
electron,O
microscope,O
were,O
identified,O
in,O
the,O
proximal,O
convoluted,O
tubules,O
.,O
The,O
pathological,O
changes,O
induced,O
by,O
gentamicin,B
in,O
the,O
human,O
neonatal,O
kidneys,O
have,O
not,O
been,O
previously,O
reported,O
.,O
Induction,O
by,O
paracetamol,B
of,O
bladder,B
and,O
liver,B
tumours,O
in,O
the,O
rat,O
.,O
Effects,O
on,O
hepatocyte,O
fine,O
structure,O
.,O
Groups,O
of,O
male,O
and,O
female,O
inbred,O
Leeds,O
strain,O
rats,O
were,O
fed,O
diets,O
containing,O
either,O
0,O
.,O
5,O
%,O
or,O
1,O
.,O
0,O
%,O
paracetamol,B
by,O
weight,O
for,O
up,O
to,O
18,O
months,O
.,O
At,O
the,O
1,O
.,O
0,O
%,O
dosage,O
level,O
",",O
20,O
%,O
of,O
rats,O
of,O
both,O
sexes,O
developed,O
neoplastic,B
nodules,O
of,O
the,O
liver,B
",",O
a,O
statistically,O
significant,O
incidence,O
.,O
These,O
rats,O
also,O
showed,O
gross,O
enlargement,O
of,O
their,O
livers,O
and,O
an,O
increase,O
in,O
foci,O
of,O
cellular,O
alteration,O
",",O
the,O
latter,O
also,O
being,O
observed,O
in,O
the,O
low,O
dosage,O
male,O
rats,O
.,O
Papillomas,B
of,O
the,O
transitional,O
epithelium,O
of,O
the,O
bladder,B
developed,O
in,O
all,O
paracetamol,B
-,O
treated,O
groups,O
",",O
and,O
three,O
rats,O
bore,O
bladder,B
carcinomas,O
.,O
However,O
",",O
significant,O
yields,O
of,O
bladder,B
tumours,O
were,O
only,O
obtained,O
from,O
low,O
dosage,O
females,O
and,O
high,O
dosage,O
males,O
.,O
Additionally,O
",",O
20,O
to,O
25,O
%,O
of,O
paracetamol,B
-,O
treated,O
rats,O
developed,O
hyperplasia,O
of,O
the,O
bladder,B
epithelium,O
",",O
which,O
was,O
not,O
coincident,O
with,O
the,O
presence,O
of,O
bladder,B
calculi,O
.,O
A,O
low,O
yield,O
of,O
tumours,O
at,O
various,O
other,O
sites,O
also,O
arose,O
following,O
paracetamol,B
feeding,O
.,O
An,O
electron,O
microscope,O
study,O
of,O
the,O
livers,O
of,O
paracetamol,B
-,O
treated,O
rats,O
revealed,O
ultrastructural,O
changes,O
in,O
the,O
hepatocytes,O
that,O
resemble,O
those,O
that,O
result,O
from,O
exposure,O
to,O
a,O
variety,O
of,O
known,O
hepatocarcinogens,B
.,O
Transient,O
hemiparesis,O
:,O
a,O
rare,O
manifestation,O
of,O
diphenylhydantoin,B
toxicity,O
.,O
Report,O
of,O
two,O
cases,O
.,O
Among,O
the,O
common,O
side,O
effects,O
of,O
diphenylhydantoin,B
(,O
DPH,B
),O
overdose,O
",",O
the,O
most,O
frequently,O
encountered,O
neurological,O
signs,O
are,O
those,O
of,O
cerebellar,O
dysfunction,O
.,O
Very,O
rarely,O
",",O
the,O
toxic,O
neurological,O
manifestations,O
of,O
this,O
drug,O
are,O
of,O
cerebral,O
origin,O
.,O
Two,O
patients,O
are,O
presented,O
who,O
suffered,O
progressive,O
hemiparesis,O
due,O
to,O
DPH,B
overdose,O
.,O
Both,O
had,O
brain,O
surgery,O
before,O
DPH,B
treatment,O
.,O
It,O
is,O
assumed,O
that,O
patients,O
with,O
some,O
cerebral,O
damage,O
are,O
liable,O
to,O
manifest,O
DPH,B
toxicity,O
as,O
focal,O
neurological,O
signs,O
.,O
Tiapride,B
in,O
levodopa,B
-,O
induced,O
involuntary,O
movements,O
.,O
Tiapride,B
",",O
a,O
substituted,O
benzamide,B
derivative,O
closely,O
related,O
to,O
metoclopramide,B
",",O
reduced,O
levodopa,B
-,O
induced,O
peak,O
dose,O
involuntary,O
movements,O
in,O
16,O
patients,O
with,O
idiopathic,O
Parkinson,B
',O
s,O
disease,O
.,O
However,O
",",O
an,O
unacceptable,O
increase,O
in,O
disability,O
from,O
Parkinsonism,B
with,O
aggravation,O
of,O
end,O
-,O
of,O
-,O
dose,O
akinesia,O
led,O
to,O
its,O
cessation,O
in,O
14,O
patients,O
.,O
Tiapride,B
had,O
no,O
effect,O
on,O
levodopa,B
-,O
induced,O
early,O
morning,O
of,O
off,O
-,O
period,O
segmental,O
dystonia,O
.,O
These,O
results,O
fail,O
to,O
support,O
the,O
notion,O
that,O
levodopa,B
-,O
induced,O
dyskinesias,O
are,O
caused,O
by,O
overstimulation,O
of,O
a,O
separate,O
group,O
of,O
dopamine,B
receptors,O
.,O
Quinidine,B
hepatitis,O
.,O
Long,O
-,O
term,O
administration,O
of,O
quinidine,B
was,O
associated,O
with,O
persistent,O
elevation,O
of,O
serum,O
concentrations,O
of,O
SGOT,B
",",O
lactic,B
acid,I
dehydrogenase,I
",",O
and,O
alkaline,B
phosphatase,I
.,O
Liver,B
biopsy,I
showed,O
active,O
hepatitis,O
.,O
Discontinuance,O
of,O
quinidine,B
therapy,O
led,O
to,O
normalization,O
of,O
liver,B
function,I
tests,I
.,O
A,O
challenge,O
dose,O
of,O
quinidine,B
caused,O
clinical,O
symptoms,O
and,O
abrupt,O
elevation,O
of,O
SGOT,B
",",O
alkaline,B
phosphatase,I
",",O
and,O
lactic,B
acid,I
dehydrogenase,I
values,I
.,O
We,O
concluded,O
that,O
this,O
patient,O
had,O
quinidine,B
hepatotoxicity,O
and,O
believe,O
that,O
this,O
is,O
the,O
first,O
case,O
reported,O
with,O
liver,B
biopsy,I
documentation,I
.,O
This,O
report,O
also,O
suggests,O
that,O
",",O
even,O
after,O
long,O
-,O
term,O
administration,O
",",O
the,O
hepatic,B
toxicity,I
is,O
reversible,O
.,O
Arterial,B
thromboembolism,I
in,O
patients,O
receiving,O
systemic,B
heparin,I
therapy,I
:,O
a,O
complication,O
associated,O
with,O
heparin,B
-,I
induced,I
thrombocytopenia,I
.,O
Arterial,B
thromboembolism,I
is,O
a,O
recognized,O
complication,O
of,O
systemic,B
heparin,I
therapy,I
.,O
Characteristic,O
of,O
the,O
entity,O
is,O
arterial,O
occlusion,O
by,O
platelet,B
-,O
fibrin,B
thrombi,O
with,O
distal,O
ischemia,O
occurring,O
four,O
to,O
twenty,O
days,O
after,O
the,O
initiation,O
of,O
heparin,B
therapy,O
",",O
preceded,O
by,O
profound,O
thrombocytopenia,O
with,O
platelet,B
counts,O
in,O
the,O
range,O
of,O
30,O
",",O
0,O
to,O
40,O
",",O
0,O
per,O
cubic,O
millimeter,O
.,O
The,O
clinically,O
apparent,O
occlusion,O
may,O
be,O
preceded,O
by,O
gastrointestinal,O
and,O
musculoskeletal,O
symptoms,O
that,O
appear,O
to,O
be,O
ischemic,O
in,O
origin,O
",",O
and,O
might,O
serve,O
to,O
warn,O
the,O
clinician,O
of,O
these,O
complications,O
.,O
Previous,O
reports,O
of,O
these,O
phenomena,O
as,O
well,O
as,O
recent,O
studies,O
of,O
the,O
effect,O
of,O
heparin,B
are,O
reviewed,O
.,O
The,O
common,O
factor,O
relating,O
thromboembolism,O
and,O
thrombocytopenia,O
is,O
heparin,B
-,O
induced,O
platelet,O
aggregation,O
.,O
Appropriate,O
treatment,O
consists,O
of,O
discontinuation,O
of,O
heparin,B
",",O
and,O
anticoagulation,O
with,O
sodium,O
warfarin,O
if,O
necessary,O
.,O
Vascular,O
procedures,O
are,O
performed,O
as,O
indicated,O
.,O
Pharmacology,O
of,O
GYKI,B
-,I
41,I
99,I
(,O
chlorpropanol,B
",",O
Tobanum,B
),O
a,O
new,O
potent,O
beta,O
-,O
adrenergic,O
antagonist,O
.,O
The,O
compound,O
GYKI,B
-,I
41,I
99,I
",",O
as,O
a,O
beta,O
-,O
adrenergic,O
antagonist,O
",",O
is,O
3,O
-,O
8,O
times,O
more,O
potent,O
than,O
propranolol,B
in,O
vitro,O
and,O
in,O
vivo,O
.,O
Its,O
antiarrhythmic,O
effectiveness,O
surpasses,O
that,O
of,O
propranolol,B
and,O
pindolol,B
inhibiting,O
the,O
ouabain,B
arrhythmia,O
in,O
dogs,O
and,O
cats,O
.,O
GYKI,B
-,O
41,I
900,I
has,O
a,O
negligible,O
cardiodepressant,O
activity,O
;,O
it,O
is,O
not,O
cardioselective,O
.,O
The,O
compound,O
shows,O
a,O
rapid,O
and,O
long,O
lasting,O
effect,O
.,O
There,O
was,O
a,O
prolonged,O
elimination,O
of,O
the,O
radioactivity,O
after,O
the,O
injection,O
of,O
14C,B
-,I
41,I
99,I
to,O
rats,O
and,O
dogs,O
.,O
The,O
half,O
life,O
of,O
the,O
unlabeled,O
substance,O
in,O
humans,O
was,O
more,O
than,O
10,O
hours,O
.,O
Adverse,O
reactions,O
to,O
bendrofluazide,B
and,O
propranolol,B
for,O
the,O
treatment,O
of,O
mild,O
hypertension,O
.,O
Report,O
of,O
Medical,O
Research,O
Council,O
Working,O
Party,O
on,O
Mild,O
to,O
Moderate,O
Hypertension,O
.,O
Participants,O
in,O
the,O
Medical,O
Research,O
Council,O
treatment,O
trial,O
for,O
mild,O
hypertension,O
are,O
randomly,O
allocated,O
to,O
one,O
of,O
four,O
treatment,O
groups,O
:,O
bendrofluazide,B
",",O
propranolol,B
",",O
or,O
a,O
placebo,O
for,O
either,O
of,O
these,O
drugs,O
.,O
The,O
trial,O
is,O
single,O
-,O
blind,O
.,O
23,O
582,O
patient,O
-,O
years,O
of,O
observation,O
have,O
been,O
completed,O
so,O
far,O
",",O
10,O
684,O
on,O
active,O
drugs,O
and,O
12,O
898,O
on,O
placebos,O
.,O
The,O
results,O
show,O
an,O
association,O
between,O
bendrofluazide,B
treatment,O
and,O
impotence,B
",",O
and,O
impotence,B
also,O
occurred,O
more,O
frequently,O
in,O
patients,O
taking,O
propranolol,B
than,O
in,O
those,O
taking,O
placebos,O
.,O
Other,O
adverse,O
reactions,O
significantly,O
linked,O
with,O
active,O
drugs,O
include,O
impaired,O
glucose,B
tolerance,I
in,O
men,O
and,O
women,O
and,O
gout,B
in,O
men,O
",",O
associated,O
with,O
bendrofluazide,B
treatment,O
",",O
and,O
Raynaud,B
',I
s,I
phenomenon,I
and,O
dyspnoea,B
in,O
men,O
and,O
women,O
taking,O
propranolol,B
.,O
No,O
corneal,O
disease,O
is,O
known,O
to,O
have,O
occurred,O
in,O
the,O
propranolol,B
group,O
.,O
Mean,O
serum,O
potassium,B
level,O
fell,O
",",O
and,O
urea,B
and,O
uric,B
acid,I
levels,O
rose,O
",",O
in,O
men,O
and,O
women,O
taking,O
bendrofluazide,O
.,O
In,O
the,O
propranolol,O
group,O
",",O
serum,O
potassium,B
and,O
uric,B
acid,I
levels,O
rose,O
in,O
both,O
sexes,O
",",O
but,O
the,O
urea,B
level,O
rose,O
significantly,O
in,O
women,O
only,O
.,O
Serotonergic,O
drugs,O
",",O
benzodiazepines,O
and,O
baclofen,O
block,O
muscimol,B
-,O
induced,O
myoclonic,O
jerks,O
in,O
a,O
strain,O
of,O
mice,O
.,O
In,O
male,O
Swiss,O
mice,O
",",O
muscimol,B
produced,O
myoclonic,O
jerks,O
.,O
A,O
3,O
mg,O
/,O
kg,O
(,O
i,O
.,O
p,O
.,O
),O
dose,O
induced,O
this,O
response,O
in,O
all,O
of,O
the,O
mice,O
tested,O
and,O
the,O
peak,O
response,O
of,O
73,O
jerks,O
per,O
min,O
was,O
observed,O
between,O
27,O
and,O
45,O
min,O
.,O
Increasing,O
the,O
brain,O
serotonin,B
levels,O
by,O
the,O
administration,O
of,O
5,O
-,O
hydroxytryptophan,B
(,O
80,O
-,O
160,O
mg,O
/,O
kg,O
),O
in,O
combination,O
with,O
a,O
peripheral,O
decarboxylase,O
inhibitor,O
resulted,O
in,O
an,O
inhibition,O
of,O
the,O
muscimol,B
effect,O
.,O
However,O
",",O
in,O
a,O
similar,O
experiment,O
l,B
-,I
dopa,I
(,O
80,O
-,O
160,O
mg,O
/,O
kg,O
),O
was,O
without,O
effect,O
.,O
In,O
doses,O
of,O
3,O
-,O
10,O
mg,O
/,O
kg,O
",",O
the,O
serotonin,B
receptor,I
agonist,I
MK,B
-,I
212,I
caused,O
a,O
dose,O
-,O
dependent,O
blockade,O
of,O
the,O
response,O
of,O
muscimol,B
.,O
Of,O
the,O
benzodiazepines,B
",",O
clonazepam,B
(,O
0,O
.,O
1,O
-,O
0,O
.,O
3,O
mg,O
/,O
kg,O
),O
was,O
found,O
to,O
be,O
several,O
fold,O
more,O
potent,O
than,O
diazepam,B
(,O
0,O
.,O
3,O
-,O
3,O
mg,O
/,O
kg,O
),O
in,O
blocking,O
the,O
myoclonic,O
jerks,O
.,O
While,O
(,O
-,O
),O
-,O
baclofen,B
(,O
1,B
-,I
3,I
mg,I
/,I
kg,I
),O
proved,O
to,O
be,O
an,O
effective,O
antagonist,O
of,O
muscimol,B
",",O
its,O
(,O
+,O
),O
-,O
isomer,O
(,O
5,B
-,I
20,I
mg,I
/,I
kg,I
),O
lacked,O
this,O
property,O
.,O
Considering,O
the,O
fact,O
that,O
5,B
-,I
HTP,I
and,O
the,O
benzodiazepines,B
have,O
been,O
found,O
to,O
be,O
beneficial,O
in,O
the,O
management,O
of,O
clinical,O
myoclonus,O
",",O
the,O
muscimol,B
-,O
induced,O
myoclonus,O
seems,O
to,O
be,O
a,O
satisfactory,O
animal,O
model,O
that,O
may,O
prove,O
useful,O
for,O
the,O
development,O
of,O
new,O
drug,O
treatments,O
for,O
this,O
condition,O
.,O
Our,O
present,O
study,O
indicated,O
the,O
possible,O
value,O
of,O
MK,B
-,O
212,I
and,O
(,O
-,O
),O
-,O
baclofen,B
in,O
the,O
management,O
of,O
clinical,O
myoclonus,O
.,O
Adverse,O
interaction,O
between,O
beta,B
-,O
adrenergic,I
blocking,I
drugs,I
and,O
verapamil,B
-,O
-,O
report,O
of,O
three,O
cases,O
.,O
Three,O
patients,O
with,O
ischaemic,O
heart,O
disease,O
developed,O
profound,O
cardiac,O
failure,O
",",O
hypotension,O
and,O
bradycardia,O
during,O
combined,O
therapy,O
with,O
verapamil,B
and,O
beta,B
-,O
adrenergic,I
blocking,I
drugs,I
.,O
This,O
clinical,O
picture,O
resolved,O
completely,O
with,O
cessation,O
of,O
the,O
combined,O
therapy,O
.,O
Baseline,O
left,O
ventricular,O
function,O
",",O
assessed,O
by,O
cardiac,O
catheterisation,O
or,O
nuclear,O
angiography,O
",",O
was,O
normal,O
in,O
two,O
patients,O
and,O
only,O
mildly,O
reduced,O
in,O
the,O
other,O
.,O
Simultaneously,O
administration,O
of,O
beta,B
-,I
adrenergic,I
blocking,I
drugs,I
and,O
verapamil,B
may,O
result,O
in,O
profound,O
adverse,O
interactions,O
and,O
should,O
only,O
be,O
administered,O
with,O
great,O
caution,O
.,O
Comparison,O
of,O
the,O
effectiveness,O
of,O
ranitidine,B
and,O
cimetidine,B
in,O
inhibiting,O
acid,B
secretion,O
in,O
patients,O
with,O
gastric,O
hypersecretory,O
states,O
.,O
The,O
H2,O
-,O
histamine,B
receptor,O
antagonists,O
ranitidine,B
and,O
cimetidine,B
were,O
compared,O
for,O
their,O
abilities,O
to,O
control,O
gastric,O
acid,B
hypersecretion,O
on,O
a,O
short,O
-,O
and,O
long,O
-,O
term,O
basis,O
in,O
22,O
patients,O
with,O
gastric,O
acid,B
hypersecretory,O
states,O
.,O
Nineteen,O
patients,O
had,O
Zollinger,B
-,I
Ellison,I
syndrome,I
",",O
one,O
patient,O
had,O
systemic,B
mastocytosis,I
",",O
and,O
two,O
patients,O
had,O
idiopathic,B
hypersecretion,I
.,O
The,O
rates,O
of,O
onset,O
of,O
the,O
action,O
of,O
cimetidine,B
and,O
ranitidine,B
were,O
the,O
same,O
.,O
The,O
actions,O
of,O
both,O
drugs,O
were,O
increased,O
by,O
anticholinergic,B
agents,I
",",O
and,O
there,O
was,O
a,O
close,O
correlation,O
between,O
the,O
daily,O
maintenance,O
dose,O
of,O
each,O
drug,O
needed,O
to,O
control,O
acid,O
secretion,O
.,O
However,O
",",O
ranitidine,B
was,O
threefold,O
more,O
potent,O
than,O
cimetidine,B
both,O
in,O
acute,O
inhibition,O
studies,O
and,O
in,O
the,O
median,O
maintenance,O
dose,O
needed,O
(,O
1,O
.,O
2,O
g,O
per,O
day,O
for,O
ranitidine,B
and,O
3,O
.,O
6,O
g,O
per,O
day,O
for,O
cimetidine,B
.,O
Sixty,O
percent,O
of,O
the,O
males,O
developed,O
breast,O
changes,O
or,O
impotence,O
while,O
taking,O
cimetidine,B
and,O
in,O
all,O
cases,O
these,O
changes,O
disappeared,O
when,O
cimetidine,B
was,O
replaced,O
by,O
ranitidine,B
.,O
Treatment,O
with,O
high,O
doses,O
of,O
cimetidine,B
(,O
one,O
to,O
60,O
months,O
;,O
median,O
",",O
11,O
months,O
),O
or,O
ranitidine,B
(,O
two,O
to,O
31,O
months,O
;,O
median,O
",",O
14,O
months,O
),O
was,O
not,O
associated,O
with,O
hepatic,O
or,O
hematologic,O
toxicity,O
or,O
alterations,O
of,O
serum,O
gastrin,B
concentrations,O
",",O
but,O
ranitidine,B
therapy,O
was,O
associated,O
with,O
a,O
significantly,O
lower,O
serum,O
creatinine,B
level,O
than,O
seen,O
with,O
cimetidine,B
therapy,O
.,O
The,O
results,O
show,O
that,O
both,O
drugs,O
can,O
adequately,O
inhibit,O
acid,B
secretion,O
in,O
patients,O
with,O
gastric,O
hypersecretory,O
states,O
.,O
Both,O
are,O
safe,O
at,O
high,O
doses,O
",",O
but,O
ranitidine,B
is,O
threefold,O
more,O
potent,O
and,O
does,O
not,O
cause,O
the,O
antiandrogen,O
side,O
effects,O
frequently,O
seen,O
with,O
high,O
doses,O
of,O
cimetidine,B
.,O
Epileptogenic,O
properties,O
of,O
enflurane,B
and,O
their,O
clinical,O
interpretation,O
.,O
Three,O
cases,O
of,O
EEG,O
changes,O
induced,O
by,O
single,O
exposure,O
to,O
enflurane,B
anesthesia,O
are,O
reported,O
.,O
In,O
one,O
patient,O
",",O
enflurane,B
administered,O
during,O
a,O
donor,O
nephrectomy,O
resulted,O
in,O
unexpected,O
partial,O
motor,O
seizures,O
.,O
Until,O
the,O
cause,O
of,O
the,O
seizures,O
was,O
correctly,O
identified,O
",",O
the,O
patient,O
was,O
inappropriately,O
treated,O
with,O
anticonvulsants,B
.,O
Two,O
other,O
patients,O
suffered,O
from,O
partial,O
",",O
complex,O
and,O
generalized,O
seizures,O
uncontrolled,O
by,O
medication,O
.,O
Epileptic,O
foci,O
delineated,O
and,O
activated,O
by,O
enflurane,B
were,O
surgically,O
ablated,O
and,O
the,O
patients,O
are,O
now,O
seizure,O
-,O
free,O
.,O
Previous,O
exposures,O
to,O
enflurane,B
have,O
to,O
be,O
disclosed,O
to,O
avoid,O
mistakes,O
in,O
clinical,O
interpretation,O
of,O
the,O
EEG,O
.,O
On,O
the,O
other,O
hand,O
",",O
enflurane,B
may,O
prove,O
to,O
be,O
a,O
safe,O
fast,O
acting,O
activator,O
of,O
epileptic,O
foci,O
during,O
corticography,O
or,O
depth,O
electrode,O
intraoperative,O
recordings,O
.,O
Development,O
of,O
isoproterenol,B
-,I
induced,O
cardiac,O
hypertrophy,O
.,O
The,O
development,O
of,O
cardiac,O
hypertrophy,O
was,O
studied,O
in,O
adult,O
female,O
Wistar,O
rats,O
following,O
daily,O
subcutaneous,O
injections,O
of,O
isoproterenol,B
(,O
ISO,B
),O
(,O
0,O
.,O
3,O
mg,O
/,O
kg,O
body,O
weight,O
),O
.,O
A,O
time,O
course,O
was,O
established,O
for,O
the,O
change,O
in,O
tissue,O
mass,O
",",O
RNA,B
and,O
DNA,B
content,O
",",O
as,O
well,O
as,O
hydroxyproline,B
content,O
.,O
Heart,O
weight,O
increased,O
44,O
%,O
after,O
8,O
days,O
of,O
treatment,O
with,O
a,O
half,O
time,O
of,O
3,O
.,O
4,O
days,O
.,O
Ventricular,O
RNA,B
content,O
was,O
elevated,O
26,O
%,O
after,O
24,O
h,O
of,O
a,O
single,O
injection,O
and,O
reached,O
a,O
maximal,O
level,O
following,O
8,O
days,O
of,O
therapy,O
.,O
The,O
half,O
time,O
for,O
RNA,B
accumulation,O
was,O
2,O
.,O
0,O
days,O
.,O
The,O
total,O
content,O
of,O
hydroxyproline,B
remained,O
stable,O
during,O
the,O
first,O
2,O
days,O
of,O
treatment,O
but,O
increased,O
46,O
%,O
after,O
4,O
days,O
of,O
therapy,O
.,O
Ventricular,O
DNA,B
content,O
was,O
unchanged,O
during,O
the,O
early,O
stage,O
(,O
1,O
-,O
4,O
days,O
),O
of,O
hypertrophic,O
growth,O
but,O
increased,O
to,O
a,O
new,O
steady,O
-,O
state,O
level,O
19,O
%,O
above,O
the,O
controls,O
after,O
8,O
days,O
of,O
treatment,O
.,O
Intraventricular,O
pressures,O
and,O
coronary,O
flow,O
measures,O
were,O
similar,O
for,O
control,O
and,O
experimental,O
animals,O
following,O
4,O
days,O
of,O
developed,O
hypertrophy,O
.,O
However,O
",",O
dP,O
/,O
dt,O
in,O
the,O
ISO,B
-,O
treated,O
hearts,O
was,O
slightly,O
but,O
significantly,O
(,O
P,O
less,O
than,O
0,O
.,O
5,O
),O
elevated,O
.,O
These,O
data,O
indicate,O
that,O
the,O
adaptive,O
response,O
to,O
ISO,B
shows,O
an,O
early,O
hypertrophic,O
phase,O
(,O
1,O
-,O
4,O
days,O
),O
characterized,O
by,O
a,O
substantial,O
increase,O
in,O
RNA,B
content,O
and,O
cardiac,O
mass,O
in,O
the,O
absence,O
of,O
changes,O
in,O
DNA,B
.,O
However,O
",",O
prolonged,O
stimulation,O
(,O
8,O
-,O
12,O
days,O
),O
appears,O
to,O
represent,O
a,O
complex,O
integration,O
of,O
both,O
cellular,O
hypertrophy,O
and,O
hyperplasia,O
within,O
the,O
heart,O
.,O
Multiple,O
side,O
effects,O
of,O
penicillamine,B
therapy,O
in,O
one,O
patient,O
with,O
rheumatoid,O
arthritis,O
.,O
Skin,O
rashes,O
",",O
proteinuria,O
",",O
systemic,O
lupus,O
erythematosus,O
",",O
polymyositis,O
and,O
myasthenia,O
gravis,O
have,O
all,O
been,O
recorded,O
as,O
complications,O
of,O
penicillamine,B
therapy,O
in,O
patients,O
with,O
rheumatoid,O
arthritis,O
.,O
A,O
patient,O
who,O
had,O
developed,O
all,O
5,O
is,O
now,O
described,O
.,O
The,O
skin,O
lesion,O
resembled,O
elastosis,B
perforans,I
serpiginosa,I
",",O
which,O
has,O
been,O
reported,O
as,O
a,O
rare,O
side,O
effect,O
in,O
patients,O
with,O
Wilson,B
',O
s,O
disease,O
but,O
not,O
in,O
patients,O
with,O
rheumatoid,B
arthritis,I
treated,O
with,O
penicillamine,B
.,O
Obsolete,O
but,O
dangerous,O
antacid,B
preparations,O
.,O
One,O
case,O
of,O
acute,O
hypercalcaemia,B
and,O
two,O
of,O
recurrent,O
nephrolithiasis,B
are,O
reported,O
in,O
patients,O
who,O
had,O
regularly,O
consumed,O
large,O
amounts,O
of,O
calcium,B
carbon,I
-,I
ate,I
-,I
sodium,I
bicarbonate,I
powders,O
for,O
more,O
than,O
20,O
years,O
.,O
The,O
powders,O
had,O
been,O
obtained,O
from,O
pharmacists,O
unknown,O
to,O
the,O
patients,O
',O
medical,O
practitioners,O
',O
.,O
It,O
is,O
suggested,O
that,O
these,O
preparations,O
were,O
responsible,O
for,O
the,O
patient,O
',O
s,O
problems,O
",",O
and,O
that,O
such,O
powders,O
should,O
no,O
longer,O
be,O
freely,O
obtainable,O
.,O
Doxorubicin,B
cardiomyopathy,O
in,O
children,O
with,O
left,O
-,O
sided,O
Wilms,O
tumor,O
.,O
Two,O
children,O
with,O
Wilms,O
tumor,O
of,O
the,O
left,O
kidney,O
experienced,O
severe,O
anthracycline,B
cardiomyopathy,O
after,O
irradiation,O
to,O
the,O
tumor,O
bed,O
and,O
conventional,O
dosage,O
of,O
doxorubicin,B
.,O
The,O
cardiomyopathy,B
is,O
attributed,O
1,O
),O
to,O
the,O
fact,O
that,O
radiation,O
fields,O
for,O
left,O
Wilms,B
tumor,I
include,O
the,O
lower,O
portion,O
of,O
the,O
heart,B
and,O
2,O
),O
to,O
the,O
interaction,O
of,O
doxorubicin,B
and,O
irradiation,O
on,O
cardiac,B
muscle,I
.,O
It,O
is,O
recommended,O
that,O
doxorubicin,B
dosage,O
be,O
sharply,O
restricted,O
in,O
children,O
with,O
Wilms,B
tumor,I
of,O
the,O
left,O
kidney,B
who,O
receive,O
postoperative,O
irradiation,O
.,O
Effects,O
of,O
calcitonin,B
on,O
rat,O
extrapyramidal,O
motor,O
system,O
:,O
behavioral,O
and,O
biochemical,O
data,O
.,O
The,O
effects,O
of,O
i,O
.,O
v,O
.,O
c,O
.,O
injection,O
of,O
human,O
and,O
salmon,B
calcitonin,I
on,O
biochemical,O
and,O
behavioral,O
parameters,O
related,O
to,O
the,O
extrapyramidal,O
motor,O
system,O
",",O
were,O
investigated,O
in,O
male,O
rats,O
.,O
Calcitonin,B
injection,O
resulted,O
in,O
a,O
potentiation,O
of,O
haloperidol,O
-,O
induced,O
catalepsy,O
and,O
a,O
partial,O
prevention,O
of,O
apomorphine,O
-,O
induced,O
hyperactivity,O
.,O
Moreover,O
calcitonin,B
induced,O
a,O
significant,O
decrease,O
in,O
nigral,O
GAD,B
activity,O
but,O
no,O
change,O
in,O
striatal,O
DA,B
and,O
DOPAC,B
concentration,O
or,O
GAD,B
activity,O
.,O
The,O
results,O
are,O
discussed,O
in,O
view,O
of,O
a,O
primary,O
action,O
of,O
calcitonin,B
on,O
the,O
striatonigral,O
GABAergic,O
pathway,O
mediating,O
the,O
DA,B
-,O
related,O
behavioral,O
messages,O
of,O
striatal,O
origin,O
.,O
Naloxazone,B
pretreatment,O
modifies,O
cardiorespiratory,O
",",O
temperature,O
",",O
and,O
behavioral,O
effects,O
of,O
morphine,B
.,O
Behavioral,O
and,O
cardiorespiratory,O
responses,O
to,O
a,O
lethal,O
dose,O
of,O
morphine,B
were,O
evaluated,O
in,O
rats,O
pretreated,O
with,O
saline,B
or,O
naloxazone,B
",",O
an,O
antagonist,O
of,O
high,O
-,O
affinity,O
mu,O
1,O
opioid,O
receptors,O
.,O
Pretreatment,O
with,O
naloxazone,B
significantly,O
blocked,O
morphine,B
analgesia,O
",",O
catalepsy,O
and,O
hypothermia,O
at,O
a,O
dose,O
which,O
completely,O
eliminated,O
high,O
-,O
affinity,O
binding,O
in,O
brain,O
membranes,O
.,O
Moreover,O
",",O
naloxazone,B
significantly,O
attenuated,O
the,O
morphine,B
-,O
induced,O
hypotension,O
and,O
respiratory,O
depression,O
",",O
whereas,O
morphine,B
-,O
induced,O
bradycardia,O
was,O
less,O
affected,O
.,O
Results,O
indicate,O
that,O
subpopulations,O
of,O
mu,O
receptors,O
may,O
mediate,O
selective,O
behavioral,O
and,O
cardiorespiratory,O
responses,O
to,O
morphine,B
.,O
Modification,O
of,O
drug,O
action,O
by,O
hyperammonemia,B
.,O
Pretreatment,O
with,O
ammonium,B
acetate,I
(,O
NH4Ac,B
),O
(,O
6,O
mmol,O
/,O
kg,O
s,O
.,O
c,O
.,O
),O
approximately,O
doubled,O
the,O
time,O
morphine,B
-,O
treated,O
mice,O
remained,O
on,O
a,O
hot,O
surface,O
and,O
similarly,O
increased,O
muscular,O
incoordination,O
by,O
diazepam,B
",",O
but,O
NH4Ac,B
treatment,O
alone,O
had,O
no,O
effect,O
.,O
Thus,O
",",O
hyperammonemia,B
is,O
capable,O
of,O
altering,O
drug,O
action,O
and,O
must,O
be,O
considered,O
along,O
with,O
impaired,O
drug,O
metabolism,O
in,O
enhanced,O
drug,O
responses,O
associated,O
with,O
liver,O
disease,O
.,O
Experiments,O
in,O
vitro,O
showed,O
that,O
acetylcholine,B
-,O
induced,O
catecholamine,B
release,O
from,O
bovine,O
adrenal,O
medulla,O
is,O
depressed,O
as,O
much,O
as,O
50,O
%,O
by,O
0,O
.,O
3,O
mM,O
NH4Ac,B
and,O
KCl,B
-,O
induced,O
contractions,O
of,O
guinea,O
-,O
pig,O
ileum,O
were,O
inhibited,O
20,O
%,O
by,O
5,O
mM,O
NH4Ac,B
.,O
Addition,O
of,O
excess,O
calcium,B
reversed,O
the,O
depression,O
in,O
both,O
tissues,O
",",O
but,O
calcium,B
-,O
independent,O
catecholamine,B
release,O
by,O
acetaldehyde,B
was,O
not,O
blocked,O
by,O
NH4Ac,B
.,O
These,O
results,O
suggested,O
that,O
ammonia,B
blocks,O
calcium,B
channels,O
.,O
Parallels,O
in,O
the,O
actions,O
of,O
NH4Ac,B
and,O
the,O
calcium,B
channel,O
blocker,O
verapamil,B
support,O
this,O
concept,O
.,O
Both,O
verapamil,B
(,O
10,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
and,O
NH4Ac,B
pretreatment,O
enhanced,O
morphine,B
analgesia,O
-,O
and,O
diazepam,B
-,O
induced,O
muscular,O
incoordination,O
and,O
antagonized,O
amphetamine,B
-,O
induced,O
motor,O
activity,O
",",O
and,O
neither,O
verapamil,B
nor,O
NH4Ac,B
affected,O
the,O
convulsant,O
action,O
of,O
metrazol,B
.,O
The,O
data,O
suggest,O
that,O
hyperammonemia,O
exerts,O
a,O
calcium,B
channel,I
blocking,I
action,I
which,O
enhances,O
the,O
effects,O
of,O
central,O
nervous,O
system,O
depressants,O
and,O
certain,O
opioid,B
analgesics,I
.,O
Levodopa,O
-,O
induced,O
dyskinesia,O
and,O
thalamotomy,O
.,O
Levodopa,O
-,O
induced,O
dyskinesia,O
of,O
the,O
limbs,O
in,O
thirteen,O
cases,O
of,O
Parkinsonism,O
",",O
which,O
was,O
choreic,O
",",O
ballistic,O
or,O
dystonic,O
in,O
type,O
",",O
was,O
alleviated,O
almost,O
completely,O
by,O
stereotaxic,O
surgery,O
using,O
a,O
microelectrode,O
technique,O
for,O
the,O
ventralis,O
oralis,O
anterior,O
and,O
posterior,O
nuclei,O
of,O
the,O
thalamus,O
",",O
but,O
much,O
less,O
by,O
the,O
ventralis,O
intermedius,O
nucleus,O
.,O
Control,O
of,O
levodopa,B
-,O
induced,O
dyskinesias,O
by,O
thalamic,O
lesions,O
in,O
the,O
course,O
of,O
routine,O
treatment,O
of,O
Parkinsonism,O
is,O
discussed,O
.,O
Treatment,O
of,O
ifosfamide,B
-,O
induced,O
urothelial,O
toxicity,O
by,O
oral,O
administration,O
of,O
sodium,B
2,I
-,I
mercaptoethane,I
sulphonate,I
(,I
MESNA,I
),I
to,O
patients,O
with,O
inoperable,O
lung,O
cancer,O
.,O
The,O
protective,O
effect,O
of,O
oral,O
administration,O
of,O
the,O
thiol,O
compound,O
sodium,B
2,I
-,I
mercaptoethane,I
sulphonate,I
(,I
MESNA,I
),I
against,O
urothelial,O
toxicity,O
induced,O
by,O
ifosfamide,B
(,O
IF,O
),O
was,O
tested,O
in,O
a,O
group,O
of,O
45,O
patients,O
with,O
inoperable,O
lung,O
cancer,O
under,O
treatment,O
with,O
IF,O
(,O
2250,O
mg,O
/,O
m2,O
on,O
days,O
2,O
-,O
5,O
),O
as,O
part,O
of,O
a,O
polychemotherapy,O
regimen,O
repeated,O
in,O
a,O
4,O
-,O
week,O
cycle,O
.,O
MESNA,B
was,O
given,O
orally,O
on,O
the,O
days,O
of,O
treatment,O
with,O
IF,B
in,O
3,O
doses,O
of,O
840,B
mg,I
/,I
m2,I
",",O
each,O
administered,O
at,O
0,O
hr,O
(,O
=,O
injection,O
of,O
IF,B
),O
",",O
4,O
hr,O
and,O
8,O
hr,O
p,O
.,O
i,O
.,O
Out,O
of,O
a,O
total,O
of,O
88,O
courses,O
of,O
this,O
treatment,O
we,O
observed,O
10,O
episodes,O
of,O
asymptomatic,O
microscopic,O
haematuria,O
and,O
no,O
episodes,O
of,O
gross,O
haematuria,O
.,O
In,O
this,O
group,O
of,O
45,O
patients,O
under,O
protection,O
with,O
MESNA,B
there,O
were,O
5,O
complete,O
remissions,O
and,O
9,O
partial,O
remissions,O
(,O
total,O
31,O
%,O
),O
.,O
A,O
further,O
group,O
of,O
25,O
patients,O
under,O
polychemotherapy,O
with,O
IF,B
were,O
treated,O
by,O
conventional,O
prophylactic,O
measures,O
(,O
raised,O
fluid,B
intake,O
and,O
forced,O
diuresis,O
),O
.,O
In,O
this,O
group,O
there,O
were,O
1,O
complete,O
and,O
5,O
partial,O
remissions,O
(,O
total,O
24,O
%,O
),O
",",O
but,O
nearly,O
all,O
patients,O
developed,O
either,O
gross,O
haematuria,B
and,O
/,O
or,O
symptoms,O
of,O
bladder,B
irritation,O
(,O
cystitis,B
and,O
pollakisuria,B
),O
.,O
There,O
were,O
no,O
appreciable,O
differences,O
between,O
the,O
MESNA,B
series,O
and,O
the,O
conventional,O
prophylaxis,O
series,O
with,O
respect,O
to,O
either,O
haematological,O
or,O
systemic,O
toxicity,O
of,O
the,O
cytostatic,O
treatment,O
.,O
Our,O
results,O
support,O
the,O
view,O
that,O
MESNA,B
",",O
given,O
orally,O
in,O
conjunction,O
with,O
combined,O
cytostatic,O
regimens,O
which,O
include,O
IF,O
",",O
simplifies,O
the,O
treatment,O
and,O
provides,O
optimum,O
protection,O
for,O
the,O
urinary,O
epithelium,O
.,O
Protection,O
with,O
oral,O
MESNA,B
is,O
particularly,O
suitable,O
for,O
outpatients,O
.,O
Myoclonic,B
",",O
atonic,B
",",O
and,O
absence,B
seizures,O
following,O
institution,O
of,O
carbamazepine,B
therapy,O
in,O
children,O
.,O
Five,O
children,O
",",O
aged,O
3,O
to,O
11,O
years,O
",",O
treated,O
with,O
carbamazepine,B
for,O
epilepsy,O
",",O
had,O
an,O
acute,O
aberrant,O
reaction,O
characterized,O
by,O
the,O
onset,O
of,O
myoclonic,B
",",O
atypical,O
absence,B
and,O
/,O
or,O
atonic,B
(,O
minor,O
motor,O
),O
seizures,O
within,O
a,O
few,O
days,O
.,O
When,O
the,O
carbamazepine,B
was,O
discontinued,O
",",O
two,O
of,O
the,O
children,O
returned,O
to,O
their,O
former,O
state,O
very,O
quickly,O
",",O
two,O
had,O
the,O
minor,O
motor,O
seizures,O
resolve,O
in,O
3,O
and,O
6,O
months,O
",",O
and,O
one,O
had,O
the,O
seizures,O
persist,O
.,O
The,O
child,O
in,O
whom,O
the,O
seizures,O
persisted,O
was,O
later,O
found,O
to,O
have,O
ceroid,B
lipofuscinosis,I
.,O
The,O
other,O
children,O
are,O
doing,O
well,O
on,O
other,O
anticonvulsants,O
.,O
Effect,O
of,O
prostaglandin,B
synthetase,I
inhibitors,I
on,O
experimentally,O
induced,O
convulsions,O
in,O
rats,O
.,O
To,O
investigate,O
the,O
relationship,O
of,O
prostaglandins,B
(,O
PGs,I
),O
to,O
seizure,O
induction,O
",",O
the,O
effects,O
of,O
six,O
PG,B
synthetase,I
inhibitors,I
on,O
convulsions,O
induced,O
by,O
flurothyl,O
",",O
picrotoxin,O
",",O
pentetrazol,O
(,O
PTZ,B
),O
",",O
electroshock,O
or,O
bicuculline,O
were,O
evaluated,O
.,O
Ibuprofen,B
",",O
sulindac,B
",",O
mefenamic,B
acid,I
",",O
and,O
low,O
dose,O
meclofenamic,B
acid,I
increased,O
the,O
latency,O
-,O
to,O
-,O
onset,O
in,O
the,O
flurothyl,B
and,O
/,O
or,O
PTZ,B
models,O
;,O
the,O
electroshock,B
",",O
picrotoxin,B
and,O
bicuculline,B
models,O
were,O
not,O
significantly,O
affected,O
by,O
any,O
of,O
the,O
pretreatment,O
agents,O
.,O
These,O
results,O
suggest,O
that,O
PGs,B
are,O
involved,O
in,O
the,O
mechanism,O
(,O
s,O
),O
underlying,O
fluorthyl,B
-,O
and,O
PTZ,B
-,O
induced,O
convulsions,O
",",O
but,O
not,O
picrotoxin,B
-,O
",",O
electroshock,B
-,O
",",O
or,O
bicuculline,B
-,O
induced,O
convulsions,O
.,O
Acute,O
changes,O
of,O
blood,O
ammonia,B
may,O
predict,O
short,O
-,O
term,O
adverse,O
effects,O
of,O
valproic,B
acid,I
.,O
Valproic,B
acid,I
(,O
VPA,B
),O
was,O
given,O
to,O
24,O
epileptic,O
patients,O
who,O
were,O
already,O
being,O
treated,O
with,O
other,O
antiepileptic,O
drugs,O
.,O
A,O
standardized,O
loading,O
dose,O
of,O
VPA,B
was,O
administered,O
",",O
and,O
venous,O
blood,O
was,O
sampled,O
at,O
0,O
",",O
1,O
",",O
2,O
",",O
3,O
",",O
and,O
4,O
hours,O
.,O
Ammonia,B
(,O
NH3,B
),O
was,O
higher,O
in,O
patients,O
who,O
",",O
during,O
continuous,O
therapy,O
",",O
complained,O
of,O
drowsiness,O
(,O
7,O
patients,O
),O
than,O
in,O
those,O
who,O
were,O
symptom,O
-,O
free,O
(,O
17,O
patients,O
),O
",",O
although,O
VPA,O
plasma,O
levels,O
were,O
similar,O
in,O
both,O
groups,O
.,O
By,O
measuring,O
VPA,O
-,O
induced,O
changes,O
of,O
blood,O
NH3,B
content,O
",",O
it,O
may,O
be,O
possible,O
to,O
identify,O
patients,O
at,O
higher,O
risk,O
of,O
obtundation,O
when,O
VPA,O
is,O
given,O
chronically,O
.,O
Effect,O
of,O
captopril,B
on,O
pre,O
-,O
existing,O
and,O
aminonucleoside,B
-,I
induced,I
proteinuria,O
in,O
spontaneously,O
hypertensive,O
rats,O
.,O
Proteinuria,O
is,O
a,O
side,O
effect,O
of,O
captopril,B
treatment,O
in,O
hypertensive,O
patients,O
.,O
The,O
possibility,O
of,O
reproducing,O
the,O
same,O
renal,O
abnormality,O
with,O
captopril,B
was,O
examined,O
in,O
SHR,O
.,O
Oral,O
administration,O
of,O
captopril,B
at,O
100,O
mg,O
/,O
kg,O
for,O
14,O
days,O
failed,O
to,O
aggravate,O
proteinuria,O
pre,O
-,O
existing,O
in,O
SHR,O
.,O
Also,O
",",O
captopril,B
treatment,O
failed,O
to,O
potentiate,O
or,O
facilitate,O
development,O
of,O
massive,O
proteinuria,O
invoked,O
by,O
puromycin,B
aminonucleoside,I
in,O
SHR,O
.,O
Captopril,B
had,O
little,O
or,O
no,O
demonstrable,O
effects,O
on,O
serum,O
electrolyte,O
concentrations,O
",",O
excretion,O
of,O
urine,O
",",O
sodium,B
and,O
potassium,B
",",O
endogenous,O
creatinine,B
clearance,I
",",O
body,O
weight,O
",",O
and,O
food,O
and,O
water,O
consumption,O
.,O
However,O
",",O
ketone,B
bodies,I
were,O
consistently,O
present,O
in,O
urine,O
and,O
several,O
lethalities,O
occurred,O
during,O
multiple,O
dosing,O
of,O
captopril,B
in,O
SHR,O
.,O
Complete,O
heart,O
block,O
following,O
a,O
single,O
dose,O
of,O
trazodone,B
.,O
Forty,O
minutes,O
after,O
receiving,O
a,O
single,O
starting,O
dose,O
of,O
trazodone,B
",",O
a,O
patient,O
developed,O
complete,O
heart,O
block,O
.,O
The,O
case,O
illustrates,O
that,O
",",O
despite,O
the,O
results,O
of,O
earlier,O
studies,O
",",O
trazodone,B
',O
s,O
effect,O
on,O
cardiac,O
conduction,O
may,O
be,O
severe,O
in,O
individuals,O
at,O
risk,O
for,O
conduction,O
delay,O
.,O
Phenobarbital,B
-,I
induced,O
dyskinesia,O
in,O
a,O
neurologically,O
-,O
impaired,O
child,O
.,O
A,O
2,O
-,O
year,O
-,O
old,O
child,O
with,O
known,O
neurologic,O
impairment,O
developed,O
a,O
dyskinesia,O
soon,O
after,O
starting,O
phenobarbital,B
therapy,O
for,O
seizures,O
.,O
Known,O
causes,O
of,O
movement,O
disorders,O
were,O
eliminated,O
after,O
evaluation,O
.,O
On,O
repeat,O
challenge,O
with,O
phenobarbital,B
",",O
the,O
dyskinesia,O
recurred,O
.,O
Phenobarbital,B
should,O
be,O
added,O
to,O
the,O
list,O
of,O
anticonvulsant,O
drugs,O
that,O
can,O
cause,O
movement,O
disorders,O
.,O
Effects,O
of,O
amine,B
pretreatment,O
on,O
ketamine,B
catatonia,O
in,O
pinealectomized,O
or,O
hypophysectomized,O
animals,O
.,O
The,O
present,O
studies,O
were,O
designed,O
to,O
clarify,O
the,O
role,O
of,O
catecholamines,B
and,O
pineal,B
idolamines,I
on,O
ketamine,B
-,O
induced,O
catatonia,O
in,O
the,O
intact,O
",",O
pinealectomized,O
or,O
hypophysectomized,O
chick,O
and,O
rat,O
.,O
In,O
the,O
pinealectomized,O
chick,O
",",O
pretreatment,O
with,O
dopamine,B
increased,O
the,O
duration,O
of,O
catatonia,O
(,O
DOC,O
),O
after,O
ketamine,B
",",O
but,O
pretreatment,O
with,O
norepinephrine,B
did,O
not,O
.,O
The,O
pineal,B
indolamines,O
exhibited,O
mixed,O
actions,O
.,O
Serotonin,B
and,O
N,B
-,I
acetyl,I
serotonin,I
which,O
augmented,O
ketamine,B
DOC,I
",",O
did,O
not,O
do,O
so,O
in,O
the,O
absence,O
of,O
the,O
pineal,B
gland,I
",",O
whereas,O
melatonin,B
potentiated,O
the,O
ketamine,B
DOC,I
in,O
both,O
the,O
intact,O
and,O
pinealectomized,O
chick,O
.,O
Ketamine,B
was,O
more,O
potent,O
in,O
the,O
hypophysectomized,O
chick,O
and,O
the,O
circadian,O
rhythm,O
noted,O
in,O
the,O
intact,O
chick,O
was,O
absent,O
;,O
furthermore,O
",",O
melatonin,B
did,O
not,O
augment,O
the,O
ketamine,B
DOC,I
whereas,O
dopamine,B
continued,O
to,O
do,O
so,O
.,O
This,O
study,O
did,O
not,O
demonstrate,O
a,O
species,O
difference,O
regarding,O
the,O
role,O
of,O
the,O
amines,B
on,O
the,O
pineal,O
in,O
spite,O
of,O
the,O
immature,O
blood,O
-,O
brain,O
barrier,O
in,O
the,O
young,O
chick,O
and,O
the,O
intact,O
barrier,O
in,O
the,O
rat,O
.,O
In,O
addition,O
",",O
these,O
data,O
indicate,O
a,O
direct,O
role,O
of,O
the,O
pituitary,O
in,O
the,O
augmentation,O
of,O
ketamine,B
DOC,O
induced,O
by,O
melatonin,B
.,O
Furthermore,O
",",O
dopamine,B
appeared,O
to,O
act,O
on,O
systems,O
more,O
closely,O
involved,O
with,O
the,O
induction,O
of,O
ketamine,B
catatonia,I
rather,O
than,O
directly,O
on,O
the,O
pituitary,O
.,O
Heparin,B
-,I
induced,I
thrombocytopenia,I
",",O
thrombosis,B
",",O
and,O
hemorrhage,B
.,O
Sixty,O
-,O
two,O
patients,O
with,O
a,O
heparin,B
-,I
induced,I
thrombocytopenia,I
are,O
reported,O
.,O
Clinical,O
manifestations,O
of,O
this,O
disorder,O
include,O
hemorrhage,B
or,O
",",O
more,O
frequently,O
",",O
thromboembolic,B
events,I
in,O
patients,O
receiving,O
heparin,B
.,O
Laboratory,O
testing,O
has,O
revealed,O
a,O
falling,O
platelet,B
count,O
",",O
increased,O
resistance,O
to,O
heparin,B
",",O
and,O
aggregation,O
of,O
platelets,B
by,O
the,O
patient,O
',O
s,O
plasma,O
when,O
heparin,B
is,O
added,O
.,O
Immunologic,O
testing,O
has,O
demonstrated,O
the,O
presence,O
of,O
a,O
heparin,B
-,O
dependent,O
platelet,B
membrane,O
antibody,O
.,O
The,O
20,O
deaths,O
",",O
52,O
hemorrhagic,O
and,O
thromboembolic,O
complications,O
",",O
and,O
21,O
surgical,O
procedures,O
to,O
manage,O
the,O
complications,O
confirm,O
the,O
seriousness,O
of,O
the,O
disorder,O
.,O
Specific,O
risk,O
factors,O
have,O
not,O
been,O
identified,O
;,O
therefore,O
",",O
all,O
patients,O
receiving,O
heparin,B
should,O
be,O
monitored,O
.,O
If,O
the,O
platelet,B
count,O
falls,O
to,O
less,O
than,O
100,O
",",O
0,O
/,O
mm3,O
",",O
while,O
the,O
patient,O
is,O
receiving,O
heparin,B
",",O
platelet,B
aggregation,O
testing,O
",",O
using,O
the,O
patient,O
',O
s,O
plasma,O
",",O
is,O
indicated,O
.,O
Management,O
consists,O
of,O
cessation,O
of,O
heparin,B
",",O
platelet,B
anti,O
-,O
aggregating,O
agents,O
",",O
and,O
alternate,O
forms,O
of,O
anticoagulation,O
when,O
indicated,O
.,O
Ventricular,O
fibrillation,O
from,O
diatrizoate,B
with,O
and,O
without,O
chelating,O
agents,O
.,O
The,O
toxicity,O
of,O
Renografin,B
76,O
%,O
was,O
compared,O
with,O
that,O
of,O
Hypaque,B
76,O
%,O
by,O
selective,O
injection,O
of,O
each,O
into,O
the,O
right,O
coronary,O
artery,O
of,O
dogs,O
.,O
Renografin,B
contains,O
the,O
chelating,O
agents,O
sodium,B
citrate,I
and,O
disodium,B
edetate,I
",",O
while,O
Hypaque,B
contains,O
calcium,B
disodium,I
edetate,I
and,O
no,O
sodium,B
citrate,I
.,O
Ventricular,B
fibrillation,I
occurred,O
significantly,O
more,O
often,O
with,O
Renografin,B
",",O
suggesting,O
that,O
chelating,O
agents,O
contribute,O
to,O
toxicity,O
in,O
coronary,O
angiography,O
.,O
Long,O
-,O
term,O
efficacy,O
and,O
toxicity,O
of,O
high,O
-,O
dose,O
amiodarone,B
therapy,O
for,O
ventricular,O
tachycardia,O
or,O
ventricular,O
fibrillation,I
.,O
Amiodarone,B
was,O
administered,O
to,O
154,O
patients,O
who,O
had,O
sustained,O
",",O
symptomatic,O
ventricular,O
tachycardia,O
(,O
VT,B
),O
(,O
n,O
=,O
118,O
),O
or,O
a,O
cardiac,O
arrest,O
(,O
n,O
=,O
36,O
),O
and,O
who,O
were,O
refractory,O
to,O
conventional,O
antiarrhythmic,O
drugs,O
.,O
The,O
loading,O
dose,O
was,O
800,B
mg,I
/,I
day,O
for,O
6,O
weeks,O
and,O
the,O
maintenance,O
dose,O
was,O
600,B
mg,I
/,I
day,O
.,O
Sixty,O
-,O
nine,O
percent,O
of,O
patients,O
continued,O
treatment,O
with,O
amiodarone,B
and,O
had,O
no,O
recurrence,O
of,O
symptomatic,O
VT,B
or,O
ventricular,O
fibrillation,O
(,O
VF,B
),O
over,O
a,O
follow,O
-,O
up,O
of,O
6,O
to,O
52,O
months,O
(,O
mean,O
+,O
/,O
-,O
standard,O
deviation,O
14,O
.,O
2,O
+,O
/,O
-,O
8,O
.,O
2,O
),O
.,O
Six,O
percent,O
of,O
the,O
patients,O
had,O
a,O
nonfatal,O
recurrence,O
of,O
VT,B
and,O
were,O
successfully,O
managed,O
by,O
continuing,O
amiodarone,B
at,O
a,O
higher,O
dose,O
or,O
by,O
the,O
addition,O
of,O
a,O
conventional,O
antiarrhythmic,O
drug,O
.,O
One,O
or,O
more,O
adverse,O
drug,O
reactions,O
occurred,O
in,O
51,O
%,O
of,O
patients,O
.,O
Adverse,O
effects,O
forced,O
a,O
reduction,O
in,O
the,O
dose,O
of,O
amiodarone,B
in,O
41,O
%,O
and,O
discontinuation,O
of,O
amiodarone,B
in,O
10,O
%,O
of,O
patients,O
.,O
The,O
most,O
common,O
symptomatic,O
adverse,O
reactions,O
were,O
tremor,B
or,O
ataxia,B
(,O
35,O
%,O
),O
",",O
nausea,B
and,O
anorexia,B
(,O
8,O
%,O
),O
",",O
visual,O
halos,B
or,O
blurring,B
(,O
6,O
%,O
),O
",",O
thyroid,B
function,I
abnormalities,I
(,O
6,O
%,O
),O
and,O
pulmonary,B
interstitial,I
infiltrates,I
(,O
5,O
%,O
),O
.,O
Although,O
large,O
-,O
dose,O
amiodarone,B
is,O
highly,O
effective,O
in,O
the,O
long,O
-,O
term,O
treatment,O
of,O
VT,B
or,O
VF,B
refractory,O
to,O
conventional,O
antiarrhythmic,O
drugs,O
",",O
it,O
causes,O
significant,O
toxicity,O
in,O
approximately,O
50,O
%,O
of,O
patients,O
.,O
However,O
",",O
when,O
the,O
dose,O
is,O
adjusted,O
based,O
on,O
clinical,O
response,O
or,O
the,O
development,O
of,O
adverse,O
effects,O
",",O
75,O
%,O
of,O
patients,O
with,O
VT,O
or,O
VF,O
can,O
be,O
successfully,O
managed,O
with,O
amiodarone,B
.,O
Why,O
may,O
epsilon,B
-,I
aminocaproic,I
acid,I
(,O
EACA,B
),O
induce,O
myopathy,O
in,O
man,O
?,O
Report,O
of,O
a,O
case,O
and,O
literature,O
review,O
.,O
A,O
case,O
of,O
necrotizing,O
myopathy,O
due,O
to,O
a,O
short,O
epsilon,B
-,I
aminocaproic,I
acid,I
(,O
EACA,B
),O
treatment,O
in,O
a,O
72,O
year,O
-,O
old,O
patient,O
with,O
subarachnoid,O
haemorrhage,O
(,O
SAH,O
),O
is,O
described,O
.,O
Pathogenetic,O
hypotheses,O
are,O
discussed,O
.,O
Cerebral,O
hemorrhage,O
associated,O
with,O
phenylpropanolamine,B
in,O
combination,O
with,O
caffeine,B
.,O
Phenylpropanolamine,B
(,O
PPA,O
),O
is,O
a,O
drug,O
that,O
has,O
been,O
associated,O
with,O
serious,O
side,O
effects,O
including,O
stroke,O
.,O
It,O
is,O
often,O
combined,O
with,O
caffeine,B
in,O
diet,O
preparations,O
and,O
look,O
-,O
alike,O
pills,O
.,O
In,O
order,O
to,O
determine,O
if,O
PPA,B
/,O
caffeine,B
can,O
lead,O
to,O
stroke,O
in,O
normotensive,O
and,O
/,O
or,O
hypertensive,O
rats,O
",",O
we,O
administered,O
the,O
combination,O
in,O
six,O
times,O
the,O
allowed,O
human,O
dose,O
calculated,O
on,O
a,O
per,O
weight,O
basis,O
for,O
the,O
rats,O
two,O
times,O
per,O
day,O
for,O
five,O
days,O
.,O
Subarachnoid,B
and,O
cerebral,B
hemorrhage,O
was,O
noted,O
in,O
18,O
%,O
of,O
the,O
hypertensive,O
rats,O
.,O
A,O
single,O
PPA,B
/,O
caffeine,B
administration,O
(,O
same,O
dose,O
),O
lead,O
to,O
acute,O
hypertension,O
in,O
both,O
the,O
normotensive,O
and,O
hypertensive,O
animals,O
.,O
These,O
results,O
suggest,O
that,O
PPA,B
/,O
caffeine,B
can,O
lead,O
to,O
cerebral,O
hemorrhage,O
in,O
previously,O
hypertensive,O
animals,O
when,O
administered,O
in,O
greater,O
than,O
the,O
allowed,O
dosage,O
.,O
An,O
acute,O
elevation,O
in,O
blood,O
pressure,O
may,O
be,O
a,O
contributing,O
factor,O
.,O
Renal,B
papillary,I
necrosis,I
due,O
to,O
naproxen,B
.,O
A,O
31,O
-,O
year,O
-,O
old,O
man,O
with,O
rheumatoid,O
arthritis,O
",",O
who,O
had,O
previously,O
been,O
treated,O
with,O
sulindac,B
",",O
fenoprofen,B
calcium,I
",",O
high,O
dose,O
salicylates,B
and,O
gold,B
salts,I
",",O
developed,O
renal,B
papillary,I
necrosis,I
(,O
RPN,B
),O
4,O
months,O
after,O
institution,O
of,O
naproxen,B
therapy,O
.,O
No,O
other,O
factor,O
predisposing,O
to,O
RPN,B
could,O
be,O
discovered,O
.,O
Sulindac,B
was,O
substituted,O
for,O
naproxen,B
and,O
no,O
further,O
adverse,O
renal,O
effects,O
occurred,O
over,O
the,O
next,O
12,O
months,O
.,O
We,O
review,O
previous,O
reports,O
linking,O
RPN,O
to,O
antiinflammatory,O
drug,O
use,O
and,O
discuss,O
possible,O
advantages,O
of,O
sulindac,B
in,O
patients,O
who,O
have,O
experienced,O
renal,O
toxicity,O
from,O
other,O
antiinflammatory,O
agents,O
.,O
Nephrotoxic,O
effects,O
of,O
aminoglycoside,B
treatment,O
on,O
renal,O
protein,O
reabsorption,O
and,O
accumulation,O
.,O
To,O
quantify,O
the,O
effects,O
of,O
gentamicin,B
",",O
kanamycin,B
and,O
netilmicin,B
on,O
renal,O
protein,O
reabsorption,O
and,O
accumulation,O
",",O
these,O
drugs,O
were,O
administered,O
to,O
rats,O
intraperitoneally,O
(,O
30,O
mg,O
/,O
kg,O
/,O
day,O
),O
for,O
7,O
",",O
14,O
or,O
21,O
days,O
.,O
Scanning,O
electron,O
microscopy,O
of,O
the,O
glomerular,O
endothelia,O
",",O
urinary,O
measurements,O
of,O
sodium,B
",",O
potassium,B
",",O
endogenous,O
lysozyme,B
",",O
N,B
-,I
acetyl,I
-,I
beta,I
-,I
D,I
-,I
glucosaminidase,I
(,O
NAG,B
),O
as,O
well,O
as,O
clearance,O
and,O
accumulation,O
experiments,O
after,O
i,O
.,O
v,O
.,O
administration,O
of,O
egg,B
-,I
white,I
lysozyme,I
and,O
measurements,O
of,O
inulin,B
clearance,O
(,O
GFR,B
),O
were,O
done,O
in,O
each,O
treatment,O
group,O
.,O
Gentamicin,B
administration,O
decreased,O
diameter,O
",",O
density,O
and,O
shape,O
of,O
endothelial,B
fenestrae,O
.,O
Kanamycin,B
and,O
netilmicin,B
appeared,O
to,O
have,O
no,O
effect,O
at,O
the,O
dose,O
used,O
.,O
All,O
three,O
aminoglycosides,B
decreased,O
GFR,B
and,O
increased,O
urinary,B
excretion,O
of,O
sodium,B
and,O
potassium,B
.,O
While,O
gentamicin,B
and,O
kanamycin,B
decreased,O
the,O
percentage,O
reabsorption,O
and,O
accumulation,O
of,O
lysozyme,B
after,O
i,O
.,O
v.,O
administration,O
of,O
egg,B
-,I
white,I
lysozyme,B
netilmicin,B
had,O
no,O
effect,O
.,O
Daily,O
excretion,O
of,O
total,O
protein,B
",",O
endogenous,O
lysozyme,B
and,O
NAG,B
increased,O
only,O
after,O
treatment,O
with,O
kanamycin,B
and,O
gentamicin,B
.,O
Thus,O
",",O
aminoglycosides,B
may,O
act,O
as,O
nephrotoxicants,O
at,O
glomerular,O
and,O
/,O
or,O
tubular,O
level,O
inducing,O
impairment,O
of,O
renal,O
reabsorption,O
and,O
accumulation,O
of,O
proteins,B
.,O
Induction,O
of,O
the,O
obstructive,O
sleep,O
apnea,O
syndrome,O
in,O
a,O
woman,O
by,O
exogenous,O
androgen,B
administration,O
.,O
We,O
documented,O
airway,O
occlusion,O
during,O
sleep,O
and,O
an,O
abnormally,O
high,O
supraglottic,O
resistance,O
while,O
awake,O
in,O
a,O
54,O
-,O
yr,O
-,O
old,O
woman,O
who,O
had,O
developed,O
physical,O
changes,O
and,O
the,O
syndrome,O
of,O
obstructive,O
sleep,O
apnea,O
while,O
being,O
administered,O
exogenous,O
androgens,B
.,O
When,O
the,O
androgens,B
were,O
withdrawn,O
",",O
the,O
patient,O
',O
s,O
physical,O
changes,O
",",O
symptoms,O
",",O
sleep,O
study,O
",",O
and,O
supraglottic,O
resistance,O
all,O
returned,O
to,O
normal,O
.,O
A,O
rechallenge,O
with,O
androgen,B
produced,O
symptoms,O
of,O
obstructive,O
sleep,O
apnea,O
that,O
abated,O
upon,O
withdrawal,O
of,O
the,O
hormone,O
.,O
Previous,O
reports,O
have,O
favored,O
a,O
role,O
of,O
androgens,B
in,O
the,O
pathogenesis,O
of,O
sleep,O
apnea,O
.,O
Our,O
report,O
provides,O
direct,O
evidence,O
for,O
this,O
role,O
.,O
Structural,O
and,O
functional,O
measurements,O
indicate,O
that,O
androgens,B
exert,O
a,O
permissive,O
or,O
necessary,O
action,O
on,O
the,O
structural,O
configuration,O
of,O
the,O
oropharynx,O
that,O
predisposes,O
to,O
obstruction,O
during,O
sleep,O
.,O
Development,O
of,O
the,O
obstructive,O
sleep,O
apnea,O
syndrome,O
must,O
be,O
considered,O
a,O
possible,O
side,O
effect,O
of,O
androgen,B
therapy,O
.,O
Cardiotoxic,B
and,O
possible,O
leukemogenic,O
effects,O
of,O
adriamycin,B
in,O
nonhuman,O
primates,O
.,O
10,O
monkeys,O
(,O
macaques,O
),O
received,O
adriamycin,B
by,O
monthly,O
intravenous,O
injections,O
at,O
12,O
mg,O
/,O
m2,O
(,O
1,O
mg,O
/,O
kg,O
),O
.,O
8,O
of,O
the,O
10,O
monkeys,O
developed,O
congestive,O
heart,O
failure,O
at,O
an,O
average,O
cumulative,O
adriamycin,B
dose,O
(,O
310,O
mg,O
/,O
m2,O
),O
well,O
below,O
that,O
considered,O
the,O
safe,O
upper,O
limit,O
(,O
550,O
mg,O
/,O
m2,O
),O
in,O
man,O
.,O
Histologically,O
",",O
the,O
myocardial,O
lesions,O
resembled,O
those,O
found,O
in,O
human,O
anthracycline,B
-,I
induced,I
cardiomyopathy,I
.,O
1,O
of,O
the,O
10,O
monkeys,O
developed,O
acute,O
myeloblastic,O
leukemia,B
after,O
receiving,O
324,O
mg,O
/,O
m2,O
of,O
adriamycin,B
;,O
the,O
10th,O
monkey,O
is,O
alive,O
and,O
well,O
26,O
months,O
after,O
the,O
last,O
dose,O
of,O
drug,O
.,O
Our,O
results,O
suggest,O
that,O
adriamycin,B
is,O
a,O
more,O
potent,O
cardiotoxin,O
in,O
monkeys,O
than,O
in,O
man,O
",",O
and,O
that,O
leukemia,O
may,O
be,O
a,O
consequence,O
of,O
prolonged,O
treatment,O
with,O
this,O
drug,O
.,O
Tricuspid,B
valve,I
regurgitation,I
and,O
lithium,B
carbonate,I
toxicity,I
in,O
a,O
newborn,O
infant,O
.,O
A,O
newborn,O
with,O
massive,O
tricuspid,B
regurgitation,I
",",O
atrial,B
flutter,I
",",O
congestive,O
heart,O
failure,O
",",O
and,O
a,O
high,O
serum,O
lithium,B
level,I
is,O
described,O
.,O
This,O
is,O
the,O
first,O
patient,O
to,O
initially,O
manifest,O
tricuspid,B
regurgitation,I
and,O
atrial,B
flutter,I
",",O
and,O
the,O
11th,O
described,O
patient,O
with,O
cardiac,O
disease,O
among,O
infants,O
exposed,O
to,O
lithium,B
compounds,I
in,O
the,O
first,O
trimester,O
of,O
pregnancy,O
.,O
Sixty,O
-,O
three,O
percent,O
of,O
these,O
infants,O
had,O
tricuspid,B
valve,I
involvement,O
.,O
Lithium,B
carbonate,I
may,O
be,O
a,O
factor,O
in,O
the,O
increasing,O
incidence,O
of,O
congenital,B
heart,I
disease,I
when,O
taken,O
during,O
early,O
pregnancy,O
.,O
It,O
also,O
causes,O
neurologic,O
depression,O
",",O
cyanosis,B
",",O
and,O
cardiac,B
arrhythmia,I
when,O
consumed,O
prior,O
to,O
delivery,O
.,O
Effects,O
of,O
the,O
novel,O
compound,O
aniracetam,B
(,O
Ro,B
13,I
-,I
5057,I
),O
upon,O
impaired,O
learning,O
and,O
memory,O
in,O
rodents,O
.,O
The,O
effect,O
of,O
aniracetam,B
(,O
Ro,B
13,I
-,I
5057,I
",",O
1,O
-,O
anisoyl,B
-,I
2,I
-,I
pyrrolidinone,I
),O
was,O
studied,O
on,O
various,O
forms,O
of,O
experimentally,O
impaired,O
cognitive,O
functions,O
(,O
learning,O
and,O
memory,O
),O
in,O
rodents,O
and,O
produced,O
the,O
following,O
effects,O
:,O
(,O
1,O
),O
almost,O
complete,O
prevention,O
of,O
the,O
incapacity,O
to,O
learn,O
a,O
discrete,O
escape,O
response,O
in,O
rats,O
exposed,O
to,O
sublethal,O
hypercapnia,B
immediately,O
before,O
the,O
acquisition,O
session,O
;,O
(,O
2,O
),O
partial,O
(,O
rats,O
),O
or,O
complete,O
(,O
mice,O
),O
prevention,O
of,O
the,O
scopolamine,B
-,I
induced,O
short,O
-,O
term,O
amnesia,O
for,O
a,O
passive,O
avoidance,O
task,O
;,O
(,O
3,O
),O
complete,O
protection,O
against,O
amnesia,O
for,O
a,O
passive,O
avoidance,O
task,O
in,O
rats,O
submitted,O
to,O
electroconvulsive,O
shock,O
immediately,O
after,O
avoidance,O
acquisition,O
;,O
(,O
4,O
),O
prevention,O
of,O
the,O
long,O
-,O
term,O
retention,O
-,O
or,O
retrieval,O
-,O
deficit,O
for,O
a,O
passive,O
avoidance,O
task,O
induced,O
in,O
rats,O
and,O
mice,O
by,O
chloramphenicol,B
or,O
cycloheximide,B
administered,O
immediately,O
after,O
acquisition,O
;,O
(,O
5,O
),O
reversal,O
",",O
when,O
administered,O
as,O
late,O
as,O
1,O
h,O
before,O
the,O
retention,O
test,O
",",O
of,O
the,O
deficit,O
in,O
retention,O
or,O
retrieval,O
of,O
a,O
passive,O
avoidance,O
task,O
induced,O
by,O
cycloheximide,B
injected,O
2,O
days,O
previously,O
;,O
(,O
6,O
),O
prevention,O
of,O
the,O
deficit,O
in,O
the,O
retrieval,O
of,O
an,O
active,O
avoidance,O
task,O
induced,O
in,O
mice,O
by,O
subconvulsant,O
electroshock,O
or,O
hypercapnia,B
applied,O
immediately,O
before,O
retrieval,O
testing,O
(,O
24,O
h,O
after,O
acquisition,O
),O
.,O
These,O
improvements,O
or,O
normalizations,O
of,O
impaired,O
cognitive,O
functions,O
were,O
seen,O
at,O
oral,O
aniracetam,B
doses,O
of,O
10,O
-,O
100,O
mg,O
/,O
kg,O
.,O
Generally,O
",",O
the,O
dose,O
-,O
response,O
curves,O
were,O
bell,O
-,O
shaped,O
.,O
The,O
mechanisms,O
underlying,O
the,O
activity,O
of,O
aniracetam,B
and,O
its,O
',O
therapeutic,O
window,O
',O
are,O
unknown,O
.,O
Piracetam,B
",",O
another,O
pyrrolidinone,B
derivative,O
was,O
used,O
for,O
comparison,O
.,O
It,O
was,O
active,O
only,O
in,O
six,O
of,O
nine,O
tests,O
and,O
had,O
about,O
one,O
-,O
tenth,O
the,O
potency,O
of,O
aniracetam,B
.,O
The,O
results,O
indicate,O
that,O
aniracetam,B
improves,O
cognitive,O
functions,O
which,O
are,O
impaired,O
by,O
different,O
procedure,O
and,O
in,O
different,O
phases,O
of,O
the,O
learning,O
and,O
memory,O
process,O
.,O
Effect,O
of,O
calcium,B
chloride,I
on,O
gross,O
behavioural,O
changes,O
produced,O
by,O
carbachol,B
and,O
eserine,B
in,O
cats,O
.,O
The,O
effect,O
of,O
calcium,B
chloride,I
injected,O
into,O
the,O
cerebral,O
ventricles,O
of,O
group,O
-,O
housed,O
unanaesthetized,O
cats,O
upon,O
vocalization,O
(,O
rage,O
",",O
hissing,O
and,O
snarling,O
),O
",",O
fighting,O
(,O
attack,O
with,O
paws,O
and,O
claws,O
",",O
defense,O
with,O
paws,O
and,O
claws,O
and,O
biting,O
),O
",",O
mydriasis,O
",",O
tremor,O
and,O
clonic,O
-,O
tonic,O
convulsions,O
produced,O
by,O
carbachol,B
and,O
eserine,B
injected,O
similarly,O
was,O
investigated,O
.,O
Calcium,B
chloride,I
depressed,O
or,O
almost,O
completely,O
abolished,O
the,O
vocalization,O
and,O
fighting,O
due,O
to,O
carbachol,B
and,O
eserine,B
.,O
On,O
the,O
other,O
hand,O
",",O
mydriasis,O
",",O
tremor,O
and,O
clonic,O
-,O
tonic,O
convulsions,O
evoked,O
by,O
carbachol,B
and,O
eserine,B
were,O
not,O
significantly,O
changed,O
by,O
calcium,B
chloride,I
.,O
It,O
is,O
apparent,O
that,O
calcium,B
chloride,I
can,O
dissociate,O
vocalization,O
and,O
fighting,O
from,O
autonomic,O
and,O
motor,O
phenomena,O
such,O
as,O
mydriasis,O
",",O
tremor,O
and,O
clonic,O
-,O
tonic,O
convulsions,O
caused,O
by,O
carbachol,B
and,O
eserine,B
.,O
Calcium,B
chloride,I
inhibited,O
the,O
vocalization,O
and,O
fighting,O
produced,O
by,O
carbachol,B
and,O
eserine,B
most,O
probably,O
by,O
a,O
nonspecific,O
stabilizing,O
action,O
on,O
central,O
muscarinic,O
cholinoceptive,O
sites,O
.,O
These,O
results,O
further,O
support,O
the,O
view,O
that,O
calcium,B
ions,I
in,O
excess,O
have,O
an,O
atropine,O
-,O
like,O
action,O
also,O
in,O
the,O
central,O
nervous,O
system,O
.,O
Thiazide,B
diuretics,I
",",O
hypokalemia,B
and,O
cardiac,O
arrhythmias,O
.,O
Thiazide,B
diuretics,I
are,O
widely,O
accepted,O
as,O
the,O
cornerstone,O
of,O
antihypertensive,O
treatment,O
programs,O
.,O
Hypokalemia,B
is,O
a,O
commonly,O
encountered,O
metabolic,O
consequence,O
of,O
chronic,O
thiazide,B
therapy,O
.,O
We,O
treated,O
38,O
patients,O
(,O
22,O
low,O
renin,O
",",O
16,O
normal,O
renin,O
),O
with,O
moderate,O
diastolic,O
hypertension,O
with,O
hydrochlorothiazide,B
(,O
HCTC,B
),O
administered,O
on,O
a,O
twice,O
daily,O
schedule,O
.,O
Initial,O
dose,O
was,O
50,O
mg,O
and,O
the,O
dose,O
was,O
increased,O
at,O
monthly,O
intervals,O
to,O
100,O
mg,O
",",O
150,O
mg,O
and,O
200,O
mg,O
daily,O
until,O
blood,O
pressure,O
normalized,O
.,O
The,O
serum,O
K,B
during,O
the,O
control,O
period,O
was,O
4,O
.,O
5,O
+,O
/,O
-,O
0,O
.,O
2,O
mEq,O
/,O
l,O
an,O
on,O
50,O
",",O
100,O
",",O
150,O
and,O
200,O
mg,O
HCTZ,B
daily,O
3,O
.,O
9,O
+,O
/,O
-,O
0,O
.,O
3,O
",",O
3,O
0.4,O
+,O
/,O
-,O
0,O
.,O
2,O
",",O
and,O
2,O
.,O
4,O
+,O
/,O
-,O
0,O
.,O
3,O
mEq,O
/,O
l,O
",",O
respectively,O
.,O
Corresponding,O
figures,O
for,O
whole,O
body,O
K,B
were,O
4107,O
+,O
/,O
-,O
208,O
",",O
3722,O
+,O
/,O
-,O
319,O
",",O
3628,O
+,O
/,O
-,O
257,O
",",O
3551,O
+,O
/,O
-,O
336,O
",",O
and,O
3269,O
+,O
/,O
-,O
380,O
mEq,O
",",O
respectively,O
.,O
In,O
13,O
patients,O
we,O
observed,O
the,O
effects,O
of,O
HCTZ,B
therapy,O
(,O
100,O
mg,O
daily,O
),O
on,O
the,O
occurrence,O
of,O
PVC,B
',O
s,O
during,O
rest,O
as,O
well,O
as,O
during,O
static,O
and,O
dynamic,O
exercise,O
.,O
During,O
rest,O
we,O
observed,O
0,O
.,O
6,B
+,O
/,O
-,O
0,O
.,O
8,O
PVC,B
beats,O
/,O
min,O
+,O
/,O
-,O
SEM,O
and,O
during,O
static,O
and,O
dynamic,O
exercise,O
0,O
.,O
6,B
+,O
/,O
-,O
0,O
.,O
6,O
and,O
0,O
.,O
8,O
+,O
/,O
-,O
0,O
.,O
15,O
",",O
respectively,O
.,O
Corresponding,O
figures,O
during,O
HCTZ,B
therapy,O
100,O
mg,O
daily,O
were,O
1,O
.,O
4,B
+,O
/,O
-,O
0,O
.,O
1,O
",",O
3,O
.,O
6,B
+,O
/,O
-,O
0,O
.,O
7,O
and,O
5,B
.,O
7,I
4,I
/,I
-,I
0,I
.,I
8,I
",",O
respectively,O
.,O
The,O
occurrence,O
of,O
PVC,B
',O
s,O
correlated,O
significantly,O
with,O
the,O
fall,O
in,O
serum,O
K,B
+,O
observed,O
r,O
=,O
0,O
.,O
72,O
",",O
p,O
less,O
than,O
0,O
.,O
1,O
.,O
In,O
conclusion,O
we,O
found,O
that,O
thiazide,B
diuretics,I
cause,O
hypokalemia,O
and,O
depletion,O
of,O
body,O
potassium,O
.,O
The,O
more,O
profound,O
hypokalemia,O
",",O
the,O
greater,O
the,O
propensity,O
for,O
the,O
occurrence,O
of,O
PVC,B
',O
s,O
.,O
Circulating,O
lysosomal,O
enzymes,O
and,O
acute,O
hepatic,O
necrosis,O
.,O
The,O
activities,O
of,O
the,O
lysosomal,O
enzymes,O
acid,B
and,O
neutral,O
protease,O
",",O
N,B
-,I
acetylglucosaminidase,I
",",O
and,O
acid,B
phosphatase,I
were,O
measured,O
in,O
the,O
serum,O
of,O
patients,O
with,O
fulminant,O
hepatic,O
failure,O
.,O
Acid,B
protease,I
(,O
cathepsin,B
D,I
),O
activity,O
was,O
increased,O
about,O
tenfold,O
in,O
patients,O
who,O
died,O
and,O
nearly,O
fourfold,O
in,O
those,O
who,O
survived,O
fulminant,O
hepatic,O
failure,O
after,O
paracetamol,B
overdose,I
",",O
whereas,O
activities,O
were,O
increased,O
equally,O
in,O
patients,O
with,O
fulminant,O
hepatic,O
failure,O
due,O
to,O
viral,B
hepatitis,I
whether,O
or,O
not,O
they,O
survived,O
.,O
A,O
correlation,O
was,O
found,O
between,O
serum,O
acid,B
protease,I
activity,I
and,O
prothrombin,O
time,O
",",O
and,O
the,O
increase,O
in,O
cathepsin,B
D,I
activity,I
was,O
sustained,O
over,O
several,O
days,O
compared,O
with,O
aspartate,B
aminotransferase,I
",",O
which,O
showed,O
a,O
sharp,O
early,O
peak,O
and,O
then,O
a,O
fall,O
.,O
Circulating,O
lysosomal,B
proteases,I
can,O
damage,O
other,O
organs,O
",",O
and,O
measurement,O
of,O
their,O
activity,O
may,O
therefore,O
be,O
of,O
added,O
value,O
in,O
assessing,O
prognosis,O
in,O
this,O
condition,O
.,O
Hepatic,B
veno,I
-,I
occlusive,I
disease,I
caused,O
by,O
6,B
-,I
thioguanine,I
.,O
Clinically,O
reversible,O
veno,B
-,I
occlusive,I
disease,I
of,O
the,O
liver,B
developed,O
in,O
a,O
23,O
-,O
year,O
-,O
old,O
man,O
with,O
acute,O
lymphocytic,O
leukemia,O
after,O
10,O
months,O
of,O
maintenance,O
therapy,O
with,O
6,B
-,I
thioguanine,I
.,O
Serial,O
liver,B
biopsies,O
showed,O
the,O
development,O
and,O
resolution,O
of,O
intense,O
sinusoidal,O
engorgement,O
.,O
Although,O
this,O
disease,O
was,O
clinically,O
reversible,O
",",O
some,O
subintimal,O
fibrosis,O
about,O
the,O
terminal,O
hepatic,O
veins,O
persisted,O
.,O
This,O
case,O
presented,O
a,O
unique,O
opportunity,O
to,O
observe,O
the,O
histologic,O
features,O
of,O
clinically,O
reversible,O
hepatic,O
veno,B
-,I
occlusive,I
disease,I
over,O
time,O
",",O
and,O
may,O
be,O
the,O
first,O
case,O
of,O
veno,B
-,I
occlusive,I
related,O
solely,O
to,O
6,B
-,I
thioguanine,I
.,O
Chlorpropamide,B
-,O
induced,O
optic,B
neuropathy,I
.,O
A,O
65,O
-,O
year,O
-,O
old,O
woman,O
with,O
adult,O
-,O
onset,O
diabetes,O
treated,O
with,O
chlorpropamide,B
(,O
Diabenese,B
),O
had,O
a,O
toxic,O
optic,B
neuropathy,I
that,O
resolved,O
with,O
discontinuation,O
of,O
chlorpropamide,B
therapy,O
.,O
Visual,O
loss,O
occurs,O
in,O
diabetics,O
for,O
a,O
variety,O
of,O
reasons,O
",",O
and,O
accurate,O
diagnosis,O
is,O
necessary,O
to,O
institute,O
appropriate,O
therapy,O
.,O
The,O
possibility,O
of,O
a,O
drug,B
-,O
induced,O
optic,O
neuropathy,O
should,O
be,O
considered,O
in,O
the,O
differential,O
diagnosis,O
of,O
visual,O
loss,O
in,O
diabetics,O
.,O
Plasma,O
and,O
urinary,O
lipids,B
and,O
lipoproteins,O
during,O
the,O
development,O
of,O
nephrotic,O
syndrome,O
induced,O
in,O
the,O
rat,O
by,O
puromycin,B
aminonucleoside,I
.,O
This,O
study,O
was,O
undertaken,O
to,O
ascertain,O
whether,O
the,O
alterations,O
of,O
plasma,O
lipoproteins,O
found,O
in,O
nephrotic,O
syndrome,O
induced,O
by,O
puromycin,B
aminonucleoside,I
were,O
due,O
to,O
nephrotic,O
syndrome,O
per,O
se,O
",",O
or,O
",",O
at,O
least,O
in,O
part,O
",",O
to,O
the,O
aminonucleoside,O
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
changes,O
in,O
plasma,B
and,O
urinary,B
lipoproteins,O
during,O
the,O
administration,O
of,O
puromycin,B
aminonucleoside,I
(,O
20,O
mg,O
/,O
kg,O
for,O
7,O
days,O
),O
and,O
the,O
subsequent,O
development,O
of,O
nephrotic,B
syndrome,O
.,O
Since,O
massive,O
albuminuria,B
occurred,O
after,O
6,O
days,O
of,O
treatment,O
",",O
the,O
time,O
-,O
course,O
study,O
was,O
divided,O
into,O
two,O
stages,O
:,O
pre,O
-,O
nephrotic,B
stage,O
(,O
day,O
1,O
-,O
5,O
),O
and,O
nephrotic,B
stage,O
(,O
day,O
6,O
-,O
11,O
),O
.,O
In,O
pre,O
-,O
nephrotic,O
stage,O
the,O
plasma,O
level,O
of,O
fatty,B
acids,I
",",O
triacylglycerol,B
and,O
VLDL,B
decreased,O
while,O
that,O
of,O
phospholipid,B
",",O
cholesteryl,B
esters,I
and,O
HDL,B
remained,O
constant,O
.,O
Plasma,O
apolipoprotein,B
A,I
-,I
I,I
tended,O
to,O
increase,O
(,O
40,O
%,O
increase,O
at,O
day,O
5,O
),O
.,O
At,O
the,O
beginning,O
of,O
nephrotic,O
stage,O
(,O
day,O
6,O
),O
the,O
concentration,O
of,O
plasma,O
albumin,B
dropped,O
to,O
a,O
very,O
low,O
level,O
",",O
while,O
that,O
of,O
apolipoprotein,B
A,I
-,I
I,I
increased,O
abruptly,O
(,O
4,O
-,O
fold,O
increase,O
),O
and,O
continued,O
to,O
rise,O
",",O
although,O
less,O
steeply,O
",",O
in,O
the,O
following,O
days,O
.,O
The,O
plasma,O
concentration,O
of,O
HDL,B
followed,O
the,O
same,O
pattern,O
.,O
Plasma,O
VLDL,B
and,O
LDL,B
increased,O
at,O
a,O
later,O
stage,O
(,O
day,O
9,O
),O
.,O
Plasma,O
apolipoprotein,O
A,O
-,O
I,O
was,O
found,O
not,O
only,O
in,O
HDL,B
(,O
1,O
.,O
63,O
-,O
1,O
.,O
210,O
g,O
/,O
ml,O
),O
but,O
also,O
in,O
the,O
LDL,B
density,O
class,O
(,O
1,O
.,O
25,O
-,O
1,O
.,O
50,O
g,O
/,O
ml,O
),O
.,O
In,O
the,O
pre,O
-,O
nephrotic,O
stage,O
lipoproteinuria,O
was,O
negligible,O
",",O
while,O
in,O
the,O
early,O
nephrotic,O
stage,O
the,O
urinary,O
loss,O
of,O
plasma,O
lipoproteins,O
consisted,O
mainly,O
of,O
HDL,B
.,O
These,O
observations,O
indicate,O
that,O
puromycin,B
aminonucleoside,I
alters,O
plasma,O
lipoproteins,O
by,O
lowering,O
VLDL,B
and,O
increasing,O
HDL,B
.,O
It,O
is,O
likely,O
that,O
the,O
early,O
and,O
striking,O
increase,O
of,O
plasma,O
HDL,B
found,O
in,O
nephrotic,O
rats,O
is,O
related,O
to,O
a,O
direct,O
effect,O
of,O
the,O
drug,O
on,O
HDL,B
metabolism,O
.,O
Fatal,O
aplastic,O
anemia,O
following,O
topical,O
administration,O
of,O
ophthalmic,O
chloramphenicol,B
.,O
A,O
73,O
-,O
year,O
-,O
old,O
woman,O
died,O
of,O
aplastic,B
anemia,I
less,O
than,O
two,O
months,O
after,O
undergoing,O
cataract,O
extraction,O
and,O
beginning,O
topical,O
therapy,O
with,O
chloramphenicol,B
.,O
The,O
first,O
signs,O
of,O
pancytopenia,B
began,O
within,O
one,O
month,O
of,O
the,O
surgery,O
.,O
The,O
pattern,O
of,O
the,O
aplastic,B
anemia,I
was,O
associated,O
with,O
an,O
idiosyncratic,O
response,O
to,O
chloramphenicol,B
.,O
This,O
was,O
the,O
second,O
report,O
of,O
fatal,O
aplastic,O
anemia,O
after,O
topical,O
treatment,O
with,O
chloramphenicol,B
for,O
ocular,O
conditions,O
",",O
although,O
two,O
cases,O
of,O
reversible,O
bone,O
marrow,O
hypoplasia,O
have,O
also,O
been,O
reported,O
.,O
Any,O
other,O
suspected,O
cases,O
of,O
ocular,O
toxicity,O
associated,O
with,O
topically,O
applied,O
chloramphenicol,B
should,O
be,O
reported,O
to,O
the,O
National,O
Registry,O
of,O
Drug,O
-,O
Induced,O
Ocular,O
Side,O
Effects,O
",",O
Oregon,O
Health,O
Sciences,O
University,O
",",O
Portland,O
",",O
OR,O
97201,O
.,O
Midazolam,B
compared,O
with,O
thiopentone,B
as,O
an,O
induction,O
agent,O
.,O
In,O
patients,O
premedicated,O
with,O
scopolamine,B
+,O
morphine,B
(,O
+,O
5,O
mg,O
nitrazepam,B
the,O
evening,O
before,O
surgery,O
),O
",",O
the,O
sleep,O
-,O
inducing,O
effect,O
of,O
midazolam,B
0,O
.,O
15,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
was,O
clearly,O
slower,O
in,O
onset,O
than,O
that,O
of,O
thiopentone,B
4,O
.,O
67,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
Somewhat,O
fewer,O
cardiovascular,O
and,O
local,O
sequelae,O
were,O
found,O
in,O
the,O
midazolam,B
group,O
",",O
but,O
",",O
although,O
apnoea,O
occurred,O
less,O
often,O
in,O
the,O
midazolam,B
group,O
it,O
lasted,O
longer,O
.,O
On,O
the,O
whole,O
",",O
the,O
differences,O
between,O
midazolam,B
and,O
thiopentone,B
had,O
no,O
apparent,O
clinical,O
consequences,O
.,O
Midazolam,B
is,O
a,O
new,O
alternative,O
agent,O
for,O
induction,O
in,O
combination,O
anaesthesia,O
.,O
Extrapyramidal,B
side,I
effects,I
and,O
oral,O
haloperidol,B
:,O
an,O
analysis,O
of,O
explanatory,O
patient,O
and,O
treatment,O
characteristics,O
.,O
The,O
incidence,O
of,O
extrapyramidal,B
side,I
effects,I
(,O
EPS,B
),O
was,O
evaluated,O
in,O
98,O
patients,O
treated,O
with,O
haloperidol,B
.,O
The,O
incidence,O
of,O
parkinsonism,B
was,O
higher,O
at,O
higher,O
doses,O
of,O
haloperidol,B
and,O
in,O
younger,O
patients,O
.,O
Prophylactic,O
antiparkinsonian,B
medication,O
was,O
effective,O
in,O
younger,O
but,O
not,O
in,O
older,O
patients,O
.,O
However,O
",",O
these,O
medications,O
were,O
more,O
effective,O
in,O
both,O
young,O
and,O
old,O
patients,O
when,O
given,O
after,O
parkinsonism,B
developed,O
.,O
Akathisia,O
was,O
controlled,O
by,O
the,O
benzodiazepine,B
lorazepam,I
in,O
14,O
out,O
of,O
16,O
patients,O
",",O
while,O
prophylactic,O
antiparkinsonians,O
were,O
ineffective,O
.,O
The,O
present,O
study,O
points,O
to,O
patient,O
characteristics,O
that,O
may,O
be,O
of,O
significance,O
in,O
the,O
development,O
of,O
EPS,O
due,O
to,O
haloperidol,B
.,O
Deaths,O
from,O
local,O
anesthetic,B
-,I
induced,I
convulsions,I
in,O
mice,O
.,O
Median,O
convulsant,O
(,O
CD50,B
),O
and,O
median,O
lethal,O
(,O
LD50,B
),O
doses,O
of,O
three,O
representative,O
local,O
anesthetics,O
were,O
determined,O
in,O
adult,O
mice,O
to,O
evaluate,O
the,O
threat,O
to,O
life,O
of,O
local,O
anesthetic,O
-,O
induced,O
convulsions,O
.,O
The,O
CD50,B
and,O
LD50,B
",",O
respectively,O
",",O
were,O
57,O
.,O
7,O
and,O
58,O
.,O
7,O
mg,O
/,O
kg,O
for,O
bupivacaine,B
",",O
111,O
.,O
0,O
and,O
133,O
.,O
1,O
mg,O
/,O
kg,O
for,O
lidocaine,B
",",O
and,O
243,O
.,O
4,O
and,O
266,O
.,O
5,O
mg,O
/,O
kg,O
for,O
chloroprocaine,B
.,O
When,O
given,O
intraperitoneally,O
",",O
bupivacaine,B
thus,O
was,O
only,O
about,O
twice,O
as,O
toxic,O
as,O
lidocaine,B
and,O
four,O
times,O
as,O
toxic,O
as,O
chloroprocaine,B
.,O
Convulsions,O
always,O
preceded,O
death,O
",",O
except,O
after,O
precipitous,O
cardiopulmonary,O
arrest,O
from,O
extreme,O
doses,O
.,O
A,O
CD50,O
dose,O
of,O
local,B
anesthetic,I
(,O
causing,O
convulsions,O
in,O
50,O
%,O
of,O
mice,O
),O
was,O
fatal,O
in,O
90,O
%,O
of,O
bupivacaine,B
-,O
induced,O
seizures,O
",",O
in,O
57,O
%,O
of,O
the,O
chloroprocaine,B
group,O
",",O
and,O
in,O
6,O
%,O
of,O
the,O
lidocaine,B
group,O
.,O
The,O
narrow,O
gap,O
between,O
convulsant,O
and,O
lethal,O
doses,O
of,O
local,B
anesthetics,I
indicates,O
that,O
untreated,O
convulsions,O
present,O
much,O
more,O
of,O
a,O
threat,O
to,O
life,O
than,O
heretofore,O
appreciated,O
.,O
REM,B
sleep,I
deprivation,I
changes,O
behavioral,O
response,O
to,O
catecholaminergic,B
and,O
serotonergic,B
receptor,I
activation,I
in,O
rats,O
.,O
The,O
effects,O
of,O
REM,B
sleep,I
deprivation,I
(,O
REMD,B
),O
on,O
apomorphine,B
-,O
induced,O
aggressiveness,O
and,O
quipazine,B
-,O
induced,O
head,O
twitches,O
in,O
rats,O
were,O
determined,O
.,O
Forty,O
-,O
eight,O
hr,O
of,O
REMD,B
increased,O
apomorphine,B
-,O
induced,O
aggressiveness,O
",",O
and,O
reduced,O
(,O
immediately,O
after,O
completing,O
of,O
REMD,B
),O
or,O
increased,O
(,O
96,O
hr,O
after,O
completing,O
of,O
REMD,B
),O
quipazine,B
-,O
induced,O
head,O
twitches,O
.,O
Results,O
are,O
discussed,O
in,O
terms,O
of,O
similarity,O
to,O
pharmacological,O
effects,O
of,O
other,O
antidepressive,O
treatments,O
.,O
Fatal,O
aplastic,O
anemia,O
due,O
to,O
indomethacin,B
-,O
-,O
lymphocyte,O
transformation,O
tests,O
in,O
vitro,O
.,O
Although,O
indomethacin,B
has,O
been,O
implicated,O
as,O
a,O
possible,O
cause,O
of,O
aplastic,O
anemia,O
on,O
the,O
basis,O
of,O
a,O
few,O
clinical,O
observations,O
",",O
its,O
role,O
has,O
not,O
been,O
definitely,O
established,O
.,O
A,O
case,O
of,O
fatal,O
aplastic,B
anemia,I
is,O
described,O
in,O
which,O
no,O
drugs,O
other,O
than,O
allopurinol,B
and,O
indomethacin,B
were,O
given,O
.,O
Indomethacin,B
was,O
first,O
given,O
four,O
weeks,O
prior,O
to,O
the,O
onset,O
of,O
symptoms,O
.,O
A,O
positive,O
lymphocyte,O
transformation,O
test,O
with,O
indomethacin,B
in,O
vitro,O
further,O
substantiates,O
the,O
potential,O
role,O
of,O
this,O
drug,O
in,O
causing,O
aplastic,B
anemia,I
in,O
a,O
susceptible,O
patient,O
.,O
Fortunately,O
",",O
this,O
seems,O
to,O
be,O
a,O
very,O
rare,O
complication,O
.,O
Dose,O
-,O
effect,O
and,O
structure,O
-,O
function,O
relationships,O
in,O
doxorubicin,B
cardiomyopathy,O
.,O
The,O
cardiomyopathy,O
(,O
CM,O
),O
produced,O
by,O
the,O
anticancer,O
drug,O
doxorubicin,B
(,O
DXR,O
),O
(,O
Adriamycin,O
),O
provides,O
a,O
unique,O
opportunity,O
to,O
analyze,O
dose,O
-,O
effect,O
and,O
structure,O
-,O
function,O
relationships,O
during,O
development,O
of,O
myocardial,O
disease,O
.,O
We,O
measured,O
the,O
degree,O
of,O
morphologic,O
damage,O
by,O
ultrastructural,O
examination,O
of,O
endomyocardial,O
biopsy,O
and,O
the,O
degree,O
of,O
performance,O
abnormally,O
by,O
right,O
heart,O
catheterization,O
in,O
patients,O
receiving,O
DXR,B
.,O
Morphologic,O
damage,O
was,O
variable,O
but,O
was,O
proportional,O
to,O
the,O
total,O
cumulative,O
DXR,B
dose,O
between,O
100,O
and,O
600,O
mg,O
/,O
m2,O
.,O
Performance,O
abnormalities,O
correlated,O
weakly,O
with,O
dose,O
",",O
exhibited,O
a,O
curvilinear,O
relationship,O
",",O
and,O
had,O
a,O
threshold,B
for,O
expression,O
.,O
Catheterization,O
abnormalities,O
correlated,O
well,O
with,O
morphologic,B
damage,O
(,O
r,O
=,O
0,O
.,O
57,O
to,O
0,O
.,O
78,O
),O
in,O
a,O
subgroup,O
of,O
patients,O
in,O
whom,O
exercise,O
hemodynamics,O
were,O
measured,O
",",O
and,O
this,O
relationship,O
also,O
exhibited,O
a,O
curvilinear,O
",",O
threshold,B
configuration,O
.,O
In,O
DXR,B
-,O
CM,O
myocardial,O
damage,O
is,O
proportional,O
to,O
the,O
degree,O
of,O
cytotoxic,O
insult,O
(,O
DXR,B
dose,O
),O
while,O
myocardial,O
function,O
is,O
preserved,O
until,O
a,O
critical,O
dose,O
or,O
degree,O
of,O
damage,O
is,O
reached,O
",",O
after,O
which,O
myocardial,O
performance,O
deteriorates,O
rapidly,O
.,O
Massive,O
cerebral,O
edema,O
associated,O
with,O
fulminant,O
hepatic,O
failure,O
in,O
acetaminophen,B
overdose,O
:,O
possible,O
role,O
of,O
cranial,O
decompression,O
.,O
Cerebral,B
edema,I
may,O
complicate,O
the,O
course,O
of,O
fulminant,O
hepatic,O
failure,O
.,O
Response,O
to,O
conventional,O
therapy,O
has,O
been,O
disappointing,O
.,O
We,O
present,O
a,O
patient,O
with,O
fatal,O
acetaminophen,B
-,I
induced,O
fulminant,O
hepatic,O
failure,O
",",O
with,O
signs,O
and,O
symptoms,O
of,O
cerebral,B
edema,I
",",O
unresponsive,O
to,O
conventional,O
medical,O
therapy,O
.,O
Cranial,O
decompression,O
was,O
carried,O
out,O
.,O
A,O
justification,O
of,O
the,O
need,O
for,O
further,O
evaluation,O
of,O
cranial,O
decompression,O
in,O
such,O
patients,O
is,O
presented,O
.,O
Subjective,O
assessment,O
of,O
sexual,O
dysfunction,O
of,O
patients,O
on,O
long,O
-,O
term,O
administration,O
of,O
digoxin,B
.,O
Various,O
data,O
suggest,O
that,O
male,O
patients,O
who,O
have,O
received,O
digoxin,B
on,O
a,O
longterm,O
basis,O
have,O
increased,O
levels,O
of,O
serum,O
estrogen,B
and,O
decreased,O
levels,O
of,O
plasma,O
testosterone,B
and,O
luteinizing,B
hormone,I
(,I
LH,I
),I
.,O
This,O
study,O
was,O
undertaken,O
to,O
investigate,O
the,O
links,O
between,O
the,O
long,O
-,O
term,O
administration,O
of,O
digoxin,B
therapy,O
and,O
sexual,O
behavior,O
",",O
and,O
the,O
effect,O
of,O
digoxin,B
on,O
plasma,O
levels,O
of,O
estradiol,B
",",O
testosterone,B
",",O
and,O
LH,B
.,O
The,O
patients,O
of,O
the,O
study,O
and,O
control,O
group,O
(,O
without,O
digoxin,B
),O
were,O
of,O
similar,O
cardiac,O
functional,O
capacity,O
and,O
age,O
(,O
25,O
-,O
40,O
years,O
),O
and,O
were,O
randomly,O
selected,O
from,O
the,O
rheumatic,O
heart,O
disease,O
patients,O
.,O
A,O
subjective,O
assessment,O
of,O
sexual,O
behavior,O
in,O
the,O
study,O
and,O
control,O
groups,O
was,O
carried,O
out,O
",",O
using,O
parameters,O
such,O
as,O
sexual,O
desire,O
",",O
sexual,O
excitement,O
",",O
and,O
frequency,O
of,O
sexual,O
relations,O
. Personal,O
interviews,O
and,O
a,O
questionnaire,O
were,O
also,O
used,O
for,O
the,O
evaluation,O
of,O
sexual,O
behavior,O
. The,O
findings,O
support,O
the,O
reports,O
concerning,O
digoxin,B
effect,O
on,O
plasma,O
estradiol,B
",",O
testosterone,B
",",O
and,O
LH,B
.,O
The,O
differences,O
in,O
the,O
means,O
were,O
significant,O
.,O
Tests,O
used,O
to,O
evaluate,O
the,O
changes,O
in,O
sexual,O
behavior,O
showed,O
a,O
significant,O
decrease,O
in,O
sexual,O
desire,O
",",O
sexual,O
excitement,O
phase,O
(,O
erection,O
),O
",",O
and,O
frequency,O
of,O
sexual,O
relations,O
in,O
the,O
study,O
group,O
.,O
Endometrial,B
carcinoma,I
after,O
Hodgkin,B
disease,I
in,O
childhood,O
.,O
A,O
34,O
-,O
year,O
-,O
old,O
patient,O
developed,O
metastic,B
endometrial,I
carcinoma,I
after,O
Hodgkin,O
disease,O
in,O
childhood,O
.,O
She,O
had,O
ovarian,B
failure,I
after,O
abdominal,O
irradiation,O
and,O
chemotherapy,O
for,O
Hodgkin,O
disease,O
",",O
and,O
received,O
exogenous,O
estrogens,B
",",O
a,O
treatment,O
implicated,O
in,O
the,O
development,O
of,O
endometrial,B
cancer,I
in,O
menopausal,O
women,O
.,O
Young,O
women,O
on,O
replacement,O
estrogens,B
for,O
ovarian,O
failure,O
after,O
cancer,O
therapy,O
may,O
also,O
have,O
increased,O
risk,O
of,O
endometrial,B
carcinoma,I
and,O
should,O
be,O
examined,O
periodically,O
.,O
Long,O
-,O
term,O
lithium,B
treatment,O
and,O
the,O
kidney,O
.,O
Interim,O
report,O
on,O
fifty,O
patients,O
.,O
This,O
is,O
a,O
report,O
on,O
the,O
first,O
part,O
of,O
our,O
study,O
of,O
the,O
effects,O
of,O
long,O
-,O
term,O
lithium,B
treatment,O
on,O
the,O
kidney,O
.,O
Creatinine,B
clearance,I
",",O
maximum,O
urinary,O
osmolality,O
and,O
24,O
hour,O
urine,O
volume,O
have,O
been,O
tested,O
in,O
50,O
affectively,O
ill,O
patients,O
who,O
have,O
been,O
on,O
long,O
-,O
term,O
lithium,B
for,O
more,O
than,O
one,O
year,O
.,O
These,O
findings,O
have,O
been,O
compared,O
with,O
norms,O
and,O
with,O
values,O
of,O
the,O
same,O
tests,O
from,O
screening,O
prior,O
to,O
lithium,B
",",O
available,O
for,O
most,O
of,O
our,O
patients,O
.,O
No,O
evidence,O
was,O
found,O
for,O
any,O
reduction,O
of,O
glomerular,B
filtration,I
during,O
lithium,B
treatment,O
.,O
Low,O
clearance,O
values,O
found,O
in,O
several,O
patients,O
could,O
be,O
accounted,O
for,O
by,O
their,O
age,O
and,O
their,O
pre,O
-,O
lithium,B
values,O
.,O
Urinary,B
concentration,I
defect,I
appeared,O
frequent,O
but,O
the,O
extent,O
of,O
the,O
impairment,O
is,O
difficult,O
to,O
assess,O
because,O
of,O
the,O
uncertainty,O
about,O
the,O
norms,O
applicable,O
to,O
this,O
group,O
of,O
patients,O
.,O
The,O
concentration,O
defect,O
appeared,O
reversible,O
",",O
at,O
least,O
in,O
part,O
.,O
Polyuria,O
above,O
3,O
litres,O
/,O
24,O
hours,O
was,O
found,O
in,O
10,O
%,O
of,O
patients,O
.,O
An,O
attempt,O
is,O
made,O
to,O
draw,O
practical,O
conclusions,O
from,O
the,O
preliminary,O
findings,O
.,O
Nephrotoxicity,O
of,O
cyclosporin,B
A,I
and,O
FK506,B
:,O
inhibition,O
of,O
calcineurin,B
phosphatase,I
.,O
Cyclosporin,B
A,I
(,O
CsA,B
;,O
50,O
mg,O
/,O
kg,O
),O
and,O
Fujimycine,B
(,O
FK506,B
;,O
5,O
mg,O
/,O
kg,O
),O
",",O
but,O
not,O
the,O
related,O
macrolide,O
immunosuppressant,O
rapamycin,B
(,O
5,O
mg,O
/,O
kg,O
),O
",",O
caused,O
a,O
reduction,O
of,O
glomerular,O
filtration,O
rate,O
",",O
degenerative,O
changes,O
of,O
proximal,O
tubular,O
epithelium,O
",",O
and,O
hypertrophy,O
of,O
the,O
juxtaglomerular,O
apparatus,O
in,O
male,O
Wistar,O
rats,O
when,O
given,O
for,O
10,O
days,O
.,O
The,O
molecular,O
mechanisms,O
of,O
CsA,B
and,O
FK506,B
toxicity,O
were,O
investigated,O
.,O
Cyclophilin,B
A,I
and,O
FK506,B
-,O
binding,O
protein,O
",",O
the,O
main,O
intracytoplasmic,O
receptors,O
for,O
CsA,B
and,O
FK506,B
",",O
respectively,O
",",O
were,O
each,O
detected,O
in,O
renal,O
tissue,O
extract,O
.,O
In,O
the,O
kidney,O
",",O
high,O
levels,O
of,O
immunoreactive,O
and,O
enzymatically,O
active,O
calcineurin,B
were,O
found,O
which,O
were,O
inhibited,O
by,O
the,O
immunosuppressants,O
CsA,B
and,O
FK506,B
",",O
but,O
not,O
by,O
rapamycin,B
.,O
Finally,O
",",O
specific,O
immunophilin,B
-,I
drug,O
-,O
calcineurin,B
complexes,O
formed,O
only,O
in,O
the,O
presence,O
of,O
CsA,B
and,O
FK506,B
",",O
but,O
not,O
rapamycin,O
.,O
These,O
results,O
suggest,O
that,O
the,O
nephrotoxic,O
effects,O
of,O
CsA,B
and,O
FK506,B
is,O
likely,O
mediated,O
through,O
binding,O
to,O
renal,O
immunophilin,B
and,O
inhibiting,O
calcineurin,B
phosphatase,O
.,O
Acute,O
renal,O
failure,O
in,O
high,O
dose,O
carboplatin,B
chemotherapy,O
.,O
Carboplatin,B
has,O
been,O
reported,O
to,O
cause,O
acute,O
renal,O
failure,O
when,O
administered,O
in,O
high,O
doses,O
to,O
adult,O
patients,O
.,O
We,O
report,O
a,O
4,O
1,O
/,O
2,O
-,O
year,O
-,O
old,O
girl,O
who,O
was,O
treated,O
with,O
high,O
-,O
dose,O
carboplatin,B
for,O
metastatic,O
parameningeal,O
embryonal,O
rhabdomyosarcoma,O
.,O
Acute,O
renal,O
failure,O
developed,O
followed,O
by,O
a,O
slow,O
partial,O
recovery,O
of,O
renal,O
function,O
.,O
Possible,O
contributing,O
factors,O
are,O
discussed,O
.,O
Clinical,O
evaluation,O
on,O
combined,O
administration,O
of,O
oral,O
prostacyclin,B
analogue,O
beraprost,B
and,O
phosphodiesterase,B
inhibitor,O
cilostazol,B
.,O
Among,O
various,O
oral,O
antiplatelets,O
",",O
a,O
combination,O
of,O
a,O
novel,O
prostacyclin,B
analogue,O
beraprost,B
(,O
BPT,B
),O
and,O
a,O
potent,O
phosphodiesterase,B
inhibitor,O
cilostazol,B
(,O
CLZ,B
),O
may,O
result,O
in,O
untoward,O
clinical,O
effects,O
due,O
to,O
possible,O
synergistic,O
elevation,O
of,O
intracellular,O
cAMP,B
(,O
cyclic,B
adenosine,I
3,I
',I
",",I
5,I
',I
-,I
monophosphate,I
),O
.,O
Thereby,O
",",O
a,O
clinical,O
study,O
of,O
the,O
combined,O
administration,O
of,O
the,O
two,O
agents,O
was,O
attempted,O
.,O
Twelve,O
healthy,O
volunteers,O
were,O
assigned,O
to,O
take,O
BPT,B
/,O
CLZ,B
in,O
the,O
following,O
schedule,O
;,O
BPT,B
:,O
40,O
micrograms,O
at,O
day,O
1,O
and,O
120,O
micrograms,O
t,O
.,O
i,O
.,O
d,O
.,O
from,O
day,O
7,O
to,O
14,O
",",O
CLZ,B
:,O
200,O
mg,O
t,O
.,O
i,O
.,O
d,O
.,O
from,O
day,O
3,O
to,O
14,O
.,O
At,O
various,O
time,O
intervals,O
",",O
physical,O
examination,O
and,O
blood,O
collection,O
for,O
ex,O
vivo,O
platelet,O
aggregation,O
and,O
determination,O
of,O
intraplatelet,O
cAMP,B
were,O
performed,O
.,O
Throughout,O
the,O
observation,O
period,O
",",O
no,O
significant,O
alteration,O
in,O
vital,O
signs,O
was,O
observed,O
.,O
Seven,O
out,O
of,O
12,O
subjects,O
experienced,O
headache,O
of,O
a,O
short,O
duration,O
accompanying,O
facial,O
flush,O
in,O
one,O
and,O
nausea,O
in,O
one,O
",",O
especially,O
after,O
ingestion,O
of,O
CLZ,B
.,O
All,O
of,O
these,O
symptoms,O
",",O
probably,O
caused,O
by,O
the,O
vasodilating,O
effect,O
of,O
the,O
two,O
agents,O
",",O
were,O
of,O
mild,O
degree,O
and,O
no,O
special,O
treatment,O
was,O
required,O
.,O
Intraplatelet,O
cAMP,B
content,O
was,O
gradually,O
but,O
significantly,O
increased,O
to,O
9,O
.,O
84,O
+,O
/,O
-,O
4,O
59,O
pmol,O
per,O
10,O
(,O
9,O
),O
platelets,O
at,O
day,O
14,O
in,O
comparison,O
with,O
the,O
initial,O
value,O
(,O
6,O
.,O
87,O
+,O
/,O
-,O
2,O
25,O
pmol,O
.,O
The,O
platelet,O
aggregability,O
was,O
significantly,O
suppressed,O
at,O
various,O
time,O
intervals,O
but,O
no,O
additive,O
or,O
synergistic,O
inhibitory,O
effect,O
by,O
the,O
combined,O
administration,O
was,O
noted,O
.,O
In,O
conclusion,O
",",O
the,O
combined,O
administration,O
of,O
BPT,B
/,I
CLZ,I
is,O
safe,O
at,O
doses,O
used,O
in,O
the,O
study,O
",",O
though,O
the,O
beneficial,O
clinical,O
effect,O
of,O
the,O
combined,O
administration,O
has,O
yet,O
to,O
be,O
elucidated,O
.,O
Pravastatin,B
-,I
associated,I
myopathy,I
.,O
Report,O
of,O
a,O
case,O
.,O
A,O
case,O
of,O
acute,O
inflammatory,O
myopathy,O
associated,O
with,O
the,O
use,O
of,O
pravastatin,B
",",O
a,O
new,O
hydrophilic,O
3,O
-,O
hydroxy,O
-,O
3,O
methylglutaril,O
coenzyme,O
A,O
reductase,O
inhibitor,O
",",O
is,O
reported,O
.,O
The,O
patient,O
",",O
a,O
69,O
-,O
year,O
-,O
old,O
man,O
was,O
affected,O
by,O
non,O
-,O
insulin,B
-,I
dependent,I
diabetes,I
mellitus,I
and,O
hypertension,O
.,O
He,O
assumed,O
pravastatin,B
(,O
20,O
mg,O
/,O
day,O
),O
because,O
of,O
hypercholesterolemia,O
.,O
He,O
was,O
admitted,O
with,O
acute,O
myopathy,O
of,O
the,O
lower,O
limbs,O
which,O
resolved,O
in,O
a,O
few,O
days,O
after,O
pravastatin,B
discontinuation,O
.,O
A,O
previously,O
unknown,O
hypothyroidism,B
",",O
probably,O
due,O
to,O
chronic,O
autoimmune,O
thyroiditis,B
",",O
was,O
evidenced,O
.,O
Muscle,O
biopsy,O
(,O
left,O
gastrocnemius,O
),O
revealed,O
a,O
perimysial,O
and,O
endomysial,O
inflammatory,O
infiltrate,O
with,O
a,O
prevalence,O
of,O
CD4,B
+,O
lymphocytes,O
.,O
While,O
lovastatin,B
and,O
simvastatin,B
have,O
been,O
associated,O
with,O
toxic,O
myopathy,O
",",O
pravastatin,B
-,O
associated,O
myopathy,O
could,O
represent,O
a,O
distinct,O
",",O
inflammatory,O
entity,O
.,O
Reversal,O
of,O
ammonia,B
coma,I
in,O
rats,O
by,O
L,B
-,I
dopa,I
:,O
a,O
peripheral,O
effect,O
.,O
Ammonia,B
coma,I
was,O
produced,O
in,O
rats,O
within,O
10,O
to,O
15,O
minutes,O
of,O
an,O
intraperitonealinjection,O
of,O
1,O
.,O
7,O
mmol,O
NH4CL,B
.,O
This,O
coma,I
was,O
prevented,O
with,O
1,O
.,O
68,O
mmol,O
L,B
-,I
dopa,I
given,O
by,O
gastric,O
intubation,O
15,O
minutes,O
before,O
the,O
ammonium,B
salt,I
injection,O
.,O
The,O
effect,O
of,O
L,B
-,I
dopa,I
was,O
correlated,O
with,O
a,O
decrease,O
in,O
blood,B
and,O
brain,B
ammonia,I
",",O
an,O
increase,O
in,O
brain,B
dopamine,I
",",O
and,O
an,O
increase,O
in,O
renal,B
excretion,I
of,I
ammonia,I
and,O
urea,B
.,O
Intraventricular,O
infusion,O
of,O
dopamine,B
sufficient,O
to,O
raise,O
the,O
brain,B
dopamine,I
to,O
the,O
same,O
extent,O
did,O
not,O
prevent,O
the,O
ammonia,B
coma,I
nor,O
affect,O
the,O
blood,B
and,O
brain,B
ammonia,I
concentrations,I
.,O
Bilateral,O
nephrectomy,O
eliminated,O
the,O
beneficial,O
effect,O
of,O
L,B
-,O
dopa,I
on,O
blood,B
and,O
brain,B
ammonia,I
and,O
the,O
ammonia,B
coma,I
was,O
not,O
prevented,O
.,O
Thus,O
",",O
the,O
reduction,O
in,O
blood,B
and,O
brain,B
ammonia,I
and,O
the,O
prevention,O
of,O
ammonia,B
coma,I
after,O
L,B
-,O
dopa,I
",",O
can,O
be,O
accounted,O
for,O
by,O
the,O
peripheral,O
effect,O
of,O
dopamine,B
on,O
renal,O
function,O
rather,O
than,O
its,O
central,O
action,O
.,O
These,O
results,O
provide,O
a,O
reasonable,O
explanation,O
for,O
the,O
beneficial,O
effects,O
observed,O
in,O
some,O
encephalopathic,O
patients,O
receiving,O
L,B
-,I
dopa,I
.,O
Etoposide,B
-,I
related,I
myocardial,I
infarction,I
.,O
The,O
occurrence,O
of,O
a,O
myocardial,I
infarction,I
is,O
reported,O
after,O
chemotherapy,O
containing,O
etoposide,B
",",O
in,O
a,O
man,O
with,O
no,O
risk,O
factors,O
for,O
coronary,O
heart,O
disease,O
.,O
Possible,O
causal,O
mechanisms,O
are,O
discussed,O
.,O
Halogenated,B
anesthetics,I
form,O
liver,O
adducts,O
and,O
antigens,O
that,O
cross,O
-,O
react,O
with,O
halothane,B
-,O
induced,O
antibodies,O
.,O
Two,O
halogenated,B
anesthetics,I
",",O
enflurane,B
and,O
isoflurane,B
",",O
have,O
been,O
associated,O
with,O
an,O
allergic,O
-,O
type,O
hepatic,O
injury,O
both,O
alone,O
and,O
following,O
previous,O
exposure,O
to,O
halothane,B
.,O
Halothane,B
hepatitis,I
appears,O
to,O
involve,O
an,O
aberrant,O
immune,O
response,O
.,O
An,O
antibody,O
response,O
to,O
a,O
protein,O
-,O
bound,O
biotransformation,O
product,O
(,O
trifluoroacetyl,B
adduct,I
),O
has,O
been,O
detected,O
on,O
halothane,B
hepatitis,I
patients,O
.,O
This,O
study,O
was,O
performed,O
to,O
determine,O
cross,O
-,O
reactivity,O
between,O
enflurane,B
and,O
isoflurane,B
with,O
the,O
hypersensitivity,O
induced,O
by,O
halothane,B
.,O
The,O
subcellular,O
and,O
lobular,O
production,O
of,O
hepatic,O
neoantigens,B
recognized,O
by,O
halothane,O
-,O
induced,O
antibodies,O
following,O
enflurane,O
and,O
isoflurane,O
",",O
and,O
the,O
biochemical,O
nature,O
of,O
these,O
neoantigens,B
was,O
investigated,O
in,O
two,O
animal,O
models,O
.,O
Enflurane,O
administration,O
resulted,O
in,O
neoantigens,B
detected,O
in,O
both,O
the,O
microsomal,O
and,O
cytosolic,O
fraction,O
of,O
liver,O
homogenates,O
and,O
in,O
the,O
centrilobular,O
region,O
of,O
the,O
liver,O
.,O
In,O
the,O
same,O
liver,B
",",O
biochemical,O
analysis,O
detected,O
fluorinated,B
liver,I
adducts,I
that,O
were,O
up,O
to,O
20,O
-,O
fold,O
greater,O
in,O
guinea,O
pigs,O
than,O
in,O
rats,O
.,O
This,O
supports,O
and,O
extends,O
previous,O
evidence,O
for,O
a,O
mechanism,O
by,O
which,O
enflurane,B
and,O
/,O
or,O
isoflurane,B
could,O
produce,O
a,O
hypersensitivity,O
condition,O
similar,O
to,O
that,O
of,O
halothane,B
hepatitis,I
either,O
alone,O
or,O
subsequent,O
to,O
halothane,B
administration,O
.,O
The,O
guinea,B
pig,I
would,O
appear,O
to,O
be,O
a,O
useful,O
model,O
for,O
further,O
investigations,O
of,O
the,O
immunological,O
response,O
to,O
these,O
antigens,B
.,O
Cholinergic,B
toxicity,O
resulting,O
from,O
ocular,O
instillation,O
of,O
echothiophate,B
iodide,I
eye,I
drops,I
.,O
A,O
patient,O
developed,O
a,O
severe,O
cholinergic,B
syndrome,O
from,O
the,O
use,O
of,O
echothiophate,B
iodide,I
ophthalmic,I
drops,I
",",O
presented,O
with,O
profound,O
muscle,O
weakness,O
and,O
was,O
initially,O
given,O
the,O
diagnosis,O
of,O
myasthenia,B
gravis,I
.,O
Red,O
blood,O
cell,O
and,O
serum,O
cholinesterase,B
levels,O
were,O
severely,O
depressed,O
and,O
symptoms,O
resolved,O
spontaneously,O
following,O
discontinuation,O
of,O
the,O
eye,O
drops,O
.,O
Seizure,O
after,O
flumazenil,B
administration,O
in,O
a,O
pediatric,O
patient,O
.,O
Flumazenil,B
is,O
a,O
benzodiazepine,B
receptor,O
antagonist,O
used,O
to,O
reverse,O
sedation,O
and,O
respiratory,O
depression,O
induced,O
by,O
benzodiazepines,O
.,O
Seizures,O
and,O
cardiac,O
arrhythmias,O
have,O
complicated,O
its,O
use,O
in,O
adult,O
patients,O
.,O
Overdose,O
patients,O
who,O
have,O
coingested,O
tricyclic,B
antidepressants,I
have,O
a,O
higher,O
risk,O
of,O
these,O
complications,O
.,O
Little,O
information,O
exists,O
concerning,O
adverse,O
effects,O
of,O
flumazenil,B
in,O
children,O
.,O
We,O
report,O
the,O
occurrence,O
of,O
a,O
generalized,O
tonic,O
-,O
clonic,O
seizure,O
in,O
a,O
pediatric,O
patient,O
following,O
the,O
administration,O
of,O
flumazenil,B
.,O
Phase,O
I,O
trial,O
of,O
13,B
-,I
cis,I
-,I
retinoic,I
acid,I
in,O
children,O
with,O
neuroblastoma,O
following,O
bone,O
marrow,O
transplantation,O
.,O
PURPOSE,O
:,O
Treatment,O
of,O
neuroblastoma,O
cell,O
lines,O
with,O
13,B
-,I
cis,I
-,I
retinoic,I
acid,I
(,O
cis,B
-,I
RA,I
),O
can,O
cause,O
sustained,O
inhibition,O
of,O
proliferation,O
.,O
Since,O
cis,B
-,I
RA,I
has,O
demonstrated,O
clinical,O
responses,O
in,O
neuroblastoma,O
patients,O
",",O
it,O
may,O
be,O
effective,O
in,O
preventing,O
relapse,O
after,O
cytotoxic,O
therapy,O
.,O
This,O
phase,O
I,O
trial,O
was,O
designed,O
to,O
determine,O
the,O
maximal,O
-,O
tolerated,O
dosage,O
(,O
MTD,B
),O
",",O
toxicities,O
",",O
and,O
pharmacokinetics,O
of,O
cis,B
-,O
RA,I
administered,O
on,O
an,O
intermittent,O
schedule,O
in,O
children,O
with,O
neuroblastoma,O
following,O
bone,O
marrow,O
transplantation,O
(,O
BMT,B
),O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
Fifty,O
-,O
one,O
assessable,O
patients,O
",",O
2,O
to,O
12,O
years,O
of,O
age,O
",",O
were,O
treated,O
with,O
oral,O
cis,B
-,O
RA,I
administered,O
in,O
two,O
equally,O
divided,O
doses,O
daily,O
for,O
2,O
weeks,O
",",O
followed,O
by,O
a,O
2,O
-,O
week,O
rest,O
period,O
",",O
for,O
up,O
to,O
12,O
courses,O
.,O
The,O
dose,O
was,O
escalated,O
from,O
100,O
to,O
200,B
mg,I
/,I
m2,I
/,I
d,I
until,O
dose,O
-,O
limiting,O
toxicity,O
(,O
DLT,O
),O
was,O
observed,O
.,O
A,O
single,O
intrapatient,O
dose,O
escalation,O
was,O
permitted,O
.,O
RESULTS,O
:,O
The,O
MTD,O
of,O
cis,B
-,I
RA,I
was,O
160,B
mg,I
/,I
m2,I
/,I
d,I
.,O
Dose,O
-,O
limiting,O
toxicities,O
in,O
six,O
of,O
nine,O
patients,O
at,O
200,B
mg,I
/,I
m2,I
/,I
d,I
included,O
hypercalcemia,B
(,O
n,O
=,O
3,O
),O
",",O
rash,B
(,O
n,O
=,O
2,O
),O
",",O
and,O
anemia,B
/,I
thrombocytopenia,I
/,I
emesis,I
/,I
rash,I
(,O
n,O
=,O
1,O
),O
.,O
All,O
toxicities,O
resolved,O
after,O
cis,B
-,I
RA,I
was,O
discontinued,O
.,O
Three,O
complete,O
responses,O
were,O
observed,O
in,O
marrow,O
metastases,O
.,O
Serum,O
levels,O
of,O
7,O
.,O
4,B
+,O
/,O
-,O
3,I
.,O
0,I
mumol,I
/,I
L,I
(,O
peak,O
),O
and,O
4,B
.,O
0,I
+,O
/,O
-,O
2,I
.,O
8,I
mumol,I
/,I
L,I
(,O
trough,O
),O
at,O
the,O
MTD,O
were,O
maintained,O
during,O
14,O
days,O
of,O
therapy,O
.,O
The,O
DLT,O
correlated,O
with,O
serum,O
levels,O
>,O
or,O
=,O
10,O
mumol,I
/,I
L,I
.,O
CONCLUSION,O
:,O
The,O
MTD,O
of,O
cis,B
-,I
RA,I
given,O
on,O
this,O
intermittent,O
schedule,O
was,O
160,O
mg,O
/,O
m2,O
/,O
d,O
.,O
Serum,O
levels,O
known,O
to,O
be,O
effective,O
against,O
neuroblastoma,O
in,O
vitro,O
were,O
achieved,O
at,O
this,O
dose,O
.,O
The,O
DLT,O
included,O
hypercalcemia,B
",",O
and,O
may,O
be,O
predicted,O
by,O
serum,O
cis,B
-,I
RA,I
levels,O
.,O
Monitoring,O
of,O
serum,O
calcium,B
and,O
cis,B
-,I
RA,I
levels,O
is,O
indicated,O
in,O
future,O
trials,O
.,O
Time,O
dependence,O
of,O
plasma,O
malondialdehyde,B
",",O
oxypurines,B
",",O
and,O
nucleosides,B
during,O
incomplete,O
cerebral,O
ischemia,O
in,O
the,O
rat,O
.,O
Incomplete,O
cerebral,O
ischemia,O
(,O
30,O
min,O
),O
was,O
induced,O
in,O
the,O
rat,O
by,O
bilaterally,O
clamping,O
the,O
common,O
carotid,O
arteries,O
.,O
Peripheral,O
venous,O
blood,O
samples,O
were,O
withdrawn,O
from,O
the,O
femoral,O
vein,O
four,O
times,O
(,O
once,O
every,O
5,O
min,O
),O
before,O
ischemia,O
(,O
0,O
time,O
),O
and,O
5,O
",",O
15,O
",",O
and,O
30,O
min,O
after,O
ischemia,O
.,O
Plasma,B
extracts,O
were,O
analyzed,O
by,O
a,O
highly,O
sensitive,O
high,O
-,O
performance,O
liquid,O
chromatographic,O
method,O
for,O
the,O
direct,O
determination,O
of,O
malondialdehyde,B
",",O
oxypurines,B
",",O
and,O
nucleosides,B
.,O
During,O
ischemia,O
",",O
a,O
time,O
-,O
dependent,O
increase,O
of,O
plasma,B
oxypurines,B
and,O
nucleosides,B
was,O
observed,O
.,O
Plasma,B
malondialdehyde,B
",",O
which,O
was,O
present,O
in,O
minimal,O
amount,O
at,O
zero,O
time,O
(,O
0,O
.,O
58,O
mumol,B
/,I
liter,I
plasma,I
;,O
SD,O
0,O
.,O
15,O
),O
",",O
increased,O
after,O
5,O
min,O
of,O
ischemia,B
",",O
resulting,O
in,O
a,O
fivefold,O
increase,O
after,O
30,O
min,O
of,O
carotid,O
occlusion,O
(,O
0,O
.,O
298,O
mumol,B
/,I
liter,I
plasma,I
;,O
SD,O
0,O
.,O
78,O
),O
.,O
Increased,O
plasma,I
malondialdehyde,B
was,O
also,O
recorded,O
in,O
two,O
other,O
groups,O
of,O
animals,O
subjected,O
to,O
the,O
same,O
experimental,O
model,O
",",O
one,O
receiving,O
20,O
mg,O
/,O
kg,O
b,O
.,O
w,O
.,O
of,O
the,O
cyclooxygenase,B
inhibitor,O
acetylsalicylate,B
intravenously,O
immediately,O
before,O
ischemia,O
",",O
the,O
other,O
receiving,O
650,O
micrograms,O
/,O
kg,O
b,O
.,O
w,O
.,O
of,O
the,O
hypotensive,O
drug,O
nitroprusside,B
at,O
a,O
flow,O
rate,O
of,O
103,O
microliters,O
/,O
min,O
intravenously,O
during,O
ischemia,O
",",O
although,O
in,O
this,O
latter,O
group,O
malondialdehyde,B
was,O
significantly,O
higher,O
.,O
The,O
present,O
data,O
indicate,O
that,O
the,O
determination,O
of,O
malondialdehyde,B
",",O
oxypurines,B
",",O
and,O
nucleosides,B
in,O
peripheral,O
blood,O
",",O
may,O
be,O
used,O
to,O
monitor,O
the,O
metabolic,O
alterations,O
of,O
tissues,O
occurring,O
during,O
ischemic,O
phenomena,O
.,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Acute,O
renal,O
toxicity,O
of,O
doxorubicin,B
(,O
adriamycin,I
),O
-,O
loaded,O
cyanoacrylate,B
nanoparticles,O
.,O
Acute,O
doxorubicin,B
-,O
loaded,O
nanoparticle,O
(,O
DXNP,B
),O
renal,O
toxicity,O
was,O
explored,O
in,O
both,O
normal,O
rats,O
and,O
rats,O
with,O
experimental,O
glomerulonephritis,O
.,O
In,O
normal,O
rats,O
",",O
2,O
/,O
6,O
rats,O
given,O
free,O
doxorubicin,B
(,O
DX,B
),O
(,O
5,O
mg,O
/,O
kg,O
),O
died,O
within,O
one,O
week,O
",",O
whereas,O
all,O
control,O
animals,O
and,O
all,O
rats,O
having,O
received,O
free,O
NP,B
or,O
DXNP,B
survived,O
.,O
A,O
3,O
times,O
higher,O
proteinuria,O
appeared,O
in,O
animals,O
treated,O
with,O
DXNP,B
than,O
in,O
those,O
treated,O
with,O
DX,B
.,O
Free,O
NP,B
did,O
not,O
provoke,O
any,O
proteinuria,O
.,O
Two,O
hr,O
post,O
-,O
injection,O
",",O
DXNP,B
was,O
2,O
.,O
7,O
times,O
more,O
concentrated,O
in,O
kidneys,O
than,O
free,O
DX,B
(,O
p,O
<,O
0,O
.,O
25,O
),O
.,O
In,O
rats,O
with,O
immune,O
experimental,O
glomerulonephritis,O
",",O
5,O
/,O
6,O
rats,O
given,O
DX,B
died,O
within,O
7,O
days,O
",",O
in,O
contrast,O
to,O
animals,O
treated,O
by,O
DXNP,B
",",O
NP,B
",",O
or,O
untreated,O
",",O
which,O
all,O
survived,O
.,O
Proteinuria,O
appeared,O
in,O
all,O
series,O
",",O
but,O
was,O
2,O
-,O
5,O
times,O
more,O
intense,O
(,O
p,O
>,O
0,O
.,O
1,O
),O
and,O
prolonged,O
after,O
doxorubicin,B
treatment,O
(,O
400,O
-,O
700,O
mg,O
/,O
day,O
),O
",",O
without,O
significant,O
difference,O
between,O
DXNP,B
and,O
DX,B
.,O
Rats,O
treated,O
by,O
unloaded,O
NP,B
behaved,O
as,O
controls,O
.,O
These,O
results,O
demonstrate,O
that,O
",",O
in,O
these,O
experimental,O
conditions,O
",",O
DXNP,B
killed,O
less,O
animals,O
than,O
free,O
DX,B
",",O
despite,O
of,O
an,O
enhanced,O
renal,O
toxicity,O
of,O
the,O
former,O
.,O
Both,O
effects,O
(,O
better,O
survival,O
and,O
nephrosis,O
),O
are,O
most,O
probably,O
related,O
to,O
an,O
enhanced,O
capture,O
of,O
DXNP,B
by,O
cells,O
of,O
the,O
mononuclear,O
phagocyte,O
system,O
",",O
including,O
mesangial,O
cells,O
.,O
Prostaglandin,B
E2,I
-,I
induced,I
bladder,I
hyperactivity,I
in,O
normal,O
",",O
conscious,O
rats,O
:,O
involvement,O
of,O
tachykinins,O
?,O
In,O
normal,O
conscious,O
rats,O
investigated,O
by,O
continuous,O
cystometry,O
",",O
intravesically,O
instilled,O
prostaglandin,B
(,I
PG,I
),I
E2,I
facilitated,I
micturition,I
and,I
increased,I
basal,I
intravesical,I
pressure,I
.,O
The,O
effect,O
was,O
attenuated,O
by,O
both,O
the,O
NK1,B
receptor,O
selective,O
antagonist,O
RP,B
67,I
",",O
580,I
and,O
the,O
NK2,B
receptor,O
selective,O
antagonist,O
SR,B
48,I
",",O
968,I
",",O
given,O
intra,O
-,O
arterially,O
",",O
suggesting,O
that,O
it,O
was,O
mediated,O
by,O
stimulation,O
of,O
both,O
NK1,B
and,O
NK2,B
receptors,O
.,O
Intra,O
-,O
arterially,O
given,O
PGE2,B
produced,O
a,O
distinct,O
increase,O
in,O
bladder,O
pressure,O
before,O
initiating,O
a,O
micturition,O
reflex,O
",",O
indicating,O
that,O
the,O
PG,B
had,O
a,O
direct,O
contractant,O
effect,O
on,O
the,O
detrusor,O
smooth,O
muscle,O
.,O
The,O
effect,O
of,O
intra,O
-,O
arterial,O
PGE2,B
could,O
not,O
be,O
blocked,O
by,O
intra,O
-,O
arterial,O
RP,B
67,I
",",O
580,I
or,O
SR,B
48,I
",",O
968,I
",",O
which,O
opens,O
the,O
possibility,O
that,O
the,O
micturition,O
reflex,O
elicited,O
by,O
intra,O
-,O
arterial,O
PGE2,B
was,O
mediated,O
by,O
pathways,O
other,O
than,O
the,O
reflex,O
initiated,O
when,O
the,O
PG,B
was,O
given,O
intravesically,O
.,O
The,O
present,O
results,O
thus,O
suggest,O
that,O
intra,O
-,O
arterial,O
PGE2,B
",",O
given,O
near,O
the,O
bladder,O
",",O
may,O
initiate,O
micturition,O
in,O
the,O
normal,O
rat,O
chiefly,O
by,O
directly,O
contracting,O
the,O
smooth,O
muscle,O
of,O
the,O
detrusor,O
.,O
However,O
",",O
when,O
given,O
intravesically,O
",",O
PGE2,B
may,O
stimulate,O
micturition,O
by,O
releasing,O
tachykinins,B
from,O
nerves,O
in,O
and,O
/,O
or,O
immediately,O
below,O
the,O
urothelium,O
.,O
These,O
tachykinins,B
",",O
in,O
turn,O
",",O
initiate,O
a,O
micturition,O
reflex,O
by,O
stimulating,O
NK1,B
and,O
NK2,B
receptors,O
.,O
Prostanoids,B
may,O
",",O
via,O
release,O
of,O
tachykinins,B
",",O
contribute,O
to,O
both,O
urge,O
and,O
bladder,O
hyperactivity,O
seen,O
in,O
inflammatory,O
conditions,O
of,O
the,O
lower,O
urinary,O
tract,O
.,O
Refractory,O
cardiogenic,O
shock,O
and,O
complete,O
heart,O
block,O
after,O
verapamil,B
SR,I
and,O
metoprolol,B
treatment,O
.,O
A,O
case,O
report,O
.,O
A,O
seventy,O
-,O
eight,O
-,O
year,O
-,O
old,O
woman,O
presented,O
with,O
complete,O
heart,O
block,O
and,O
refractory,O
hypotension,O
two,O
days,O
after,O
a,O
therapeutic,O
dose,O
of,O
sustained,O
-,O
release,O
verapamil,B
with,O
concomitant,O
use,O
of,O
metoprolol,B
.,O
The,O
patient,O
continued,O
to,O
remain,O
hypotensive,O
with,O
complete,O
heart,O
block,O
",",O
even,O
with,O
multiple,O
uses,O
of,O
intravenous,O
atropine,B
as,O
well,O
as,O
high,O
doses,O
of,O
pressor,O
agents,O
such,O
as,O
dopamine,B
and,O
dobutamine,B
.,O
However,O
",",O
shortly,O
after,O
the,O
use,O
of,O
intravenous,O
calcium,B
chloride,I
",",O
the,O
refractory,O
hypotension,O
and,O
complete,O
heart,O
block,O
resolved,O
.,O
Protective,O
effect,O
of,O
misoprostol,B
on,O
indomethacin,B
induced,O
renal,O
dysfunction,O
in,O
elderly,O
patients,O
.,O
OBJECTIVE,O
:,O
To,O
evaluate,O
the,O
possible,O
protective,O
effects,O
of,O
misoprostol,B
on,O
renal,O
function,O
in,O
hospitalized,O
elderly,O
patients,O
treated,O
with,O
indomethacin,B
.,O
METHODS,O
:,O
Forty,O
-,O
five,O
hospitalized,O
elderly,O
patients,O
(,O
>,O
65,O
years,O
old,O
),O
who,O
required,O
therapy,O
with,O
nonsteroidal,O
antiinflammatory,O
drugs,O
(,O
NSAID,B
),O
were,O
randomly,O
assigned,O
to,O
receive,O
either,O
indomethacin,B
",",O
150,O
mg,O
/,O
day,O
(,O
Group,O
A,O
),O
",",O
or,O
indomethacin,B
150,O
mg,O
/,O
day,O
plus,O
misoprostol,B
at,O
0,O
.,O
6,O
mg,O
/,O
day,O
(,O
Group,O
B,O
),O
.,O
Laboratory,O
variables,O
of,O
renal,O
function,O
[,O
serum,B
creatinine,I
",",O
blood,B
urea,I
nitrogen,I
(,O
BUN,B
),O
and,O
electrolytes,B
],O
were,O
evaluated,O
before,O
initiation,O
of,O
therapy,O
and,O
every,O
2,O
days,O
",",O
until,O
termination,O
of,O
the,O
study,O
(,O
a,O
period,O
of,O
at,O
least,O
6,O
days,O
),O
.,O
Response,O
to,O
treatment,O
was,O
estimated,O
by,O
the,O
visual,O
analog,O
scale,O
for,O
severity,O
of,O
pain,O
.,O
RESULTS,O
:,O
Forty,O
-,O
two,O
patients,O
completed,O
the,O
study,O
",",O
22,O
in,O
Group,O
A,O
and,O
20,O
in,O
Group,O
B,O
.,O
BUN,B
and,O
creatinine,B
increased,O
by,O
>,O
50,O
%,O
of,O
baseline,O
levels,O
in,O
54,O
and,O
45,O
%,O
of,O
Group,O
A,O
patients,O
",",O
respectively,O
",",O
compared,O
to,O
only,O
20,O
and,O
10,O
%,O
of,O
Group,O
B,O
patients,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
.,O
Potassium,B
(,O
K,B
),O
increment,O
of,O
0,O
.,O
6,O
mEq,O
/,O
l,O
or,O
more,O
was,O
observed,O
in,O
50,O
%,O
of,O
Group,O
A,O
",",O
but,O
in,O
only,O
15,O
%,O
of,O
Group,O
B,O
patients,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
.,O
The,O
mean,O
increments,O
in,O
BUN,B
",",O
creatinine,B
",",O
and,O
K,B
were,O
reduced,O
by,O
63,O
",",O
80,O
",",O
and,O
42,O
%,O
",",O
respectively,O
",",O
in,O
Group,O
B,O
patients,O
compared,O
to,O
Group,O
A,O
.,O
Response,O
to,O
treatment,O
did,O
not,O
differ,O
significantly,O
between,O
the,O
2,O
groups,O
.,O
CONCLUSION,O
:,O
Hospitalized,O
elderly,O
patients,O
are,O
at,O
risk,O
for,O
developing,O
indomethacin,B
related,O
renal,B
dysfunction,O
.,O
Addition,O
of,O
misoprostol,B
can,O
minimize,O
this,O
renal,O
impairment,O
without,O
affecting,O
pain,O
control,O
.,O
Cognitive,O
deterioration,O
from,O
long,O
-,O
term,O
abuse,O
of,O
dextromethorphan,B
:,O
a,O
case,O
report,O
.,O
Dextromethorphan,B
(,O
DM,B
),O
",",O
the,O
dextrorotatory,O
isomer,O
of,O
3,O
-,O
hydroxy,B
-,I
N,I
-,I
methylmorphinan,I
",",O
is,O
the,O
main,O
ingredient,O
in,O
a,O
number,O
of,O
widely,O
available,O
",",O
over,O
-,O
the,O
-,O
counter,O
antitussives,O
.,O
Initial,O
studies,O
(,O
Bornstein,B
1968,O
),O
showed,O
that,O
it,O
possessed,O
no,O
respiratory,O
suppressant,O
effects,O
and,O
no,O
addiction,O
liability,O
.,O
Subsequently,O
",",O
however,O
",",O
several,O
articles,O
reporting,O
abuse,O
of,O
this,O
drug,B
have,O
appeared,O
in,O
the,O
literature,O
.,O
The,O
drug,B
is,O
known,O
to,O
cause,O
a,O
variety,O
of,O
acute,O
toxic,O
effects,O
",",O
ranging,O
from,O
nausea,B
",",O
restlessness,B
",",O
insomnia,B
",",O
ataxia,B
",",O
slurred,B
speech,I
and,O
nystagmus,B
to,O
mood,B
changes,I
",",O
perceptual,B
alterations,I
",",O
inattention,B
",",O
disorientation,B
and,O
aggressive,B
behavior,I
(,O
Rammer,B
et,I
al,I
1988,O
;,O
Katona,B
and,I
Watson,I
1986,O
;,O
Isbell,B
and,I
Fraser,I
1953,O
;,O
Devlin,B
et,I
al,I
1985,O
;,O
McCarthy,B
1971,O
;,O
Dodds,B
and,I
Revai,I
1967,O
;,O
Degkwitz,B
1964,O
;,O
Hildebrand,B
et,I
al,I
1989,O
),O
.,O
There,O
have,O
also,O
been,O
two,O
reported,O
fatalities,O
from,O
DM,B
overdoses,O
(,O
Fleming,O
1986,O
),O
.,O
However,O
",",O
there,O
are,O
no,O
reports,O
describing,O
the,O
effects,O
of,O
chronic,O
abuse,O
.,O
This,O
report,O
describes,O
a,O
case,O
of,O
cognitive,O
deterioration,O
resulting,O
from,O
prolonged,O
use,O
of,O
DM,B
.,O
Effects,O
of,O
ouabain,B
on,O
myocardial,O
oxygen,O
supply,O
and,O
demand,O
in,O
patients,O
with,O
chronic,O
coronary,O
artery,O
disease,O
.,O
A,O
hemodynamic,O
",",O
volumetric,O
",",O
and,O
metabolic,O
study,O
in,O
patients,O
without,O
heart,O
failure,O
.,O
The,O
effects,O
of,O
digitalis,B
glycosides,I
on,O
myocardial,O
oxygen,O
supply,O
and,O
demand,O
are,O
of,O
particular,O
interest,O
in,O
the,O
presence,O
of,O
obstructive,O
coronary,O
artery,O
disease,O
",",O
but,O
have,O
not,O
been,O
measured,O
previously,O
in,O
man,O
.,O
We,O
assessed,O
the,O
effects,O
of,O
ouabain,B
(,O
0,O
.,O
15,O
mg,O
/,O
kg,O
body,O
weight,O
),O
on,O
hemodynamic,O
",",O
volumetric,O
",",O
and,O
metabolic,O
parameters,O
in,O
11,O
patients,O
with,O
severe,O
chronic,O
coronary,O
artery,O
disease,O
without,O
clinical,O
congestive,O
heart,O
failure,O
.,O
Because,O
the,O
protocol,O
was,O
long,O
and,O
involved,O
interventions,O
which,O
might,O
affect,O
the,O
determinations,O
",",O
we,O
also,O
studied,O
in,O
nine,O
patients,O
using,O
an,O
identical,O
protocol,O
except,O
that,O
ouabain,B
administration,O
was,O
omitted,O
.,O
Left,O
ventricular,O
end,O
-,O
diastolic,O
pressure,O
and,O
left,O
ventricular,O
end,O
-,O
diastolic,O
volume,O
fell,O
in,O
each,O
patient,O
given,O
ouabain,B
",",O
even,O
though,O
they,O
were,O
initially,O
elevated,O
in,O
only,O
two,O
patients,O
.,O
Left,O
ventricular,O
end,O
-,O
diastolic,O
pressure,O
fell,O
from,O
11,O
.,O
5,O
+,O
/,O
-,O
1,O
.,O
4,O
(,O
mean,O
+,O
/,O
-,O
SE,O
),O
to,O
5,O
.,O
6,O
+,O
/,O
-,O
0,O
.,O
9,O
mm,O
Hg,O
(,O
P,O
less,O
than,O
0,O
.,O
1,O
),O
and,O
left,O
ventricular,O
end,O
-,O
diastolic,O
volume,O
fell,O
from,O
100,O
+,O
/,O
-,O
17,O
to,O
82,O
+,O
/,O
-,O
12,O
ml,O
/,O
m2,O
(,O
P,O
less,O
than,O
0,O
.,O
1,O
),O
1,O
h,O
after,O
ouabain,B
infusion,O
was,O
completed,O
.,O
The,O
maximum,O
velocity,O
of,O
contractile,O
element,O
shortening,O
increased,O
from,O
1,O
.,O
68,O
+,O
/,O
-,O
0,O
11,O
ml,O
/,O
s,O
to,O
2,O
.,O
18,O
+,O
/,O
-,O
0,O
21,O
muscle,O
-,O
lengths,O
/,O
s,O
(,O
P,O
less,O
than,O
0,O
5,O
),O
and,O
is,O
consistent,O
with,O
an,O
increase,O
in,O
contractility,O
.,O
No,O
significant,O
change,O
in,O
these,O
parameters,O
occurred,O
in,O
the,O
control,O
patients,O
.,O
No,O
significant,O
change,O
in,O
myocardial,O
oxygen,O
consumption,O
occurred,O
after,O
ouabain,B
administration,O
but,O
this,O
may,O
be,O
related,O
to,O
a,O
greater,O
decrease,O
in,O
mean,O
arterial,O
pressure,O
in,O
the,O
ouabain,B
patients,O
than,O
in,O
the,O
control,O
patients,O
.,O
We,O
conclude,O
that,O
in,O
patients,O
with,O
chronic,O
coronary,B
artery,I
disease,I
who,O
are,O
not,O
in,O
clinical,O
congestive,O
heart,O
failure,O
left,O
ventricular,O
end,O
-,O
diastolic,O
volume,O
falls,O
after,O
ouabain,B
administration,O
even,O
when,O
it,O
is,O
initially,O
normal,O
.,O
Though,O
this,O
fall,O
would,O
be,O
associated,O
with,O
a,O
decrease,O
in,O
wall,O
tension,O
",",O
and,O
",",O
therefore,O
",",O
of,O
myocardial,O
oxygen,O
consumption,O
",",O
it,O
may,O
not,O
be,O
of,O
sufficient,O
magnitude,O
to,O
prevent,O
a,O
net,O
increase,O
in,O
myocardial,O
oxygen,O
consumption,O
.,O
Nevertheless,O
",",O
compensatory,O
mechanisms,O
prevent,O
a,O
deterioration,O
of,O
resting,O
myocardial,O
metabolism,O
.,O
Dexamethasone,B
-,O
induced,O
ocular,B
hypertension,I
in,O
perfusion,O
-,O
cultured,O
human,O
eyes,O
.,O
PURPOSE,O
:,O
Glucocorticoid,B
administration,O
can,O
lead,O
to,O
the,O
development,O
of,O
ocular,B
hypertension,I
and,O
corticosteroid,B
glaucoma,I
in,O
a,O
subset,O
of,O
the,O
population,O
through,O
a,O
decrease,O
in,O
the,O
aqueous,B
humor,I
outflow,I
facility,I
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
glucocorticoid,B
treatment,O
can,O
directly,O
affect,O
the,O
outflow,O
facility,O
of,O
isolated,O
",",O
perfusion,O
-,O
cultured,O
human,O
eyes,O
.,O
METHODS,O
:,O
The,O
anterior,O
segments,O
of,O
human,O
donor,O
eyes,O
from,O
regional,O
eye,O
banks,O
were,O
placed,O
in,O
a,O
constant,O
flow,O
",",O
variable,O
pressure,O
perfusion,O
culture,O
system,O
.,O
Paired,O
eyes,O
were,O
perfused,O
in,O
serum,B
-,I
free,I
media,I
with,O
or,O
without,O
10,B
(,O
-,O
7,O
),O
M,O
dexamethasone,B
for,O
12,O
days,O
.,O
Intraocular,O
pressure,O
was,O
monitored,O
daily,O
.,O
After,O
incubation,O
",",O
the,O
eyes,O
were,O
morphologically,O
characterized,O
by,O
light,O
microscopy,O
",",O
transmission,O
and,O
scanning,O
electron,O
microscopy,O
",",O
and,O
scanning,O
laser,O
confocal,O
microscopy,O
.,O
RESULTS,O
:,O
A,O
significant,O
increase,O
in,O
intraocular,O
pressure,O
developed,O
in,O
13,O
of,O
the,O
44,O
pairs,O
of,O
eyes,O
perfused,O
with,O
dexamethasone,B
with,O
an,O
average,O
pressure,O
rise,O
of,O
17,O
.,O
5,O
+,O
/,O
-,O
3,O
.,O
8,O
mm,O
Hg,O
after,O
12,O
days,O
of,O
dexamethasone,B
exposure,O
The,O
contralateral,O
control,O
eyes,O
",",O
which,O
did,O
not,O
receive,O
dexamethasone,O
",",O
maintained,O
a,O
stable,O
intraocular,O
pressure,O
during,O
the,O
same,O
period,O
.,O
The,O
outflow,O
pathway,O
of,O
the,O
untreated,O
eyes,O
appeared,O
morphologically,O
normal,O
.,O
In,O
contrast,O
",",O
the,O
dexamethasone,B
-,I
treated,O
hypertensive,O
eyes,O
had,O
thickened,O
trabecular,O
beams,O
",",O
decreased,O
intertrabecular,O
spaces,O
",",O
thickened,O
juxtacanalicular,O
tissue,O
",",O
activated,O
trabecular,O
meshwork,O
cells,O
",",O
and,O
increased,O
amounts,O
of,O
amorphogranular,O
extracellular,O
material,O
",",O
especially,O
in,O
the,O
juxtacanalicular,O
tissue,O
and,O
beneath,O
the,O
endothelial,O
lining,O
of,O
the,O
canal,O
of,O
Schlemm,B
.,O
The,O
dexamethasone,B
-,O
treated,O
nonresponder,O
eyes,O
appeared,O
to,O
be,O
morphologically,O
similar,O
to,O
the,O
untreated,O
eyes,O
",",O
although,O
several,O
subtle,O
dexamethasone,B
-,O
induced,O
morphologic,O
changes,O
were,O
evident,O
.,O
CONCLUSION,O
:,O
Dexamethasone,B
treatment,O
of,O
isolated,O
",",O
perfusion,O
-,O
cultured,O
human,O
eyes,O
led,O
to,O
the,O
generation,O
of,O
ocular,O
hypertension,O
in,O
approximately,O
30,O
%,O
of,O
the,O
dexamethasone,B
-,O
treated,O
eyes,O
.,O
Steroid,B
treatment,O
resulted,O
in,O
morphologic,O
changes,O
in,O
the,O
trabecular,B
meshwork,I
similar,O
to,O
those,O
reported,O
for,O
corticosteroid,B
glaucoma,I
and,O
open,B
angle,I
glaucoma,I
.,O
This,O
system,O
may,O
provide,O
an,O
acute,O
model,O
in,O
which,O
to,O
study,O
the,O
pathogenic,O
mechanisms,O
involved,O
in,O
steroid,B
glaucoma,I
and,O
primary,B
open,I
angle,I
glaucoma,I
.,O
Auditory,O
disturbance,O
associated,O
with,O
interscalene,B
brachial,I
plexus,I
block,I
.,O
We,O
performed,O
an,O
audiometric,O
study,O
in,O
20,O
patients,O
who,O
underwent,O
surgery,O
of,O
the,O
shoulder,O
region,O
under,O
an,O
interscalene,B
brachial,I
plexus,I
block,I
(,O
IBPB,O
),O
.,O
Bupivacaine,B
0,O
.,O
75,O
%,O
with,O
adrenaline,B
was,O
given,O
followed,O
by,O
a,O
24,O
-,O
hr,O
continuous,O
infusion,O
of,O
0,O
.,O
25,O
%,O
bupivacaine,B
.,O
Three,O
audiometric,O
threshold,O
measurements,O
(,O
0,O
.,O
25,O
-,O
18,O
kHz,O
),O
were,O
made,O
:,O
the,O
first,O
before,O
IBPB,O
",",O
the,O
second,O
2,O
-,O
6,O
h,O
after,O
surgery,O
and,O
the,O
third,O
on,O
the,O
first,O
day,O
after,O
operation,O
.,O
In,O
four,O
patients,O
hearing,O
impairment,O
on,O
the,O
side,O
of,O
the,O
block,O
was,O
demonstrated,O
after,O
operation,O
",",O
in,O
three,O
measurements,O
on,O
the,O
day,O
of,O
surgery,O
and,O
in,O
one,O
on,O
the,O
following,O
day,O
.,O
The,O
frequencies,O
at,O
which,O
the,O
impairment,O
occurred,O
varied,O
between,O
patients,O
;,O
in,O
one,O
only,O
low,O
frequencies,O
(,O
0,B
.,I
25,I
-,I
0,I
.,I
5,I
kHz,I
),O
were,O
involved,O
. The,O
maximum,O
change,O
in,O
threshold,O
was,O
35,B
dB,I
at,O
6,B
kHz,I
measured,O
at,O
the,O
end,O
of,O
the,O
continuous,O
infusion,O
of,O
bupivacaine,B
. This,O
patient,O
had,O
hearing,O
threshold,O
changes,O
(,O
15,B
-,I
20,I
dB,I
),O
at,O
6,B
-,I
10,I
kHz,I
on,O
the,O
opposite,O
side,O
also,O
.,O
IBPB,O
may,O
cause,O
transient,O
auditory,O
dysfunction,O
in,O
the,O
ipsilateral,O
ear,O
",",O
possibly,O
via,O
an,O
effect,O
on,O
sympathetic,O
innervation,O
.,O
The,O
safety,O
and,O
efficacy,O
of,O
combination,O
N,B
-,I
butyl,I
-,I
deoxynojirimycin,I
(,O
SC,B
-,I
48334,I
),O
and,O
zidovudine,B
in,O
patients,O
with,O
HIV,B
-,I
1,I
infection,O
and,O
200,O
-,O
500,O
CD4,B
cells,O
/,O
mm3,O
.,O
We,O
conducted,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
phase,O
II,O
study,O
to,O
evaluate,O
the,O
safety,O
and,O
activity,O
of,O
combination,O
therapy,O
with,O
N,B
-,I
butyl,I
-,I
deoxynojirimycin,I
(,O
SC,B
-,I
48334,I
),O
(,O
an,O
alpha,O
-,O
glucosidase,O
I,O
inhibitor,O
),O
and,O
zidovudine,B
versus,O
zidovudine,B
alone,O
.,O
Patients,O
with,O
200,B
to,O
500,I
CD4,I
cells,I
/,O
mm3,O
who,O
tolerated,O
<,O
or,O
=,O
12,O
weeks,O
of,O
prior,O
zidovudine,B
therapy,O
received,O
SC,B
-,I
48334,I
(,O
1000,B
mg,I
every,I
8,I
h,I
),O
and,O
zidovudine,B
(,O
100,B
mg,I
every,I
8,I
h,I
),O
or,O
zidovudine,B
and,O
placebo,B
.,O
Sixty,O
patients,O
received,O
combination,O
therapy,O
and,O
58,O
",",O
zidovudine,B
and,O
placebo,B
.,O
Twenty,O
-,O
three,O
patients,O
(,O
38,O
%,O
),O
and,O
15,O
(,O
26,O
%,O
),O
",",O
in,O
the,O
combination,O
and,O
zidovudine,B
groups,O
",",O
respectively,O
",",O
discontinued,O
therapy,O
(,O
p,O
=,O
0,O
.,O
15,O
),O
.,O
The,O
mean,O
SC,B
-,I
48334,I
steady,O
-,O
state,O
trough,O
level,O
(,O
4,O
.,O
4,O
+,O
/,O
-,O
0,O
.,O
99,O
micrograms,O
/,O
ml,O
),O
was,O
below,O
the,O
in,O
vitro,O
inhibitory,O
concentration,O
for,O
human,O
immunodeficiency,B
virus,I
(,I
HIV,I
.,O
The,O
mean,O
increase,O
in,O
CD4,B
cells,I
at,O
week,O
4,O
was,O
73,O
.,O
8,O
cells,O
/,O
mm3,O
and,O
52,O
.,O
4,O
cells,O
/,O
mm3,O
for,O
the,O
combination,O
and,O
zidovudine,B
groups,O
",",O
respectively,O
(,O
p,O
>,O
0,O
.,O
36,O
),O
.,O
For,O
patients,O
with,O
prior,O
zidovudine,B
therapy,O
",",O
the,O
mean,O
change,O
in,O
CD4,B
cells,O
in,O
the,O
combination,O
and,O
zidovudine,B
groups,O
was,O
63,O
0.7,O
cells,O
/,O
mm3,O
and,O
4,O
0.9,O
cells,O
/,O
mm3,O
at,O
week,O
8,O
and,O
6,O
0.8,O
cells,O
/,O
mm3,O
and,O
-,O
45,O
0.1,O
cells,O
/,O
mm3,O
at,O
week,O
16,O
",",O
respectively,O
.,O
The,O
number,O
of,O
patients,O
with,O
suppression,O
of,O
HIV,B
p24,I
antigenemia,I
in,O
the,O
combination,O
and,O
zidovudine,B
groups,O
was,O
six,O
(,O
40,O
%,O
),O
and,O
two,O
(,O
11,O
%,O
),O
at,O
week,O
4,O
(,O
p,O
=,O
0,O
0.89,O
10,O
),O
and,O
five,O
(,O
45,O
%,O
),O
and,O
two,O
(,O
14,O
%,O
),O
at,O
week,O
24,O
(,O
p,O
=,O
0,O
.,O
8,O
),O
",",O
respectively,O
.,O
Diarrhea,B
",",O
flatulence,B
",",O
abdominal,B
pain,I
",",O
and,O
weight,B
loss,I
were,O
common,O
for,O
combination,O
recipients,O
.,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Prolonged,O
paralysis,O
due,O
to,O
nondepolarizing,O
neuromuscular,O
blocking,O
agents,O
and,O
corticosteroids,O
.,O
The,O
long,O
-,O
term,O
use,O
of,O
nondepolarizing,O
neuromuscular,O
blocking,O
agents,O
(,O
ND,B
-,I
NMBA,I
),O
has,O
recently,O
been,O
implicated,O
as,O
a,O
cause,O
of,O
prolonged,O
muscle,O
weakness,O
",",O
although,O
the,O
site,O
of,O
the,O
lesion,O
and,O
the,O
predisposing,O
factors,O
have,O
been,O
unclear,O
.,O
We,O
report,O
3,O
patients,O
(,O
age,O
37,O
-,O
52,O
years,O
),O
with,O
acute,O
respiratory,O
insufficiency,O
who,O
developed,O
prolonged,O
weakness,O
following,O
the,O
discontinuation,O
of,O
ND,B
-,I
NMBAs,I
.,O
Two,O
patients,O
also,O
received,O
intravenous,O
corticosteroids,B
.,O
Renal,O
function,O
was,O
normal,O
but,O
hepatic,O
function,O
was,O
impaired,O
in,O
all,O
patients,O
",",O
and,O
all,O
had,O
acidosis,B
.,O
Electrophysiologic,O
studies,O
revealed,O
low,O
amplitude,O
compound,O
motor,O
action,O
potentials,O
",",O
normal,O
sensory,O
studies,O
",",O
and,O
fibrillations,O
.,O
Repetitive,O
stimulation,O
at,O
2,O
Hz,O
showed,O
a,O
decremental,O
response,O
in,O
2,O
patients,O
.,O
The,O
serum,O
vecuronium,B
level,O
measured,O
in,O
1,O
patient,O
14,O
days,O
after,O
the,O
drug,O
had,O
been,O
discontinued,O
was,O
172,O
ng,O
/,O
mL,O
.,O
A,O
muscle,O
biopsy,O
in,O
this,O
patient,O
showed,O
loss,O
of,O
thick,O
",",O
myosin,B
filaments,O
.,O
The,O
weakness,O
in,O
these,O
patients,O
is,O
due,O
to,O
pathology,O
at,O
both,O
the,O
neuromuscular,O
junction,O
(,O
most,O
likely,O
due,O
to,O
ND,B
-,O
NMBA,B
),O
and,O
muscle,O
(,O
most,O
likely,O
due,O
to,O
corticosteroids,B
),O
.,O
Hepatic,B
dysfunction,I
and,O
acidosis,B
are,O
contributing,O
risk,O
factors,O
.,O
Failure,O
of,O
ancrod,B
in,O
the,O
treatment,O
of,O
heparin,B
-,I
induced,I
arterial,I
thrombosis,I
.,O
The,O
morbidity,O
and,O
mortality,O
associated,O
with,O
heparin,B
-,I
induced,I
thrombosis,I
remain,O
high,O
despite,O
numerous,O
empirical,O
therapies,O
.,O
Ancrod,B
has,O
been,O
used,O
successfully,O
for,O
prophylaxis,O
against,O
development,O
of,O
thrombosis,O
in,O
patients,O
with,O
heparin,B
induced,I
platelet,I
aggregation,I
who,O
require,O
brief,O
reexposure,O
to,O
heparin,B
",",O
but,O
its,O
success,O
in,O
patients,O
who,O
have,O
developed,O
the,O
thrombosis,O
syndrome,O
is,O
not,O
well,O
defined,O
.,O
The,O
authors,O
present,O
a,O
case,O
of,O
failure,O
of,O
ancrod,B
treatment,O
in,O
a,O
patient,O
with,O
heparin,B
-,O
induced,O
thrombosis,O
.,O
Water,B
intoxication,O
associated,O
with,O
oxytocin,B
administration,O
during,O
saline,B
-,O
induced,O
abortion,O
.,O
Four,O
cases,O
of,O
water,B
intoxication,O
in,O
connection,O
with,O
oxytocin,B
administration,O
during,O
saline,B
-,O
induced,O
abortions,O
are,O
described,O
.,O
The,O
mechanism,O
of,O
water,B
intoxication,I
is,O
discussed,O
in,O
regard,O
to,O
these,O
cases,O
.,O
Oxytocin,B
administration,O
during,O
midtrimester,O
-,O
induced,O
abortions,O
is,O
advocated,O
only,O
if,O
it,O
can,O
be,O
carried,O
out,O
under,O
careful,O
observations,O
of,O
an,O
alert,O
nursing,O
staff,O
",",O
aware,O
of,O
the,O
symptoms,O
of,O
water,B
intoxication,I
and,O
instructed,O
to,O
watch,O
the,O
diuresis,O
and,O
report,O
such,O
early,O
signs,O
of,O
the,O
syndrome,O
as,O
asthenia,O
",",O
muscular,O
irritability,O
",",O
or,O
headaches,O
.,O
The,O
oxytocin,B
should,O
be,O
given,O
only,O
in,O
Ringers,B
lactate,I
or,O
",",O
alternately,O
",",O
in,O
Ringers,B
lactate,I
and,O
a,O
5,O
per,O
cent,O
dextrose,B
and,O
water,O
solutions,O
.,O
The,O
urinary,O
output,O
should,O
be,O
monitored,O
and,O
the,O
oxytocin,B
administration,O
discontinued,O
and,O
the,O
serum,O
electrolytes,O
checked,O
if,O
the,O
urinary,O
output,O
decreases,O
.,O
The,O
oxytocin,B
should,O
not,O
be,O
administered,O
in,O
excess,O
of,O
36,O
hours,O
.,O
If,O
the,O
patient,O
has,O
not,O
aborted,O
by,O
then,O
the,O
oxytocin,B
should,O
be,O
discontinued,O
for,O
10,O
to,O
12,O
hours,O
in,O
order,O
to,O
perform,O
electrolyte,B
determinations,O
and,O
correct,O
any,O
electrolyte,B
imbalance,O
.,O
Light,O
chain,B
proteinuria,I
and,O
cellular,O
mediated,O
immunity,O
in,O
rifampin,B
treated,O
patients,O
with,O
tuberculosis,O
.,O
Light,O
chain,B
proteinuria,I
was,O
found,O
in,O
9,O
of,O
17,O
tuberculosis,O
patients,O
treated,O
with,O
rifampin,B
.,O
Concomitant,O
assay,O
of,O
cellular,O
mediated,O
immunity,O
in,O
these,O
patients,O
using,O
skin,B
test,I
antigen,I
and,O
a,O
lymphokine,O
in,O
vitro,O
test,O
provided,O
results,O
that,O
were,O
different,O
.,O
Response,O
to,O
Varidase,B
skin,I
test,I
antigen,I
was,O
negative,O
for,O
all,O
eight,O
tuberculosis,O
patients,O
tested,O
",",O
but,O
there,O
occurred,O
a,O
hyper,O
-,O
responsiveness,O
of,O
the,O
lymphocytes,O
of,O
these,O
eight,O
patients,O
to,O
phytomitogen,B
(,O
PHA,I
-,I
P,I
),I
.,O
as,O
well,O
as,O
of,O
those,O
of,O
seven,O
other,O
tuberculous,B
patients,O
.,O
This,O
last,O
finding,O
may,O
be,O
related,O
to,O
time,O
of,O
testing,O
and,O
/,O
or,O
endogenous,O
serum,O
binding,O
of,O
rifampin,B
which,O
could,O
have,O
inhibited,O
mitogen,O
activity,O
for,O
the,O
lymphocyte,O
.,O
KF17837,B
:,O
a,O
novel,O
selective,O
adenosine,B
A2A,I
receptor,I
antagonist,O
with,O
anticataleptic,O
activity,O
.,O
KF17837,B
is,O
a,O
novel,O
selective,O
adenosine,B
A2A,I
receptor,I
antagonist,O
.,O
Oral,O
administration,O
of,O
KF17837,B
(,O
2,O
.,O
5,O
",",O
10,O
.,O
0,O
and,O
30,O
.,O
0,O
mg,O
/,O
kg,O
),O
significantly,O
ameliorated,O
the,O
cataleptic,O
responses,O
induced,O
by,O
intracerebroventricular,O
administration,O
of,O
an,O
adenosine,B
A2A,I
receptor,I
agonist,O
",",O
CGS,B
21680,I
(,O
10,O
micrograms,O
),O
",",O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
KF17837,B
also,O
reduced,O
the,O
catalepsy,O
induced,O
by,O
haloperidol,B
(,O
1,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
and,O
by,O
reserpine,B
(,O
5,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
.,O
These,O
anticataleptic,O
effects,O
were,O
exhibited,O
dose,O
dependently,O
at,O
doses,O
from,O
0,O
.,O
625,O
and,O
2,O
.,O
5,O
mg,O
/,O
kg,O
p,O
.,O
o,O
.,O
",",O
respectively,O
.,O
Moreover,O
",",O
KF17837,B
(,O
0,O
.,O
625,O
mg,O
/,O
kg,O
p,O
.,O
o,O
.,O
),O
potentiated,O
the,O
anticataleptic,O
effects,O
of,O
a,O
subthreshold,O
dose,O
of,O
L,B
-,I
3,I
",",I
4,I
-,I
dihydroxyphenylalanine,I
(,I
L,I
-,I
DOPA,I
;,I
25,I
mg,I
/,I
kg,I
i,I
p,O
.,O
),O
plus,O
benserazide,B
(,O
6,O
.,O
25,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
.,O
These,O
results,O
suggested,O
that,O
KF17837,B
is,O
a,O
centrally,O
active,O
adenosine,B
A2A,I
receptor,I
antagonist,I
and,O
that,O
the,O
dopaminergic,O
function,O
of,O
the,O
nigrostriatal,O
pathway,O
is,O
potentiated,O
by,O
adenosine,B
A2A,I
receptor,I
antagonists,I
.,O
Furthermore,O
",",O
KF17837,B
may,O
be,O
a,O
useful,O
drug,O
in,O
the,O
treatment,O
of,O
parkinsonism,O
.,O
Effect,O
of,O
nondopaminergic,B
drugs,I
on,O
L,B
-,I
dopa,I
-,I
induced,I
dyskinesias,I
in,O
MPTP,B
-,I
treated,I
monkeys,I
.,O
A,O
group,O
of,O
four,O
monkeys,O
was,O
rendered,O
parkinsonian,O
with,O
the,O
toxin,B
MPTP,I
.,O
They,O
were,O
then,O
treated,O
chronically,O
with,O
L,B
-,I
DOPA,I
/,I
benserazide,I
50,I
/,I
12,I
.,O
5,O
mg,O
/,O
kg,O
given,O
orally,O
daily,O
for,O
2,O
months,O
.,O
This,O
dose,O
produced,O
a,O
striking,O
antiparkinsonian,O
effect,O
",",O
but,O
all,O
animals,O
manifested,O
dyskinesia,O
.,O
A,O
series,O
of,O
agents,O
acting,O
primarily,O
on,O
neurotransmitters,O
other,O
than,O
dopamine,B
were,O
then,O
tested,O
in,O
combination,O
with,O
L,B
-,I
DOPA,I
to,O
see,O
if,O
the,O
dyskinetic,O
movements,O
would,O
be,O
modified,O
.,O
Several,O
drugs,O
",",O
including,O
clonidine,B
",",O
physostigmine,B
",",O
methysergide,B
",",O
5,B
-,I
MDOT,I
",",O
propranolol,B
",",O
and,O
MK,B
-,I
801,I
",",O
markedly,O
reduced,O
the,O
dyskinetic,O
movements,O
but,O
at,O
the,O
cost,O
of,O
a,O
return,O
of,O
parkinsonian,O
symptomatology,O
.,O
However,O
",",O
yohimbine,B
and,O
meperidine,B
reduced,O
predominantly,O
the,O
dyskinetic,O
movements,O
.,O
Baclofen,B
was,O
also,O
useful,O
in,O
one,O
monkey,O
against,O
a,O
more,O
dystonic,O
form,O
of,O
dyskinesia,O
.,O
Atropine,B
converted,O
the,O
dystonic,O
movements,O
into,O
chorea,O
.,O
Hallucinations,B
and,O
ifosfamide,B
-,O
induced,O
neurotoxicity,O
.,O
BACKGROUND,O
:,O
Hallucinations,B
as,O
a,O
symptom,O
of,O
central,O
neurotoxicity,O
are,O
a,O
known,O
but,O
poorly,O
described,O
side,O
effect,O
of,O
ifosfamide,B
.,O
Most,O
cases,O
of,O
ifosfamide,B
-,O
induced,O
hallucinations,O
have,O
been,O
reported,O
with,O
other,O
mental,O
status,O
changes,O
.,O
METHODS,O
:,O
The,O
authors,O
interviewed,O
six,O
persons,O
with,O
ifosfamide,B
-,O
induced,O
hallucinations,O
in,O
the,O
presence,O
of,O
a,O
clear,O
sensorium,O
.,O
All,O
patients,O
were,O
receiving,O
high,O
-,O
dose,O
ifosfamide,B
as,O
part,O
of,O
their,O
bone,O
marrow,O
transplant,O
procedure,O
.,O
RESULTS,O
:,O
Hallucinations,B
occurred,O
only,O
when,O
the,O
patient,O
',O
s,O
eyes,O
were,O
closed,O
and,O
",",O
in,O
all,O
but,O
one,O
case,O
",",O
were,O
reported,O
as,O
disturbing,O
or,O
frightening,O
.,O
Underreporting,O
of,O
these,O
hallucinations,B
by,O
patients,O
is,O
likely,O
.,O
CONCLUSIONS,O
:,O
Hallucinations,B
may,O
be,O
the,O
sole,O
or,O
first,O
manifestation,O
of,O
neurotoxicity,B
.,O
The,O
incidence,O
may,O
be,O
dose,O
and,O
infusion,O
-,O
time,O
related,O
.,O
The,O
clinician,O
should,O
be,O
alerted,O
for,O
possible,O
ifosfamide,B
-,O
induced,O
hallucinations,O
",",O
which,O
may,O
occur,O
without,O
other,O
signs,O
of,O
neurotoxicity,O
.,O
Eyes,O
-,O
closed,O
hallucinatory,O
experiences,O
appear,O
to,O
be,O
an,O
unusual,O
feature,O
of,O
this,O
presentation,O
.,O
Patients,O
anxious,O
about,O
this,O
experience,O
respond,O
well,O
to,O
support,O
and,O
education,O
about,O
this,O
occurrence,O
.,O
Optimal,O
pharmacologic,O
management,O
of,O
disturbed,O
patients,O
is,O
unclear,O
.,O
If,O
agitation,O
becomes,O
marked,O
",",O
high,O
-,O
potency,O
neuroleptics,O
(,O
i,O
.,O
e,O
.,O
",",O
haloperidol,B
),O
may,O
be,O
effective,O
.,O
Photodistributed,O
nifedipine,B
-,O
induced,O
facial,O
telangiectasia,O
.,O
Five,O
months,O
after,O
starting,O
nifedipine,B
(,O
Adalat,B
),O
",",O
two,O
patients,O
developed,O
photodistributed,O
facial,O
telangiectasia,O
",",O
which,O
became,O
more,O
noticeable,O
with,O
time,O
.,O
Neither,O
patient,O
complained,O
of,O
photosensitivity,B
or,O
flushing,B
.,O
Both,O
patients,O
reported,O
a,O
significant,O
cosmetic,O
improvement,O
after,O
discontinuing,O
the,O
drug,O
.,O
One,O
commenced,O
the,O
closely,O
related,O
drug,O
amlodipine,B
3,O
years,O
later,O
",",O
with,O
recurrence,O
of,O
telangiectasia,B
.,O
The,O
photodistribution,O
of,O
the,O
telangiectasia,B
suggests,O
a,O
significant,O
drug,O
/,O
light,O
interaction,O
.,O
Penicillamine,B
-,O
induced,O
rapidly,O
progressive,O
glomerulonephritis,B
in,O
a,O
patient,O
with,O
rheumatoid,O
arthritis,O
.,O
A,O
67,O
-,O
year,O
-,O
old,O
woman,O
with,O
rheumatoid,O
arthritis,O
presented,O
rapidly,O
progressive,O
glomerulonephritis,B
(,O
RPGN,B
),O
after,O
5,O
months,O
of,O
D,B
-,O
penicillamine,I
(,O
250,O
mg,O
/,O
day,O
),O
treatment,O
.,O
Light,O
microscopy,O
study,O
showed,O
severe,O
glomerulonephritis,B
with,O
crescent,O
formation,O
in,O
60,O
%,O
of,O
the,O
glomeruli,O
and,O
infiltration,O
of,O
inflammatory,O
cells,O
in,O
the,O
wall,O
of,O
an,O
arteriole,O
.,O
Immunofluorescence,O
revealed,O
scanty,O
granular,O
IgG,B
",",O
IgA,B
and,O
C3,B
deposits,O
along,O
the,O
capillary,O
walls,O
and,O
mesangium,O
.,O
The,O
patient,O
was,O
treated,O
with,O
steroid,O
pulse,O
",",O
plasmapheresis,O
",",O
cyclophosphamide,B
and,O
antiplatelet,O
agents,O
.,O
A,O
complete,O
recovery,O
of,O
renal,O
function,O
was,O
achieved,O
in,O
a,O
few,O
weeks,O
.,O
This,O
new,O
case,O
of,O
RPGN,O
in,O
the,O
course,O
of,O
D,O
-,O
penicillamine,B
treatment,O
emphasizes,O
the,O
need,O
for,O
frequent,O
monitoring,O
of,O
renal,O
function,O
and,O
evaluation,O
of,O
urinary,O
sediment,O
and,O
proteinuria,O
in,O
these,O
patients,O
.,O
The,O
prompt,O
discontinuation,O
of,O
D,B
-,I
penicillamine,I
and,O
vigorous,O
treatment,O
measures,O
could,O
allow,O
for,O
a,O
good,O
prognosis,O
as,O
in,O
this,O
case,O
.,O
A,O
case,O
of,O
polymyositis,O
in,O
a,O
patient,O
with,O
primary,O
biliary,O
cirrhosis,O
treated,O
with,O
D,B
-,I
penicillamine,I
.,O
Although,O
D,B
-,I
penicillamine,I
has,O
been,O
used,O
for,O
many,O
rheumatologic,O
diseases,O
",",O
toxicity,O
limits,O
its,O
usefulness,O
in,O
many,O
patients,O
.,O
Polymyositis,B
/,I
dermatomyositis,I
can,O
develop,O
as,O
one,O
of,O
the,O
autoimmune,O
complications,O
of,O
D,B
-,I
penicillamine,I
treatment,O
",",O
but,O
its,O
exact,O
pathogenesis,O
remains,O
unclear,O
.,O
We,O
report,O
a,O
patient,O
with,O
primary,O
biliary,O
cirrhosis,O
",",O
who,O
developed,O
polymyositis,B
while,O
receiving,O
D,B
-,I
penicillamine,I
therapy,O
.,O
We,O
described,O
the,O
special,O
clinical,O
course,O
of,O
the,O
patient,O
.,O
Patients,O
receiving,O
D,B
-,I
penicillamine,I
therapy,O
should,O
be,O
followed,O
carefully,O
for,O
the,O
development,O
of,O
autoimmune,O
complications,O
like,O
polymyositis,B
/,I
dermatomyositis,I
.,O
Hyperalgesia,O
and,O
myoclonus,O
in,O
terminal,O
cancer,O
patients,O
treated,O
with,O
continuous,O
intravenous,O
morphine,B
.,O
Eight,O
cancer,O
patients,O
in,O
the,O
terminal,O
stages,O
of,O
the,O
disease,O
treated,O
with,O
high,O
doses,O
of,O
intravenous,O
morphine,B
developed,O
hyperalgesia,O
.,O
All,O
cases,O
were,O
retrospectively,O
sampled,O
from,O
three,O
different,O
hospitals,O
in,O
Copenhagen,O
.,O
Five,O
patients,O
developed,O
universal,O
hyperalgesia,B
and,O
hyperesthesia,B
which,O
in,O
2,O
cases,O
were,O
accompanied,O
by,O
myoclonus,B
.,O
In,O
3,O
patients,O
a,O
pre,O
-,O
existing,O
neuralgia,B
increased,O
to,O
excruciating,O
intensity,O
and,O
in,O
2,O
of,O
these,O
cases,O
myoclonus,B
occurred,O
simultaneously,O
.,O
Although,O
only,O
few,O
clinical,O
descriptions,O
of,O
the,O
relationship,O
between,O
hyperalgesia,B
/,I
myoclonus,B
and,O
high,O
doses,O
of,O
morphine,B
are,O
available,O
",",O
experimental,O
support,O
from,O
animal,O
studies,O
indicates,O
that,O
morphine,B
",",O
or,O
its,O
metabolites,O
",",O
plays,O
a,O
causative,O
role,O
for,O
the,O
observed,O
behavioural,O
syndrome,O
.,O
The,O
possible,O
mechanisms,O
are,O
discussed,O
and,O
treatment,O
proposals,O
given,O
suggesting,O
the,O
use,O
of,O
more,O
efficacious,O
opioids,B
with,O
less,O
excitatory,O
potency,O
in,O
these,O
situations,O
.,O
Liposomal,B
daunorubicin,B
in,O
advanced,O
Kaposi,B
',I
s,I
sarcoma,I
:,O
a,O
phase,O
II,O
study,O
.,O
We,O
report,O
a,O
non,O
-,O
randomized,O
Phase,O
II,O
clinical,O
trial,O
to,O
assess,O
the,O
efficacy,O
and,O
safety,O
of,O
liposomal,B
daunorubicin,B
(,O
DaunoXome,B
),O
in,O
the,O
treatment,O
of,O
AIDS,B
related,O
Kaposi,B
',I
s,I
sarcoma,I
.,O
Eleven,O
homosexual,O
men,O
with,O
advanced,O
Kaposi,B
',I
s,I
sarcoma,I
were,O
entered,O
in,O
the,O
trial,O
.,O
Changes,O
in,O
size,O
",",O
colour,O
and,O
associated,O
oedema,O
of,O
selected,O
',O
target,O
',O
lesions,O
were,O
measured,O
.,O
Clinical,O
",",O
biochemical,O
and,O
haematological,O
toxicities,O
were,O
assessed,O
.,O
Ten,O
subjects,O
were,O
evaluated,O
.,O
A,O
partial,O
response,O
was,O
achieved,O
in,O
four,O
",",O
of,O
whom,O
two,O
subsequently,O
relapsed,O
.,O
Stabilization,O
of,O
Kaposi,B
',O
s,O
sarcoma,O
occurred,O
in,O
the,O
remaining,O
six,O
",",O
maintained,O
until,O
the,O
end,O
of,O
the,O
trial,O
period,O
in,O
four,O
.,O
The,O
drug,O
was,O
generally,O
well,O
tolerated,O
",",O
with,O
few,O
mild,O
symptoms,O
of,O
toxicity,O
.,O
The,O
main,O
problem,O
encountered,O
was,O
haematological,B
toxicity,I
",",O
with,O
three,O
subjects,O
experiencing,O
severe,O
neutropenia,B
(,O
neutrophil,B
count,I
<,O
0,O
.,O
5,O
x,O
10,O
(,O
9,O
),O
/,O
l,O
.,O
There,O
was,O
no,O
evidence,O
of,O
cardiotoxicity,B
.,O
In,O
this,O
small,O
patient,O
sample,O
",",O
liposomal,B
daunorubicin,I
was,O
an,O
effective,O
and,O
well,O
tolerated,O
agent,O
in,O
the,O
treatment,O
of,O
Kaposi,O
',O
s,O
sarcoma,O
.,O
Long,O
-,O
term,O
effects,O
of,O
vincristine,B
on,O
the,O
peripheral,O
nervous,O
system,O
.,O
Forty,O
patients,O
with,O
Non,B
-,I
Hodgkin,I
',I
s,I
Lymphoma,I
treated,O
with,O
vincristine,B
between,O
1984,O
and,O
1990,O
(,O
cumulative,O
dose,O
12,O
mg,O
in,O
18,O
-,O
24,O
weeks,O
),O
were,O
investigated,O
in,O
order,O
to,O
evaluate,O
the,O
long,O
term,O
effects,O
of,O
vincristine,B
on,O
the,O
peripheral,O
nervous,O
system,O
.,O
The,O
patients,O
were,O
interviewed,O
with,O
emphasis,O
on,O
neuropathic,O
symptoms,O
.,O
Physical,O
and,O
quantitative,O
sensory,O
examination,O
with,O
determination,O
of,O
vibratory,O
perception,O
and,O
thermal,O
discrimination,O
thresholds,O
were,O
performed,O
",",O
four,O
to,O
77,O
months,O
(,O
median,O
34,O
months,O
),O
after,O
vincristine,B
treatment,O
.,O
Twenty,O
-,O
seven,O
patients,O
reported,O
neuropathic,O
symptoms,O
.,O
In,O
13,O
of,O
these,O
27,O
patients,O
symptoms,O
were,O
still,O
present,O
at,O
the,O
time,O
of,O
examination,O
.,O
In,O
these,O
patients,O
sensory,O
signs,O
and,O
symptoms,O
predominated,O
.,O
In,O
the,O
other,O
14,O
patients,O
symptoms,O
had,O
been,O
present,O
in,O
the,O
past,O
.,O
Symptoms,O
persisted,O
maximally,O
40,O
months,O
since,O
cessation,O
of,O
therapy,O
.,O
There,O
was,O
no,O
age,O
difference,O
between,O
patients,O
with,O
and,O
without,O
complaints,O
at,O
the,O
time,O
of,O
examination,O
.,O
Normal,O
reflexes,O
were,O
found,O
in,O
two,O
third,O
of,O
patients,O
.,O
Neuropathic,O
complaints,O
were,O
not,O
very,O
troublesome,O
on,O
the,O
long,O
term,O
.,O
It,O
is,O
concluded,O
that,O
with,O
the,O
above,O
mentioned,O
vincristine,B
dose,O
schedule,O
signs,O
and,O
symptoms,O
of,O
vincristine,B
neuropathy,O
are,O
reversible,O
for,O
a,O
great,O
deal,O
and,O
prognosis,O
is,O
fairly,O
good,O
.,O
Hepatic,B
adenomas,I
and,O
focal,B
nodular,I
hyperplasia,I
of,I
the,I
liver,I
in,I
young,I
women,I
on,I
oral,I
contraceptives,I
:,O
case,O
reports,O
.,O
Two,O
cases,O
of,O
hepatic,B
adenoma,I
and,O
one,O
of,O
focal,B
nodular,I
hyperplasia,I
presumably,O
associated,O
with,O
the,O
use,O
of,O
oral,B
contraceptives,I
",",O
are,O
reported,O
.,O
Special,O
reference,O
is,O
made,O
to,O
their,O
clinical,O
presentation,O
",",O
which,O
may,O
be,O
totally,O
asymptomatic,O
.,O
Liver,B
-,I
function,I
tests,I
are,O
of,O
little,O
diagnostic,O
value,O
",",O
but,O
valuable,O
information,O
may,O
be,O
obtained,O
from,O
both,O
liver,B
scanning,I
and,O
hepatic,B
angiography,I
.,O
Histologic,O
differences,O
and,O
clinical,O
similarities,O
between,O
hepatic,B
adenoma,I
and,O
focal,B
nodular,I
hyperplasia,I
of,O
the,O
liver,B
are,O
discussed,O
.,O
Loss,O
of,O
glutamate,B
decarboxylase,I
mRNA,I
-,O
containing,O
neurons,O
in,O
the,O
rat,O
dentate,O
gyrus,O
following,O
pilocarpine,B
-,O
induced,O
seizures,O
.,O
In,O
situ,O
hybridization,O
methods,O
were,O
used,O
to,O
determine,O
if,O
glutamic,B
acid,I
decarboxylase,I
(,O
GAD,B
),O
mRNA,I
-,O
containing,O
neurons,O
within,O
the,O
hilus,O
of,O
the,O
dentate,O
gyrus,O
are,O
vulnerable,O
to,O
seizure,O
-,O
induced,O
damage,O
in,O
a,O
model,O
of,O
chronic,O
seizures,O
.,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
injected,O
intraperitoneally,O
with,O
pilocarpine,B
",",O
and,O
the,O
hippocampal,O
formation,O
was,O
studied,O
histologically,O
at,O
1,O
",",O
2,O
",",O
4,O
",",O
and,O
8,O
week,O
intervals,O
after,O
pilocarpine,O
-,O
induced,O
seizures,O
.,O
In,O
situ,O
hybridization,O
histochemistry,O
",",O
using,O
a,O
digoxigenin,B
-,O
labeled,O
GAD,B
cRNA,I
probe,O
",",O
demonstrated,O
a,O
substantial,O
decrease,O
in,O
the,O
number,O
of,O
GAD,B
mRNA,I
-,I
containing,I
neurons,O
in,O
the,O
hilus,O
of,O
the,O
dentate,O
gyrus,O
in,O
the,O
pilocarpine,O
-,O
treated,O
rats,O
as,O
compared,O
to,O
controls,O
at,O
all,O
time,O
intervals,O
.,O
Additional,O
neuronanatomical,O
studies,O
",",O
including,O
cresyl,B
violet,I
staining,O
",",O
neuronal,O
degeneration,O
methods,O
",",O
and,O
histochemical,O
localization,O
of,O
glial,B
fibrillary,I
acidic,I
protein,I
",",O
suggested,O
that,O
the,O
decrease,O
in,O
the,O
number,O
of,O
GAD,B
mRNA,I
-,I
containing,I
neurons,I
was,O
related,O
to,O
neuronal,O
loss,O
rather,O
than,O
to,O
a,O
decrease,O
in,O
GAD,B
mRNA,I
levels,I
.,O
The,O
loss,O
of,O
GAD,B
mRNA,I
-,I
containing,I
neurons,O
in,O
the,O
hilus,O
contrasted,O
with,O
the,O
relative,O
preservation,O
of,O
labeled,O
putative,O
basket,O
cells,O
along,O
the,O
inner,O
margin,O
of,O
the,O
granule,O
cell,O
layer,O
.,O
Quantitative,O
analyses,O
of,O
labeled,O
neurons,O
in,O
three,O
regions,O
of,O
the,O
dentate,O
gyrus,O
in,O
the,O
1,O
and,O
2,O
week,O
groups,O
showed,O
statistically,O
significant,O
decreases,O
in,O
the,O
mean,O
number,O
of,O
GAD,B
mRNA,I
-,I
containing,I
neurons,O
in,O
the,O
hilus,O
of,O
both,O
groups,O
of,O
experimental,O
animals,O
.,O
No,O
significant,O
differences,O
were,O
found,O
in,O
the,O
molecular,O
layer,O
or,O
the,O
granule,O
cell,O
layer,O
",",O
which,O
included,O
labeled,O
neurons,O
along,O
the,O
lower,O
margin,O
of,O
the,O
granule,O
cell,O
layer,O
.,O
The,O
results,O
indicate,O
that,O
",",O
in,O
this,O
model,O
",",O
a,O
subpopulation,O
of,O
GAD,B
mRNA,I
-,I
containing,I
neurons,O
within,O
the,O
dentate,O
gyrus,O
is,O
selectively,O
vulnerable,O
to,O
seizure,O
-,O
induced,O
damage,O
.,O
Such,O
differential,O
vulnerability,O
appears,O
to,O
be,O
another,O
indication,O
of,O
the,O
heterogeneity,O
of,O
GABA,B
neurons,O
.,O
Effects,O
of,O
deliberate,O
hypotension,O
induced,O
by,O
labetalol,B
with,O
isoflurane,B
on,O
neuropsychological,O
function,O
.,O
The,O
effect,O
of,O
deliberate,O
hypotension,O
on,O
brain,O
function,O
measured,O
by,O
neuropsychological,O
tests,O
was,O
studied,O
in,O
41,O
adult,O
patients,O
.,O
Twenty,O
-,O
four,O
patients,O
were,O
anaesthetized,O
for,O
middle,O
-,O
ear,O
surgery,O
with,O
deliberate,O
hypotension,O
induced,O
by,O
labetalol,B
with,O
isoflurane,B
(,O
hypotensive,O
group,O
),O
.,O
Seventeen,O
patients,O
without,O
hypotension,O
served,O
as,O
a,O
control,O
group,O
.,O
The,O
mean,O
arterial,O
pressure,O
was,O
77,O
+,O
/,O
-,O
2,O
mmHg,B
(,O
10,O
.,O
3,O
+,O
/,O
-,O
0,O
kPa,B
),O
before,O
hypotension,O
and,O
50,O
+,O
/,O
-,O
0,O
mmHg,B
(,O
6,O
.,O
7,O
+,O
/,O
-,O
0,O
.,O
kPa,B
),O
during,O
hypotension,O
in,O
the,O
hypotensive,O
group,O
",",O
and,O
86,O
+,O
/,O
-,O
2,O
mmHg,B
(,O
11,O
.,O
5,O
+,O
/,O
-,O
0,O
.,O
kPa,B
),O
during,O
anaesthesia,O
in,O
the,O
control,O
group,O
.,O
The,O
following,O
psychological,O
tests,O
were,O
performed,O
:,O
four,O
subtests,O
of,O
the,O
Wechsler,O
Adult,O
Intelligence,O
Scale,O
(,O
similarities,O
",",O
digit,O
span,O
",",O
vocabulary,O
and,O
digit,O
symbol,O
),O
",",O
Trail,O
-,O
Making,O
tests,O
A,O
and,O
B,O
",",O
Zung,O
tests,O
(,O
self,O
-,O
rating,O
anxiety,O
scale,O
and,O
self,O
-,O
rating,O
depression,O
scale,O
),O
and,O
two,O
-,O
part,O
memory,O
test,O
battery,O
with,O
immediate,O
and,O
delayed,O
recall,O
.,O
The,O
tests,O
were,O
performed,O
preoperatively,O
and,O
2,O
days,O
postoperatively,O
.,O
There,O
were,O
no,O
statistically,O
significant,O
differences,O
between,O
the,O
groups,O
in,O
any,O
of,O
the,O
tests,O
in,O
the,O
changes,O
from,O
preoperative,O
value,O
to,O
postoperative,O
value,O
.,O
The,O
results,O
indicate,O
that,O
hypotension,O
induced,O
by,O
labetalol,B
with,O
isoflurane,B
has,O
no,O
significant,O
harmful,O
effects,O
on,O
mental,O
functions,O
compared,O
to,O
normotensive,O
anaesthesia,O
.,O
Apparent,O
cure,O
of,O
rheumatoid,B
arthritis,I
by,O
bone,B
marrow,I
transplantation,I
.,O
We,O
describe,O
the,O
induction,O
of,O
sustained,O
remissions,O
and,O
possible,O
cure,O
of,O
severe,O
erosive,O
rheumatoid,B
arthritis,I
(,O
RA,B
),O
by,O
bone,B
marrow,I
transplantation,I
(,O
BMT,B
),O
in,O
2,O
patients,O
.,O
BMT,B
was,O
used,O
to,O
treat,O
severe,O
aplastic,O
anemia,O
which,O
was,O
caused,O
by,O
gold,B
in,O
one,O
case,O
and,O
D,B
-,I
penicillamine,I
in,O
the,O
other,O
.,O
In,O
the,O
8,O
and,O
6,O
years,O
since,O
the,O
transplants,O
(,O
representing,O
8,O
and,O
4,O
years,O
since,O
cessation,O
of,O
all,O
immunosuppressive,O
therapy,O
",",O
respectively,O
),O
",",O
the,O
RA,O
in,O
each,O
case,O
has,O
been,O
completely,O
quiescent,O
.,O
Although,O
short,O
term,O
remission,O
of,O
severe,O
RA,O
following,O
BMT,O
has,O
been,O
reported,O
",",O
these,O
are,O
the,O
first,O
cases,O
for,O
which,O
prolonged,O
followup,O
has,O
been,O
available,O
.,O
This,O
experience,O
raises,O
the,O
question,O
of,O
the,O
role,O
of,O
BMT,B
itself,O
as,O
a,O
therapeutic,O
option,O
for,O
patients,O
with,O
uncontrolled,O
destructive,O
synovitis,O
.,O
Seizures,O
induced,O
by,O
combined,O
levomepromazine,B
-,O
fluvoxamine,B
treatment,O
.,O
We,O
report,O
a,O
case,O
of,O
combined,O
levomepromazine,B
-,O
fluvoxamine,B
treatment,O
-,O
induced,O
seizures,O
.,O
It,O
seems,O
that,O
combined,O
treatment,O
of,O
fluvoxamine,B
with,O
phenothiazines,B
may,O
possess,O
proconvulsive,O
activity,O
.,O
Case,O
report,O
:,O
pentamidine,B
and,O
polymorphic,O
ventricular,O
tachycardia,O
revisited,O
.,O
Pentamidine,B
isethionate,O
has,O
been,O
associated,O
with,O
ventricular,O
tachyarrhythmias,O
",",O
including,O
torsade,O
de,O
pointes,O
.,O
This,O
article,O
reports,O
two,O
cases,O
of,O
this,O
complication,O
and,O
reviews,O
all,O
reported,O
cases,O
to,O
date,O
.,O
Pentamidine,B
-,O
induced,O
torsade,O
de,O
pointes,O
may,O
be,O
related,O
to,O
serum,O
magnesium,B
levels,O
and,O
hypomagnesemia,O
may,O
synergistically,O
induce,O
torsade,O
.,O
Torsade,B
de,I
pointes,I
occurred,O
after,O
an,O
average,O
of,O
10,O
days,O
of,O
treatment,O
with,O
pentamidine,B
.,O
In,O
these,O
patients,O
",",O
no,O
other,O
acute,O
side,O
effects,O
of,O
pentamidine,B
were,O
observed,O
.,O
Torsade,B
de,I
pointes,I
can,O
be,O
treated,O
when,O
recognized,O
early,O
",",O
possibly,O
without,O
discontinuation,O
of,O
pentamidine,B
.,O
When,O
QTc,B
interval,I
prolongation,I
is,O
observed,O
",",O
early,O
magnesium,B
supplementation,I
is,O
advocated,O
.,O
Efficacy,O
and,O
tolerability,O
of,O
lovastatin,B
in,O
3390,O
women,O
with,O
moderate,O
hypercholesterolemia,O
.,O
OBJECTIVE,O
:,O
To,O
evaluate,O
the,O
efficacy,O
and,O
safety,O
of,O
lovastatin,B
in,O
women,O
with,O
moderate,O
hypercholesterolemia,O
.,O
DESIGN,O
:,O
The,O
Expanded,O
Clinical,O
Evaluation,O
of,O
Lovastatin,B
(,O
EXCEL,O
),O
Study,O
",",O
a,O
multicenter,O
",",O
double,O
-,O
blind,O
",",O
diet,O
-,O
and,O
placebo,O
-,O
controlled,O
trial,O
",",O
in,O
which,O
participants,O
were,O
randomly,O
assigned,O
to,O
receive,O
placebo,O
or,O
lovastatin,B
at,O
doses,O
of,O
20,O
or,O
40,O
mg,O
once,O
daily,O
",",O
or,O
20,O
or,O
40,O
mg,O
twice,O
daily,O
for,O
48,O
weeks,O
.,O
SETTING,O
:,O
Ambulatory,O
patients,O
recruited,O
by,O
362,O
participating,O
centers,O
throughout,O
the,O
United,O
States,O
.,O
PATIENTS,O
:,O
Women,O
(,O
n,O
=,O
3390,O
),O
from,O
the,O
total,O
cohort,O
of,O
8245,O
volunteers,O
.,O
MEASUREMENTS,O
:,O
Plasma,B
total,O
",",O
low,B
-,I
density,I
lipoprotein,I
(,O
LDL,B
),O
",",O
and,O
high,B
-,I
density,I
lipoprotein,I
(,O
HDL,B
),O
cholesterol,O
",",O
and,O
triglycerides,B
;,O
and,O
laboratory,O
and,O
clinical,O
evidence,O
of,O
adverse,O
events,O
monitored,O
periodically,O
throughout,O
the,O
study,O
.,O
RESULTS,O
:,O
Among,O
women,O
",",O
lovastatin,B
(,O
20,O
to,O
80,O
mg,O
/,O
d,O
),O
produced,O
sustained,O
(,O
12,O
-,O
to,O
48,O
-,O
week,O
),O
",",O
dose,O
-,O
related,O
changes,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
:,O
decreases,O
in,O
LDL,B
cholesterol,I
(,O
24,O
%,O
to,O
40,O
%,O
),O
and,O
triglycerides,B
(,O
9,O
%,O
to,O
18,O
%,O
),O
",",O
and,O
increases,O
in,O
HDL,B
cholesterol,I
(,O
6,O
.,O
7,O
%,O
to,O
8,O
.,O
6,O
%,O
),O
.,O
Depending,O
on,O
the,O
dose,O
",",O
from,O
82,O
%,O
to,O
95,O
%,O
of,O
lovastatin,B
-,O
treated,O
women,O
achieved,O
the,O
National,O
Cholesterol,O
Education,O
Program,O
goal,O
of,O
LDL,B
cholesterol,I
levels,O
less,O
than,O
4,O
.,O
14,O
mmol,B
/,O
L,O
(,O
160,B
mg,I
/,I
dL,I
),O
",",O
and,O
40,O
%,O
to,O
87,O
%,O
achieved,O
the,O
goal,O
of,O
3,O
.,O
36,B
mmol,I
/,I
L,I
(,O
130,B
mg,I
/,I
dL,I
),O
.,O
Successive,O
transaminase,O
elevations,O
greater,O
than,O
three,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
occurred,O
in,O
0,O
.,O
1,O
%,O
of,O
women,O
and,O
were,O
dose,O
dependent,O
above,O
the,O
20,O
-,O
mg,O
dose,O
.,O
Myopathy,O
",",O
defined,O
as,O
muscle,O
symptoms,O
with,O
creatine,B
kinase,I
elevations,I
greater,I
than,I
10,I
times,I
the,I
upper,I
limit,I
of,I
normal,I
",",O
was,O
rare,O
and,O
associated,O
with,O
the,O
highest,O
recommended,O
daily,O
dose,O
of,O
lovastatin,B
(,O
80,B
mg,I
),O
.,O
Estrogen,B
-,O
replacement,O
therapy,O
appeared,O
to,O
have,O
no,O
effect,O
on,O
either,O
the,O
efficacy,O
or,O
safety,O
profile,O
of,O
lovastatin,B
.,O
CONCLUSION,O
:,O
Lovastatin,B
is,O
highly,O
effective,O
and,O
generally,O
well,O
tolerated,O
as,O
therapy,O
for,O
primary,O
hypercholesterolemia,O
in,O
women,O
.,O
Tetany,O
and,O
rhabdomyolysis,O
due,O
to,O
surreptitious,O
furosemide,B
-,O
-,O
importance,O
of,O
magnesium,B
supplementation,O
.,O
Diuretics,B
may,O
induce,O
hypokalemia,B
",",O
hypocalcemia,B
and,O
hypomagnesemia,B
.,O
While,O
severe,O
hypokalemia,B
may,O
cause,O
muscle,O
weakness,O
",",O
severe,O
hypomagnesemia,B
is,O
associated,O
with,O
muscle,O
spasms,O
and,O
tetany,O
which,O
cannot,O
be,O
corrected,O
by,O
potassium,B
and,O
calcium,B
supplementation,O
alone,O
(,O
1,O
",",O
2,O
),O
.,O
Surreptitious,O
diuretic,B
ingestion,O
has,O
been,O
described,O
",",O
mainly,O
in,O
women,O
who,O
are,O
concerned,O
that,O
they,O
are,O
obese,O
or,O
edematous,O
.,O
Symptomatic,O
hypokalemia,B
has,O
been,O
reported,O
in,O
such,O
patients,O
(,O
3,O
-,O
7,O
),O
and,O
in,O
one,O
case,O
hypocalcemia,B
was,O
observed,O
(,O
8,O
),O
",",O
but,O
the,O
effects,O
of,O
magnesium,B
depletion,O
were,O
not,O
noted,O
in,O
these,O
patients,O
.,O
Ciprofloxacin,B
-,O
induced,O
nephrotoxicity,O
in,O
patients,O
with,O
cancer,O
.,O
Nephrotoxicity,O
associated,O
with,O
ciprofloxacin,B
is,O
uncommon,O
.,O
Five,O
patients,O
with,O
cancer,B
who,O
developed,O
acute,O
renal,O
failure,O
that,O
followed,O
treatment,O
with,O
ciprofloxacin,B
are,O
described,O
and,O
an,O
additional,O
15,O
cases,O
reported,O
in,O
the,O
literature,O
are,O
reviewed,O
.,O
Other,O
than,O
elevation,O
of,O
serum,O
creatinine,B
levels,O
",",O
characteristic,O
clinical,O
manifestations,O
and,O
abnormal,O
laboratory,O
findings,O
are,O
not,O
frequently,O
present,O
.,O
Allergic,B
interstitial,I
nephritis,I
is,O
believed,O
to,O
be,O
the,O
underlying,O
pathological,O
-,O
process,O
.,O
Definitive,O
diagnosis,O
requires,O
performance,O
of,O
renal,B
biopsy,I
",",O
although,O
this,O
is,O
not,O
always,O
feasible,O
.,O
An,O
improvement,O
in,O
renal,B
function,I
that,O
followed,O
the,O
discontinuation,O
of,O
the,O
offending,O
antibiotic,B
supports,O
the,O
presumptive,O
diagnosis,O
of,O
ciprofloxacin,B
-,I
induced,I
acute,I
renal,I
failure,I
.,O
Venous,O
complications,O
of,O
midazolam,B
versus,O
diazepam,B
.,O
Although,O
some,O
studies,O
have,O
suggested,O
fewer,O
venous,O
complications,O
are,O
associated,O
with,O
midazolam,B
than,O
with,O
diazepam,B
for,O
endoscopic,O
procedures,O
",",O
this,O
variable,O
has,O
not,O
been,O
well,O
documented,O
.,O
We,O
prospectively,O
evaluated,O
the,O
incidence,O
of,O
venous,O
complications,O
after,O
intravenous,O
injection,O
of,O
diazepam,B
or,O
midazolam,B
in,O
122,O
consecutive,O
patients,O
undergoing,O
colonoscopy,O
and,O
esophagogastroduodenoscopy,O
.,O
Overall,O
",",O
venous,O
complications,O
were,O
more,O
frequent,O
with,O
diazepam,B
(,O
22,O
of,O
62,O
patients,O
),O
than,O
with,O
midazolam,B
(,O
4,O
of,O
60,O
patients,O
),O
(,O
p,O
<,O
0,O
0.28,O
1,O
),O
.,O
A,O
palpable,O
venous,O
cord,O
was,O
present,O
in,O
23,O
%,O
(,O
14,O
of,O
62,O
),O
of,O
patients,O
in,O
the,O
diazepam,B
group,O
",",O
compared,O
with,O
2,O
%,O
(,O
1,O
of,O
60,O
patients,O
),O
in,O
the,O
midazolam,B
group,O
(,O
p,O
<,O
0,O
0.71,O
2,O
),O
.,O
Pain,O
at,O
the,O
injection,O
site,O
occurred,O
in,O
35,O
%,O
(,O
22,O
of,O
62,O
),O
of,O
patients,O
in,O
the,O
diazepam,B
group,O
compared,O
with,O
7,O
%,O
(,O
4,O
of,O
60,O
patients,O
),O
in,O
the,O
midazolam,B
group,O
(,O
p,O
<,O
0,O
.,O
1,O
),O
.,O
Swelling,O
and,O
warmth,O
at,O
the,O
injection,O
site,O
were,O
not,O
significantly,O
different,O
between,O
the,O
two,O
groups,O
.,O
Smoking,O
",",O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
use,O
",",O
intravenous,O
catheter,O
site,O
",",O
dwell,O
time,O
of,O
the,O
needle,O
",",O
alcohol,O
use,O
",",O
and,O
pain,O
during,O
the,O
injection,O
had,O
no,O
effect,O
on,O
the,O
incidence,O
of,O
venous,O
complications,O
.,O
Clarithromycin,B
-,O
associated,O
visual,O
hallucinations,O
in,O
a,O
patient,O
with,O
chronic,O
renal,O
failure,O
on,O
continuous,O
ambulatory,O
peritoneal,O
dialysis,O
.,O
Visual,O
hallucinations,O
are,O
a,O
rare,O
event,O
in,O
chronic,O
renal,O
failure,O
and,O
not,O
related,O
to,O
uremia,O
per,O
se,O
.,O
Unreported,O
in,O
the,O
literature,O
is,O
visual,O
hallucinations,O
occurring,O
in,O
association,O
with,O
the,O
new,O
macrolide,B
antibiotic,O
",",O
clarithromycin,B
.,O
We,O
describe,O
such,O
a,O
case,O
in,O
a,O
patient,O
with,O
end,B
-,I
stage,I
renal,I
disease,I
(,O
ESRD,B
),O
maintained,O
on,O
continuous,O
ambulatory,O
peritoneal,O
dialysis,O
(,O
CAPD,B
),O
.,O
The,O
combination,O
of,O
a,O
relatively,O
high,O
dose,O
of,O
clarithromycin,B
in,O
face,O
of,O
chronic,O
renal,B
failure,I
in,O
a,O
functionally,O
anephric,O
patient,O
",",O
with,O
underlying,O
aluminum,B
intoxication,I
",",O
may,O
have,O
facilitated,O
the,O
appearance,O
of,O
this,O
neurotoxic,O
side,O
effect,O
.,O
It,O
is,O
important,O
to,O
understand,O
the,O
pharmacokinetics,O
of,O
medications,O
in,O
face,O
of,O
chronic,O
renal,O
failure,O
",",O
the,O
possibility,O
of,O
drug,O
interactions,O
",",O
and,O
how,O
these,O
factors,O
should,O
help,O
guide,O
medication,O
therapy,O
in,O
the,O
ESRD,O
patient,O
.,O
Changes,O
in,O
peroxisomes,O
in,O
preneoplastic,O
liver,O
and,O
hepatoma,O
of,O
mice,O
induced,O
by,O
alpha,B
-,I
benzene,I
hexachloride,I
.,O
Peroxisomes,B
in,O
hepatomas,O
and,O
hyperplastic,O
preneoplastic,O
liver,O
lesions,O
induced,O
in,O
mice,O
by,O
500,O
ppm,O
alpha,B
-,I
benzene,I
hexachloride,I
were,O
examined,O
histochemically,O
and,O
electron,O
microscopically,O
.,O
Although,O
most,O
of,O
the,O
hepatomas,O
were,O
well,O
-,O
differentiated,O
tumors,O
and,O
contained,O
a,O
considerable,O
number,O
of,O
peroxisomes,B
",",O
the,O
tumor,O
cells,O
did,O
not,O
respond,O
to,O
ethyl,B
-,I
alpha,I
-,I
p,I
-,I
chlorophenoxyisobutyrate,I
with,O
proliferation,O
of,O
peroxisomes,B
.,O
At,O
the,O
16th,O
week,O
of,O
carcinogen,B
feeding,O
",",O
hyperplastic,O
nodules,O
appeared,O
and,O
advanced,O
to,O
further,O
stages,O
.,O
A,O
majority,O
of,O
the,O
nodules,O
showed,O
a,O
considerable,O
number,O
of,O
peroxisomes,B
and,O
the,O
inductive,O
proliferation,O
of,O
peroxisomes,B
.,O
Within,O
the,O
nodules,O
",",O
foci,O
of,O
proliferation,O
of,O
the,O
cells,O
that,O
showed,O
no,O
inducibility,O
of,O
proliferation,O
of,O
peroxisomes,B
appeared,O
.,O
These,O
cells,O
proliferated,O
further,O
",",O
replacing,O
the,O
most,O
part,O
of,O
the,O
nodules,O
",",O
and,O
with,O
this,O
process,O
hepatomas,B
appeared,O
to,O
have,O
been,O
formed,O
.,O
No,O
abnormal,O
matrical,O
inclusions,O
of,O
peroxisomes,B
were,O
formed,O
in,O
the,O
cells,O
of,O
hyperplastic,O
nodules,O
by,O
ethyl,B
-,I
alpha,I
-,I
p,I
-,I
chlorophenoxyisobutyrate,I
unlike,O
in,O
the,O
case,O
of,O
rats,O
.,O
Contribution,O
of,O
the,O
sympathetic,O
nervous,O
system,O
to,O
salt,B
-,O
sensitivity,O
in,O
lifetime,O
captopril,B
-,O
treated,O
spontaneously,O
hypertensive,O
rats,O
.,O
OBJECTIVE,O
:,O
To,O
test,O
the,O
hypothesis,O
that,O
",",O
in,O
lifetime,O
captopril,B
-,O
treated,O
spontaneously,O
hypertensive,O
rats,O
(,O
SHR,O
),O
",",O
the,O
sympathetic,O
nervous,O
system,O
contributes,O
importantly,O
to,O
the,O
hypertensive,O
effect,O
of,O
dietary,O
sodium,B
chloride,I
supplementation,O
.,O
METHODS,O
:,O
Male,O
SHR,O
(,O
aged,O
6,O
weeks,O
),O
that,O
had,O
been,O
treated,O
from,O
conception,O
onward,O
with,O
either,O
captopril,B
or,O
vehicle,O
remained,O
on,O
a,O
basal,O
sodium,B
chloride,I
diet,O
or,O
were,O
fed,O
a,O
high,O
sodium,B
chloride,I
diet,O
.,O
After,O
2,O
weeks,O
",",O
the,O
rats,O
were,O
subjected,O
to,O
ganglionic,O
blockade,O
and,O
2,O
days,O
later,O
",",O
an,O
infusion,O
of,O
clonidine,B
.,O
RESULTS,O
:,O
Lifetime,O
captopril,B
treatment,O
significantly,O
lowered,O
mean,O
arterial,O
pressure,O
in,O
both,O
groups,O
.,O
Intravenous,O
infusion,O
of,O
the,O
ganglionic,O
blocker,O
hexamethonium,B
resulted,O
in,O
a,O
rapid,O
decline,O
in,O
MAP,O
that,O
eliminated,O
the,O
dietary,O
sodium,B
chloride,I
-,I
induced,O
increase,O
in,O
MAP,O
in,O
both,O
groups,O
.,O
Infusion,O
of,O
the,O
central,O
nervous,O
system,O
alpha2,B
-,I
adrenergic,I
receptor,I
agonist,I
clonidine,B
also,O
resulted,O
in,O
a,O
greater,O
reduction,O
in,O
MAP,O
in,O
both,O
groups,O
of,O
SHR,O
that,O
were,O
fed,O
the,O
high,O
(,O
compared,O
with,O
the,O
basal,O
),O
sodium,B
chloride,I
diet,O
.,O
CONCLUSIONS,O
:,O
In,O
both,O
lifetime,O
captopril,B
-,I
treated,O
and,O
control,O
SHR,O
",",O
the,O
sympathetic,O
nervous,O
system,O
contributes,O
to,O
the,O
pressor,O
effects,O
of,O
a,O
high,O
sodium,B
chloride,I
diet,O
.,O
Angioedema,B
associated,O
with,O
droperidol,B
administration,O
.,O
Angioedema,B
",",O
also,O
known,O
as,O
angioneurotic,O
edema,O
or,O
Quincke,B
',O
s,O
disease,O
",",O
is,O
a,O
well,O
-,O
demarcated,O
",",O
localized,O
edema,O
involving,O
the,O
subcutaneous,O
tissues,O
that,O
may,O
cause,O
upper,O
-,O
airway,O
obstruction,O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
previously,O
healthy,O
19,O
-,O
year,O
-,O
old,O
man,O
with,O
no,O
known,O
drug,O
allergies,O
in,O
whom,O
angioedema,O
with,O
significant,O
tongue,O
swelling,O
and,O
protrusion,O
developed,O
within,O
10,O
minutes,O
of,O
the,O
administration,O
of,O
a,O
single,O
IV,O
dose,O
of,O
droperidol,B
.,O
Late,O
cardiotoxicity,O
after,O
treatment,O
for,O
a,O
malignant,O
bone,O
tumor,O
.,O
Cardiac,O
function,O
was,O
assessed,O
in,O
long,O
-,O
term,O
survivors,O
of,O
malignant,O
bone,O
tumors,O
who,O
were,O
treated,O
according,O
to,O
Rosen,O
',O
s,O
T5,O
or,O
T10,O
protocol,O
",",O
both,O
including,O
doxorubicin,B
.,O
Thirty,O
-,O
one,O
patients,O
",",O
age,O
10,O
-,O
45,O
years,O
(,O
median,O
age,O
17,O
.,O
8,O
years,O
),O
were,O
evaluated,O
2,O
.,O
3,O
-,O
14,O
.,O
1,O
years,O
(,O
median,O
8,O
.,O
9,O
years,O
),O
following,O
completion,O
of,O
treatment,O
.,O
Cumulative,O
doses,O
of,O
doxorubicin,B
were,O
225,O
-,O
550,O
mg,O
/,O
m2,O
(,O
median,O
dose,O
360,O
),O
.,O
The,O
evaluation,O
consisted,O
of,O
a,O
history,O
",",O
physical,O
examination,O
",",O
electrocardiogram,B
(,O
ECG,B
),O
",",O
signal,O
averaged,O
ECG,B
",",O
24,O
-,O
hour,O
ambulatory,O
ECG,B
",",O
echocardiography,B
and,O
radionuclide,B
angiography,I
.,O
Eighteen,O
of,O
31,O
(,O
58,O
%,O
),O
patients,O
showed,O
cardiac,O
toxicity,O
",",O
defined,O
as,O
having,O
one,O
or,O
more,O
of,O
the,O
following,O
abnormalities,O
:,O
late,O
potentials,O
",",O
complex,O
ventricular,O
arrhythmias,O
",",O
left,O
ventricular,O
dilation,O
",",O
decreased,O
shortening,O
fraction,O
",",O
or,O
decreased,O
ejection,O
fraction,O
.,O
The,O
incidence,O
of,O
cardiac,B
abnormalities,I
increased,O
with,O
length,O
of,O
follow,O
-,O
up,O
(,O
P,B
<,O
or,O
=,O
.,O
5,O
)-19,O
.,O
No,O
correlation,O
could,O
be,O
demonstrated,O
between,O
cumulative,O
dose,O
of,O
doxorubicin,B
and,O
cardiac,B
status,O
",",O
except,O
for,O
heart,O
rate,O
variability,O
.,O
When,O
adjusted,O
to,O
body,O
surface,O
area,O
",",O
the,O
left,O
ventricular,O
posterior,O
wall,O
thickness,O
(,O
LVPW,B
index,I
)-57,O
was,O
decreased,O
in,O
all,O
patients,O
.,O
The,O
incidence,O
of,O
doxorubicin,B
-,O
induced,O
cardiotoxicity,O
is,O
high,O
and,O
increases,O
with,O
follow,O
-,O
up,O
",",O
irrespective,O
of,O
cumulative,O
dose,O
.,O
Life,O
-,O
long,O
cardiac,O
follow,O
-,O
up,O
in,O
these,O
patients,O
is,O
warranted,O
.,O
The,O
results,O
of,O
our,O
study,O
suggest,O
that,O
heart,O
rate,O
variability,O
and,O
LVPW,B
index,O
could,O
be,O
sensitive,O
indicators,O
for,O
cardiotoxicity,O
.,O
Acute,O
blood,O
pressure,O
elevations,O
with,O
caffeine,B
in,O
men,O
with,O
borderline,O
systemic,O
hypertension,O
.,O
Whether,O
the,O
vasoconstrictive,O
actions,O
of,O
caffeine,B
are,O
enhanced,O
in,O
hypertensive,O
persons,O
has,O
not,O
been,O
demonstrated,O
.,O
Thus,O
",",O
caffeine,B
(,O
3,O
.,O
3,O
mg,O
/,O
kg,O
),O
versus,O
placebo,O
was,O
tested,O
in,O
48,O
healthy,O
men,O
(,O
aged,O
20,O
to,O
35,O
years,O
),O
selected,O
after,O
screening,O
on,O
2,O
separate,O
occasions,O
.,O
Borderline,O
hypertensive,O
men,O
(,O
n,O
=,O
24,O
),O
were,O
selected,O
with,O
screening,O
systolic,B
blood,I
pressure,I
(,O
BP,O
),O
of,O
140,O
to,O
160,O
mm,O
Hg,O
and,O
/,O
or,O
diastolic,B
BP,I
90,O
to,O
99,O
mm,O
Hg,O
.,O
Low,O
-,O
risk,O
controls,O
(,O
n,O
=,O
24,O
),O
reported,O
no,O
parental,O
history,O
of,O
hypertension,O
and,O
had,O
screening,O
BP,O
<,O
130,O
/,O
85,O
mm,O
Hg,O
.,O
Participants,O
were,O
then,O
tested,O
on,O
2,O
occasions,O
after,O
12,O
-,O
hour,O
abstinence,O
from,O
caffeine,B
in,O
each,O
of,O
2,O
protocols,O
;,O
this,O
required,O
a,O
total,O
of,O
4,O
laboratory,O
visits,O
.,O
Caffeine,B
-,O
induced,O
changes,O
in,O
diastolic,O
BP,O
were,O
2,O
to,O
3,O
times,O
larger,O
in,O
borderline,O
subjects,O
than,O
in,O
controls,O
(,O
+,O
8,O
.,O
4,O
vs,O
+,O
3,O
.,O
8,O
mm,O
Hg,O
",",O
p,O
<,O
0,O
.,O
1,O
.,O
"),",O
and,O
were,O
attributable,O
to,O
larger,O
changes,O
in,O
impedance,B
-,I
derived,I
measures,O
of,O
systemic,O
vascular,O
resistance,O
(,O
+,O
135,O
vs,O
+,O
45,O
dynes,O
.,O
s,O
.,O
cm,O
-,O
5,O
",",O
p,O
<,O
0,O
.,O
4,O
.,O
These,O
findings,O
were,O
consistent,O
and,O
reached,O
significance,O
in,O
both,O
protocols,O
.,O
The,O
percentage,O
of,O
borderline,O
subjects,O
in,O
whom,O
diastolic,O
BP,O
changes,O
exceeded,O
the,O
median,O
control,O
response,O
was,O
96,O
%,O
.,O
Consequently,O
",",O
whereas,O
all,O
participants,O
exhibited,O
normotensive,O
levels,O
during,O
the,O
resting,O
predrug,O
baseline,O
",",O
33,O
%,O
of,O
borderline,O
subjects,O
achieved,O
hypertensive,O
BP,O
levels,O
after,O
caffeine,B
ingestion,O
.,O
Thus,O
",",O
in,O
borderline,O
hypertensive,O
men,O
",",O
exaggerated,O
responses,O
to,O
caffeine,B
were,O
:,O
selective,O
for,O
diastolic,B
BP,I
",",O
consistent,O
with,O
greater,O
vasoconstriction,O
",",O
replicated,O
in,O
2,O
protocols,O
",",O
and,O
representative,O
of,O
nearly,O
all,O
borderline,O
hypertensives,O
.,O
We,O
suspect,O
that,O
the,O
potential,O
for,O
caffeine,B
to,O
stabilize,O
high,O
resistance,O
states,O
in,O
susceptible,O
persons,O
suggests,O
that,O
its,O
use,O
may,O
facilitate,O
their,O
disease,O
progression,O
",",O
as,O
well,O
as,O
hinder,O
accurate,O
diagnosis,O
and,O
treatment,O
.,O
Absence,O
of,O
effect,O
of,O
sertraline,B
on,O
time,O
-,O
based,O
sensitization,O
of,O
cognitive,O
impairment,O
with,O
haloperidol,B
.,O
This,O
double,O
-,O
blind,O
",",O
randomized,O
",",O
placebo,B
-,I
controlled,I
study,O
evaluated,O
the,O
effects,O
of,O
haloperidol,B
alone,O
and,O
haloperidol,B
plus,O
sertraline,B
on,O
cognitive,O
and,O
psychomotor,O
function,O
in,O
24,O
healthy,O
male,O
subjects,O
.,O
METHOD,O
:,O
All,O
subjects,O
received,O
placebo,B
on,O
Day,O
1,O
and,O
haloperidol,B
2,O
mg,O
on,O
Days,O
2,O
and,O
25,O
.,O
From,O
Days,O
9,O
to,O
25,O
",",O
subjects,O
were,O
randomly,O
assigned,O
to,O
either,O
sertraline,B
(,O
12,O
subjects,O
),O
or,O
placebo,B
(,O
12,O
subjects,O
),O
;,O
the,O
sertraline,B
dose,O
was,O
titrated,O
from,O
50,O
to,O
200,O
mg,O
/,O
day,O
from,O
Days,O
9,O
to,O
16,O
",",O
and,O
remained,O
at,O
200,O
mg,O
/,O
day,O
for,O
the,O
final,O
10,O
days,O
of,O
the,O
drug,O
administration,O
period,O
.,O
Cognitive,O
function,O
testing,O
was,O
performed,O
before,O
dosing,O
and,O
over,O
a,O
24,O
-,O
hour,O
period,O
after,O
dosing,O
on,O
Days,O
1,O
",",O
2,O
",",O
and,O
25,O
.,O
RESULTS,O
:,O
Impairment,O
of,O
cognitive,O
function,O
was,O
observed,O
6,O
to,O
8,O
hours,O
after,O
administration,O
of,O
haloperidol,B
on,O
Day,O
2,O
but,O
was,O
not,O
evident,O
23,O
hours,O
after,O
dosing,O
.,O
When,O
single,O
-,O
dose,O
haloperidol,B
was,O
given,O
again,O
25,O
days,O
later,O
",",O
greater,O
impairment,O
with,O
earlier,O
onset,O
was,O
noted,O
in,O
several,O
tests,O
in,O
both,O
treatment,O
groups,O
",",O
suggesting,O
enhancement,O
of,O
this,O
effect,O
.,O
There,O
was,O
no,O
indication,O
that,O
sertraline,B
exacerbated,O
the,O
impairment,O
produced,O
by,O
haloperidol,B
since,O
an,O
equivalent,O
effect,O
also,O
occurred,O
in,O
the,O
placebo,B
group,O
.,O
Three,O
subjects,O
(,O
2,O
on,O
sertraline,B
and,O
1,O
on,O
placebo,B
),O
withdrew,O
from,O
the,O
study,O
because,O
of,O
side,O
effects,O
.,O
Ten,O
subjects,O
in,O
each,O
group,O
reported,O
side,O
effects,O
related,O
to,O
treatment,O
.,O
The,O
side,O
effect,O
profiles,O
of,O
sertraline,B
and,O
of,O
placebo,B
were,O
similar,O
.,O
CONCLUSION,O
:,O
Haloperidol,B
produced,O
a,O
clear,O
profile,O
of,O
cognitive,O
impairment,O
that,O
was,O
not,O
worsened,O
by,O
concomitant,O
sertraline,B
administration,O
.,O
Coexistence,O
of,O
cerebral,O
venous,O
sinus,O
and,O
internal,O
carotid,O
artery,O
thrombosis,O
associated,O
with,O
exogenous,O
sex,O
hormones,O
.,O
A,O
case,O
report,O
.,O
A,O
forty,O
-,O
six,O
year,O
-,O
old,O
premenopausal,O
woman,O
developed,O
headache,O
",",O
nausea,O
and,O
vomiting,O
",",O
left,O
hemiparesis,O
and,O
seizure,O
two,O
days,O
after,O
parenteral,O
use,O
of,O
progesterone,B
and,O
estradiol,B
.,O
Diabetes,B
mellitus,I
(,I
DM,I
),I
was,O
found,O
during,O
admission,O
.,O
Computed,O
tomography,O
showed,O
a,O
hemorrhagic,O
infarct,O
in,O
the,O
right,O
frontal,O
lobe,O
and,O
increased,O
density,O
in,O
the,O
superior,O
sagittal,O
sinus,O
(,O
SSS,O
),O
.,O
Left,O
carotid,O
angiography,O
found,O
occlusion,O
of,O
the,O
left,O
internal,O
carotid,O
artery,B
(,O
ICA,B
),O
.,O
Right,O
carotid,O
angiograms,O
failed,O
to,O
show,O
the,O
SSS,O
and,O
inferior,O
sagittal,O
sinus,O
",",O
suggestive,O
of,O
venous,O
sinus,O
thrombosis,O
.,O
Coexistence,O
of,O
the,O
cerebral,O
artery,B
and,O
the,O
venous,O
sinus,O
occlusion,O
has,O
been,O
described,O
infrequently,O
.,O
In,O
this,O
case,O
",",O
the,O
authors,O
postulate,O
that,O
the,O
use,O
of,O
estradiol,B
and,O
progesterone,B
and,O
the,O
underlying,O
DM,O
increased,O
vascular,O
thrombogenicity,O
",",O
which,O
provided,O
a,O
common,O
denominator,O
for,O
thrombosis,O
of,O
both,O
the,O
ICA,B
and,O
the,O
venous,O
sinus,O
.,O
Chemotherapy,O
of,O
advanced,O
inoperable,O
non,O
-,O
small,O
cell,O
lung,O
cancer,O
with,O
paclitaxel,B
:,O
a,O
phase,O
II,O
trial,O
.,O
Paclitaxel,B
(,O
Taxol,B
;,O
Bristol,B
-,I
Myers,I
Squibb,I
Company,I
",",O
Princeton,B
",",O
NJ,B
),O
has,O
demonstrated,O
significant,O
antineoplastic,O
activity,O
against,O
different,O
tumor,O
types,O
",",O
notably,O
ovarian,B
and,O
breast,B
carcinoma,I
.,O
Two,O
phase,O
II,O
trials,O
of,O
24,O
-,O
hour,O
paclitaxel,B
infusions,O
in,O
chemotherapy,O
-,O
naive,O
patients,O
with,O
stage,O
IIIB,O
or,O
IV,O
non,O
-,O
small,O
cell,O
lung,O
cancer,O
(,O
NSCLC,B
),O
reported,O
response,O
rates,O
of,O
21,O
%,O
and,O
24,O
%,O
.,O
Leukopenia,B
was,O
dose,O
limiting,O
:,O
as,O
many,O
as,O
62,O
.,O
5,O
%,O
of,O
patients,O
experienced,O
grade,O
4,O
leukopenia,B
.,O
We,O
investigated,O
the,O
efficacy,O
and,O
toxicity,O
of,O
a,O
3,O
-,O
hour,O
paclitaxel,B
infusion,O
in,O
a,O
phase,O
II,O
trial,O
in,O
patients,O
with,O
inoperable,O
stage,O
IIIB,O
or,O
IV,O
NSCLC,O
.,O
The,O
58,O
patients,O
treated,O
(,O
41,O
men,O
and,O
17,O
women,O
),O
had,O
a,O
median,O
age,O
of,O
59,O
years,O
(,O
age,O
range,O
",",O
25,O
to,O
75,O
),O
and,O
a,O
performance,O
status,O
of,O
0,O
through,O
2,O
.,O
Most,O
patients,O
(,O
72,O
.,O
4,O
%,O
),O
had,O
stage,O
IV,O
NSCLC,B
.,O
Paclitaxel,B
225,O
mg,O
/,O
m2,O
was,O
infused,O
over,O
3,O
hours,O
every,O
3,O
weeks,O
with,O
standard,O
prophylactic,O
premedication,O
.,O
Of,O
50,O
patients,O
evaluable,O
for,O
response,O
",",O
12,O
(,O
24,O
%,O
),O
had,O
partial,O
remission,O
",",O
26,O
(,O
52,O
%,O
),O
had,O
no,O
change,O
",",O
and,O
12,O
had,O
disease,O
progression,O
(,O
24,O
%,O
),O
.,O
Hematologic,O
toxicities,O
were,O
mild,O
:,O
only,O
one,O
patient,O
(,O
2,O
%,O
),O
developed,O
grade,O
3,O
or,O
4,O
neutropenia,B
",",O
while,O
29,O
%,O
had,O
grade,O
1,O
or,O
2,O
.,O
Grade,O
1,O
or,O
2,O
polyneuropathy,B
affected,O
56,O
%,O
of,O
patients,O
while,O
only,O
one,O
(,O
2,O
%,O
),O
experienced,O
severe,B
polyneuropathy,I
.,O
Similarly,O
",",O
grade,O
1,O
or,O
2,O
myalgia,B
/,I
arthralgia,I
was,O
observed,O
in,O
63,O
0.2,O
%,O
of,O
patients,O
",",O
but,O
only,O
14,O
0.3,O
%,O
experienced,O
grade,O
3,O
or,O
4,O
.,O
Nausea,B
and,I
vomiting,I
were,O
infrequent,O
",",O
with,O
14,O
%,O
of,O
patients,O
experiencing,O
grade,O
1,O
or,O
2,O
and,O
only,O
2,O
%,O
experiencing,O
grade,O
3,O
or,O
4,O
.,O
Paclitaxel,B
is,O
thus,O
an,O
active,O
single,O
agent,O
in,O
this,O
patient,O
population,O
",",O
with,O
a,O
3,O
-,O
hour,O
infusion,O
proving,O
comparably,O
effective,O
to,O
a,O
24,O
-,O
hour,O
infusion,O
and,O
superior,O
in,O
terms,O
of,O
the,O
incidence,O
of,O
hematologic,B
and,O
nonhematologic,B
toxicity,O
.,O
Further,O
phase,O
II,O
studies,O
with,O
paclitaxel,B
combined,O
with,O
other,O
drugs,O
active,O
against,O
NSCLC,B
are,O
indicated,O
",",O
and,O
phase,O
III,O
studies,O
comparing,O
paclitaxel,B
with,O
standard,O
chemotherapy,O
remain,O
to,O
be,O
completed,O
.,O
Paclitaxel,B
combined,O
with,O
carboplatin,B
in,O
the,O
first,O
-,O
line,O
treatment,O
of,O
advanced,O
ovarian,O
cancer,O
.,O
In,O
a,O
phase,O
I,O
study,O
to,O
determine,O
the,O
maximum,O
tolerated,O
dose,O
of,O
paclitaxel,B
(,O
Taxol,B
;,O
Bristol,B
-,O
Myers,I
Squibb,I
Company,I
",",O
Princeton,B
",",O
NJ,B
),O
given,O
as,O
a,O
3,O
-,O
hour,O
infusion,O
in,O
combination,O
with,O
carboplatin,B
administered,O
every,O
21,O
days,O
to,O
women,O
with,O
advanced,O
ovarian,O
cancer,O
",",O
paclitaxel,B
doses,O
were,O
escalated,O
as,O
follows,O
:,O
level,O
1,O
",",O
135,O
mg,O
/,O
m2,O
;,O
level,O
2,O
",",O
160,O
mg,O
/,O
m2,O
;,O
level,O
3,O
",",O
185,O
mg,O
/,O
m2,O
;,O
and,O
level,O
4,O
",",O
210,O
mg,O
/,O
m2,O
.,O
The,O
fixed,O
dose,O
of,O
carboplatin,B
at,O
levels,O
1,O
through,O
4,O
was,O
given,O
to,O
achieve,O
an,O
area,O
under,O
the,O
concentration,O
-,O
time,O
curve,O
(,O
AUC,B
),O
of,O
5,O
using,O
the,O
Calvert,O
formula,O
.,O
In,O
levels,O
5,O
and,O
6,O
the,O
carboplatin,B
dose,O
was,O
targeted,O
at,O
AUCs,O
of,O
6,O
and,O
7,O
.,O
5,O
",",O
respectively,O
",",O
combined,O
with,O
a,O
fixed,O
paclitaxel,B
dose,O
of,O
185,O
mg,O
/,O
m2,O
.,O
To,O
date,O
",",O
30,O
previously,O
untreated,O
patients,O
",",O
all,O
with,O
a,O
good,O
performance,O
status,O
(,O
Eastern,O
Cooperative,O
Oncology,O
Group,O
0,O
to,O
2,O
),O
have,O
been,O
entered,O
into,O
this,O
ongoing,O
study,O
.,O
The,O
dose,O
-,O
limiting,O
toxicity,O
of,O
the,O
combination,O
was,O
myelosuppression,B
(,O
leukopenia,B
",",O
granulocytopenia,B
",",O
and,O
thrombocytopenia,B
),O
.,O
Neurotoxicity,O
was,O
largely,O
moderate,O
.,O
So,O
far,O
",",O
14,O
patients,O
are,O
evaluable,O
for,O
response,O
;,O
of,O
these,O
",",O
eight,O
(,O
57,O
%,O
),O
showed,O
objective,O
(,O
complete,O
or,O
partial,O
),O
response,O
and,O
disease,O
stabilized,O
in,O
six,O
patients,O
.,O
No,O
patient,O
had,O
disease,O
progression,O
.,O
We,O
conclude,O
that,O
the,O
combination,O
of,O
paclitaxel,B
185,O
mg,O
/,O
m2,O
administered,O
as,O
a,O
3,O
-,O
hour,O
infusion,O
followed,O
immediately,O
by,O
a,O
1,O
-,O
hour,O
infusion,O
of,O
carboplatin,B
at,O
an,O
AUC,B
of,O
6,O
can,O
be,O
administered,O
safely,O
in,O
a,O
21,O
-,O
day,O
schedule,O
in,O
the,O
outpatient,O
setting,O
.,O
The,O
recommended,O
dose,O
for,O
phase,O
III,O
studies,O
is,O
paclitaxel,B
185,O
mg,O
/,O
m2,O
and,O
carboplatin,B
AUC,O
6,O
.,O
Effects,O
of,O
acute,O
steroid,B
administration,O
on,O
ventilatory,O
and,O
peripheral,O
muscles,O
in,O
rats,O
.,O
Occasional,O
case,O
reports,O
have,O
shown,O
that,O
acute,O
myopathy,O
may,O
occur,O
in,O
patients,O
treated,O
with,O
massive,O
doses,O
of,O
corticosteroids,B
.,O
The,O
mechanism,O
of,O
this,O
myopathy,O
is,O
poorly,O
understood,O
.,O
Therefore,O
",",O
60,O
male,O
rats,O
were,O
randomly,O
assigned,O
to,O
receive,O
daily,O
injection,O
of,O
saline,B
(,O
C,B
),O
",",O
methylprednisolone,B
(,O
M,B
),O
",",O
or,O
triamcinolone,B
(,O
T,B
),O
80,O
mg,O
/,O
kg,O
/,O
d,O
for,O
5,O
d,O
.,O
Nutritional,O
intake,O
",",O
measured,O
daily,O
in,O
15,O
animals,O
",",O
showed,O
a,O
significant,O
reduction,O
of,O
food,O
intake,O
in,O
the,O
steroid,O
-,O
treated,O
groups,O
(,O
-,O
50,O
and,O
-,O
79,O
%,O
in,O
M,B
and,O
T,B
",",O
respectively,O
.,O
This,O
was,O
associated,O
with,O
a,O
similar,O
loss,O
in,O
body,O
weight,O
.,O
In,O
the,O
45,O
remaining,O
animals,O
",",O
diaphragm,O
contractility,O
and,O
histopathologic,O
features,O
of,O
several,O
muscles,O
were,O
studied,O
.,O
Weights,O
of,O
respiratory,O
and,O
peripheral,O
muscles,O
were,O
similarly,O
decreased,O
after,O
steroid,O
treatment,O
.,O
Maximal,O
twitches,O
of,O
the,O
diaphragm,O
were,O
lower,O
in,O
the,O
C,O
group,O
(,O
653,O
+,O
/,O
-,O
174,O
g,O
/,O
cm,O
(,O
2,O
),O
than,O
in,O
the,O
M,O
group,O
(,O
837,O
+,O
/,O
-,O
171,O
g,O
/,O
cm,O
(,O
2,O
),O
;,O
p,O
<,O
0,O
.,O
5,O
),O
and,O
the,O
T,B
group,O
(,O
765,O
+,O
/,O
-,O
145,O
g,O
/,O
cm,O
(,O
2,O
),O
",",O
NS,B
.,O
Half,O
-,O
relaxation,O
time,O
was,O
prolonged,O
in,O
both,O
steroid,B
groups,O
",",O
and,O
time,O
to,O
peak,O
tension,O
was,O
longer,O
with,O
M,B
",",O
whereas,O
tetanic,O
tensions,O
were,O
similar,O
.,O
Steroid,B
treatment,O
also,O
induced,O
a,O
leftward,O
shift,O
of,O
the,O
force,O
-,O
frequency,O
curve,O
at,O
25,O
and,O
50,O
Hz,B
when,O
compared,O
with,O
saline,B
treatment,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
.,O
ATPase,B
staining,O
of,O
the,O
diaphragm,O
",",O
scalenus,O
medius,O
",",O
and,O
gastrocnemius,O
showed,O
type,O
IIb,O
fiber,O
atrophy,O
in,O
the,O
steroid,O
groups,O
and,O
also,O
diaphragmatic,O
type,O
IIa,O
atrophy,O
with,O
T,B
",",O
whereas,O
histologic,O
examinations,O
revealed,O
a,O
normal,O
muscular,O
pattern,O
with,O
absence,O
of,O
necrosis,O
.,O
Finally,O
",",O
a,O
pair,O
-,O
fed,O
(,O
PF,B
),O
study,O
",",O
performed,O
in,O
18,O
rats,O
(,O
C,B
",",O
T,B
",",O
and,O
PF,B
),O
",",O
showed,O
that,O
muscle,O
atrophy,O
was,O
considerably,O
less,O
pronounced,O
in,O
PF,B
animals,O
than,O
in,O
T,B
-,O
treated,O
animals,O
.,O
We,O
conclude,O
that,O
(,O
1,O
),O
short,O
-,O
term,O
treatment,O
with,O
massive,O
doses,O
of,O
steroids,B
induced,O
severe,O
respiratory,O
and,O
limb,O
muscle,O
wasting,O
;,O
(,O
2,O
),O
both,O
types,O
of,O
steroids,B
induced,O
predominantly,O
type,O
IIb,O
atrophy,O
",",O
resulting,O
in,O
the,O
expected,O
alterations,O
in,O
diaphragm,O
contractile,O
properties,O
;,O
(,O
3,O
),O
neither,O
steroid,B
caused,O
muscle,O
necrosis,O
;,O
(,O
4,O
),O
type,O
IIb,O
atrophy,O
was,O
not,O
caused,O
by,O
acute,O
nutritional,O
deprivation,O
alone,O
.,O
Continuous,O
subcutaneous,O
administration,O
of,O
mesna,B
to,O
prevent,O
ifosfamide,B
-,O
induced,O
hemorrhagic,O
cystitis,O
.,O
Hemorrhagic,O
cystitis,O
is,O
a,O
major,O
potential,O
toxicity,O
of,O
ifosfamide,B
that,O
can,O
be,O
prevented,O
by,O
administering,O
mesna,B
along,O
with,O
the,O
cytotoxic,O
agent,O
.,O
Mesna,B
is,O
generally,O
administered,O
by,O
the,O
intravenous,O
route,O
",",O
although,O
experience,O
with,O
oral,O
delivery,O
of,O
the,O
drug,O
has,O
increased,O
.,O
The,O
continuous,O
subcutaneous,O
administration,O
of,O
mesna,B
has,O
the,O
advantage,O
of,O
not,O
requiring,O
intravenous,O
access,O
.,O
In,O
addition,O
",",O
subcutaneous,O
delivery,O
of,O
the,O
neutralizing,O
agent,O
will,O
not,O
be,O
associated,O
with,O
the,O
risk,O
of,O
inadequate,O
urinary,O
mesna,B
concentrations,O
",",O
such,O
as,O
in,O
a,O
patient,O
taking,O
oral,O
mesna,B
who,O
experiences,O
severe,O
ifosfamide,B
-,I
induced,O
emesis,O
and,O
is,O
unable,O
to,O
absorb,O
the,O
drug,O
.,O
Limited,O
clinical,O
experience,O
with,O
continuous,O
subcutaneous,O
mesna,B
administration,O
suggests,O
it,O
is,O
a,O
safe,O
",",O
practical,O
",",O
and,O
economic,O
method,O
of,O
drug,O
delivery,O
that,O
permits,O
ifosfamide,B
to,O
be,O
administered,O
successfully,O
in,O
the,O
outpatient,O
setting,O
.,O
Leg,O
and,O
back,O
pain,O
after,O
spinal,O
anaesthesia,O
involving,O
hyperbaric,O
5,O
%,O
lignocaine,B
.,O
Fifty,O
-,O
four,O
patients,O
",",O
aged,O
27,O
-,O
90,O
years,O
",",O
who,O
were,O
given,O
lignocaine,B
5,O
%,O
in,O
6,O
.,O
8,O
%,O
glucose,B
solution,O
for,O
spinal,O
anaesthesia,O
were,O
studied,O
.,O
Thirteen,O
of,O
these,O
patients,O
experienced,O
pain,O
in,O
the,O
legs,O
and,O
/,O
or,O
back,O
after,O
recovery,O
from,O
anaesthesia,O
.,O
The,O
patients,O
affected,O
were,O
younger,O
(,O
p,O
<,O
0,O
.,O
5,O
),O
and,O
the,O
site,O
of,O
the,O
dural,O
puncture,O
was,O
higher,O
(,O
p,O
<,O
0,O
.,O
1,O
),O
than,O
those,O
individuals,O
without,O
pain,O
.,O
Five,O
of,O
the,O
13,O
patients,O
(,O
38,O
%,O
),O
with,O
pain,O
and,O
seven,O
of,O
the,O
41,O
patients,O
(,O
17,O
%,O
),O
without,O
pain,O
admitted,O
to,O
a,O
high,O
alcohol,O
intake,O
",",O
which,O
might,O
be,O
a,O
contributing,O
factor,O
.,O
Leg,O
and,O
/,O
or,O
back,O
pain,O
is,O
associated,O
with,O
the,O
intrathecal,O
use,O
of,O
hyperbaric,O
5,B
%,I
lignocaine,I
.,O
The,O
use,O
of,O
serum,B
cholinesterase,I
in,O
succinylcholine,B
apnoea,O
.,O
Fifteen,O
patients,O
demonstrating,O
unexpected,O
prolonged,O
apnoea,O
lasting,O
several,O
hours,O
after,O
succinylcholine,B
have,O
been,O
treated,O
by,O
a,O
new,O
preparation,O
of,O
human,B
serum,I
cholinesterase,I
.,O
Adequate,O
spontaneous,O
respiration,O
was,O
re,O
-,O
established,O
in,O
an,O
average,O
period,O
of,O
ten,O
minutes,O
after,O
the,O
injection,O
.,O
In,O
12,O
patients,O
biochemical,O
genetic,O
examinations,O
confirmed,O
the,O
presence,O
of,O
an,O
atypical,B
serum,I
cholinesterase,I
.,O
In,O
three,O
patients,O
none,O
of,O
the,O
usual,O
variants,O
were,O
found,O
.,O
It,O
is,O
therefore,O
supposed,O
that,O
other,O
unknown,O
variants,O
of,O
serum,B
cholinesterase,I
exist,O
which,O
cannot,O
hydrolyze,O
succinylcholine,O
.,O
The,O
use,O
of,O
serum,B
cholinesterase,I
in,O
succinylcholine,O
apnoea,O
provided,O
considerable,O
relief,O
to,O
both,O
patient,O
and,O
anaesthetist,O
.,O
Increased,O
sulfation,B
and,O
decreased,O
7alpha,B
-,I
hydroxylation,I
of,O
deoxycholic,B
acid,I
in,O
ethinyl,B
estradiol,I
-,I
induced,I
cholestasis,I
in,I
rats,I
.,O
Deoxycholic,B
acid,I
conjugation,I
",",O
transport,B
capacity,I
",",O
and,O
metabolism,B
were,O
compared,O
in,O
control,B
and,O
ethinyl,B
estradiol,I
-,I
treated,I
rats,I
.,O
Control,B
rats,I
were,O
found,O
to,O
have,O
a,O
lower,O
capacity,I
to,O
transport,B
deoxycholic,B
acid,I
than,O
taurodeoxycholic,B
acid,I
",",O
and,O
both,O
were,O
decreased,O
by,O
ethinyl,B
estradiol,I
treatment,I
.,O
During,O
[,O
24,B
-,I
14C,I
],O
sodium,B
deoxycholate,I
infusion,O
",",O
[,O
14C,B
],O
biliary,O
bile,O
acid,O
secretion,O
increased,O
",",O
but,O
bile,O
flow,O
did,O
not,O
change,O
significantly,O
in,O
either,O
control,O
or,O
ethinyl,B
estradiol,I
-,I
treated,I
rats,O
.,O
Ethinyl,B
estradiol,I
-,I
treated,I
animals,O
excreted,O
significantly,O
less,O
14C,B
as,O
taurocholic,B
acid,I
than,O
did,O
control,O
animals,O
",",O
consistent,O
with,O
an,O
impairment,O
of,O
7alpha,B
-,I
hydroxylation,I
of,O
taurodeoxycholic,B
acid,I
.,O
Ethinyl,B
estradiol,I
treatment,O
did,O
not,O
impair,O
conjugation,O
of,O
deoxycholic,B
acid,I
",",O
but,O
did,O
result,O
in,O
an,O
increase,O
in,O
sulfation,O
of,O
taurodeoxycholic,B
acid,I
from,O
1,O
.,O
5,O
%,O
in,O
controls,O
to,O
nearly,O
4,O
.,O
0,O
%,O
(,O
P,O
less,O
than,O
0,O
.,O
1,O
(,O
P,O
less,O
than,O
0,O
.,O
1,O
),O
.,O
These,O
results,O
are,O
consistent,O
with,O
the,O
hypothesis,O
that,O
the,O
rat,O
has,O
a,O
poorer,O
tolerance,O
for,O
deoxycholic,B
acid,I
than,O
do,O
certain,O
other,O
species,O
.,O
Furthermore,O
",",O
the,O
rat,O
converts,O
deoxycholic,B
acid,I
",",O
a,O
poor,O
choleretic,O
",",O
to,O
taurocholic,B
acid,I
",",O
a,O
good,O
choleretic,O
.,O
When,O
this,O
conversion,O
is,O
impaired,O
with,O
ethinyl,B
estradiol,I
treatment,O
",",O
sulfation,O
may,O
be,O
an,O
important,O
alternate,O
pathway,O
for,O
excretion,O
of,O
this,O
potentially,O
harmful,O
bile,B
acid,I
.,O
Influence,O
of,O
diet,O
free,O
of,O
NAD,B
-,I
precursors,I
on,O
acetaminophen,B
hepatotoxicity,I
in,O
mice,O
.,O
Recently,O
",",O
we,O
demonstrated,O
the,O
hepatoprotective,O
effects,O
of,O
nicotinic,B
acid,I
amide,I
",",O
a,O
selective,O
inhibitor,O
of,O
poly,B
(,I
ADP,I
-,I
ribose,I
),I
polymerase,I
(,O
PARP,B
;,O
EC,O
2,O
.,O
4,O
.,O
2,O
.,O
30,O
),O
on,O
mice,O
suffering,O
from,O
acetaminophen,B
(,O
AAP,B
),O
-,O
hepatitis,O
",",O
suggesting,O
that,O
the,O
AAP,B
-,O
induced,O
liver,O
injury,O
involves,O
a,O
step,O
which,O
depends,O
on,O
adenoribosylation,O
.,O
The,O
present,O
study,O
investigates,O
the,O
effects,O
of,O
a,O
diet,O
free,O
of,O
precursors,O
of,O
NAD,B
",",O
the,O
substrate,O
on,O
which,O
PARP,B
acts,O
",",O
in,O
female,O
NMRI,O
mice,O
with,O
AAP,B
hepatitis,O
and,O
evaluates,O
the,O
influence,O
of,O
simultaneous,O
ethanol,O
consumption,O
in,O
these,O
animals,O
.,O
Liver,O
injuries,O
were,O
quantified,O
as,O
serum,O
activities,O
of,O
glutamate,B
-,O
oxaloacetate,I
transaminase,I
(,O
GOT,B
),O
and,O
glutamate,B
-,O
pyruvate,I
transaminase,I
(,O
GPT,B
),O
.,O
While,O
AAP,B
caused,O
a,O
117,O
-,O
fold,O
elevation,O
of,O
serum,O
transaminase,O
activities,O
in,O
mice,O
kept,O
on,O
a,O
standard,O
laboratory,O
diet,O
",",O
which,O
was,O
significantly,O
exacerbated,O
by,O
ethanol,O
and,O
inhibited,O
by,O
nicotinic,B
acid,I
amide,I
(,O
NAA,O
),O
",",O
adverse,O
effects,O
were,O
noted,O
in,O
animals,O
fed,O
a,O
diet,O
free,O
of,O
precursors,O
of,O
NAD,B
.,O
In,O
these,O
animals,O
",",O
only,O
minor,O
increases,O
of,O
serum,O
transaminase,O
activities,O
were,O
measured,O
in,O
the,O
presence,O
of,O
AAP,B
",",O
and,O
unlike,O
the,O
exacerbation,O
caused,O
by,O
ethanol,O
in,O
mice,O
on,O
a,O
standard,O
diet,O
",",O
the,O
liver,O
damage,O
was,O
inhibited,O
by,O
50,O
%,O
by,O
ethanol,O
.,O
A,O
further,O
64,O
%,O
reduction,O
of,O
hepatitis,B
was,O
observed,O
",",O
when,O
NAA,B
was,O
given,O
to,O
ethanol,O
/,O
AAP,B
-,O
mice,O
.,O
Our,O
results,O
provide,O
evidence,O
that,O
the,O
AAP,B
-,O
induced,O
hepatitis,B
and,O
its,O
exacerbation,O
by,O
ethanol,O
can,O
either,O
be,O
reduced,O
by,O
end,O
-,O
product,O
inhibition,O
of,O
PARP,B
by,O
NAA,B
or,O
by,O
dietary,O
depletion,O
of,O
the,O
enzyme,O
',O
s,O
substrate,O
NAD,B
.,O
We,O
see,O
the,O
main,O
application,O
of,O
NAA,B
as,O
for,O
the,O
combinational,O
use,O
in,O
pharmaceutical,O
preparations,O
of,O
acetaminophen,B
in,O
order,O
to,O
avoid,O
hepatic,O
damage,O
in,O
patients,O
treated,O
with,O
this,O
widely,O
used,O
analgesic,O
.,O
Nightmares,O
and,O
hallucinations,O
after,O
long,O
-,O
term,O
intake,O
of,O
tramadol,B
combined,O
with,O
antidepressants,O
.,O
Tramadol,B
is,O
a,O
weak,O
opioid,O
with,O
effects,O
on,O
adrenergic,O
and,O
serotonergic,O
neurotransmission,O
that,O
is,O
used,O
to,O
treat,O
cancer,O
pain,O
and,O
chronic,O
non,O
malignant,O
pain,O
.,O
This,O
drug,O
was,O
initiated,O
in,O
association,O
with,O
paroxetine,B
and,O
dosulepine,B
hydrochloride,I
in,O
a,O
tetraparetic,O
patient,O
with,O
chronic,O
pain,O
.,O
Fifty,O
-,O
six,O
days,O
after,O
initiation,O
of,O
the,O
treatment,O
the,O
patient,O
presented,O
hallucinations,O
that,O
only,O
stopped,O
after,O
the,O
withdrawal,O
of,O
psycho,B
-,I
active,I
drugs,I
and,O
tramadol,B
.,O
The,O
case,O
report,O
questions,O
the,O
long,O
term,O
use,O
of,O
pain,O
killers,O
combined,O
with,O
psycho,B
-,I
active,I
drugs,I
in,O
chronic,O
non,O
malignant,O
pain,O
",",O
especially,O
if,O
pain,O
is,O
under,O
control,O
.,O
Effect,O
of,O
calcium,B
chloride,I
and,O
4,B
-,I
aminopyridine,I
therapy,O
on,O
desipramine,O
toxicity,O
in,O
rats,O
.,O
BACKGROUND,O
:,O
Hypotension,O
is,O
a,O
major,O
contributor,O
to,O
mortality,O
in,O
tricyclic,O
antidepressant,O
overdose,O
.,O
Recent,O
data,O
suggest,O
that,O
tricyclic,O
antidepressants,O
inhibit,O
calcium,B
influx,O
in,O
some,O
tissues,O
.,O
This,O
study,O
addressed,O
the,O
potential,O
role,O
of,O
calcium,B
channel,I
blockade,I
in,O
tricyclic,O
antidepressant,O
-,O
induced,O
hypotension,O
.,O
METHODS,O
:,O
Two,O
interventions,O
were,O
studied,O
that,O
have,O
been,O
shown,O
previously,O
to,O
improve,O
blood,O
pressure,O
with,O
calcium,B
channel,I
blocker,I
overdose,I
.,O
CaCl2,B
and,O
4,B
-,I
aminopyridine,I
.,O
Anesthetized,O
rats,O
received,O
the,O
tricyclic,O
antidepressant,O
desipramine,O
IP,O
to,O
produce,O
hypotension,O
",",O
QRS,O
prolongation,O
",",O
and,O
bradycardia,O
.,O
Fifteen,O
min,O
later,O
",",O
animals,O
received,O
CaCl2,B
",",O
NaHCO3,B
",",O
or,O
saline,O
.,O
In,O
a,O
second,O
experiment,O
",",O
rats,O
received,O
tricyclic,B
antidepressant,I
desipramine,I
IP,O
followed,O
in,O
15,O
min,O
by,O
4,B
-,I
aminopyridine,I
or,O
saline,O
.RESULTS,O
:,O
NaHCO3,B
briefly,O
(,O
5,O
min,O
),O
reversed,O
hypotension,O
and,O
QRS,O
prolongation,O
.CaCl2,B
and,O
4,B
-,I
aminopyridine,I
failed,O
to,O
improve,O
blood,O
pressure,O
.The,O
incidence,O
of,O
ventricular,O
arrhythmias,O
(,O
p,O
=,O
0,O
.,O
4,O
),O
and,O
seizures,O
(,O
p,O
=,O
0,O
.,O
3,O
),O
in,O
the,O
CaCl2,B
group,O
was,O
higher,O
than,O
the,O
other,O
groups,O
.,O
CONCLUSION,O
:,O
The,O
administration,O
of,O
CaCl2,B
or,O
4,B
-,I
aminopyridine,I
did,O
not,O
reverse,O
tricyclic,O
antidepressant,O
-,O
induced,O
hypotension,O
in,O
rats,O
.,O
CaCl2,B
therapy,O
may,O
possibly,O
worsen,O
both,O
cardiovascular,O
and,O
central,O
nervous,O
system,O
toxicity,O
.,O
These,O
findings,O
do,O
not,O
support,O
a,O
role,O
for,O
calcium,B
channel,I
inhibition,I
in,O
the,O
pathogenesis,O
of,O
tricyclic,O
antidepressant,O
-,O
induced,O
hypotension,O
.,O
Valsartan,B
",",O
a,O
new,O
angiotensin,B
II,I
antagonist,I
for,O
the,O
treatment,O
of,O
essential,O
hypertension,O
:,O
a,O
comparative,O
study,O
of,O
the,O
efficacy,O
and,O
safety,O
against,O
amlodipine,B
.,O
OBJECTIVE,O
:,O
To,O
compare,O
the,O
antihypertensive,O
efficacy,O
of,O
a,O
new,O
angiotensin,B
II,I
antagonist,I
",",O
valsartan,B
",",O
with,O
a,O
reference,O
therapy,O
",",O
amlodipine,B
.,O
METHODS,O
:,O
One,O
hundred,O
sixty,O
-,O
eight,O
adult,O
outpatients,O
with,O
mild,O
to,O
moderate,O
hypertension,O
were,O
randomly,O
allocated,O
in,O
double,O
-,O
blind,O
fashion,O
and,O
equal,O
number,O
to,O
receive,O
80,O
mg,O
valsartan,B
or,O
5,O
mg,O
amlodipine,B
for,O
12,O
weeks,O
.,O
After,O
8,O
weeks,O
of,O
therapy,O
",",O
in,O
patients,O
whose,O
blood,O
pressure,O
remained,O
uncontrolled,O
",",O
5,O
mg,O
amlodipine,B
was,O
added,O
to,O
the,O
initial,O
therapy,O
.,O
Patients,O
were,O
assessed,O
at,O
4,O
",",O
8,O
",",O
and,O
12,O
weeks,O
.,O
The,O
primary,O
efficacy,O
variable,O
was,O
change,O
from,O
baseline,O
in,O
mean,O
sitting,O
diastolic,B
blood,I
pressure,I
at,O
8,O
weeks,O
.,O
Secondary,O
variables,O
included,O
change,O
in,O
sitting,O
systolic,B
blood,I
pressure,I
and,O
responder,O
rates,O
.,O
RESULTS,O
:,O
Both,O
valsartan,B
and,O
amlodipine,B
were,O
effective,O
at,O
lowering,O
blood,I
pressure,I
at,O
4,O
",",O
8,O
",",O
and,O
12,O
weeks,O
.,O
Similar,O
decreases,O
were,O
observed,O
in,O
both,O
groups,O
",",O
with,O
no,O
statistically,O
significant,O
differences,O
between,O
the,O
groups,O
for,O
any,O
variable,O
analyzed,O
.,O
For,O
the,O
primary,O
variable,O
the,O
difference,O
was,O
0,O
.,O
5,O
mm,O
Hg,O
in,O
favor,O
of,O
valsartan,B
(,O
p,O
=,O
0,O
.,O
68,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
-,O
2,O
.,O
7,O
to,O
1,O
.,O
7,O
.,O
Responder,O
rates,O
at,O
8,O
weeks,O
were,O
66,O
.,O
7,O
%,O
for,O
valsartan,B
and,O
60,O
.,O
2,O
%,O
for,O
amlodipine,B
(,O
p,O
=,O
0,O
.,O
39,O
),O
.,O
Both,O
treatments,O
were,O
well,O
tolerated,O
.,O
The,O
incidence,O
of,O
drug,O
-,O
related,O
dependent,O
edema,O
was,O
somewhat,O
higher,O
in,O
the,O
amlodipine,B
group,O
",",O
particularly,O
at,O
a,O
dose,O
of,O
10,O
mg,O
per,O
day,O
(,O
2,O
.,O
4,O
%,O
for,O
80,O
mg,O
valsartan,B
;,O
3,O
.,O
6,O
%,O
for,O
5,O
mg,O
amlodipine,B
;,O
0,O
%,O
for,O
valsartan,B
plus,O
5,O
mg,O
amlodipine,B
;,O
14,O
3,O
%,O
for,O
10,O
mg,O
amlodipine,B
),O
.,O
CONCLUSIONS,O
:,O
The,O
data,O
show,O
that,O
valsartan,B
is,O
at,O
least,O
as,O
effective,O
as,O
amlodipine,O
in,O
the,O
treatment,O
of,O
mild,O
to,O
moderate,O
hypertension,O
.,O
The,O
results,O
also,O
show,O
valsartan,B
to,O
be,O
well,O
tolerated,O
and,O
suggest,O
that,O
it,O
is,O
not,O
associated,O
with,O
side,O
effects,O
characteristic,O
of,O
this,O
comparator,O
class,O
",",O
dihydropyridine,B
calcium,I
antagonists,I
.,O
A,O
measure,O
of,O
pupillary,O
oscillation,O
as,O
a,O
marker,O
of,O
cocaine,B
-,I
induced,I
paranoia,I
.,O
Cocaine,B
-,I
induced,I
paranoia,I
(,O
CIP,B
),O
remains,O
an,O
important,O
drug,O
-,O
induced,O
model,O
of,O
idiopathic,O
paranoia,O
for,O
which,O
no,O
psychophysiologic,O
marker,O
has,O
yet,O
emerged,O
.,O
Measures,O
of,O
pupillary,O
oscillation,O
were,O
able,O
to,O
significantly,O
distinguish,O
a,O
group,O
of,O
abstinent,O
crack,B
cocaine,I
abusers,O
endorsing,O
past,O
CIP,B
(,O
n,O
=,O
32,O
),O
from,O
another,O
group,O
of,O
crack,B
addicts,O
who,O
denied,O
past,O
CIP,B
(,O
n,O
=,O
29,O
),O
.,O
Serotonin,B
syndrome,I
from,O
venlafaxine,B
-,O
tranylcypromine,B
interaction,O
.,O
Excessive,O
stimulation,O
of,O
serotonin,B
5HT1A,I
receptors,O
causes,O
a,O
syndrome,O
of,O
serotonin,B
excess,O
that,O
consists,O
of,O
shivering,O
",",O
muscle,O
rigidity,O
",",O
salivation,O
",",O
confusion,O
",",O
agitation,O
and,O
hyperthermia,O
.,O
The,O
most,O
common,O
cause,O
of,O
this,O
syndrome,O
is,O
an,O
interaction,O
between,O
a,O
monoamine,O
oxidase,O
inhibitor,O
(,O
MAOI,B
),O
and,O
a,O
specific,O
serotonin,B
reuptake,I
inhibitor,I
.,O
Venlafaxine,B
is,O
a,O
new,O
antidepressant,O
agent,O
that,O
inhibits,O
the,O
reuptake,O
of,O
serotonin,B
and,O
norepinephrine,B
.,O
We,O
report,O
a,O
venlafaxine,B
-,O
MAOI,B
interaction,O
that,O
resulted,O
in,O
the,O
serotonin,B
syndrome,O
in,O
a,O
23,O
-,O
y,O
-,O
old,O
male,O
who,O
was,O
taking,O
tranylcypromine,B
for,O
depression,O
.,O
He,O
had,O
been,O
well,O
until,O
the,O
morning,O
of,O
presentation,O
when,O
he,O
took,O
1,O
/,O
2,O
tab,O
of,O
venlafaxine,B
.,O
Within,O
2,O
h,O
he,O
became,O
confused,O
with,O
jerking,O
movements,O
of,O
his,O
extremities,O
",",O
tremors,O
and,O
rigidity,O
.,O
He,O
was,O
brought,O
directly,O
to,O
a,O
hospital,O
where,O
he,O
was,O
found,O
to,O
be,O
agitated,O
and,O
confused,O
with,O
shivering,O
",",O
myoclonic,O
jerks,O
",",O
rigidity,O
",",O
salivation,O
and,O
diaphoresis,O
.,O
His,O
pupils,O
were,O
7,O
mm,O
and,O
sluggishly,O
reactive,O
to,O
light,O
.,O
Vital,O
signs,O
were,O
:,O
blood,B
pressure,I
120,O
/,O
67,O
mm,O
Hg,O
",",O
heart,B
rate,I
127,O
/,O
min,O
",",O
respiratory,B
rate,I
28,O
/,O
min,O
",",O
and,O
temperature,B
97,O
F,O
.,O
After,O
180,O
mg,O
of,O
diazepam,B
i,O
.,O
v,O
.,O
he,O
remained,O
tremulous,O
with,O
muscle,O
rigidity,O
and,O
clenched,O
jaws,O
.,O
He,O
was,O
intubated,O
for,O
airway,O
protection,O
and,O
because,O
of,O
hypoventilation,O
",",O
and,O
was,O
paralyzed,O
to,O
control,O
muscle,O
rigidity,O
.,O
His,O
subsequent,O
course,O
was,O
remarkable,O
for,O
non,O
-,O
immune,O
thrombocytopenia,B
which,O
resolved,O
.,O
The,O
patient,O
',O
s,O
maximal,O
temperature,O
was,O
101,O
.,O
2,O
F,O
and,O
his,O
CPK,B
remained,O
<,O
500,O
units,O
/,O
L,O
with,O
no,O
other,O
evidence,O
of,O
rhabdomyolysis,B
.,O
His,O
mental,O
status,O
normalized,O
and,O
he,O
was,O
transferred,O
to,O
a,O
psychiatry,O
ward,O
.,O
This,O
patient,O
survived,O
without,O
sequelae,O
due,O
to,O
the,O
aggressive,O
sedation,O
and,O
neuromuscular,O
paralysis,O
.,O
Cyclophosphamide,B
associated,O
bladder,O
cancer,O
-,O
-,O
a,O
highly,O
aggressive,O
disease,O
:,O
analysis,O
of,O
12,O
cases,O
.,O
PURPOSE,O
:,O
We,O
gained,O
knowledge,O
of,O
the,O
etiology,O
",",O
treatment,O
and,O
prevention,O
of,O
cyclophosphamide,B
associated,O
urothelial,O
cancer,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
The,O
medical,O
records,O
of,O
6,O
men,O
and,O
6,O
women,O
(,O
mean,O
age,O
55,O
years,O
),O
with,O
cyclophosphamide,B
associated,O
bladder,O
cancer,O
were,O
reviewed,O
.,O
RESULTS,O
:,O
All,O
tumors,O
were,O
grade,O
3,O
or,O
4,O
transitional,B
cell,I
carcinoma,I
.,O
Of,O
the,O
5,O
patients,O
initially,O
treated,O
with,O
endoscopic,O
resection,O
alone,O
only,O
1,O
is,O
alive,O
without,O
disease,O
.,O
Of,O
the,O
6,O
patients,O
who,O
underwent,O
early,O
cystectomy,O
4,O
were,O
alive,O
at,O
24,O
to,O
111,O
months,O
.,O
The,O
remaining,O
patient,O
with,O
extensive,O
cancer,O
underwent,O
partial,O
cystectomy,O
for,O
palliation,O
and,O
died,O
3,O
months,O
later,O
.,O
CONCLUSIONS,O
:,O
Cyclophosphamide,B
associated,O
bladder,O
tumor,O
is,O
an,O
aggressive,O
disease,O
.,O
However,O
",",O
long,O
-,O
term,O
survival,O
is,O
possible,O
when,O
radical,O
cystectomy,O
is,O
performed,O
for,O
bladder,O
tumors,O
with,O
any,O
sign,O
of,O
invasion,O
and,O
for,O
recurrent,O
high,O
grade,O
disease,O
",",O
even,O
when,O
noninvasive,O
.,O
A,O
phase,O
I,O
clinical,O
study,O
of,O
the,O
antipurine,B
antifolate,I
lometrexol,I
(,O
DDATHF,B
),O
given,O
with,O
oral,O
folic,O
acid,O
.,O
Lometrexol,B
is,O
an,O
antifolate,B
which,O
inhibits,O
glycinamide,B
ribonucleotide,I
formyltransferase,I
(,O
GARFT,B
),O
",",O
an,O
enzyme,O
essential,O
for,O
de,O
novo,O
purine,B
synthesis,I
.,O
Extensive,O
experimental,O
and,O
limited,O
clinical,O
data,O
have,O
shown,O
that,O
lometrexol,B
has,O
activity,O
against,O
tumours,O
which,O
are,O
refractory,O
to,O
other,O
drugs,O
",",O
notably,O
methotrexate,B
.,O
However,O
",",O
the,O
initial,O
clinical,O
development,O
of,O
lometrexol,B
was,O
curtailed,O
because,O
of,O
severe,O
and,O
cumulative,O
antiproliferative,O
toxicities,O
.,O
Preclinical,O
murine,O
studies,O
demonstrated,O
that,O
the,O
toxicity,O
of,O
lometrexol,B
can,O
be,O
prevented,O
by,O
low,O
dose,O
folic,B
acid,I
administration,O
",",O
i,O
.,O
e,O
.,O
for,O
7,O
days,O
prior,O
to,O
and,O
7,O
days,O
following,O
a,O
single,O
bolus,O
dose,O
.,O
This,O
observation,O
prompted,O
a,O
Phase,O
I,O
clinical,O
study,O
of,O
lometrexol,B
given,O
with,O
folic,B
acid,I
supplementation,I
which,O
has,O
confirmed,O
that,O
the,O
toxicity,O
of,O
lometrexol,B
can,O
be,O
markedly,O
reduced,O
by,O
folic,B
acid,I
supplementation,I
.,O
Thrombocytopenia,B
and,O
mucositis,B
were,O
the,O
major,O
toxicities,O
.,O
There,O
was,O
no,O
clear,O
relationship,O
between,O
clinical,O
toxicity,O
and,O
the,O
extent,O
of,O
plasma,O
folate,B
elevation,O
.,O
Associated,O
studies,O
demonstrated,O
that,O
lometrexol,B
plasma,O
pharmacokinetics,O
were,O
not,O
altered,O
by,O
folic,B
acid,I
administration,O
indicating,O
that,O
supplementation,O
is,O
unlikely,O
to,O
reduce,O
toxicity,O
by,O
enhancing,O
lometrexol,B
plasma,O
clearance,O
.,O
The,O
work,O
described,O
in,O
this,O
report,O
has,O
identified,O
for,O
the,O
first,O
time,O
a,O
clinically,O
acceptable,O
schedule,O
for,O
the,O
administration,O
of,O
a,O
GARFT,B
inhibitor,O
.,O
This,O
information,O
will,O
facilitate,O
the,O
future,O
evaluation,O
of,O
this,O
class,O
of,O
compounds,O
in,O
cancer,B
therapy,O
.,O
Fatal,O
excited,O
delirium,O
following,O
cocaine,B
use,O
:,O
epidemiologic,O
findings,O
provide,O
new,O
evidence,O
for,O
mechanisms,O
of,O
cocaine,B
toxicity,O
.,O
We,O
describe,O
an,O
outbreak,O
of,O
deaths,O
from,O
cocaine,B
-,O
induced,O
excited,O
delirium,O
(,O
EDDs,O
),O
in,O
Dade,O
County,O
",",O
Florida,O
between,O
1979,O
and,O
1990,O
.,O
From,O
a,O
registry,O
of,O
all,O
cocaine,B
-,O
related,O
deaths,O
in,O
Dade,O
County,O
",",O
Florida,O
",",O
from,O
1969,O
-,O
1990,O
",",O
58,O
EDDs,O
were,O
compared,O
with,O
125,O
victims,O
of,O
accidental,O
cocaine,B
overdose,O
without,O
excited,O
delirium,O
.,O
Compared,O
with,O
controls,O
",",O
EDDs,O
were,O
more,O
frequently,O
black,O
",",O
male,O
",",O
and,O
younger,O
.,O
They,O
were,O
less,O
likely,O
to,O
have,O
a,O
low,O
body,O
mass,O
index,O
",",O
and,O
more,O
likely,O
to,O
have,O
died,O
in,O
police,O
custody,O
",",O
to,O
have,O
received,O
medical,O
treatment,O
immediately,O
before,O
death,O
",",O
to,O
have,O
survived,O
for,O
a,O
longer,O
period,O
",",O
to,O
have,O
developed,O
hyperthermia,B
",",O
and,O
to,O
have,O
died,O
in,O
summer,O
months,O
.,O
EDDs,O
had,O
concentrations,O
of,O
cocaine,B
and,O
benzoylecgonine,B
in,O
autopsy,O
blood,O
that,O
were,O
similar,O
to,O
those,O
for,O
controls,O
.,O
The,O
epidemiologic,O
findings,O
are,O
most,O
consistent,O
with,O
the,O
hypothesis,O
that,O
chronic,O
cocaine,B
use,O
disrupts,O
dopaminergic,O
function,O
and,O
",",O
when,O
coupled,O
with,O
recent,O
cocaine,B
use,O
",",O
may,O
precipitate,O
agitation,O
",",O
delirium,O
",",O
aberrant,O
thermoregulation,O
",",O
rhabdomyolysis,O
",",O
and,O
sudden,O
death,O
.,O
Pemoline,B
induced,O
acute,O
choreoathetosis,O
:,O
case,O
report,O
and,O
review,O
of,O
the,O
literature,O
.,O
BACKGROUND,O
:,O
Pemoline,B
is,O
an,O
oxazolidine,B
derivative,O
that,O
is,O
structurally,O
different,O
from,O
amphetamines,B
and,O
used,O
in,O
the,O
treatment,O
of,O
attention,O
deficit,O
disorder,O
.,O
Pemoline,B
has,O
not,O
been,O
commonly,O
associated,O
in,O
the,O
literature,O
as,O
a,O
cause,O
of,O
acute,O
movement,O
disorders,O
.,O
The,O
following,O
case,O
describes,O
two,O
children,O
acutely,O
poisoned,O
with,O
pemoline,B
who,O
experienced,O
profound,O
choreoathetosis,O
.,O
CASE,O
REPORT,O
:,O
Two,O
",",O
3,O
-,O
year,O
-,O
old,O
male,O
",",O
identical,O
twin,O
siblings,O
presented,O
to,O
the,O
emergency,O
department,O
after,O
found,O
playing,O
with,O
a,O
an,O
empty,O
bottle,O
of,O
pemoline,B
originally,O
containing,O
59,O
tablets,O
.,O
The,O
children,O
had,O
a,O
medical,O
history,O
significant,O
for,O
attention,B
deficit,I
disorder,I
previously,O
treated,O
with,O
methylphenidate,B
without,O
success,O
.,O
This,O
was,O
their,O
first,O
day,O
of,O
pemoline,B
therapy,O
.,O
The,O
choreoathetoid,O
movements,O
began,O
45,O
min,O
to,O
1,O
h,O
after,O
ingestion,O
.,O
The,O
children,O
gave,O
no,O
history,O
of,O
prior,O
movement,O
disorders,O
and,O
there,O
was,O
no,O
family,O
history,O
of,O
movement,O
disorders,O
.,O
The,O
children,O
received,O
gastrointestinal,B
decontamination,I
and,O
high,O
doses,O
of,O
intravenous,B
benzodiazepines,I
in,O
an,O
attempt,O
to,O
control,O
the,O
choreoathetoid,B
movements,I
.,O
Despite,O
treatment,O
",",O
the,O
children,O
continued,O
to,O
have,O
choreoathetosis,B
for,O
approximately,O
24,O
hours,O
.,O
Forty,O
-,O
eight,O
hours,O
after,O
admission,O
",",O
the,O
children,O
appeared,O
to,O
be,O
at,O
their,O
baseline,O
and,O
were,O
discharged,O
home,O
.,O
CONCLUSION,O
:,O
Pemoline,B
associated,O
movement,O
disorder,O
has,O
been,O
rarely,O
reported,O
in,O
the,O
acute,O
toxicology,O
literature,O
.,O
The,O
possibility,O
of,O
choreoathetoid,O
movements,O
should,O
be,O
considered,O
in,O
patients,O
presenting,O
after,O
pemoline,B
overdose,O
.,O
Effect,O
of,O
myopic,O
excimer,O
laser,O
photorefractive,O
keratectomy,O
on,O
the,O
electrophysiologic,O
function,O
of,O
the,O
retina,B
and,O
optic,B
nerve,I
.,O
PURPOSE,O
:,O
To,O
assess,O
by,O
electrophysiologic,O
testing,O
the,O
effect,O
of,O
photorefractive,B
keratectomy,I
(,O
PRK,B
),O
on,O
the,O
retina,B
and,O
optic,B
nerve,I
.,O
SETTING,O
:,O
Eye,B
Clinic,I
",",O
S,B
.,O
Salvatore,I
Hospital,I
",",O
L,B
',I
Aquila,I
University,I
",",O
Italy,B
.,O
METHODS,O
:,O
Standard,B
pattern,I
electroretinograms,I
(,O
P,B
-,I
ERGs,I
),O
and,O
standard,B
pattern,I
visual,I
evoked,I
potentials,I
(,O
P,B
-,I
VEPs,I
),O
were,O
done,O
in,O
25,O
eyes,O
of,O
25,O
patients,O
who,O
had,O
myopic,B
PRK,I
for,O
an,O
attempted,O
correction,O
between,O
5,O
.,O
0,O
and,O
15,O
.,O
0,O
diopters,O
(,O
D,B
),O
(,O
mean,O
8,O
.,O
0,O
D,B
.,O
Testing,O
was,O
done,O
preoperatively,O
and,O
3,O
",",O
6,O
",",O
12,O
",",O
and,O
18,O
months,O
postoperatively,O
.,O
The,O
contralateral,O
eyes,O
served,O
as,O
controls,O
.,O
During,O
the,O
follow,O
-,O
up,O
",",O
3,O
patients,O
(,O
12,O
%,O
),O
developed,O
steroid,B
-,O
induced,O
elevated,O
intraocular,O
pressure,O
(,O
IOP,B
),O
that,O
resolved,O
after,O
corticosteroid,B
therapy,O
was,O
discontinued,O
.,O
RESULTS,O
:,O
No,O
statistically,O
significant,O
differences,O
were,O
seen,O
between,O
treated,O
and,O
control,O
eyes,O
nor,O
between,O
treated,O
eyes,O
preoperatively,O
and,O
postoperatively,O
.,O
CONCLUSION,O
:,O
Myopic,O
excimer,O
laser,O
PRK,O
did,O
not,O
seem,O
to,O
affect,O
the,O
posterior,O
segment,O
.,O
The,O
transient,O
steroid,B
-,I
induced,I
IOP,I
rise,O
did,O
not,O
seem,O
to,O
cause,O
functional,O
impairment,O
.,O
Neutrophil,O
superoxide,B
and,O
hydrogen,B
peroxide,I
production,O
in,O
patients,O
with,O
acute,O
liver,O
failure,O
.,O
Defects,O
in,O
superoxide,B
and,O
hydrogen,B
peroxide,I
production,O
may,O
be,O
implicated,O
in,O
the,O
high,O
incidence,O
of,O
bacterial,O
infections,O
in,O
patients,O
with,O
acute,O
liver,O
failure,O
(,O
ALF,O
),O
.,O
In,O
the,O
present,O
study,O
",",O
oxygen,O
radical,O
production,O
in,O
patients,O
with,O
ALF,O
due,O
to,O
paracetamol,B
overdose,O
was,O
compared,O
with,O
that,O
of,O
healthy,O
volunteers,O
.,O
Neutrophils,O
from,O
14,O
ALF,B
patients,O
were,O
stimulated,O
via,O
the,O
complement,B
receptors,O
using,O
zymosan,B
opsonized,O
with,O
ALF,B
or,O
control,B
serum,O
.,O
Superoxide,O
and,O
hydrogen,B
peroxide,I
production,O
by,O
ALF,B
neutrophils,O
stimulated,O
with,O
zymosan,B
opsonized,O
with,O
ALF,B
serum,O
was,O
significantly,O
reduced,O
compared,O
with,O
the,O
control,B
subjects,O
(,O
P,O
<,O
0,O
0.47,O
1,O
),O
.,O
This,O
defect,O
persisted,O
when,O
zymosan,B
opsonized,O
by,O
control,O
serum,O
was,O
used,O
(,O
P,O
<,O
0,O
.,O
5,O
),O
.,O
Superoxide,B
and,O
hydrogen,B
peroxide,I
production,O
in,O
neutrophils,O
stimulated,O
with,O
formyl,B
-,I
methionyl,I
-,I
leucyl,I
-,I
phenylalanine,I
(,O
fMLP,B
),O
from,O
a,O
further,O
18,O
ALF,O
patients,O
was,O
unaffected,O
compared,O
with,O
control,O
neutrophils,O
.,O
Serum,O
C3,B
complement,I
levels,O
were,O
significantly,O
reduced,O
in,O
ALF,O
patients,O
compared,O
with,O
control,O
subjects,O
(,O
P,B
<,I
0,I
.,I
5,I
),O
.,O
These,O
results,O
demonstrate,O
a,O
neutrophil,O
defect,O
in,O
ALF,O
due,O
to,O
paracetamol,B
overdose,O
",",O
that,O
is,O
complement,O
dependent,O
but,O
independent,O
of,O
serum,O
complement,O
",",O
possibly,O
connected,O
to,O
the,O
complement,O
receptor,O
.,O
Cholesteryl,B
hemisuccinate,I
treatment,O
protects,O
rodents,O
from,O
the,O
toxic,O
effects,O
of,O
acetaminophen,B
",",O
adriamycin,B
",",O
carbon,B
tetrachloride,I
",",O
chloroform,B
and,O
galactosamine,B
.,O
In,O
addition,O
to,O
its,O
use,O
as,O
a,O
stabilizer,O
/,O
rigidifier,O
of,O
membranes,O
",",O
cholesteryl,B
hemisuccinate,I
",",O
tris,B
salt,I
(,I
CS,I
),I
administration,O
has,O
also,O
been,O
shown,O
to,O
protect,O
rats,O
from,O
the,O
hepatotoxic,O
effects,O
of,O
carbon,B
tetrachloride,I
(,I
CCl4,I
),I
.,O
To,O
further,O
our,O
understanding,O
of,O
the,O
mechanism,O
of,O
CS,B
cytoprotection,O
",",O
we,O
examined,O
in,O
rats,O
and,O
mice,O
the,O
protective,O
abilities,O
of,O
CS,B
and,O
the,O
non,O
-,O
hydrolyzable,O
ether,O
form,O
of,O
CS,B
",",O
gamma,B
-,I
cholesteryloxybutyric,I
acid,I
",",O
tris,B
salt,I
(,I
CSE,I
),I
against,O
acetaminophen,B
-,I
",",O
adriamycin,B
-,I
",",O
carbon,B
tetrachloride,I
-,I
",",O
chloroform,B
-,I
",",O
and,O
galactosamine,B
-,I
induced,I
toxicity,I
.,O
The,O
results,O
of,O
these,O
studies,O
demonstrated,O
that,O
CS,B
-,O
mediated,O
protection,O
is,O
not,O
selective,O
for,O
a,O
particular,O
species,O
",",O
organ,O
system,O
or,O
toxic,B
chemical,I
. A,O
24,O
-,O
h,O
pretreatment,O
of,O
both,O
rats,O
and,O
mice,O
with,O
a,O
single,O
dose,O
of,O
CS,B
(,O
100mg,O
/,O
kg,O
",",O
i,O
. p,O
. ),O
",",O
resulted,O
in,O
significant,O
protection,O
against,O
the,O
hepatotoxic,B
effects,O
of,O
CCl4,B
",",O
CHCl3,B
",",O
acetaminophen,B
and,O
galactosamine,B
and,O
against,O
the,O
lethal,O
(,O
and,O
presumably,O
cardiotoxic,B
),O
effect,O
of,O
adriamycin,B
administration,O
. ,O
Maximal,O
CS,B
-,O
mediated,O
protection,O
was,O
observed,O
in,O
experimental,O
animals,O
pretreated,O
24,O
h,O
prior,O
to,O
the,O
toxic,O
insult,O
.,O
These,O
data,O
suggest,O
that,O
CS,B
intervenes,O
in,O
a,O
critical,O
cellular,O
event,O
that,O
is,O
an,O
important,O
common,O
pathway,O
to,O
toxic,O
cell,O
death,O
.,O
The,O
mechanism,O
of,O
CS,B
protection,O
does,O
not,O
appear,O
to,O
be,O
dependent,O
on,O
the,O
inhibition,O
of,O
chemical,B
bioactivation,I
to,I
a,I
toxic,I
reactive,I
intermediate,I
(,I
in,I
light,I
of,I
the,I
protection,I
observed,I
against,I
galactosamine,I
hepatotoxicity,I
),I
.,O
However,O
",",O
based,O
on,O
the,O
data,O
presented,O
",",O
we,O
can,O
not,O
exclude,O
the,O
possibility,O
that,O
CS,B
administration,O
inhibits,O
chemical,B
bioactivation,O
.,O
Our,O
findings,O
do,O
suggest,O
that,O
CS,B
-,O
mediated,O
protection,O
is,O
dependent,O
on,O
the,O
action,O
of,O
the,O
intact,O
anionic,O
CS,B
molecule,O
(,O
non,O
-,O
hydrolyzable,O
CSE,O
was,O
as,O
protective,O
as,O
CS,B
),O
",",O
whose,O
mechanism,O
has,O
yet,O
to,O
be,O
defined,O
.,O
A,O
murine,O
model,O
of,O
adenomyosis,B
:,O
the,O
effects,O
of,O
hyperprolactinemia,O
induced,O
by,O
fluoxetine,B
hydrochloride,I
",",O
a,O
selective,O
serotonin,O
reuptake,O
inhibitor,O
",",O
on,O
adenomyosis,B
induction,O
in,O
Wistar,O
albino,O
rats,O
.,O
OBJECTIVE,O
:,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
whether,O
fluoxetine,B
given,O
to,O
castrated,O
and,O
noncastrated,O
rats,O
caused,O
hyperprolactinemia,O
and,O
its,O
effects,O
with,O
respect,O
to,O
adenomyosis,B
.,O
DESIGN,O
:,O
Fluoxetine,B
",",O
a,O
serotonin,B
reuptake,I
inhibitor,I
",",O
was,O
given,O
to,O
Wistar,O
Albino,O
rats,O
for,O
98,O
days,O
to,O
produce,O
hyperprolactinemia,O
.,O
The,O
drug,O
was,O
given,O
to,O
two,O
groups,O
consisting,O
of,O
castrated,O
and,O
noncastrated,O
rats,O
and,O
compared,O
to,O
two,O
groups,O
of,O
castrated,O
and,O
noncastrated,O
controls,O
.,O
Prolactin,B
levels,O
were,O
measured,O
and,O
the,O
uteri,O
of,O
the,O
rats,O
were,O
removed,O
for,O
histopathological,O
analysis,O
at,O
the,O
end,O
of,O
98,O
days,O
.,O
SETTING,O
:,O
Marmara,O
University,O
School,O
of,O
Medicine,O
",",O
Department,O
of,O
Histology,O
and,O
Embryology,O
",",O
Zeynep,O
Kamil,O
Women,O
and,O
Children,O
',O
s,O
Hospital,O
.,O
MAIN,O
OUTCOME,O
MEASURES,O
:,O
Serum,O
prolactin,B
levels,O
",",O
uterine,O
histopathology,O
.,O
RESULTS,O
:,O
The,O
prolactin,B
levels,O
of,O
castrated,O
and,O
noncastrated,O
groups,O
treated,O
with,O
fluoxetine,B
were,O
statistically,O
significantly,O
higher,O
when,O
compared,O
to,O
their,O
respective,O
control,O
groups,O
.,O
Histological,O
studies,O
revealed,O
11,O
cases,O
of,O
adenomyosis,B
",",O
all,O
within,O
the,O
noncastrated,O
group,O
receiving,O
fluoxetine,B
.,O
CONCLUSION,O
:,O
It,O
was,O
suggested,O
that,O
high,O
serum,O
prolactin,O
levels,O
cause,O
degeneration,O
of,O
myometrial,O
cells,O
in,O
the,O
presence,O
of,O
ovarian,O
steroids,O
that,O
results,O
in,O
a,O
myometrial,O
invasion,O
by,O
endometrial,B
stroma,I
.,O
This,O
invasion,O
eventually,O
progresses,O
to,O
adenomyosis,B
.,O
Postinfarction,O
ventricular,B
septal,I
defect,I
associated,O
with,O
long,O
-,O
term,O
steroid,B
therapy,I
.,O
Two,O
cases,O
of,O
postinfarction,O
ventricular,B
septal,I
rupture,I
in,O
patients,O
on,O
long,O
-,O
term,O
steroid,B
therapy,I
are,O
presented,O
and,O
the,O
favourable,O
outcome,O
in,O
both,O
cases,O
described,O
.,O
A,O
possible,O
association,O
between,O
steroid,B
therapy,O
and,O
subsequent,O
postinfarction,O
septal,O
rupture,O
is,O
discussed,O
.,O
Neuroactive,O
steroids,B
protect,O
against,O
pilocarpine,B
-,O
and,O
kainic,B
acid,I
-,O
induced,O
limbic,O
seizures,O
and,O
status,O
epilepticus,O
in,O
mice,O
.,O
Several,O
structurally,O
related,O
metabolites,O
of,O
progesterone,B
(,O
3,B
alpha,I
-,I
hydroxy,I
pregnane,I
-,I
20,I
-,I
ones,I
),O
and,O
deoxycorticosterone,B
(,O
3,B
alpha,I
-,I
hydroxy,I
pregnane,I
-,I
21,I
-,I
diol,I
-,I
20,I
-,I
ones,I
),O
and,O
their,O
3,B
beta,I
-,I
epimers,I
were,O
evaluated,O
for,O
protective,O
activity,O
against,O
pilocarpine,B
-,O
",",O
kainic,B
acid,I
-,O
and,O
N,B
-,I
methyl,I
-,I
D,I
-,I
aspartate,I
(,I
NMDA,I
),I
-,O
induced,O
seizures,O
in,O
mice,O
.,O
Steroids,B
with,O
the,O
3,O
-,O
hydroxy,O
group,O
in,O
the,O
alpha,B
-,O
position,O
and,O
5,O
-,O
H,O
in,O
the,O
alpha,B
-,O
or,O
beta,B
-,O
-,O
configurations,O
were,O
highly,O
effective,O
in,O
protecting,O
against,O
pilocarpine,B
(,O
416,O
mg,O
/,O
kg,O
",",O
s,O
.,O
c,O
.,O
)-,O
induced,O
limbic,O
motor,O
seizures,O
and,O
status,O
epilepticus,O
(,O
ED50,O
values,O
",",O
7,O
.,O
0,O
-,O
18,O
.,O
7,O
mg,O
/,O
kg,O
",",O
i,O
.,O
p,O
.,O
)-,O
The,O
corresponding,O
epimers,O
with,O
the,O
3,O
-,O
hydroxy,O
group,O
in,O
the,O
beta,B
-,O
position,O
were,O
also,O
effective,O
but,O
less,O
potent,O
(,O
ED50,O
values,O
",",O
33,O
.,O
8,O
-,O
63,O
.,O
5,O
",",O
i,O
.,O
p,O
.,O
),O
.,O
Although,O
the,O
neuroactive,O
steroids,B
were,O
considerably,O
less,O
potent,O
than,O
the,O
benzodiazepine,B
clonazepam,I
in,O
protecting,O
against,O
pilocarpine,B
seizures,O
",",O
steroids,B
with,O
the,O
5,O
alpha,O
",",O
3,O
alpha,O
-,O
configuration,O
had,O
comparable,O
or,O
higher,O
protective,O
index,O
values,O
(,O
TD50,O
for,O
motor,O
impairment,O
divided,O
by,O
ED50,O
for,O
seizure,O
protection,O
),O
than,O
clonazepam,B
",",O
indicating,O
that,O
some,O
neuroactive,O
steroids,B
may,O
have,O
lower,O
relative,O
toxicity,O
.,O
Steroids,B
with,O
the,O
5,B
alpha,I
",",O
3,B
alpha,I
-,O
or,O
5,B
beta,I
",",O
3,B
alpha,I
-,O
configurations,O
also,O
produced,O
a,O
dose,O
-,O
dependent,O
delay,O
in,O
the,O
onset,O
of,O
limbic,O
seizures,O
induced,O
by,O
kainic,B
acid,I
(,O
32,O
mg,O
/,O
kg,O
",",O
s,O
.,O
c,O
.,O
),O
",",O
but,O
did,O
not,O
completely,O
protect,O
against,O
the,O
seizures,O
.,O
However,O
",",O
when,O
a,O
second,O
dose,O
of,O
the,O
steroid,B
was,O
administered,O
1,O
hr,O
after,O
the,O
first,O
dose,O
",",O
complete,O
protection,O
from,O
the,O
kainic,B
acid,I
-,O
induced,O
limbic,O
seizures,O
and,O
status,O
epilepticus,O
was,O
obtained,O
.,O
The,O
steroids,B
also,O
caused,O
a,O
dose,O
-,O
dependent,O
delay,O
in,O
NMDA,B
(,O
257,B
mg,I
/,I
kg,I
",",O
s,O
.,O
c,O
.,O
)-,O
induced,O
lethality,O
",",O
but,O
did,O
not,O
completely,O
protect,O
against,O
NMDA,B
seizures,O
or,O
lethality,O
.,O
We,O
conclude,O
that,O
neuroactive,O
steroids,B
are,O
highly,O
effective,O
in,O
protecting,O
against,O
pilocarpine,B
-,I
and,I
kainic,B
acid,I
-,I
induced,I
seizures,O
and,O
status,O
epilepticus,O
in,O
mice,O
",",O
and,O
may,O
be,O
of,O
utility,O
in,O
the,O
treatment,O
of,O
some,O
forms,O
of,O
status,O
epilepticus,O
in,O
humans,O
.,O
Hepatic,B
and,O
extrahepatic,B
angiotensinogen,B
gene,O
expression,O
in,O
rats,O
with,O
acute,O
nephrotic,O
syndrome,O
.,O
Plasma,O
concentration,O
and,O
urine,O
excretion,O
of,O
the,O
renin,B
-,I
angiotensin,I
system,I
proteins,O
are,O
altered,O
in,O
rats,O
with,O
nephrotic,O
syndrome,O
(,O
NS,O
),O
.,O
In,O
this,O
work,O
the,O
messenger,O
ribonucleic,O
acid,O
(,O
mRNA,O
),O
levels,O
of,O
angiotensinogen,B
(,O
Ao,O
),O
were,O
analyzed,O
with,O
the,O
slot,O
-,O
blot,O
hybridization,O
technique,O
in,O
liver,B
and,O
other,O
extrahepatic,B
tissues,O
:,O
kidney,B
",",O
heart,B
",",O
brain,B
",",O
and,O
adrenal,B
gland,O
from,O
control,O
",",O
nephrotic,O
",",O
and,O
pair,O
-,O
fed,O
(,O
PF,O
),O
rats,O
.,O
NS,O
was,O
induced,O
by,O
a,O
single,O
injection,O
of,O
puromycin,B
amino,I
-,I
nucleoside,I
(,O
PAN,B
),O
.,O
Although,O
a,O
great,O
urinary,O
excretion,O
and,O
half,O
-,O
normal,O
plasma,O
levels,O
of,O
Ao,B
were,O
observed,O
on,O
day,O
6,O
after,O
PAN,O
injection,O
",",O
when,O
NS,O
was,O
clearly,O
established,O
",",O
hepatic,O
Ao,B
mRNA,I
levels,O
did,O
not,O
change,O
.,O
Furthermore,O
",",O
the,O
Ao,B
mRNA,I
levels,O
did,O
not,O
change,O
in,O
any,O
of,O
the,O
extrahepatic,O
tissues,O
studied,O
on,O
day,O
6,O
",",O
nor,O
did,O
its,O
hepatic,O
levels,O
at,O
days,O
1,O
",",O
3,O
",",O
5,O
",",O
or,O
7,O
after,O
PAN,O
injection,O
.,O
These,O
data,O
suggest,O
that,O
the,O
hepatic,O
and,O
extrahepatic,O
Ao,O
mRNA,O
levels,O
are,O
unaltered,O
during,O
the,O
development,O
of,O
the,O
acute,O
NS,O
induced,O
by,O
PAN,B
.,O
Neuroleptic,O
malignant,O
syndrome,O
with,O
risperidone,B
.,O
Neuroleptic,O
malignant,O
syndrome,O
is,O
thought,O
to,O
be,O
a,O
result,O
of,O
dopamine,B
D2,I
receptor,I
blockade,O
in,O
the,O
striatum,B
of,O
the,O
basal,O
ganglia,O
.,O
Risperidone,B
",",O
a,O
benzisoxazole,B
derivative,O
antipsychotic,O
",",O
has,O
high,O
serotonin,B
5,I
-,I
HT2,I
receptor,I
blockade,I
and,O
dose,O
-,O
related,O
D2,B
receptor,I
blockade,I
.,O
The,O
high,O
ratio,O
is,O
believed,O
to,O
impart,O
the,O
low,O
frequency,O
of,O
extrapyramidal,O
symptoms,O
with,O
risperidone,B
at,O
low,O
dosages,O
.,O
With,O
this,O
low,O
frequency,O
of,O
extrapyramidal,O
symptoms,O
",",O
it,O
was,O
thought,O
the,O
frequency,O
of,O
neuroleptic,O
malignant,O
syndrome,O
might,O
also,O
be,O
lowered,O
.,O
A,O
73,O
-,O
year,O
-,O
old,O
woman,O
developed,O
neuroleptic,B
malignant,I
syndrome,I
after,O
monotherapy,O
with,O
risperidone,B
.,O
The,O
syndrome,O
reversed,O
after,O
discontinuing,O
risperidone,B
and,O
starting,O
treatment,O
with,O
dantrolene,B
and,O
bromocriptine,B
.,O
It,O
appears,O
that,O
the,O
protection,O
from,O
extrapyramidal,O
side,O
effects,O
observed,O
with,O
risperidone,B
does,O
not,O
ensure,O
protection,O
from,O
neuroleptic,B
malignant,I
syndrome,I
.,O
The,O
attenuating,O
effect,O
of,O
carteolol,B
hydrochloride,I
",",O
a,O
beta,B
-,I
adrenoceptor,I
antagonist,I
",",O
on,O
neuroleptic,O
-,O
induced,O
catalepsy,O
in,O
rats,O
.,O
It,O
is,O
known,O
that,O
beta,B
-,I
adrenoceptor,I
antagonists,I
are,O
effective,O
in,O
the,O
treatment,O
of,O
akathisia,O
",",O
one,O
of,O
the,O
extrapyramidal,O
side,O
effects,O
that,O
occur,O
during,O
neuroleptic,O
treatment,O
.,O
Neuroleptic,B
-,O
induced,O
catalepsy,O
",",O
a,O
model,O
of,O
neuroleptic,B
-,O
induced,O
extrapyramidal,O
side,O
effects,O
",",O
was,O
considered,O
suitable,O
as,O
a,O
model,O
for,O
predicting,O
neuroleptic,B
-,O
induced,O
akathisia,O
in,O
humans,O
",",O
although,O
neuroleptic,B
-,O
induced,O
catalepsy,O
was,O
not,O
considered,O
a,O
specific,O
test,O
for,O
neuroleptic,B
-,O
induced,O
akathisia,O
.,O
Therefore,O
",",O
the,O
effects,O
of,O
carteolol,B
",",O
a,O
beta,B
-,I
adrenoceptor,I
antagonist,I
",",O
on,O
haloperidol,B
-,O
induced,O
catalepsy,O
in,O
rats,O
were,O
behaviorally,O
studied,O
and,O
compared,O
with,O
those,O
of,O
propranolol,B
and,O
biperiden,B
",",O
a,O
muscarinic,B
receptor,I
antagonist,I
.,O
Carteolol,B
",",O
as,O
well,O
as,O
propranolol,B
and,O
biperiden,B
",",O
inhibited,O
the,O
haloperidol,B
-,O
induced,O
catalepsy,O
.,O
The,O
inhibitory,O
effect,O
of,O
carteolol,B
was,O
almost,O
comparable,O
to,O
that,O
of,O
propranolol,B
",",O
but,O
was,O
weaker,O
than,O
that,O
of,O
biperiden,B
.,O
Carteolol,B
did,O
not,O
evoke,O
postsynaptic,O
dopamine,B
receptor,I
-,I
stimulating,I
behavioral,I
signs,I
such,O
as,O
stereotypy,B
and,O
hyperlocomotion,B
in,O
rats,O
.,O
Carteolol,B
did,O
not,O
antagonize,O
the,O
inhibitory,O
effects,O
of,O
haloperidol,B
on,O
apomorphine,B
-,I
induced,I
stereotypy,I
and,O
locomotor,B
activity,I
in,O
rats,O
.,O
In,O
addition,O
",",O
carteolol,B
did,O
not,O
evoke,O
5,B
-,I
HT1A,I
receptor,I
-,I
stimulating,O
behavioral,O
signs,O
such,O
as,O
flat,O
body,O
posture,O
and,O
forepaw,O
treading,O
and,O
did,O
not,O
inhibit,O
5,B
-,I
hydroxytryptophan,I
-,I
induced,I
head,I
twitch,I
in,O
rats,O
.,O
Finally,O
",",O
carteolol,B
did,O
not,O
inhibit,O
physostigmine,B
-,I
induced,I
lethality,I
in,O
rats,O
.,O
These,O
results,O
strongly,O
suggest,O
that,O
carteolol,B
improves,O
haloperidol,B
-,I
induced,I
catalepsy,I
via,O
its,O
beta,O
-,O
adrenoceptor,O
antagonistic,O
activity,O
and,O
is,O
expected,O
to,O
be,O
effective,O
in,O
the,O
treatment,O
of,O
akathisia,O
without,O
attenuating,O
neuroleptic,O
-,O
induced,O
antipsychotic,O
effects,O
due,O
to,O
its,O
postsynaptic,O
dopamine,O
receptor,O
antagonistic,O
activity,O
.,O
Granulosa,B
cell,I
tumor,I
of,O
the,O
ovary,B
associated,O
with,O
antecedent,O
tamoxifen,B
use,O
.,O
BACKGROUND,O
:,O
Increased,O
attention,O
has,O
been,O
focused,O
recently,O
on,O
the,O
estrogenic,O
effects,O
of,O
tamoxifen,B
.,O
Review,O
of,O
the,O
literature,O
reveals,O
an,O
association,O
between,O
tamoxifen,B
use,O
and,O
gynecologic,O
tumors,O
.,O
CASE,O
:,O
A,O
52,O
-,O
year,O
-,O
old,O
postmenopausal,O
woman,O
was,O
treated,O
with,O
tamoxifen,B
for,O
stage,O
II,O
estrogen,O
receptor,O
-,O
positive,O
breast,O
carcinoma,O
.,O
Her,O
aspartate,B
transaminase,I
and,O
alanine,B
transaminase,I
levels,O
increase,O
markedly,O
after,O
6,O
months,O
of,O
tamoxifen,O
use,O
.,O
After,O
an,O
additional,O
17,O
months,O
of,O
elevated,O
serum,O
transaminases,O
",",O
the,O
patient,O
was,O
found,O
to,O
have,O
a,O
stage,O
Ic,O
granulosa,O
cell,O
tumor,O
of,O
the,O
ovary,O
.,O
CONCLUSION,O
:,O
Patients,O
with,O
tamoxifen,O
-,O
induced,O
liver,O
dysfunction,O
may,O
be,O
at,O
increased,O
risk,O
for,O
granulosa,O
cell,O
tumors,O
because,O
of,O
alterations,O
in,O
tamoxifen,O
metabolism,O
.,O
Lifetime,O
treatment,O
of,O
mice,O
with,O
azidothymidine,B
(,O
AZT,I
),O
produces,O
myelodysplasia,O
.,O
AZT,B
has,O
induced,O
a,O
macrocytic,O
anemia,O
in,O
AIDS,O
patients,O
on,O
long,O
term,O
AZT,B
therapy,O
.,O
It,O
is,O
generally,O
assumed,O
that,O
DNA,O
elongation,O
is,O
stopped,O
by,O
the,O
insertion,O
of,O
AZT,B
into,O
the,O
chain,O
in,O
place,O
of,O
thymidine,O
thus,O
preventing,O
the,O
phosphate,O
hydroxyl,O
linkages,O
and,O
therefore,O
suppresses,O
hemopoietic,O
progenitor,O
cell,O
proliferation,O
in,O
an,O
early,O
stage,O
of,O
differentiation,O
.,O
CBA,O
/,O
Ca,B
male,O
mice,O
started,O
on,O
AZT,B
0,O
.,O
75,O
mg,O
/,O
ml,O
H2O,O
at,O
84,O
days,O
of,O
age,O
and,O
kept,O
on,O
it,O
for,O
687,O
days,O
when,O
dosage,O
reduced,O
to,O
0,O
.,O
5,O
mg,O
/,O
ml,O
H2O,O
for,O
a,O
group,O
",",O
another,O
group,O
removed,O
from,O
AZT,B
to,O
see,O
recovery,O
",",O
and,O
third,O
group,O
remained,O
on,O
0,O
.,O
75,O
mg,O
.,O
At,O
687,O
days,O
mice,O
that,O
had,O
been,O
on,O
0,O
.,O
75,O
mg,O
had,O
average,O
platelet,O
counts,O
of,O
2,O
.,O
5,O
x,O
10,O
(,O
6,O
),O
.,O
Histological,O
examination,O
on,O
9,O
of,O
10,O
mice,O
with,O
such,O
thrombocytopenia,B
showed,O
changes,O
compatible,O
with,O
myelodysplastic,B
syndrome,I
(,O
MDS,B
),O
.,O
A,O
variety,O
of,O
histological,O
patterns,O
was,O
observed,O
.,O
There,O
were,O
two,O
cases,O
of,O
hypocellular,B
myelodysplasia,I
",",O
two,O
cases,O
of,O
hypersegmented,B
myelodysplastic,I
granulocytosis,I
",",O
two,O
cases,O
of,O
hypercellular,B
marrow,I
with,O
abnormal,O
megakaryocytes,B
with,O
bizarre,O
nuclei,O
",",O
one,O
case,O
of,O
megakaryocytic,B
myelosis,I
associated,O
with,O
a,O
hyperplastic,B
marrow,I
",",O
dysmyelopoiesis,B
and,O
a,O
hypocellular,B
marrow,I
and,O
two,O
cases,O
of,O
myelodysplasia,B
with,O
dyserythropoiesis,I
",",O
hemosiderosis,I
and,O
a,O
hypocellular,B
marrow,I
.,O
Above,O
mentioned,O
AZT,B
incorporation,O
may,O
have,O
induced,O
an,O
ineffective,O
hemopoiesis,O
in,O
the,O
primitive,O
hemopoietic,O
progenitor,O
cells,O
",",O
which,O
is,O
known,O
to,O
be,O
seen,O
commonly,O
in,O
the,O
myelodysplastic,O
syndrome,O
.,O
Biphasic,O
response,O
of,O
the,O
SA,B
node,I
of,I
the,I
dog,I
heart,I
in,O
vivo,O
to,O
selective,O
administration,O
of,O
ketamine,B
. Effect,O
of,O
ketamine,B
on,O
the,O
SA,B
node,I
of,I
the,I
dog,I
heart,I
was,O
studied,O
in,O
vivo,O
using,O
a,O
selective,O
perfusion,O
technique,O
of,O
the,O
SA,B
node,I
artery,I
.,O
Injections,O
of,O
ketamine,B
in,O
doses,O
from,O
100,O
microgram,O
to,O
3,O
mg,O
into,O
the,O
artery,O
produced,O
a,O
depression,O
of,O
the,O
SA,B
nodal,I
activity,O
by,O
a,O
direct,O
action,O
.,O
This,O
depression,O
was,O
followed,O
by,O
the,O
sudden,O
appearance,O
of,O
a,O
stimulatory,O
phase,O
.,O
Bilateral,O
vagotomy,O
and,O
sympathectomy,O
or,O
prior,O
administration,O
of,O
a,O
ganglion,O
blocker,O
failed,O
to,O
inhibit,O
the,O
occurrence,O
of,O
the,O
ketamine,B
-,I
induced,I
tachycardia,O
",",O
while,O
it,O
was,O
completely,O
abolished,O
in,O
the,O
reserpinized,O
dogs,O
or,O
by,O
a,O
prior,O
injection,O
of,O
a,O
beta,O
-,O
blocking,O
agent,O
into,O
the,O
SA,B
node,I
artery,O
.,O
This,O
may,O
indicate,O
that,O
an,O
activation,O
of,O
the,O
peripheral,O
adrenergic,B
mechanism,O
plays,O
an,O
important,O
role,O
in,O
the,O
induction,O
of,O
the,O
excitatory,O
effect,O
of,O
ketamine,B
injected,O
in,O
the,O
SA,B
node,I
artery,I
.,O
Over,O
expression,O
of,O
vascular,O
endothelial,B
growth,I
factor,I
and,O
its,O
receptor,O
during,O
the,O
development,O
of,O
estrogen,B
-,I
induced,I
rat,I
pituitary,I
tumors,I
may,O
mediate,O
estrogen,B
-,I
initiated,I
tumor,I
angiogenesis,I
.,O
Estrogens,B
",",O
which,O
have,O
been,O
associated,O
with,O
several,O
types,O
of,O
human,O
and,O
animal,O
cancers,B
",",O
can,O
induce,O
tumor,O
angiogenesis,O
in,O
the,O
pituitary,O
of,O
Fischer,O
344,O
rats,O
.,O
The,O
mechanistic,O
details,O
of,O
tumor,O
angiogenesis,O
induction,O
",",O
during,O
estrogen,B
carcinogenesis,O
",",O
are,O
still,O
unknown,O
.,O
To,O
elucidate,O
the,O
role,O
of,O
estrogen,B
in,O
the,O
regulation,O
of,O
tumor,O
angiogenesis,O
in,O
the,O
pituitary,O
of,O
female,O
rats,O
",",O
the,O
density,O
of,O
blood,O
vessels,O
was,O
analysed,O
using,O
factor,O
VIII,B
related,I
antigen,I
(,O
FVIIIRAg,I
),O
immunohistochemistry,O
and,O
the,O
expression,O
of,O
vascular,O
endothelial,O
growth,O
factor,B
/,I
vascular,I
permeability,I
factor,I
(,I
VEGF,I
/,I
VPF,I
),O
was,O
examined,O
by,O
Western,O
blot,O
and,O
immunohistochemical,O
analysis,O
.,O
The,O
expression,O
of,O
VEGF,B
receptor,O
(,O
VEGFR,B
-,I
2,I
/,I
Flk,I
-,I
1,I
/,I
KDR,I
),O
was,O
also,O
examined,O
by,O
immunohistochemistry,O
.,O
The,O
results,O
demonstrated,O
that,O
17beta,B
-,I
estradiol,I
(,O
E2,B
),O
induces,O
neovascularization,O
",",O
as,O
well,O
as,O
the,O
growth,O
and,O
enlargement,O
of,O
blood,O
vessels,O
after,O
7,O
days,O
of,O
exposure,O
.,O
The,O
high,O
tumor,O
angiogenic,O
potential,O
was,O
associated,O
with,O
an,O
elevated,O
VEGF,B
/,I
VPF,I
protein,I
expression,O
in,O
the,O
E2,B
exposed,O
pituitary,O
of,O
ovariectomized,O
(,O
OVEX,O
),O
rats,O
.,O
VEGF,B
/,I
VPF,I
and,O
FVIIIRAg,B
immunohistochemistry,O
and,O
endothelial,O
specific,O
lectin,O
(,O
UEA1,B
),O
binding,O
studies,O
",",O
indicate,O
that,O
the,O
elevation,O
of,O
VEGF,B
protein,O
expression,O
initially,O
occurred,O
in,O
both,O
blood,O
vessels,O
and,O
non,O
-,O
endothelial,O
cells,O
.,O
After,O
15,O
days,O
of,O
E2,O
exposure,O
",",O
VEGF,B
/,I
VPF,I
protein,O
expression,O
",",O
in,O
the,O
non,O
-,O
endothelial,O
cell,O
population,O
",",O
sharply,O
declined,O
and,O
was,O
restricted,O
to,O
the,O
blood,O
vessels,O
.,O
The,O
function,O
of,O
non,O
-,O
endothelial,O
-,O
derived,O
VEGF,B
is,O
not,O
clear,O
.,O
Furthermore,O
",",O
immunohistochemical,O
studies,O
demonstrated,O
that,O
VEGFR,B
-,O
2,I
(,O
flk,B
-,I
1,I
/,I
KDR,I
),O
",",O
expression,O
was,O
elevated,O
significantly,O
in,O
the,O
endothelial,O
cells,O
of,O
microblood,O
vessels,O
after,O
7,O
days,O
of,O
E2,O
exposure,O
.,O
These,O
findings,O
suggest,O
that,O
over,O
expression,O
of,O
VEGF,B
and,O
its,O
receptor,O
(,O
VEGFR,B
-,O
2,I
),O
may,O
play,O
an,O
important,O
role,O
in,O
the,O
initial,O
step,O
of,O
the,O
regulation,O
of,O
estrogen,O
induced,O
tumor,O
angiogenesis,O
in,O
the,O
rat,O
pituitary,O
.,O
Persistent,O
nephrogenic,B
diabetes,I
insipidus,I
following,O
lithium,B
therapy,O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
patient,O
who,O
developed,O
severe,O
hypernatraemic,O
dehydration,O
following,O
a,O
head,O
injury,O
.,O
Ten,O
years,O
previously,O
he,O
had,O
been,O
diagnosed,O
to,O
have,O
lithium,B
-,O
induced,O
nephrogenic,B
diabetes,I
insipidus,I
",",O
and,O
lithium,B
therapy,O
had,O
been,O
discontinued,O
.,O
He,O
remained,O
thirsty,O
and,O
polyuric,O
despite,O
cessation,O
of,O
lithium,B
and,O
investigations,O
on,O
admission,O
showed,O
him,O
to,O
have,O
normal,O
osmoregulated,O
thirst,O
and,O
vasopressin,B
secretion,O
",",O
with,O
clear,O
evidence,O
of,O
nephrogenic,B
diabetes,I
insipidus,I
.,O
Lithium,B
induced,O
nephrogenic,B
diabetes,I
insipidus,I
is,O
considered,O
to,O
be,O
reversible,O
on,O
cessation,O
of,O
therapy,O
but,O
polyuria,O
persisted,O
in,O
this,O
patient,O
for,O
ten,O
years,O
after,O
lithium,B
was,O
stopped,O
.,O
We,O
discuss,O
the,O
possible,O
renal,O
mechanisms,O
and,O
the,O
implications,O
for,O
management,O
of,O
patients,O
with,O
lithium,B
-,I
induced,I
nephrogenic,I
diabetes,I
insipidus,I
.,O
Effects,O
of,O
NIK,B
-,I
247,I
on,O
cholinesterase,B
and,O
scopolamine,B
-,I
induced,I
amnesia,I
.,O
The,O
effects,O
of,O
NIK,B
-,I
247,I
on,O
cholinesterase,B
",",O
scopolamine,B
-,I
induced,I
amnesia,I
and,O
spontaneous,O
movement,O
were,O
examined,O
and,O
compared,O
with,O
those,O
of,O
the,O
well,O
-,O
known,O
cholinesterase,B
inhibitors,O
tacrine,B
and,O
E,B
-,I
2020,I
.,O
NIK,B
-,O
247,O
",",O
tacrine,B
and,O
E,B
-,O
2020,O
all,O
strongly,O
inhibited,O
acetylcholinesterase,O
(,O
AChE,B
),O
in,O
human,O
red,O
blood,O
cells,O
(,O
IC50s,O
=,O
1,O
.,O
0,O
x,O
10,O
(,O
-,O
6,O
),O
",",O
2,O
.,O
9,O
x,O
10,O
(,O
-,O
7,O
),O
and,O
3,O
.,O
7,O
x,O
10,O
(,O
-,O
8,O
),O
M,O
",",O
respectively,O
.,O
In,O
addition,O
",",O
NIK,B
-,O
247,O
and,O
tacrine,B
",",O
but,O
not,O
E,B
-,O
2020,O
",",O
strongly,O
inhibited,O
butyrylcholinestrase,O
(,O
BuChE,B
),O
in,O
human,O
serum,O
.,O
All,O
three,O
drugs,O
produced,O
mixed,O
inhibition,O
of,O
AChE,B
activity,O
.,O
Moreover,O
",",O
the,O
inhibitory,O
effect,O
of,O
NIK,B
-,I
247,I
on,O
AChE,B
was,O
reversible,O
.,O
All,O
compounds,O
at,O
0,O
.,O
1,O
-,O
1,O
mg,O
/,O
kg,O
p,O
.,O
o,O
significantly,O
improved,O
the,O
amnesia,O
induced,O
by,O
scopolamine,B
(,O
0,O
.,O
5,O
mg,O
/,O
kg,O
s,O
.,O
c,O
.,O
),O
in,O
rats,O
performing,O
a,O
passive,O
avoidance,O
task,O
.,O
The,O
three,O
compounds,O
at,O
1,O
and,O
3,O
mg,O
/,O
kg,O
p,O
.,O
o,O
.,O
did,O
not,O
significantly,O
decrease,O
spontaneous,O
movement,O
by,O
rats,O
.,O
These,O
findings,O
suggest,O
that,O
NIK,B
-,I
247,I
at,O
a,O
low,O
dose,O
(,O
0,O
.,O
1,O
-,O
1,O
mg,O
/,O
kg,O
p,O
.,O
o,O
.,O
),O
improves,O
scopolamine,B
-,O
induced,O
amnesia,O
but,O
does,O
not,O
affect,O
spontaneous,O
movement,O
.,O
The,O
findings,O
suggest,O
that,O
NIK,B
-,I
247,I
may,O
be,O
a,O
useful,O
drug,O
for,O
the,O
treatment,O
of,O
Alzheimer,B
',I
s,I
disease,I
.,O
Potential,O
therapeutic,O
use,O
of,O
the,O
selective,O
dopamine,B
D1,I
receptor,I
agonist,O
",",O
A,B
-,I
86929,I
:,O
an,O
acute,O
study,O
in,O
parkinsonian,O
levodopa,O
-,O
primed,O
monkeys,O
.,O
The,O
clinical,O
utility,O
of,O
dopamine,B
(,O
DA,I
),O
D1,I
receptor,I
agonists,O
in,O
the,O
treatment,O
of,O
Parkinson,O
',O
s,O
disease,O
(,O
PD,I
),O
is,O
still,O
unclear,O
.,O
The,O
therapeutic,O
use,O
of,O
selective,O
DA,B
D1,I
receptor,I
agonists,O
such,O
as,O
SKF,B
-,I
82958,I
(,O
6,O
-,O
chloro,B
-,I
7,I
",",O
8,O
-,O
dihydroxy,B
-,I
3,I
-,I
allyl,I
-,I
1,I
-,I
phenyl,I
-,I
2,I
",",O
3,O
",",O
4,O
",",O
5,O
-,O
tetrahydro,B
-,I
1H,I
-,I
3,I
-,I
benzaze,I
pine,I
hydrobromide,I
),O
and,O
A,B
-,I
77636,I
(,O
[,O
1R,O
",",O
3S,O
],O
3,O
-,O
[,O
1,O
',O
-,O
admantyl,I
],O
-,O
1,O
-,O
aminomethyl,I
-,I
3,I
",",O
4,O
-,O
dihydro,B
-,I
5,I
",",O
6,O
-,O
dihydroxy,B
-,I
1H,I
-,I
2,I
-,I
benzo,I
pyran,I
hydrochloride,I
),O
seems,O
limited,O
because,O
of,O
their,O
duration,O
of,O
action,O
",",O
which,O
is,O
too,O
short,O
for,O
SKF,B
-,I
82958,I
(,O
<,O
1,O
hr,O
),O
and,O
too,O
long,O
for,O
A,B
-,I
77636,I
(,O
>,O
20,O
hr,O
",",O
leading,O
to,O
behavioral,O
tolerance,O
),O
.,O
We,O
therefore,O
conducted,O
the,O
present,O
acute,O
dose,O
-,O
response,O
study,O
in,O
four,O
1,B
-,I
methyl,I
-,I
4,I
-,I
phenyl,I
-,I
1,I
",",O
2,O
",",O
3,O
",",O
6,O
-,O
tetrahydropyridine,O
(,O
MPTP,B
),O
-,O
exposed,O
cynomolgus,O
monkeys,O
primed,O
to,O
exhibit,O
levodopa,B
-,I
induced,I
dyskinesias,I
to,O
evaluate,O
the,O
locomotor,O
and,O
dyskinetic,O
effects,O
on,O
challenge,O
with,O
four,O
doses,O
(,O
from,O
0,O
0.58,O
3,O
to,O
1,O
.,O
0,O
mg,O
/,O
kg,O
),O
of,O
A,B
-,O
86929,O
(,O
[,O
-,O
],O
-,O
[,O
5aR,O
",",O
11bS,O
].,O
-,O
4,B
",",O
5,I
",",O
5a,I
",",O
",",O
6,I
",",O
",",O
7,I
",",O
",",O
11b,I
-,O
hexahydro,I
-,O
2,I
-,O
propyl,I
-,O
3,I
-,O
thia,I
-,O
5,I
-,O
+,I
+,I
+,I
azacyclopent,I
-,O
1,I
-,O
ena,I
[,O
c,I
].,O
phenathrene,I
-,O
9,I
-,O
10,I
-,O
diol,I
),O
",",O
a,O
selective,O
and,O
full,O
DA,B
D1,I
-,O
like,O
receptor,O
agonist,O
with,O
an,O
intermediate,O
duration,O
of,O
action,O
.,O
Levodopa,B
and,O
the,O
DA,B
D2,I
-,O
like,O
receptor,O
agonist,O
",",O
LY,B
-,O
171555,O
(,O
[,O
4aR,O
-,O
trans,O
].,O
-,O
4,I
",",O
4a,I
",",O
5,I
",",O
6,I
",",O
7,I
",",O
8,I
",",O
8a,I
",",O
9,I
-,O
o,I
-,O
dihydro,I
-,O
5n,I
-,O
propyl,I
-,O
2H,I
-,O
pyrazo,I
lo,I
-,O
3,I
-,O
4,I
-,O
quinoline,I
hydrochloride,I
),O
were,O
also,O
used,O
for,O
comparison,O
.,O
Acute,O
administration,O
of,O
A,B
-,O
86929,I
was,O
as,O
efficacious,O
in,O
alleviating,O
MPTP,B
-,O
induced,O
parkinsonism,O
as,O
levodopa,B
and,O
LY,B
-,O
171555,I
",",O
but,O
was,O
less,O
likely,O
to,O
reproduce,O
the,O
levodopa,B
-,O
induced,O
dyskinesias,O
in,O
these,O
animals,O
than,O
with,O
either,O
LY,B
-,O
171555,I
or,O
subsequent,O
challenge,O
of,O
levodopa,B
.,O
Selective,O
stimulation,O
of,O
the,O
DA,B
D1,I
receptor,I
may,O
provide,O
better,O
integration,O
of,O
neural,O
inputs,O
transmitted,O
to,O
the,O
internal,O
segment,O
of,O
the,O
globus,O
pallidus,O
(,O
referred,O
to,O
as,O
the,O
basal,O
ganglia,O
output,O
),O
compared,O
with,O
levodopa,B
and,O
selective,O
DA,B
D2,I
receptor,I
agonist,O
.,O
Potent,O
DA,B
D1,I
receptor,O
agents,O
with,O
an,O
intermediate,O
duration,O
of,O
efficacy,O
such,O
as,O
A,B
-,I
86929,I
(,O
approximately,O
4,O
hr,O
at,O
higher,O
doses,O
tested,O
),O
are,O
potential,O
therapeutic,O
tools,O
in,O
PD,B
and,O
merit,O
further,O
attention,O
.,O
Neuropeptide,B
-,I
Y,I
immunoreactivity,O
in,O
the,O
pilocarpine,O
model,O
of,O
temporal,O
lobe,O
epilepsy,O
.,O
Neuropeptide,B
-,I
Y,I
(,O
NPY,B
),O
is,O
expressed,O
by,O
granule,O
cells,O
and,O
mossy,O
fibres,O
of,O
the,O
hippocampal,O
dentate,O
gyrus,O
during,O
experimental,O
temporal,O
lobe,O
epilepsy,O
(,O
TLE,B
),O
.,O
This,O
expression,O
may,O
represent,O
an,O
endogenous,O
damping,O
mechanism,O
since,O
NPY,B
has,O
been,O
shown,O
to,O
block,O
seizure,O
-,O
like,O
events,O
following,O
high,O
-,O
frequency,O
stimulation,O
in,O
hippocampal,O
slices,O
.,O
The,O
pilocarpine,B
(,O
PILO,B
),O
model,O
of,O
epilepsy,O
is,O
characterized,O
by,O
an,O
acute,O
period,O
of,O
status,O
epilepticus,O
followed,O
by,O
spontaneous,O
recurrent,O
seizures,O
and,O
related,O
brain,O
damage,O
.,O
We,O
report,O
peroxidase,B
-,I
antiperoxidase,I
immunostaining,O
for,O
NPY,B
in,O
several,O
brain,O
regions,O
in,O
this,O
model,O
.,O
PILO,B
-,I
injected,I
animals,O
exhibited,O
NPY,B
immunoreactivity,O
in,O
the,O
region,O
of,O
the,O
mossy,O
fibre,O
terminals,O
",",O
in,O
the,O
dentate,O
gyrus,O
inner,O
molecular,O
layer,O
and,O
",",O
in,O
a,O
few,O
cases,O
",",O
within,O
presumed,O
granule,O
cells,O
.,O
NPY,B
immunoreactivity,O
was,O
also,O
dramatically,O
changed,O
in,O
the,O
entorhinal,O
cortex,O
",",O
amygdala,B
and,O
sensorimotor,O
areas,O
.,O
In,O
addition,O
",",O
PILO,B
injected,O
animals,O
exhibited,O
a,O
reduction,O
in,O
the,O
number,O
of,O
NPY,B
-,O
immunoreactive,O
interneurons,O
compared,O
with,O
controls,O
.,O
The,O
results,O
demonstrate,O
that,O
changes,O
in,O
NPY,B
expression,O
",",O
including,O
expression,O
in,O
the,O
granule,O
cells,O
and,O
mossy,O
fibres,O
and,O
the,O
loss,O
of,O
vulnerable,O
NPY,B
neurons,O
",",O
are,O
present,O
in,O
the,O
PILO,B
model,O
of,O
TLE,O
.,O
However,O
",",O
the,O
significance,O
of,O
this,O
changed,O
synthesis,O
of,O
NPY,B
remains,O
to,O
be,O
determined,O
.,O
Posteroventral,O
medial,O
pallidotomy,O
in,O
advanced,O
Parkinson,B
',O
s,O
disease,O
.,O
BACKGROUND,O
:,O
Posteroventral,O
medial,O
pallidotomy,O
sometimes,O
produces,O
striking,O
improvement,O
in,O
patients,O
with,O
advanced,O
Parkinson,B
',O
s,O
disease,O
",",O
but,O
the,O
studies,O
to,O
date,O
have,O
involved,O
small,O
numbers,O
of,O
patients,O
and,O
short,O
-,O
term,O
follow,O
-,O
up,O
.,O
METHODS,O
:,O
Forty,O
patients,O
with,O
Parkinson,B
',I
s,I
disease,I
underwent,O
serial,O
",",O
detailed,O
assessments,O
both,O
after,O
drug,O
withdrawal,O
(,O
off,O
O,O
period,O
),O
and,O
while,O
taking,O
their,O
optimal,O
medical,O
regimens,O
(,O
on,O
period,O
),O
.,O
All,O
patients,O
were,O
examined,O
preoperatively,O
and,O
39,O
were,O
examined,O
at,O
six,O
months,O
;,O
27,O
of,O
the,O
patients,O
were,O
also,O
examined,O
at,O
one,O
year,O
",",O
and,O
11,O
at,O
two,O
years,O
.,O
RESULTS,O
:,O
The,O
percent,O
improvements,O
at,O
six,O
months,O
were,O
as,O
follows,O
:,O
off,O
-,O
period,O
score,O
for,O
overall,O
motor,O
function,O
",",O
28,O
percent,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
19,O
to,O
38,O
percent,O
),O
",",O
with,O
most,O
of,O
the,O
improvement,O
in,O
the,O
contralateral,O
limbs,O
;,O
off,O
-,O
period,O
score,O
for,O
activities,O
of,O
daily,O
living,O
",",O
29,O
percent,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
19,O
to,O
39,O
percent,O
),O
;,O
on,O
-,O
period,O
score,O
for,O
contralateral,O
dyskinesias,O
",",O
82,O
percent,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
72,O
to,O
91,O
percent,O
),O
;,O
and,O
on,O
-,O
period,O
score,O
for,O
ipsilateral,O
dyskinesias,O
",",O
44,O
percent,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
29,O
to,O
59,O
percent,O
),O
.,O
The,O
improvements,O
in,O
dyskinesias,B
and,O
the,O
total,O
scores,O
for,O
off,O
-,O
period,O
parkinsonism,O
",",O
contralateral,O
bradykinesia,O
",",O
and,O
rigidity,O
were,O
sustained,O
in,O
the,O
11,O
patients,O
examined,O
at,O
two,O
years,O
.,O
The,O
improvement,O
in,O
ipsilateral,O
dyskinesias,B
was,O
lost,O
after,O
one,O
year,O
",",O
and,O
the,O
improvements,O
in,O
postural,O
stability,O
and,O
gait,O
lasted,O
only,O
three,O
to,O
six,O
months,O
.,O
Approximately,O
half,O
the,O
patients,O
who,O
had,O
been,O
dependent,O
on,O
assistance,O
in,O
activities,O
of,O
daily,O
living,O
in,O
the,O
off,O
period,O
before,O
surgery,O
became,O
independent,O
after,O
surgery,O
.,O
The,O
complications,O
of,O
surgery,O
were,O
generally,O
well,O
tolerated,O
",",O
and,O
there,O
were,O
no,O
significant,O
changes,O
in,O
the,O
use,O
of,O
medication,O
.,O
CONCLUSIONS,O
:,O
In,O
late,O
-,O
stage,O
Parkinson,B
',O
s,O
disease,O
",",O
pallidotomy,O
significantly,O
reduces,O
levodopa,B
-,O
induced,O
dyskinesias,O
and,O
off,O
-,O
period,O
disability,O
.,O
Much,O
of,O
the,O
benefit,O
is,O
sustained,O
at,O
two,O
years,O
",",O
although,O
some,O
improvements,O
",",O
such,O
as,O
those,O
on,O
the,O
ipsilateral,O
side,O
and,O
in,O
axial,O
symptoms,O
",",O
wane,O
within,O
the,O
first,O
year,O
.,O
The,O
on,O
-,O
period,O
symptoms,O
that,O
are,O
resistant,O
to,O
dopaminergic,O
therapy,O
do,O
not,O
respond,O
to,O
pallidotomy,O
.,O
Clarithromycin,B
-,I
induced,I
ventricular,I
tachycardia,I
.,O
Clarithromycin,B
is,O
a,O
relatively,O
new,O
macrolide,O
antibiotic,O
that,O
offers,O
twice,O
-,O
daily,O
dosing,O
.,O
It,O
differs,O
from,O
erythromycin,B
only,O
in,O
the,O
methylation,O
of,O
the,O
hydroxyl,O
group,O
at,O
position,O
6,O
.,O
Although,O
the,O
side,O
-,O
effect,O
profile,O
of,O
erythromycin,B
is,O
established,O
",",O
including,O
gastroenteritis,B
and,O
interactions,O
with,O
other,O
drugs,O
subject,O
to,O
hepatic,O
mixed,O
-,O
function,O
oxidase,O
metabolism,O
",",O
experience,O
with,O
the,O
newer,O
macrolides,O
is,O
still,O
being,O
recorded,O
.,O
Cardiotoxicity,O
has,O
been,O
demonstrated,O
after,O
both,O
intravenous,O
and,O
oral,O
administration,O
of,O
erythromycin,B
but,O
has,O
never,O
been,O
reported,O
with,O
the,O
newer,O
macrolides,B
.,O
We,O
report,O
a,O
case,O
of,O
ventricular,O
dysrhythmias,O
that,O
occurred,O
after,O
six,O
therapeutic,O
doses,O
of,O
clarithromycin,B
.,O
The,O
dysrhythmias,O
resolved,O
after,O
discontinuation,O
of,O
the,O
drug,O
.,O
Effect,O
of,O
glyceryl,B
trinitrate,I
on,O
the,O
sphincter,O
of,O
Oddi,O
spasm,O
evoked,O
by,O
prostigmine,B
-,O
morphine,B
administration,O
.,O
OBJECTIVE,O
:,O
In,O
this,O
study,O
the,O
effect,O
of,O
glyceryl,B
trinitrate,I
on,O
the,O
prostigmine,B
-,O
morphine,B
-,O
induced,O
sphincter,O
of,O
Oddi,O
spasm,O
was,O
evaluated,O
in,O
nine,O
female,O
patients,O
with,O
sphincter,O
of,O
Oddi,O
dyskinesia,O
.,O
METHOD,O
:,O
Sphincter,O
of,O
Oddi,O
spasm,O
was,O
induced,O
by,O
prostigmine,B
-,O
morphine,B
administration,O
(,O
0,O
.,O
5,O
mg,O
prostigmine,B
intramuscularly,O
and,O
10,O
mg,O
morphine,B
subcutaneously,O
),O
and,O
visualized,O
by,O
quantitative,O
hepatobiliary,O
scintigraphy,O
.,O
The,O
entire,O
procedure,O
was,O
repeated,O
during,O
glyceryl,B
trinitrate,I
infusion,O
(,O
Nitrolingual,B
1,O
microg,O
/,O
kg,O
/,O
min,O
for,O
120,O
min,O
),O
.,O
RESULTS,O
:,O
Prostigmine,B
-,O
morphine,B
provocation,O
caused,O
significant,O
increases,O
in,O
the,O
time,O
to,O
peak,O
activity,O
(,O
Tmax,O
),O
over,O
the,O
hepatic,O
hilum,O
(,O
HH,O
:,O
34,O
.,O
33,O
+,O
/,O
-,O
5,O
vs,O
22,O
.,O
77,O
22,O
.,O
77,O
+,O
/,O
-,O
3,O
.,O
26,O
),O
and,O
the,O
common,O
bile,O
duct,O
(,O
CBD,O
:,O
60,O
.,O
44,O
+,O
/,O
-,O
5,O
.,O
99,O
vs,O
40,O
.,O
0,O
+,O
/,O
-,O
2,O
.,O
88,O
),O
and,O
in,O
the,O
half,O
-,O
time,O
of,O
excretion,O
(,O
T1,O
/,O
2,O
),O
over,O
the,O
liver,O
parenchyma,O
(,O
LP,O
:,O
120,O
4,O
+,O
/,O
-,O
16,O
.,O
1,O
vs,O
.,O
27,O
.,O
37,O
+,O
/,O
-,O
2,O
.,O
19,O
.,O
),O
",",O
HH,B
(,O
117,O
.,O
61,O
+,O
/,O
-,O
14,O
.,O
71,O
vs,O
.,O
31,O
.,O
85,O
+,O
/,O
-,O
3,O
.,O
99,O
),O
and,O
CBD,B
(,O
158,O
.,O
11,O
+,O
/,O
-,O
9,O
.,O
18,O
vs,O
.,O
40,O
.,O
1,O
+,O
/,O
-,O
6,O
.,O
24,O
),O
",",O
indicating,O
a,O
complete,O
spasm,O
at,O
the,O
level,O
of,O
the,O
sphincter,O
of,O
Oddi,O
.,O
Glyceryl,B
trinitrate,I
infusion,O
completely,O
normalized,O
the,O
prostigmine,B
-,O
morphine,B
-,O
induced,O
alterations,O
in,O
these,O
quantitative,O
parameters,O
(,O
TmaX,O
over,O
the,O
LP,O
:,O
11,O
33,O
+,O
/,O
-,O
1,O
.,O
13,O
;,O
over,O
the,O
HH,O
:,O
18,O
.,O
88,O
+,O
/,O
-,O
1,O
.,O
48,O
;,O
and,O
over,O
the,O
CBD,O
:,O
36,O
.,O
22,O
+,O
/,O
-,O
1,O
.,O
92,O
;,O
and,O
T1,O
/,O
2,O
over,O
the,O
LP,O
:,O
28,O
.,O
21,O
+,O
/,O
-,O
1,O
.,O
83,O
;,O
over,O
the,O
HH,O
:,O
33,O
.,O
42,O
+,O
/,O
-,O
3,O
.,O
10,O
;,O
and,O
over,O
the,O
CBD,O
:,O
41,O
.,O
66,O
+,O
/,O
-,O
6,O
.,O
33,O
),O
",",O
suggesting,O
an,O
effective,O
sphincter,O
-,O
relaxing,O
effect,O
of,O
glyceryl,B
trinitrate,I
.,O
CONCLUSION,O
:,O
These,O
results,O
provide,O
the,O
first,O
evidence,O
of,O
the,O
effectiveness,O
of,O
glyceryl,B
trinitrate,I
on,O
the,O
morphine,B
-,O
induced,O
sphincter,O
of,O
Oddi,O
spasm,O
in,O
humans,O
.,O
Since,O
glyceryl,B
trinitrate,I
is,O
able,O
to,O
overcome,O
even,O
the,O
drastic,O
effect,O
of,O
morphine,B
",",O
it,O
might,O
be,O
of,O
relevance,O
in,O
the,O
treatment,O
of,O
sphincter,O
of,O
Oddi,O
dyskinesia,O
.,O
Immunopathology,O
of,O
penicillamine,B
-,I
induced,I
glomerular,I
disease,I
.,O
Four,O
patients,O
with,O
rheumatoid,O
arthritis,O
developed,O
heavy,O
proteinuria,O
after,O
five,O
to,O
12,O
months,O
of,O
treatment,O
with,O
D,B
-,I
penicillamine,I
.,O
Light,O
microscopy,O
of,O
renal,O
biopsy,O
samples,O
showed,O
minimal,O
glomerular,O
capillary,O
wall,O
thickening,O
and,O
mesangial,O
matrix,O
increase,O
",",O
or,O
no,O
departure,O
from,O
normal,O
.,O
Electron,O
microscopy,O
",",O
however,O
",",O
revealed,O
subepithelial,O
electron,B
-,I
dense,I
deposits,O
",",O
fusion,O
of,O
epithelial,O
cell,O
foot,O
processes,O
",",O
and,O
evidence,O
of,O
mesangial,O
cell,O
hyperactivity,O
.,O
Immunofluorescence,O
microscopy,O
demonstrated,O
granular,O
capillary,O
wall,O
deposits,O
of,O
IgG,B
and,O
C3,B
.,O
The,O
findings,O
were,O
similar,O
to,O
those,O
in,O
early,O
membranous,O
glomerulonephritis,O
",",O
differences,O
being,O
observed,O
however,O
in,O
the,O
results,O
of,O
staining,O
for,O
the,O
early,O
-,O
acting,O
complement,B
components,O
C1q,B
and,O
C4,B
.,O
It,O
is,O
tentatively,O
concluded,O
that,O
complement,B
was,O
activated,O
by,O
the,O
classical,O
pathway,O
.,O
Experimental,O
cranial,O
pain,O
elicited,O
by,O
capsaicin,B
:,O
a,O
PET,B
study,O
.,O
Using,O
a,O
positron,B
emission,I
tomography,I
(,O
PET,I
),O
study,O
it,O
was,O
shown,O
recently,O
that,O
in,O
migraine,O
without,O
aura,O
certain,O
areas,O
in,O
the,O
brain,O
stem,O
were,O
activated,O
during,O
the,O
headache,O
state,O
",",O
but,O
not,O
in,O
the,O
headache,O
free,O
interval,O
.,O
It,O
was,O
suggested,O
that,O
this,O
brain,O
stem,O
activation,O
is,O
inherent,O
to,O
the,O
migraine,O
attack,O
itself,O
and,O
represents,O
the,O
so,O
called,O
',O
migraine,O
generator,O
',O
.,O
To,O
test,O
this,O
hypothesis,O
we,O
performed,O
an,O
experimental,O
pain,O
study,O
in,O
seven,O
healthy,O
volunteers,O
",",O
using,O
the,O
same,O
positioning,O
in,O
the,O
PET,O
scanner,O
as,O
in,O
the,O
migraine,O
patients,O
.,O
A,O
small,O
amount,O
of,O
capsaicin,B
was,O
administered,O
subcutaneously,O
in,O
the,O
right,O
forehead,O
to,O
evoke,O
a,O
burning,O
painful,O
sensation,O
in,O
the,O
first,O
division,O
of,O
the,O
trigeminal,O
nerve,O
.,O
Increases,O
of,O
regional,O
cerebral,O
blood,O
flow,O
(,O
rCBF,B
),O
were,O
found,O
bilaterally,O
in,O
the,O
insula,B
",",O
in,O
the,O
anterior,O
cingulate,B
cortex,I
",",O
the,O
cavernous,B
sinus,I
and,O
the,O
cerebellum,B
.,O
Using,O
the,O
same,O
stereotactic,O
space,O
limits,O
as,O
in,O
the,O
above,O
mentioned,O
migraine,O
study,O
no,O
brain,O
stem,O
activation,O
was,O
found,O
in,O
the,O
acute,O
pain,O
state,O
compared,O
to,O
the,O
pain,O
free,O
state,O
.,O
The,O
increase,O
of,O
activation,O
in,O
the,O
region,O
of,O
the,O
cavernous,B
sinus,I
however,O
",",O
suggests,O
that,O
this,O
structure,O
is,O
more,O
likely,O
to,O
be,O
involved,O
in,O
trigeminal,B
transmitted,O
pain,O
as,O
such,O
",",O
rather,O
than,O
in,O
a,O
specific,O
type,O
of,O
headache,O
as,O
was,O
suggested,O
for,O
cluster,O
headache,O
.,O
Value,O
of,O
methylprednisolone,B
in,O
prevention,O
of,O
the,O
arthralgia,B
-,I
myalgia,I
syndrome,I
associated,O
with,O
the,O
total,O
dose,O
infusion,O
of,O
iron,B
dextran,I
:,O
a,O
double,O
blind,O
randomized,O
trial,O
.,O
The,O
safety,O
and,O
efficacy,O
of,O
total,O
dose,O
infusion,O
(,O
TDI,O
),O
of,O
iron,B
dextran,I
has,O
been,O
well,O
documented,O
.,O
In,O
40,O
%,O
of,O
treated,O
patients,O
",",O
an,O
arthralgia,O
-,O
myalgia,O
syndrome,O
develops,O
.,O
The,O
purpose,O
of,O
this,O
randomized,O
",",O
double,O
-,O
blind,O
",",O
prospective,O
study,O
was,O
to,O
investigate,O
whether,O
intravenous,O
(,O
i,B
.,I
v,I
.,I
),O
administration,O
of,O
methylprednisolone,B
(,O
MP,O
),O
prevents,O
this,O
complication,O
.,O
Sixty,O
-,O
five,O
patients,O
",",O
34,O
women,O
and,O
31,O
men,O
",",O
ages,O
36,O
to,O
80,O
years,O
",",O
received,O
either,O
normal,B
saline,I
before,O
and,O
after,O
TDI,O
(,O
group,O
1,O
),O
",",O
125,B
mg,I
i,I
.,I
v,I
.,I
MP,I
before,O
and,O
saline,O
after,O
TDI,O
(,O
group,O
2,O
),O
",",O
or,O
125,B
mg,I
i,I
.,I
v,I
.,I
MP,I
before,O
and,O
after,O
TDI,O
(,O
group,O
3,O
),O
.,O
Patients,O
were,O
observed,O
for,O
72,O
hours,O
and,O
reactions,O
were,O
recorded,O
and,O
graded,O
according,O
to,O
severity,O
.,O
Fifty,O
-,O
eight,O
percent,O
of,O
group,O
1,O
patients,O
",",O
33,O
%,O
of,O
group,O
2,O
",",O
and,O
26,O
%,O
of,O
group,O
3,O
had,O
reactions,O
to,O
TDI,B
.,O
The,O
severity,O
of,O
reactions,O
(,O
minimal,O
",",O
mild,O
",",O
and,O
moderate,O
",",O
respectively,O
),O
was,O
as,O
follows,O
:,O
group,O
1,O
-,O
-,O
6,O
",",O
6,O
",",O
and,O
2,O
;,O
group,O
2,O
-,O
-,O
1,O
",",O
5,O
",",O
and,O
0,O
;,O
group,O
3,O
-,O
-,O
5,O
",",O
1,O
",",O
and,O
0,O
.,O
Data,O
were,O
analyzed,O
by,O
the,O
two,O
-,O
sided,O
Fisher,O
',O
s,O
exact,O
test,O
using,O
95,O
%,O
confidence,O
intervals,O
with,O
the,O
approximation,O
of,O
Woolf,O
.,O
These,O
data,O
demonstrate,O
that,O
administration,O
of,O
MP,B
before,O
and,O
after,O
TDI,O
reduces,O
the,O
frequency,O
and,O
severity,O
of,O
the,O
arthralgia,B
-,I
myalgia,I
syndrome,I
.,O
We,O
conclude,O
that,O
125,O
mg,O
i,O
.,O
v,O
MP,B
should,O
be,O
given,O
routinely,O
before,O
and,O
after,O
TDI,O
of,O
iron,B
dextran,I
.,O
Prolongation,O
of,O
the,O
QT,B
interval,I
related,O
to,O
cisapride,B
-,I
diltiazem,I
interaction,I
.,O
Cisapride,B
",",O
a,O
cytochrome,B
P450,I
3A4,I
(,O
CYP3A4,I
),O
substrate,O
",",O
is,O
widely,O
prescribed,O
for,O
the,O
treatment,O
of,O
gastrointestinal,O
motility,O
disorders,O
.,O
Prolongation,O
of,O
QT,B
interval,O
",",O
torsades,O
de,O
pointes,O
",",O
and,O
sudden,O
cardiac,O
death,O
have,O
been,O
reported,O
after,O
concomitant,O
administration,O
with,O
erythromycin,B
or,O
azole,B
antifungal,I
agents,O
",",O
but,O
not,O
with,O
other,O
CYP3A4,I
inhibitors,O
.,O
A,O
possible,O
drug,O
interaction,O
occurred,O
in,O
a,O
45,O
-,O
year,O
-,O
old,O
woman,O
who,O
was,O
taking,O
cisapride,B
for,O
gastroesophageal,O
reflux,O
disorder,O
and,O
diltiazem,B
",",O
an,O
agent,O
that,O
has,O
inhibitory,O
effect,O
on,O
CYP3A4,B
",",O
for,O
hypertension,O
.,O
The,O
patient,O
was,O
in,O
near,O
syncope,O
and,O
had,O
QT,B
-,I
interval,I
prolongation,I
.,O
After,O
discontinuing,O
cisapride,B
",",O
the,O
QT,B
interval,I
returned,O
to,O
normal,O
and,O
symptoms,O
did,O
not,O
recur,O
.,O
We,O
suggest,O
that,O
caution,O
be,O
taken,O
when,O
cisapride,B
is,O
prescribed,O
with,O
any,O
potent,O
inhibitor,O
of,O
CYP3A4,B
",",O
including,O
diltiazem,B
.,O
Cortical,O
motor,O
overactivation,O
in,O
parkinsonian,O
patients,O
with,O
L,B
-,O
dopa,I
-,O
induced,O
peak,O
-,O
dose,O
dyskinesia,O
.,O
We,O
have,O
studied,O
the,O
regional,O
cerebral,O
blood,O
flow,O
(,O
rCBF,B
),O
changes,O
induced,O
by,O
the,O
execution,O
of,O
a,O
finger,O
-,O
to,O
-,O
thumb,O
opposition,O
motor,O
task,O
in,O
the,O
supplementary,O
and,O
primary,O
motor,O
cortex,O
of,O
two,O
groups,O
of,O
parkinsonian,O
patients,O
on,O
L,B
-,O
dopa,I
medication,O
",",O
the,O
first,O
one,O
without,O
L,B
-,O
dopa,I
induced,O
dyskinesia,O
(,O
n,O
=,O
23,O
),O
and,O
the,O
other,O
with,O
moderate,O
peak,O
-,O
dose,O
dyskinesia,O
(,O
n,O
=,O
15,O
),O
",",O
and,O
of,O
a,O
group,O
of,O
14,O
normal,O
subjects,O
.,O
Single,O
photon,O
emission,O
tomography,O
with,O
i,B
.,O
v,O
.,O
133Xe,B
was,O
used,O
to,O
measure,O
the,O
rCBF,B
changes,O
.,O
The,O
dyskinetic,O
parkinsonian,O
patients,O
exhibited,O
a,O
pattern,O
of,O
response,O
which,O
was,O
markedly,O
different,O
from,O
those,O
of,O
the,O
normal,O
subjects,O
and,O
non,O
-,O
dyskinetic,O
parkinsonian,O
patients,O
",",O
with,O
a,O
significant,O
overactivation,O
in,O
the,O
supplementary,O
motor,O
area,O
and,O
the,O
ipsi,O
-,O
and,O
contralateral,O
primary,O
motor,O
areas,O
.,O
These,O
results,O
are,O
compatible,O
with,O
the,O
hypothesis,O
that,O
an,O
hyperkinetic,O
abnormal,O
involuntary,O
movement,O
",",O
like,O
L,B
-,I
dopa,I
-,I
induced,I
peak,I
dose,I
dyskinesia,I
",",O
is,O
due,O
to,O
a,O
disinhibition,O
of,O
the,O
primary,O
and,O
associated,O
motor,O
cortex,O
secondary,O
to,O
an,O
excessive,O
outflow,O
of,O
the,O
pallidothalamocortical,O
motor,O
loop,O
.,O
Open,O
-,O
label,O
assessment,O
of,O
levofloxacin,B
for,O
the,O
treatment,O
of,O
acute,O
bacterial,O
sinusitis,O
in,O
adults,O
.,O
PURPOSE,O
:,O
To,O
evaluate,O
the,O
efficacy,O
and,O
safety,O
of,O
levofloxacin,B
(,O
500,B
mg,I
orally,O
once,O
daily,O
for,O
10,O
to,O
14,O
days,O
),O
in,O
treating,O
adult,O
outpatients,O
with,O
acute,O
bacterial,O
sinusitis,O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
A,O
total,O
of,O
329,O
patients,O
enrolled,O
in,O
the,O
study,O
at,O
24,O
centers,O
.,O
All,O
patients,O
had,O
a,O
pre,O
-,O
therapy,O
Gram,B
',I
s,I
stain,I
and,O
culture,O
of,O
sinus,O
exudate,O
obtained,O
by,O
antral,O
puncture,O
or,O
nasal,O
endoscopy,O
.,O
Clinical,O
response,O
was,O
assessed,O
on,O
the,O
basis,O
of,O
signs,O
and,O
symptoms,O
and,O
sinus,O
radiograph,O
or,O
computed,O
tomography,O
results,O
.,O
Microbiologic,O
cure,O
rates,O
were,O
determined,O
on,O
the,O
basis,O
of,O
presumed,O
plus,O
documented,O
eradication,O
of,O
the,O
pre,O
-,O
therapy,O
pathogen,O
(,O
s,O
),O
.,O
RESULTS,O
:,O
The,O
most,O
common,O
pathogens,O
were,O
Haemophilus,B
influenzae,I
",",O
Streptococcus,B
pneumoniae,I
",",O
Staphylococcus,B
aureus,I
",",O
and,O
Moraxella,B
catarrhalis,I
.,O
Of,O
300,O
clinically,O
evaluable,O
patients,O
",",O
175,O
(,O
58,O
%,O
),O
were,O
cured,O
and,O
90,O
(,O
30,O
%,O
),O
were,O
improved,O
at,O
the,O
post,O
-,O
therapy,O
evaluation,O
",",O
resulting,O
in,O
a,O
clinical,O
success,O
rate,O
of,O
88,O
%,O
. Thirty,O
-,O
five,O
patients,O
(,O
12,O
%,O
),O
clinically,O
failed,O
treatment,O
. The,O
microbiologic,O
eradication,O
rate,O
(,O
presumed,O
plus,O
documented,O
),O
among,O
138,O
microbiologically,O
evaluable,O
patients,O
was,O
92,O
%,O
.,O
Microbiologic,O
eradication,O
rates,O
(,O
presumed,O
plus,O
documented,O
),O
of,O
the,O
most,O
common,O
pathogens,O
ranged,O
from,O
93,O
%,O
(,O
M,B
.,I
catarrhalis,I
),O
to,O
100,O
%,O
(,O
S,B
.,I
pneumoniae,I
),O
at,O
the,O
post,O
-,O
therapy,O
visit,O
.,O
All,O
but,O
one,O
of,O
the,O
265,O
patients,O
who,O
were,O
cured,O
or,O
improved,O
at,O
post,O
-,O
therapy,O
returned,O
for,O
a,O
long,O
-,O
term,O
follow,O
-,O
up,O
visit,O
;,O
243,O
(,O
92,O
%,O
),O
remained,O
well,O
4,O
to,O
6,O
weeks,O
after,O
therapy,O
;,O
and,O
21,O
(,O
8,O
%,O
),O
had,O
a,O
relapse,O
of,O
symptoms,O
.,O
Adverse,O
events,O
considered,O
to,O
be,O
related,O
to,O
levofloxacin,B
administration,O
were,O
reported,O
by,O
29,O
patients,O
(,O
9,O
%,O
),O
.,O
The,O
most,O
common,O
drug,O
-,O
related,O
adverse,O
events,O
were,O
diarrhea,B
",",O
flatulence,B
",",O
and,O
nausea,B
;,O
most,O
adverse,O
events,O
were,O
mild,O
to,O
moderate,O
in,O
severity,O
.,O
CONCLUSION,O
:,O
The,O
results,O
of,O
this,O
study,O
indicate,O
that,O
levofloxacin,B
500,O
mg,O
once,O
daily,O
is,O
an,O
effective,O
and,O
safe,O
treatment,O
for,O
acute,O
bacterial,O
sinusitis,O
.,O
Iatrogenic,O
risks,O
of,O
endometrial,O
carcinoma,O
after,O
treatment,O
for,O
breast,O
cancer,O
in,O
a,O
large,O
French,O
case,O
-,O
control,O
study,O
.,O
F,O
d,O
ration,O
Nationale,O
des,O
Centres,O
de,O
Lutte,O
Contre,O
le,O
Cancer,O
(,O
FNCLCC,O
),O
.,O
Since,O
tamoxifen,B
is,O
widely,O
used,O
in,O
breast,O
cancer,O
treatment,O
and,O
has,O
been,O
proposed,O
for,O
the,O
prevention,O
of,O
breast,O
cancer,O
",",O
its,O
endometrial,O
iatrogenic,O
effects,O
must,O
be,O
carefully,O
examined,O
.,O
We,O
have,O
investigated,O
the,O
association,O
between,O
endometrial,B
cancer,I
and,O
tamoxifen,B
use,O
or,O
other,O
treatments,O
in,O
women,O
treated,O
for,O
breast,B
cancer,I
in,O
a,O
case,O
-,O
control,O
study,O
.,O
Cases,O
of,O
endometrial,B
cancer,I
diagnosed,O
after,O
breast,B
cancer,I
(,O
n,O
=,O
135,O
),O
and,O
467,O
controls,O
matched,O
for,O
age,O
",",O
year,O
of,O
diagnosis,O
of,O
breast,B
cancer,I
and,O
hospital,O
and,O
survival,O
time,O
with,O
an,O
intact,O
uterus,O
were,O
included,O
.,O
Women,O
who,O
had,O
received,O
tamoxifen,B
were,O
significantly,O
more,O
likely,O
to,O
have,O
endometrial,B
cancer,I
diagnosed,O
than,O
those,O
who,O
had,O
not,O
(,O
crude,O
relative,O
risk,O
=,O
4,O
.,O
9,O
",",O
p,O
=,O
0,O
.,O
1,O
.,O
),O
.,O
Univariate,O
and,O
adjusted,O
analyses,O
showed,O
that,O
the,O
risk,O
increased,O
with,O
the,O
length,O
of,O
treatment,O
(,O
p,O
=,O
0,O
.,O
1,O
),O
or,O
the,O
cumulative,O
dose,O
of,O
tamoxifen,B
received,O
(,O
p,O
=,O
0,O
.,O
1,O
),O
",",O
irrespective,O
of,O
the,O
daily,O
dose,O
.,O
Women,O
who,O
had,O
undergone,O
pelvic,O
radiotherapy,O
also,O
had,O
a,O
higher,O
risk,O
(,O
crude,O
relative,O
risk,O
=,O
7,O
.,O
8,O
",",O
p,O
=,O
0,O
.,O
1,O
),O
.,O
After,O
adjusting,O
for,O
confounding,O
factors,O
",",O
the,O
risk,O
was,O
higher,O
for,O
tamoxifen,B
users,O
(,O
p,O
=,O
0,O
.,O
12,O
),O
",",O
treatment,O
for,O
more,O
than,O
3,O
years,O
(,O
all,O
p,O
<,O
0,O
.,O
3,O
),O
and,O
pelvic,O
radiotherapy,O
(,O
p,O
=,O
0,O
.,O
12,O
),O
.,O
Women,O
who,O
had,O
endometrial,B
cancer,I
and,O
had,O
received,O
tamoxifen,B
had,O
more,O
advanced,O
disease,O
and,O
poorer,O
prognosis,O
than,O
those,O
with,O
endometrial,B
cancer,I
who,O
had,O
not,O
received,O
this,O
treatment,O
.,O
Our,O
results,O
suggest,O
a,O
causal,O
role,O
of,O
tamoxifen,B
in,O
endometrial,B
cancer,I
",",O
particularly,O
when,O
used,O
as,O
currently,O
proposed,O
for,O
breast,O
cancer,O
prevention,O
.,O
Pelvic,O
radiotherapy,O
may,O
be,O
an,O
additional,O
iatrogenic,O
factor,O
for,O
women,O
with,O
breast,B
cancer,I
.,O
Endometrial,B
cancers,I
diagnosed,O
in,O
women,O
treated,O
with,O
tamoxifen,B
have,O
poorer,O
prognosis,O
.,O
Women,O
who,O
receive,O
tamoxifen,B
for,O
breast,B
cancer,I
should,O
be,O
offered,O
gynaecological,O
surveillance,O
during,O
and,O
after,O
treatment,O
.,O
A,O
long,O
-,O
term,O
evaluation,O
of,O
the,O
risk,O
-,O
benefit,O
ratio,O
of,O
tamoxifen,B
as,O
a,O
preventive,O
treatment,O
for,O
breast,B
cancer,I
is,O
clearly,O
warranted,O
.,O
Contribution,O
of,O
the,O
glycine,B
site,O
of,O
NMDA,B
receptors,O
in,O
rostral,O
and,O
intermediate,O
-,O
caudal,O
parts,O
of,O
the,O
striatum,O
to,O
the,O
regulation,O
of,O
muscle,O
tone,O
in,O
rats,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
assess,O
the,O
contribution,O
of,O
the,O
glycine,B
site,O
of,O
NMDA,B
receptors,O
in,O
the,O
striatum,O
to,O
the,O
regulation,O
of,O
muscle,O
tone,O
.,O
Muscle,B
tone,O
was,O
examined,O
using,O
a,O
combined,O
mechanoand,O
electromyographic,O
method,O
",",O
which,O
measured,O
simultaneously,O
the,O
muscle,B
resistance,O
(,O
MMG,B
),O
of,O
the,O
rat,O
',O
s,O
hind,O
foot,O
to,O
passive,O
extension,O
and,O
flexion,O
in,O
the,O
ankle,O
joint,O
and,O
the,O
electromyographic,O
activity,O
(,O
EMG,B
),O
of,O
the,O
antagonistic,O
muscles,B
of,O
that,O
joint,O
:,O
gastrocnemius,B
and,O
tibialis,B
anterior,I
.,O
Muscle,O
rigidity,O
was,O
induced,O
by,O
haloperidol,B
(,O
2,O
.,O
5,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
.,O
5,O
",",O
7,O
-,O
dichlorokynurenic,B
acid,I
(,O
5,O
",",O
7,O
-,O
DCKA,O
),O
",",O
a,O
selective,O
glycine,B
site,I
antagonist,I
",",O
injected,O
in,O
doses,O
of,O
2,O
.,O
5,O
and,O
4,O
.,O
5,O
microg,O
/,O
0,O
.,O
5,O
microl,O
bilaterally,O
",",O
into,O
the,O
rostral,O
region,O
of,O
the,O
striatum,B
",",O
decreased,O
both,O
the,O
haloperidol,B
-,O
induced,O
muscle,O
rigidity,O
(,O
MMG,O
),O
and,O
the,O
enhanced,O
electromyographic,O
activity,O
(,O
EMG,O
),O
.,O
5,B
",",O
7,B
-,I
DCKA,I
injected,O
bilaterally,O
in,O
a,O
dose,O
of,O
4,B
.,O
5,I
microg,O
/,O
0,B
.,O
5,I
microl,O
into,O
the,O
intermediate,O
-,O
caudal,O
region,O
of,O
the,O
striatum,O
of,O
rats,O
not,O
pretreated,O
with,O
haloperidol,O
had,O
no,O
effect,O
on,O
the,O
muscle,O
tone,O
.,O
The,O
present,O
results,O
suggest,O
that,O
blockade,O
of,O
the,O
glycine,B
site,O
of,O
NMDA,B
receptors,O
in,O
the,O
rostral,O
part,O
of,O
the,O
striatum,O
may,O
be,O
mainly,O
responsible,O
for,O
the,O
antiparkinsonian,O
action,O
of,O
this,O
drug,O
.,O
Carboplatin,B
toxic,O
effects,O
on,O
the,O
peripheral,O
nervous,O
system,O
of,O
the,O
rat,O
.,O
BACKGROUND,O
:,O
The,O
most,O
striking,O
of,O
carboplatin,B
',O
s,O
advantages,O
(,O
CBDCA,B
),O
over,O
cisplatin,B
(,O
CDDP,B
),O
is,O
its,O
markedly,O
reduced,O
rate,O
of,O
neurotoxic,O
effects,O
.,O
However,O
",",O
the,O
use,O
of,O
CBDCA,B
higher,O
-,O
intensity,O
schedules,O
and,O
the,O
association,O
with,O
other,O
neurotoxic,O
drugs,O
in,O
polychemotherapy,O
may,O
cause,O
some,O
concern,O
about,O
its,O
safety,O
with,O
respect,O
to,O
peripheral,O
nervous,O
system,O
damage,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
Two,O
different,O
schedules,O
of,O
CBDCA,B
administration,O
(,O
10,O
mg,O
/,O
kg,O
and,O
15,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
twice,O
a,O
week,O
for,O
nine,O
times,O
),O
were,O
evaluated,O
in,O
Wistar,O
rats,O
.,O
Neurotoxicity,O
was,O
assessed,O
for,O
behavioral,O
(,O
tail,O
-,O
flick,O
test,O
),O
",",O
neurophysiological,O
(,O
nerve,O
conduction,O
velocity,O
in,O
the,O
tail,O
nerve,O
),O
",",O
morphological,O
",",O
morphometrical,O
and,O
analytical,O
effects,O
.,O
RESULTS,O
:,O
CBDCA,B
administration,O
induced,O
dose,O
-,O
dependent,O
peripheral,O
neurotoxicity,O
.,O
Pain,O
perception,O
and,O
nerve,O
conduction,O
velocity,O
in,O
the,O
tail,O
were,O
significantly,O
impaired,O
",",O
particularly,O
after,O
the,O
high,O
-,O
dose,O
treatment,O
.,O
The,O
dorsal,O
root,O
ganglia,O
sensory,O
neurons,O
and,O
",",O
to,O
a,O
lesser,O
extent,O
",",O
satellite,O
cells,O
showed,O
the,O
same,O
changes,O
as,O
those,O
induced,O
by,O
CDDP,B
",",O
mainly,O
affecting,O
the,O
nucleus,O
and,O
nucleolus,O
of,O
ganglionic,O
sensory,O
neurons,O
.,O
Moreover,O
",",O
significant,O
amounts,O
of,O
platinum,B
were,O
detected,O
in,O
the,O
dorsal,O
root,O
ganglia,O
and,O
kidney,O
after,O
CBDCA,B
treatment,O
.,O
CONCLUSIONS,O
:,O
CBDCA,B
is,O
neurotoxic,O
in,O
our,O
model,O
",",O
and,O
the,O
type,O
of,O
pathological,O
changes,O
it,O
induces,O
are,O
so,O
closely,O
similar,O
to,O
those,O
caused,O
by,O
CDDP,B
that,O
it,O
is,O
probable,O
that,O
neurotoxicity,O
is,O
induced,O
in,O
the,O
two,O
drugs,O
by,O
the,O
same,O
mechanism,O
.,O
This,O
model,O
can,O
be,O
used,O
alone,O
or,O
in,O
combination,O
with,O
other,O
drugs,O
to,O
explore,O
the,O
effect,O
of,O
CBDCA,B
on,O
the,O
peripheral,O
nervous,O
system,O
.,O
Effects,O
of,O
cisapride,B
on,O
symptoms,O
and,O
postcibal,O
small,O
-,O
bowel,O
motor,O
function,O
in,O
patients,O
with,O
irritable,O
bowel,O
syndrome,O
.,O
BACKGROUND,O
:,O
Irritable,O
bowel,O
syndrome,O
is,O
a,O
common,O
cause,O
of,O
abdominal,O
pain,O
and,O
discomfort,O
and,O
may,O
be,O
related,O
to,O
disordered,O
gastrointestinal,O
motility,O
.,O
Our,O
aim,O
was,O
to,O
assess,O
the,O
effects,O
of,O
long,O
-,O
term,O
treatment,O
with,O
a,O
prokinetic,O
agent,O
",",O
cisapride,B
",",O
on,O
postprandial,O
jejunal,O
motility,O
and,O
symptoms,O
in,O
the,O
irritable,O
bowel,O
syndrome,O
(,O
IBS,B
),O
.,O
METHODS,O
:,O
Thirty,O
-,O
eight,O
patients,O
with,O
IBS,B
(,O
constipation,B
-,O
predominant,O
",",O
n,O
=,O
17,O
;,O
diarrhoea,B
-,O
predominant,O
",",O
n,O
=,O
21,O
),O
underwent,O
24,O
-,O
h,O
ambulatory,O
jejunal,O
manometry,O
before,O
and,O
after,O
12,O
week,O
',O
s,O
treatment,O
[,O
cisapride,B
",",O
5,O
mg,O
three,O
times,O
daily,O
(,O
n,O
=,O
19,O
),O
or,O
placebo,O
(,O
n,O
=,O
19,O
),O
],O
.,O
RESULTS,O
:,O
In,O
diarrhoea,O
-,O
predominant,O
patients,O
significant,O
differences,O
in,O
contraction,O
characteristics,O
were,O
observed,O
between,O
the,O
cisapride,B
and,O
placebo,O
groups,O
.,O
In,O
cisapride,B
-,O
treated,O
diarrhoea,O
-,O
predominant,O
patients,O
the,O
mean,O
contraction,O
amplitude,O
was,O
higher,O
(,O
29,O
.,O
3,O
+,O
/,O
-,O
3,O
.,O
2,O
versus,O
24,O
.,O
9,O
+,O
/,O
-,O
2,O
.,O
6,O
mm,O
Hg,O
",",O
cisapride,B
versus,O
placebo,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
;,O
pretreatment,O
",",O
25,O
.,O
7,O
+,O
/,O
-,O
6,O
.,O
0,O
mm,O
Hg,O
.,O
"),",O
the,O
mean,O
contraction,O
duration,O
longer,O
(,O
3,O
.,O
4,O
+,O
/,O
-,O
0,O
.,O
2,O
versus,O
3,O
.,O
0,O
+,O
/,O
-,O
0,O
.,O
2,O
sec,O
",",O
cisapride,B
versus,O
placebo,B
(,O
P,O
<,O
0,O
.,O
1,O
),O
;,O
pretreatment,O
",",O
3,O
.,O
1,O
+,O
/,O
-,O
0,O
.,O
5,O
sec,O
"),",O
and,O
the,O
mean,O
contraction,O
frequency,O
lower,O
(,O
2,O
.,O
0,O
+,O
/,O
-,O
0,O
.,O
2,O
versus,O
2,O
.,O
5,O
+,O
/,O
-,O
0,O
.,O
4,O
cont,O
/,O
min,O
",",O
cisapride,B
versus,O
placebo,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
;,O
pretreatment,O
",",O
2,O
.,O
5,O
+,O
/,O
-,O
1,O
.,O
1,O
cont,O
.,O
/,O
min,O
].,O
than,O
patients,O
treated,O
with,O
placebo,O
.,O
No,O
significant,O
differences,O
in,O
jejunal,O
motility,O
were,O
found,O
in,O
the,O
constipation,O
-,O
predominant,O
IBS,O
group,O
.,O
Symptoms,O
were,O
assessed,O
by,O
using,O
a,O
visual,O
analogue,O
scale,O
before,O
and,O
after,O
treatment,O
.,O
Symptom,O
scores,O
relating,O
to,O
the,O
severity,O
of,O
constipation,B
were,O
lower,O
in,O
cisapride,B
-,O
treated,O
constipation,B
-,O
predominant,O
IBS,O
patients,O
[,O
score,O
",",O
54,O
+,O
/,O
-,O
5,O
versus,O
67,O
+,O
/,O
-,O
14,O
mm,O
",",O
cisapride,B
versus,O
placebo,O
(,O
P,O
<,O
0,O
.,O
5,O
),O
;,O
pretreatment,O
",",O
62,O
+,O
/,O
-,O
19,O
mm,O
].,O
Diarrhoea,B
-,O
predominant,O
IBS,O
patients,O
had,O
a,O
higher,O
pain,O
score,O
after,O
cisapride,B
therapy,O
[,O
score,O
",",O
55,O
+,O
/,O
-,O
15,O
versus,O
34,O
+,O
/,O
-,O
12,O
mm,O
",",O
cisapride,B
versus,O
placebo,O
(,O
P,O
<,O
0,O
5,O
),O
;,O
pretreatment,O
",",O
67,O
+,O
/,O
-,O
19,O
mm,O
],O
.,O
CONCLUSION,O
:,O
Cisapride,B
affects,O
jejunal,O
contraction,O
characteristics,O
and,O
some,O
symptoms,O
in,O
IBS,O
.,O
Prevention,O
of,O
breast,B
cancer,I
with,O
tamoxifen,B
:,O
preliminary,O
findings,O
from,O
the,O
Italian,O
randomised,O
trial,O
among,O
hysterectomised,O
women,O
.,O
Italian,O
Tamoxifen,B
Prevention,I
Study,I
.,O
BACKGROUND,O
:,O
Tamoxifen,B
is,O
a,O
candidate,O
chemopreventive,O
agent,O
in,O
breast,B
cancer,I
",",O
although,O
the,O
drug,O
may,O
be,O
associated,O
with,O
the,O
development,O
of,O
endometrial,B
cancer,I
.,O
Therefore,O
we,O
did,O
a,O
trial,O
in,O
hysterectomised,O
women,O
of,O
tamoxifen,B
as,O
a,O
chemopreventive,O
.,O
METHODS,O
:,O
In,O
October,O
",",O
1992,O
",",O
we,O
started,O
a,O
double,O
-,O
blind,O
placebo,O
-,O
controlled,O
",",O
randomised,O
trial,O
of,O
tamoxifen,B
in,O
women,O
(,O
mainly,O
in,O
Italy,O
),O
who,O
did,O
not,O
have,O
breast,O
cancer,O
and,O
who,O
had,O
had,O
a,O
hysterectomy,O
.,O
Women,O
were,O
randomised,O
to,O
receive,O
tamoxifen,B
20,O
mg,O
per,O
day,O
or,O
placebo,O
",",O
both,O
orally,O
for,O
5,O
years,O
.,O
The,O
original,O
plan,O
was,O
to,O
follow,O
the,O
intervention,O
phase,O
by,O
5,O
years,O
',O
follow,O
-,O
up,O
.,O
In,O
June,O
",",O
1997,O
",",O
the,O
trialists,O
and,O
the,O
data,O
-,O
monitoring,O
committee,O
decided,O
to,O
end,O
recruitment,O
primarily,O
because,O
of,O
the,O
number,O
of,O
women,O
dropping,O
out,O
of,O
the,O
study,O
.,O
Recruitment,O
ended,O
on,O
July,O
11,O
",",O
1997,O
",",O
and,O
the,O
study,O
will,O
continue,O
as,O
planned,O
.,O
The,O
primary,O
endpoints,O
are,O
the,O
occurrence,O
of,O
and,O
deaths,O
from,O
breast,B
cancer,I
.,O
This,O
preliminary,O
interim,O
analysis,O
is,O
based,O
on,O
intention,O
-,O
to,O
-,O
treat,O
.,O
FINDINGS,O
:,O
5408,O
women,O
were,O
randomised,O
;,O
participating,O
women,O
have,O
a,O
median,O
follow,O
-,O
up,O
of,O
46,O
months,O
for,O
major,O
endpoints,O
.,O
41,O
cases,O
of,O
breast,B
cancer,I
occurred,O
so,O
far,O
;,O
there,O
have,O
been,O
no,O
deaths,O
from,O
breast,B
cancer,I
.,O
There,O
is,O
no,O
difference,O
in,O
breast,B
-,O
cancer,I
frequency,O
between,O
the,O
placebo,B
(,O
22,O
cases,O
),O
and,O
tamoxifen,B
(,O
19,O
),O
arms,O
.,O
There,O
is,O
a,O
statistically,O
significant,O
reduction,O
of,O
breast,B
cancer,I
among,O
women,O
receiving,O
tamoxifen,B
who,O
also,O
used,O
hormone,B
-,O
replacement,I
therapy,I
during,O
the,O
trial,O
:,O
among,O
390,O
women,O
on,O
such,O
therapy,I
and,O
allocated,O
to,O
placebo,B
",",O
we,O
found,O
eight,O
cases,O
of,O
breast,B
cancer,I
compared,O
with,O
one,O
case,O
among,O
362,O
women,O
allocated,O
to,O
tamoxifen,B
.,O
Compared,O
with,O
the,O
placebo,O
group,O
",",O
there,O
was,O
a,O
significantly,O
increased,O
risk,O
of,O
vascular,B
events,O
and,O
hypertriglyceridaemia,B
among,O
women,O
on,O
tamoxifen,B
.,O
INTERPRETATION,O
:,O
Although,O
this,O
preliminary,O
analysis,O
has,O
low,O
power,O
",",O
in,O
this,O
cohort,O
of,O
women,O
at,O
low,O
-,O
to,O
-,O
normal,O
risk,O
of,O
breast,B
cancer,I
",",O
the,O
postulated,O
protective,O
effects,O
of,O
tamoxifen,B
are,O
not,O
yet,O
apparent,O
.,O
Women,O
using,O
hormone,B
-,O
replacement,I
therapy,I
appear,O
to,O
have,O
benefited,O
from,O
use,O
of,O
tamoxifen,B
.,O
There,O
were,O
no,O
deaths,O
from,O
breast,O
cancer,O
recorded,O
in,O
women,O
in,O
the,O
study,O
.,O
It,O
is,O
essential,O
to,O
continue,O
follow,O
-,O
up,O
to,O
quantify,O
the,O
long,O
-,O
term,O
risks,O
and,O
benefits,O
of,O
tamoxifen,B
therapy,I
.,O
Epileptogenic,O
activity,O
of,O
folic,B
acid,I
after,O
drug,O
induces,O
SLE,O
(,O
folic,B
acid,I
and,O
epilepsy,O
),O
OBJECTIVE,O
:,O
To,O
study,O
the,O
effect,O
of,O
folic,B
acid,I
-,O
containing,O
multivitamin,O
supplementation,O
in,O
epileptic,O
women,O
before,O
and,O
during,O
pregnancy,O
in,O
order,O
to,O
determine,O
the,O
rate,O
of,O
structural,O
birth,O
defects,O
and,O
epilepsy,O
-,O
related,O
side,O
effects,O
.,O
STUDY,O
DESIGN,O
:,O
First,O
a,O
randomised,O
trial,O
",",O
later,O
periconception,O
care,O
including,O
in,O
total,O
12225,O
females,O
.,O
RESULTS,O
:,O
Of,O
60,O
epileptic,O
women,O
with,O
periconceptional,O
folic,B
acid,I
(,O
0,O
.,O
8,O
mg,O
),O
-,O
containing,O
multivitamin,O
supplementation,O
",",O
no,O
one,O
developed,O
epilepsy,O
-,O
related,O
side,O
effects,O
during,O
the,O
periconception,O
period,O
.,O
One,O
epileptic,O
woman,O
delivered,O
a,O
newborn,O
with,O
cleft,B
lip,I
and,I
palate,I
.,O
Another,O
patient,O
exhibited,O
with,O
a,O
cluster,O
of,O
seizures,O
after,O
the,O
periconception,O
period,O
using,O
another,O
multivitamin,O
.,O
This,O
22,O
-,O
year,O
-,O
old,O
epileptic,O
woman,O
was,O
treated,O
continuously,O
by,O
carbamazepine,B
and,O
a,O
folic,B
acid,I
(,I
1,I
mg,I
),I
-,I
containing,I
multivitamin,I
from,O
the,O
20th,O
week,O
of,O
gestation,O
.,O
She,O
developed,O
status,O
epilepticus,O
and,O
later,O
symptoms,O
of,O
systemic,B
lupus,I
erythematodes,I
.,O
Her,O
pregnancy,O
ended,O
with,O
stillbirth,O
.,O
CONCLUSIONS,O
:,O
The,O
epileptic,O
pregnant,O
patient,O
',O
s,O
autoimmune,O
disease,O
(,O
probably,O
drug,O
-,O
induced,O
lupus,O
),O
could,O
damage,O
the,O
blood,B
-,I
brain,I
barrier,I
",",O
therefore,O
the,O
therapeutic,O
dose,O
(,O
>,O
or,O
=,O
1,O
mg,O
),O
of,O
folic,B
acid,I
triggered,O
a,O
cluster,O
of,O
seizures,O
.,O
Physiological,O
dose,O
(,O
<,O
1,O
mg,O
),O
of,O
folic,B
acid,I
both,O
in,O
healthy,O
and,O
60,O
epileptic,O
women,O
",",O
all,O
without,O
any,O
autoimmune,O
disease,O
",",O
did,O
not,O
increase,O
the,O
risk,O
for,O
epileptic,O
seizures,O
.,O
Stroke,B
and,O
cocaine,B
or,O
amphetamine,B
use,O
.,O
The,O
association,O
of,O
cocaine,B
and,O
amphetamine,B
use,O
with,O
hemorrhagic,O
and,O
ischemic,O
stroke,O
is,O
based,O
almost,O
solely,O
on,O
data,O
from,O
case,O
series,O
.,O
The,O
limited,O
number,O
of,O
epidemiologic,O
studies,O
of,O
stroke,O
and,O
/,O
use,O
of,O
cocaine,B
and,O
/,O
or,O
amphetamine,B
have,O
been,O
done,O
in,O
settings,O
that,O
serve,O
mostly,O
the,O
poor,O
and,O
/,O
or,O
minorities,O
.,O
This,O
case,O
-,O
control,O
study,O
was,O
conducted,O
in,O
the,O
defined,O
population,O
comprising,O
members,O
of,O
Kaiser,O
Permanente,O
of,O
Northern,O
and,O
Southern,O
California,O
.,O
We,O
attempted,O
to,O
identify,O
all,O
incident,O
strokes,O
in,O
women,O
ages,O
15,O
-,O
44,O
years,O
during,O
a,O
3,O
-,O
year,O
period,O
using,O
hospital,O
admission,O
and,O
discharge,O
records,O
",",O
emergency,O
department,O
logs,O
",",O
and,O
payment,O
requests,O
for,O
out,O
-,O
of,O
-,O
plan,O
hospitalizations,O
.,O
We,O
selected,O
controls,O
",",O
matched,O
on,O
age,O
and,O
facility,O
of,O
usual,O
care,O
",",O
at,O
random,O
from,O
healthy,O
members,O
of,O
the,O
health,O
plan,O
.,O
We,O
obtained,O
information,O
in,O
face,O
-,O
to,O
-,O
face,O
interviews,O
.,O
There,O
were,O
347,O
confirmed,O
stroke,O
cases,O
and,O
1,O
",",O
21,O
controls,O
.,O
The,O
univariate,O
matched,O
odds,O
ratio,O
for,O
stroke,O
in,O
women,O
who,O
admitted,O
to,O
using,O
cocaine,B
and,O
/,O
or,O
amphetamine,B
was,O
8,O
.,O
5,O
(,O
95,O
%,O
confidence,O
interval,O
=,O
3,O
.,O
6,O
-,O
20,O
.,O
),O
.,O
After,O
further,O
adjustment,O
for,O
potential,O
confounders,O
",",O
the,O
odds,O
ratio,O
in,O
women,O
who,O
reported,O
using,O
cocaine,B
and,O
/,O
or,O
amphetamine,B
was,O
7,O
.,O
0,O
(,O
95,O
%,O
confidence,O
interval,O
=,O
2,O
.,O
8,O
-,O
17,O
.,O
9,O
),O
.,O
The,O
use,O
of,O
cocaine,B
and,O
/,O
or,O
amphetamine,B
is,O
a,O
strong,O
risk,O
factor,O
for,O
stroke,O
in,O
this,O
socioeconomically,O
heterogeneous,O
",",O
insured,O
urban,O
population,O
.,O
Acute,O
renal,O
failure,O
subsequent,O
to,O
the,O
administration,O
of,O
rifampicin,B
.,O
A,O
follow,O
-,O
up,O
study,O
of,O
cases,O
reported,O
earlier,O
.,O
A,O
clinical,O
presentation,O
is,O
made,O
of,O
a,O
2,O
-,O
3,O
year,O
follow,O
-,O
up,O
of,O
six,O
cases,O
of,O
acute,O
renal,B
failure,I
that,O
have,O
been,O
reported,O
earlier,O
.,O
The,O
patients,O
had,O
developed,O
transient,O
renal,B
failure,I
after,O
the,O
intermittent,O
administration,O
of,O
rifampicin,B
.,O
The,O
stage,O
of,O
olig,O
-,O
anuria,O
lasted,O
for,O
1,O
-,O
3,O
weeks,O
",",O
and,O
five,O
of,O
the,O
patients,O
were,O
treated,O
by,O
hemodialysis,O
.,O
Two,O
of,O
the,O
patients,O
died,O
due,O
to,O
unrelated,O
causes,O
during,O
the,O
follow,O
-,O
up,O
period,O
.,O
The,O
four,O
patients,O
re,O
-,O
examined,O
were,O
clinically,O
cured,O
.,O
Pathologic,O
findings,O
by,O
light,O
microscopy,O
and,O
immunofluorescence,O
at,O
biopsy,O
were,O
scarce,O
.,O
Nothing,O
abnormal,O
was,O
seen,O
by,O
electron,O
microscopy,O
in,O
two,O
of,O
the,O
cases,O
studied,O
.,O
Renal,O
function,O
was,O
normal,O
.,O
In,O
three,O
cases,O
the,O
excretion,O
at,O
131I,B
-,O
hippuran,B
renography,O
was,O
slightly,O
slowed,O
.,O
Although,O
in,O
the,O
acute,O
stage,O
the,O
renal,O
lesions,O
histologically,O
appeared,O
toxic,O
",",O
evidence,O
suggestive,O
of,O
an,O
immunological,O
mechanism,O
cannot,O
be,O
excluded,O
.,O
Chronic,O
effects,O
of,O
a,O
novel,O
synthetic,O
anthracycline,B
derivative,O
(,O
SM,B
-,O
5887,O
),O
on,O
normal,O
heart,O
and,O
doxorubicin,B
-,O
induced,O
cardiomyopathy,O
in,O
beagle,O
dogs,O
.,O
This,O
study,O
was,O
designed,O
to,O
investigate,O
the,O
chronic,O
cardiotoxic,O
potential,O
of,O
SM,B
-,I
5887,I
and,O
a,O
possible,O
deteriorating,O
effect,O
of,O
SM,B
-,I
5887,I
on,O
low,O
-,O
grade,O
cardiotoxicity,O
pre,O
-,O
induced,O
by,O
doxorubicin,B
in,O
beagle,O
dogs,O
.,O
In,O
the,O
chronic,O
treatment,O
",",O
beagle,O
dogs,O
of,O
each,O
sex,O
were,O
given,O
intravenously,O
once,O
every,O
3,O
weeks,O
",",O
either,O
a,O
sublethal,O
dose,O
of,O
doxorubicin,B
(,O
1,O
.,O
5,O
mg,O
/,O
kg,O
),O
or,O
SM,B
-,O
5887,I
(,O
2,O
.,O
5,O
mg,O
/,O
kg,O
),O
.,O
The,O
experiment,O
was,O
terminated,O
3,O
weeks,O
after,O
the,O
ninth,O
dosing,O
.,O
Animals,O
which,O
received,O
over,O
six,O
courses,O
of,O
doxorubicin,B
demonstrated,O
the,O
electrocardiogram,B
(,O
ECG,I
),O
changes,O
",",O
decrease,O
of,O
blood,O
pressure,O
and,O
high,O
-,O
grade,O
histopathological,O
cardiomyopathy,B
",",O
while,O
animals,O
which,O
were,O
terminally,O
sacrificed,O
after,O
the,O
SM,B
-,O
5887,I
administration,O
did,O
not,O
show,O
any,O
changes,O
in,O
ECG,B
",",O
blood,O
pressure,O
and,O
histopathological,O
examinations,O
.,O
To,O
examine,O
a,O
possibly,O
deteriorating,O
cardiotoxic,O
effect,O
of,O
SM,B
-,O
5887,I
",",O
low,O
-,O
grade,O
cardiomyopathy,O
was,O
induced,O
in,O
dogs,O
by,O
four,O
courses,O
of,O
doxorubicin,B
(,O
1,O
.,O
5,O
mg,O
/,O
kg,O
),O
.,O
Nine,O
weeks,O
after,O
pre,O
-,O
treatment,O
",",O
dogs,O
were,O
given,O
four,O
courses,O
of,O
either,O
doxorubicin,B
(,O
1,O
.,O
5,O
mg,O
/,O
kg,O
),O
or,O
SM,B
-,O
5887,I
(,O
2,O
.,O
5,O
mg,O
/,O
kg,O
),O
once,O
every,O
3,O
weeks,O
.,O
The,O
low,O
-,O
grade,O
cardiotoxic,B
changes,O
were,O
enhanced,O
by,O
the,O
additional,O
doxorubicin,B
treatment,O
.,O
On,O
the,O
contrary,O
",",O
the,O
SM,B
-,I
5887,I
treatment,O
did,O
not,O
progress,O
the,O
grade,O
of,O
cardiomyopathy,B
.,O
In,O
conclusion,O
",",O
SM,B
-,I
5887,I
does,O
not,O
have,O
any,O
potential,O
of,O
chronic,O
cardiotoxicity,B
and,O
deteriorating,O
effect,O
on,O
doxorubicin,B
-,O
induced,O
cardiotoxicity,B
in,O
dogs,O
.,O
Risk,O
for,O
valvular,O
heart,O
disease,O
among,O
users,O
of,O
fenfluramine,B
and,O
dexfenfluramine,B
who,O
underwent,O
echocardiography,O
before,O
use,O
of,O
medication,O
.,O
BACKGROUND,O
:,O
Because,O
uncontrolled,O
echocardiographic,O
surveys,O
suggested,O
that,O
up,O
to,O
30,O
%,O
to,O
38,O
%,O
of,O
users,O
of,O
fenfluramine,B
and,O
dexfenfluramine,B
had,O
valvular,O
disease,O
",",O
these,O
drugs,O
were,O
withdrawn,O
from,O
the,O
market,O
.,O
OBJECTIVE,O
:,O
To,O
determine,O
the,O
risk,O
for,O
new,O
or,O
worsening,O
valvular,O
abnormalities,O
among,O
users,O
of,O
fenfluramine,B
or,O
dexfenfluramine,B
who,O
underwent,O
echocardiography,O
before,O
they,O
began,O
to,O
take,O
these,O
medications,O
.,O
DESIGN,O
:,O
Cohort,O
study,O
.,O
SETTING,O
:,O
Academic,O
primary,O
care,O
practices,O
.,O
PATIENTS,O
:,O
46,O
patients,O
who,O
used,O
fenfluramine,B
or,O
dexfenfluramine,B
for,O
14,O
days,O
or,O
more,O
and,O
had,O
echocardiograms,O
obtained,O
before,O
therapy,O
.,O
MEASUREMENTS,O
:,O
Follow,O
-,O
up,O
echocardiography,O
.,O
The,O
primary,O
outcome,O
was,O
new,O
or,O
worsening,O
valvulopathy,O
",",O
defined,O
as,O
progression,O
of,O
either,O
aortic,B
or,O
mitral,B
regurgitation,I
by,O
at,O
least,O
one,O
degree,O
of,O
severity,O
and,O
disease,O
that,O
met,O
U,B
.,O
S,I
.,I
Food,I
and,I
Drug,I
Administration,I
criteria,I
(,O
at,O
least,O
mild,O
aortic,B
regurgitation,I
or,O
moderate,O
mitral,B
regurgitation,I
),O
.,O
RESULTS,O
:,O
Two,O
patients,O
(,O
4,O
.,O
3,O
%,O
[,O
95,O
%,O
CI,O
",",O
0,O
.,O
6,O
%,O
to,O
14,O
.,O
8,O
%,O
],O
),O
receiving,O
fenfluramine,B
-,I
phentermine,I
developed,O
valvular,O
heart,O
disease,O
.,O
One,O
had,O
baseline,O
bicuspid,O
aortic,B
valve,I
and,O
mild,O
aortic,B
regurgitation,I
that,O
progressed,O
to,O
moderate,O
regurgitation,O
.,O
The,O
second,O
patient,O
developed,O
new,O
moderate,O
aortic,B
insufficiency,I
.,O
CONCLUSION,O
:,O
Users,O
of,O
diet,O
medications,O
are,O
at,O
risk,O
for,O
valvular,O
heart,O
disease,O
.,O
However,O
",",O
the,O
incidence,O
may,O
be,O
lower,O
than,O
that,O
reported,O
previously,O
.,O
Therapeutic,O
drug,O
monitoring,O
of,O
tobramycin,B
:,O
once,O
-,O
daily,O
versus,O
twice,O
-,O
daily,O
dosage,O
schedules,O
.,O
OBJECTIVE,O
:,O
To,O
evaluate,O
the,O
effect,O
of,O
dosage,O
regimen,O
(,O
once,O
-,O
daily,O
vs,O
.,O
twice,O
-,O
daily,O
),O
of,O
tobramicyn,B
on,O
steady,O
-,O
state,O
serum,O
concentrations,O
and,O
toxicity,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
Patients,O
undergoing,O
treatment,O
with,O
i,O
.,O
v,O
.,O
tobramycin,B
(,O
4,O
mg,O
/,O
kg,O
/,O
day,O
),O
were,O
randomised,O
to,O
two,O
groups,O
.,O
Group,O
OD,O
(,O
n,O
=,O
22,O
),O
received,O
a,O
once,O
-,O
daily,O
dose,O
of,O
tobramycin,B
and,O
group,O
TD,O
(,O
n,O
=,O
21,O
),O
received,O
the,O
same,O
dose,O
divided,O
into,O
two,O
doses,O
daily,O
.,O
Tobramycin,B
serum,O
concentrations,O
(,O
peak,O
and,O
trough,O
),O
were,O
measured,O
by,O
enzyme,O
multiplied,O
immunoassay,O
.,O
The,O
renal,B
and,O
auditory,O
functions,O
of,O
the,O
patients,O
were,O
monitored,O
before,O
",",O
during,O
and,O
immediately,O
after,O
treatment,O
.,O
RESULTS,O
:,O
The,O
two,O
groups,O
were,O
comparable,O
with,O
respect,O
to,O
sex,O
",",O
age,O
",",O
body,O
weight,O
and,O
renal,B
function,O
.,O
No,O
statistically,O
significant,O
differences,O
were,O
found,O
in,O
mean,O
daily,O
dose,O
",",O
duration,O
of,O
treatment,O
",",O
or,O
cumulative,O
dose,O
.,O
Trough,O
concentrations,O
were,O
<,O
2,O
g,O
/,O
ml,O
in,O
the,O
two,O
groups,O
(,O
100,O
%,O
),O
.,O
Peak,O
concentrations,O
were,O
>,O
6,O
microg,O
/,O
ml,O
in,O
100,O
%,O
of,O
the,O
OD,B
group,O
and,O
in,O
67,O
%,O
of,O
the,O
TD,B
group,O
(,O
P,B
<,I
0,I
.,I
1,I
),I
.,O
Mean,O
peak,O
concentrations,O
were,O
markedly,O
different,O
:,O
11,O
.,O
0,O
+,O
/,O
-,O
2,O
.,O
89,O
microg,B
/,O
ml,O
in,O
OD,O
vs,O
.,O
6,O
.,O
53,O
+,O
/,O
-,O
1,O
.,O
45,O
microg,B
/,O
ml,O
in,O
TD,O
(,O
P,O
<,O
0,O
.,O
1,O
),O
.,O
The,O
pharmacokinetics,O
parameters,O
were,O
:,O
Ke,O
",",O
(,O
0,O
.,O
15,O
+,O
/,O
-,O
0,O
3,O
/,O
h,O
in,O
OD,O
vs,O
.,O
0,O
.,O
24,O
+,O
/,O
-,O
0,O
6,O
/,O
h,O
in,O
TD,O
),O
",",O
t1,O
/,O
2,O
",",O
Vd,O
(,O
0,O
.,O
35,O
+,O
/,O
-,O
0,O
11,O
l,O
/,O
kg,O
in,O
OD,O
vs,O
0,O
.,O
33,O
+,O
/,O
-,O
0,O
.,O
9,O
l,O
/,O
kg,O
in,O
TD,O
.,O
"),",O
Cl,B
(,O
0,O
.,O
86,O
+,O
/,O
-,O
0,O
29,O
ml,O
/,O
min,O
/,O
kg,O
in,O
OD,O
vs,O
.,O
1,O
.,O
28,O
+,O
/,O
-,O
0,O
33,O
ml,O
/,O
min,O
/,O
kg,O
in,O
TD,O
).,O
Increased,O
serum,O
creatinine,B
was,O
observed,O
in,O
73,O
%,O
of,O
patients,O
in,O
OD,O
versus,O
57,O
%,O
of,O
patients,O
in,O
TD,O
",",O
without,O
evidence,O
of,O
nephrotoxicity,O
.,O
In,O
TD,O
group,O
",",O
three,O
patients,O
developed,O
decreased,O
auditory,O
function,O
",",O
of,O
which,O
one,O
presented,O
with,O
an,O
auditory,O
loss,O
of,O
-,O
30,O
dB,O
",",O
whereas,O
in,O
the,O
OD,O
group,O
only,O
one,O
patient,O
presented,O
decreased,O
auditory,O
function,O
.,O
CONCLUSION,O
:,O
This,O
small,O
study,O
suggests,O
that,O
a,O
once,O
-,O
daily,O
dosing,O
regimen,O
of,O
tobramycin,B
is,O
at,O
least,O
as,O
effective,O
as,O
and,O
is,O
no,O
more,O
and,O
possibly,O
less,O
toxic,O
than,O
the,O
twice,O
-,O
daily,O
regimen,O
.,O
Using,O
a,O
single,O
-,O
dose,O
therapy,O
",",O
peak,O
concentration,O
determination,O
is,O
not,O
necessary,O
",",O
only,O
trough,O
samples,O
should,O
be,O
monitored,O
to,O
ensure,O
levels,O
below,O
2,O
microg,O
/,O
ml,O
.,O
Enhanced,O
bradycardia,O
induced,O
by,O
beta,B
-,I
adrenoceptor,I
antagonists,I
in,O
rats,O
pretreated,O
with,O
isoniazid,B
.,O
High,O
doses,O
of,O
isoniazid,B
increase,O
hypotension,O
induced,O
by,O
vasodilators,O
and,O
change,O
the,O
accompanying,O
reflex,O
tachycardia,O
to,O
bradycardia,O
",",O
an,O
interaction,O
attributed,O
to,O
decreased,O
synthesis,O
of,O
brain,O
gamma,B
-,I
aminobutyric,I
acid,I
(,O
GABA,B
),O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
possible,O
enhancement,O
by,O
isoniazid,B
of,O
bradycardia,O
induced,O
by,O
beta,B
-,I
adrenoceptor,I
antagonists,I
was,O
determined,O
in,O
rats,O
anaesthetised,O
with,O
chloralose,B
-,I
urethane,I
.,O
Isoniazid,B
significantly,O
increased,O
bradycardia,O
after,O
propranolol,B
",",O
pindolol,B
",",O
labetalol,B
and,O
atenolol,B
",",O
as,O
well,O
as,O
after,O
clonidine,B
",",O
but,O
not,O
after,O
hexamethonium,B
or,O
carbachol,B
.,O
Enhancement,O
was,O
not,O
observed,O
in,O
rats,O
pretreated,O
with,O
methylatropine,B
or,O
previously,O
vagotomised,O
.,O
These,O
results,O
are,O
compatible,O
with,O
interference,O
by,O
isoniazid,B
with,O
GABAergic,O
inhibition,O
of,O
cardiac,O
parasympathetic,O
tone,O
.,O
Such,O
interference,O
could,O
be,O
exerted,O
centrally,O
",",O
possibly,O
at,O
the,O
nucleus,O
ambiguus,O
",",O
or,O
peripherally,O
at,O
the,O
sinus,O
node,O
.,O
Structural,O
and,O
functional,O
impairment,O
of,O
mitochondria,B
in,O
adriamycin,B
-,I
induced,I
cardiomyopathy,I
in,O
mice,O
:,O
suppression,O
of,O
cytochrome,B
c,I
oxidase,I
II,I
gene,O
expression,O
.,O
The,O
use,O
of,O
adriamycin,B
(,O
ADR,B
),O
in,O
cancer,O
chemotherapy,O
has,O
been,O
limited,O
due,O
to,O
its,O
cumulative,O
cardiovascular,O
toxicity,O
.,O
Earlier,O
observations,O
that,O
ADR,B
interacts,O
with,O
mitochondrial,B
cytochrome,B
c,I
oxidase,I
(,O
COX,B
),O
and,O
suppresses,O
its,O
enzyme,O
activity,O
led,O
us,O
to,O
investigate,O
ADR,B
',O
s,O
action,O
on,O
the,O
cardiovascular,O
functions,O
and,O
heart,O
mitochondrial,B
morphology,O
in,O
Balb,O
-,O
c,O
mice,O
i,O
.,O
p,O
.,O
treated,O
with,O
ADR,B
for,O
several,O
weeks,O
.,O
At,O
various,O
times,O
during,O
treatment,O
",",O
the,O
animals,O
were,O
assessed,O
for,O
cardiovascular,O
functions,O
by,O
electrocardiography,O
and,O
for,O
heart,O
tissue,O
damage,O
by,O
electron,O
microscopy,O
.,O
In,O
parallel,O
",",O
total,O
RNA,B
was,O
extracted,O
from,O
samples,O
of,O
dissected,O
heart,O
and,O
analyzed,O
by,O
Northern,O
blot,O
hybridization,O
to,O
determine,O
the,O
steady,O
-,O
state,O
level,O
of,O
three,O
RNA,B
transcripts,O
encoded,O
by,O
the,O
COXII,B
",",O
COXIII,B
",",O
and,O
COXIV,B
genes,O
.,O
Similarly,O
",",O
samples,O
obtained,O
from,O
the,O
liver,O
of,O
the,O
same,O
animals,O
were,O
analyzed,O
for,O
comparative,O
studies,O
.,O
Our,O
results,O
indicated,O
that,O
1,O
),O
treatment,O
of,O
mice,O
with,O
ADR,B
caused,O
cardiovascular,O
arrhythmias,O
characterized,O
by,O
bradycardia,O
",",O
extension,O
of,O
ventricular,O
depolarization,O
time,O
(,O
tQRS,B
),O
",",O
and,O
failure,O
of,O
QRS,B
at,O
high,O
concentrations,O
(,O
10,O
-,O
14,O
mg,O
/,O
kg,O
body,O
weight,O
cumulative,O
dose,O
),O
;,O
2,O
),O
the,O
heart,O
mitochondria,O
underwent,O
swelling,O
",",O
fusion,O
",",O
dissolution,O
",",O
and,O
/,O
or,O
disruption,O
of,O
mitochondrial,O
cristae,O
after,O
several,O
weeks,O
of,O
treatment,O
.,O
Such,O
abnormalities,O
were,O
not,O
observed,O
in,O
the,O
mitochondria,B
of,O
liver,B
tissue,O
;,O
and,O
3,O
),O
among,O
the,O
three,O
genes,O
of,O
COX,B
enzyme,O
examined,O
",",O
only,O
COXII,B
gene,O
expression,O
was,O
suppressed,O
by,O
ADR,B
treatment,O
",",O
mainly,O
after,O
8,O
weeks,O
in,O
both,O
heart,B
and,O
liver,B
.,O
Knowing,O
that,O
heart,B
mitochondria,B
represent,O
almost,O
40,O
%,O
of,O
heart,B
muscle,O
by,O
weight,O
",",O
we,O
conclude,O
that,O
the,O
deteriorating,O
effects,O
of,O
ADR,B
on,O
cardiovascular,O
function,O
involve,O
mitochondrial,B
structural,O
and,O
functional,O
impairment,O
.,O
Quinine,B
is,O
a,O
bitter,O
tasting,O
alkaloid,B
with,O
a,O
long,O
history,O
of,O
use,O
in,O
the,O
treatment,O
of,O
malaria,B
",",O
and,O
is,O
an,O
ingredient,O
in,O
tonic,O
water,O
.,O